<SEC-DOCUMENT>0001698530-19-000030.txt : 20190319
<SEC-HEADER>0001698530-19-000030.hdr.sgml : 20190319
<ACCEPTANCE-DATETIME>20190319184515
ACCESSION NUMBER:		0001698530-19-000030
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20190319
DATE AS OF CHANGE:		20190319

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXICURE, INC.
		CENTRAL INDEX KEY:			0001698530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				815333008
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-221791
		FILM NUMBER:		19693048

	BUSINESS ADDRESS:	
		STREET 1:		8045 LAMON AVE, SUITE 410
		CITY:			SKOKIE
		STATE:			IL
		ZIP:			60077
		BUSINESS PHONE:		847-673-1700

	MAIL ADDRESS:	
		STREET 1:		8045 LAMON AVE, SUITE 410
		CITY:			SKOKIE
		STATE:			IL
		ZIP:			60077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Max-1 Acquisition Corp
		DATE OF NAME CHANGE:	20170221
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>a424b3prosupno8.htm
<DESCRIPTION>424B3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5eb516580dde474e94fad8392de5359e"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:right;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Filed pursuant to Rule 424(b)(3)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:right;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Registration No. 333-221791</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">PROSPECTUS SUPPLEMENT NO. 8</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(To the Prospectus dated February 6, 2018)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;"><img src="image95.jpg" alt="image95.jpg" style="height:61px;width:254px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">39,714,143</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Shares of Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:28.212560386473427%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Prospectus Supplement No. 8 supplements the prospectus dated February 6, 2018 (the &#8220;Prospectus&#8221;), relating to the offering and resale of up to 39,714,143 shares of common stock of Exicure, Inc. by the selling stockholders identified in the Prospectus. This Prospectus Supplement should be read in conjunction with the Prospectus which is to be delivered with this Prospectus Supplement. &#160;Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this Supplement modifies or supersedes such statement. Any statement that is modified or superseded shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Supplement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Prospectus Supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on March 8, 2019 (the &#8220;Form 10-K&#8221;), all set forth below.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:28.212560386473427%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Investing in our common stock involves a high degree of risk. Before making an investment decision, please read &#8220;Risk Factors&#8221; on page </font><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828018001204/exicurefinalprospectus424.htm"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">11</font></a><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;of the Prospectus.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Prospectus Supplement (or the Prospectus including any supplements or amendments thereto) is truthful or complete. Any representation to the contrary is a criminal offense.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:28.212560386473427%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The date of this Prospectus Supplement is March 19, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="s78A18B57F06C59C4976B3080A0AD4CCD"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">______________________________________</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:17pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.66666666666667%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:17pt;"><font style="font-family:inherit;font-size:17pt;font-weight:bold;">FORM 10-K</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">______________________________________</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.66666666666667%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the fiscal year ended December 31, 2018</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.66666666666667%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from to</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission file number 000-55764</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">______________________________________</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:22pt;"><font style="font-family:inherit;font-size:22pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">______________________________________</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.66666666666667%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:21%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">81-5333008</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(State or other jurisdiction of</font></div><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8045 Lamon Avenue</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Suite 410</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Skokie, IL 60077</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Address of principal executive offices and Zip Code)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(847) 673-1700</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">______________________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.66666666666667%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:4%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock, par value $0.0001 per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">None</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Title of each class)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Name of each exchange on which registered)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(g) of the Act:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">None</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">______________________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.Yes </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes </font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(&#167;229.405) </font><font style="font-family:inherit;font-size:10pt;">is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting </font></div><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.66666666666667%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">&#168;</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller reporting company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </font><font style="font-family:Wingdings;font-size:10pt;">&#168;</font><font style="font-family:inherit;font-size:10pt;">&#32;No </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the closing price of the registrant&#8217;s common stock on the last business day of the registrant&#8217;s most recently completed second fiscal quarter, which was June&#160;30, 2018, the aggregate market value of its shares (based on a closing price of $5.70 per share) held by&#160;non-affiliates&#160;was approximately $117.6&#160;million. Shares of the registrant&#8217;s common stock held by each executive officer and director and by each entity or person that owned five percent or more of the registrant&#8217;s outstanding common stock were excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of March 5, 2019, the registrant had 44,358,000 shares of common stock outstanding.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Portions of the registrant&#8217;s definitive Proxy Statement for the 2019 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K, are incorporated by reference in Part III, Items 10-14 of this Form 10-K. Except for the portions of the Proxy Statement specifically incorporated by reference in this Form 10-K, the Proxy Statement shall not be deemed to be filed as part hereof.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8D62D2794F565DF2940B488CE7ED91C2"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:88%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">PART I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0ABC64960FA657C1A9E90D44E1A7B15B"><font style="font-family:Times New Roman;font-size:10pt;">Item 1. Business</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0ABC64960FA657C1A9E90D44E1A7B15B">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s80BB9A6DD337560C98ABEC4DDBD478BE"><font style="font-family:Times New Roman;font-size:10pt;">Item 1A. Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s80BB9A6DD337560C98ABEC4DDBD478BE">43</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF38681DA33935DE08BEA24BB940EE041"><font style="font-family:Times New Roman;font-size:10pt;">Item 1B. Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF38681DA33935DE08BEA24BB940EE041">76</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s3CC65492063C5A61B69AAFAD015FE2C6"><font style="font-family:Times New Roman;font-size:10pt;">Item 2. Properties</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s3CC65492063C5A61B69AAFAD015FE2C6">76</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sC6B841661A6F586B958AB9ABC85887E9"><font style="font-family:Times New Roman;font-size:10pt;">Item 3. Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sC6B841661A6F586B958AB9ABC85887E9">76</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sE2AF58F86EBA55768018D608F63DF7DD"><font style="font-family:Times New Roman;font-size:10pt;">Item 4. Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sE2AF58F86EBA55768018D608F63DF7DD">76</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">PART II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sEB3CE249C9B85B1FBDB7584C961F1199"><font style="font-family:Times New Roman;font-size:10pt;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sEB3CE249C9B85B1FBDB7584C961F1199">77</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sBD5F9095851B5B7BB8042F542FD6601D"><font style="font-family:Times New Roman;font-size:10pt;">Item 6. Selected Financial Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sBD5F9095851B5B7BB8042F542FD6601D">79</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF242271E3C86583786A2679B6EAD91A9"><font style="font-family:Times New Roman;font-size:10pt;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF242271E3C86583786A2679B6EAD91A9">81</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sFCFF24E6DEA857CEA1437F3B8CE36269"><font style="font-family:Times New Roman;font-size:10pt;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sFCFF24E6DEA857CEA1437F3B8CE36269">98</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF005D3116BE25DD5A010DE44D51C96D3"><font style="font-family:Times New Roman;font-size:10pt;">Item 8. Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF005D3116BE25DD5A010DE44D51C96D3">99</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD8DE4B6836E85604BABA98AE1DC3937A"><font style="font-family:Times New Roman;font-size:10pt;">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD8DE4B6836E85604BABA98AE1DC3937A">128</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s5E9FB2352B285C5AA908348B4691D291"><font style="font-family:Times New Roman;font-size:10pt;">Item 9A. Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s5E9FB2352B285C5AA908348B4691D291">128</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s7AD40BA7BEC950C691A12FAAFE62F8AE"><font style="font-family:Times New Roman;font-size:10pt;">Item 9B. Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s7AD40BA7BEC950C691A12FAAFE62F8AE">129</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">PART III</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s07786F0E15EC5744B6CDF7E43777ABAF"><font style="font-family:Times New Roman;font-size:10pt;">Item 10. Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s07786F0E15EC5744B6CDF7E43777ABAF">130</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s92C78AD63CF05DFCB87DA3FDCC80DC84"><font style="font-family:Times New Roman;font-size:10pt;">Item 11. Executive Compensation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s92C78AD63CF05DFCB87DA3FDCC80DC84">130</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sE9A31DEC37315F2492A9ACAF0664CE91"><font style="font-family:Times New Roman;font-size:10pt;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sE9A31DEC37315F2492A9ACAF0664CE91">130</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0294592439505EFFB8C23BDE850FF4F5"><font style="font-family:Times New Roman;font-size:10pt;">Item 13. Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0294592439505EFFB8C23BDE850FF4F5">130</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s16F54F3AA84B58A7861CD5411F9FED61"><font style="font-family:Times New Roman;font-size:10pt;">Item 14. Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s16F54F3AA84B58A7861CD5411F9FED61">130</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">PART IV</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s740107D09368580DB19288F35D0D3E8C"><font style="font-family:Times New Roman;font-size:10pt;">Item 15. Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s740107D09368580DB19288F35D0D3E8C">131</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF56CA357586E53F885CA9ED468B4B30C"><font style="font-family:Times New Roman;font-size:10pt;">Item 16. Form 10-K Summary</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF56CA357586E53F885CA9ED468B4B30C">133</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#sE2D344B1C3815B8FA32E5C594EB563EF"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sE2D344B1C3815B8FA32E5C594EB563EF">134</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="s8445CD504F4D5EFCA97A4CBBE195F0B3"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Annual Report on Form 10-K, including the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains express or implied &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical fact contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221;, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part I, Item 1A &#8220;Risk Factors&#8221; below and for the reasons described elsewhere in this Annual Report on Form 10-K. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials and Investigational New Drug, or IND, application, Investigational Medicinal Product Dossier, or IMPD, Clinical Trial Application, or CTA, New Drug Application, or NDA, or other regulatory submissions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our dependence on current and future collaborators for developing, obtaining regulatory approval for and commercializing therapeutic candidates in the collaboration; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our receipt and timing of any milestone payments or royalties under any current or future research collaboration and license agreements or arrangements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to identify and develop therapeutic candidates for treatment of additional disease indications; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our or a current or future collaborator&#8217;s ability to obtain and maintain regulatory approval of any of our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the rate and degree of market acceptance of any approved therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the commercialization of any approved therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to establish and maintain collaborations and retain commercial rights for our therapeutic candidates in the collaborations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the implementation of our business model and strategic plans for our business, technologies and therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our estimates of our expenses, ongoing losses, future revenue and capital requirements, including our expectations relating to the use of proceeds from our private placement offering, and our needs for additional financing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to obtain additional funds for our operations; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to obtain and maintain intellectual property protection for our technologies and therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our reliance on third parties to conduct our preclinical studies and clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our reliance on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, preclinical and clinical trial supplies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to attract and retain qualified key management and technical personnel; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our financial performance; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the impact of government regulation and developments relating to our competitors or our industry; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">other risks and uncertainties, including those listed in Part I, Item 1A of this Annual Report on Form 10-K under the caption &#8220;Risk Factors.&#8221; </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed in Part I, Item 1A of this Annual Report on Form 10-K under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any forward-looking statement in this Annual Report on Form 10-K reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Annual Report on Form 10-K and the documents that we reference herein and have filed with the SEC as exhibits thereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by law, we assume no, and specifically decline any, obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Annual Report on Form 10-K also contains or may contain estimates, projections and other information concerning our industry, our business and the markets for certain therapeutics, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Except where the context otherwise requires, in this Annual Report on Form 10-K, the &#8220;Company,&#8221; &#8220;Exicure,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refers to Exicure, Inc., a Delaware corporation, and, where appropriate, its subsidiary. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">TRADEMARKS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">All trademarks, service marks and trade names appearing in this Annual Report on Form 10-K are the property of their respective holders. Use or display by us of other parties&#8217; trademarks, trade dress, or products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="sF466AACA21D854CC91C3BD6F66C0C93F"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART I</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Unless otherwise stated or the context otherwise indicates, references to &#8220;Exicure,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; or similar terms refer to Exicure, Inc. and our wholly-owned subsidiary, Exicure Operating Company. Exicure Operating Company, which we refer to as &#8220;Exicure OpCo,&#8221; holds all material assets and conducts all business activities and operations of the Company.</font></div><div><a name="s0ABC64960FA657C1A9E90D44E1A7B15B"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1. Business. </font></div><div><a name="s9C722364989C5F3399F8FC90F19A2A9A"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA, technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. We believe the design of our SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. Since our SNAs have shown in a Phase 1 clinical trial and in preclinical studies that they can cross certain biological barriers when administered locally, we believe that they have the therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. We have demonstrated the ability to cross certain biological barriers in Phase 1 clinical trials of three therapeutic candidates, AST-008, XCUR17 and AST-005.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Immuno-oncology</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">AST-008&#160;is an SNA consisting of toll-like receptor 9, or TLR9, agonists designed for immuno-oncology applications.&#160;TLR9 agonists bind to and activate TLR9 receptors.  We believe&#160;AST-008&#160;may be used for immuno-oncology applications as a monotherapy or in combination with checkpoint inhibitors. Checkpoint inhibitors are therapeutics that prevent tumors from evading destruction by the immune system. We have observed that administration of&#160;AST-008&#160;as a monotherapy can have anti-tumor activity in mouse models of colon cancer, breast cancer, lymphoma and melanoma. We have also observed that, in preclinical studies in a variety of tumor models,&#160;AST-008,&#160;applied in combination with certain checkpoint inhibitors, exhibited anti-tumor responses and survival rates that were greater than those demonstrated by checkpoint inhibitors alone. We have also demonstrated that&#160;AST-008&#160;was active when administered subcutaneously, intratumorally or intravenously, in both prevention and established mouse tumor models. The administration of&#160;AST-008&#160;also produced localized as well as abscopal anti-tumor activity in mouse cancer models. Additionally, administration of&#160;AST-008 in combination with certain checkpoint inhibitors conferred adaptive immunity in breast and colon cancer mouse models.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the fourth quarter of 2018 the FDA opened the IND for AST-008 and informed the&#160;Company&#160;that our proposed Phase1b/2 trial may proceed.  Early in 2019, we opened four clinical sites and began dosing and recruiting patients in that trial.  This is a Phase 1b/2, open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral&#160;AST-008&#160;injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors.  Conditions under study are planned to include advanced or metastatic: Merkel cell carcinoma, head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma and melanoma.  The primary outcome measure is the safety and tolerability of&#160;AST-008&#160;alone and in combination with pembrolizumab.  Secondary outcomes include the recommended Phase 2 dose and disease assessment with RECIST 1.1.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the second quarter of 2017, we filed a CTA for a Phase 1 clinical trial of&#160;AST-008&#160;in the United Kingdom. In the third quarter of 2017, we received an authorization from the MHRA, the competent health authority of the United Kingdom, to conduct a Phase 1 clinical trial with&#160;AST-008. We began subject dosing in our Phase 1 clinical trial for&#160;AST-008&#160;in the fourth quarter of 2017. This trial was completed in the third quarter of 2018. Based on our initial analyses of the Phase 1 clinical trial results, AST-008 was shown to be safe and tolerable in all subjects, with no serious adverse events and no dose limiting toxicity.  All AST-008-related adverse events were of short duration, reversible and consistent with TLR9 activation. In addition, AST-008 was shown to elicit high levels of certain cytokines as well as to activate important effector cells of the immune system, including T cells and natural killer cells which are the main drivers of an anti-tumor response. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Inflammatory diseases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">XCUR17</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">XCUR17, is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha, or&#160;IL-17RA,&#160;a protein that is considered essential in the initiation and maintenance of psoriasis. Although the availability of inhibitors of TNF revolutionized the systemic treatment of severe psoriasis, studies of disease pathogenesis have shifted attention to the&#160;IL-17&#160;pathway, in which&#160;IL-17RA&#160;is a key driver of psoriasis. Our strategy is to reduce the levels of&#160;IL-17RA&#160;in the skin by topically applying XCUR17. In preclinical studies, XCUR17 inhibited&#160;IL-17RA&#160;in the keratinocytes of the skin.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We filed a CTA for a Phase 1 clinical trial of XCUR17 in patients with psoriasis in Germany in the third quarter of 2017. Our CTA was approved in February 2018 and we began dosing patients in our Phase 1 clinical trial in April 2018. The Phase 1 clinical trial, which had final patient visits in the fourth quarter of 2018, was a randomized, double-blinded, placebo-controlled trial in twenty-one patients with mild to moderate chronic plaque psoriasis designed to assess the safety of XCUR17 formulated as a topical gel, and to evaluate early signs of efficacy. All patients received three strengths of XCUR17 gel, a vehicle gel, and a positive comparator (Daivonex&#174; cream), which were all applied on different areas of psoriatic skin within each individual patient.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the fourth quarter of 2018 we reported results from the Phase 1 trial of XCUR17.  In the case of XCUR17, of the twenty-one treated patients, eleven treated with the highest strength XCUR17 gel were observed to have a reduction in redness and improvement in healing as determined by blinded physician assessments. Further, the highest strength XCUR17 gel showed a statistically significant improvement in psoriasis symptoms versus the vehicle gel. By comparison, seventeen of the twenty-one patients treated with the positive comparator showed a clinical response, while four patients treated with the placebo vehicle had a clinical response.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There were no adverse safety events related to treatment with XCUR17 observed. In addition to the safety, tolerability and clinical assessments, the trial measured psoriatic infiltrate thickness over the 26-day treatment period. No relevant changes in mean psoriatic infiltrate thickness were observed for the three XCUR17 gels or the active ingredient-free vehicle gel. At this time, assessments of IL-17RA mRNA levels from skin biopsies collected from the treated areas in patients have not yet been correlated with the clinical or infiltrate thickness assessments.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Dermelix License Agreement</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 17, 2019 Exicure entered into a License and Development Agreement, or the Dermelix License Agreement, with DERMELIX, LLC, d/b/a Dermelix Biotherapeutics. Under the terms of agreement, Dermelix</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">licensed worldwide rights to research, develop, and commercialize Exicure&#8217;s technology for the treatment of Netherton Syndrome and, at Dermelix&#8217;s option, up to five additional rare skin indications.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Dermelix will initially develop a targeted therapy for the treatment of Netherton Syndrome (NS). NS is a rare and severe autosomal recessive disorder caused by loss-of-function mutations in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">SPINK5 </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">gene, which encodes the serine protease inhibitor LEKT1 involved in skin barrier function. NS affects approximately 1 in 200,000 children born each year, and is characterized by severely inflamed, red, scaled, itchy skin, and patients are at increased risk of mortality in the first year of life due to recurrent infections and dehydration as a result of the impaired skin barrier. Currently, there are no approved treatments for NS patients and off-label use of standard of care treatments are of limited utility.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the terms of the Dermerlix License Agreement, Exicure received an upfront payment of $1 million at closing of the transaction and will receive an additional $1 million upon the exercise of each of the five options granted to Dermelix. Exicure will be responsible for conducting the early stage development for each indication up to IND enabling toxicology studies.  Dermelix will undertake subsequent development, commercial activities and financial responsibility. For each of NS as well as any additional licensed product for which Dermelix exercises one of its options, Exicure is eligible to receive potential payments totaling up to $13.5 million upon achievement of certain development and regulatory milestones and up to $152.5&#160;million upon achievement of certain sales milestones per indication in each of six indications.  In addition, Exicure will receive low double-digit royalties on annual net sales for SNA therapeutics developed. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Other Inflammatory Diseases</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that one of the key strengths of our proprietary SNAs is that they have the potential to enter a number of different cells and organs. As a consequence, we are also conducting early stage research activities in  ophthalmology, pulmonology, and gastroenterology.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe promising therapeutic targets for SNAs include antibody targets with confirmed therapeutic benefit. We envision inhibiting these targets with local application of SNAs in a variety of therapeutic areas. We believe that this approach combines the benefits of specifically inhibiting validated targets without the potential safety issues associated with systemic therapy. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Genetic disorders</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are investigating the utility of our SNA technology for the treatment of neurological conditions.  In June 2018, the Company and researchers from The Ohio State University Wexner Medical Center presented a poster at the Cure SMA Annual Conference titled: &#8220;Nusinersen in spherical nucleic acid (SNA) format improves efficacy both&#160;in vitro&#160;in SMA patient fibroblasts and in&#160;&#916;7 SMA mice and reduces toxicity in mice.&#8221; It was observed in a preclinical study that nusinersen in SNA format prolonged survival by four-fold (maximal survival of 115 days compared to 28 days for nusinersen-treated mice) as well as doubled the levels of healthy full-length SMN2 mRNA and protein in SMA patient fibroblasts when compared to nusinersen.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Subsequently, in the fall of 2018, we completed a biodistribution study in rats comparing nusinersen to nusinersen in SNA format. We found that more nusinersen in SNA format was retained in the rats&#8217; brain and spinal cord compared to nusinersen retained in the rats&#8217; brain and spinal cord at 24, 72 and 168 hours.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are now formulating our strategy for developing a pipeline of SNA therapeutics targeting neurological diseases.  Preclinical research is underway in a number of indications including, spinal muscular atrophy, Huntington&#8217;s Disease, spinocerebellar ataxia type 3 (SCA3), SCA2, SCA1, Friedreich&#8217;s Ataxia, and Batten disease.  We believe this preclinical research may lead to a therapeutic candidate for one of the above neurological indications. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">AST-005</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">AST-005 is&#160;an SNA targeting TNF for the treatment of mild to moderate psoriasis. AST-005 is intended to be administered locally in a gel to psoriatic lesions. In a completed Phase 1 clinical trial,&#160;AST-005,&#160;when topically administered to the skin of patients with mild to moderate psoriasis, resulted in no drug associated adverse events, and demonstrated a reduction of TNF mRNA. The TNF mRNA reduction elicited by the highest strength of&#160;AST-005&#160;gel was statistically significant when compared to the effects of the vehicle.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December&#160;2, 2016, we entered into a research collaboration, option and license agreement with Purdue Pharma L.P., referred to as the Purdue Collaboration. As part of our collaboration with Purdue, a Phase 1b clinical trial was conducted in Germany to evaluate the effect of AST-005 gel in patients with chronic plaque psoriasis. The trial demonstrated that AST-005 is safe and tolerable in patients at higher doses than were previously studied, however, the study did not result in a statistically significant decrease in echo lucent band thickness, one of the key indicators of efficacy in patients with psoriasis. In April 2018, Purdue notified the Company it had declined to exercise its option to develop AST-005 at that time, but that it also intended to retain rights relating to the TNF target, and Purdue reserved its right to continue joint development, with Exicure, of new anti-TNF drug candidates and to retain its exclusivity and other rights to AST-005.   Purdue has not indicated that it has any plans to pursue AST-005 at this time and there no active therapeutic candidates in development. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Intellectual property</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that we have a strong intellectual property, or IP, position in the field of SNA therapeutics. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December 31, 2018, our patent portfolio consists of over 60 issued patents and allowed patent applications and over 135 pending patent applications.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;We have licensed IP from Northwestern University and have also independently filed patents to protect our IP. Our license from Northwestern University is for exclusive worldwide rights to the use </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">of SNA technology for therapeutic applications. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any patents arising from&#160;AST-005,&#160;XCUR17 or AST-008 applications would expire by 2035, 2037, and 2034 or 2035, respectively.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div><a name="s7A6376FC3C1D51E68E8885E7DB8BD866"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Our Strategy </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We intend to build a leading nucleic acid therapeutics company based on our proprietary SNA technology. The key elements of our strategy are: </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Advance AST-008 through clinical development for immuno-oncology applications.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;We have conducted preclinical studies of AST-008 in immuno-oncology applications including bladder, breast and colorectal cancer, lymphoma and melanoma. We believe AST-008 is applicable in two cancer treatment strategies: as a monotherapy or in combination with checkpoint inhibitors. We began our Phase 1 clinical trial for&#160;AST-008&#160;in the United Kingdom in the fourth quarter of 2017. This trial was completed in the third quarter of 2018. During the fourth quarter of 2018 the FDA opened the IND for AST-008 and informed the&#160;Company&#160;that our proposed Phase1b/2 trial may proceed.  We have now opened four clinical sites and are recruiting patients. We believe AST-008 may be an attractive partnership candidate and we continue to explore that possibility. We may seek to develop AST-008 through other clinical trial pathways, including investigator-initiated trials.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Continue research and development in neurological applications. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2018, it was observed in a preclinical study that nusinersen in SNA format prolonged survival by four-fold as well as doubled the levels of healthy full-length SMN2 mRNA and protein in SMA patient fibroblasts when compared to nusinersen.&#160;Subsequently, in the fall of 2018, we completed a bio-distribution study comparing nusinersen to nusinersen in SNA format in rats.  The concentration of nusinersen in the kidneys was significantly increased in comparison to nusinersen in SNA format while more nusinersen in SNA format was retained in the CNS (brain and spinal cord) compared to nusinersen at 24, 72 and 168 hours. We are now formulating our strategy for developing a pipeline of SNA therapeutics targeting neurological diseases.  Preclinical research is underway in a number of indications including, spinal muscular atrophy, Huntington&#8217;s Disease, spinocerebellar ataxia type 3 (SCA3), SCA2, SCA1, Friedreich&#8217;s Ataxia, and Batten disease.  We believe this preclinical research may lead to a therapeutic candidate for one of the above neurological indications. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Advance SNA platform in dermatological indications. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the fourth quarter of 2018 we reported results from the Phase 1 trial of XCUR17, an SNA for the treatment of mild to moderate psoriasis.  Of the twenty-one patients, eleven treated with the highest strength XCUR17 gel were observed to have a reduction in redness and improvement in healing as determined by blinded physician assessments. Informed by these results, on February 17, 2019, we entered into a License and Development Agreement with Dermelix.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the terms of agreement, Dermelix</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">licensed worldwide rights to research, develop, and commercialize Exicure&#8217;s technology for the treatment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Netherton Syndrome</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and up to five additional rare skin indications. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Use our proprietary SNA technology to develop additional therapeutic candidates.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;We have demonstrated in preclinical studies that in certain application, SNAs exhibit superior biodistribution properties compared to linear oligonucleotides being both more persistent and more stable in the tissue or organ of interest. As a consequence, SNAs may have potential applications in a variety of additional organs including the central nervous system, eye, gastrointestinal tract and lungs. We believe that we have the opportunity to take known oligonucleotides of clinical utility and enhance their therapeutic potential by incorporating them in our SNA platform. In addition, we may be able to develop novel therapeutic candidates targeting validated therapeutic targets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Enter into additional partnerships to accelerate development and commercialization of our SNA therapeutic candidates.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe our</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;proprietary SNA technology lends itself to license agreements or development partnerships with pharmaceutical companies that have development or commercial expertise in a particular therapeutic area of interest where it would be uneconomical or impractical for us to develop SNA therapeutics independently. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Build, enhance and protect our proprietary SNA intellectual property. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe the three-dimensional structure of our SNAs provides novel technological and commercial opportunities. We have licensed IP from Northwestern University and have also filed patents independently to protect our IP. Our license from Northwestern University is for exclusive worldwide rights to the use of SNA technology for therapeutic </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:24px;padding-bottom:12px;text-align:left;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">applications. We will continue to protect our IP and innovations arising from our research and development efforts, and prudently in-license technologies where appropriate for protection of our therapeutic pipeline and the broader SNA technology.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any patents arising from&#160;AST-005,&#160;XCUR17 or AST-008 applications would expire by 2035, 2037, and 2034 or 2035, respectively.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div><a name="sB64941C8670D57849274CDE6DA986091"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Introduction to Nucleic Acid Therapeutics </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Overview of nucleic acids as a therapeutic modality </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Historically, therapeutic development has been focused on small molecules and biologics, or protein-based therapeutics, including antibodies. Development of small molecule therapeutics often involves screening thousands of compounds, sometimes without a known protein structure or active site to which the small molecule can bind and affect its disease-related function. Protein-based therapeutics are also subject to limitations. For example, the choice of targets that antibodies can address is typically limited to extracellular protein targets. However, the majority of protein targets are located inside the cell, making them undruggable by antibodies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Nucleic acid therapeutics represent a treatment approach differing in many important ways from small molecules and biologics.  Nucleic acid therapeutics are based on the well-established scientific understanding that DNA in the nucleus of cells is converted into an intermediate molecule, called messenger RNA, or mRNA, that serves as the template for making proteins. Therapeutic gene regulation is the use of nucleic acid therapeutics to modulate the production of target proteins by changing the amount of mRNA that is converted to protein, thereby providing an approach to treating diseases at their genetic origin. Our SNAs are a type of nucleic acid therapeutic. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe the development timeline for nucleic acid therapeutic candidates will be shorter than that of small molecules and antibodies. Nucleic acid therapeutics can be directed against most mRNA, including the mRNA of proteins that cannot be targeted by small molecules or antibodies. Due to the detailed knowledge of mRNA sequences in humans, nucleic acid therapeutics can be engineered to be specific to a region of an mRNA sequence while interacting minimally with all other mRNA sequences. Moreover, due to the well-defined length and composition of mRNA sequences, a relatively small set of rationally designed therapeutic candidates, usually hundreds, can be synthesized and tested for activity against an mRNA target. This is in contrast to the small molecule drug development process that requires a much larger number of candidates to be screened. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Challenges in developing nucleic acid therapeutics </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Significant progress has been made in the development of nucleic acid therapeutics. However, we believe there are ongoing technical challenges in the nucleic acid therapeutics field. Nucleic acids are molecules that, when administered without proper formulation, encounter a number of barriers to their bioavailability, biodistribution, and desired biological activity. These challenges have often been met by chemically modifying the oligonucleotide and by encapsulating or complexing it with a lipid or polymer carrier. Despite these advances in the delivery of oligonucleotides, the biodistribution of these molecules remains a challenge since oligonucleotides typically accumulate in the liver after subcutaneous or intravenous administration, thereby limiting their primary application to diseases of the liver. In an array of experiments, we have demonstrated that SNAs, administered locally without encapsulation or complexation, enter cells and organs. We believe the local administration of our gene regulatory SNAs will potentially enable safe and efficacious therapeutic applications to organs beyond the liver. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="s260A1A2F7E8054518D8BA8E6B378BEDF"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Our Proprietary Technology: Spherical Nucleic Acids </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our therapeutic discovery and development efforts rely on our proprietary SNA technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid molecules that are radially arranged in three dimensions. We refer to these synthetic nucleic acid molecules in our SNAs as oligonucleotides and the radial orientation of the oligonucleotides without lipid or polymer encapsulation as our &#8220;inside out&#8221; or &#8220;3-D&#8221; approach. Our SNAs, unlike many other nucleic acid therapeutics, do not require lipid or polymer encapsulation or complexation in order to be delivered. Encapsulation is the process of confining the nucleic acids inside the cavities </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">of larger structures, typically liposomes, whereas complexation is the process of creating an assembly of nucleic acids bound together with other molecules, typically lipids or polymers. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This arrangement of oligonucleotides allows our proprietary SNAs to enter cells through class A scavenger receptors. Class&#160;A scavenger receptors are commonly found on the surface of cells throughout the body, which we believe provides a ubiquitous mechanism of cellular entry for the local administration of our SNA therapeutic candidates. This mechanism of cellular entry is different from many other nucleic acid therapeutics that typically bind to receptors found only in the liver. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The broad tissue penetration and biodistribution properties of SNAs potentially enable three distinct therapeutic approaches. SNAs may be designed to reduce target protein levels by reducing corresponding mRNA levels in cytoplasm. SNAs may also be designed to modulate splicing of pre-mRNA in the nucleus to enhance or alter the product of a target protein and mitigate a genetic defect. Finally, SNAs may be designed to potentially elicit an anti-tumor immune response by agonizing toll like receptors in the endosomes.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Examples of our proprietary SNA constructs </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;"><img src="twosnasa04.jpg" alt="twosnasa04.jpg" style="height:261px;width:624px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">All of our SNAs contain oligonucleotides that are densely packed and radially oriented. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe the key advantages of our proprietary SNAs include:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">SNAs cross certain biological barriers to deliver nucleic acid therapeutics</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Local delivery of nucleic acid therapeutics through biological barriers, such as the skin, has been a significant technical challenge. In a Phase 1 clinical trial of XCUR17 in patients with mild to moderate psoriasis, eleven of the twenty-one patients treated with the highest strength XCUR17 gel were observed to have a reduction in redness and improvement in healing as determined by blinded physician assessments. Further, in preclinical studies, we have demonstrated delivery and activity of our SNAs in the central nervous system, eye, lung, and gastrointestinal tract.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">SNAs potentially exhibit superior biodistribution properties compared to linear oligonucleotides.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;In the fall of 2018, we completed a biodistribution study in rats comparing nusinersen to nusinersen in SNA format. We found that more nusinersen in SNA format was retained in the rats&#8217; brain and spinal cord compared to nusinersen retained in the rats&#8217; brain and spinal cord at 24, 72 and 168 hours. We believe that we have the opportunity to take known oligonucleotides of clinical utility and enhance their therapeutic potential by incorporating them in our SNA platform. In addition, we may be able to develop novel therapeutic candidates.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">SNAs are potentially well-tolerated.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;In each of the Phase 1 clinical trials of AST-005 and XCUR17, we observed no drug associated adverse events when the SNA therapeutic candidate was applied topically to the skin of patients with mild to moderate psoriasis.  No serious adverse events were observed in our Phase 1 trial </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:24px;padding-bottom:12px;text-align:left;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">after injecting AST-008 subcutaneously into healthy volunteers. There are three key elements to our safety strategy. First, by administering SNAs locally, we expect to minimize systemic exposure thereby decreasing safety risk. Second, because SNAs enter cells and tissues without lipid or polymer encapsulation or complexation, we expect to avoid the toxicity risks associated with these delivery systems. Finally, due to the nuclease resistance attributable to the architecture of the SNA, we use fewer chemical modifications than are customary in nucleic acid therapeutic development.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">SNAs can be administered locally into a number of different cell and tissue types. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">SNAs enter cells through class A scavenger receptors, which are present on the surface of many cell types. We believe that by accessing this mechanism, our SNAs could have therapeutic applications in organs beyond the liver, such as the brain, eye, gastrointestinal tract, lung, and skin. In preclinical studies, more than 50 cell lines and primary cells have been shown to internalize SNAs. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Immuno-oncology SNAs may produce a powerful immune response against tumors.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;In its Phase 1 trial, AST-008 was shown to elicit high levels of certain cytokines as well as activate important effector cells of the immune system, including T cells and natural killer cells which are the main drivers of an anti-tumor response. In preclinical studies, SNAs localized to endosomes and stimulated the immune system via TLRs. We have also observed in preclinical studies that SNAs can generate a cancer-specific adaptive immune response. In addition, in preclinical studies in a variety of cancer models, SNAs, in combination with certain checkpoint inhibitors, exhibited a greater anti-tumor response and increased survival than did such checkpoint inhibitors alone. Moreover, when administered as a monotherapy, AST-008 exhibited anti-tumor activity in mouse cancer models.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">SNAs have shown greater resistance to nuclease degradation.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Nucleases are proteins that degrade oligonucleotides. In preclinical studies, SNAs have been shown to have an increased nuclease resistance compared to linear oligonucleotides. We believe this is a result of our 3-D approach, and as a consequence, we believe that smaller amounts of SNAs may be required to achieve therapeutic efficacy compared to linear oligonucleotides.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">SNAs can be manufactured at commercial scale. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Based on our manufacturing work to date, we believe</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">SNAs can be made in a low cost, high-throughput, scalable, and reproducible manner using cGMPs. </font></div></td></tr></table><div><a name="s369E75058C815F6BA77D833B2CBEA7B8"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Our Clinical Development Programs </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our clinical development programs include the development of one SNA therapeutic candidate to address unmet medical needs in the treatment of solid tumors and one SNA therapeutic candidate to address unmet medical needs in the treatment of mild to moderate psoriasis. We are also conducting early stage research activities in neurology, ophthalmology, respiratory and gastrointestinal applications. These early stage research activities are described in more detail in the sections entitled &#8220;&#8212;Preclinical research programs.&#8221;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The table below sets forth the stage of development of our SNA therapeutic candidates as of March 5, 2019:</font><img src="a201810kdevelopmentpipeline.jpg" alt="a201810kdevelopmentpipeline.jpg" style="height:149px;width:624px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">TLR9 = Toll-like Receptor 9; IL17RA = Interleukin 17 Receptor Alpha</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Regulatory documents are prepared and submitted to the appropriate health authority to enable clinical trials in any given jurisdiction. In the United States, this document is called an IND application, while in other jurisdictions, </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">this document is often called an IMPD, which is submitted as part of a CTA. The content and scope of an IND and a CTA are similar.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SNAs for immuno-oncology </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Overview of immuno-oncology as a therapeutic modality </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In healthy individuals, the immune system fights off pathogens, such as bacteria and viruses. The immune system should also recognize cancer cells as foreign and eliminate them. However, cancers present a challenge because they have developed strategies to resist detection and clearance by the immune system. Immuno-oncology approaches help the patient&#8217;s immune system identify a cancer as foreign and stimulate a tumor-clearing immune response. One of the greatest benefits of the immuno-oncology approach is the continuous, durable anti-tumor response that can be achieved long after discontinuation of treatment. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Current immuno-oncology therapeutic approaches generally fall into three broad categories. First, there are approaches that stimulate the immune system to detect and eliminate tumors. Examples include cytokines and toll-like receptor, or TLR, agonists. Second, some therapeutics make a cancer more readily visible to the immune system. These therapeutics include checkpoint inhibitors, such as those that target CTLA4, or cytotoxic T-lymphocyte-associated protein 4, PD-1, and PD-L1, or programmed death-ligand 1. Third, there are adoptive cell transfer therapies, including dendritic cell vaccines and chimeric antigen receptor T-cells, or CAR-Ts, that direct the immune system to target a specific type of cancer. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The knowledge of the TLR activation pathway is central to the understanding of how the immune system is stimulated to target cancer. TLRs are membrane- and endosome-bound receptors found on a number of cell types, including specialized immune cells. TLRs recognize specific molecular patterns ordinarily presented by pathogens. When cells recognize pathogens, they produce and release protein signals called cytokines that mobilize the immune system to fight invading pathogens. In addition, they activate antigen presenting cell and helper T-cells, which then coordinate the longer-term pathogen specific adaptive immune response, and as a result, confer long-term immunity to the host.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Checkpoint proteins, such as CTLA4 and PD-1, are expressed on the surface of T-cells and inhibit the function of activated T-cells. Cancers are difficult to treat because they have developed mechanisms to take advantage of these checkpoint proteins thereby evading detection and clearance by the immune system. Inhibiting these checkpoint proteins, especially PD-1 and PD-L1, has proven to be a highly effective anti-cancer therapy in some patients. Nevertheless, checkpoint inhibitors targeting the PD-1 pathway have limited clinical efficacy as monotherapy, with response rates of 20% or less in many common types of cancers, including breast and colon cancers. Emerging evidence suggests that checkpoint inhibitors are effective primarily in patients whose tumors already have pre-existent CD8 T-cell infiltrate, i.e. immune system is already capable of recognizing the tumors. We believe the challenge in the field is to increase the efficacy of checkpoint inhibitors in a broader cancer patient population by converting tumors that are non-T-cell inflamed to T-cell inflamed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">AST-008</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">an SNA for immuno-oncology</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">AST-008, an SNA consisting of a TLR9 agonist, is being developed for the treatment of cancer. We believe AST-008 may be used for immuno-oncology applications as a monotherapy or in combination with checkpoint inhibitors. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Preclinical data suggest AST-008 delivered in combination with certain checkpoint inhibitors generate a greater anti-tumor activity than such checkpoint inhibitors alone. In mouse tumor models, administration of AST-008 with anti-PD-1 antibodies suppresses regulatory T-cells, or Tregs, and myeloid-derived suppressor cells, or MDSCs, and increases the levels of CD8 effector T-cells. We believe these important results suggest that the combination of immuno-oncology SNAs and checkpoint inhibitors could potentially treat a larger proportion of cancer patients than checkpoint inhibitors alone.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Phase 1b/2 clinical development of AST-008</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the fourth quarter of 2018 the FDA opened the IND for AST-008 and informed the&#160;Company&#160;that our </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">proposed Phase1b/2 trial may proceed.  Early in 2019, we opened four clinical sites and began dosing and recruiting patients in that trial.  This is a Phase 1b/2, open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral&#160;AST-008&#160;injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors.  Conditions under study are planned to include advanced or metastatic: Merkel cell carcinoma, head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma and melanoma.  The primary outcome measure is the safety and tolerability of&#160;AST-008&#160;alone and in combination with pembrolizumab.  Secondary outcomes include the recommended Phase 2 dose and disease assessment with RECIST 1.1.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Phase 1 clinical development of AST-008 </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Phase 1 clinical trial was a first-in-human clinical trial of AST-008 evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AST-008 in healthy volunteers. The trial was a randomized, single ascending dose, or SAD, trial. Sixteen healthy subjects were recruited and organized into four SAD cohorts. We began&#160;subject dosing in the fourth quarter of 2017 and announced our initial analyses of the results of the trial on September 20, 2018.    </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Based on our initial analyses of the Phase 1 clinical trial results, AST-008 was shown to be safe and tolerable in all subjects, with no serious adverse events and no dose limiting toxicity.  AST-008 was well tolerated and all AST-008-related adverse events were of short duration, reversible and consistent with TLR9 activation.  Such adverse events included flu-like symptoms, injections site reactions, and non-clinically significant lymphopenia and neutropenia.   </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to the principal safety and tolerability endpoint, the trial screened for levels of select cytokines and markers of immune cell activation. AST-008 was shown to elicit high levels of certain cytokines as well as activate important effector cells of the immune system including T cells and natural killer cells. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For the four subjects receiving the trial&#8217;s top dose of about 20 &#181;g/kg of AST-008, initial analyses suggest that the average fold-increase above baseline for these cytokines is approximately as follows:  IFN-gamma: 3 fold; IL-6: 57 fold; IL-12: 2 fold; IP-10: 32 fold; and MCP-1: 4 fold.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that such cytokine induction has clinical importance because these cytokines play an important role in immune system activity.  IL-12, is an important T cell-stimulating factor,&#160;involved in the differentiation of naive&#160;T cells&#160;into&#160;Th1 cells. IP-10, also known as CXCL10, acts as a chemo-attractant for macrophages, T cells,&#160;NK cells, and&#160;dendritic cells and in antitumor activity. IL-6 is a key player in the activation, proliferation and survival of lymphocytes during active immune responses and supports shifting the immune system from a suppressive to a responsive state that can effectively act against tumors. MCP-1, or CCL2, is a small cytokine which helps recruiting&#160;monocytes,&#160;memory T cells, and&#160;dendritic cells.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to the cytokine response, AST-008 was shown to activate important effector cells of the immune system, including natural killer cells or NK cells which are cytotoxic lymphocytes critical to the innate immune system, and T cells which are key effector cells of the adaptive immune system. At the trial&#8217;s top dose of about 20 &#181;g/kg, AST-008 elicited 9.5 fold and 3.5 fold increases in the fraction of activated T cells and natural killer cells, respectively, compared to baseline.  NK cells continually scan the body for abnormal cells to attack. T cells form the basis of a targeted and durable immune response and immunological memory. We believe that activation by AST-008 of the key effectors cells of both the innate and adaptive immune system makes AST-008 suitable for combination with checkpoint inhibitors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Historical TLR9 Agonist Healthy Volunteer Data</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2015, Mologen AG published results (European Journal of Cancer, 2015, volume 51, supplement 1, page S12) from a healthy volunteer trial. In a single cohort, 13 subjects each received one 60 mg dose (equivalent to 923 &#181;g/kg for a 65 kg subject) of lefitolimod subcutaneously. On average, across the cohort, there was a 7 fold-increase in IP-10 expression above baseline. No cell activation data were reported. Lefitolimod is currently in a Phase 3 clinical trial.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2004, Coley Pharmaceutical Group (now Pfizer, Inc.) published results (Journal of Immunotherapy, 2004, Volume 27, pages 460-471) from a single ascending dose healthy volunteer trial. In that trial, their TLR9 agonist, PF-03512676, was administered subcutaneously to six subjects per dose level. For the 20 &#181;g/kg dose level, the average fold-increase above baseline for these cytokines is as follows: IFN-gamma: no change from baseline; IL-6: 8 fold; IL-12: no change from baseline; IP-10: 9 fold; and MCP-1: 3 fold.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Preclinical data for AST-008</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have observed that administration of AST-008 as a monotherapy can have anti-tumor activity in colon cancer, breast cancer, lymphoma and melanoma mouse models. We have also observed that, in preclinical studies in a variety of tumor models, AST-008 applied in combination with certain checkpoint inhibitors exhibited anti-tumor responses and survival rates that were greater than those demonstrated by checkpoint inhibitors alone. Importantly, in an anti-PD-1 antibody-resistant breast cancer mouse model, administration of AST-008 with certain anti-PD-1, or programmed death 1, antibodies restored the anti-tumor activity of these antibodies. We have also demonstrated that AST-008 is active when administered subcutaneously, intratumorally or intravenously, in both prevention and established mouse tumor models. The administration of AST-008 also produced localized as well as abscopal anti-tumor activity in mouse cancer models. Additionally, administration of AST-008 in combination with certain checkpoint inhibitors confers adaptive immunity in breast and colon cancer mouse models.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our preclinical data with AST-008 illustrate many of the important attributes of our proprietary SNA technology. Our immuno-oncology SNAs bind to class A scavenger receptors and are localized on the endosomes of immune cells. These same endosomes contain TLRs and are responsible for inducing an innate immune response. SNAs present their TLR agonists externally, in a 3-D configuration, which allows SNAs to bind to TLRs efficiently. We have designed and prepared SNAs which activate multiple classes of TLRs. Our preclinical data show that SNAs induce a broad immune response. We believe that such broad immune response includes the production of cytokines that induce a potent adaptive immune response, which in turn, may confer long-term immunity. In preclinical studies, local administration of AST-008 elicits systemic pro-inflammatory cytokine response. In mouse tumor models, administration of AST-008 with anti-PD-1 antibodies suppresses regulatory T-cells, or Tregs, and myeloid-derived suppressor cells, or MDSCs, and increases the levels of CD8 effector T-cells. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">AST-008 in combination with checkpoint inhibitors </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have demonstrated that the combination of AST-008 with certain anti-PD-1 antibodies enhances therapeutic activity in a number of animal models, including breast and colorectal cancers, as well as lymphoma and melanoma. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Breast cancer mouse model.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;We have demonstrated that administration of AST-008 with a selected anti-PD-1 antibody shows a durable anti-tumor response in an anti-PD-1 antibody insensitive mouse breast cancer model. This study was carried out with four groups, each consisting of eight mice per group. The four groups were vehicle treatment, antibody treatment alone, linear oligonucleotide plus antibody treatment, and AST-008 plus antibody treatment. Both the AST-008 and the linear oligonucleotide comparator treatments consisted of subcutaneous administration on days 3, 6, 9, 12, and 15 after tumor implantation at a dose of 0.8 mg/kg per injection. In the three groups where mice received anti-PD-1 antibody therapy, drug administration was performed intraperitoneally on days 3, 8 and 13 at a dose of 10 mg/kg per injection. The mice were monitored for mortality and their tumor volumes were periodically measured. The mice treated with the combination of AST-008 and the anti-PD-1 antibody had average tumor volume reductions of greater than 90% compared to anti-PD-1 antibody treatment alone. In addition, treatment with AST-008 resulted in an 88% average decrease in tumor volume compared to mice treated with linear oligonucleotides at the same dose. At the conclusion of the initial phase of the experiment, seven out of eight mice in the group treated with the combination of AST-008 and the anti-PD-1 antibody had no palpable tumors. In contrast, no mice treated with linear oligonucleotides and the anti-PD-1 antibody survived. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the next phase of this study, we re-challenged the seven surviving mice from the combination group that was treated with AST-008 and anti-PD-1 with the same breast cancer tumor type. A new group of six mice that had never received any therapy, referred to here as na&#239;ve mice, was also inoculated with the same breast cancer tumor type for comparison. The tumor growth and survival were monitored in both groups of mice without further treatment with the AST-008 and anti-PD-1 antibody combination. No palpable tumors were observed in the surviving mice from the combination group through day 105 of the study, whereas na&#239;ve mice showed tumor growth. Finally, on day 105 of </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the study, the mice from the combination group that had survived two rounds of tumor implantation were injected with different tumor types. The mouse colon cancer tumors grew in the animals that had survived two challenges with breast cancer cells. Taken together, we believe these data demonstrate an adaptive immune response and a systemic anti-cancer vaccination against the treated tumor type. We believe these data also demonstrate that AST-008 has the potential to synergize with checkpoint inhibitors for immuno-oncology applications. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Importantly, AST-008 in combination with selected anti-PD-1 antibodies shows significantly greater activity compared to the linear oligonucleotides of the same sequence and concentration. We believe this demonstrates the potential advantage of our proprietary SNA design compared to linear oligonucleotides for effecting a tumor clearing response. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">AST-008 in combination with a certain anti-PD-1 antibody in breast cancer mouse model resistant to anti-PD-1 treatment. Surviving mice from the experiment treated with anti-PD-1 and AST-008 survived when re-injected with the same EMT6 breast cancer cells, but did not survive when injected with unrelated CT-26 or 4T1 cancer cells. * p &lt; 0.0001 versus vehicle treated group. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;"><img src="ast008breastcancer.jpg" alt="ast008breastcancer.jpg" style="height:307px;width:624px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SNAs for inflammatory diseases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Overview of gene regulation utilizing oligonucleotides</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Gene regulation is the process of modulating target protein levels within cells. This could be a powerful approach for developing targeted therapies for diseases with known genetic origins. This approach may be for therapeutic targets that are identified as &#8220;undruggable&#8221; with small molecules or antibodies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Gene regulation can be achieved with a number of approaches, three of which, siRNA-, miRNA-, and antisense-based therapeutics, have been the focus of commercial development. Small interfering RNAs, or siRNAs, are double-stranded RNA-like oligonucleotides that harness RNA interference, or RNAi, a potent and natural biological mechanism. When delivered into cells, siRNAs can lead to target mRNA degradation and a decrease in protein expression. miRNAs are naturally occurring small RNA molecules that modulate protein expression. Antisense therapeutics are short single-stranded oligonucleotides that bind to target mRNA and thus prevent its translation into protein. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">XCUR17&#8212;a topically applied anti-IL-17RA SNA </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Overview </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">XCUR17 targets the mRNA that encodes IL-17RA, a protein that is considered essential in the initiation and maintenance of psoriasis. Although the availability of inhibitors of TNF revolutionized the systemic treatment of severe psoriasis, studies of disease pathogenesis have shifted attention to the IL-17 pathway, in which IL-17RA is a key driver of psoriasis. IL-17 binding to IL-17RA on keratinocytes stimulates and perpetuates the inflammation cascade of psoriasis. IL-17RA-mediated inflammation can be inhibited by disrupting the protein&#8217;s function. Brodalumab, an anti-IL-17RA monoclonal antibody, was approved by the FDA as an effective treatment for chronic moderate to severe plaque psoriasis. Our strategy is to reduce the levels of IL-17RA in the skin by topically applying XCUR17. In preclinical studies, XCUR17 showed inhibition of IL-17RA expression in the keratinocytes of the skin.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Psoriasis market and current treatments </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">According to a 2016 Global Report on Psoriasis issued by the World Health Organization, the prevalence of psoriasis in countries ranges between 0.09% and 11.43%, making psoriasis a serious global problem with at least 100&#160;million individuals affected worldwide. According to LeadDiscovery, in 2009, over 4.5&#160;million prescriptions were written for patients with psoriasis in the U.S., with approximately 3.9&#160;million of these prescriptions written for topical therapies.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup>&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Patients suffering from severe psoriasis can benefit from antibody therapeutics, such as etanercept or adalimumab. These antibodies target TNF, a cytokine that plays a central role in the inflammation underlying psoriasis. When injected, the antibodies bind to TNF, diminishing TNF&#8217;s ability to act as an inflammatory signal. Patients with limited disease, or mild to moderate psoriasis, can be treated with topical or oral anti-inflammatory therapeutic agents. These patients are generally not treated with systemic anti-TNF antibodies due to adverse health risks. According to the American Academy of Dermatology, patients with limited skin disease should not automatically be treated with systemic treatments if they do not improve, because treatment with systemic therapy may carry more risk than the disease itself. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accordingly, topically applied agents, such as corticosteroids, are widely used to treat mild to moderate psoriasis. Unlike antibodies that target a specific pathway to treat psoriasis, topical therapies generally have a non-specific mechanism of action, which may cause skin thinning, skin irritation, and other side effects. Moreover, many of these therapies become less effective at treating the disease over time as patients become refractory to treatment. Findings from National Psoriasis Foundation surveys conducted between 2003 and 2011 indicate that 52.3% of patients with psoriasis were dissatisfied with their treatment.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup>&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe there is an unmet medical need in mild to moderate psoriasis for a locally administered therapeutic that combines the specificity of antibodies with the convenience of topical corticosteroids without the side effects of either class of therapeutics. To date, the skin has proven to be a barrier to the penetration of many potential therapies. Some approaches for delivering oligonucleotides directly into the skin require injections, which may be uncomfortable and painful. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Our approach </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The clinical success of a systemically delivered anti-IL-17RA antibody has validated that target as a clinically relevant target for psoriasis. The IL-17 pathway is important for initiating and sustaining inflammatory responses. IL-17RA stimulation in the skin causes keratinocyte and T-cell proliferation as well as immune cell infiltration, which results in the formation of psoriatic lesions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are developing XCUR17, an SNA containing IL-17RA antisense oligonucleotides, for the treatment of mild to moderate psoriasis, which is often defined as psoriasis that affects less than 10% body surface area and is generally not treated with systemic antibody therapy. XCUR17 is intended to be applied locally as a topically applied gel to psoriatic lesions. We expect XCUR17 to enter into cells of the epidermis, especially keratinocytes, and modulate the production of IL-17RA. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Phase 1 clinical development for XCUR17 </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We filed a CTA for a Phase 1 clinical trial of XCUR17 in patients with psoriasis in Germany in the third quarter of 2017. Our CTA was approved in February 2018 and we began dosing patients in our Phase 1 clinical trial in April 2018. The Phase 1 clinical trial, which had final patient visits in the fourth quarter of 2018, was a randomized, double-blinded, placebo-controlled trial in twenty-one patients with mild to moderate chronic plaque psoriasis designed to assess the safety of XCUR17 formulated as a topical gel, and to evaluate early signs of efficacy. All patients received three strengths of XCUR17 gel, a vehicle gel, and a positive comparator (Daivonex&#174; cream), which were all applied on different areas of psoriatic skin within each individual patient.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The clinical trial design allows for intra-patient comparisons of XCUR17 to a placebo and a currently approved therapeutic. A mask containing 5 holes is placed on the patient&#8217;s skin, enabling the application of three different strengths of a gel containing XCUR17 as well as a placebo and a currently approved therapeutic within one psoriatic lesion. The drug is applied daily for 26 days in up to 25 patients. Over the course of the clinical trial, the safety and tolerability of XCUR17 is monitored. In addition, the severity of psoriasis in the treated areas is assessed. At the end of the clinical trial, biopsy samples from XCUR17- and vehicle-treated areas will be taken and interrogated for IL-17RA and downstream mRNA modulation to demonstrate that XCUR17 engages the target of interest and has an effect on inflammation in the skin. We believe our clinical trial design is consistent with the clinical trial design for other topically applied therapeutic candidates that have been accepted by the FDA and EMA. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the fourth quarter of 2018 we reported results from the Phase 1 trial of XCUR17.  In the case of XCUR17, of the twenty-one treated patients, eleven treated with the highest strength XCUR17 gel were observed to have a reduction in redness and improvement in healing as determined by blinded physician assessments. Further, the highest strength XCUR17 gel showed a statistically significant improvement in psoriasis symptoms versus the vehicle gel. By comparison, seventeen of the twenty-one patients treated with the positive comparator showed a clinical response, while four patients treated with the placebo vehicle had a clinical response.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Preclinical development of XCUR17 </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have gathered experimental evidence of the biological activity of XCUR17 in healthy human skin samples prior to undertaking a Phase 1 clinical trial. As a consequence, we believe we have a deeper understanding of how XCUR17 will perform during clinical trials than would be ordinarily possible with traditional therapeutic development. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">XCUR17 exhibits cellular uptake and skin penetration properties. Specifically, XCUR17 enters into keratinocytes </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">in&#160;vitro</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and enters into healthy human skin </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">ex vivo</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;after topical application. In addition, it also down-regulates the expression of IL-17RA mRNA and protein in keratinocytes </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">in vitro</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Further, XCUR17 gel down-regulates IL-17RA mRNA in healthy human skin </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">ex vivo</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Topical application of XCUR17 in a prototype gel to healthy human skin ex vivo results in a dose-dependent decrease in IL-17RA mRNA expression. * p &lt; 0.05; *** p&lt; 0.001 vs the controls </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;"><img src="xcur17preclinicalresults.jpg" alt="xcur17preclinicalresults.jpg" style="height:325px;width:398px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">AST-005</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8212;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">topically applied SNAs for psoriasis</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Overview </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">AST-005 is an SNA containing TNF antisense oligonucleotides and is intended to be applied in a gel to psoriatic lesions.  We conducted a Phase 1 clinical trial to assess the safety, antipsoriatic efficacy and pharmacodynamic effect of AST-005 in 15 mild to moderate psoriasis patients in Germany. The primary endpoint of the clinical trial was the change in psoriatic infiltrate thickness compared to the start of the study, which is a method of measuring antipsoriatic effects. Secondary endpoints included evaluation of antipsoriatic efficacy by a clinical score, safety and tolerability assessments, and target mRNA reduction. The results of the clinical trial showed no adverse events related to treatment with AST-005. In addition, AST-005 application reduced the expression of TNF mRNA in a dose dependent manner in the psoriatic skin of the patients. The TNF mRNA reduction elicited by the highest strength of AST-005 gel was statistically significant when compared to the effects of the vehicle. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December&#160;2, 2016, we entered into the Purdue Collaboration for further development of AST-005 in mild to moderate psoriasis and in other indications. As part of our collaboration with Purdue, a Phase 1b clinical trial was conducted in Germany to evaluate the effect of AST-005 gel in patients with chronic plaque psoriasis. The trial evaluated the safety, tolerability, and plaque thickness following topical application of different strengths of AST-005 formulated as a topical gel. The trial demonstrated that AST-005 is safe and tolerable in patients at higher doses than were previously studied, however, the study did not result in a statistically significant decrease in echo lucent band thickness, one of the key indicators of efficacy in patients with psoriasis. In April 2018, Purdue notified the Company it had declined to exercise its option to develop AST-005 at that time, but that it also intended to retain rights relating to the TNF target, and Purdue reserved its right to continue joint development, with Exicure, of new anti-TNF drug candidates and to retain its exclusivity and other rights to AST-005.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Preclinical research programs </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to our named pipeline programs, a variety of early stage research efforts are ongoing in areas we believe will best leverage the properties of the SNA. Potential applications of the SNA include those in neurology, ophthalmology, pulmonology, and the gastroenterology. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Neurology </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Despite delivery challenges, nucleic-acid based therapy has been successfully developed to treat a central nervous system, or CNS, disorder. Nusinersen, by Ionis Pharmaceuticals and Biogen Inc., was approved in late 2016 for the treatment of spinal muscular atrophy, or SMA by the FDA. SMA is a genetic disorder characterized by progressive muscle wasting and loss of muscle function due to motor neuron dysfunction. SMA is characterized by reduced amount of survival of motor neuron 1, or SMN1, protein. The severity of the disease depends on the amount of a related protein, SMN2, where lesser quantities of SMN2 are correlated to more severe disease. SMN2 is similar to SMN1, but leads to production of truncated protein, which is normally rapidly degraded. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Nusinersen is an antisense oligonucleotide designed to modulate splicing of SMN2 pre-mRNA in the nucleus to generate an alternative version of SMN2 mRNA that leads to production of a functional SMN protein. Nusinersen is designed to enhance the production of the full-length, more stable variant of SMN2, increasing the level of SMN2 protein, and thus improving motor function. In clinical trials, SMA patients treated with nusinersen achieved and sustained meaningful improvement in motor function and survival compared to untreated patients.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To evaluate the potential superiority of the SNA over linear oligonucleotides in directing the production of a more stable variant of the SMN2 protein, we compared the effects of nusinersen in linear format with nusinersen in SNA format in cells derived from SMA patients. The data showed that treatment with SNA format of nusinersen results in greater levels of the more stable variant of SMN2 mRNA compared with linear format. SNA format of nusinersen resulted in up to 45-fold increase in the more stable SMN2 mRNA variant versus controls, while a much smaller 2.5-fold increase was observed using nusinersen in the linear format. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We collaborated with The&#160;Ohio State University Wexner Medical Center&#160;to further study the pharmacology of our nusinersen SNA in mouse models. We tested nusinersen SNA in &#916;7 SMA mouse model in which the untreated SMA-bearing mice have mean survival of approximately 15 days. New born &#916;7 SMA mice were treated with a single dose of nusinersen SNA or nusinersen at 10, 20 or 30 &#956;g by via intracerebroventricular injection on day 0. Following administration of compounds, mouse survival and body weights were recorded.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Nusinersen in SNA format prolonged survival compared to linear nusinersen in &#916;7 SMA mice. The 20 &#956;g treatment group is shown below.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;"><img src="smainvivogreyscale.jpg" alt="smainvivogreyscale.jpg" style="height:262px;width:436px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2018, the Company and researchers from The Ohio State University Wexner Medical Center presented a poster at the Cure SMA Annual Conference titled: &#8220;Nusinersen in spherical nucleic acid (SNA) format improves efficacy both&#160;in vitro&#160;in SMA patient fibroblasts and in &#916;7 SMA mice and reduces toxicity in mice.&#8221; It was observed in a preclinical study that nusinersen in SNA format prolonged survival by four-fold (maximal survival of 115 days compared to 28 days for nusinersen-treated mice) as well as doubled the levels of healthy full-length SMN2 mRNA </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and protein in SMA patient fibroblasts when compared to nusinersen. Based on the results of this preclinical study, we intend to further pursue our early stage research activities in neurological applications.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Subsequently, in the fall of 2018, we completed a biodistribution study in rats comparing nusinersen to nusinersen in SNA format. We found that more nusinersen in SNA format was retained in the rats&#8217; brain and spinal cord compared to nusinersen retained in the rats&#8217; brain and spinal cord at 24, 72 and 168 hours.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are now formulating our strategy for developing a pipeline of SNA therapeutics targeting neurological diseases.  Preclinical research is underway in a number of indications including, spinal muscular atrophy, Huntington&#8217;s Disease, spinocerebellar ataxia type 3 (SCA3), SCA2, SCA1, Friedreich&#8217;s Ataxia, and Batten disease.  We believe this preclinical research may lead to a therapeutic candidate for one of the above neurological indications. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Gastroenterology </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A variety of gastrointestinal disorders, including ulcerative colitis and Crohn&#8217;s disease, collectively referred to as irritable bowel disease, or IBD, are inadequately treated with existing therapies such as immunosuppressive steroids and anti-TNF antibodies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that orally applied SNAs may provide the opportunity to treat diseases such as IBD by taking advantage of the local tissue penetration of the SNA technology. Accordingly, the effect of oral SNA treatment was assessed in an induced IBD mouse model. After the induction of colitis, the mice were treated with anti-TNF SNAs on day 1, 2, 3 and 4, for a total four doses, at 200 or 1000 &#181;g/dose/mouse by oral gavage. Control mice were treated with vehicle only. The mice were monitored for mortality and scored clinically for seven days.  On day 7, the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">surviving animals were sacrificed. Gross pathology assessment was performed on the proximal colon.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Clinical scores for the mice during the course of the study were assigned by considering the body weight, stool consistency, bleeding and any abnormalities observed in fur coat and abdomen. Gross pathology scores were assigned on the last day of study from the colons removed from the animals after euthanization. Gross pathology scores ranging from 0 to 5, indicating no abnormalities and multiple ulcers, respectively, were assigned based on the severity of the inflammation and ulceration in the colon. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The results showed statistically significant improvement in clinical score and gross pathology for animals treated with 1000 &#181;g/dose of anti-TNF SNAs compared to those treated with vehicle only. Overall, the results suggest that oral administration of SNA had a positive effect on disease symptoms as reflected by lower clinical and pathology scores. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Ophthalmology </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Ophthalmic therapies, such as antibodies, peptides or aptamers, are typically injected into the eye to reach their target tissues and achieve therapeutic effects. We believe that the penetration properties of the SNA may result in the delivery of therapeutically relevant concentrations of oligonucleotides to certain tissues in the eye. We have observed in preclinical studies the delivery of SNAs into the eye either through eyedrops or intravitreal injections.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In one study, to assess penetration into the eye, Dutch belted rabbits were given either eyedrops containing no SNAs, referred to as vehicle, or an SNA in a formulation targeting an ocular gene of interest. The eyedrops were administered to the animals 18 times over the course of five days. On the fifth day, the rabbit eyes were analyzed for SNA content. The results indicate that SNAs were detected in tissues at the surface of the eye, where the application occurred, but also in the retina and vitreous humor, indicating that the SNA had penetrated into the eye.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe these results are a promising step in demonstrating that SNAs may be used to treat ophthalmic diseases. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Pulmonology </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Altering the immunological state of the lung has promising therapeutic implications for the treatment of allergic diseases, such as asthma. In a preliminary assessment, we demonstrated an alteration of the immunological state </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">both locally in the lung and systemically in mice after the inhalation of SNAs. An intranasal dose of PBS or nebulized formulation of AST-008 was administered to mice at 7.5 mg/kg to assess the pharmacodynamic effects of SNA delivery to the lungs. Four mice per group were used. At 4, 10, 16, or 24 hours following administration, serum was collected from the animals and bronchoalveolar lavage, or BAL, was performed to produce fluid from the lung surface. Finally, lung tissue was also collected from the animals. The fluids and tissue were subjected to cytokine concentration analysis. The results show that nebulized SNAs can produce a cytokine response in the lung tissue and BAL fluid, as well as systemically, as measured in the mouse serum. We believe these results have implications for the potential treatment of allergic diseases of the lung. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Dermelix License Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 17, 2019 Exicure entered into a License and Development Agreement, or the Dermelix License Agreement, with DERMELIX, LLC, d/b/a Dermelix Biotherapeutics. Under the terms of agreement, Dermelix</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">licensed worldwide rights to research, develop, and commercialize Exicure&#8217;s technology for the treatment of Netherton Syndrome and, at Dermelix&#8217;s option, up to five additional rare skin indications.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Dermelix will initially develop a targeted therapy for the treatment of Netherton Syndrome (NS). NS is a rare and severe autosomal recessive disorder caused by loss-of-function mutations in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">SPINK5 </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">gene, which encodes the serine protease inhibitor LEKT1 involved in skin barrier function. NS affects approximately 1 in 200,000 children born each year, and is characterized by severely inflamed, red, scaled, itchy skin, and patients are at increased risk of mortality in the first year of life due to recurrent infections and dehydration as a result of the impaired skin barrier. Currently, there are no approved treatments for NS patients and off-label use of standard of care treatments are of limited utility.  </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the terms of the Dermerlix License Agreement, Exicure received an upfront payment of $1 million at closing of the transaction and will receive an additional $1 million upon the exercise of each of the five options granted to Dermelix. Exicure will be responsible for conducting the early stage development for each indication up to IND enabling toxicology studies.  Dermelix will undertake subsequent development, commercial activities and financial responsibility. For each of NS as well as any additional licensed product for which Dermelix exercises one of its options, Exicure is eligible to receive potential payments totaling up to $13.5 million upon achievement of certain development and regulatory milestones and up to $152.5&#160;million upon achievement of certain sales milestones per indication in each of six indications.  In addition, Exicure will receive low double-digit royalties on annual net sales for SNA therapeutics developed. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Purdue Collaboration </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the Purdue Collaboration we entered into with Purdue on December&#160;2, 2016, Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005, an option to obtain three additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the three additional collaboration targets. In connection with the Purdue Collaboration, we received a non-refundable development fee of $10.0 million.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, we are eligible to potentially receive additional payments for certain research, regulatory and commercial sales milestones if a program under the collaboration was pursued and the milestones were successfully completed</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In April 2018, Purdue notified the Company it had declined to exercise its option to develop AST-005 at that time and there are currently no active therapeutic candidates in development under the Purdue Collaboration. There can be no assurance that any research, regulatory and commercial sales milestones or royalties will be achieved as they are subject to highly significant risks and uncertainties, many of which are outside of our control.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Purdue is entitled to terminate the Purdue Collaboration by providing the Company with advance written notice. The agreement also provides termination provisions for material breaches of contract provisions that are customary for agreements of this type.</font></div><div><a name="sE65D7F6007B35D29957892ACAAA2897B"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Our Intellectual Property </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Proprietary Protection </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our therapeutic candidates, manufacturing and process discoveries and other know-how, to operate without infringing the proprietary rights of others, and to prevent others from infringing on our proprietary rights. We have been building and continue to build our intellectual property portfolio relating to our AST-005, XCUR17 and AST-008 therapeutic candidates and our SNA technology platform. Our policy is to seek to protect our proprietary position by, among other methods, filing and licensing U.S. and certain foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also intend to rely on trade secrets, know-how, and technological innovation to develop and maintain our proprietary position. We cannot be sure that patents will be granted with respect to any of our owned or licensed pending patent applications or with respect to any patent applications filed or licensed by us in the future, nor can we be sure that any of our existing owned or licensed patents or any patents that may be granted or licensed to us in the future will be commercially useful in protecting our technology. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Patent Rights </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our patent portfolio includes pending patent applications and issued patents in the United States and in foreign countries. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December 31, 2018, our patent portfolio consists of over 60 issued patents and allowed patent applications and over 135 pending patent applications.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Our general practice is to seek patent protection in major markets worldwide, including the U.S., Canada, China, Japan, Australia, certain members of the European Union, among others. Majority of the issued patents and allowed patent applications are licensed from Northwestern University. Among the pending patent applications, we license over 45 from NU, we exclusively own 80, and we jointly own 8 with Northwestern University. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our license from Northwestern University is for royalty bearing worldwide exclusive rights to the use of SNAs for therapeutic applications. Pursuant to the license, we are allowed to manufacture, use, offer for sale, sell and import products covered by the licensed patent rights. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our AST-008 patent portfolio includes one allowed and 39 pending U.S. nonprovisional and foreign patent applications. Foreign jurisdictions where we are seeking patent protection for our AST-008 patent portfolio include Canada, China, Japan, Australia, the European Union, India, South Korea and Mexico. Each of these applications is a composition of matter and method of use type application. The claims of these applications are directed to certain nanoscale constructs, liposomal particles, and multivalent nanostructures, and their methods of use for treating cancer and other disorders. Any patents that may issue from these applications would expire by 2034 or 2035. The expiration dates do not take into consideration any potential patent term adjustment that may be applied by the U.S. Patent Office upon issuance of the patent, any terminal disclaimers that may be filed in the future or any regulatory extensions that may be obtained. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our XCUR17 patent portfolio includes 8 pending U.S. nonprovisional and foreign patent applications. The pending applications are composition of matter and method of use type applications and include claims to one or more oligonucleotides that are 18 nucleotides in length, and methods of use for treating dermal and other disorders. Any patents that may issue from this application would expire by 2037. The expiration date does not take into consideration any potential patent term adjustment that may be applied by the U.S. Patent Office upon issuance of the patent, any terminal disclaimers that may be filed in the future or any regulatory extensions that may be obtained. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our AST-005 patent portfolio includes one allowed U.S. patent application and corresponding pending applications in 7 foreign jurisdictions. The applications are composition of matter and method of use type applications and include claims to an oligonucleotide that is 18 nucleotides in length, and methods of use for treating </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">dermal and other disorders. Any patents that may issue from these applications would expire by 2035. The expiration dates do not take into consideration any potential patent term adjustment that may be applied by the U.S. Patent Office upon issuance of the patent, any terminal disclaimers that may be filed in the future or any regulatory extensions that may be obtained. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon receiving FDA approval for AST-008, XCUR17 or AST-005, we intend to list applicable patents in the FDA&#8217;s Orange Book. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Patent life determination depends on the date of filing of the application and other factors as promulgated under the patent laws. In most countries, including the United States, the patent term is generally 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable country. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Trade Secret and Other Protection </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to patented intellectual property, we also rely on trade secrets and proprietary know-how to protect our technology, especially when we do not believe that patent protection is appropriate or can be obtained. It is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships. These agreements provide that all confidential information developed or made known to these individuals during the course of the individual&#8217;s relationship with the company is to be kept confidential and is not to be disclosed to third parties except in specific circumstances. The agreements provide that all inventions conceived by an employee shall be the property of our Company. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Intellectual Property Rights </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We seek trademark protection in the United States when appropriate. We have filed for trademark protection for the following marks: LIFE HAPPENS IN 3D, LIFE IN 3D, and EXICURE. We currently have one registered trademark, EXICURE. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From time to time, we may find it necessary or prudent to obtain licenses from third party intellectual property holders. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Northwestern University License Agreements </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In September 2009, Northwestern University and AuraSense LLC, or ASLLC, one of our significant stockholders, entered into a license agreement under which Northwestern University granted ASLLC an exclusive, worldwide license under certain Northwestern University patents and patent applications to exploit products and processes in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as or accompanying therapeutics or theradiagonostics and in or for intracellular diagnostic applications and intracellular research. On December&#160;12, 2011, ASLLC assigned to us all of its worldwide rights and interests under the Northwestern University-ASLLC license in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;assigned field&#8221;). In accordance with the terms and conditions of this assignment, we assumed all liabilities and obligations of ASLLC to Northwestern University as set forth Northwestern University its license agreement in the assigned field and in August 2015 we entered into a restated license agreement with Northwestern University. In February 2016, we obtained exclusive license as to Northwestern University&#8217;s rights in certain SNA technology we jointly own with Northwestern University. Our license to Northwestern University&#8217;s rights is limited to the assigned field, however we have no such limitation as to our own rights in this jointly owned technology. In June 2016, we entered into an exclusive license with Northwestern University to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes. Our rights and obligations in these 2016 agreements&#160;are substantially the same as in the restated license agreement from August 2015. For purposes of the assigned field, therapeutic uses means the use of products and processes that are covered by the patents and patent applications licensed from Northwestern University for the purpose of providing a therapy or course of medical treatment to address a medical condition or </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">disease. The Northwestern University license agreements provide to us the exclusive, worldwide right to make, have made, use, modify, sell, offer for sale and import any product or process that is covered by any claim in the licensed Northwestern University patents and patent applications. We have the right to sublicense these rights to third parties. The Northwestern University license agreements require us to use commercially reasonable efforts, consistent with demand in the marketplace, regulatory procedures and industry conditions and development timelines, to research, develop, market and manufacture the licensed products. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our rights under the Northwestern University license agreements are subject to a variety of material limitations. First, the license specifically excludes use of the licensed patent rights to perform qualitative or quantitative </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">in vitro </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">analysis, testing, or measurement as well as detection of a variety of combinations of biodiagnostics field subsets and targets. Second, the license specifically prohibits us from using the licensed patent rights with regard to diagnostics, including without limitation, theradiagnostics. Third, though the license is otherwise exclusive in the assigned field, Northwestern University retains the right to use the licensed patent rights for research, teaching, and other educational purposes, including the right to distribute and publish materials related to the licensed patent rights. Fourth, the license is subject to the rights of the U.S. government under any and all applicable laws including substantially manufacturing all licensed products in the U.S. unless such requirement is waived by the U.S. government. Fifth, other than in certain circumstances, the Northwestern University license agreements are non-transferable without the consent of Northwestern University. Under the terms of the Northwestern University license agreements, depending on the circumstances, either we or Northwestern University can sue to enforce the patent rights against third party infringers. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In order to secure the assignment of the Northwestern University-ASLLC license in the field, we assumed the obligation to pay Northwestern University an annual license fee, which may be credited against any royalties based on sales of licensed products that are due to Northwestern University in the same year, and to reimburse Northwestern University for expenses associated with the prosecution and maintenance of the licensed patent rights. In addition, we assumed the obligation to pay Northwestern University royalties at a low single-digit percentage of any net revenue generated by our sale or transfer of any licensed product. In the event we grant a sublicense under the licensed patent rights, we also assumed the obligation to pay Northwestern University, on a quarterly basis, the greater of a mid-teen percentage of all sublicensee royalties or a low single-digit percent of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may terminate our license agreements with Northwestern University at any time by providing 90 days written notice to Northwestern University. Northwestern University may terminate the agreements or, alternatively, convert our exclusive rights to non-exclusive rights if we fail to comply with certain prescribed timelines for research, development, marketing and manufacturing milestones for the licensed products. Northwestern University may also terminate the agreements if we sue, or do not terminate all agreements with a sublicensee who sues Northwestern University, in a matter not arising from the agreements themselves. Either party may terminate the agreements in the event of a material breach by the other that remains uncured for a period of 30 days after the non-breaching party provides notice to the breaching party. The agreements will automatically terminate if we reach specified thresholds of financial distress. In the event of termination, all rights immediately revert to Northwestern University. The agreements will automatically expire upon the expiration of the last to expire patent rights. In the event of expiration, the license automatically becomes a non-exclusive, irrevocable, fully-paid license to use or sublicense the use of know-how to make and sell products in each country where the license had previously been in effect. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our technology licenses and assignments </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our strategy around protection of our proprietary technology, including any innovations and improvements, is to obtain worldwide patent coverage with a focus on jurisdictions that represent significant global pharmaceutical markets. Generally, patents have a term of twenty years from the earliest priority date, assuming that all maintenance fees are paid, no portion of the patent has been terminally disclaimed and the patent has not been invalidated. In certain jurisdictions, and in certain circumstances, patent terms can be extended or shortened. We are pursuing worldwide patent protection for at least novel molecules, compositions of matter, pharmaceutical formulations, methods of use, including treatment of disease, methods of manufacture and other novel uses for the inventive molecules originating from our research and development efforts. We continuously assess whether it is strategically </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">more favorable to maintain confidentiality for the &#8220;know-how&#8221; regarding a novel invention rather than pursue patent protection. For each patent application that is filed we strategically tailor our claims in accordance with the existing patent landscape around a particular technology. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There can be no assurance that an issued patent will remain valid and enforceable in a court of law through the entire patent term. Should the validity of a patent be challenged, the legal process associated with defending the patent can be costly and time consuming. Issued patents can be subject to oppositions, interferences and other third party challenges that can result in the revocation of the patent or limit patent claims such that patent coverage lacks sufficient breadth to protect subject matter that is commercially relevant. Competitors may be able to circumvent our patents. Development and commercialization of pharmaceutical products can be subject to substantial delays and it is possible that at the time of commercialization any patent covering the product has expired or will be in force for only a short period of time following commercialization. We cannot predict with any certainty if any third party U.S. or foreign patent rights, or other proprietary rights, will be deemed infringed by the use of our technology. Nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. Should we need to defend ourselves and our partners against any such claims, substantial costs may be incurred. Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief, which could effectively block our ability to develop or commercialize some or all of our products in the U.S. and abroad, and could result in the award of substantial damages. In the event of a claim of infringement, we or our partners may be required to obtain one or more licenses from a third party. There can be no assurance that we can obtain a license on a reasonable basis should we deem it necessary to obtain rights to an alternative technology that meets our needs. The failure to obtain a license may have a material adverse effect on our business, results of operations and financial condition. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We also rely on trade secret protection for our confidential and proprietary information. No assurance can be given that we can meaningfully protect our trade secrets on a continuing basis. Others may independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">It is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships. These agreements provide that all confidential information developed or made known to these individuals during the course of the individual&#8217;s relationship with the company is to be kept confidential and is not to be disclosed to third parties except in specific circumstances. The agreements provide that all inventions conceived by an employee shall be the property of the company. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our success will depend in part on our ability to obtain and maintain patent protection, preserve trade secrets, prevent third parties from infringing upon our proprietary rights and operate without infringing upon the proprietary rights of others, both in the U.S. and other territories worldwide.</font></div><div><a name="s37FC3D0BB38451E6A6A95EC5FB93EE97"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Manufacturing and Supply </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do not currently own or operate manufacturing facilities for the production of preclinical, clinical or commercial quantities of any of our therapeutic candidates. We currently contract with two therapeutic substance and two drug product manufacturers for the supply of SNAs and we expect to continue to do so to meet the preclinical and any clinical requirements of our therapeutic candidates. We do not have a long-term agreement with these third parties. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have agreements for the supply of such therapeutic materials with manufacturers or suppliers that we believe have sufficient capacity to meet our demands. In addition, we believe that adequate alternative sources for such supplies exist. However, there is a risk that, if supplies are interrupted, it would materially harm our business. We typically order raw materials and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements, which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. Our contract manufacturing organizations manufacture our therapeutic candidates </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">subject to cGMP conditions. cGMPs are regulatory requirements for the production of therapeutics that will be used in humans.</font></div><div><a name="sDF665B336E4757D99B0B40B069907A6F"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Competition </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that our scientific knowledge and expertise in SNA-based therapies provide us with competitive advantages over the various companies and other entities that are attempting to develop oligonucleotide based-therapeutics. However, we face competition at the technology and therapeutic indication levels from both large and small biotechnology companies, academic institutions, government agencies and public and private research institutions. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our success will be based in part upon our ability to identify, develop and manage a portfolio of therapeutics that are safer and more effective than competing products in the treatment of our targeted patients. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient or are less expensive than any therapeutics we may develop. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Competition in oligonucleotide-based therapeutics </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There is intense and rapidly evolving competition in the biotechnology, pharmaceutical and oligonucleotide therapeutics fields. We believe that while our SNA technology, its associated intellectual property and our scientific and technical know-how gives us a competitive advantage in this space, competition from many sources remains. Our competition includes larger and better funded pharmaceutical, biotechnological and oligonucleotide therapeutic firms. Moreover, we not only compete with other firms, but also with current and future therapeutics. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are aware of several companies that are developing oligonucleotide delivery platforms and oligonucleotide based therapeutics. These competitors include Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Arbutus Biopharma Corp., Wave Life Sciences Ltd., Arrowhead Pharmaceuticals, Inc., ProQR Therapeutics N.V., Dynavax Technologies Corp., Idera Pharmaceuticals, Inc., Mologen AG, and Checkmate Pharmaceuticals, Inc. These and other competitors compete with us in recruiting scientific and managerial talent, and for the finite funding available from biotechnology and pharmaceutical companies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our success will partially depend on our ability to develop and protect therapeutics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, or less expensive than the therapeutics we develop. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If our lead therapeutic candidates are approved for the indications for which we undertake clinical trials, they will compete with therapies that are either in development or currently marketed, such as the following: </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Competition in immuno-oncology </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There are a number of competitive products to SNAs for immuno-oncology on the market and in development. Ipilimumab and nivolumab from Bristol-Myers Squibb Company, atezolizumab from the Roche Group, as well as pembrolizumab from Merck&#160;&amp; Co., Inc., are now marketed for the treatment of advanced melanoma or other cancers, and these and other therapeutic products are in development for other immuno-oncology applications. A number of our competitors are already conducting clinical trials testing combination of TLR9 agonists with checkpoint inhibitors in cancer patients. In addition, adoptive cell therapies such as CAR-T cells are showing great promise for the treatment of B-cell malignancies in clinical trials.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Competition in psoriasis </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There are currently a number of therapeutics on the market for the treatment of psoriasis. Over the counter medications such as salicylic acid and zinc pyrithione are used for treating mild to moderate psoriatic lesions. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prescription medications such as corticosteroids, calcipotriene, retinoids are available and can be applied topically. Oral therapeutics like cyclosporine and methotrexate are also used. Finally, injectable antibody-based therapies are used to decrease psoriasis-associated inflammation and thus reduce the symptoms of the disorder in the case of severe psoriasis. </font></div><div><a name="sA5AC03A76FF253AD9C02DE5CE68217E0"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Government Regulation and Product Approval </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Governmental authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing, sales, and export and import of products such as those we are developing. Our therapeutic candidates must be approved by the FDA through the NDA process before they may be legally marketed in the U.S. and will be subject to similar requirements in other countries prior to marketing in those countries. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">U.S. government regulation </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">NDA approval processes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act of 1938, or the FDCA, and implementing regulations. If we fail to comply with applicable FDA or other requirements at any time during the product development or approval process, or after approval, we may become subject to administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">refusal to approve pending applications; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">license suspension or revocation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">withdrawal of an approval; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">imposition of a clinical hold; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">warning or untitled letters; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">seizures or administrative detention of product; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">product recalls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">total or partial suspension of production or distribution; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">injunctions, fines, disgorgement, or civil or criminal penalties. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The process required by the FDA before a therapeutic candidate may be marketed in the U.S. generally involves the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">completion of nonclinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practices, or GLPs, and other applicable regulations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">performance of adequate and well-controlled human clinical trials according to Good Clinical Practices, or GCPs, to establish the safety and efficacy of the therapeutic candidate for its intended use; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">submission to the FDA of an NDA; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the therapeutic candidate is produced to assess readiness for commercial manufacturing and conformance to the manufacturing-related elements of the application, to conduct a data integrity audit, and to assess compliance with cGMPs to assure that the facilities, methods and controls are adequate to preserve the therapeutic candidate&#8217;s identity, strength, quality and purity; and </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">FDA review and approval of the NDA. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain any approvals for our therapeutic candidates will be granted on a timely basis, if at all. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Once a therapeutic candidate is identified for development, it enters the preclinical or nonclinical testing stage. Nonclinical tests include laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as animal studies. An IND sponsor must submit the results of the nonclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some nonclinical testing may continue even after the IND is submitted. In addition to including the results of the nonclinical studies, the IND will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. Currently, the IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND may result in the FDA not allowing the clinical trials to commence or not allowing the clinical trials to commence on the terms originally specified in the IND. A separate submission to an existing IND must also be made for each successive clinical trial conducted during drug development, and the FDA must grant permission, either explicitly or implicitly by not objecting, before each clinical trial can begin. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs. They must be conducted under protocols detailing the objectives of the trial, dosing procedures, research subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol, and any subsequent material amendment to the protocol, must be submitted to the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors also must report to the FDA serious and unexpected adverse reactions in a timely manner, any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigation brochure or any findings from other studies or animal or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">in vitro</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;testing that suggest a significant risk in humans exposed to the therapeutic. An IRB at each institution participating in the clinical trial must review and approve the protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each research subject or the subject&#8217;s legal representative, monitor the trial until completed and otherwise comply with IRB regulations. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trials results to public registries. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Phase 1-The therapeutic candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and elimination. In the case of some therapeutic candidates for severe or life-threatening diseases, such as cancer, especially when the therapeutic candidate may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Phase 2-Clinical trials are performed on a limited patient population intended to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Phase 3-Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These studies are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product labeling. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Human clinical trials are inherently uncertain and Phase 1, Phase 2 and Phase 3 testing may not be successfully completed. The FDA or the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">accordance with the IRB&#8217;s requirements or if the therapeutic candidate has been associated with unexpected serious harm to patients. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A drug being studied in clinical trials may be made available to individual patients, in certain circumstances. Pursuant to the 21st Century Cures Act, or Cures Act, which was signed into law in December 2016, the manufacturer of an investigational drug for a serious disease or condition is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for individual patient access to such investigational drug. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the development of a new therapeutic candidate, sponsors are given opportunities to meet with the FDA at certain points; specifically, prior to the submission of an IND, at the end of Phase 2 and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on the next phase of development. Sponsors typically use the meeting at the end of Phase 2 to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3 clinical trial that they believe will support the approval of the new therapeutic. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Concurrent with clinical trials, sponsors usually complete additional animal safety studies and also develop additional information about the chemistry and physical characteristics of the therapeutic candidate and finalize a process for manufacturing commercial quantities of the therapeutic candidate in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the therapeutic candidate and the manufacturer must develop methods for testing the quality, purity and potency of the therapeutic candidate. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the therapeutic candidate does not undergo unacceptable deterioration over its proposed&#160;shelf-life. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The results of product development, nonclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests and other control mechanisms, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. Under the Prescription Drug User Fee Act, or PDUFA, as amended, each NDA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual product fee for products and an annual establishment fee on facilities used to manufacture prescription drug products. Fee waivers or reductions are available in certain circumstances, such as where a waiver is necessary to protect the public health, where the fee would present a significant barrier to innovation, or where the applicant is a small business submitting its first human therapeutic application for review. Within 60 days following submission of the application, the FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. It may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Once the submission is accepted for filing, the FDA begins an in-depth substantive review. NDAs receive either standard or priority review. A therapeutic representing a significant improvement in treatment, prevention or diagnosis of disease may receive priority review. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant. The FDA may refer the NDA to an advisory committee for review and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations carefully when making decisions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant must incur significant expenditures of time, money and effort in the areas of training, record keeping, production and quality control. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the product approval process, the FDA also will determine whether a REMS plan is necessary to assure the safe use of the product. If the FDA concludes a REMS plan is needed, the sponsor of the NDA must submit a proposed REMS plan. The FDA will not approve an NDA without a REMS plan, if required. The FDA has authority to require a REMS plan under the Food and Drug Administration Amendments Act of 2007, or FDAAA, when necessary to ensure that the benefits of a therapeutic outweigh the risks. In determining whether a REMS plan is necessary, the FDA must consider the size of the population likely to use the therapeutic, the seriousness of the disease or condition to be treated, the expected benefit of the therapeutic, the duration of treatment, the seriousness of known or potential adverse events, and whether the therapeutic is a new molecular entity. A REMS plan may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate health care providers of the risks, limitations on who may prescribe or dispense the therapeutic, or other measures that the FDA deems necessary to assure the safe use of the therapeutic. In addition, the REMS plan must include a timetable to assess the strategy at 18 months, three years, and seven years after the strategy&#8217;s approval. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The FDA may also require a REMS plan for a therapeutic that is already on the market if it determines, based on new safety information, that a REMS plan is necessary to ensure that the product&#8217;s benefits outweigh its risks. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the NDA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the NDA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the NDA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if the NDA is resubmitted, FDA may again decide that the resubmitted NDA does not satisfy the criteria for approval. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Even if a product receives regulatory approval, the approval may be significantly limited to specific indications and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post-marketing clinical trials, sometimes referred to as &#8220;Phase 4&#8221; clinical trials, designed to further assess a product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Companion Diagnostics</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The FDA has issued a final guidance document addressing the agency&#8217;s policy in relation to in vitro companion diagnostic tests. The guidance explains that for some therapeutics, the use of a companion diagnostic test is essential for the safe and effective use of the product, such as when the use of a product is limited to a specific patient subpopulation that can be identified by using the test. According to the guidance, the FDA generally will not approve such a product if the companion diagnostic is not also approved or cleared for the appropriate indication, and accordingly the therapeutic product and the companion diagnostic should be developed and approved or cleared contemporaneously. However, the FDA may decide that it is appropriate to approve such a product without an approved or cleared in vitro companion diagnostic device when the therapeutic is intended to treat a serious or life-threatening condition for which no satisfactory alternative treatment exists and the FDA determines that the benefits from the use of a product with an unapproved or uncleared in vitro companion diagnostic device are so pronounced as to outweigh the risks from the lack of an approved or cleared in vitro companion diagnostic device. The FDA encourages sponsors considering developing a therapeutic product that requires a companion diagnostic to request a meeting with both relevant device and therapeutic product review divisions to ensure that the product development plan will produce sufficient data to establish the safety and effectiveness of both the therapeutic product and the companion diagnostic. Because the FDA&#8217;s policy on companion diagnostics is set forth only in guidance, this policy is subject to change and is not legally binding. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Expedited review and approval.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The FDA has various programs, including Fast Track, priority review, accelerated approval and breakthrough therapy, which are intended to expedite or simplify the process for reviewing </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">therapeutic candidates, or provide for the approval of a therapeutic candidate on the basis of a surrogate endpoint. Even if a therapeutic candidate qualifies for one or more of these programs, the FDA may later decide that the therapeutic candidate no longer meets the conditions for qualification or that the time period for FDA review or approval will be lengthened. Generally, therapeutic candidates that are eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate the development and expedite the review of therapeutic candidates to treat serious or life-threatening diseases or conditions and fill unmet medical needs. Priority review is designed to give a therapeutic candidate that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness, an initial review within eight months as compared to a standard review time of twelve months. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Although Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track designated therapeutic candidate and expedite review of the application for a therapeutic candidate designated for priority review. Accelerated approval, which is described in Subpart H of 21 CFR Part 314, provides for an earlier approval for a new therapeutic candidate that is intended to treat a serious or life-threatening disease or condition, generally provides a meaningful advantage over available therapies and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. A surrogate endpoint is a laboratory measurement or physical sign used as an indirect or substitute measurement representing a clinically meaningful outcome. As a condition of approval, the FDA may require that a sponsor of a therapeutic candidate receiving accelerated approval perform post-marketing clinical trials to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the product may be subject to accelerated withdrawal procedures. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the Food and Drug Administration Safety and Innovation Act, or FDASIA, which was signed into law in July 2012, the U.S. Congress encouraged the FDA to utilize innovative and flexible approaches to the assessment of therapeutic candidates under accelerated approval. The law required the FDA to issue related guidance and also promulgate confirming regulatory changes. In May 2014, the FDA published a final Guidance for Industry titled &#8220;Expedited Programs for Serious Conditions&#8212;Drugs and Biologics,&#8221; which provides guidance on FDA programs that are intended to facilitate and expedite development and review of new therapeutic candidates as well as threshold criteria generally applicable to concluding that a therapeutic candidate is a candidate for these expedited development and review programs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to the Fast Track, accelerated approval and priority review programs discussed above, the FDA also provided guidance on a new program for Breakthrough Therapy Designation, established by FDASIA to subject a new category of drugs to accelerated approval. A sponsor may seek FDA designation of a therapeutic candidate as a &#8220;breakthrough therapy&#8221; if the therapeutic is intended, alone or in combination with one or more other therapeutics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapeutic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. A request for Breakthrough Therapy designation should be submitted concurrently with, or as an amendment to, an IND, but ideally no later than the end of the Phase 2 meeting. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Similar to FDASIA, the Cures Act, which was signed into law in December 2016, includes numerous provisions intended to accelerate the development of new products regulated by the FDA. As an example, the Cures Act provides that the FDA may allow the sponsor of an NDA for a genetically targeted drug or variant protein targeted drug to rely upon data and information previously developed by the same sponsor (or another sponsor that has provided the sponsor with a contractual right of reference to such data and information) and submitted by the sponsor in support of one or more previously approved applications submitted to the FDA for a drug that incorporates or utilizes the same or similar genetically targeted technology or the same variant protein targeted drug. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Patent term restoration and marketing exclusivity.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Depending upon the timing, duration and specifics of FDA approval of the use of our therapeutic candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14&#160;years from the therapeutic candidate&#8217;s approval date. The patent term restoration period is generally one half of the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved therapeutic candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity. A therapeutic candidate is a new chemical entity if the FDA has not previously approved any other new therapeutic candidate containing the same active moiety, which is the molecule or ion responsible for the action of the therapeutic candidate substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such therapeutic candidate where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an approved NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing therapeutic candidate. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for therapeutic candidates containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Orphan drug designation.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to therapeutic candidates intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S. or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a therapeutic candidate for this type of disease or condition will be recovered from sales in the U.S. for that therapeutic candidate. Orphan drug designation must be requested before submitting a marketing application for the therapeutic for that particular disease or condition. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. The FDA may revoke orphan drug designation, and if it does, it will publicize the drug is no longer designated as an orphan drug. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If a therapeutic candidate with orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the therapeutic candidate is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same therapeutic candidate for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same therapeutic candidate as defined by the FDA or if our therapeutic candidate is determined to be contained within the competitor&#8217;s therapeutic candidate for the same indication or disease. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Pediatric exclusivity and pediatric use.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Best Pharmaceuticals for Children Act, or BPCA, certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor submits information requested in writing by the FDA, referred to as a Written Request, relating to the use of the active moiety of the therapeutic candidate in children. The FDA may not issue a Written Request for studies on unapproved or approved </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">indications where it determines that information relating to the use of a therapeutic candidate in a pediatric population, or part of the pediatric population, may not produce health benefits in that population. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric studies for most therapeutic candidates and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, BLAs and supplements thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must assess the safety and effectiveness of the therapeutic candidate for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the therapeutic candidate is safe and effective. The sponsor or the FDA may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug or biologic is ready for approval for use in adults before pediatric studies are complete or that additional safety or effectiveness data needs to be collected before the pediatric studies begin. The FDA must send a noncompliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. The FDA also must post the PREA noncompliance letter and sponsor&#8217;s response. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As part of the FDASIA, the U.S. Congress made a few revisions to BPCA and PREA, which were slated to expire on September&#160;30, 2012, and made both laws permanent. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Post-approval requirements.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the therapeutic candidate reaches the market. Later discovery of previously unknown problems with a therapeutic candidate may result in restrictions on the therapeutic candidate or even complete withdrawal of the therapeutic candidate from the market. After approval, some types of changes to the approved therapeutic candidate, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval. In addition, the FDA may under some circumstances require testing and surveillance programs to monitor the effect of approved therapeutic candidates that have been commercialized, and the FDA under some circumstances has the power to prevent or limit further marketing of a therapeutic candidate based on the results of these post-marketing programs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any therapeutic candidates manufactured or distributed by us or our collaborators pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">record-keeping requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">reporting of adverse experiences associated with the therapeutic candidate; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">providing the FDA with updated safety and efficacy information; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">therapeutic sampling and distribution requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">notifying the FDA and gaining its approval of specified manufacturing or labeling changes; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">complying with FDA promotion and advertising requirements, which include, among other things, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling, limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Therapeutic manufacturers, their subcontractors, and other entities involved in the manufacture and distribution of approved therapeutic candidates are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMPs and other laws. The FDA periodically inspects manufacturing facilities to assess compliance with ongoing regulatory requirements, including cGMPs, which impose extensive procedural, substantive and record-keeping requirements upon us and any third-party manufacturers that we may decide to use if our therapeutic candidates are approved. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations would also require investigation and correction of any deviations from cGMPs and impose reporting and documentation </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">requirements upon us and the third-party manufacturers. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizures of products, injunctive actions or other civil penalties. We cannot be certain we or our present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may halt our clinical trials or require us to recall a product from distribution. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">New Legislation and Regulations</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. From time to time, legislation is drafted, introduced and passed in the U.S. Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations will be changed or what the effect of such changes, if any, may be. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Regulation outside of the U.S. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to regulations in the U.S., we will be subject to regulations of other countries governing any clinical trials and commercial sales and distribution of our therapeutic candidates. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The currently applicable Clinical Trials Directive 2001/20/EC and Commission Directive 2005/28/EC on GCP setting out the system for the approval of clinical trials in the European Union, or EU, have been implemented through national legislation in the EU Member States. Under this system, an applicant must obtain approval from the national competent authorities in all EU Member States in which the clinical trials are to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site once approved by the competent ethics committee. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2014, a new Clinical Trials Regulation 536/2014, replacing the current Clinical Trials Directive, was adopted. The new Regulation will become directly applicable in all EU Member States (without national implementation) once the EU Portal and Database are fully functional. The Regulation was expected to apply by October 2018. However, due to technical difficulties with the development of the IT systems, it is currently expected that the&#160;new&#160;Regulation&#160;will come into application during 2019. The new Regulation seeks to simplify and streamline the approval of clinical trials in the EU. For example, the sponsor shall submit a single application for approval of a clinical trial via the EU Portal. As part of the application process, the sponsor shall propose a reporting Member State, who will coordinate the validation and evaluation of the application. The reporting Member State shall consult and coordinate with the other concerned Member States. If an application is rejected, it can be amended and resubmitted through the EU Portal. If an approval is issued, the sponsor can start the clinical trial in all concerned Member States. However, a concerned Member State can in limited circumstances declare an &#8220;opt-out&#8221; from an approval. In such a case, the clinical trial cannot be conducted in that Member State. The Regulation also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the EU, a company may submit a marketing authorization application either: (i)&#160;at the national level with the national competent authorities in one EU Member State, or the national procedure; (ii)&#160;via mutual recognition of a national authorization in other EU Member States, or the mutual recognition procedure; (iii)&#160;at the national level in several EU Member States, or the decentralized procedure; or (iv)&#160;at centralized level with the European Medicines Agency, or EMA, referred to as the centralized procedure. The national procedure allows sponsor to choose the EU Member State in which he wishes to first submit an application. The mutual recognition procedure allows a marketing authorization granted in one EU Member State via the national procedure to be recognized in other EU </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Member States. The decentralized procedure allows a medicine that has not yet been authorized in the EU to be authorized in several EU Member States. The centralized procedure, whereby a medicine receives marketing authorization in all EU Member States, is compulsory for certain medicines and is optional for other types of medicines if the applicant can show eligibility. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As in the U.S., we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the EU before the application for marketing authorization is made. Orphan drugs in the EU enjoy economic and marketing benefits, including up to ten (10)&#160;years of market exclusivity for the approved indication unless certain exceptions apply. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Healthcare Reform </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In March 2010, Congress passed the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry, and impose additional policy reforms. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes, and fraud and abuse, impacting existing government healthcare programs and resulting in the development of new programs, including Medicare payment for performance initiatives, and improvements to the physician quality reporting system and feedback program. Other aspects of the ACA include, but are not limited to: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Increases in pharmaceutical manufacturer rebate liability under the Medicaid Drug Rebate Program due to an increase in the minimum basic Medicaid rebate on most branded prescription drugs, and the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed care plans. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Expansion of the 340B Drug Pricing Program to require discounts for &#8220;covered outpatient drugs&#8221; sold to certain children&#8217;s hospitals, critical access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospital. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Requirements on pharmaceutical companies to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly referred to as the &#8220;Donut Hole.&#8221; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Requirements on pharmaceutical companies to pay an annual non-tax-deductible fee to the federal government based on each company&#8217;s market share of prior year total sales of branded drugs to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs, and Department of Defense. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Establishment of the Independent Payment Advisory Board, which, since 2014, has had authority to recommend certain changes to the Medicare program to reduce expenditures by the program when spending exceeds a certain growth rate and such changes could result in reduced payments for prescription drugs. Under certain circumstances, these recommendations will become law unless Congress enacts legislation achieving the same or greater Medicare cost savings. However, as of early 2017, the President has yet to nominate anyone to serve on the board. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Establishment of the Patient-Centered Outcomes Research Institute to identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The research conducted by the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Establishment the Center for Medicare and Medicaid Innovation within the Centers for Medicare and Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. Funding has been allocated to support the mission of the Center for Medicare and Medicaid Innovation from 2011 to 2019. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From time to time, legislation is drafted, introduced, and passed in Congress that could significantly change the statutory provisions governing the sale, marketing, coverage, and reimbursement of products regulated by CMS or </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">other government agencies. In addition to new legislation, CMS regulations and policies are often revised or interpreted by the agency in ways significantly affecting our business and our products. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In particular, we expect that the new administration and the U.S. Congress will seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the U.S. healthcare reform legislation. Since taking office, President Trump has continued to support the repeal of all or portions of the ACA. President Trump has also issued an executive order in which he stated it is his administration&#8217;s policy to seek the prompt repeal of the ACA and directed executive departments and federal agencies to waive, defer, grant exemptions from, or delay the implementation of the provisions of the ACA to the maximum extent permitted by law. There is still uncertainty with respect to the impact President Trump&#8217;s administration and the U.S. Congress may have, if any, and any changes will likely take time to unfold. Such reforms could have an adverse effect on anticipated revenues from therapeutic candidates we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop therapeutic candidates. However, we cannot predict the ultimate content, timing, or effect of any healthcare reform legislation or the impact of potential legislation on us. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Furthermore, political, economic, and regulatory influences frequently subject the healthcare industry in the U.S. to fundamental change. For example, initiatives to reduce the federal budget and debt and to reform healthcare coverage are increasing cost-containment efforts. We anticipate federal agencies, Congress, state legislatures, and the private sector will continue to review and assess alternative healthcare benefits, controls on healthcare spending, and other fundamental changes to the healthcare delivery system. Any proposed or actual changes could limit coverage for or the amounts federal and state governments will pay for health care products and services, which could also result in reduced demand for our products or additional pricing pressures, and limit or eliminate our spending on development projects and affect our ultimate profitability. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Third-Party Payor Coverage and Reimbursement </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the U.S., sales of any products for which we may receive regulatory marketing approval will depend, in part, on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities such as Medicare, Medicaid, TRICARE, and the Veterans Administration, managed care providers, private health insurers, and other organizations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Medicaid Drug Rebate Program, which is part of the federal Medicaid program (a program for financially needy patients, among others), requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for receiving federal reimbursement for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In order for a pharmaceutical product to (i)&#160;receive federal reimbursement under Medicaid and Medicare Part B (the part of the federal Medicare program covering outpatient items and services for the aged and disabled) or (ii)&#160;be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program, which is a federal program that requires manufacturers to provide discounts to certain statutorily defined safety-net providers. The required 340B discount on a given product is calculated based on certain Medicaid Drug Rebate Program metrics the manufacturer is required to report to CMS. The failure to report or the misreporting of such pricing metrics could result in significant civil monetary penalties and fines, including up to $178,156 (adjusted for inflation) for each item of false or omitted information and $17,816 (adjusted for inflation) per day per labeler code for each day the submission of such pricing information is late beyond the due date. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or MMA, imposed requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities, which will provide coverage of outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for our products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list or formulary, which may not include all FDA-approved products for a particular indication. Also, third-party payors may refuse to include a particular branded product on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available. Furthermore, a payor&#8217;s decision to provide coverage for a product does not imply an adequate reimbursement rate will be available. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services. Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the prices of therapeutics have been a focus in this effort. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Our drug candidates may not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be&#160;cost-effective compared to other available therapies, they may not cover an approved product as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Further, the American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness. The plan for the research was published in 2012 by the Department of Health and Human Services, the Agency for Healthcare Research and Quality, or AHRQ, and the National Institutes for Health, and periodic reports on the status of the research and related expenditures will be made to the U.S.&#160;Congress. In addition, the ACA requires, among other things, that AHRQ broadly disseminate findings from federally funded comparative clinical effectiveness research. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of our therapeutic candidates if any such therapeutic, or the condition that it is intended to treat, is the subject of a study. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#8217;s product could adversely affect the sales of our therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On August&#160;2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by the U.S. Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, started in April 2013, and, due to subsequent legislative amendments, will stay in effect through 2025 unless additional Congressional action is taken. On January&#160;2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, or the ATRA, which among other things, also reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. We expect that additional federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">pay for healthcare drugs and services, and in turn could significantly reduce the projected value of certain development projects and reduce our profitability. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Finally, in some foreign countries, the proposed pricing for a therapeutic candidate must be approved before it may be lawfully marketed. The requirements governing therapeutic pricing vary widely from country to country. For example, in the EU, pricing and reimbursement of pharmaceutical products are regulated at a national level under the individual EU Member States&#8217; social security systems. Some foreign countries provide options to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A country may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our therapeutic candidates. Even if approved for reimbursement, historically, therapeutic candidates launched in some foreign countries such as some countries in the EU do not follow price structures of the U.S.&#160;and prices generally tend to be significantly lower. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Healthcare Laws and Regulations </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we obtain regulatory approval of our products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing strategies. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, and physician sunshine laws and regulations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, an item or reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. Violations of the federal Anti-Kickback Statute can result in significant civil monetary and criminal penalties, including $21,916 (adjusted annually for inflation) per kickback plus three times the amount of remuneration and a five year prison term per violation. Further, violation of the federal Anti-Kickback Statute can also form the basis for False Claims Act liability (discussed below). The Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced the&#160;Anti-Kickback Statute to reach large settlements with healthcare companies based on allegedly inappropriate consulting, discounting and other financial arrangements with physicians and others in a position to refer patients to receive items or services reimbursable by a federal healthcare program. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only government programs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, the civil False Claims Act prohibits knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the False Claims Act can result in very significant monetary penalties, including $10,957-$21,916 (adjusted annually for inflation) for each false claim and treble the amount of the government&#8217;s damages. The federal government continues to use the False Claims Act, and the accompanying threat of significant liability, in its investigations and prosecutions of pharmaceutical and biotechnology companies throughout the U.S. Such investigations and prosecutions frequently involve, for example, the alleged promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the False Claims Act in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with the False Claims Act and other applicable fraud and abuse laws. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The U.S.&#160;federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, includes a fraud and abuse provision referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by HITECH, and its implementing regulations, including the final omnibus rule published on January&#160;25, 2013, imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Penalties include up to $55,010 per violation (with a maximum fine of $1,650,300 per violation category per year) (adjusted for inflation) and ten years in prison. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may also be subject to federal transparency laws, including the federal Physician Payment Sunshine Act, which was part of the ACA and requires manufacturers of certain drugs and biologics, among others, to track and disclose payments and other transfers of value they make to U.S. physicians and teaching hospitals, as well as physician ownership and investment interests in the manufacturer. This information is subsequently made publicly available in a searchable format on a CMS website. Failure to disclose required information may result in civil monetary penalties of up to an aggregate of $163,117 per year (or up to an aggregate of $1,087,450 per year for &#8220;knowing failures&#8221;) (adjusted for inflation), for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Certain states also mandate implementation of compliance programs, impose restrictions on drug manufacturer marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians and/or other healthcare providers. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Finally, as noted above, analogous state laws and regulations, such as, state anti-kickback and false claims laws may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. Similarly, many states also have laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Environment </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our third party manufacturers are subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. We have incurred, and may continue to incur, significant expenditures to ensure we are in compliance with these laws and regulations. We would be subject to significant penalties for failure to comply with these laws and regulations. </font></div><div><a name="s654B108C91545B169CED0ACF0D73647C"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Sales and Marketing </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our current focus is on the development of our existing portfolio, the initiation and completion of clinical trials and, if and where appropriate, the registration of our therapeutic candidates. We currently do not have marketing, sales and distribution capabilities. If we receive marketing and commercialization approval for any of our therapeutic candidates, we intend to market the product through strategic alliances and distribution agreements with </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">third parties. The ultimate implementation of our strategy for realizing the financial value of our therapeutic candidates is dependent on the results of clinical trials for our therapeutic candidates, the availability of funds and the ability to negotiate acceptable commercial terms with third parties. </font></div><div><a name="s1C16C2C6C4FA593BA4C91E5FCAEDAF6A"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Advisors </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We seek advice from our advisory board, which consists of a number of leading executive officers, scientists and physicians, on strategic direction, scientific and medical matters. Our advisory board may provide advice regarding </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our research and development programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the design and implementation of our clinical programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our patent and publication strategies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">new technologies relevant to our research and development programs; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">specific scientific and technical issues relevant to our business. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The current members of our advisory board are as follows. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:67%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Position and Institutional Affiliation</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Freddy Boey, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deputy President and Provost, Nanyang Technological University</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Michael Hodges, MBBS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Chief Medical Officer, Amplyx Pharmaceuticals</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Amy S. Paller, M.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Walter J. Hamlin Professor and Chair Department of Dermatology, Northwestern University Feinberg School of Medicine</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Steven T. Rosen, M.D., F.A.C.P.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Provost/Chief Scientific Officer, City of Hope</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Robert P. Schleimer, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Chief, Division of Medicine-Allergy-Immunology, Northwestern University</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Oliver von Stein, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Founder&#160;&amp; CEO, iModia Biotech GmbH</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">John J. Renger, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Head of Clinical R&amp;D/Translational Medicine, Purdue Pharma, L.P.</font></div></td></tr></table></div></div><div><a name="s3209B3C092925FD199135BFC22D15797"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Employees </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December 31, 2018, we have 27 full time employees, of whom 20 are engaged in research and development activities and 7 are engaged in finance, legal, human resources, business development and general management. We have no collective bargaining agreement with our employees and we have not experienced any work stoppages. We consider our relations with our employees to be good. </font></div><div><a name="sA43D0B919F965388A0D485ED72B70000"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Corporate Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We were originally incorporated in the State of Delaware on February 6, 2017 under the name &#8220;Max-1 Acquisition Corporation.&#8221; Prior to the Merger, Max-1 was a &#8220;shell&#8221; company registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act, with no specific business plan or purpose until it began operating the business of Exicure OpCo through the Merger transaction on September 26, 2017. Exicure OpCo was originally formed as a limited liability company under the name AuraSense Therapeutics, LLC in the State of Delaware in June 2011 and was a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on its proprietary SNA technology. AuraSense Therapeutics, LLC was subsequently converted into AuraSense Therapeutics, Inc., a Delaware corporation, on July&#160;9, 2015, and changed its name on the same date to Exicure, Inc. Immediately after giving effect to the Merger and the initial closing of the 2017 Private Placement, the business of Exicure OpCo became our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our corporate headquarters are located at 8045 Lamon Avenue, Suite 410, Skokie, IL 60077, and our telephone number is (847) 673-1700.  </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">All trademarks, service marks and trade names appearing in this prospectus are the property of their respective holders. Use or display by us of other parties&#8217; trademarks, trade dress, or products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners.</font></div><div><a name="sB8219A3FC73557B2BAB278AC4703AFC3"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Available Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We maintain a website at www.exicuretx.com, to which we regularly post copies of our press releases as well as additional information about us. Our filings with the SEC will be available free of charge through the website as soon as reasonably practicable after being electronically filed with or furnished to the SEC. Information contained in our website is not a part of, nor incorporated by reference into, this prospectus or our other filings with the SEC, and should not be relied upon. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><a name="s80BB9A6DD337560C98ABEC4DDBD478BE"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1A. Risk Factors. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">We are providing the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results and our forward-looking statements. We note these factors for investors as permitted by Section 21E of the Exchange Act and Section 27A of the Securities Act. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Business  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are a clinical-stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a biotechnology company developing gene regulatory and immuno-oncology therapeutics based on our proprietary SNA technology.  We have a limited operating history.  Since our inception in June 2011, we have devoted our resources to the development of SNA technology.  We have had significant operating losses since our inception.  As of December 31, 2018, we have generated an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  For the years ended December 31, 2018 and 2017, our net loss was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$22.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$11.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.  Substantially all of our losses have resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations. Our technology and therapeutic candidates are in early stages of development, and we are subject to the risks of failure inherent in the development of therapeutic candidates based on novel technologies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have not generated, and do not expect to generate, any product revenue for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies, clinical trials, and the regulatory approval process for therapeutic candidates. The amount of future losses is uncertain. Our ability to achieve profitability, if ever, will depend on, among other things, us, or any current or future collaborators, successfully developing therapeutic candidates, obtaining regulatory approvals to market and commercialize therapeutic candidates, manufacturing any approved products on commercially reasonable terms, establishing a sales and marketing organization or suitable third party alternatives for any approved product and raising sufficient funds to finance business activities. If we, or any current or future collaborators, are unable to develop and commercialize one or more of our therapeutic candidates or if sales revenue from any therapeutic candidate that receives approval is insufficient, we will not achieve profitability, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our approach to the discovery and development of innovative therapeutic treatments based on our technology is unproven and may not result in marketable products. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We plan to develop a pipeline of therapeutic candidates using our proprietary SNAs as therapeutic agents. We believe that therapeutic candidates identified with our therapeutic discovery technology may offer an improved therapeutic approach to small molecules and antibodies, as well as several advantages over linear oligonucleotide-based therapeutics. However, the scientific research that forms the basis of our efforts to develop therapeutic candidates based on our SNAs and the identification and optimization of SNAs is relatively new. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on SNAs is both preliminary and limited. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Therapeutic candidates based on SNA technology have not been extensively tested in humans, and a number of clinical trials conducted by other companies using oligonucleotide technologies have not been successful. We may discover that the SNAs do not possess certain properties required for therapeutic treatment to be effective, such as the ability to remain stable in the human body for the period of time required for the therapeutic candidate to reach the target tissue or the ability to cross the cell membrane and enter into cells within the target tissue for effective delivery. We currently have only limited data, and no conclusive evidence, to suggest that we can introduce these necessary drug-like properties into SNAs. We may spend substantial funds attempting to introduce these properties and may never succeed in doing so. In addition, therapeutic candidates based on SNAs may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. Even if therapeutic candidates have successful results in animal studies, they may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, we may never succeed in developing a marketable therapeutic, we may not become profitable and the value of our common stock would decline. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Further, the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), has limited experience with SNA-based therapeutics. No regulatory authority has granted approval to any person or entity, including us, to market and commercialize therapeutics using SNAs, which may increase the complexity, uncertainty and length of the regulatory approval process for our therapeutic candidates. We and any current or future collaborators may never receive approval to market and commercialize any therapeutic candidate. Even if we or a future collaborator obtain regulatory approval, the approval may be for disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a future collaborator may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If our SNA technology proves to be ineffective, unsafe or commercially unviable, our technology and pipeline would have little, if any, value, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our therapeutic candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have no therapeutics on the market and all of our therapeutic candidates are in early stages of development. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals, including an institutional review board (&#8220;IRB&#8221;), approval to conduct clinical trials at particular sites for, and successfully commercializing, our therapeutic candidates, either alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our therapeutic candidates, we or an existing or a future collaborator must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy in humans of our therapeutic candidates. Preclinical studies and clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. The start or end of a clinical trial is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparative therapeutic or required prior therapy, clinical outcomes or financial constraints. For instance, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times or termination of a clinical trial. Clinical trials of a new therapeutic candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the therapeutic candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites and the availability of effective treatments for the relevant disease. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A therapeutic candidate can unexpectedly fail at any stage of preclinical and clinical development. In our completed Phase 1 trial, AST-005 did not show an antipsoriatic effect. There is no guarantee that AST-005 will show an antipsoriatic effect in future clinical trials of longer duration. The historical failure rate for therapeutic candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical studies or early clinical trials of a therapeutic candidate may not predict the results that will be obtained in later phase clinical trials of the therapeutic candidate. We, the FDA, an IRB, an independent ethics committee, or other applicable regulatory authorities may suspend clinical trials of a therapeutic candidate at any time for various reasons, including a finding that subjects participating in such trials are being exposed to unreasonable and significant risk of illness or injury. Similarly, an IRB or ethics committee may suspend a clinical trial at a particular trial site. We may not have the financial resources to continue development of, or to enter into collaborations for, a therapeutic candidate if we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, therapeutic candidates, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">negative or inconclusive results from our clinical trials or the clinical trials of others for therapeutic candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">therapeutic-related side effects experienced by participants in our clinical trials or by individuals using therapeutics similar to our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">delays in submitting INDs or CTAs, or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or IRBs to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">conditions imposed by the FDA or comparable foreign authorities, such as the European Medicines Agency (&#8220;EMA&#8221;), or European Union national competent authorities, regarding the scope or design of our clinical trials; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">delays in enrolling research subjects in clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">high drop-out rates of research subjects; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">inadequate supply or quality of therapeutic candidate components or materials or other supplies necessary for the conduct of our clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">greater than anticipated clinical trial costs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">poor effectiveness of our therapeutic candidates during clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">failure of our third party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular, especially in light of the novelty of our therapeutic candidates;  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">varying interpretations of data by the FDA and similar foreign regulatory agencies; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">refusal of the FDA to accept data from clinical trials conducted outside the United States, or acceptance of these data subject to certain conditions by the FDA. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Clinical testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can occur at any time and at any stage during the clinical trial process. The results of preclinical studies and early clinical trials of our therapeutic candidates may not be predictive of the result of any subsequent clinical trials. Therapeutic candidates that have shown promising results in early stage clinical trials may still suffer significant setbacks in subsequent clinical trials. We will have to conduct trials in our proposed indications to verify the results obtained to date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in clinical trials due to&#160;lack of efficacy or adverse safety profiles despite promising results in earlier clinical trials. Moreover, clinical data is often susceptible to varying interpretations and analyses. We do not know whether Phase 1, Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our therapeutic candidates. &#160;If we experience delays in the completion of, or termination of, any clinical trial of our therapeutic candidates, the commercial prospects of our therapeutic candidates may be harmed, and our ability to generate product revenues from any of these therapeutic candidates will be delayed.&#160; In addition, any delays in completing clinical trials will increase our costs, slow down our therapeutic candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.&#160; Any of these occurrences could materially and adversely affect our business, financial condition, results of operations or prospects.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We will need substantial additional funds to advance the development of our therapeutic candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or future therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If our existing therapeutic candidates or our future therapeutic candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing, and sales capabilities or contract with other organizations to provide these capabilities for us. We have used substantial funds to develop our therapeutic candidates and will require significant funds to conduct further research and development and preclinical studies and clinical trials of our therapeutic candidates, to seek regulatory approvals for our therapeutic candidates and to manufacture and market products, if any, that are approved for commercial sale.  As of December 31, 2018 and 2017, we had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$26.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in cash and cash equivalents, respectively.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Based on the Company&#8217;s current operating plans, we believe that existing working capital at December 31, 2018 is sufficient to fund our current operating plans into January 2020.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing development and corporate activities. Since the length of time </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and activities associated with successful development of our therapeutic candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. To execute our business plan, we will need, among other things: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to obtain the human and financial resources necessary to develop, test, obtain regulatory approval for, manufacture and market our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to build and maintain a strong intellectual property portfolio and avoid infringing the intellectual property of third parties; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to establish and maintain successful licenses, collaborations and alliances; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to satisfy the requirements of clinical trial protocols, including patient enrollment; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to establish and demonstrate the clinical efficacy and safety of our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to obtain regulatory approvals; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to manage our spending as costs and expenses increase due to preclinical studies and clinical trials, regulatory approvals, and commercialization; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to obtain additional capital to support and expand our operations; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to market our products to achieve acceptance and use by the medical community in general. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, if any, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technology or therapeutic candidates that we would otherwise pursue on our own. We do not expect to realize revenue from product sales, milestone payments or royalties in the foreseeable future, if at all. Our revenue sources are, and will remain, extremely limited unless and until our therapeutic candidates are clinically tested, approved for commercialization and successfully marketed. To date, we have primarily financed our operations through the sale of equity securities, payments received in connection with our research collaboration, license, and option agreement with Purdue Pharma L.P., or Purdue, or as a primary contractor or as a subcontractor on government grants, and proceeds from our loan agreement with Hercules Technology Growth Capital, or Hercules. We will be required to seek additional funding in the future and intend to do so through either collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of equity securities received any distribution of corporate assets. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">variations in the level of expense related to our therapeutic candidates or future development programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">results of clinical trials, or the addition or termination of clinical trials or funding support by us, or a future collaborator or licensing partner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our execution of any collaboration, licensing or similar arrangement, and the timing of payments we may make or receive under such existing or future arrangements or the termination or modification of any such existing or future arrangements; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">additions and departures of key personnel; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">whether or not any of our therapeutic candidates receives regulatory approval, market acceptance and demand for such therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">regulatory developments affecting our therapeutic candidates or those of our competitors; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">changes in general market and economic conditions. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:6px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expense and present significant distractions to our management.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases and&#160;out-&#160;or&#160;in-licensing&#160;of product candidates or technologies. In particular, in addition to our current arrangements with Dermelix, which began in February 2019 and is in its early stages, and Purdue, with which there no active therapeutic candidates in development and which has not indicated any further interest in development, we will evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or pharmaceutical companies. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may be unable to maintain any new or existing collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product do not meet expectations or the collaborator terminates the collaboration. Any such collaboration, or other strategic transaction, may require us to incur&#160;non-recurring&#160;or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material adverse effect on our business, results of operations, financial condition and prospects. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If third parties on which we depend to conduct our preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements, or miss expected deadlines, our development program could be delayed with materially adverse effects on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We rely on third party clinical investigators, contract research organizations (&#8220;CROs&#8221;), clinical data management organizations and consultants to design, conduct, supervise and monitor preclinical studies and clinical trials for our therapeutic candidates. Because we rely on third parties and do not have the ability to conduct preclinical studies or clinical trials independently, we have less control over the timing, quality and other aspects of preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">draw time and resources away from our programs. The third parties with which we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. The FDA requires preclinical studies to be conducted in accordance with applicable Good Laboratory Practices (&#8220;GLPs&#8221;), and clinical trials to be conducted in accordance with applicable FDA regulations and Good Clinical Practices (&#8220;GCPs&#8221;), including requirements for conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or clinical trials could have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Because we rely on third party manufacturing and supply partners, our supply of research and development, preclinical studies and clinical trial materials may become limited or interrupted or may not be of satisfactory quantity or quality. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We rely on third party partners to manufacture and supply the materials and components for our research and development, preclinical study and clinical trial supplies. We do not own manufacturing facilities or supply sources for such components and materials. Our manufacturing requirements include oligonucleotides and lipids. We procure our nonclinical toxicology and clinical development materials from a single source supplier on a purchase order basis. There can be no assurance that our supply of research and development, preclinical study and clinical trial therapeutic candidates and other materials will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our drug product manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The manufacturing process for a therapeutic candidate is subject to oversight by the FDA and foreign regulatory authorities. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory requirements, such as current Good Manufacturing Practices (&#8220;cGMPs&#8221;). In the event that any of our suppliers or manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our therapeutic candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our therapeutic candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop therapeutic candidates in a timely manner or within budget. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect to continue to rely on third party manufacturers if we receive regulatory approval for any therapeutic candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third party manufacturing for therapeutic candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our therapeutic candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">an inability to initiate or continue preclinical studies or clinical trials of our therapeutic candidates under development; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">delay in submitting regulatory applications, or receiving regulatory approvals, for therapeutic candidates; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">loss of the cooperation of a future collaborator; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">subjecting manufacturing facilities of our therapeutic candidates to additional inspections by regulatory authorities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">requirements to cease distribution or to recall batches of our therapeutic candidates; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in the event of approval to market and commercialize a therapeutic candidate, an inability to meet commercial demands for our therapeutics. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies, including delivery technologies, or therapeutic candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The development and commercialization of therapeutic candidates is highly competitive. We compete with a number of multinational pharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or will develop therapeutic candidates and processes competitive with our therapeutic candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that enter the market. We believe that a significant number of therapeutics are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop therapeutic candidates. There is intense and rapidly evolving competition in the biotechnology, pharmaceutical and oligonucleotide therapeutics fields. While we believe that our SNA technology, its associated intellectual property and our scientific and technical know-how give us a competitive advantage in this space, competition from many sources remains. Our competitors include larger and better funded pharmaceutical, biotechnology and oligonucleotide therapeutics companies. Moreover, we also compete with current and future therapeutics developed at universities and other research institutions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are aware of several companies that are developing oligonucleotide delivery platforms and oligonucleotide-based therapeutics. These competitors include Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Arbutus Biopharma Corp., Wave Life Sciences Ltd., Dynavax Technologies Corp., Idera Pharmaceuticals, Inc., Mologen AG, and Checkmate Pharmaceuticals, Inc. These and other competitors compete with us in recruiting scientific and managerial talent, and for funding from pharmaceutical companies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our success will partially depend on our ability to develop and protect therapeutics that are safer and more effective than competing therapeutics. Our commercial opportunity and success will be reduced or eliminated if competing therapeutics are safer, more effective, or less expensive than the therapeutics we develop. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If our therapeutic candidates are approved for the indications we are currently pursuing, they will compete with a range of therapeutic treatments that are either in development or currently marketed. A number of therapeutics for treating psoriasis and cancers are on the market or in clinical development. For the treatment of psoriasis, marketed therapies range from small molecules like topical steroids to biologics, such as AbbVie Inc.&#8217;s adalimumab. In addition, numerous compounds are in clinical development for psoriasis treatment. With respect to immunogenic cancers such as melanoma, the most common treatments are chemotherapeutic compounds, radiation therapy and now immunotherapeutic antibodies such as ipilimumab, atezolizumab and pembrolizumab. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any therapeutic candidate, we will face competition based on many different factors, including the safety and effectiveness of our therapeutics, the ease with which our therapeutics can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these therapeutics, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing therapeutics could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any therapeutics we may develop. Competitive therapeutics may make any therapeutics we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our therapeutic candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The market may not be receptive to our therapeutic candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Even if approval is obtained for a therapeutic candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and otherwise accepted in the market. The therapeutic candidates that we are developing are based on our SNA technology. Market participants with significant influence over acceptance of new treatments, such as physicians and third party payors, may not adopt a treatment based on SNA technology, and we may not be able to convince the medical community and third party payors to accept and use, or to provide favorable reimbursement for, any therapeutic candidates developed by us or any current or future collaborators. Market acceptance of our therapeutic candidates will depend on, among other factors: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing of our receipt of any marketing and commercialization approvals; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the terms of any approvals and the countries in which approvals are obtained; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the safety and efficacy of our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the prevalence and severity of any adverse side effects associated with our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">relative convenience and ease of administration of our therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the willingness of patients to accept any new methods of administration; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the success of our physician education programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the availability of adequate government and third party payor reimbursement; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the pricing of our products, particularly as compared to alternative treatments; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">availability of alternative effective treatments for indications our therapeutic candidates are intended to treat and the relative risks, benefits and costs of those treatments. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With our focus on SNAs, these risks may increase to the extent the space becomes more competitive or less favored in the commercial marketplace. Additional risks apply in relation to any disease indications we may pursue which are classified as rare diseases and allow for orphan drug designation by regulatory agencies in major commercial markets, such as the U.S., Europe and Japan. Because of the small patient population for a rare disease, if pricing is not approved or accepted in the market at an appropriate level for an approved product with orphan drug designation, such therapeutic may not generate enough revenue to offset costs of development, manufacturing, marketing and commercialization despite any benefits received from the orphan drug designation, such as market exclusivity, assistance in clinical trial design or a reduction in user fees or tax credits related to development expense. Market size is also a variable in disease indications not classified as rare. Our estimates regarding potential market size for any indication may be materially different from what we discover to exist at the time we commence commercialization, if any, for a therapeutic, which could result in significant changes in our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If a therapeutic candidate that has orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the therapeutic candidate is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same therapeutic candidate for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same therapeutic candidate as defined by the FDA or if our therapeutic candidate is determined to be contained within the competitor&#8217;s therapeutic candidate for the same indication or disease. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As in the U.S., we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made.  Sponsors of orphan drugs in the European Union can enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication.  During such period, marketing applications for similar medicinal products will not be accepted, unless certain exceptions apply.  In the EU, a &#8220;similar medicinal product&#8221; is a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our success largely depends on the continued service of key management and other specialized personnel, including David A. Giljohann, Ph.D., our Chief Executive Officer, David S. Snyder, our Chief Financial Officer, and Matthias G. Schroff, our Chief Operating Officer. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and materially harm our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our therapeutic candidates and our technology and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members or key employees. Our future success will depend in large part on our continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If our therapeutic candidates advance into clinical trials, we may experience difficulties in managing our growth and expanding our operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have limited experience in therapeutic development and limited experience with clinical trials of therapeutic candidates. As our therapeutic candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If any of our therapeutic candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future therapeutics. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently have no sales, marketing or distribution capabilities or experience. If any of our therapeutic candidates is approved, we will need to develop internal sales, marketing and distribution capabilities to appropriately commercialize such therapeutics, which would be expensive and time-consuming, or enter into collaborations with third parties to perform these services. If we decide to market our approved therapeutics directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market our approved therapeutics or decide to co-promote therapeutics with collaborators, we will need to establish and maintain compliant marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and there can be no assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved therapeutic. If we are not successful in commercializing any therapeutic approved in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we fail to comply with U.S. or foreign regulatory requirements, regulatory authorities could withhold marketing or commercialization approvals, limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We and our therapeutic candidates, as well as our suppliers, contract manufacturers, distributors, and contract testing laboratories are subject to extensive regulation by governmental authorities in the European Union, the U.S., and other countries, with the regulations differing from country to country. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we or current or future collaborators, manufacturers or service providers fail to comply with applicable requirements, these regulatory authorities could refuse to issue necessary approvals for marketing and commercialization. Even if we receive marketing and commercialization approval of a therapeutic candidate, we and our third party service </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">providers will be subject to continuing regulatory requirements, including a broad array of regulations related to establishment, registration and product listing, manufacturing processes, risk management measures, quality and pharmacovigilance systems, pre- and post-approval clinical data, labeling, advertising and promotional activities for such therapeutic, record keeping, distribution, and import and export of therapeutics for any therapeutic for which we obtain marketing approval. We are required to submit safety and other post market information and reports and are subject to continuing regulatory review, including in relation to adverse patient experiences with the therapeutic and clinical results that are reported after a therapeutic is made commercially available, both in the U.S. and any foreign jurisdiction in which we seek regulatory approval. The FDA and certain foreign regulatory authorities, such as the EMA, have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a therapeutic or to require withdrawal of the therapeutic from the market. The FDA also has the authority to require a Risk Evaluation and Mitigation Strategies, or REMS, plan either before or after approval, which may impose further requirements or restrictions on the distribution or use of an approved therapeutic. The EMA now routinely requires risk management plans, or RMPs, as part of the marketing authorization application process, and such plans must be continually modified and updated throughout the lifetime of the product as new information becomes available. In addition, for nationally authorized medicinal products, the relevant governmental authority of any European Union member state can request an RMP whenever there is a concern about the risk/benefit balance of the product. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The manufacturer and manufacturing facilities we use to make a future therapeutic, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third party manufacturers, manufacturing processes or facilities may result in restrictions on the therapeutic, manufacturer or facility, including withdrawal of the therapeutic from the market. If we rely on third party manufacturers, we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. If we or our future collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our therapeutics, we or they may be subject to, among other things, fines, warning and untitled letters, clinical holds, delay or refusal by the FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension, refusal to renew or withdrawal of regulatory approval, recalls, seizures or administrative detention of products, refusal to permit the import or export of therapeutics, operating restrictions, inability to participate in government programs including Medicare and Medicaid, and total or partial suspension of production or distribution, injunction, restitution, disgorgement, debarment, civil and criminal penalties and criminal prosecution. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Price controls imposed in foreign markets may adversely affect our future profitability. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control at the national level, and in some cases also at the regional level. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing and reimbursement negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our SNA therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any therapeutic candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our business entails a significant risk of product liability and our inability to obtain sufficient insurance coverage could have a material adverse effect on our business, financial condition, results of operations or prospects. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing therapeutics, such claims could result in an investigation by certain regulatory authorities, such as the FDA or foreign regulatory authorities, of the safety and effectiveness of our therapeutics, our manufacturing processes and facilities or our marketing programs and potentially a recall of our therapeutics or more </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our therapeutics, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels of product liability insurance prior to marketing any of our therapeutic candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements which could have an adverse effect on our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include, but is not limited to, intentional failures to comply with FDA, the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), the Department of Health and Human Services (&#8220;HHS&#8221;), Office of Inspector General (&#8220;OIG&#8221;) or other agency regulations, applicable laws, regulations, guidance or codes of conduct set by foreign governmental authorities or self-regulatory industry organizations, or provide accurate information to any governmental authorities, such as the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws, regulations, guidance and codes of conduct intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws, regulations, guidance and codes of conduct may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions, including, fines, debarment, or disqualification of those employees from participation in certain government-regulated activities, and serious harm to our reputation. This could include violations of the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including exclusion from participation in the U.S. federal healthcare programs, the imposition of significant fines or other sanctions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our technology. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Animal Welfare Act, or AWA, is the federal law that covers the treatment of certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations that govern the humane handling, care, treatment and transportation of certain animals by producers and users of research animals, most notably relating to personnel, facilities, sanitation, cage size, and feeding, watering and shipping conditions. Third parties with whom we contract are subject to registration, inspections and reporting requirements under the AWA. Furthermore, some states have their own regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations, and or obligations exist in many foreign jurisdictions. If we or our contractors fail to comply with regulations concerning the treatment of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our therapeutic development programs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions of our operations. For </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">instance, the loss of preclinical study or clinical trial data involving our therapeutic candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, theft or other exposure of data may interfere with our ability to protect our intellectual property, trade secrets, and other information critical to our operations. We can provide no assurances that certain sensitive and proprietary information relating to one or more of our therapeutic candidates has not been, or will not in the future be, compromised. Although we have invested resources to enhance the security of our computer systems, there can be no assurances we will not experience additional unauthorized intrusions into our computer systems, or those of our CROs and other contractors and consultants, that we will successfully detect future unauthorized intrusions in a timely manner, or that future unauthorized intrusions will not result in material adverse effects on our financial condition, reputation, or business prospects. Payments related to the elimination of ransomware may materially affect our financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain data breaches must also be reported to affected individuals and the government, and in some cases to the media, under provisions of HIPAA, as amended by HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive.  Financial penalties may also apply in some data breaches where noncompliance with the applicable law is identified.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of our therapeutic candidates could be delayed. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to European data protection laws, including the new EU General Data Protection Regulation 2016/679, or GDPR.  If we fail to comply with existing or future data protection regulations, our business, financial condition, results of operations and prospects may be materially adversely affected.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">By virtue of our clinical trial activities in the United Kingdom and Germany, we are subject to European data protection laws, including GDPR.  The GDPR which came into effect on May&#160;25, 2018, establishes new requirements applicable to the processing of personal data (</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">i.e</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">., data which identifies an individual or from which an individual is identifiable), affords new data protection rights to individuals (e.g., the right to erasure of personal data) and imposes penalties for serious breaches of up to 4% annual worldwide turnover or &#8364;20&#160;million, whichever is greater.  Individuals (</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">e.g</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">., study subjects) also have a right to compensation for financial or non-financial losses (</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">e.g</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">., distress).  There may be circumstances under which a failure to comply with GDPR, or the exercise of individual rights under the GDPR, would limit our ability to utilize clinical trial data collected on certain subjects.  The GDPR will likely impose additional responsibility and liability in relation to our processing of personal data.  This may be onerous and materially adversely affect our business, financial condition, results of operations and prospects.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic chemicals in our facilities in Skokie, Illinois that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Skokie facilities comply with the relevant guidelines of Skokie, the state of Illinois, and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our information technology systems could face serious disruptions that could adversely affect our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A significant </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions and delays in our research and development work. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our current operations are concentrated in one location and any events affecting this location may have material adverse consequences. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our current operations are located in our facilities situated in Skokie, Illinois. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize the facilities, may have a material adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our therapeutic candidates or interruption of our business operations. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material adverse effect on our business, financial position, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The investment of our cash, cash equivalents and fixed income marketable securities is subject to risks which may cause losses and affect the liquidity of these investments. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December&#160;31, 2018 and 2017, we had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$26.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in cash and cash equivalents, respectively.  We historically have invested excess cash in certificates of deposit or money market mutual funds that invest in U.S.&#160;government or U.S.&#160;government agency securities, floating rate and variable rate demand notes of U.S.&#160;and foreign corporations, and commercial paper.  These investments are subject to general credit, liquidity, market and interest rate risks, including potential future impacts similar to the impact of U.S.&#160;sub-prime mortgage defaults that have affected various sectors of the financial markets and caused credit and liquidity issues.  We may realize losses in the fair value of these investments, an inability to access cash in these investments for a potentially meaningful period, or a complete loss of these investments, which would have a negative effect on our financial statements. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Changes in accounting rules and regulations, or interpretations thereof, could result in unfavorable accounting charges or require us to change our compensation policies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accounting methods and policies for biotechnology companies, including policies governing revenue recognition, research and development and related expenses, and accounting for stock-based compensation, are subject to review, interpretation and guidance from our auditors and relevant accounting authorities, including the SEC. Changes to accounting methods or policies, or interpretations thereof, may require us to reclassify, restate or otherwise change or revise our historical financial statements, including those contained in this Annual Report on Form 10-K. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We previously identified a material weakness in our internal control over financial reporting, and if we are unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock may be adversely effected, and we may become subject to litigation and regulatory investigation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the quarter ended March&#160;31, 2018, we identified a material weakness in internal control over financial reporting related to a deficiency in the Company&#8217;s information and communication controls, which led to ineffectively designed controls over management&#8217;s review of certain research and development contracts to ensure expenses were recognized as incurred by third-party contract research organizations.  Those ineffectively designed controls arose in a prior period and resulted in an immaterial error.  The immaterial error has been corrected in previously issued financial statements as disclosed in Note&#160;1 to the accompanying consolidated financial statements for the period ended December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As further described above and in Part II, Item 9A &#8220;Controls and Procedures,&#8221; of this Form 10-K, management has implemented applicable remedial controls, believes those remedial controls have operated for a sufficient period of time and has concluded that the material weakness discussed above is remediated at December 31, 2018.  If the additional </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">controls and procedures we have implemented are not effective, or if we identify new material weaknesses in the future in our internal controls over financial reporting, we may not detect errors in a timely manner and our consolidated financial statements may be materially misstated.  We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall.  We may also fail to report our financial results on a timely and accurate basis, which could result in sanctions, lawsuits, or other adverse consequences that would materially harm our business.  In addition, we could become subject to investigations by the national stock exchange on which our securities are eventually listed, the SEC, or other regulatory authorities, and become subject to litigation from investors and stockholders, which could harm our reputation and our financial condition, or divert financial and management resources from our core business.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We have incurred significant losses since our inception and expect to incur continued losses in the future.  We must obtain additional funds to finance our operations and to remain a going concern. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our recurring losses from operations raise substantial doubt about our ability to continue as a going concern.  As a result, we included an explanatory paragraph in our consolidated financial statements for the period ended December 31, 2018 with respect to this uncertainty.  Our ability to continue as a going concern will require us to obtain additional funding.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Based on the Company&#8217;s current operating plans, we believe that existing working capital at December 31, 2018 is sufficient to fund our current operating plans into January 2020.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;We have based these estimates, however, on assumptions that may prove to be wrong, and we could spend our available financial resources much faster than we currently expect and need to raise additional funds sooner than we anticipate.  The perception of our ability to continue as a going concern may make it more difficult for us to obtain financing for the continuation of our operations and could result in the loss of confidence by investors, suppliers and employees.  If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate our research and development programs and commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our business may be affected by litigation and government investigations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may from time to time receive inquiries and subpoenas and other types of information requests from government authorities and others and we may become subject to claims and other actions related to our business activities. While the ultimate outcome of investigations, inquiries, information requests and legal proceedings is difficult to predict, defense of litigation claims can be expensive, time-consuming and distracting, and adverse resolutions or settlements of those matters may result in, among other things, modification of our business practices, costs and significant payments, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Intellectual Property </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are not able to obtain and enforce patent protection for our technology or therapeutic candidates, development and commercialization of our therapeutic candidates may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our therapeutic candidates, methods used to manufacture our therapeutic candidates and methods for treating patients using our therapeutic candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December 31, 2018, our patent portfolio consists of over 60 issued patents and allowed patent applications and over 135 pending patent applications.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;We may not be able to apply for patents on certain aspects of our therapeutic candidates in a timely fashion or at all. Our existing issued and granted patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing therapeutics and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable or that any issued or granted patents will include claims that are sufficiently broad to cover our therapeutic candidates or to provide meaningful protection from our competitors. Moreover, the patent position of pharmaceutical and biotechnology companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and therapeutic candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely impact our position in the market. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and pharmaceutical patents. As such, we do not know the degree of future protection that we will have on our proprietary therapeutics and technology. While we will endeavor to try to protect our therapeutic candidates with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and sometimes unpredictable. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, there are numerous recent changes to the patent laws and proposed changes to the rules of the USPTO, which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, the Leahy-Smith America Invents Act enacted in 2011, involves significant changes in patent legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, some of which cases either narrow the scope of patent protection available in certain circumstances or weaken the rights of patent owners in certain situations. The 2013 decision by the Supreme Court in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Association for Molecular Pathology v. Myriad Genetics, Inc.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;precludes a claim to a nucleic acid having a stated nucleotide sequence that is identical to a sequence found in nature and unmodified. We currently are not aware of an immediate impact of this decision on our patents or patent applications because we are developing oligonucleotide therapeutics which contain modifications that we believe are not found in nature. However, this decision has yet to be clearly interpreted by courts and by the USPTO. We cannot assure you that the interpretations of this decision or subsequent rulings will not adversely impact our patents or patent applications. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that may weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. In addition, there can be no assurance that: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Others will not or may not be able to make, use or sell compounds that are the same as or similar to our therapeutic candidates but that are not covered by the claims of the patents that we own or license. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We or our licensors, or any current or future collaborators, are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We or our licensors, or any current or future collaborators, are the first to file patent applications covering certain aspects of our inventions. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Others will not independently develop similar or alternative technologies or duplicate any of our technology without infringing our intellectual property rights. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A third party will not challenge our patents and, if challenged, a court may not hold that our patents are valid, enforceable and infringed. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We will develop additional proprietary technologies that are patentable. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The patents of others will not have an adverse effect on our business. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our competitors will not conduct research and development activities in countries where we lack enforceable patent rights and then use the information learned from such activities to develop competitive therapeutics for sale in our major commercial markets. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We currently license patent rights from Northwestern University and may in the future license patent rights from third party owners or licensees. If Northwestern University or such other owners or licensees do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do, and will continue to, rely on intellectual property rights licensed from third parties to protect our technology. We are a party to a number of licenses that give us rights to third party intellectual property that is necessary or useful for our business. In particular, we have a license from Northwestern University, which provides us the exclusive worldwide right under certain patents and patent applications owned by Northwestern University to exploit therapeutics and processes using nanoparticles, nanotechnology, microtechnology and nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of administration. We may also license additional third party intellectual property in the future. Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, and in particular, for those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications licensed to us. Even if patents issue or are granted, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue litigation less aggressively than we would. Further, we may not obtain exclusive rights, which would allow for third parties to develop competing therapeutics. Without protection for, or exclusive rights to, the intellectual property we license, other companies might be able to offer substantially identical therapeutics for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, the U.S. government has certain rights to the inventions covered by the patent rights licensed to us by third parties and Northwestern University, as an academic research and medical center, has reserved the right to practice the patent rights it has licensed to us (i)&#160;for research, teaching and/or other educationally related purposes (including the right to distribute materials for such purposes) and (ii)&#160;for use in the field of diagnostics (including theradiagnostics) and in any field other than the field of use licensed to us. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Other companies or organizations may challenge our or our licensors&#8217; patent rights or may assert patent rights that prevent us from developing and commercializing our therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Oligonucleotide and SNA-based therapeutics are a relatively new scientific field. We have obtained grants and issuances of SNA therapeutic patents and have licensed many of these patents from a third party on an exclusive basis for therapeutics applications. The issued patents and pending patent applications in the U.S. and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of SNA therapeutics. Specifically, we own and have licensed a portfolio of patents, patent applications and other intellectual property covering SNA compositions of matter as well as their methods of use. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As the field of SNA therapeutics matures, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material adverse effect on our business and our ability to successfully compete. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There are many issued and pending patents that claim aspects of oligonucleotide chemistry and modifications that we may need to apply to our SNA therapeutic candidates. There are also many issued patents that claim targeting genes or portions of genes that may be relevant for SNA therapeutics we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may not be able to market therapeutics or perform research and development or other activities covered by these patents. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to protect our intellectual property rights throughout the world. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Obtaining a valid and enforceable issued or granted patent covering our technology in the U.S. and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors may use our technology to develop their own therapeutics and, further, may export otherwise infringing therapeutics to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the U.S. Competitor therapeutics may compete with our future therapeutics in jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biotechnology and pharmaceuticals. This could make it difficult for us to prevent the infringement of our patents or marketing of competing therapeutics in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We generally file a provisional patent application first, also known as a priority filing, at the USPTO. An international application under the Patent Cooperation Treaty, or PCT, is usually filed within twelve months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in the U.S., European Union, Japan, Australia and Canada and, depending on the individual case, also in any or all of, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">inter alia</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, China, India, South Korea, and Mexico. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes of patent protection may be granted on the same therapeutic candidate or technology. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the U.S., and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We or our licensors, or any current or future strategic partners, may become subject to third party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development and commercialization of our therapeutic candidates, or put our patents and other proprietary rights at risk. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We or our licensors, or any current or future strategic partners, may be subject to third party claims for infringement or misappropriation of patent or other proprietary rights. We are generally obligated under our license agreements to indemnify and hold harmless our licensors for damages arising from intellectual property infringement by us. If we or our licensors, or any current or future strategic partners, are found to infringe a third party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our licensors, or any current or future strategic partners, may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we or any current or future collaborator may be unable to effectively market therapeutic candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our therapeutics or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our therapeutics or certain aspects of our technology. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">It is also possible that we have failed to identify relevant third party patents or applications. For example, U.S. applications filed before November&#160;29, 2000 and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our therapeutics or technology could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our SNA technology, our therapeutics or the use of our therapeutics. Third party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our therapeutics. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our therapeutic candidates that are held to be infringing. We might, if possible, also be forced to redesign therapeutic candidates so that we no longer infringe the third party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our therapeutic candidates or we could lose certain rights to grant sublicenses. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell therapeutics that are covered by the licensed technology or could enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights in such unlicensed intellectual property. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future therapeutics, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in therapeutics that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize therapeutics, we may be unable to achieve or maintain profitability. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If we are unable to pr</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">otect the con</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">fidentiality of our trade secrets, our business and competitive position would be harmed.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to seeking patent protection for certain aspects of our therapeutic candidates, we also consider trade secrets, including confidential and unpatented know-how important to the maintenance of our competitive position. We protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the U.S. and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the terms of the Northwestern University License Agreements, Northwestern University could publish research findings relating to the patent rights licensed to us by Northwestern University, which could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are also subject both in the U.S. and outside the U.S. to various regulatory schemes regarding requests for the information we provide to regulatory authorities, which may include, in whole or in part, trade secrets or confidential commercial information. While we are likely to be notified in advance of any disclosure of such information and would likely object to such disclosure, there can be no assurance that our challenge to the request would be successful. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Many of our employees were previously employed at universities or pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our therapeutic candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Third parties may independently develop similar or superior technology. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There can be no assurance that others will not independently develop, or have not already developed, similar or more advanced technologies than our technology; or that others will not design around, or have not already designed around, aspects of our technology and/or our trade secrets developed therefrom. If third parties develop technology similar or superior to our technology, or they successfully design around our current or future technology, our competitive position, business prospects, and results of operations could be materially and adversely affected. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The intellectual property which we have licensed from Northwestern University was discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to contract with non-U.S. manufacturers. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have licensed certain intellectual property from Northwestern University pursuant to the Northwestern University License Agreements. The Northwestern University License Agreements indicate that the rights licensed to us by Northwestern University are subject to the obligations to and the rights of the U.S. government, including those set&#160;forth in the Bayh-Dole Act of 1980, or the Bayh-Dole Act. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future therapeutics based on the licensed Northwestern University intellectual property. These U.S. government rights&#160;in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide&#160;license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or nonexclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, also referred to as&#160;&#8220;march-in rights.&#8221; While the U.S. government has sparingly used, and to the Company&#8217;s knowledge never successfully exercised, such march-in rights, any exercise of the march-in rights by the U.S. government could harm our competitive position, business, financial condition, results of operations, and prospects. If the U.S. government exercises such march-in rights, </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">we may receive compensation that is deemed reasonable by the U.S. government in its sole discretion, which may be less than what we might be able to obtain in the open market. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the U.S. government requires that any therapeutics embodying any invention generated through the use of U.S. government funding be manufactured substantially in the U.S. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. therapeutic manufacturers for therapeutics covered by such intellectual property. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Government Regulation </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our therapeutic candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing, sampling, and distribution of therapeutics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new therapeutic can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that none of the therapeutic candidates we may develop will obtain the regulatory approvals necessary for us or any current or future collaborators to begin selling them. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA as well as foreign regulatory authorities, such as the EMA and European Union national competent authorities. The time required to obtain FDA and foreign regulatory approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the therapeutic candidate. The standards that the FDA and its foreign counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in the policy of the FDA or foreign regulatory authorities during the period of therapeutic development, clinical trials and regulatory review by the FDA or foreign regulatory authorities. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign laws, regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Because the therapeutics we are developing may represent a new class of therapeutic, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to these therapeutics. While we believe the therapeutic candidates that we are currently developing are regulated as new drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the FDA could decide to regulate them or other therapeutics we may develop as biologics under the Public Health Service Act. The lack of policies, practices or guidelines may hinder or slow review by the FDA or foreign regulatory authorities of any regulatory filings that we may submit. Moreover, the FDA may respond to these submissions by defining requirements we may not have anticipated. Such responses could lead to significant delays in the clinical development of our therapeutic candidates. In addition, because there may be therapeutic candidates approved for some of the diseases for which we may seek approval, in order to receive regulatory approval, we may need to demonstrate through clinical trials that the therapeutic candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular therapeutic candidate for which we are seeking approval. Furthermore, any regulatory approval to market a therapeutic may be subject to limitations on the approved uses for which we may market the therapeutic or the labeling or other restrictions. Regulatory authorities also may impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic. In addition, the FDA has the authority to require a REMS plan as part of a NDA or a Biologics License Application, or BLA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the therapeutic and affect coverage and reimbursement by third party payors. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the U.S. and vice versa. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Certain of our therapeutic candidates may require companion diagnostics in certain indications.  Failure to successfully develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our therapeutic candidates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain of our therapeutic candidates may require companion diagnostics to identify appropriate patients for those therapeutic candidates in certain indications.  Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as a medical device and may require separate regulatory authorization prior to commercialization.  We may rely on third parties for the design, development, testing and manufacturing of these companion diagnostics, the application for and receipt of any required regulatory authorization, and the commercial supply of these companion diagnostics.  If these parties are unable to successfully develop companion diagnostics for these therapeutic candidates, or experience delays in doing so, the development of our therapeutic candidates may be adversely affected and we may not be able to obtain marketing authorization for these therapeutic candidates.  Furthermore, our ability to market and sell, as well as the commercial success, of any of our therapeutic candidates that require a companion diagnostic will be tied to, and dependent upon, the receipt of required regulatory authorization and the continued ability of such third parties to make the companion diagnostic commercially available on reasonable terms in the relevant geographies.  Any failure to develop, validate, obtain and maintain marketing authorization for a companion diagnostic and supply such companion diagnostic will harm our business, results of operations and financial condition</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we or current or future collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our therapeutics and may harm our reputation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Although we do not currently have any products on the market, once our therapeutic candidates or clinical trials are covered by federal health care programs, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal, state and foreign governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain marketing approval. Our arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell or distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include, but are not limited to, the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made, in whole or in part, under a federal healthcare program, such as Medicare or Medicaid; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the U.S.&#160;federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">HIPAA includes a fraud and abuse provision referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program (i.e., not just federal healthcare programs), or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:24px;padding-bottom:12px;text-align:left;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">HIPAA, as amended by HITECH, and its implementing regulations, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the federal Physician Payment Sunshine Act and the implementing regulations, also referred to as &#8220;Open Payments,&#8221; issued under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the ACA, which require that manufacturers of pharmaceutical and biological drugs reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program report to the Department of Health and Human Services all consulting fees, travel reimbursements, research grants, and other payments, transfers of value or gifts made to U.S.-licensed physicians and U.S. teaching hospitals with limited exceptions; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">analogous state laws and regulations, such as, state anti-kickback and false claims laws potentially applicable to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and state transparency laws that require the reporting of certain pricing information; among other state laws. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Ensuring that our future business arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect our financial results. Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we or current or future collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our therapeutics successfully and could harm our reputation and lead to reduced acceptance of our therapeutics by the market. These enforcement actions include, among others: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">adverse regulatory inspection findings; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">warning or untitled letters; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">voluntary product recalls or public notification or medical product safety alerts to healthcare professionals; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">restrictions on, or prohibitions against, marketing our therapeutics; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">restrictions on, or prohibitions against, importation or exportation of our therapeutics; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">suspension of review or refusal to approve pending applications or supplements to approved applications; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">exclusion from participation in government-funded healthcare programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">exclusion from eligibility for the award of government contracts for our therapeutics; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">FDA debarment; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">suspension or withdrawal of therapeutic approvals; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">seizures or administrative detention of therapeutics; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">injunctions; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">civil and criminal penalties and fines. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Any therapeutics we develop may become subject to unfavorable pricing regulations, third party coverage and reimbursement practices or healthcare reform initiatives, thereby harming our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The regulations that govern marketing approvals, pricing and reimbursement for new therapeutics vary widely from country to country. Some countries require approval of the sale price of a therapeutic before it can be marketed. In many countries, the pricing review period begins after marketing or therapeutic licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently in the early stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result, we might obtain regulatory approval for a therapeutic in a particular country, but then be subject to price regulations that delay our commercial launch of the therapeutic and negatively impact the revenues we are able to generate from the sale of the therapeutic in that country.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our ability to commercialize any therapeutics successfully also will depend in part on the extent to which coverage and reimbursement for these therapeutics and related treatments will be available from government health administration authorities, private health insurers and other organizations. However, there may be significant delays in obtaining coverage for newly-approved therapeutics. Moreover, eligibility for coverage does not necessarily signify that a therapeutic will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution costs. Also, interim payments for new therapeutics, if applicable, may be insufficient to cover our costs and may not be made permanent. Thus, even if we succeed in bringing one or more therapeutics to the market, these therapeutics may not be considered cost-effective, and the amount reimbursed for any therapeutics may be insufficient to allow us to sell our therapeutics on a competitive basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of reimbursement. Increasingly, the third party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are seeking greater upfront discounts, additional rebates and other concessions to reduce the prices for therapeutics. If the price we are able to charge for any therapeutics we develop, or the reimbursement provided for such therapeutics, is inadequate in light of our development and other costs, our return on investment could be adversely affected.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently expect that some therapeutics we develop may need to be administered under the supervision of a physician on an outpatient basis. Under currently applicable U.S. law, certain therapeutics that are not usually self-administered (including injectable therapeutics) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part B is part of original Medicare, the federal health care program that provides health care benefits to the aged and disabled, and covers outpatient services and supplies, including certain pharmaceutical products that are medically necessary to treat a beneficiary&#8217;s health condition. Specifically, Medicare Part B coverage may be available for eligible beneficiaries when the following, among other requirements, have been satisfied:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the product is reasonable and necessary for the diagnosis or treatment of the illness or injury for which the product is administered according to accepted standards of medical practice; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the product is typically furnished incident to a physician&#8217;s services; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the product has been approved by the FDA. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Medicaid Drug Rebate Statute, a manufacturer must participate in the Medicaid Drug Rebate Program in order to receive payment for its covered outpatient drugs under Medicare Part B (the Medicare program that generally covers physician-administered, outpatient drugs).&#160; 42 U.S.C. &#167; 1396r-8(a)(1).  In addition, manufacturers who participate in the Medicaid Drug Rebate Program are also required to (1) sign the Pharmaceutical Pricing Agreement and participate in the 340B Drug Pricing Program, and (2) sign the VA Master Agreement for inclusion of the manufacturer&#8217;s drugs on the Federal Supply Schedule (&#8220;FSS&#8221;).  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Id</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities eligible to </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">participate in the program. Average prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of therapeutics from countries where they may be sold at lower prices than in the U.S. Self-administered therapeutics are typically reimbursed under Medicare Part D, and therapeutics that are administered in an inpatient hospital setting are typically reimbursed under Medicare Part A under a bundled payment. It is difficult for us to predict how Medicare coverage and reimbursement policies will be applied to our therapeutics in the future and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Third-party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage, and adequate reimbursement from both government-funded and private payors for new therapeutics we develop and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that the efforts of governments and third party payors to contain or reduce the cost of healthcare, and specifically, therapeutics, and legislative and regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biotechnology companies. A number of legislative and regulatory changes in the healthcare system in the U.S. and other major healthcare markets have been proposed. These developments could, directly or indirectly, affect our ability to sell our therapeutics, if approved, at a favorable price.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For example, in the U.S., in 2010, the U.S. Congress passed the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional policy reforms.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Although the future of the ACA is uncertain, provisions of the ACA addressing coverage and reimbursement of pharmaceutical products that may be of importance to our potential therapeutic candidates include the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Increases to pharmaceutical manufacturer rebate liability under the Medicaid Drug Rebate Program due to an increase in the minimum basic Medicaid rebate on most branded prescription drugs and the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed care plans.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The expansion of the 340B Drug Pricing Program to require discounts for &#8220;covered outpatient drugs&#8221; sold to certain children&#8217;s hospitals, critical access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospitals. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Requirements imposed on pharmaceutical companies to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly referred to as the &#8220;Donut Hole.&#8221; In February 2018, Congress passed the Bipartisan Budget Act of 2018, which, beginning in 2019, increased the discount to be paid by pharmaceutical companies from 50% to 70% of a brand-name drug&#8217;s negotiated price and added biosimilars to the coverage gap discount program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Requirements imposed on pharmaceutical companies to pay an annual non-tax-deductible fee to the federal government based on each company&#8217;s market share of prior year total sales of branded drugs to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs, and Department of Defense. Since we currently expect our branded pharmaceutical sales to constitute a small portion of the total federal healthcare program pharmaceutical market, we do not currently expect this annual assessment to have a material impact on our financial condition. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For therapeutic candidates classified as biologics, marketing approval for a follow-on biologic therapeutic may not become effective until 12 years after the date on which the reference innovator biologic therapeutic was first licensed by the FDA, with a possible six-month extension for pediatric therapeutics. After this exclusivity ends, it may be possible for biosimilar manufacturers to enter the market, which is likely to reduce the pricing for such therapeutics and could affect our profitability if our therapeutics are classified as biologics. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Separately, pursuant to the health reform legislation and related initiatives, the Centers for Medicare and Medicaid Services, or CMS, is working with various healthcare providers to develop, refine, and implement Accountable Care Organizations, or ACOs, and other innovative models of care for Medicare and Medicaid beneficiaries, including the Bundled Payments for Care Improvement Initiative, the Financial Alignment Initiative Demonstration, and other models. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The continued development and expansion of ACOs and other innovative models of care will have an uncertain impact on any future reimbursement we may receive for approved therapeutics administered by such organizations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From time to time, legislation is drafted, introduced and passed in the U.S. Congress that could significantly change the statutory provisions governing coverage, reimbursement, sales, and marketing of products regulated by CMS or other government agencies. In addition to new legislation, CMS, OIG, and other agency rules and policies addressing fraud and abuse, privacy, and coverage and reimbursement, among other things, are often revised or interpreted in ways that may significantly affect our business and our products. In particular, we expect that the Administration and the U.S. Congress may continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the U.S. healthcare reform legislation. Since taking office, President Trump has continued to support the repeal of all or portions of the ACA. President Trump has also issued an executive order in which he stated that it is his administration&#8217;s policy to seek the prompt repeal of the ACA and in which he directed executive departments and federal agencies to waive, defer, grant exemptions from, or delay the implementation of the provisions of the ACA to the maximum extent permitted by law.  Congress has also enacted legislation that repeals certain portions of the ACA, including the Tax Cuts and Jobs Act, passed in December 2017, which included a provision that eliminates the penalty under the ACA&#8217;s individual mandate, effective January&#160;1, 2019, as well as the Bipartisan Budget Act of 2018, passed in February 2018, which, among other things, repealed the Independent Payment Advisory Board that was established by the ACA and was intended to reduce the rate of growth in Medicare spending. However, attempts to completely repeal the ACA have been unsuccessful to date. There is still uncertainty with respect to the impact President Trump&#8217;s Administration and the U.S. Congress may have, if any, and any changes will likely take time to unfold. For example, in May 2018, the Trump Administration recently published in the Federal Register a request for information regarding its Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (the &#8220;RFI&#8221;).  In the RFI, the Administration sought feedback on actions it could take to restrict or reduce the use of rebates, including by prohibiting the use of rebates in contracts between Medicare Part D plan sponsors and drug manufactures and removing federal Anti-Kickback Statute safe harbor protection for such rebates.  Subsequent to this, in July 2018, the Administration submitted to the White House Office of Management and Budget (&#8220;OMB&#8221;) for regulatory review a proposed rule entitled &#8220;Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.&#8221;  The Administration has not specified the substantive changes it may make to the federal Anti-Kickback Statute safe harbors or subregulatory guidance and the rule is not yet publicly available.  The Administration&#8217;s Blueprint also suggests that the Administration is looking at options to require drug-pricing transparency, including requiring the inclusion of drug list prices in direct-to-consumer advertising.  In August 2018, the Administration sent a proposed rule to OMB titled &#8220;Medicare and Medicaid Programs; Regulations to Require Drug Pricing Transparency.&#8221;  Like the federal Anti-Kickback Statute proposed rule, the substance of this rule is also not currently publicly available, but many speculate that the proposal seeks to implement direct-to-consumer advertising requirements regarding list price noted above.  Separately, in a July 2018 speech outlining the Trump Administrations&#8217; healthcare regulatory reform efforts, the HHS Secretary announced that the Administration will soon begin considering changes to federal health privacy regulations.  Such reforms, however, could have an adverse effect on anticipated revenues from therapeutic candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop therapeutic candidates. The financial impact of U.S. healthcare reform legislation over the next few years will depend on a number of factors, including the policies reflected in implementing regulations and guidance and changes in sales volumes for therapeutics affected by the legislation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">However, we cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The healthcare industry is heavily regulated in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">the</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;U.S. at the federal, state, and local levels, and our failure to comply with applicable requirements may subject us to penalties and negatively affect our financial condition. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a healthcare company, our operations, clinical trial activities and interactions with healthcare providers may be subject to extensive regulation in the U.S., particularly if the company receives FDA approval for any of its therapeutics in the future. For example, if we receive FDA approval for a therapeutic for which reimbursement is available under a federal healthcare program (e.g., Medicare, Medicaid), it would be subject to a variety of federal laws and regulations, including those that prohibit the filing of false or improper claims for payment by federal healthcare programs (e.g., the False Claims Act), prohibit unlawful inducements for the referral of business reimbursable by federal healthcare programs (e.g., the federal Anti-Kickback Statute), and require disclosure of certain payments or other transfers of value made to U.S.-licensed physicians and teaching hospitals, or Open Payments. We are not able to predict how third parties will interpret these laws and apply applicable governmental guidance and may challenge our practices and activities under one or more of these laws. If our past or present operations are found to be in violation of any of these laws, we could be subject to civil and criminal penalties, which could hurt our business, our operations and financial condition. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Similarly, HIPAA prohibits, among other offenses, knowingly and willfully executing a scheme to defraud any health care benefit program, including private payors, or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for items or services under a health care benefit program. To the extent that we act as a business associate to a healthcare provider engaging in electronic transactions, we may also be subject to the privacy and security provisions of HIPAA, as amended by HITECH, which restricts the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the privacy and security of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare provider customers with respect to such information. Additionally, many states have enacted similar laws that may impose more stringent requirements on entities like ours. Failure to comply with applicable laws and regulations could result in substantial penalties and adversely affect our financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">obtain</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;services, reimbursement or funding from the federal government may be impacted by possible reductions in federal spending. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">U.S. federal government agencies currently face potentially significant spending reductions. The Budget Control Act of 2011, or the BCA, established a Joint Select Committee on Deficit Reduction, which was tasked with achieving a reduction in the federal debt level of at least $1.2 trillion. That committee did not draft a proposal by the BCA&#8217;s deadline. As a result, automatic cuts, referred to as sequestration, in various federal programs were scheduled to take place, beginning in January 2013, although the American Taxpayer Relief Act of 2012 delayed the BCA&#8217;s automatic cuts until March&#160;1, 2013. While the Medicare program&#8217;s eligibility and scope of benefits are generally exempt from these cuts, Medicare payments to providers and Part D health plans are not exempt. The BCA did, however, provide that the Medicare cuts to providers and Part D health plans would not exceed two percent. President Obama issued the sequestration order on March&#160;1, 2013, and cuts went into effect on April&#160;1, 2013. Additionally, the Bipartisan Budget Act of 2018 extended sequestration for Medicare through fiscal year 2027.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The U.S.&#160;federal budget remains in flux, which could, among other things, cut Medicare payments to providers.  Although the BBA passed in February 2018 enacts a two-year federal spending agreement and raises the federal spending cap on non-defense spending for fiscal years 2018 and 2019, the Medicare program is frequently identified as a target for spending cuts.  The full impact on our business of any future cuts in Medicare or other programs is uncertain.  In addition, we cannot predict any impact President Trump&#8217;s administration and the U.S.&#160;Congress may have on the federal budget.  If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health, to continue to function at current levels.  Amounts allocated to federal grants and contracts may be reduced or eliminated.  These reductions may also impact the ability of relevant agencies to timely review and approve therapeutic research and development, manufacturing, and marketing activities, which may delay our ability to develop, market, and sell any therapeutics we may develop.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If any of our therapeutic candidates receives marketing approval and we or others later identify undesirable side effects caused by the therapeutic candidate, our ability to market and derive revenue from the therapeutic candidates could be compromised. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the event that any of our therapeutic candidates receive regulatory approval and we or others identify undesirable side effects, adverse events or other problems caused by one of our therapeutics, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">regulatory authorities may withdraw their approval of the therapeutic or seize the therapeutic; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">we may need to recall the therapeutic or change the way the therapeutic is administered to patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">additional restrictions may be imposed on the marketing of the particular therapeutic or the manufacturing processes for the therapeutic or any component thereof; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">we may be subject to fines, restitution or disgorgement of profits or revenues, injunctions, or the imposition of civil penalties or criminal prosecution; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">regulatory authorities may require us to implement a REMS, or to conduct post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">we could be sued and held liable for harm caused to patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the therapeutic may become less competitive; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our reputation may suffer. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Significant developments stemming from the United Kingdom&#8217;s recent referendum on membership in the European Union could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On June&#160;23, 2016, the United Kingdom held a referendum and voted in favor of leaving the European Union. This referendum has created political and economic uncertainty, particularly in the United Kingdom and the European Union, and this uncertainty may last for years. Any business we conduct, now and in the future, in the United Kingdom, the European Union, and worldwide could be affected during this period of uncertainty, and perhaps longer, by the impact of the United Kingdom&#8217;s referendum. The referendum, and the likely withdrawal of the United Kingdom from the European Union it triggers, has caused and, along with events potentially occurring in the future as a consequence of the United Kingdom&#8217;s withdrawal, including the possible breakup of the United Kingdom, may continue to cause significant volatility in global financial markets, including in global currency and debt markets. This volatility could cause a slowdown in economic activity in the United Kingdom, Europe, or globally, which could adversely affect our operating results and growth prospects. In addition, our business could be negatively affected by new trade agreements between the United Kingdom and other countries, including the U.S., and by the possible imposition of trade or other regulatory barriers in the United Kingdom. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">It is currently unclear how regulations affecting clinical trials, the approval of our future therapeutic candidates, and the sale of these therapeutic candidates will be affected by this referendum either in the United Kingdom or elsewhere in Europe. These possible negative impacts, and others resulting from the United Kingdom&#8217;s actual or threatened withdrawal from the European Union, may adversely affect our operating results and growth prospects. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Common Stock </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (1)&#160;not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, (2)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (3)&#160;exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we are only required to provide two years of audited financial statements and two years of selected financial data. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held by non-affiliates exceeds $700.0&#160;million as of any June&#160;30 before that time or if we have total annual gross revenue of $1.07&#160;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December&#160;31, or if we issue more than $1.0&#160;billion in non-convertible debt during any three-year period before that time, in which case we would no longer be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our stock price may be volatile and purchasers of our common stock could incur substantial losses. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If a market for our common stock develops, its market price could fluctuate substantially due to a variety of factors, including the other risks described in this section titled &#8220;Risk Factors&#8221; and the following: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the success of competitive therapeutics or technologies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">results of our preclinical studies and clinical trials of our therapeutic candidates, or those of our competitors, or any current or future collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">regulatory or legal developments in the U.S. and other countries, especially changes in laws or regulations applicable to our therapeutics; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">introductions and announcements of new therapeutics by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">actions taken by regulatory agencies with respect to our therapeutics, clinical studies, manufacturing process or sales and marketing terms; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the success of our efforts to acquire or in-license additional technologies, therapeutics or therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">developments concerning any current or future collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our therapeutics; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability or inability to raise additional capital and the terms on which we raise it; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the recruitment or departure of key personnel; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">changes in the structure of healthcare payment systems; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">market conditions in the pharmaceutical and biotechnology sectors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">fluctuations in the valuation of companies perceived by investors to be comparable to us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">announcement and expectation of additional financing efforts; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">speculation in the press or investment community; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">trading volume of our common stock; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sales of our common stock by us or our stockholders; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the concentrated ownership of our common stock; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">changes in accounting principles; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">terrorist acts, acts of war or periods of widespread civil unrest; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">natural disasters and other calamities; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">general economic, industry and market conditions. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the stock markets in general, and the markets for pharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The future issuance of equity or of debt securities that are convertible into equity may dilute your investment and reduce your equity interest. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may choose to raise additional capital in the future, depending on market conditions, strategic considerations and operational requirements.  To the extent that we raise additional capital through the issuance of shares or other securities convertible into shares, our stockholders will be diluted.  Future issuances of our common stock or other equity securities, or the perception that such sales may occur, could adversely affect the prevailing market price of our common stock and impair our ability to raise capital through future offerings of equity or equity-linked securities.  For example, we have filed, and the SEC has declared effective, a registration statement to register the resale of up to 39,714,143 shares of our common stock issued in connection with the Merger and the 2017 Private Placement or held by pre-Merger stockholders of us.  Additionally, we have filed, and the SEC has declared effective, a registration statement to register the resale of up to 5,034,683 shares of our common stock, consisting of (i) 4,889,217 shares that were privately issued through the August 2018 Private Placement and (ii) 145,466 shares that were privately issued in connection with consulting services on February 1, 2018.  Such registration statements will permit the resale of these shares at any time while the registration statements remain effective.  The resale of a substantial number of shares of our common stock in the public market could adversely affect the market price for our common stock and make it more difficult for you to sell shares of our common stock at times and prices that you feel are appropriate. Accordingly, the adverse market and price pressures resulting from an offering pursuant to this registration statement may continue for an extended period of time and continued negative pressure on the market price of our common stock could have a material adverse effect on our ability to raise additional equity capital.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our&#160;debt obligations expose us to risks that could adversely affect our business, operating results and&#160;financial condition and may result in further dilution to our stockholders. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have entered into a loan and security agreement with Hercules pursuant to which we may borrow in an aggregate principal amount of up to $10.0&#160;million from Hercules at a floating per annum interest rate (based on a year consisting of 360&#160;days) equal to the greater of either (i)&#160;9.95% or (ii)&#160;the sum of (a)&#160;9.95% plus (b)&#160;the prime rate (as reported in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">The Wall Street Journal</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) minus 3.50%.  We were required to make interest only payments on the amounts borrowed until June 2017.  Commencing on July&#160;1, 2017, the loan began amortizing in equal monthly installments of principal and interest in an amount sufficient to fully amortize the outstanding principal balance of the loan over the remaining scheduled monthly payments due prior to the maturity date on September&#160;1, 2019.  Pursuant to an amendment dated January&#160;15, 2018, amortization payments due for the thirteen (13)&#160;consecutive months commencing on December&#160;1, 2017 through and including December&#160;1, 2018 were deferred.  Commencing on January&#160;1, 2019, and continuing on the first business day of each month thereafter, the loan, including the deferred payments, was to begin amortizing in equal monthly installments of principal and interest based upon an amortization schedule equal to eighteen (18)&#160;consecutive months.  Any remaining obligations under the loan agreement and other loan documents (other than the warrant) were due and payable on the maturity date on September 1, 2019. On December&#160;28, 2018, the Company and Hercules further amended its loan agreement so that interest amounts are payable on the first day of each business month and any remaining obligations under the loan agreement and other loan documents are due and payable on the maturity date on September 1, 2019.  On the earliest to occur of the maturity date, the date we prepay the term loan in full or the date the loan otherwise becomes due and payable, we must pay the lender under the agreement an additional charge equal to 3.85% of the total amounts funded under the loan agreement.  To the extent we desire to prepay the indebtedness prior to maturity, and after the date hereof, we would be obligated to pay a prepayment penalty to Hercules of 1% of the amounts being prepaid.  Under the loan agreement, Hercules or its affiliates have a right to participate in a single subsequent unregistered financing by us in an amount of up $1.0&#160;million on the same terms, conditions and pricing afforded to others participating in such financing.  Hercules has not yet exercised this right to participate. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our ability to make payments on this indebtedness depends on our ability to generate cash in the future. We expect to experience negative cash flow for the foreseeable future as we fund our operations and capital expenditures. There can be no assurance that we will be in a position to repay this indebtedness when due or obtain extensions of the maturity date. We anticipate that we will need to secure additional funding in order for us to be able to satisfy our obligations when due. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If that additional funding involves the sale of equity securities or convertible securities, it would result in the issuance of additional shares of our capital stock, which would result in dilution to our stockholders. The indebtedness is secured by </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">substantially all of our assets other than intellectual property, on which we have given Hercules a negative pledge. In addition, under the loan agreement, we are subject to certain customary covenants that limit or restrict our ability to, among other things, incur additional indebtedness, grant any security interests, pay cash dividends, repurchase our common stock, make loans, or enter into certain transactions without the prior consent of Hercules.  The loan agreement was amended on October&#160;10, 2016 to revise the language granting Hercules a contingent security interest in certain of our assets.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This level of debt could have important consequences to you as an investor in our securities. For example, it could: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">limit our flexibility in planning for the development, clinical testing, approval and marketing of our products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">place us at a competitive disadvantage compared to any of our competitors that are less leveraged than we are; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase our vulnerability to both general and industry-specific adverse economic conditions; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">limit our ability to obtain additional funds. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The employment agreements with our executive officers may require us to pay severance benefits to officers in connection with termination of employment or upon a change of control of us, which could harm our financial condition. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Each of David A. Giljohann, our Chief Executive Officer, David S. Snyder, our Chief Financial Officer, and Matthias G. Schroff, our Chief Operating Officer, is entitled to receive cash severance equal to twelve months, six months, and six months, respectively, of his base salary if his employment is terminated by us without cause (as such term is defined in his employment offer letter).  In addition, our 2015 Plan, which was assumed by us in the Merger, generally provides for accelerated vesting of equity awards upon the involuntary termination of an employee within the twelve month period following a change in control (as defined under the plan) and accelerated vesting of equity awards upon a change of control (as defined under the plan) for each of our executive officers.  This vesting acceleration is intended to provide each of our executive officers with the full benefit of their equity awards and reward them for a successful outcome for our stockholders.  The accelerated vesting of equity awards could result in dilution to our existing stockholders and harm the market price of our common stock.  The payment of these severance benefits could harm our financial condition.  In addition, these potential severance payments may discourage or prevent third parties from seeking a business combination with us. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our common stock recently commenced trading on the OTCQB instead of a national exchange or quotation system, so you may be unable to sell your shares to raise money or otherwise desire to liquidate your shares.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our common stock is currently quoted on the OTC Market Group&#8217;s OTCQB Market quotation system under the ticker symbol &#8220;XCUR.&#8221;  The OTCQB are regulated quotation services that display real-time quotes, last sale prices and volume limitations in over-the-counter securities.  Trading in shares quoted on the OTCQB is often thin and characterized by volatility in trading prices.  This volatility may be caused by a variety of factors, including the lack of readily available price quotations, the absence of consistent administrative supervision of bid and ask quotations, lower trading volume and market conditions.  As a result, there may be wide fluctuations in the market price of the shares of our common stock for reasons unrelated to operating performance, and this volatility, when it occurs, may have a negative effect on the market price for our securities.  Moreover, the OTCQB is not a stock exchange, and trading of securities on them is often more sporadic than the trading of securities listed on a national quotation system or stock exchange.  Accordingly, our stockholders may not be able to realize a fair price from their shares when they determine to sell them or may have to hold them for a substantial period of time until the market for our common stock improves.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our common stock may not be eligible for listing or quotation on any securities exchange.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do not currently meet the initial quantitative listing standards of any national securities exchange.  We</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">cannot assure you that we will be able to meet the initial listing standards of any national securities exchange, or, if we do meet such initial listing</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">standards, that we will be able to maintain any such listing.  Until our common stock is listed on a national securities exchange, we expect that it will continue to be eligible and quoted on the OTCQB.  In those venues, however, an investor may find it difficult to obtain accurate quotations as to the market value of our common stock.  Further, the national securities exchanges are adopting so-called &#8220;seasoning&#8221; rules that</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">will require that we meet certain requirements, including prescribed periods of time trading over-the-counter and minimum filings of periodic reports</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">with the SEC, before we are eligible to apply for listing on such national securities exchanges.  In addition, if we fail to meet the criteria set forth in SEC regulations,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">various requirements would be imposed by law on broker-dealers who sell our securities to persons other than established customers and</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">accredited investors.  Consequently, such regulations may deter </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">broker-dealers from recommending or selling our common stock, which may further</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">affect its liquidity.  This would also make it more difficult for us to raise additional capital</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The designation of our common stock as a &#8220;penny stock&#8221; would limit the liquidity of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our common stock may be deemed a &#8220;penny stock&#8221; (as that term is defined under Rule 3a51-1 of the Exchange Act) in any market that may develop in the future. Generally, a &#8220;penny stock&#8221; is a common stock that is not listed on a securities exchange and trades for less than $5.00 a share. Prices often are not available to buyers and sellers and the market may be very limited. Penny stocks in start-up companies are among the riskiest equity investments. Broker-dealers who sell penny stocks must provide purchasers of these stocks with a standardized risk-disclosure</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">document prepared by the SEC. The document provides information about penny stocks and the nature and level of risks involved in investing in</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the penny stock market. A broker must also provide purchasers with bid and offer quotations and information regarding broker and salesperson</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">compensation and make a written determination that the penny stock is a suitable investment for the purchaser and obtain the purchaser&#8217;s written</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">agreement to the purchase. Many brokers choose not to participate in penny stock transactions. Because of the penny stock rules, there may be</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">less trading activity in penny stocks in any market that develops for our common stock in the future and stockholders are likely to have difficulty</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">selling their shares. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">FINRA sales practice requirements may limit a stockholder&#8217;s ability to buy and sell our stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Financial Industry Regulatory Authority, or FINRA, has adopted rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business.  Our research coverage by securities and industry analysts is currently limited.  In addition, because we did not become a reporting company by conducting an underwritten initial public offering of our common stock, and because we are not listed on a national securities exchange, security analysts of brokerage firms may not provide wider coverage of our Company.  In addition, investment banks may be less likely to agree to underwrite secondary offerings on our behalf than they might if we became a public reporting company by means of an underwritten initial public offering, because they may be less familiar with our Company as a result of more limited coverage by analysts and the media, and because we became public at an early stage in our development.  The failure to receive wider research coverage or support in the market for our shares will have an adverse effect on our ability to develop a liquid market for our common stock and the trading price for our stock would be negatively impacted.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the event we obtain wider securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our target studies and operating results fail to meet the expectations of analysts, our stock price would likely decline.  If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Based on the beneficial ownership of our common stock as of December 31, 2018, our executive officers and directors, together with holders of five percent or more of our outstanding common stock and their respective affiliates, will beneficially own approximately&#160;42.4 percent of our outstanding common stock. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our Company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under the General Corporation Law of the State of Delaware could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Provisions in our amended and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders, and the ability of the board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, or the DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined organization voting stock from merging or combining with the combined organization. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then-current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents could discourage, delay or prevent a change in control of us and may affect the trading price of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our corporate documents and the DGCL contain provisions that may enable our board of directors to resist a change in control of us even if a change in control were to be considered favorable by our stockholders. These provisions: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">stagger the terms of our board of directors and require 66 and 2/3% stockholder voting to remove directors, who may only be removed for cause; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">authorize our board of directors to issue &#8220;blank check&#8221; preferred stock and to determine the rights and preferences of those shares, which may be senior to our common stock, without prior stockholder approval; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">establish advance notice requirements for nominating directors and proposing matters to be voted on by stockholders at stockholders&#8217; meetings; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">prohibit our stockholders from calling a special meeting and prohibit stockholders from acting by written consent; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">require 66 and 2/3% stockholder voting to effect certain amendments to our certificate of incorporation and bylaws; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These provisions could discourage, delay or prevent a transaction involving a change in control of us. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and cause us to take other corporate actions our stockholders desire. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The requirements of being a public company may strain our resources and divert management&#8217;s attention.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Act, and other applicable securities rules and regulations.  In the future, we may also be subject to the listing requirements of the NASDAQ Stock Market.  Despite recent reforms made possible by the JOBS Act, compliance with these rules and regulations nonetheless increases our legal and financial compliance costs, makes some activities more difficult, time-consuming or costly, and increases demand on our systems and resources, particularly after we will no longer be an &#8220;emerging growth company.&#8221;  The Exchange Act requires, among other things, that we file annual, quarterly, and current reports with respect to our business and operating results.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of disclosure of information in this report and in other filings required of a public company, our business and financial condition are more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties.  If such claims are successful, our business and operating results could be harmed, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">necessary to resolve them, could divert the resources of our management and adversely affect our business, brand and reputation and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We also expect that being a public company and these new rules and regulations will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage.  These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may incur significant costs from class action litigation due to our expected stock volatility. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our stock price may fluctuate for many reasons, including as a result of public announcements regarding the progress of our development efforts or the development efforts of current or future collaborators or competitors, the addition or departure of our key personnel, variations in our quarterly operating results and changes in market valuations of pharmaceutical and biotechnology companies. This risk is especially relevant to us because pharmaceutical and biotechnology companies have experienced significant stock price volatility in recent years. When the market price of a stock has been volatile as our stock price may be, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit of this type against us, even if the lawsuit is without merit, we could incur substantial costs defending the lawsuit. The lawsuit could also divert the time and attention of our management. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our common stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation. This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. Under Sections 382 and 383 of the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. The Merger, our prior equity offerings and other changes in our stock ownership may have resulted in ownership changes. In addition, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside of our control. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </font></div><div><a name="sF38681DA33935DE08BEA24BB940EE041"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1B. Unresolved Staff Comments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None.</font></div><div><a name="s3CC65492063C5A61B69AAFAD015FE2C6"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Properties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our corporate headquarters are located in Skokie, Illinois, where we lease approximately 12,000 square feet of office and laboratory space. The lease term for our office and laboratory space in Skokie, Illinois commenced in March 2012 for a lease term of three years. In March 2014, we amended the lease agreement to extend the term for an additional six years, which expires in 2021. In May 2016, we amended the lease agreement to include additional space to be used primarily for administrative functions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that our existing facilities are adequate for our current needs and have sufficient laboratory space to house additional scientists as we grow. When our lease expires, we may exercise our renewal options or look for additional or alternate space for our operations. We believe that suitable additional or alternative space will be available in the future on commercially reasonable terms. </font></div><div><a name="sC6B841661A6F586B958AB9ABC85887E9"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Legal Proceedings.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="sE2AF58F86EBA55768018D608F63DF7DD"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Mine Safety Disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><a name="s2F31CAC656345537ABF8ADB297BEC507"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART II</font></div><div><a name="sEB3CE249C9B85B1FBDB7584C961F1199"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 5. Market For Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Market Information for Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our common stock commenced trading on the OTC Market Group&#8217;s OTCQB&#174;&#160;Market quotation system under the ticker symbol &#8220;XCUR&#8221; effective at the market open on May 24, 2018.  On March 5, 2019, the price of our common stock last reported on the OTC Markets was $2.80 per share. The following table sets forth, for each of the quarterly periods indicated, the high and low sales prices of our common stock, as reported on the OTCQB.  These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:72.22222222222221%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:60%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Second Quarter (beginning May 22, 2018)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Third Quarter </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.50</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.90</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fourth Quarter </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Holders of Record</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 5, 2019, we have 44,358,000 shares of common stock outstanding held by 108 stockholders of record.  Because many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of beneficial stockholders represented by these record holders.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dividend Policy</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently intend to retain future earnings, if any, for use in the operation of our business and to fund future growth. We have never declared or paid cash dividends on our common stock and we do not intend to pay any cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors in light of conditions then-existing, including factors such as our results of operations, financial condition and requirements, business conditions and covenants under any applicable contractual arrangements. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Securities Authorized for Issuance under Equity Compensation Plans</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Information about our equity compensation plans is incorporated herein by reference to Part III, Item&#160;12 of this Annual Report</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Performance Graph</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to&#160;the accompanying instructions, the information called for by&#160;Item 201(e)&#160;of Regulation S-K&#160;is not required.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unregistered Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On August 22, 2018, in connection with the closing of the August 2018 Private Placement, we issued a total of 4,889,217 shares of the Company&#8217;s common stock at a purchase price of $4.50 per share, &#160;resulting in approximately&#160;$22.0 million in gross proceeds to the Company.  The aggregate net proceeds from the August 2018 Private Placement (after deducting placement agent fees and expenses of the offering of approximate&#160;$1.9 million) were&#160;$20.1 million.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The offer and sale of the shares in the August 2018 Private Placement were exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended or Rule 506 of Regulation D promulgated by the SEC. The closing of the 2018 August Private Placement was conducted on a &#8220;reasonable best efforts&#8221; basis.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company also entered into a registration rights agreement with the investors in the August 2018 Private Placement, which required us to file a &#8220;resale&#8221; registration statement with the SEC covering the Shares issued in the August 2018 Private Placement within 30 calendar days from the final closing of the August 2018 Private Placement Offering.  The Company filed such registration statement was filed with the SEC on October 5, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><a name="sBD5F9095851B5B7BB8042F542FD6601D"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 6. Selected Financial Data.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">The following tables set forth selected financial data for us as of and for the years ended December 31, 2018, 2017, 2016 and 2015 and should be read together with the consolidated financial statements and the related notes and the sections of this Annual Report on Form 10-K entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; appearing elsewhere in this Annual Report on Form 10-K. The selected financial data in this section is not intended to replace our financial statements and related notes. The selected financial data as of and for the years ended December 31, 2018, 2017, 2016 and 2015 are derived from our audited consolidated financial statements.  Our audited consolidated financial statements as of and for the years ended December&#160;31, 2018 and 2017 are included elsewhere in this Annual Report on Form&#160;10-K. Our historical results are not necessarily indicative of our future results.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.67521367521367%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018 &#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017 &#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December&#160;31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December&#160;31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2015 </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Balance Sheet Data</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,268</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25,764</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">18,731</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">27,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">27,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20,041</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28,756</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28,987</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20,576</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,621</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,043</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,356</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">12,158</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,343</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Long-term debt, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Preferred stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Common stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">797</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,804</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,012</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">18,128</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Non-redeemable preferred stock</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Series C</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">33,483</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">33,039</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Series B-2</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Series B-1</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,371</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,371</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Series A</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Common stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">75,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">53,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(17,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(18,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(54,994</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(33,615</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(22,604</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5,663</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Times New Roman;font-size:1pt;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20,952</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">18,230</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands except share and per share data)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Statement of Operations Data</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,719</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Grant income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,388</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,719</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,036</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">14,119</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13,080</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13,659</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10,124</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,818</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,046</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,539</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20,126</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">17,198</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">15,532</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(21,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(10,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(16,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(13,144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(672</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(779</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss attributable to members of AuraSense Therapeutics, LLC</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(7,488</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss attributable to stockholders of Exicure, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(22,413</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(11,011</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(16,941</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(22,413</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(11,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(16,941</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(13,151</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1.09</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(149.37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(244.13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Basic and diluted weighted-average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">41,189,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10,119,569</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">113,418</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">53,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><a name="sF242271E3C86583786A2679B6EAD91A9"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties as described under the heading &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; elsewhere in this Annual Report on Form 10-K. You should review the disclosure under the heading &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </font></div><div><a name="s9A036BA8A18B5396A2C267531D85DA6A"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Operating Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA, technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. We believe the design of our SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. Since our SNAs have shown in a Phase 1 clinical trial and in preclinical studies that they can cross certain biological barriers when administered locally, we believe that they have the therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. We have demonstrated the ability to cross certain biological barriers in Phase 1 clinical trials of three therapeutic candidates, AST-008, XCUR17 and AST-005.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Immuno-oncology</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">AST-008&#160;is an SNA consisting of toll-like receptor 9, or TLR9, agonists designed for immuno-oncology applications.&#160;TLR9 agonists bind to and activate TLR9 receptors.  We believe&#160;AST-008&#160;may be used for immuno-oncology applications as a monotherapy or in combination with checkpoint inhibitors. Checkpoint inhibitors are therapeutics that prevent tumors from evading destruction by the immune system. We have observed that administration of&#160;AST-008&#160;as a monotherapy can have anti-tumor activity in mouse models of colon cancer, breast cancer, lymphoma and melanoma. We have also observed that, in preclinical studies in a variety of tumor models,&#160;AST-008,&#160;applied in combination with certain checkpoint inhibitors, exhibited anti-tumor responses and survival rates that were greater than those demonstrated by checkpoint inhibitors alone. We have also demonstrated that&#160;AST-008&#160;was active when administered subcutaneously, intratumorally or intravenously, in both prevention and established mouse tumor models. The administration of&#160;AST-008&#160;also produced localized as well as abscopal anti-tumor activity in mouse cancer models. Additionally, administration of&#160;AST-008 in combination with certain checkpoint inhibitors conferred adaptive immunity in breast and colon cancer mouse models.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the fourth quarter of 2018 the FDA opened the IND for AST-008 and informed the&#160;Company&#160;that our proposed Phase1b/2 trial may proceed.  Early in 2019, we opened four clinical sites and began dosing and recruiting patients in that trial.  This is a Phase 1b/2, open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral&#160;AST-008&#160;injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors.  Conditions under study are planned to include advanced or metastatic: Merkel cell carcinoma, head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma and melanoma.  The primary outcome measure is the safety and tolerability of&#160;AST-008&#160;alone and in combination with pembrolizumab.  Secondary outcomes include the recommended Phase 2 dose and disease assessment with RECIST 1.1.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the second quarter of 2017, we filed a CTA for a Phase 1 clinical trial of&#160;AST-008&#160;in the United Kingdom. In the third quarter of 2017, we received an authorization from the MHRA, the competent health authority of the United Kingdom, to conduct a Phase 1 clinical trial with&#160;AST-008. We began subject dosing in our Phase 1 clinical trial for&#160;AST-008&#160;in the fourth quarter of 2017. This trial was completed in the third quarter of 2018. Based on our initial analyses of the Phase 1 clinical trial results, AST-008 was shown to be safe and tolerable in all subjects, with no serious adverse events and no dose limiting toxicity.  All AST-008-related adverse events were of short duration, reversible and consistent with TLR9 activation. In addition, AST-008 was shown to elicit high levels </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">of certain cytokines as well as to activate important effector cells of the immune system, including T cells and natural killer cells which are the main drivers of an anti-tumor response. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Inflammatory diseases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">XCUR17</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">XCUR17, is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha, or&#160;IL-17RA,&#160;a protein that is considered essential in the initiation and maintenance of psoriasis. Although the availability of inhibitors of TNF revolutionized the systemic treatment of severe psoriasis, studies of disease pathogenesis have shifted attention to the&#160;IL-17&#160;pathway, in which&#160;IL-17RA&#160;is a key driver of psoriasis. Our strategy is to reduce the levels of&#160;IL-17RA&#160;in the skin by topically applying XCUR17. In preclinical studies, XCUR17 inhibited&#160;IL-17RA&#160;in the keratinocytes of the skin.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We filed a CTA for a Phase 1 clinical trial of XCUR17 in patients with psoriasis in Germany in the third quarter of 2017. Our CTA was approved in February 2018 and we began dosing patients in our Phase 1 clinical trial in April 2018. The Phase 1 clinical trial, which had final patient visits in the fourth quarter of 2018, was a randomized, double-blinded, placebo-controlled trial in twenty-one patients with mild to moderate chronic plaque psoriasis designed to assess the safety of XCUR17 formulated as a topical gel, and to evaluate early signs of efficacy. All patients received three strengths of XCUR17 gel, a vehicle gel, and a positive comparator (Daivonex&#174; cream), which were all applied on different areas of psoriatic skin within each individual patient.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the fourth quarter of 2018 we reported results from the Phase 1 trial of XCUR17.  In the case of XCUR17, of the twenty-one treated patients, eleven treated with the highest strength XCUR17 gel were observed to have a reduction in redness and improvement in healing as determined by blinded physician assessments. Further, the highest strength XCUR17 gel showed a statistically significant improvement in psoriasis symptoms versus the vehicle gel. By comparison, seventeen of the twenty-one patients treated with the positive comparator showed a clinical response, while four patients treated with the placebo vehicle had a clinical response.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There were no adverse safety events related to treatment with XCUR17 observed. In addition to the safety, tolerability and clinical assessments, the trial measured psoriatic infiltrate thickness over the 26-day treatment period. No relevant changes in mean psoriatic infiltrate thickness were observed for the three XCUR17 gels or the active ingredient-free vehicle gel. At this time, assessments of IL-17RA mRNA levels from skin biopsies collected from the treated areas in patients have not yet been correlated with the clinical or infiltrate thickness assessments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Dermelix License Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 17, 2019 Exicure entered into a License and Development Agreement, or the Dermelix License Agreement, with DERMELIX, LLC, d/b/a Dermelix Biotherapeutics. Under the terms of agreement, Dermelix</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">licensed worldwide rights to research, develop, and commercialize Exicure&#8217;s technology for the treatment of Netherton Syndrome and, at Dermelix&#8217;s option, up to five additional rare skin indications.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Dermelix will initially develop a targeted therapy for the treatment of Netherton Syndrome (NS). NS is a rare and severe autosomal recessive disorder caused by loss-of-function mutations in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">SPINK5 </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">gene, which encodes the serine protease inhibitor LEKT1 involved in skin barrier function. NS affects approximately 1 in 200,000 children born each year, and is characterized by severely inflamed, red, scaled, itchy skin, and patients are at increased risk of mortality in the first year of life due to recurrent infections and dehydration as a result of the impaired skin barrier. Currently, there are no approved treatments for NS patients and off-label use of standard of care treatments are of limited utility.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the terms of the Dermerlix License Agreement, Exicure received an upfront payment of $1 million at closing of the transaction and will receive an additional $1 million upon the exercise of each of the five options granted to Dermelix. Exicure will be responsible for conducting the early stage development for each indication up to IND enabling toxicology studies.  Dermelix will undertake subsequent development, commercial activities and financial responsibility. For each of NS as well as any additional licensed product for which Dermelix exercises one of its options, Exicure is eligible to receive potential payments totaling up to $13.5 million upon achievement of </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">certain development and regulatory milestones and up to $152.5&#160;million upon achievement of certain sales milestones per indication in each of six indications.  In addition, Exicure will receive low double-digit royalties on annual net sales for SNA therapeutics developed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Other Inflammatory Diseases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that one of the key strengths of our proprietary SNAs is that they have the potential to enter a number of different cells and organs. As a consequence, we are also conducting early stage research activities in  ophthalmology, pulmonology, and gastroenterology.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe promising therapeutic targets for SNAs include antibody targets with confirmed therapeutic benefit. We envision inhibiting these targets with local application of SNAs in a variety of therapeutic areas. We believe that this approach combines the benefits of specifically inhibiting validated targets without the potential safety issues associated with systemic therapy. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Genetic disorders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are investigating the utility of our SNA technology for the treatment of neurological conditions.  In June 2018, the Company and researchers from The Ohio State University Wexner Medical Center presented a poster at the Cure SMA Annual Conference titled: &#8220;Nusinersen in spherical nucleic acid (SNA) format improves efficacy both&#160;in vitro&#160;in SMA patient fibroblasts and in&#160;&#916;7 SMA mice and reduces toxicity in mice.&#8221; It was observed in a preclinical study that nusinersen in SNA format prolonged survival by four-fold (maximal survival of 115 days compared to 28 days for nusinersen-treated mice) as well as doubled the levels of healthy full-length SMN2 mRNA and protein in SMA patient fibroblasts when compared to nusinersen.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Subsequently, in the fall of 2018, we completed a biodistribution study in rats comparing nusinersen to nusinersen in SNA format. We found that more nusinersen in SNA format was retained in the rats&#8217; brain and spinal cord compared to nusinersen retained in the rats&#8217; brain and spinal cord at 24, 72 and 168 hours.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are now formulating our strategy for developing a pipeline of SNA therapeutics targeting neurological diseases.  Preclinical research is underway in a number of indications including, spinal muscular atrophy, Huntington&#8217;s Disease, spinocerebellar ataxia type 3 (SCA3), SCA2, SCA1, Friedreich&#8217;s Ataxia, and Batten disease.  We believe this preclinical research may lead to a therapeutic candidate for one of the above neurological indications. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">AST-005</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">AST-005 is&#160;an SNA targeting TNF for the treatment of mild to moderate psoriasis. AST-005 is intended to be administered locally in a gel to psoriatic lesions. In a completed Phase 1 clinical trial,&#160;AST-005,&#160;when topically administered to the skin of patients with mild to moderate psoriasis, resulted in no drug associated adverse events, and demonstrated a reduction of TNF mRNA. The TNF mRNA reduction elicited by the highest strength of&#160;AST-005&#160;gel was statistically significant when compared to the effects of the vehicle.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December&#160;2, 2016, we entered into a research collaboration, option and license agreement with Purdue Pharma L.P., referred to as the Purdue Collaboration. As part of our collaboration with Purdue, a Phase 1b clinical trial was conducted in Germany to evaluate the effect of AST-005 gel in patients with chronic plaque psoriasis. The trial demonstrated that AST-005 is safe and tolerable in patients at higher doses than were previously studied, however, the study did not result in a statistically significant decrease in echo lucent band thickness, one of the key indicators of efficacy in patients with psoriasis. In April 2018, Purdue notified the Company it had declined to exercise its option to develop AST-005 at that time, but that it also intended to retain rights relating to the TNF target, and Purdue reserved its right to continue joint development, with Exicure, of new anti-TNF drug candidates and to retain its exclusivity and other rights to AST-005.   Purdue has not indicated that it has any plans to pursue AST-005 at this time and there no active therapeutic candidates in development. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other operating, financing, and cash flow considerations</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since our inception in 2011, we have devoted substantial resources to the research and development of SNAs and the protection and enhancement of our intellectual property. We have no products approved for sale and all of our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$15.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in revenue since inception through December 31, 2018 has been earned through our research collaboration, license, and option agreement with Purdue or as a primary contractor or as a subcontractor on government grants. In addition to our revenue, from inception through December 31, 2018, we have funded our operations through private placements of preferred stock with gross proceeds totaling $42.8&#160;million, sales of common stock in the 2017 Private Placement with gross proceeds totaling $31.5 million, sales of common stock in the August 2018 Private Placement with gross proceeds totaling </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$22.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and debt financing totaling $6.0&#160;million. As of December 31, 2018, our cash and cash equivalents were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$26.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since our inception, we have incurred significant operating losses. Our net loss was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$22.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$11.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018, our accumulated deficit was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Substantially all of our operating losses resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect to continue to incur significant and increasing losses in the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">advance AST-008 through clinical development for immuno-oncology applications;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">continue research and development in neurological applications;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">advance SNA platform in dermatological indications;</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase research and development for the discovery and development of additional therapeutic candidates;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">advance other therapeutic candidates through preclinical and clinical development;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase our research and development to enhance our technology;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">procure clinical trial materials;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">seek regulatory approval for our therapeutic candidates that successfully complete clinical trials;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">maintain, expand and protect our intellectual property portfolio;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operate as a public company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have not generated any commercial product revenue nor do we expect to generate substantial revenue from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our therapeutic candidates. Successful therapeutic development and regulatory approval are subject to significant uncertainties and we expect such activities will take at least five years. If we obtain regulatory approval for any of our therapeutic candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Other sources of revenue could include a combination of research and development payments, license fees and other upfront payments, milestone payments, and royalties in connection with our current and any future collaborations and licenses. Until such time, if ever, that we generate revenue from whatever source, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings and research collaboration and license agreements. We may be unable to raise capital or enter into such other arrangements when needed or on favorable terms. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our therapeutic candidates.</font></div><div><a name="s7B6EBB3D6E91584D84A78829E6DF4245"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The audited financial statements of Exicure, Inc. for the fiscal years ended December&#160;31, 2018 and 2017, contained herein, include a summary of our significant accounting policies and should be read in conjunction with the discussion below. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><a name="sC6739EF0AADD5B7D99065129E7640F50"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Developments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">AST-008</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the fourth quarter of 2018 the FDA opened the IND for AST-008 and informed the&#160;Company&#160;that our proposed Phase1b/2 trial may proceed.  Early in 2019, we opened four clinical sites and began dosing and recruiting patients in that trial.  This is a Phase 1b/2, open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral&#160;AST-008&#160;injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors.  Conditions under study are planned to include advanced or metastatic: Merkel cell carcinoma, head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma and melanoma.  The primary outcome measure is the safety and tolerability of&#160;AST-008&#160;alone and in combination with pembrolizumab.  Secondary outcomes include the recommended Phase 2 dose and disease assessment with RECIST 1.1.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">XCUR17</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the fourth quarter of 2018 we reported results from the Phase 1 trial of XCUR17.  In the case of XCUR17, of the twenty-one treated patients, eleven treated with the highest strength XCUR17 gel were observed to have a reduction in redness and improvement in healing as determined by blinded physician assessments. Further, the highest strength XCUR17 gel showed a statistically significant improvement in psoriasis symptoms versus the vehicle gel. By comparison, seventeen of the twenty-one patients treated with the positive comparator showed a clinical response, while four patients treated with the placebo vehicle had a clinical response.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There were no adverse safety events related to treatment with XCUR17 observed. In addition to the safety, tolerability and clinical assessments, the trial measured psoriatic infiltrate thickness over the 26-day treatment period. No relevant changes in mean psoriatic infiltrate thickness were observed for the three XCUR17 gels or the active ingredient-free vehicle gel. At this time, assessments of IL-17RA mRNA levels from skin biopsies collected from the treated areas in patients have not yet been correlated with the clinical or infiltrate thickness assessments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Dermelix License Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 17, 2019 Exicure entered into a License and Development Agreement, or the Dermelix License Agreement, with DERMELIX, LLC, d/b/a Dermelix Biotherapeutics. Under the terms of agreement, Dermelix</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">licensed worldwide rights to research, develop, and commercialize Exicure&#8217;s technology for the treatment of Netherton Syndrome and, at Dermelix&#8217;s option, up to five additional rare skin indications.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the terms of the Dermerlix License Agreement, Exicure received an upfront payment of $1 million at closing of the transaction and will receive an additional $1 million upon the exercise of each of the five options granted to Dermelix. Exicure will be responsible for conducting the early stage development for each indication up to IND enabling toxicology studies.  Dermelix will undertake subsequent development, commercial activities and financial responsibility. For each of NS as well as any additional licensed product for which Dermelix exercises one of its options, Exicure is eligible to receive potential payments totaling up to $13.5 million upon achievement of certain development and regulatory milestones and up to $152.5&#160;million upon achievement of certain sales milestones per indication in each of six indications.  In addition, Exicure will receive low double-digit royalties on annual net sales for SNA therapeutics developed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">August 2018 Private Placement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On August 22, 2018, we entered into subscription agreements with several accredited investors, pursuant to which we issued and sold a total of 4,889,217 shares of the Company&#8217;s common stock, at a purchase price of $4.50 per share, resulting in approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$22.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in gross proceeds to the Company (the &#8220;August 2018 Private Placement&#8221;).  The aggregate net proceeds from the August 2018 Private Placement (after deducting accrued or paid placement agent fees and expenses of the offering of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) were&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We filed and caused to become effective a registration statement with the SEC on October 5, 2018 registering the resale of 5,034,683 shares of common stock of Exicure, Inc., par value $0.0001 per share, consisting of (i) </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,889,217 shares that were privately issued in the August 2018 Private Placement and (ii) 145,466 shares that were privately issued to certain selling stockholders in connection with consulting services on February 1, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Trading of Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The common stock of Exicure, Inc. commenced trading on the OTC Market Group&#8217;s OTCQB&#174;&#160;Market quotation system under the ticker symbol &#8220;XCUR&#8221; effective at the market open on May 24, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Registration Statement - 2017 Private Placement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We filed and caused to become effective a registration statement with the SEC on February 6, 2018 registering the resale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">39,714,143</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock issued in connection with the 2017 Private Placement. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Appointment of Chief Operating Officer</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On April 20, 2018, we announced that Matthias G. Schroff, Ph.D, was appointed to serve as Chief Operating Officer (&#8220;COO&#8221;) of the Company, effective April 16, 2018.  Dr. Schroff is a biotechnology industry veteran who brings more than 15 years of senior leadership experience within global biopharmaceutical companies where he gained deep scientific and clinical experience in immuno-oncology, TLR9 biology and broad clinical program management. For more information on the appointment of Dr. Schroff, please see the Current Report on Form 8-K filed with the SEC on April 20, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Purdue Collaboration</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In April 2018, Purdue has notified the Company it has declined to exercise its option to develop AST-005 at this time </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and there are currently no active therapeutic candidates in development under the Purdue Collaboration</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We view our operations and manage our business as one segment, which is the discovery, research and development of treatments based on our SNA technology.</font></div><div><a name="sD1B4778D207C5131A7C6AAC80A15DF89"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Critical Accounting Policies and Significant Judgments and Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the revenue and expenses incurred during the reported periods. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While our significant accounting policies are described in the notes to our financial statements appearing in this Annual Report on Form 10-K, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Effective January 1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance, while the reported results for 2017 were prepared under the guidance of ASC 605,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue Recognition</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;(ASC 605).  Under ASC 605, the Company&#8217;s revenue recognition accounting policy was consistent with ASC 606 revenue recognition accounting policies, except the Company used to recognize upfront license fees on a straight line basis.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Identify the contract with the customer.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration. The Company applies judgment in determining the customer&#8217;s intent and ability to pay, which is based on a variety of factors including the customer&#8217;s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Identify the performance obligations in the contract.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Determine the transaction price.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Allocate the transaction price to performance obligations in the contract.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, the Company must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Recognize revenue when or as the Company satisfies a performance obligation.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, (ii) the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Licenses of intellectual property</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&#160;If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or&#160;at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Milestone payments:</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Royalties</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&#160;For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaboration agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December 31, 2018, the Company&#8217;s only revenue recognized is related to the Purdue Collaboration (see Note 3). </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Equity-based compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We measure the cost of common stock option awards at fair value and record the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. We measure fair value for all common stock options using the Black-Scholes option-pricing model. For all common stock option awards to employees, the fair value measurement date is the date of grant and the requisite service period is the period over which the employee is required to provide service in exchange for the common stock option awards, which is generally the vesting period.  For all common stock option awards to nonemployees, we remeasure fair value at each financial statement reporting date and recognize compensation expense as services are rendered, generally on a straight-line basis.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Black-Scholes option-pricing model requires the input of highly subjective assumptions, including: (1)&#160;the estimated grant date fair value of Exicure's or Exicure OpCo&#8217;s (as the case may be) common stock; (2)&#160;the option exercise price; (3)&#160;the expected term of the option in years; (4)&#160;the annualized volatility of the stock; (5)&#160;the risk-free interest rate; and (6)&#160;the annual rate of quarterly dividends on the stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the commencement of trading of the common stock of Exicure, Inc. on the OTC Market Group&#8217;s OTCQB&#174;&#160;Market quotation system under the ticker symbol &#8220;XCUR&#8221; effective at the market open on May 24, 2018, the Company&#8217;s common stock had not yet been publicly traded, therefore the Company estimated the fair value of its common stock underlying its common stock options. The grant date fair value of the Company&#8217;s common stock had been determined by the Board exercising their judgment in the consideration of a variety of factors. For financial reporting purposes, the Company had periodically estimated the per share fair value of Exicure&#8217;s common stock at various dates using valuations performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (Practice Aid). At December 31, 2017, for financial reporting purposes and principally to aid Exicure </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in the revaluation of certain common stock option awards to non-employees and certain warrant liabilities, Exicure estimated the per share fair value of its common stock to be $3.00, which was the per share price paid by outside investors in the 2017 Private Placement on September 26, 2017, October 27, 2017, and November 2, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Common stock warrant liability</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Freestanding warrants related to shares that are redeemable, contingently redeemable, or for purchases of common stock that are not indexed to the Company&#8217;s own stock are classified as a liability on the Company&#8217;s balance sheet. The common stock warrants are recorded at fair value, estimated using the Black-Scholes option-pricing model, and marked to market at each balance sheet date with changes in the fair value of the liability recorded in other income (expense), net in the statements of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A 10% change in the estimate of expected volatility at December 31, 2018 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  A 10% change in the estimate of fair value of the common stock at December 31, 2018 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recently adopted accounting pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Refer to Note 2 of the accompanying consolidated financial statements for a description of recently adopted accounting pronouncements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recent accounting pronouncements not yet adopted</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Refer to Note 2 of the accompanying consolidated financial statements for a description of recent accounting pronouncements not yet adopted.</font></div><div><a name="s715C661BF8E95373808DFEAA97EE1DCA"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Components of Statements of Operations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have earned all of our revenue through December 31, 2018 through our research collaboration, license, and option agreement with Purdue or as a primary contractor or as a subcontractor on government grants. We do not intend for government grants to be a principal commercial or strategic focus, but will evaluate opportunities when consistent with our strategic priorities. We have not generated any commercial product revenue and do not expect to generate any product revenue for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the future, we may generate revenue from partnership activities including a combination of research and development payments, license fees and other upfront payments, milestone payments, product sales and royalties, and reimbursement of certain research and development expenses, in connection with the Purdue Collaboration or any future collaborations and licenses. We expect that any such revenue we generate will fluctuate in future periods as a result of the timing of achievement, if at all, of preclinical, clinical, regulatory and commercialization milestones, the timing and amount of any payments to us relating to such milestones and the extent to which any of our therapeutic candidates are approved and successfully commercialized by us or potential development partners. If we, or any potential development partner fails to develop therapeutic candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue, and our results of operations and financial position, would be materially and adversely affected.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and development expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development expense consists of costs associated with our research activities, including basic research on our SNA platform,  discovery and development of novel SNAs as prospective therapeutic candidates, preclinical and clinical development activities for SNAs we have nominated for clinical development as well as maintaining and protecting our intellectual property.   Our research and development expenses include:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">employee-related expenses, including salaries, bonuses, benefits and equity-based compensation expense; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">early research and development expenses incurred under arrangements with third parties, such as contract research organizations, contract manufacturing organizations, and consultants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">preclinical and clinical development expenses with third parties such as contract research organizations, contract manufacturing organizations, and consultants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">costs of maintaining and protecting our intellectual property portfolio, including legal advisory fees,  license fees, sublicense fees, patent maintenance and other similar fees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">laboratory materials and supplies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment and laboratory and other supplies.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expense research and development costs as they are incurred. A significant portion of our research and development costs are not tracked by project as they benefit multiple projects or our technology.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect our research and development expenses to increase for the foreseeable future as we advance our therapeutic candidates through preclinical studies and clinical trials. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time-consuming. We or future development partners may never succeed in obtaining marketing approval for any of our therapeutic candidates. The probability of success for each therapeutic candidate may be affected by numerous factors, including preclinical data, clinical data, competition, manufacturing capability and commercial viability.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">All of our research and development programs are at an early stage and successful development of future therapeutic candidates from these programs is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each future therapeutic candidate and are difficult to predict. We anticipate we will make determinations as to which therapeutic candidates to pursue and how much funding to direct to each therapeutic candidate on an ongoing basis in response to the early scientific, preclinical and clinical success of each therapeutic candidate, our ability to maintain or enter into development partnerships with respect to a given therapeutic candidate, as well as ongoing assessments of the commercial potential of therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We will need to raise additional capital to fund our research and development activities.   We have entered into, and may in the future seek, collaborations, licensing or other commercial relationships with other companies in order to advance our various therapeutic candidates. Such collaborations may provide near-term cash payments from the collaborators to us in exchange for license rights or for expense reimbursement, but may also materially reduce the long-term economic benefits that could otherwise be realized from a therapeutic candidate subject to a collaboration in the event that such therapeutic candidate becomes commercially viable.  Additional private or public financings may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and our ability to pursue our business strategy.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">General and administrative expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">General and administrative expense consists primarily of salaries and related benefits, including equity-based compensation, related to our executive, finance, legal, business development and support functions. Other general and administrative expenses include travel expenses, professional fees for auditing, tax and legal services and allocated facility-related costs not otherwise included in research and development expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect that general and administrative expenses will increase in the future as we expand our operating activities and incur additional costs associated with being a growing, publicly-traded company. These increases will likely include legal, accounting and filing fees, directors&#8217; and officers&#8217; liability insurance premiums and fees associated with investor relations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Interest expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Interest expense consists of interest expense pursuant to the loan and security agreement with Hercules Technology Growth Capital, or Hercules, that we closed on February&#160;17, 2016 with an initial advance of $6.0&#160;million.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other income (loss), net</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other income (loss), net consists of interest income earned on our cash and cash equivalents, fair value adjustments of our preferred and common stock warrant liabilities, and gains and losses on foreign currency transactions.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></div><hr style="page-break-after:always"><div><a name="s36AB8722B8DF5C3E8D69D9B2CF61A565"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Results of Operations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Comparison of the Year Ended December 31, 2018 and 2017</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the results of our operations for the years ended December 31, 2018 and 2017:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.15384615384616%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year&#160;Ended<br>December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;">(dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,719</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,601</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,601</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">14,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,818</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,046</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20,126</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,811</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(21,819</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(10,407</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(11,412</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(672</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(795</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">123</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(113</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">n/m</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(22,413</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(11,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(11,402</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Revenue</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year&#160;Ended<br>December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;">(dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,719</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,601</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,719</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,601</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(99</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Revenue in both the years ended December 31, 2018 and 2017 related to the Purdue Collaboration, and decreased from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended December 31, 2017 to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended December 31, 2018, or approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">99%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, mostly due to</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;the absence of revenue recognized in the prior period related to the amortization of the upfront payment, and certain reimbursable research and development activities due to the completion of the AST-005 Phase 1b trial during 2018, under the Purdue Collaboration.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;In connection with the Purdue Collaboration, we received a non-refundable development fee of $10.0&#160;million in December 2016.  Prior to the adoption of ASC 606, the upfront payment of $10.0&#160;million was accounted for pursuant to ASC 605 and was recorded as deferred revenue and recognized on a ratable basis over the estimated performance period of the relevant research and development activities.  On January 1, 2018, in connection with the adoption of ASC 606, we recorded the unamortized deferred revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as an adjustment to the beginning balance of accumulated deficit at January 1, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The collaboration revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;during the year ended December 31, 2018 related to research and development activities that is reimbursable by Purdue and is presented on a gross basis in the accompanying consolidated statement of operations.  We recognized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of collaboration revenue in the year ended December 31, 2017, which consisted of twelve months of amortization of deferred revenue mentioned above and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to research and development activities that was reimbursed by Purdue and is presented on a gross basis in the accompanying consolidated statement of operations.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do not expect to generate any product revenue for the foreseeable future. However, future revenue may include amounts attributable to partnership activities including, a combination of research and development payments, license fees and other upfront payments, milestone payments, product sales and royalties, and reimbursement of certain research and development expenses, in connection with the Dermelix License Agreement or the Purdue Collaboration or any future collaboration and licenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Research and development expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes our research and development expenses incurred during the periods indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year&#160;Ended<br>December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;">(dollars&#160;in&#160;thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Clinical development programs expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6,490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Platform and discovery-related expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,764</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,146</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">618</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Employee-related expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,751</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Facilities, depreciation, and other expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">997</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">861</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">136</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">14,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,039</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Full time employees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development expense was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$14.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended December 31, 2018 and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended December 31 2017, an increase of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  The increase in research and development expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was primarily due to higher employee-related expenses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and higher platform and discovery-related expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, partially offset by a net decrease in costs related to our clinical development programs of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Higher employee-related expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was due to higher compensation and related costs, non-cash stock-based compensation, and relocation costs all mostly in connection with the hire of our Chief Operating Officer as well as in connection with salary increases for existing employees.  The increase in platform and discovery-related expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is mostly due to higher costs to maintain our intellectual property portfolio.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The net decrease in clinical development programs expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was mostly due to lower costs associated with AST-005 (for which the Phase 1b clinical trial, subject of the Purdue Collaboration, ended during the first quarter of 2018) and net lower costs associated with AST-008 (a decrease in costs related to the Phase 1 trial of AST-008 more than offset an increase in costs related to the preparation for the Phase 1b/2 trial of AST-008), partially offset by net higher costs associated with XCUR17 (an increase in costs to prepare for a Phase 2 clinical trial of XCUR17 was more than offset by a decrease in costs related to the Phase 1 clinical trial of XCUR17).  Included in clinical development expense for the years ended December 31, 2018 and 2017 was approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, of expense that is reimbursed by Purdue (included in revenue) related to the Phase 1b trial of AST-005.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect our research and development expenses to increase in 2019 as we continue spending on our clinical development programs, further develop our SNA technology platform and broaden our pipeline of SNA-based therapeutic candidates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">General and administrative expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year&#160;Ended<br>December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;">(dollars&#160;in&#160;thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Full time employees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">General and administrative expense was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$7.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended December 31, 2018 and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$7.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended December 31, 2017, an increase of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This increase is due to higher costs associated with being a public company of $0.9 million, including higher expense for investor and public relations and director and officer insurance, as well as higher compensation and related expense of $0.5 million associated with salary increases and the addition of an executive during 2018, partially offset by lower legal and accounting costs of $0.7 million resulting in a change in mix of transaction support in 2018 as compared to 2017. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Interest expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Interest expense consists of interest expense pursuant to the loan and security agreement with Hercules that we closed on February&#160;17, 2016 with an initial advance of $6.0&#160;million.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Other income (loss), net</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other income (loss), net consists of interest income earned on our cash and cash equivalents, fair value adjustments of our common stock warrant liabilities, and gains and losses on foreign currency transactions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Inflation </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do not believe that inflation has had a material adverse impact on our revenues or operations in any of the past three years.</font></div><div><a name="sFE4F11DD05C75E7DAC738D838E8DA8E0"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To date we have primarily funded our operations through private placements of equity securities, the Purdue Collaboration, a debt financing, and grants from governmental agencies. Since inception and through December 31, 2018, we have received approximately $117.3 million in aggregate gross proceeds from these transactions, including: $42.8 million in aggregate gross proceeds from private placement offerings of preferred stock; $31.5 million in gross proceeds from sales of common stock in the 2017 Private Placement; </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$22.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in gross proceeds from the sales of common stock in the August 2018 Private Placement; an upfront payment of $10.0&#160;million in connection with the Purdue Collaboration; $6.0 million in debt financing; and an aggregate of $5.0 million from grants awarded by governmental agencies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since our inception, we have not generated any product revenue and have incurred recurring net losses.  Our Company is not profitable, and we cannot provide any assurance that we will ever be profitable. As of December 31, 2018, we have an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Based on the Company&#8217;s current operating plans, it believes that existing working capital at December 31, 2018 is sufficient to fund its current operating plans into January 2020.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to us. If we are unable to obtain such additional financing, we will need to reevaluate future operating plans. Accordingly, there is substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;See &#8220;&#8212;Funding Requirements&#8221; below for additional information on our future capital needs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cash Flows</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table shows a summary of our cash flows for the years ended December 31, 2018 and 2017:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Years&#160;Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-style:italic;">(in&#160;thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net cash used in operating activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(19,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(19,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net cash used in investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(94</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(926</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net cash provided by financing activities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20,085</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,856</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net increase in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6,141</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Operating activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Net cash used in operating activities was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$19.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$19.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the years ended December&#160;31, 2018 and 2017, respectively. The decrease in cash used in operating activities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was primarily due to lower prepaid research and development contract costs in the 2018 period and the absence of the first quarter 2017 payment of $1.5&#160;million in connection with the Northwestern University License Agreements, partially offset by higher cash used for working capital.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Investing activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Net cash used in investing activities was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the years ended December 31, 2018 and 2017, respectively. Cash used in investing activities for each of the years ended December 31, 2018 and 2017 was primarily due to the purchase of scientific equipment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Financing activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Net cash provided by financing activities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended December 31, 2018 is primarily due to the sale of common stock in the August 2018 Private Placement.   On August 22, 2018, we sold 4,889,217 shares of the Company&#8217;s common stock at a purchase price of $4.50 per share, resulting in approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$22.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in gross proceeds to the Company. The aggregate net proceeds from the August 2018 Private Placement (after deducting placement agent fees and expenses of the offering of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) were&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Net cash provided by financing activities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$26.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended December 31, 2017 is primarily due to the sale of common stock in the 2017 Private Placement. On September 26, 2017, October 27, 2017, and November 2, 2017, we sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,504,196</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of the Company&#8217;s common stock at a purchase price of $3.00 per share, resulting in approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$31.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of gross proceeds to the Company.  The aggregate net proceeds from the 2017 Private Placement (after deducting placement agent fees and expenses of the offering paid in 2017 of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$27.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  This was partially offset by the repayment of debt of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Hercules Loan and Security Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February&#160;17, 2016, we entered into a loan and security agreement with Hercules. The loan agreement provided for funding in an aggregate principal amount of up to $10.0&#160;million in two separate tranches. The first tranche was funded on February&#160;17, 2016 in the amount of $6.0&#160;million. A second tranche of $4.0&#160;million was available provided that we met certain milestones on or before December&#160;31, 2016. We did not meet these milestones and, therefore, we did not draw the second tranche, the availability of which expired on December&#160;31, 2016. The principal balance of the term loan under the Hercules loan facility bears interest at a floating per annum interest rate (based on a year consisting of 360 days) equal to the greater of either (i) 9.95% or (ii)&#160;the sum of (a) 9.95% plus (b)&#160;the prime rate (as reported in The Wall Street Journal) minus 3.50%. We were required to make interest-only payments through June 2017. Commencing on July&#160;1, 2017, the loan began amortizing in equal monthly installments of principal and interest in an amount sufficient to fully amortize the outstanding principal balance of the loan over the remaining scheduled monthly payments due prior to the maturity date on September&#160;1, 2019. Pursuant to an amendment dated January 15, 2018, amortization payments due for the thirteen (13) consecutive months commencing on December 1, 2017 through and including December 1, 2018 were deferred.&#160; Commencing on January 1, 2019, and continuing on the first business day of each month thereafter, the loan, including the deferred payments, was to begin amortizing in equal monthly installments of principal and interest based upon an amortization schedule equal to eighteen (18) consecutive months. Any remaining obligations under the loan agreement and other loan documents were due and payable on the maturity date. On December&#160;28, 2018, the Company and Hercules further amended its loan agreement so that interest amounts are payable on the first day of each business month and any remaining obligations under the loan agreement and other loan documents are due and payable on the maturity date on September 1, 2019.  On the earliest to occur of the maturity date, the date we prepay the term loan in full or the date the loan otherwise becomes due and payable, we must pay the lender under the agreement an additional charge equal to 3.85% of the total amounts funded under the loan agreement. In addition, if we prepaid the term loan on or prior to February&#160;1, 2017, we would have been required to pay a prepayment charge equal to 3% of the amount being prepaid, if we prepaid the term loan after February&#160;1, 2017 but on or prior to February&#160;1, 2018, we would have been required to pay a prepayment charge equal to 2% of the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">amount being prepaid, and if we prepay the term loan after February&#160;1, 2018, we must pay a prepayment charge of 1% of the amount being prepaid. As of the date of this Annual Report on Form 10-K, we have not prepaid the Hercules term loan. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The term loan under the Hercules loan facility is secured by substantially all of our assets, other than intellectual property, which is the subject of a negative pledge. Under the loan agreement, we are subject to certain customary covenants that limit or restrict our ability to, among other things, incur additional indebtedness, grant any security interests, pay cash dividends, repurchase our common stock, make loans, or enter into certain transactions without Hercules&#8217; prior consent. The loan agreement was amended on October&#160;10, 2016 to revise the language granting Hercules a contingent security interest in certain of our assets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the loan agreement, Hercules or its affiliates have a right to participate in a single subsequent unregistered financing by us in an amount of up $1.0&#160;million on the same terms, conditions and pricing afforded to others participating in such financing. Hercules has not yet exercised this right to participate which expires on the earliest to occur of the maturity date, the date we prepay the term loan in full or the date the loan otherwise becomes due and payable.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Refer to Note 15, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, in the accompanying Notes to Consolidated Financial Statements included elsewhere in this report for more information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Funding Requirements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect that our primary uses of capital will continue to be third-party clinical and research and development services, compensation and related expenses, laboratory and related supplies, legal and other regulatory expenses and general overhead costs. Based on the Company&#8217;s current operating plans, we believe that existing working capital at December 31, 2018 is sufficient to fund our current operating plans into January 2020.  However, we may require additional capital for the further development of our existing therapeutic candidates and may also need to raise additional funds sooner to pursue other development activities related to additional therapeutic candidates. We believe that we will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements to fund our current operating plans, which we believe will allow us to execute on the strategy and pipeline development as described in this Annual Report on Form 10-K. To the extent that we raise additional capital through future equity financings, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. We cannot assure you that such additional financing, if available, can be obtained on terms acceptable to us. If we are unable to obtain such additional financing, we would need to reevaluate our future operating plans.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements are difficult to forecast and will depend on many factors, including:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the terms and timing of any other collaboration, licensing and other arrangements that we may establish;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the initiation, progress, timing and completion of preclinical studies and clinical trials for our potential therapeutic candidates;</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the number and characteristics of therapeutic candidates that we pursue;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the progress, costs and results of our preclinical studies and clinical trials;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the outcome, timing and cost of regulatory approvals;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">delays that may be caused by changing regulatory requirements;</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost and timing of hiring new employees to support our continued growth;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">unknown legal, administrative, regulatory, accounting, and information technology costs as well as additional costs associated with operating as a public company;</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the costs of filing and prosecuting intellectual property rights and enforcing and defending any intellectual property-related claims;</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the costs and timing of procuring clinical and commercial supplies of our therapeutic candidates;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the extent to which we acquire or in-license other therapeutic candidates and technologies; and</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:12px;text-align:left;"><font style="padding-bottom:12px;text-align:left;font-family:Times New Roman;font-size:10pt;color:#000000;padding-right:48px;">&#8226;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the extent to which we acquire or invest in other businesses, therapeutic candidates or technologies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Please see the section titled &#8220;Risk Factors&#8221; elsewhere in this Annual Report on Form 10-K for additional risks associated with our substantial capital requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Until such time, if ever, we generate product revenue, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings and research collaboration and license agreements. We may be unable to raise capital or enter into such other arrangements when needed or on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our therapeutic candidates.</font></div><div><a name="s4D9EC7337409517AB31C8D169743F148"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Obligations and Commitments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is a summary of our significant contractual obligations as of December&#160;31, 2018 (in thousands):</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments&#160;Due&#160;by&#160;Period </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual Obligations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Less&#160;than&#160;1</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1-3&#160;Years </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">3-5&#160;Years </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">After&#160;5&#160;Years </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease obligations (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">412</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest payments on long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,212</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">801</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,411</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">________________________</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Includes principal only.  Refer to Note 15, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, in the accompanying Notes to Consolidated Financial Statements included elsewhere in this report for more information.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Future minimum lease payments under our non-cancelable operating lease for our current office and lab space in Skokie, Illinois that expires in February 2021. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We enter into agreements in the normal course of business with contract research organizations&#160;and vendors for clinical trials, preclinical studies, and other services and products for operating purposes which are cancelable at any time by us, generally upon 30 days prior written notice. We also have obligations to make future payments to Northwestern University that become due and payable on the achievement of certain commercial milestones. These payments are not included in this table of contractual obligations.</font></div><div><a name="s1176A782920852A1808FB09449DFA937"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Off-balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">97</font></div></div><hr style="page-break-after:always"><div><a name="s98394615271E5DA893DFE80830F18F9A"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">JOBS Act</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) was enacted by the federal government. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, as an emerging growth company, we will not be required to provide an auditor&#8217;s attestation report on our internal control over financial reporting in future annual reports on Form 10-K as otherwise required by Section&#160;404(b) of the Sarbanes-Oxley Act.</font></div><div><a name="sFCFF24E6DEA857CEA1437F3B8CE36269"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item&#160;7A. Quantitative and Qualitative Disclosures about Market Risk.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The primary objectives of our investment activities are to ensure liquidity and to preserve principal while at the same time maximizing the income we receive from our marketable securities without significantly increasing risk. Some of the securities that we invest in may have market risk related to changes in interest rates. As of December&#160;31, 2018 and 2017, we had cash and cash equivalents of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$26.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, consisting of interest-bearing money market accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, an immediate 100&#160;basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents. To minimize the risk in the future, we intend to maintain our portfolio of cash equivalents and short-term investments in a variety of securities, including commercial paper, money market funds, government and non-government debt securities and corporate obligations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are subject to interest rate risk in connection with our borrowings under the $6.0 million term loan with Hercules.  The principal balance of the term loan under the Hercules loan facility bears interest at a floating per annum interest rate (based on a year consisting of 360 days) equal to the greater of (i) 9.95% or (ii)&#160;the sum of (a) 9.95% plus (b)&#160;the prime rate (as reported in The Wall Street Journal) minus 3.50% which bears interest at a variable per annum rate calculated for any day as the greater of (i) the prime rate plus 6.80%, and (ii) 10.55%. We currently do not engage in any interest rate hedging activity and we have no intention to do so in the foreseeable future. Based on the current interest rate of the term loan with Hercules and the scheduled payments thereunder, we believe a 100 basis point increase in interest rates would not have a material impact on our financial condition or results of operations.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></div><hr style="page-break-after:always"><div><a name="sF005D3116BE25DD5A010DE44D51C96D3"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8. Financial Statements and Supplementary Data.</font></div><div><a name="s270FFAD4952451D8B990E9E67B9190F8"></a></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:93%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">PAGE</font><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s7A6FAB2DD271515180A8E019F925AE32"><font style="font-family:Times New Roman;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s7A6FAB2DD271515180A8E019F925AE32">100</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s6FFA93AFEBBD534BB8550A342A92D953"><font style="font-family:Times New Roman;font-size:10pt;">Consolidated Balance Sheets as of December 31, 2018 and 2017</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s6FFA93AFEBBD534BB8550A342A92D953">101</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:20px;text-indent:-20px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sE532B1C758255A5AB6C2DC33D8AA0C99"><font style="font-family:Times New Roman;font-size:10pt;">Consolidated Statements of Operations for the years ended December 31, 2018 and 2017</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sE532B1C758255A5AB6C2DC33D8AA0C99">102</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:20px;text-indent:-20px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sE393AFC1B8E25336AD0B03ADDBFC070B"><font style="font-family:Times New Roman;font-size:10pt;">Consolidated Statements of Changes in Stockholders&#8217; Equity for the years ended December 31, 2018 and 2017</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sE393AFC1B8E25336AD0B03ADDBFC070B">103</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:20px;text-indent:-20px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s95D393339E4E5AE7B2ABAADE2152C290"><font style="font-family:Times New Roman;font-size:10pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2018 and 2017</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s95D393339E4E5AE7B2ABAADE2152C290">104</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;padding-left:20px;text-indent:-20px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s63D76621D34A5EEABF07233B35664FC6"><font style="font-family:Times New Roman;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s63D76621D34A5EEABF07233B35664FC6">105</a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99</font></div></div><hr style="page-break-after:always"><div><a name="s7A6FAB2DD271515180A8E019F925AE32"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Stockholders and Board of Directors</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exicure, Inc.:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Opinion on the Consolidated Financial Statements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Exicure, Inc. and subsidiary (the Company) as of December&#160;31, 2018 and 2017, the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows for each of the years in the two&#8209;year period ended December&#160;31, 2018, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2018 and 2017, and the results of its operations and its cash flows for each of the years in the two&#8209;year period ended December&#160;31, 2018, in conformity with U.S.&#160;generally accepted accounting principles.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in Accounting Principle </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in Note 2 to the consolidated financial statements, the Company has changed its method of accounting for revenue recognition in 2018 due to the adoption of the Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Going Concern </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1  to the consolidated financial statements, the Company has suffered recurring losses from operations and will be required to raise additional capital or alternative means of financial support to fund operations.  These factors raise substantial doubt about its ability to continue as a going concern.  Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis for Opinion</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:20px;padding-top:20px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(signed) KPMG LLP</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have served as the Company&#8217;s auditor since 2014.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chicago, Illinois</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 8, 2019</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></div><hr style="page-break-after:always"><div><a name="s6FFA93AFEBBD534BB8550A342A92D953"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CONSOLIDATED BALANCE SHEETS </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December&#160;31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December&#160;31, <br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,268</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25,764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Unbilled revenue receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Receivable from related party</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,382</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,844</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">27,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">27,638</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,061</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,317</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other noncurrent assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:100px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28,756</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,049</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,543</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,273</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion of deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,034</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,043</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,356</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Long-term debt, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Common stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">797</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">523</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,804</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,012</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 44,358,000 issued and outstanding, December 31, 2018; 39,300,823 shares issued and outstanding, December 31, 2017 </font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">75,942</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">53,586</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(54,994</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(33,615</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20,952</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,975</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:30px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28,756</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See Accompanying Notes to Consolidated Financial Statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></div><hr style="page-break-after:always"><div><a name="sE532B1C758255A5AB6C2DC33D8AA0C99"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.72649572649573%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year Ended<br>December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,719</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">118</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,719</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">14,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,818</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,046</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20,126</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(21,819</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(10,407</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(672</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(795</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total other income (loss), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(604</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(22,413</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(11,011</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Basic and diluted loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Basic and diluted weighted-average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">41,189,177</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10,119,569</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See Accompanying Notes to Consolidated Financial Statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102</font></div></div><hr style="page-break-after:always"><div><a name="sE393AFC1B8E25336AD0B03ADDBFC070B"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except shares)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.84567901234568%;border-collapse:collapse;text-align:left;"><tr><td colspan="47"></td></tr><tr><td style="width:11%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Non-Redeemable Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Series C</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Series B-2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Series B-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Series A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Additional Paid-in- Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">Total Stockholders&#8217; Equity</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Balance at<br>December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">11,239,359</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">33,483</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">1,403,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">3,641</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2,451,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">5,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">11,381,640</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">135</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">131,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(17,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(22,604</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Exercise of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">58,440</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Equity-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Share conversion in connection with the Merger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(11,239,359</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(33,483</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(1,403,984</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(3,641</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(2,451,560</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(5,371</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(11,381,640</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(135</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">28,556,543</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">42,596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(31</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Issuance of common stock, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10,554,196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">27,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">27,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(11,011</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(11,011</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Balance at</font></div><div style="font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">39,300,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">53,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(33,615</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">19,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Adoption of new accounting standard - ASC 606</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1,034</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1,034</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Balance at January 1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">39,300,823</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">53,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(32,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">21,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Exercise of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">22,494</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Equity-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Issuance of common stock to consultants, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">145,466</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Issuance of common stock in private placement, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">4,889,217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">20,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">20,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(22,413</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(22,413</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Balance at</font></div><div style="font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">44,358,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">75,942</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(54,994</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">20,952</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See Accompanying Notes to Consolidated Financial Statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></div><hr style="page-break-after:always"><div><a name="s95D393339E4E5AE7B2ABAADE2152C290"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(22,413</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(11,011</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Adjustments to reconcile net loss to cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">358</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">232</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Equity-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Amortization of long-term debt issuance costs and fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">189</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in fair value of warrant liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">274</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(214</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Unbilled revenue receivable and accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Receivable from related party</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">498</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,442</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">270</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(906</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(8,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(239</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(19,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(19,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Capital expenditures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(94</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(926</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(94</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(926</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Proceeds from common stock offering</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">22,001</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">31,513</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Proceeds from exercise of common stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Repayment of long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,001</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Payment of long-term debt fees and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Payment of common stock financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,931</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,699</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20,085</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6,141</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Cash and cash equivalents - beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25,764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Cash and cash equivalents - end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25,764</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Supplemental disclosure of cash flow information</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Non-cash financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Issuance of common stock for professional services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Issuance of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">536</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Common stock issuance costs (accounts payable and accrued expenses)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">214</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Non-cash investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Capital expenditures (accounts payable and accrued expenses)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See Accompanying Notes to Consolidated Financial Statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104</font></div></div><hr style="page-break-after:always"><div><a name="s63D76621D34A5EEABF07233B35664FC6"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="s3AA12407FDE25408AE6FA4BE9EDBB388"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">1. Description of Business and Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Description of Business</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Exicure is a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">clinical-stage</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on the Company&#8217;s proprietary Spherical Nucleic Acid (&#8220;SNA&#8221;) technology. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe the</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;design of the Company&#8217;s SNAs gives rise to distinct chemical and biological properties that </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The Company intends to build a leading nucleic acid therapeutics company focused on the discovery and development of therapeutics based on the Company&#8217;s proprietary SNA technology, either on its own or in collaboration with pharmaceutical partners.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Throughout these consolidated financial statements, the terms &#8220;the Company&#8221; and &#8220;Exicure&#8221; refer to Exicure, Inc. and its 100% owned subsidiary, Exicure Operating Company.  Exicure Operating Company holds all material assets, and conducts all business activities and operations, of the Company.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">The Merger</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On September 26, 2017, pursuant to the merger agreement,&#160;Max-1&#160;Acquisition Sub, Inc., a wholly-owned subsidiary of&#160;Max-1&#160;Acquisition Corporation (&#8220;Max-1&#8221;),&#160;merged with and into Exicure Operating Company (f/k/a Exicure, Inc.), a privately-held Delaware corporation referred to herein as Exicure OpCo, with Exicure OpCo remaining as the surviving entity and a wholly-owned operating subsidiary of&#160;Max-1 (the &#8220;Merger&#8221;). The Merger was effective as of September 26, 2017 (the &#8220;Effective Time&#8221;), upon the filing of a Certificate of Merger with the Secretary of State of the State of Delaware.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At the Effective Time, the legal existence of&#160;Max-1&#160;Acquisition Sub, Inc. ceased. At the Effective Time, each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of&#160;Max-1&#8217;s&#160;common stock, and each share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of&#160;Max-1&#8217;s&#160;common stock. As a result, an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26,666,627</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of&#160;Max-1&#8217;s&#160;common stock were issued to the holders of Exicure OpCo&#8217;s capital stock, which is incremental to the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,080,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of Max-1 common stock that were outstanding immediately prior to the Merger. In addition, pursuant to the Merger Agreement, options to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7,414,115</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;shares of Exicure OpCo common stock issued and outstanding immediately prior to the closing of the Merger were assumed by Max-1 and converted into options to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,680,997</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;shares of&#160;Max-1&#8217;s&#160;common stock. After the filing of the Certificate of Merger with the Secretary of State of the State of Delaware,&#160;Max-1 changed its name to Exicure, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Merger is considered a &#8220;reverse merger,&#8221; whereby Exicure OpCo is considered the accounting acquirer in the Merger. Exicure OpCo was determined to be the accounting acquirer based on the terms of the Merger and other factors including: (i)&#160;legacy Exicure OpCo shareholders own approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">94%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the combined company on a fully diluted basis immediately following the closing of the Merger, (ii)&#160;legacy Exicure OpCo directors will hold all six board seats of the combined company, and (iii)&#160;legacy Exicure OpCo management will hold all positions in management of the combined company. The transaction is accounted for as an asset acquisition rather than a business combination because as of the acquisition date,&#160;Max-1 does not meet the definition of a business as defined by accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).  Consequently, the assets, liabilities and operations that are reflected in Exicure&#8217;s historical financial statements prior to the Merger will be those of&#160;Exicure OpCo, and the consolidated financial statements after completion of the Merger will include the assets, liabilities and results of operations of Exicure OpCo up to the day prior to the closing of the Merger and the assets, liabilities and results of operations of the combined company from and after the closing date of the Merger.  The assets and liabilities of Max-1 included in the accompanying consolidated financial statements are recorded at the historical cost basis of&#160;Max-1.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In these consolidated financial statements, unless otherwise indicated, all share and per share figures are retrospectively adjusted to reflect the conversion of each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock), preferred stock warrant liability, and common stock options issued and outstanding immediately prior to the closing of the Merger into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of&#160;the Company&#8217;s common stock, and each share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of&#160;the Company&#8217;s&#160;common stock.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Capitalization Prior to the Merger</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">AuraSense Therapeutics, LLC was formed on June 13, 2011 as a wholly owned subsidiary of AuraSense, LLC, but did not conduct substantive business until December 12, 2011, which is considered the inception date.  On December 12, 2011, AuraSense, LLC contributed the assets and liabilities comprising the business of the Company to the Company through a Bill of Sale and Assumption Agreement.  Pursuant to this agreement AuraSense, LLC received </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11,381,611</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Class A Units of the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The assets and liabilities contributed by AuraSense, LLC were transferred at their historical cost and consisted of an unbilled revenue receivable of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$143</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, scientific equipment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$309</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and a liability of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$317</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for accrued legal expenses related to patent protection. The net book value of AuraSense, LLC&#8217;s contribution at inception was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$135</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Also on December 12, 2011, the Company and AuraSense, LLC entered into a Partial Assignment of License Agreement whereby certain license rights held by AuraSense, LLC pursuant to a License Agreement with Northwestern University were assigned to the Company.  Under the terms of the License Agreement and the Partial Assignment of License Agreement, Northwestern University received </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the Class A units received by AuraSense, LLC in the formation transaction, which amounted to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">113,816</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;units. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On July 9, 2015, AuraSense Therapeutics, LLC was converted into AuraSense Therapeutics, Inc., a Delaware corporation, and on the same date changed its name to Exicure, Inc., which actions together are referred to in these Notes to Consolidated Financial Statements as the corporate conversion. In connection with the corporate conversion, each common unit, Class A unit, Class B-1 unit, Class B-2 unit and Class C unit of AuraSense Therapeutics, LLC issued and outstanding immediately prior to the effectiveness of the corporate conversion was converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;share of common stock, Series A preferred stock, Series B-1 preferred stock, Series B-2 preferred stock and Series C preferred stock of Exicure OpCo, respectively. No preferred stock was provided in consideration for fractional membership units.  Each outstanding option to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;common unit of AuraSense Therapeutics, LLC was converted into an option to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;share of common stock of Exicure OpCo. In connection with the corporate conversion, the accumulated deficit of AuraSense Therapeutics, LLC of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$18,837</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was reclassified to Additional paid in capital.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Refer to Note 6, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Stockholders&#8217; Equity, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for more information on capital stock transactions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying consolidated financial statements as of December 31, 2018 and 2017, and for the years then ended, have been presented in conformity with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying consolidated financial statements include the accounts of Exicure, Inc. and its 100% owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Going Concern </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December 31, 2018, the Company has generated an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73,831</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Based on the Company&#8217;s current operating plans, it believes that existing working capital at December 31, 2018 is sufficient to fund its </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">current operating plans into January 2020.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Management believes that it will be able to obtain additional working capital through equity financings, partnerships and licensing, or other arrangements, to fund operations. However, there can be no assurance that such additional financing will be available and, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, the Company will need to reevaluate future operating plans. Accordingly, there is substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management bases its estimates on certain assumptions which it believes are reasonable in the circumstance and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company&#8217;s financial position, results of operations or cash flows.  Actual results in future periods could differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Revision of Prior Period Financial Statements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with preparing our condensed consolidated interim financial information for the three months ended March 31, 2018, we identified errors that affected prior interim and annual periods related to the timing of recognition of research and development expense related to a contract for the clinical trial of one of our therapeutic candidates. We evaluated whether our previously issued consolidated financial statements were materially misstated and concluded that the errors individually and in the aggregate were not material to any of our previously issued financial statements. We revised the financial statements to correct the immaterial errors, and the accompanying comparative financial statements reflect these corrections. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The correction of the errors increased prepaid expense and other current assets by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$933</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, decreased accrued expenses by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$95</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and decreased accumulated deficit by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,028</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;at December 31, 2017; and decreased research and development expense, operating loss, and net loss by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,028</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and loss per share by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended December 31, 2017.</font></div><div><a name="s4658CC04E5D55795851F18715AF5450B"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2. Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cash and cash equivalents</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company considers all highly liquid investments with original maturities of three&#160;months or less to be cash equivalents. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Accounts receivable and unbilled revenue receivable</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accounts receivable and unbilled revenue receivable consist of reimbursement for research and development activities in connection with the research collaboration, license, and option agreement with Purdue Pharma L.P. (&#8220;Purdue&#8221;). The Company&#8217;s management believes these receivables are fully collectible.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Fair value of financial instruments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The carrying amounts of financial instruments, which include cash and cash equivalents and accounts payable, approximate their respective fair values due to the relatively short-term nature of these instruments.  Management believes that the Company&#8217;s long-term debt bears interest at the prevailing market rate for instruments with similar characteristics and, accordingly, the carrying value of long-term debt also approximates their fair value.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Concentrations of credit risk and other risks and uncertainties</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents.  As of December 31, 2018 and 2017, the Company had cash and cash equivalents of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$26,268</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25,764</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.  The cash balances at each respective period were maintained at two institutions.  These deposits exceed federally insured limits.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the years ended December&#160;31, 2018 and 2017, one counterparty accounted for all of the Company&#8217;s revenue.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is currently not profitable and no assurance can be provided that it will ever be profitable.  The Company&#8217;s research and development activities have required significant investment since inception and operations are expected to continue to require cash investment in excess of its revenues.  See also Note 1, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Description of Business and Basis of Presentation&#8212;Going Concern</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for more information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common in therapeutic development including, but not limited to, therapeutic candidates that appear promising in the early phases of development often fail because they prove to be inefficacious or unsafe, clinical trial results are unsuccessful, regulatory bodies may not approve the therapeutic or the therapeutic may not be economical in production or distribution.  The Company is also subject to risks common to biotechnology firms including, but not limited to new and disruptive technological innovations, dependence on key personnel, protection of proprietary technology, the validity of and continued access to its owned and licensed intellectual property, limitations on the supply of critical materials, compliance with governmental regulations and market acceptance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Property and equipment</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the various classes of property and equipment, which range from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">seven</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;years. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining terms of the respective leases or the estimated lives of the assets.  Depreciation begins at the time the asset is placed in service.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Property and equipment are reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">No</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;impairment losses were recorded from inception in December 2011 through December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Common stock warrant liability</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Freestanding warrants related to shares that are redeemable, contingently redeemable, or for purchases of common stock that are not indexed to the Company&#8217;s own stock are classified as a liability on the Company&#8217;s balance sheet. The common stock warrants are recorded at fair value, estimated using the Black-Scholes option-pricing model, and marked to market at each balance sheet date with changes in the fair value of the liability recorded in other income (expense), net in the statements of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenue recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Effective January 1, 2018, the Company adopted the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;using the modified retrospective method for all contracts not completed as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance, while the reported results for 2017 were prepared under the guidance of ASC 605,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#160;Revenue Recognition</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;(ASC 605).  Under ASC 605, the Company&#8217;s revenue recognition accounting policy was consistent with ASC 606 revenue recognition accounting policies, except the Company used to recognize upfront license fees on a straight line basis.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Identify the contract with the customer.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party&#8217;s rights regarding the goods or services to be transferred and identifies the related payment terms, (ii) the contract has commercial substance, and (iii) the Company determines that collection of substantially all consideration for goods and services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration. The Company applies judgment in determining the customer&#8217;s intent and ability to pay, which is based on a variety of factors including the customer&#8217;s historical payment experience, or in the case of a new customer, published credit and financial information pertaining to the customer.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Identify the performance obligations in the contract.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;Performance obligations promised in a contract are identified based on the goods and services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the good or service either on its own or together with other available resources, and are distinct in the context of the contract, whereby the transfer of the good or service is separately identifiable from other promises in the contract. To the extent a contract includes multiple promised goods and services, the Company must apply judgment to determine whether promised goods and services are both capable of being distinct and distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Determine the transaction price.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;The transaction price is determined based on the consideration to which the Company will be entitled in exchange for transferring goods and services to the customer. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing either the expected value method or the most likely amount method, depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in the Company&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. Determining the transaction price requires significant judgment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Allocate the transaction price to performance obligations in the contract.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. However, if a series of distinct services that are substantially the same qualifies as a single performance obligation in a contract with variable consideration, the Company must determine if the variable consideration is attributable to the entire contract or to a specific part of the contract. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation on a relative standalone selling price basis unless the transaction price is variable and meets the criteria to be allocated entirely to a performance obligation or to a distinct service that forms part of a single performance obligation. The consideration to be received is allocated among the separate performance obligations based on relative standalone selling prices. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Recognize revenue when or as the Company satisfies a performance obligation.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company satisfies performance obligations either over time or at a point in time. Revenue is recognized over time if either (i) the customer simultaneously receives and consumes the benefits provided by the entity&#8217;s performance, (ii) the entity&#8217;s performance creates or enhances an asset that the customer controls as the asset is created or enhanced, or (iii) the entity&#8217;s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. If the entity does not satisfy a performance obligation over time, the related performance obligation is satisfied at a point in time by transferring the control of a promised good or service to a customer. Examples of control are using the asset to produce goods or services, enhance the value of other assets, or settle liabilities, and holding or selling the asset.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Licenses of intellectual property</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&#160;If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or&#160;at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Milestone payments:</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;At the inception of each arrangement that includes development milestone payments, the Company evaluates the probability of reaching the milestones and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received and therefore revenue recognized is constrained as management is unable to assert that a reversal of revenue would not be possible. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues and earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Royalties</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:&#160;For arrangements that include sales-based royalties, including milestone payments based on levels of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaboration agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For the years ended December 31, 2018 and 2017, the Company&#8217;s only revenue recognized is related to the Purdue Collaboration (see Note 3). </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Equity-based compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company measures the cost of common stock option awards at fair value and records the cost of the awards, net of estimated forfeitures, on a straight-line basis over the requisite service period. The Company measures fair value for all common stock options using the Black-Scholes option-pricing model. For all common stock option awards to employees, the fair value measurement date is the date of grant and the requisite service period is the period over which the employee is required to provide service in exchange for the common stock option awards, which is generally the vesting period.  For all common stock option awards to nonemployees, the Company remeasures fair value at each financial statement reporting date and recognizes compensation expense as services are rendered, generally on a straight-line basis.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Segments and geographic information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has determined it has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;reporting segment. Disaggregating the Company&#8217;s operations is impracticable because the Company&#8217;s research and development activities and its assets overlap and management reviews its business as a single operating segment. Thus, discrete financial information is not available by more than one operating segment.  All long-lived assets of the Company are located in the United States. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Deferred rent</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Deferred rent consists of rent escalation payment terms, tenant improvement allowances and other incentives received from the landlord related to the Company&#8217;s operating lease and is presented in &#8220;Other noncurrent assets&#8221; in the accompanying balance sheet. Rent escalation represents the difference between actual operating lease payments </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">due and straight-line rent expense, which is recorded by the Company over the term of the lease. Tenant improvement allowances and other incentives are recorded as deferred rent and amortized as a reduction of periodic rent expense, over the term of the applicable lease. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and development expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development expense includes wages, benefits, research materials, external services, legal fees related to patent protection, overhead and other expenses directly related to research and development operations. Research and development costs are expensed as incurred in accordance with ASC 730, Research and Development.  Research and development costs that are paid in advance of performance are deferred as a prepaid expense and recognized as expense as the services are provided.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Income taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From inception through July 9, 2015, the Company was a Delaware LLC for federal and state tax purposes and, therefore, all items of income or loss through July 9, 2015 flowed through to the members of AuraSense Therapeutics, LLC.  Effective July 9, 2015, the Company converted from an LLC to a C corporation for federal and state income tax purposes.  Accordingly, prior to the conversion to a C corporation, the Company did not record deferred tax assets or liabilities or have any net operating loss carryforwards. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, is applied during the years in which temporary differences are expected to be settled and is reflected in the financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. At December 31, 2018 and 2017, the Company established a full valuation allowance against its deferred tax assets to an amount that is more likely than not to be realized.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 (ASC 606), </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This ASU, as amended by ASU 2015-14, affects any entity that either enters into contracts with customers to transfer goods and services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 replaces most existing revenue recognition guidance in GAAP when it becomes effective. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under the currently effective guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for Exicure in the first quarter of 2018 and early adoption is permitted beginning in the first quarter of 2017.  The Company adopted ASC 606 on a modified retrospective basis.  See above &#8220;Revenue Recognition&#8221; for a discussion of the Company&#8217;s updated policies related to revenue recognition effective January 1, 2018.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:underline;">Impact of adoption of ASC 606</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers that were not completed as of January 1, 2018 was recorded as an adjustment to accumulated deficit as of the adoption date.  As a result of applying the modified retrospective method to adopt the new guidance, the Company recorded reductions to both accumulated deficit and deferred revenue, current of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as of the date of adoption.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of the adoption of ASC 606: (i) there were no impacts to the totals of our cash flows from operating activities, cash flows from investing activities, or cash flows from financing activities in the accompanying consolidated statement of cash flows for the year ended December 31, 2018; (ii) there were no impacts to the balances of the accompanying consolidated balance sheet as of December 31, 2018, and (iii) total revenue, operating loss, and net loss were lower by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;each in the accompanying consolidated statement of operations for the year ended December 31, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Cash Flows</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2016, the FASB issued ASU 2016-15, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. ASU 2016-15 addresses the classification of certain specific cash flow issues including debt prepayment or extinguishment costs, settlement of certain debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of certain insurance claims and distributions received from equity method investees. ASU 2016-15 is effective for the Company in the first quarter of 2018 and early adoption is permitted. An entity that elects early adoption must adopt all of the amendments in the same period. The Company adopted this guidance on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact to the Company&#8217;s statement of cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2017, the FASB issued ASU 2017-09, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. ASU 2017-09 clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. ASU 2017-09 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance on January 1, 2018.  The adoption of ASU 2017-09 did not have a material impact to the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, FASB issued ASU 2016-02, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. ASU 2016-02 is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. ASU 2016-02 will be effective for the Company beginning in the first quarter of 2019. ASU 2016-02 requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. In July 2018, the FASB issued ASU 2018-11,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#160;Leases (Topic 842): Targeted Improvements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;(&#8220;ASU 2018-11&#8221;), which allows entities to initially apply the new lease guidance at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption.  We expect to adopt the new standard on January 1, 2019 and use the effective date as our date of initial application. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. The Company is in the process of gathering a complete inventory of its lease contracts&#160;and evaluating the impact of the new guidance on its consolidated financial statements and related disclosures; however,&#160;management expects that the adoption of ASU 2016-02 will result in </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the recognition of a right-of-use asset and related liability&#160;associated&#160;with&#160;the&#160;Company&#8217;s non-cancelable operating lease arrangement for office and laboratory space&#160;that was executed in 2012&#160;(see&#160;Note 12, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">).&#160;</font></div><div><a name="s71A4679E3C4A5A3AACB60C407F22EBDF"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">3. Purdue Collaboration</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 2, 2016, the Company entered into a research collaboration, option and license agreement with Purdue and referred to herein as the &#8220;Purdue Collaboration.&#8221; Purdue has the option to obtain from us the full worldwide development and commercial rights to AST-005 (the Company&#8217;s therapeutic candidate that targets tumor necrosis factor), an option to obtain </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;additional collaboration targets and a further option to obtain from us the full worldwide development and commercial rights to any therapeutic candidates developed targeting the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;additional collaboration targets. In connection with the Purdue Collaboration, the Company received a non-refundable development fee of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Company is eligible to receive up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$776,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;upon successful completion of certain research, regulatory and commercial sales milestones. The research milestones are payable upon target identification and IND-enabling pre-clinical development, per program, with an aggregate total of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The regulatory milestones are payable upon the initiation or completion of clinical trials, and regulatory approval in the United States and outside the United States, per program, with an aggregate total of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$410,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The commercial sales milestones are payable upon achievement of specified aggregate product sales thresholds and total up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$350,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In the event a therapeutic candidate subject to the collaboration results in commercial sales, the Company is eligible to receive royalties ranging from the low single digits to a maximum of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;on future net sales of such commercialized therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In April 2018, Purdue notified the Company it had declined to exercise its option to develop AST-005 at that time and there are currently no active therapeutic candidates in development under the Purdue Collaboration. There can be no assurance that any research, regulatory and commercial sales milestones or royalties will be achieved as they are subject to highly significant risks and uncertainties, many of which are outside of our control. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the adoption of ASC 606, the upfront payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was accounted for pursuant to ASC 605 and was recorded as deferred revenue and recognized on a ratable basis over the estimated performance period of the relevant research and development activities.  On January 1, 2018, in connection with the adoption of ASC 606, the Company recorded the unamortized deferred revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as an adjustment to the beginning balance of retained deficit at January 1, 2018.  See Note 2, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for more information related to the adoption of ASC 606.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company identified multiple performance obligations as part of the Purdue Collaboration agreement, including the upfront payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, discussed above, and the research and development services.  The Company determined that the performance obligations should not be combined, the license should be recognized at the time the license is granted, and the research and development services should be recognized at the time the service is performed.  The Purdue Collaboration agreement includes contingent promises related to specified research, development and regulatory milestones and sale-based milestones.  Each contingent promise related to contingent and milestone payment is evaluated to determine whether it represents a material right.  The Company recognizes any payment that is contingent upon the achievement of a substantive milestone entirely in the period in which it is determined that the revenue is not subject to a significant reversal.  To date, the Company has not recognized any contingent payments in connection with the Purdue Collaboration agreement as revenue.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the year ended December 31, 2018, the Company recognized collaboration revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$118</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which consisted entirely of research and development activities that will be reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations.  During the year ended December 31, 2017, the Company recognized collaboration revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9,719</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which included </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,443</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of research and development activities that was reimbursed by Purdue and is presented on a gross basis in the accompanying statement of operations. </font></div><div><a name="sF4EC67C9E1B953FAA6B2F8BAD8471650"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">4. Supplemental Balance Sheet Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Property and equipment, net</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Scientific equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,979</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,797</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Computers and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Construction in process</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,189</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,317</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Depreciation and amortization expense was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$358</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$232</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for the years ended December 31, 2018 and 2017, respectively.   </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Accrued expenses and other current liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued legal expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">189</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">251</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued payroll-related expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">899</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">718</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued clinical, contract research and manufacturing costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">102</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">99</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,543</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,273</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sEAC6C60BBA755DB6866101F57C2A2E1C"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">5. Debt</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 17, 2016, the Company closed a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;loan facility, with an initial advance against this loan facility of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, with Hercules Technology Growth Capital (&#8220;Hercules&#8221;). The loan bears a floating interest rate equal to the greater of either (i) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">9.95%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or (ii) the sum of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">9.95%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;plus the United States prime rate minus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.50%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. &#160; Total proceeds net of fees and issuance costs were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5,839</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160; Fees and issuance costs of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$161</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, as well as fees of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$231</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;that are payable to the lender at maturity, are recorded as a reduction in the carrying amount of long-term debt on our balance sheet and will be amortized to interest expense through the maturity date of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;1, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;using the effective interest method.&#160; Interest amounts were payable monthly beginning on March 1, 2016 through the maturity date of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;1, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160; Initially, principal amounts were payable monthly beginning on April 1, 2017 through the maturity date.  In 2016, the Company met certain terms in the loan agreement so that principal amounts became payable monthly beginning on July 1, 2017.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 15, 2018, the Company and Hercules amended its loan agreement so that amortization payments due for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">thirteen</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;(13) consecutive months commencing on December 1, 2017 through and including December 1, 2018 were deferred.&#160; Commencing on January 1, 2019, and continuing on the first business day of each month thereafter, the loan, including the deferred payments, was to begin amortizing in equal monthly installments of principal and interest based upon an amortization schedule equal to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">eighteen</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;(18) consecutive months. Any remaining obligations under the loan agreement and other loan documents were due and payable on the maturity date on September 1, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;On December&#160;28, 2018, the Company and Hercules further amended its loan agreement so that interest amounts are payable on the first day of each business month and any remaining obligations under the loan agreement and other loan documents are due and payable on the maturity date on September 1, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The loan is collateralized by a security interest in all tangible assets. In addition, the Company is subject to certain financial reporting requirements and certain negative covenants requiring lender consent.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the February 2016 Hercules loan, Hercules also had the right to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">80,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of Series C preferred stock at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share under the terms of a warrant agreement with the Company. The preferred stock warrant liability was recorded at fair value at the date of issuance of February 17, 2016 in the amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$134</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and recorded as a reduction in the carrying amount of long-term debt on our balance sheet.  This discount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$134</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;will be amortized to interest expense through the loan maturity date of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;1, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;using the effective interest method.&#160; The Company estimated the fair value of the preferred stock warrant liability at the end of each reporting period using the Black-Scholes model and recorded any changes in fair value to other income (expense), net on its statement of operations. See Note 10, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for more information on the fair value of the preferred stock warrant liability.  The warrant agreement to purchase shares of preferred stock was terminated on September 26, 2017 in connection with the Merger. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At December 31, 2018 and 2017, the aggregate carrying value of the current and noncurrent portion of long-term debt is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,925</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,855</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At December 31, 2018, the principal maturities of the long-term debt were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,999</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Principal balance outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">less: unamortized discount</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(69</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">less: unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,925</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Noncurrent portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,925</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company paid interest on debt of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$572</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$611</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;during the years ended December 31, 2018 and 2017, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Refer to Note 15, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Subsequent Events</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for more information on our loan agreement with Hercules.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></div><hr style="page-break-after:always"><div><a name="s4E0FEAF9CF35589F92493247856AFEBB"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">6. Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December 31, 2018 and 2017, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of preferred stock, par value </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;authorized and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December 31, 2018 and 2017, the Company had authorized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">200,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock, par value </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As of December 31, 2018, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">44,358,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares issued and outstanding.  As of December 31, 2017, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">39,300,823</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The holders of shares of the Company&#8217;s common stock are entitled to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;vote per share on all matters to be voted upon by Exicure stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company&#8217;s common stock are entitled to receive ratably any dividends that may be declared from time to time by Exicure&#8217;s board of directors (the &#8220;Board&#8221;) out of funds legally available for that purpose. In the event of the Company&#8217;s liquidation, dissolution or winding up, the holders of shares of Exicure common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. Exicure common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to Exicure common stock. The outstanding shares of Exicure common stock are fully paid and&#160;non-assessable.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">August 2018 Private Placement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On August 22, 2018, the Company entered into subscription agreements with several accredited investors, pursuant to which it agreed to issue and sell a total of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,889,217</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of the Company&#8217;s common stock, at a purchase price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.50</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share, resulting in approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$22,001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in gross proceeds to the Company (the &#8220;August 2018 Private Placement&#8221;).  The aggregate net proceeds from the August 2018 Private Placement (after deducting placement agent fees and expenses of the offering of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,931</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) were&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20,070</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company also entered into a registration rights agreement with the investors in the August 2018 Private Placement, which required it to file a &#8220;resale&#8221; registration statement with the SEC covering the shares issued in the August 2018 Private Placement within 30 calendar days from the final closing of the August 2018 Private Placement Offering.  The Company filed and caused to become effective a registration statement with the SEC on October 5, 2018 registering the resale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,034,683</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock, consisting of (i) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,889,217</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares that were privately issued through the August 2018 Private Placement and (ii) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">145,466</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares that were privately issued on February 1, 2018 in connection with consulting services.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the closing of the August 2018 Private Placement, the placement agents received an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,680</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in cash placement fees, and the Company reimbursed up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$87</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of expenses incurred by the placement agents in connection with this closing of the August 2018 Private Placement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">2017 Private Placement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On September 26, 2017, following the Effective Time of the Merger,&#160;the Company sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">6,767,360</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of Exicure, Inc. common stock pursuant to an initial closing of a private placement offering (the &#8220;Offering&#8221;) for up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">13,333,333</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of Exicure, Inc. common stock at a purchase price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share (the &#8220;Offering Price&#8221;).  The aggregate net proceeds from the initial closing of the Offering (after deducting placement agent fees and expenses of the initial offering of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,037</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$17,235</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On October 27, 2017 and November 2, 2017, Exicure entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with several accredited investors (the &#8220;Investors&#8221;) pursuant to which the Company agreed to issue and sell a total of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,736,836</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of the Company&#8217;s common stock, par value </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.0001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share (the &#8220;Shares&#8221;) </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">resulting in approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$11,211</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in gross proceeds to the Company. These shares were issued in Subsequent Closings of the Offering for up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">13,333,333</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock (the &#8220;Maximum Amount&#8221;) at a purchase price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share (the &#8220;Sale Price&#8221;). </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has sold a total of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,504,196</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock for a total of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$31,513</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in connection with all closings of the Offering (before deducting placement agent fees and expenses which are estimated at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,966</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) (the &#8220;2017 Private Placement&#8221;). Placement Agents have received an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,968</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in cash placement fees and have received warrants to purchase an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">413,320</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of Exicure common stock (the &#8220;Warrants&#8221;) in connection with the 2017 Private Placement. The Warrants expire on March 27, 2021, have an exercise price of  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share, and have been issued on the same terms in all closings of the Offering.  The warrants to purchase common stock are classified as a liability and presented as a dividend that offsets the gross proceeds of the 2017 Private Placement within the accompanying consolidated statement of changes in stockholders&#8217; equity.  The common stock warrant liability will be remeasured each period at fair value.  See Note 10, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for more information on the common stock warrant liability. The Placement Agents also received </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of Exicure common stock in connection with all closings of the Offering.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Subject to certain customary exceptions, investors in the 2017 Private Placement have anti-dilution protection with respect to the shares of common stock sold in the Offering such that if within </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">eighteen</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(18)&#160;months after the initial closing of the Offering the Company issues certain additional shares of common stock or common stock equivalents for a consideration per share less than the Offering Price (the &#8220;Lower Price&#8221;), each such investor will be entitled to receive from the Company additional shares of common stock in an amount such that, when added to the number of shares of common stock initially purchased by such investor in the Offering and still held of record and beneficially owned by such investor at the time of the dilutive issuance (the &#8220;Held Shares&#8221;), will equal the number of shares of common stock that such investor&#8217;s aggregate purchase price for the Held Shares would have purchased at the Lower Price. Either (i)&#160;holders of a majority of the then Held Shares or (ii)&#160;a representative of the holders of the then Held Shares, which representative shall be appointed by the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;investors who then hold the largest number of Held Shares, may waive the anti-dilution rights of all Offering investors with respect to a particular issuance by the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This price-based anti-dilution protection automatically terminated on August 22, 2018 in connection with the August 2018 Private Placement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The 2017 Private Placement was exempt from registration under Section&#160;4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Rule 506 of Regulation D promulgated by the SEC. The common stock in the Offering was sold to &#8220;accredited investors,&#8221; as defined in Regulation D, and was conducted on a &#8220;reasonable best efforts&#8221; basis.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Merger and the 2017 Private Placement, the Company entered into a Registration Rights Agreement, pursuant to which the Company has agreed that promptly, but no later than 60 calendar days from the final closing of the Offering, the Company will file a registration statement with the SEC, or the Registration Statement.  Each Investor in the Subsequent Closing also entered into the same registration rights agreement signed by investors in the initial closing of the Offering, which requires that the Company file a &#8220;resale&#8221; registration statement with the SEC covering the shares of common stock and warrants issued in the 2017 Private Placement, certain other shares of common stock issued in connection with the Company&#8217;s recently closed reverse merger, and shares held by the Company&#8217;s&#160;pre-merger stockholders, within 60 calendar days from the final closing of the Offering.  The Company filed and caused to become effective a registration statement with the SEC on February 6, 2018 registering the resale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">39,714,143</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock issued in connection with the Reverse Merger and the 2017 Private Placement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Common Stock Warrants</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As discussed above, in connection with the 2017 Private Placement, placement agents received warrants to purchase an aggregate of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">413,320</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;shares of Exicure common stock in connection with all closings of the 2017 </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Private Placement.  The Warrants expire on March 27, 2021, have an exercise price of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;per share, and have been issued on the same terms in all closings of the 2017 Private Placement. The Warrants are classified as a liability.  The common stock warrant liability is remeasured each period at fair value.  As of December 31, 2018, Warrants to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">413,320</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock remain outstanding.  See Note 10,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for more information on the fair value of the common stock warrant liability.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The Merger</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On September 26, 2017, in connection with the Merger, each share of Exicure OpCo common and preferred stock (other than shares of Exicure OpCo&#8217;s Series C preferred stock) issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">0.49649</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of&#160;Max-1&#8217;s&#160;common stock, and each share of Exicure OpCo&#8217;s Series C preferred stock issued and outstanding immediately prior to the closing of the Merger was converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">0.7666652</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of&#160;Max-1&#8217;s&#160;common stock. As a result, an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26,666,627</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of&#160;the Max-1&#8217;s&#160;common stock were issued to the holders of Exicure OpCo&#8217;s capital stock, which is incremental to the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,080,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of Max-1&#8217;s common stock that were outstanding immediately prior to the Merger. In addition, pursuant to the Merger Agreement options to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7,414,115</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of Exicure OpCo common stock issued and outstanding immediately prior to the closing of the Merger were assumed by Max-1 and converted into options to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,680,997</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;shares of&#160;the Max-1&#8217;s&#160;common stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Other - Prior to the Merger</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Series C Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 11, 2016, the Company sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">149,999</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of its Series C preferred stock at a price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share.  Total gross proceeds raised thereby were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$450</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  Net proceeds after associated costs and expenses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$444</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Liquidation preference</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Series C preferred stock were senior to the Class A and Class B preferred stock and common stock in rights and privileges as established in the Exicure OpCo Operating Agreement. Principal among the rights of Class C preferred stock was the creation of the Class C liquidation preference whereby, in the event of a liquidation event (i.e., a liquidation, dissolution or winding up of the Company or a sale of the Company), the Class C preferred stock holders were entitled to receive </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;times the aggregate cash contribution of all holders of Class C preferred units/stock.</font></div><div><a name="sD1803C6E76F75182A27DC8E4EA1DC908"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">7. Equity-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On September&#160;22, 2017, the Board adopted and Exicure&#8217;s stockholders approved the Exicure, Inc. 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;), which became effective on November 15, 2017. The 2017 Plan provides for the issuance of incentive awards of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,842,525</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of Exicure common stock, which includes </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,169,905</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of Exicure common stock to be issued to officers, employees, consultants and directors, plus a number of shares not to exceed </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,683,817</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;that are subject to issued and outstanding awards under the Exicure OpCo 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;) and were assumed in the Merger. Awards that may be awarded under the 2017 Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards.  The 2017 Plan also provides that the number of shares reserved for issuance thereunder will be increased annually on the first day of each year beginning in 2020 by the least of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares, five percent (</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">)&#160;of the shares of Exicure common stock outstanding on the last day of the immediately preceding year, or a lesser number of shares as determined by the Company&#8217;s compensation committee. No future awards will be made under the 2015 Plan upon the effectiveness of the 2017 Plan.  As of December 31, 2018, the aggregate number of common stock options available for grant under the 2017 Equity Incentive Plan was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">928,443</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The common stock options are contingent on the participants&#8217; continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason.  The initial stock option grant to an employee, director or consultant vests </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;on the first 12-month anniversary of the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">grant date and vests 1/48th monthly thereafter until fully vested at the end of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">48 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  Subsequent stock option grants vest 1/48th monthly until fully vested at the end of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">48 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  The term of common stock option grants is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ten</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;years unless terminated earlier as described above.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Equity-based compensation expense is classified in the statements of operations as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">485</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">General and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,324</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Unamortized equity-based compensation expense at December 31, 2018 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,172</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which is expected to be amortized over a weighted-average period of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable.  The model also requires the input of highly subjective assumptions.  In addition to an assumption on the expected term of the option grants as discussed below, application of the Black-Scholes model requires additional inputs for which we have assumed the values described in the table below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:59%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.3 to 6.0 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.3 to 6.5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.72% to 2.87%; weighted avg. 2.78%</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.97% to 2.17%; weighted avg. 2.07%</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">78.1% to 82.4%; weighted avg. 80.6%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">80.8% to 83.1%; weighted avg. 81.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Forfeiture rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The expected term is based upon the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the &#8220;simplified method&#8221; until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant.  The expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development.  The estimated forfeiture rates were based on historical experience for similar classes of employees.  The dividend yield was based on expected dividends at the time of grant.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of the underlying common stock and the exercise price for the common stock options granted during the years ended December 31, 2018 and 2017 are summarized in the table below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:57%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Common Stock Options Granted During Period Ended:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value of Underlying Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Exercise Price of Common Stock Option</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Year ended December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$3.00 to $5.82; weighted avg. $3.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$3.00 to $5.82; weighted avg. $3.45</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Year ended December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$4.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$4.21</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The weighted-average grant date fair value of common stock options granted in the years ended December 31, 2018 and 2017 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.40</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.92</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per common stock option, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of common stock option activity as of the periods indicated is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:41%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Weighted-Average Remaining Contractual Term (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Outstanding - December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,672,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,277,744</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.45</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(22,494</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(36,282</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Outstanding - December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,891,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Exercisable - December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,238,798</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.70</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6,352</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Vested and Expected to Vest -</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,799,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The aggregate intrinsic value of common stock options exercised during the years ended December 31, 2018 and 2017 was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$44</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$202</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div><div><a name="sF56C105F9C9F53B793C41B31593F83AF"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">8. Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pretax loss before income taxes was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$22,413</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$11,011</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the years ended December 31, 2018 and 2017, respectively, which consists entirely of losses in the U.S. and resulted in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;provision for income tax expense during the years then ended.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The differences between income taxes computed using the U.S. federal income tax rate and the provision for income taxes are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.15384615384616%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year Ended </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Federal income tax expense at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(4,707</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(4,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State income tax expense at statutory rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,595</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(610</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Permanent differences</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Impact of Tax Reform Act</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(31.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(27.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,078</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s effective income tax rate for the years ended December 31, 2018 and 2017 is 0% because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets to an amount that is more likely than not to be realized.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The significant components of the Company&#8217;s net deferred tax assets are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.15384615384616%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Tax Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Net operating losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">14,827</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8,748</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">271</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">198</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Equity-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">295</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Less: Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(16,225</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(10,166</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Tax Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Fixed assets and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred taxes, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has recorded a full valuation allowance against its deferred tax assets to an amount that is more likely than not to be realized at December 31, 2018 and 2017.  This determination is based on significant negative evidence, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Cumulative losses:</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The Company has been in a significant cumulative loss position since its inception in 2011. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Projected realization of net operating loss carry forward amounts:</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;Projections of future pre-tax book loss and taxable losses based on the Company&#8217;s recent actual performance and current industry data indicate it is more likely than not that the benefits will not be recognized.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The legislation significantly changes U.S. tax law by, among other things, lowering corporate income tax rates, implementing a modified territorial tax system and imposing a repatriation tax on deemed repatriated earnings of foreign subsidiaries. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018.  The Company&#8217;s U.S. deferred tax assets, net of deferred tax liabilities, were remeasured at December 31, 2017 and reduced by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,760</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, entirely offset by a valuation allowance reduction. As a result, the remeasurement of the Company&#8217;s deferred tax assets, net of deferred tax liabilities, including the valuation allowance, did not impact the Company&#8217;s income tax expense or net loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At December 31, 2018, the Company had a federal net operating loss carryforward of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$52,629</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which will begin to expire in 2035.  The Company has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50,294</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of state net operating loss carryforwards which will begin to expire in 2027.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At December&#160;31, 2018 and 2017, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;unrecognized tax benefits. The Company&#8217;s estimate of the potential outcome of any uncertain tax position is subject to management&#8217;s assessment of relevant risks, facts and circumstances existing at that time. The Company evaluates uncertain tax positions to determine if it is more-likely-than-not that they would be sustained upon examination. The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to taxation in the U.S. and various state jurisdictions. The Company remains subject to examination by U.S. federal and state tax authorities for the years 2015 through 2018. There are no pending examinations in any jurisdiction.  </font></div><div><a name="s422EE810E72C526BABAB80AAF9591AEB"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">9. Loss Per Common Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding.  Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods.  Therefore, basic and diluted loss per common share is the same for each of the years ended December 31, 2018 and 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is the computation of loss per common share for the years ended December 31, 2018 and 2017:</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.34188034188034%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Year Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(22,413</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(11,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Weighted-average basic and diluted common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">41,189,177</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10,119,569</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Loss per share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The outstanding securities presented below were excluded from the calculation of net loss per common share, because such securities would have been anti-dilutive due to the Company&#8217;s net loss per share during the periods ending on the dates presented:</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,891,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,672,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Warrants to purchase common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">413,320</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">413,320</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s6F24C08ADDA555EA898266A39486C62C"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">10. Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASC Topic 820, Fair Value Measurement, establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company uses the market approach and Level 1 inputs to value its cash equivalents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s long-term debt bore interest at the prevailing market rates for instruments with similar characteristics and, accordingly, the carrying value for this instrument also approximates its fair value and the financial measurement is also classified within Level&#160;2 of the fair value hierarchy.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s common stock warrant liability (refer to Note 6, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Stockholders&#8217; Equity</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for more information) and preferred stock warrant liability (terminated on September 26, 2017 in connection with the Merger; see Note 5, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Debt</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for more information) are classified within Level 3 of the fair value hierarchy.  The fair values of the common stock warrant liability and preferred stock warrant liability were determined using the Black-Scholes option-pricing model.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of the common stock warrant liability is based significantly on the fair value of the Company&#8217;s common stock.  At the date of issuance, the common stock warrant liability was determined using the following weighted-average assumptions: expected term of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.0 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, risk-free interest rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.53%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, expected volatility of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">78.97%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;expected dividends.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of the preferred stock warrant liability was based significantly on the fair value of the Series C preferred stock, which was developed using unobservable inputs, which are classified within Level 3. At the date of issuance, the preferred stock warrant liability was determined using the following assumptions: expected term of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.0 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, risk-free interest rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.26%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, expected volatility of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">62.99%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;expected dividends.  In connection with the Merger, the warrants to purchase preferred stock were terminated and therefore the related liability was reduced to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">zero</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;during 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following weighted-average assumptions were used to estimate the fair value of the common stock warrant liability at December 31, 2018:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:79%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">86.74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;change in the estimate of expected volatility at December 31, 2018 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$53</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  A </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;change in the estimate of fair value of the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">common stock at December 31, 2018 would increase or decrease the fair value of the common stock warrant liability in the amount of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$118</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is a reconciliation of the Company&#8217;s liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) for the years ended December 31, 2018 and 2017:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Preferred Stock Warrant Liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Common Stock Warrant Liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">536</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">536</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Gain included in other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(201</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(214</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">523</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">523</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Loss included in other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">274</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">274</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">797</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">797</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s8E983C2F86105BD0B064E84BEEF4640B"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">11. Defined Contribution Plan</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Exicure maintains a defined contribution savings plan for the benefit of its employees.  During 2018, Exicure began contributing to the defined contribution plan.  Company contributions are determined under various formulas. The expense recognized for this plan was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$107</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the year ended December 31, 2018.</font></div><div><a name="sEC9F58221031501387B19BD52053B15C"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">12. Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company conducts all operations in a facility under an operating lease which commenced in March 2012 and was originally scheduled to end in February 2015.  The lease was extended for an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;through February 2021 during the first quarter of 2014 and includes a renewal option. During the second quarter of 2016, the Company amended the lease agreement to include additional space to be used primarily for administrative functions effective in May 2016.  Lease payments include a fixed payment amount as well as contingent payments related to a proportionate share of operating and real estate expenses. At the inception of the lease, the lessor paid for leasehold improvements totaling </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$52</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which has been capitalized and is being amortized over the lease term. The fixed payment amounts, including those in connection with the amended lease agreement in the second quarter of 2016, increase over the term of the lease but rent expense is recognized on a straight-line basis resulting in the recognition of deferred rent liability of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$48</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as of December 31, 2018 and December 31, 2017, respectively, calculated on the basis of the extended lease agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Rent expense consisted of the following: </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Straight-line rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Contingent rent expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Total rent expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Future minimum lease payments as of December 31, 2018 are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:78%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Years Ending December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Northwestern University License Agreements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 12, 2011, (1) AuraSense, LLC assigned to the Company all of its worldwide rights and interests under AuraSense, LLC&#8217;s 2009 license agreement with Northwestern University (&#8220;NU&#8221;) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the &#8220;assigned field&#8221;); (2)&#160;in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3)&#160;in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company&#8217;s sale or transfer of any licensed product, and (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee&#8217;s sale or transfer of any licensed product.  In August 2015, we entered into a restated license agreement with NU (the &#8220;restated license agreement&#8221;). In February 2016, we obtained exclusive license as to NU&#8217;s rights in certain SNA technology we jointly own with NU. Our license to NU&#8217;s rights is limited to the assigned field, however we have no such limitation as to our own rights in this jointly owned technology. In June 2016, we entered into an exclusive license with NU to obtain worldwide rights to certain inhibitors of glucosylceramide synthase and their use in wound healing in diabetes. Our rights and obligations in these 2016 agreements&#160;are substantially the same as in the restated license agreement from August 2015 (collectively referred to as &#8220;the Northwestern University License Agreements&#8221;).  As of December 31, 2018, the Company has paid to NU an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,864</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in consideration of each of the obligations described above. </font></div><div><a name="sDE44B4A9D1A5523A9D26B4A71C5959D5"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">13. Related-Party Transactions</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since its inception in 2011, the Company has shared facilities, certain staff members and certain operating expenses with AuraSense, LLC, our former parent and largest stockholder.  On an infrequent basis, the Company also pays certain expenses directly on behalf of AuraSense, LLC which are related to AuraSense, LLC&#8217;s grants, and AuraSense, LLC sometimes pays expenses directly on behalf of the Company. These costs are summarized and directly billed between the Company and AuraSense, LLC on a quarterly basis. In addition, certain expense and administrative activities are shared between the Company and AuraSense, LLC.  Effective January 1, 2016, the Company and AuraSense, LLC amended its shared services agreement to simplify the billing arrangement.  Under the amended shared services agreement, the Company bills AuraSense, LLC </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$8</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per quarter for indirect costs incurred by the Company plus a specified rate for hours worked by Company scientists on projects directly related to AuraSense, LLC.  The amended shared services arrangement continues to require direct non-labor expenses incurred by the Company to be billed to AuraSense, LLC.  Effective January 1, 2017, the Company and AuraSense, LLC further amended its shared services agreement so that the quarterly fee related to administrative activities billed by the Company to AuraSense, LLC be reduced to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per quarter.  This decrease was to reflect the current and expected future reduction in administrative activities to be provided by the Company to AuraSense, LLC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The amounts due from AuraSense, LLC in connection with the above mentioned activities were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$17</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;at December 31, 2018 and 2017, respectively. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is a summary of amounts billed to AuraSense, LLC and recognized in the accompanying consolidated statement of operations in connection with the above mentioned activities:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.51282051282051%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Quarterly fee for indirect costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Direct costs of AuraSense LLC paid by the Company</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company received consulting services from, and paid fees to, one of its co-founders who is not an employee but serves as a member of the Board. The Company paid </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in each of the years ended December 31, 2018 and 2017 in connection with these consulting services and these amounts are recognized as an expense in the accompanying consolidated statement of operations.</font></div><div><a name="s4A5AFA672F88518EAC1D1C225233A81B"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">14. Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Selected quarterly financial data for the years ended December&#160;31, 2018 and 2017 are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.00854700854701%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Revenue</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">(1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss (1)(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5,509</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(6,825</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(5,324</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(4,755</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Basic and diluted loss per common share (3)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(0.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(0.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(0.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.00854700854701%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,095</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,652</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,984</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,932</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,443</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Basic and diluted loss per common share (3)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">___________</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(1) - As discussed in Note 2,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#32;Significant Accounting Policies - Recently Adopted Accounting Pronouncements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company adopted ASC 606 on a modified retrospective basis effective January 1, 2018.  As a result of the adoption of ASC 606, total revenue and net loss were lower by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;each in the three months ended March 31, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(2) - Net loss includes a non-cash unrealized (loss) gain related to the fair value adjustment of the common stock warrant liability of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">($128)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">($915)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$581</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$186</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the three months ended March 31, 2018, June 30, 2018, September 30, 2018, and December 31, 2018, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(3) - As discussed in Note 1, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Description of Business and Basis of Presentation - The Merger</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, shares of preferred stock issued and outstanding immediately prior to the closing of the Merger were converted into an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26,476,543</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock.  As such, these shares of common stock are included in the computation of basic and diluted loss per common share beginning with September 26, 2017 and </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">excluded from the computation of basic and diluted loss per common share for dates prior to September 26, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="s6B05A5AB0F1F50398EC655CDB09D57B9"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">15. Subsequent Events</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has evaluated subsequent events which may require adjustment to or disclosure in the accompanying consolidated financial statements and has concluded that, other than the Hercules loan amendment and license agreement with Dermelix disclosed below, there are no subsequent events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the accompanying consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Hercules loan amendment</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 8, 2019, the Company and Hercules amended its loan agreement so that the maturity date of its loan agreement is extended to March 1, 2020 and amortization payments are deferred to, and payable at, the new maturity date of March 1, 2020. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Dermelix license agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 17, 2019, Exicure entered into a License and Development Agreement (the &#8220;Dermelix License Agreement&#8221;) with Dermelix, LLC d/b/a Dermelix Biotherapeutics (&#8220;Dermelix&#8221;).  Pursuant to the Dermelix License Agreement, the Company granted to Dermelix exclusive, worldwide royalty-bearing license rights to, develop, manufacture, have manufactured, use and commercialize the Company&#8217;s spherical nucleic acid (&#8220;SNA&#8221;) technology for the treatment of Netherton Syndrome (&#8220;NS&#8221;) and, at Dermelix&#8217;s option, up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">five</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;additional specified orphan diseases that are within the dermatology field. Upon written notice to the Company, Dermelix may exercise its option at any time following the effective date of the Dermelix License Agreement until the date that is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(6) years from the date that the first collaboration SNA therapeutic achieves first dosing in humans in a Phase 1 clinical trial for NS.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Dermelix will initially seek to develop a targeted therapy for the treatment of NS.  Under the terms of the Dermelix License Agreement, the Company will be responsible for conducting the early stage development for each indication up to IND enabling toxicology studies.  Dermelix will assume subsequent development, commercial activities and financial responsibility for such indications.  Dermelix will pay the costs and expenses of development and commercialization of any licensed products under the Dermelix License Agreement, including the Company&#8217;s expenses incurred in connection with development activities and in accordance with the development budget.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the terms of the Dermerlix License Agreement, Exicure received an upfront payment of</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, to be applied against the initial </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the Company&#8217;s development expenses.  If Dermelix exercises any of its option rights for additional indications, Dermelix will pay an option exercise fee equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for each exercised option (each, an &#8220;Option Exercise Fee&#8221;).  Any Option Exercise Fee will be applied against the Company&#8217;s development expenses with respect to the particular indication for which the option was exercised.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the Dermelix License Agreement, the Company shall have the right to pursue the development and commercialization of SNA technology for the treatment of orphan diseases which are neither NS nor one of the additional specified orphan diseases selected by Dermelix pursuant to its option rights.  If the Company commences development activities of SNA technology for the treatment of such an orphan disease, the Company will notify Dermelix in writing of such development and Dermelix will have </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">thirty</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(30) days following receipt of such notice to use one of its remaining option rights on such orphan disease.  If Dermelix does not use one of its remaining option rights on such orphan disease, or has no option rights remaining, then the Company will have no further obligations to Dermelix with respect to the development of SNA therapeutics for such orphan disease and shall be free to continue commercialization and development activities with respect thereto.  </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">126</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">EXICURE, INC.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For each of NS as well as any additional licensed product for which Dermelix exercises one of its options, the Company shall be eligible to receive additional cash payments totaling up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;upon achievement of certain development and regulatory milestones and up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$152,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;upon achievement of certain sales milestones.  In addition, the Company will receive low double-digit royalties on annual net sales for such licensed products.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Dermelix License Agreement will remain in effect, unless terminated earlier, until the last-to-expire royalty term under the Dermelix License Agreement.  Each party has the right to terminate the Dermelix License Agreement for the other party&#8217;s material breach of its obligations or representations and warranties under the Dermelix License Agreement, subject to cure rights.  Additionally, Dermelix may terminate the Dermelix License Agreement in its sole discretion and in its entirety with specified prior written notice.  The Company may also terminate the Dermelix License Agreement in part with respect to a particular indication if Dermelix fails to pay a development milestone payment following non-achievement of a development milestone.  Upon termination of the term with respect to a particular licensed product, the license for such product will convert to a fully-paid, royalty-free, irrevocable, perpetual, exclusive and sublicensable license.  Upon termination of the Dermelix License Agreement by Dermelix for convenience, by the Company following non-achievement of a development milestone, or by either party for the other&#8217;s breach or bankruptcy, all licenses granted by the Company to Dermelix will terminate.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Dermelix License Agreement includes customary representations and warranties on behalf of both the Company and Dermelix, including representations and operative provisions as to the licensed intellectual property.  The Dermelix License Agreement also provides for certain mutual indemnities for breaches of representations, warranties and covenants.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon a change of control of the Company, Dermelix will have </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">90</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;days to exercise any of its remaining options for additional indications, and any options that are not exercised within such </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">90</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-day period will lapse.  Either party may assign the Dermelix License Agreement or delegate its obligations to an affiliate or to a successor without the consent of the other party.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></div><hr style="page-break-after:always"><div><a name="sD8DE4B6836E85604BABA98AE1DC3937A"></a></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None.</font></div><div><a name="s5E9FB2352B285C5AA908348B4691D291"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item&#160;9A. Controls and Procedures.</font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As we are an emerging growth company and a newly public company, we have not engaged an independent registered public accounting firm to perform an audit of our internal control over financial reporting as of any balance sheet date in our condensed consolidated interim financial statements. Our compliance with Section 404 of the Sarbanes-Oxley Act first became subject to management&#8217;s assessment regarding internal control over financial reporting in connection with the filing of our Annual Report on Form 10-K for the fiscal year ending December 31, 2018, and we will not be required to have an independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting until the filing of our first Annual Report on Form 10-K after we lose emerging growth company status, which may not be until the 2022 Annual Report on Form 10-K. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2018. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.  Based on the evaluation of our disclosure controls and procedures as of December 31, 2018, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective.</font></div><div style="line-height:174%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the preparation of our financial statements for the period ended March 31, 2018, we concluded that our disclosure controls and procedures were not effective to provide reasonable assurance that all information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, due to a material weakness in internal control over financial reporting. The material weakness related to a deficiency in the Company&#8217;s information and communication controls, which led to ineffectively designed controls over management&#8217;s review of certain research and development contracts to ensure expenses were recognized as incurred by third-party contract research organizations. Specifically these ineffectively designed controls, which arose in a prior period and were identified in the quarter ended March 31, 2018, resulted in an immaterial error, which we corrected in previously issued financial statements beginning with those included in our Quarterly Reports on Form 10-Q for the period ended March 31, 2018 and as further discussed in Note 1 to the accompanying consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the periods subsequent to March 31, 2018, we worked towards remediation of the deficiencies that led to the material weakness by enhancing the information used for periodic assessment of contract progress and increasing the frequency of communication in the process for accounting for certain research and development contracts with contract research organization</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">s</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to ensure expenses are recognized as incurred.  As of December 31, 2018, we believe that the applicable remedial controls have operated for a sufficient period of time and therefore management has concluded that the material weakness discussed above is remediated at December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other than the remedial controls discussed above, no changes occurred in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">128</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Act during the fiscal quarter ended December 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><a name="s7AD40BA7BEC950C691A12FAAFE62F8AE"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 9B. Other Information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></div><hr style="page-break-after:always"><div><a name="s455CD3A6DD675A81942FBE40B84D2F7F"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART III</font></div><div><a name="s07786F0E15EC5744B6CDF7E43777ABAF"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 10. Directors, Executive Officers and Corporate Governance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The information required by this item and not set forth below will be set forth in the definitive proxy statement for our 2019 Annual Meeting of Stockholders to be filed with the SEC pursuant to Regulation&#160;14A , or the Proxy Statement, not later than 120&#160;days after the end of the fiscal year covered by this Annual Report on&#160;Form&#160;10-K,&#160;and is incorporated herein by reference.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have adopted a Code of Business Conduct and Ethics applicable to all employees, including the principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The Code of Business Conduct and Ethics is posted on our website at&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">www.exicuretx.com</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Amendments to, and waivers from, the Code of Business Conduct and Ethics that apply to any of these officers, or persons performing similar functions, and that relate to any element of the code of ethics definition enumerated in Item&#160;406(b) of&#160;Regulation&#160;S-K&#160;will be disclosed at the website address provided above and, to the extent required by applicable regulations, on a current report on&#160;Form&#160;8-K.</font></div><div><a name="s92C78AD63CF05DFCB87DA3FDCC80DC84"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 11. Executive Compensation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The information required by this item will be set forth in our Proxy Statement and is incorporated herein by reference.</font></div><div><a name="sE9A31DEC37315F2492A9ACAF0664CE91"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The information required by this item will be set forth in our Proxy Statement and is incorporated herein by reference.</font></div><div><a name="s0294592439505EFFB8C23BDE850FF4F5"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 13. Certain Relationships and Related Transactions, and Director Independence.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The information required by this item will be set forth in our Proxy Statement and is incorporated herein by reference.</font></div><div><a name="s16F54F3AA84B58A7861CD5411F9FED61"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 14. Principal Accounting Fees and Services.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The information required by this item will be set forth in our Proxy Statement and is incorporated herein by reference.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130</font></div></div><hr style="page-break-after:always"><div><a name="s70DEDF613FD555098EE95BE5603EE73E"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART IV</font></div><div><a name="s740107D09368580DB19288F35D0D3E8C"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 15. Exhibits, Financial Statement Schedules.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(a)&#160;&#160;&#160;&#160;The following documents are filed as part of this report:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1. Financial Statements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See Index to Financial Statements on page 100 of this Annual Report on Form 10-K.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2. Financial Statement Schedules</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3. Exhibits</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Except as so indicated in Exhibit&#160;32.1, the following exhibits are filed as part of, or incorporated by reference into, this Annual Report on&#160;Form&#160;10-K.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Filed with this Report</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Incorporated by Reference herein from Form or Schedule</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">SEC File/Reg. Number</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">2.1&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex21.htm"><font style="font-family:Times New Roman;font-size:8pt;">Agreement and Plan of Merger and Reorganization, dated September 26, 2017, by and among Max-1 Acquisition Corporation, Max-1 Acquisition Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, and Exicure OpCo, a Delaware corporation.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 2.1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex31.htm"><font style="font-family:Times New Roman;font-size:8pt;">Certificate of Merger relating to the merger of Max-1 Acquisition Sub., Inc. with and into Exicure OpCo, filed with the Secretary of State of the State of Delaware on September 26, 2017.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 3.1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex32.htm"><font style="font-family:Times New Roman;font-size:8pt;">Certificate of Amendment to Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on September 26, 2017.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 3.2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex33.htm"><font style="font-family:Times New Roman;font-size:8pt;">Form of Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on November 15, 2017.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 3.3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">3.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex34.htm"><font style="font-family:Times New Roman;font-size:8pt;">Amended and Restated Bylaws, as currently in effect.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 3.4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex41.htm"><font style="font-family:Times New Roman;font-size:8pt;">Form of Warrant to Purchase Shares of Common Stock issued to Placement Agent.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 4.1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex42.htm"><font style="font-family:Times New Roman;font-size:8pt;">Form of Registration Rights Agreement by and among the Company and the persons named therein.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 4.2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000169853018000060/a8k82818exhibit41.htm"><font style="font-family:Times New Roman;font-size:8pt;">Form of Registration Rights Agreement by and among the Company and the persons named therein.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 4.1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8/28/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.1+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex101.htm"><font style="font-family:Times New Roman;font-size:8pt;">2015 Equity Incentive Plan and forms of awards thereunder, assumed in the Merger.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.2+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex102.htm"><font style="font-family:Times New Roman;font-size:8pt;">2017 Equity Incentive Plan and forms of award agreements thereunder.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.3+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex103.htm"><font style="font-family:Times New Roman;font-size:8pt;">2017 Employee Stock Purchase Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.4+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex104.htm"><font style="font-family:Times New Roman;font-size:8pt;">Form of Indemnification Agreement by and between the Company and each of its directors and executive officers.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex105.htm"><font style="font-family:Times New Roman;font-size:8pt;">Form of Subscription Agreement by and between the Company and each investor in the initial closing of the 2017 Private Placement.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.6+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex106.htm"><font style="font-family:Times New Roman;font-size:8pt;">Form of Amended and Restated Board Member Service Agreement by and between Exicure OpCo and each of its non-executive directors.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.6)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.7+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex107.htm"><font style="font-family:Times New Roman;font-size:8pt;">Employment Agreement dated as of February&#160;2, 2016 by and between Exicure OpCo and David A. Giljohann, Ph.D.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.7)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.8+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex108.htm"><font style="font-family:Times New Roman;font-size:8pt;">Amended and Restated Employment Agreement dated as of February&#160;2, 2016 by and between Exicure OpCo and David&#160;S. Snyder.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.8)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.9+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex109.htm"><font style="font-family:Times New Roman;font-size:8pt;">Employment Offer Letter dated as of September&#160;16, 2015 by and between Exicure OpCo and Ekambar Kandimalla, Ph.D.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.9)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.10+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1010.htm"><font style="font-family:Times New Roman;font-size:8pt;">First Amendment to Offer Letter dated as of January&#160;8, 2016 by and between Exicure OpCo and Ekambar Kandimalla, Ph.D.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.10)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.11+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000169853018000021/exicureexhibit101-33118.htm"><font style="font-family:Times New Roman;font-size:8pt;">Offer Letter dated as of January 18, 2018 by and between Exicure, Inc. and Matthias G. Schroff, Ph.D.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10-Q (Exhibit 10.1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">5/15/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.12+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1011.htm"><font style="font-family:Times New Roman;font-size:8pt;">Consulting Agreement dated as of October&#160;1, 2011 by and between AuraSense Therapeutics, LLC and Chad A. Mirkin, Ph.D.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.11)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1012.htm"><font style="font-family:Times New Roman;font-size:8pt;">Lease Agreement dated as of February&#160;13, 2012 by and between AuraSense Therapeutics, LLC and FC Skokie SPE, LLC.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.12)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1013.htm"><font style="font-family:Times New Roman;font-size:8pt;">Letter dated as of March&#160;12, 2012 regarding the Lease Agreement by and between AuraSense Therapeutics, LLC and FC Skokie SPE, LLC.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.13)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1014.htm"><font style="font-family:Times New Roman;font-size:8pt;">First Amendment to Lease dated as of March&#160;31, 2014 by and between AuraSense Therapeutics, LLC and FC Skokie PQ, LLC, as successor in interest to FC Skokie SPE, LLC.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.14)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1015.htm"><font style="font-family:Times New Roman;font-size:8pt;">Second Amendment to Lease dated as of May&#160;26, 2016 by and between Exicure OpCo and FC Skokie PQ, LLC, as successor in interest to FC Skokie SPE, LLC.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.15)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1016.htm"><font style="font-family:Times New Roman;font-size:8pt;">Loan and Security Agreement dated as of February&#160;17, 2016 by and between Exicure OpCo and Hercules.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.16)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1017.htm"><font style="font-family:Times New Roman;font-size:8pt;">Amendment No.&#160;1 to Loan and Security Agreement dated as of October&#160;10, 2016 by and between Exicure OpCo and Hercules.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.17)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.18.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828018000633/exhibit10171.htm"><font style="font-family:Times New Roman;font-size:8pt;">Amendment No. 2 to Loan and Security Agreement dated as of January 15, 2018 by and between Exicure OpCo and Hercules.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">S-1/A (Exhibit 10.17.1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">1/26/2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">333-221791</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.18.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000169853019000015/exicureexhibit10182.htm"><font style="font-family:Times New Roman;font-size:8pt;">Amendment No. 3 to Loan and Security Agreement dated as of December 28, 2018 by and between Exicure OpCo and Hercules.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">X</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.19+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517301064/d461080dex1018.htm"><font style="font-family:Times New Roman;font-size:8pt;">Form of Pre-Merger Indemnity Agreement.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.18)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000121390017006605/f8k061517ex10i_max1acq.htm"><font style="font-family:Times New Roman;font-size:8pt;">Form of Common Stock Purchase Agreement.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">6/19/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.21*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828017011102/a8-kaexhibit1020x11717.htm"><font style="font-family:Times New Roman;font-size:8pt;">Restated License Agreement between Exicure OpCo and Northwestern University dated as of August 15, 2015.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K/A (Exhibit 10.20)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">11/7/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.22*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828017011102/a8-kaexhibit1021x11717.htm"><font style="font-family:Times New Roman;font-size:8pt;">License Agreement between Exicure OpCo and Northwestern University dated as of February 10, 2016 and effective as of May 27, 2014.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K/A (Exhibit 10.21)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">11/7/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.23*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828017011102/a8-kaexhibit1022x11717.htm"><font style="font-family:Times New Roman;font-size:8pt;">License Agreement between Exicure OpCo and Northwestern University dated as of June 17, 2016.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K/A (Exhibit 10.22)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">11/7/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.24*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828017011102/a8-kaexhibit1023x11717.htm"><font style="font-family:Times New Roman;font-size:8pt;">Amendment One to the Amended Restated License Agreement between Exicure OpCo and Northwestern University dated as of September 27, 2016.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K/A (Exhibit 10.23)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">11/7/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.25*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828017011102/a8-kaexhibit1024x11717.htm"><font style="font-family:Times New Roman;font-size:8pt;">Research Collaboration, Option and License Agreement between Exicure OpCo and Purdue Pharma L.P. dated as of December 2, 2016.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K/A (Exhibit 10.24)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">11/7/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000162828017011102/a8-kaexhibit1025x11717.htm"><font style="font-family:Times New Roman;font-size:8pt;">Side Agreement to Northwestern Agreements by and among Exicure OpCo, Northwestern University and Purdue Pharma L.P. dated as of October 11, 2016.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K/A (Exhibit 10.25)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">11/7/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.27</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517331329/d487646dex101.htm"><font style="font-family:Times New Roman;font-size:8pt;">Form of Subscription Agreement by and between the Company and each investor in connection with the subsequent closings of the 2017 Private Placement.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.1 )</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">11/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">132</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000119312517331329/d487646dex102.htm"><font style="font-family:Times New Roman;font-size:8pt;">Form of Purchaser Rights Letter to be delivered by the Company to each investor in the initial closing of the 2017 Private Placement.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.2 )</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">11/2/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10.29</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000169853018000060/a8k82818exhibit101.htm"><font style="font-family:Times New Roman;font-size:8pt;">Form of Subscription Agreement by and between the Company and each investor in connection with the initial closing of the August 2018 Private Placement.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8-K (Exhibit 10.1 )</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">8/28/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">000-55764</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000169853019000015/exicureexhibit211123118.htm"><font style="font-family:Times New Roman;font-size:8pt;">Subsidiaries of Exicure, Inc.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">X</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">23.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000169853019000015/exicureexhibit231123118.htm"><font style="font-family:Times New Roman;font-size:8pt;">Consent of KPMG LLP, independent registered public accounting firm.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">X</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">24.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="#sE2D344B1C3815B8FA32E5C594EB563EF"><font style="font-family:Times New Roman;font-size:8pt;">Power of Attorney (included on the signature page hereto).</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">X</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000169853019000015/exicureexhibit311123118.htm"><font style="font-family:Times New Roman;font-size:8pt;">Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">X</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000169853019000015/exicureexhibit312123118.htm"><font style="font-family:Times New Roman;font-size:8pt;">Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">X</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">32**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><a style="font-family:Times New Roman;font-size:8pt;" href="http://www.sec.gov/Archives/edgar/data/1698530/000169853019000015/exicureexhibit321123118.htm"><font style="font-family:Times New Roman;font-size:8pt;">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">X</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">XBRL Instance Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">X</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">XBRL Taxonomy Extension Schema Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">X</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">X</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">XBRL Taxonomy Extension Definition.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">X</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">XBRL Taxonomy Extension Label Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">X</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">XBRL Taxonomy Presentation Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">X</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;  Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(b)(2) of Regulation&#160;S-K.&#160;We hereby undertake to furnish supplementally a copy of any of the omitted schedules and exhibits to the SEC on a confidential basis upon request.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">+  Indicates&#160;a&#160;management&#160;contract&#160;or&#160;compensatory&#160;plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Portions of this exhibit have been omitted pursuant to a request for confidential treatment granted by the SEC, and omitted portions have been filed separately with the SEC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">** Furnished herewith. </font></div><div><a name="sF56CA357586E53F885CA9ED468B4B30C"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 16. Form 10-K Summary.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></div><hr style="page-break-after:always"><div><a name="sE2D344B1C3815B8FA32E5C594EB563EF"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">SIGNAT</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">URES</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Skokie, State of Illinois, on March 8, 2019.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:24px;text-indent:-24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.58119658119658%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:59%;"></td><td style="width:5%;"></td><td style="width:36%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">EXICURE, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David A. Giljohann</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David A. Giljohann, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Chief Executive Officer and Director (</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">principal executive officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David S. Snyder</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David S. Snyder</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">principal financial officer and principal accounting officer</font><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:bold;" href="#s8D62D2794F565DF2940B488CE7ED91C2"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">POWER OF ATTORNEY</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We, the undersigned directors and officers of Exicure, Inc., hereby severally constitute and appoint David A. Giljohann and David S. Snyder, and each of them singly, our true and lawful attorneys-in-fact, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Annual Report on&#160;Form&#160;10-K and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that said attorneys-in-fact, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney. This Power of Attorney does not revoke any power of attorney previously granted by the undersigned, or any of them.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.86324786324786%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">SIGNATURE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">TITLE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">DATE</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David A. Giljohann</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Chief Executive Officer and Director </font></div><div style="font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">principal executive officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;David A. Giljohann, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 8, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David S. Snyder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">principal financial officer and principal accounting officer</font><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David S. Snyder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 8, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Chad A. Mirkin</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director and Chairman of the Board of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Chad A. Mirkin, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 8, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ C. Shad Thaxton</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">C. Shad Thaxton, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 8, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David R. Walt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David R. Walt, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 8, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Jay R. Venkatesan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Jay R. Venkatesan, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 8, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Helen S. Kim</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Helen S. Kim</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">March 8, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></div><hr style="page-break-after:always"><div><a name="s3a29eaf5bd984d7ebbb6fc8eebda3f3e"></a></div><div><div style="line-height:120%;padding-bottom:12px;text-align:right;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Exhibit 10.18.2</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">AMENDMENT NO. 3 TO LOAN AND SECURITY AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Amendment No. 3 to Loan and Security Agreement (this</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Amendment</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221;) is entered into this 28th day of December, 2018 by and among (a) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">HERCULES CAPITAL, INC. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(f/k/a Hercules Technology Growth Capital, Inc.), a Maryland corporation, in its capacity as administrative agent for itself and the Lender (as defined herein) (in such capacity, the &#8220;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Agent</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221;); (b) the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (as defined below) (collectively, referred to as the &#8220;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Lender</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221;); and (c) </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">EXICURE OPERATING COMPANY </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(f/k/a Exicure, Inc.), a Delaware corporation (&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Borrower</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">WHEREAS</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Lender and Borrower are parties to that certain Loan and Security Agreement dated as of February 17, 2016, as amended by that certain Amendment No. 1 to Loan and Security Agreement dated as of October 10, 2016 among Lender and Borrower, and as further amended by that certain Amendment No. 2 to Loan and Security Agreement dated as of January 15, 2018, among Lender and Borrower (as the same has been and may from time to time be further amended, modified, supplemented or restated, the &#8220;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Loan Agreement</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221;); and </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">WHEREAS</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, in accordance with Section 11.3 of the Loan Agreement, Borrower and Lender desire to amend the Loan Agreement as more fully set forth herein.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;padding-right:48px;">1.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Definitions.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">2.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Amendment to Loan Agreement- </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Subject to the satisfaction of the conditions set forth in Section 3 of this Amendment, the Loan Agreement is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(a)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Loan Agreement shall be amended by inserting the following new definitions to appear alphabetically in Section 1.1 thereof:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:144px;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8220;&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Amendment No. 3 Commitment Fee</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221; means a fully earned, non-refundable commitment fee of Twenty-Five Thousand Dollars, ($25,000.00), which is due to Agent on or prior to the Amendment No. 3 Effective Date.&#8221; </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:144px;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:144px;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8220;&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Amendment No. 3 Effective Date</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221; is December 28, 2018.&#8221;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:144px;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(b)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Section 2.1(d) of the Loan Agreement is deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:144px;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8220;(d)&#160;&#160;&#160;&#160;Payment.  Borrower will pay interest on each Term Loan Advance on the first (1</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">st</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) Business Day of each month, beginning the month after the Advance Date.  On the Term Loan Maturity Date, Borrower shall repay the aggregate principal balance of Term Loan Advances that are outstanding on the Term Loan Maturity Date and any accrued but unpaid interest hereunder and all other Secured Obligations with respect to the Term Loan Advances (Lender acknowledges receipt of principal payments from Borrower in the amount of $1,001,007.75 as of the Amendment No. 3 Effective Date).  Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense.  Lender will initiate debit entries to Borrower&#8217;s account as authorized on the ACH Authorization (i) on each payment date of all periodic obligations payable to Lender under each Term Advance and (ii) out-of-pocket legal fees and costs </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">incurred by Agent or Lender in connection with Section 11.11 of this Agreement.  Once repaid, a Term Loan Advance or any portion thereof may not be reborrowed."</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">3.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Conditions to Effectiveness.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Agent, Lender and Borrower agree that this Amendment shall become effective upon the satisfaction of the following conditions precedent, each in form and substance satisfactory to Lender:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(a)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Agent and Lender shall have received a fully-executed counterpart of this Amendment signed by Borrower; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(b)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Borrower shall have paid to Agent the Amendment No. 3 Commitment Fee on or prior to the Amendment No. 3 Effective Date;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(c)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Agent shall have received payment for all reasonable and documented out-of-pocket fees and expenses incurred by Lender and Agent in connection with this Amendment, including, but not limited to, all legal fees and expenses, payable pursuant to Section 11.11 of the Loan Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">4.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Representations and Warranties.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Borrower hereby represents and warrants to Lender as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(a)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:underline;">Representations and Warranties in the Agreement</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  The representations and warranties of Borrower set forth in Section 5 of the Loan Agreement (after giving effect to this Amendment) are true and correct in all material respects on and as of the date hereof with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, in which case they are true and correct as of such date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(b)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:underline;">Authority, Etc</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  The execution and delivery by Borrower of this Amendment and the performance by Borrower of all of its agreements and obligations under the Loan Agreement and the other Loan Documents, as amended hereby, are within the corporate authority of Borrower and have been duly authorized by all necessary corporate action on the part of Borrower.  With respect to Borrower, the execution and delivery by Borrower of this Amendment does not and will not require any registration with, consent or approval of, or notice to any Person (including any governmental authority).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(c)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:underline;">Enforceability of Obligations</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  This Amendment, the Loan Agreement and the other Loan Documents, as amended hereby, constitute the legal, valid and binding obligations of Borrower enforceable against Borrower in accordance with their terms, except as enforceability is limited by bankruptcy, insolvency, reorganization, moratorium, general equitable principles or other laws relating to or affecting generally the enforcement of, creditors&#8217; rights and except to the extent that availability of the remedy of specific performance or injunctive relief is subject to the discretion of the court before which any proceeding therefor may be brought.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(d)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:underline;">No Default</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  Before and after giving effect to this Amendment (i) no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default, and (ii) no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(e)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:underline;">Event of Default</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  By its signature below, Borrower hereby agrees that it shall constitute an Event of Default if any representation or warranty made herein should be false or misleading in any material respect when made.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">5.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Reaffirmations.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Except as expressly provided in this Amendment, all of the terms and conditions of the Loan Agreement and the other Loan Documents remain in full force and effect.  Nothing contained in this Amendment shall in any way prejudice, impair or effect any rights or remedies of Agent or Lender under the Loan Agreement and the other Loan Documents.  Except as specifically amended hereby, Borrower hereby ratifies, confirms, and reaffirms all covenants contained in the Loan Agreement and the other Loan Documents.  The Loan Agreement, together with this Amendment, shall be read and construed as a single agreement.  All references in the Loan Documents </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to the Loan Agreement or any other Loan Document shall hereafter refer to the Loan Agreement or any other Loan Document as amended hereby.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">6.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Execution in Counterparts.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Amendment may be signed in any number of counterparts, and by different parties hereto in separate counterparts, with the same effect as if the signatures to each such counterpart were upon a single instrument.  All counterparts shall be deemed an original of this Amendment.  This Amendment may be executed by facsimile, portable document format (.pdf) or similar technology signature, and such signature shall constitute an original for all purposes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">7.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Release</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In consideration of the agreements of Agent and each Lender contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower, on behalf of itself and its successors, assigns, and other legal representatives, hereby fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and each Lender, and its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, each Lender and all such other persons being hereinafter referred to collectively as the &#8220;Releasees&#8221; and individually as a &#8220;Releasee&#8221;), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, for or on account of, or in relation to, or in any way in connection with the Loan Agreement, or any of the other Loan Documents or transactions thereunder or related thereto.  Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release.  Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">8.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Miscellaneous.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(a)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF CALIFORNIA, EXCLUDING CONFLICT OF LAWS PRINCIPLES THAT WOULD CAUSE THE APPLICATION OF LAWS OF ANY OTHER JURISDICTION.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(b)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The captions in this Amendment are for convenience of reference only and shall not define or limit the provisions hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(c)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Amendment expresses the entire understanding of the parties with respect to the transactions contemplated hereby. No prior negotiations or discussions shall limit, modify, or otherwise affect the provisions hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(d)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any determination that any provision of this Amendment or any application hereof is invalid, illegal or unenforceable in any respect and in any instance shall not affect the validity, legality, or enforceability of such provision in any other instance, or the validity, legality or enforceability of any other provisions of this Amendment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">[Signature page follows.]</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">IN WITNESS WHEREOF,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;the parties hereto have caused this Amendment to be duly executed and delivered as of the date first written above.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:bold;">LENDER</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:bold;">BORROWER</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;">HERCULES CAPITAL FUNDING TRUST 2018-1</font></div><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;"><br></font></div><div style="padding-top:8px;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;">By:&#160;&#160;___/s/ Jennifer Choe____________</font></div><div style="padding-top:8px;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;">Name:&#160;___Jennifer Choe ____________</font></div><div style="padding-top:8px;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;">Title:&#160;&#160;___Assistant General Counsel___</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;">EXICURE OPERATING COMPANY (f/k/a Exicure, Inc.)</font></div><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;"><br></font></div><div style="padding-top:8px;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;">By:&#160;&#160;___/s/ David S. Snyder_______</font></div><div style="padding-top:8px;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;">Name:&#160;___ David S. Snyder_______</font></div><div style="padding-top:8px;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;">Title:&#160;&#160;____CFO ________________</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:bold;">AGENT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;">HERCULES CAPITAL, INC.</font></div><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;"><br></font></div><div style="padding-top:8px;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;">By:&#160;&#160;___/s/ Jennifer Choe____________</font></div><div style="padding-top:8px;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;">Name:&#160;___Jennifer Choe ____________</font></div><div style="padding-top:8px;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;">Title:&#160;&#160;___Assistant General Counsel___</font></div><div style="padding-top:8px;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s2688ec63b17c487cac0c6f807fc903a4"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:right;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Exhibit 21.1 </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;text-decoration:underline;">Subsidiaries of Exicure, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:51%;"></td><td style="width:1%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Jurisdiction of Organization:</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Exicure Operating Company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Delaware</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s2ca61dff00f14e9e9f601ee5540d908b"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:84px;text-align:right;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Exhibit 23.1</font></div><div style="line-height:120%;padding-bottom:26px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:26px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Board of Directors</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Exicure, Inc.:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We consent to the incorporation by reference in the registration statement (No.&#160;333&#8209;222999) on Form S-8 of Exicure, Inc. of our report dated March 8, 2019, with respect to the consolidated balance sheets of Exicure, Inc. as of December&#160;31, 2018 and 2017, and the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended December&#160;31, 2018, and the related notes (collectively, the consolidated financial statements), which report appears in the December&#160;31, 2018 annual report on Form 10&#8209;K of Exicure, Inc. Our report dated March 8, 2019, on the consolidated financial statements refers to the adoption of Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Our report dated March 8, 2019 contains an explanatory paragraph that states that the Company has suffered recurring losses from operations and will be required to raise additional capital or alternative means of financial support to fund operations, which raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Chicago, Illinois</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 8, 2019</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sc7fd76e8aa5d4713954d1b536755dca2"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:right;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Exhibit 31.1 </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">CERTIFICATIONS </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">I, David A. Giljohann, Ph.D., certify that: </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1. I have reviewed this Annual Report on Form 10-K of Exicure, Inc.; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Date: March 8, 2019 </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:47.42063492063492%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David A. Giljohann, Ph.D.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">David A. Giljohann, Ph.D.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s818fd78337424803b4c2c3842b2890b4"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:right;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Exhibit 31.2 </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">CERTIFICATIONS </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">I, David S. Snyder, certify that: </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1. I have reviewed this Annual Report on Form 10-K of Exicure, Inc.; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3. Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Date: March 8, 2019 </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:47.42063492063492%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David S. Snyder</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">David S. Snyder</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sbc6cf52b1a6e41048766973ab7555e67"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:right;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Exhibit 32.1 </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:center;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">SECTION 1350 CERTIFICATIONS* </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), David A. Giljohann, Ph. D., President and Chief Executive Officer of Exicure, Inc. (the &#8220;Company&#8221;), and David S. Snyder, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1. The Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Dated: March 8, 2019 </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:46%;"></td><td style="width:2%;"></td><td style="width:3%;"></td><td style="width:2%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David A. Giljohann, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David S. Snyder</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">David A. Giljohann, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">David S. Snyder</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:100%;padding-bottom:2px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">This certification accompanies the Annual Report on Form 10-K, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Annual Report on Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>a201810kdevelopmentpipeline.jpg
<TEXT>
begin 644 a201810kdevelopmentpipeline.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P@ 1" +'"Z # 1$  A$! Q$!_\0
M'0 !  ,! 0$! 0$           8'" 4$ P() ?_$ !0! 0
M      #_V@ , P$  A #$    <L'I/\ 0
M
M
M                                    ?D\Y\RQ3V@
M              F((<                      601$XH
M      +B*=
M             +@*A/R
M   >$KL%KG1                            !/@0$
M      ML@A'P                    7V4(
M                                       7R42?@
M                             YI5(+7.B
M     "? @(                     !;9!"/@                    OL
MH0
M     ODHD_                                            !S2J06
MN=$                            $^! 0                     "VR
M"$?                    !?90@
M                              !?)1)^
M                    #FE4@M<Z(                            )\"
M @                     %MD$(^                    "^RA
M          "6'K/ 1<     $O(@          #Z'S!T":$?(V#Z'S
M               +Y*)/P
M     <TJD%KG1                            !/@0$
M        ML@A'P                    7V4(                 :\(82
M$B)09]C\GS  /0?$_)LLQH?Z>D\H!Z3S _1]3YG[/B?H^QYP?Z>@\Q?I7!"0
M; *P+3,V%F%<$)/:>0_)]#_3Y ^Q^3Y@                %\E$GX
M                                      .:52"USH@
M               GP("                      6V00CX
M       +[*$                 ->&73FFSC+1H0_!0!H\R":_*++@/H9?-
M<&1C4YX"('.+*/T4^3L]Q*R$DV,I&F#Q%5$P)"=\SX:1($9K!K@X) 2KS8I
MCE'9) 9@-4$0)49T-"'X,Y$:                !?)1)^
M                              #FE4@M<Z(
M       )\" @ ZIIXZ)X2HRQS+P          !89P2PR(D%   !;9!"/@
M                 OLH0                 UX9=.6;1*D)0? @!,SDGJ.
MJ?,Z)3AH<H<EI0!M I@^1!2^3F%5EO%,EXD +9(.>H\)!B1'A)N4^0D^Y+SH
M%U%6$Y*?.R34M(SV2TI$U85\2@^! "H0                7R42?@
M                                      YI5(+7.B
M              "? @(  -=&8#PFOR D.*G+Z/:4*6L=TKPL\_TH N,]!^2A
M2VR=E*DE(L=P\IH\KX@I'#J%ME>E2@ %MD$(^                    "^R
MA                 #7A!SND>(B62<DJ8^QK8Q\60=@]!1!K,RT:9*Q)L0(
ML8C)SCL%4%P%+%Z%.E\E8G():0,DAXB9'"*+/J;#*K+"*6+$.$6D4@:#,F&G
M"!DV*4+).25,1,                %\E$GX
M                    .:52"USH@                            GP(
M"  #71F \)L,QV; *%+1(V?(EQ4A%2=%I%.%[F8"^"N2]BB"X"(E>$M.06$5
M$6&08T$9#++*E  +;((1\                    %]E"
M  $O/8<\B@)L?Z0@$T(6?HGASB)$S(82 DA BXS[D/("2$Y)V3B'=. =HD!
M3MG@/2?@_P!)&0,'1)P<8AYV21G#.V> \I;1$"XC*!-C_2$
M    %\E$GX                                            .:52"U
MSH@                            GP("  #71F \)K$R";+*(+,( <<M\
MST6,=HZ16Y>QF(O4KPO(H D9UB%DW(D3PJ8L4@QH0R*7 4<?D %MD$(^
M                "^RA                           ":'R(@
M      #Z%S'7*H(J                  "^2B3\
M                        '-*I!:YT0
M 3X$!  !>I39YB[RB"_RAR_3WE$%FE5G8+H.(0$T.0$^!09<)."H#Q%UD;("
M=0G1"B-G6+<*[*D  +;((1\                    %]E"
M                                                  %\E$GX
M                                        .:52"USH@
M                 GP("          #5!ET^(         !;9!"/@
M              OLH0
M                     ODHD_
M          !S2J06N=$                            $^! 0
M             "VR"$?                    !H8BP
M     !^S\                     _T_P!/R                  629</
MP                                            <TJD%KG1 )22H A
M9[R(@          'N/"6.5P   6>5X>,      $^! 0  #W%EGA*V/R    >
M\E)RC_2-@EQRCC  ]QX0 =0[!$P  6V00CX  )><LX@  +'(.2D@X   /<=4
M_P!(V      #21)0                     >@[1'0
M   >\]9Q0                 #MF,3Y@                'Z+*.@5L<P]
MQX0 >@_)\0                    <TJD%KG1 )>626@4P<PFI4!'C\$C.,
M><Z1[#@DE.4<\Z1ZSDGF.R?,Y1UCE'3/,:Y,E%QE&GO.H1P F9K$SX4\=8]!
MPSN'@/ >T[A&SY  GP("  #]&NBKB8D3*1)*<HYYTCTG./&=H[Y<Q3!_I""1
M%Q%?D&.X1LM8DA01USYG*+8.,0   %MD$(^  #0Y!B#GS/J<@]YZ369DLL,J
M4[1^3CGM.X1LM8DA71_A!B0G-/ =8^9]3D   %]E"
M   D)>QF@                    %B$Q**                  +Y*)/P
M                6\3PB).2F2V#-ITSUG -5F>#E'A/8>4^IW2-GR
M           .:52"USH@ DYH@R@607T14XIYSN$D,T&O2IR.$D+&,G&ORJB;
M%"%VGZ* -)F1C492YIHS8: ,I&GR.$#*A!HXB9;AD$VV5T0<L(ZIF8T"<P^Q
MF\ $^! 0  2<T<9*/H?@N DA8QDHV$503HS\7^< ^I!3_25'Y)T9_+5.8?8$
MG*/+E/T4 6Z9^/(  "VR"$?  !H<@Q>!!"S#*)J0KLM4RF7N566\?8ST7B<P
M^P).5J? [!W"1&:S2Q!"S#(1S0  7V4(                     "0E[&:
M                    6(3$HH                  ODHD_
M      !.33! 2GBP2T#.!=AZ" EU%(D^*!+I*L-"%;'R*-
M   .:52"USH@ DYH@R@603PJTN<[Y#CKE-F@3(A:9-BRC*!I@R&:_(:=8YI7
MY>)D<U(9P-6F,S990Q+"A3]'Q/6;5*[+%,H&GC%YIL^)^BJ"QSTG5,M  GP(
M"  "0FGC(!(#KG<)L649+-0&0#994IS2(EW$%/\ 2XS'IH(@)/#TG5*U.J>T
MDQS2ORQ3-(  !;9!"/@  T.08O$R<:;*N+",RFSS+1>YRRM2"'^&@#TG5*U.
MJ>0_TN0QZ7 ?Z6L9.--F>2.   OLH0                     $A+V,T
M                  L0F)10                 !?)1)^
M    ":GC)(:',TEH%'%Y'<*^+*,QFC"@BZ2JRP"RRNC/H
M !S2J06N=$ $G-$&4"R"=E7%SG".D=DSL:8,DFHR,%KF5S694A-BBBZ#R%$E
M_$:++,GFIBAR_C*1J,C9$"D2VB9%&ECDP)T8T+?)^>@H4TX5P2LRF "? @(
M !IP_9(BB2V",%KF4C2YD(V69L-!$>/L04_TDY]":%*EVE<$K*D+D*9+=/(4
M^3\S^   6V00CX  -#D&+Q,F&G"B#29 "S3*Y>Y5A<1]BE2_"N"5E2%R%=GD
M.X=8D9FPTN9,-.&>B.   OLH0    ]Q;Y^"M#@    LXY!'SD %G%8@  L4@
M9Y@   2$O8S0                    "Q"8E%                  %\E$
MGX                 +-+R(J=HH,T>5(6(><AI."OR1'W)@9]+J(&6,9+
M               .:52"USH@ ^IT3DGI/N>4]IS22G)/$=0Y!ZCLG./N:@,S
M'(/,=L'$/4=<\1SSI'^GZ.,=$Z9&P=(^!Y#Z'5!Q@2$\9RCM'P/L<8 $^! 0
M   24\!R3U'9.<>8]YQSLG&.V>8_1\ >0DAR3X'1/@?8Y!)B-'8!SST',
M+;((1\  '1/@>XY)TSG'L/4?DYA[SEG</P<8[1\#['(),<8_)XB1G-.<=@Y)
MTSG'S  !?90@   !W30Q4!;A4AVB#ECE3'7+#*H-(%1$4)L=8JDM4I\MXBQP
M"T2O2Y#/YRP   2$O8S0                    "Q"8E%
M    %\E$GX                 !V#I$8/P28X!WCDG[/\/8<@D!R3SG[) 1
ML^                 !S2J06N=$         'W)V5Z
M"? @(                     !;9!"/@                    OLH0
M [IJ\BA619!41>!!#LD@,]GK+T(<5V:(*8.D6$04CX/ 3@E!Y#/YRP   2$O
M8S0                    "Q"8E%                  %\E$GX
M                                     .:52"USH@
M              GP("                      6V00CX
M      +[*$    .Z7N9K!IPS@:4(,<LM4K(^!:9#BNR\RF"5$_*W.N>PZ1#2
M?'B,_G+   !(2]C-                     +$)B44
M 7R42?@                                            YI5(+7.B
M                           "? @(     !H4FY^B)F;0     "URN3G
M     %MD$(^                    "^RA    #[G>(T"3D;/830@QZ"8$$
M)&>,YQW3BGJ.@18GAP#XG>/$?,CY\@   2$O8S0     2HO0^92I9!0X
M !>)59P@    "Q"8E%    &HSRE>'^$-(X     =<O@X11H   !?)1)^
M                                        #FE4@M<Z(
M                 )\" @      N(Z11I?AW"ER2$M("3P^)YRFB_#X%-FN
M"E2D@     "VR"$?                    !?90@
M  )"7L9H     )V3\AI/23D2(J?HFQ6A+#M%.EE'8*).:607<9P(P     6(
M3$HH    UF9A-2E>G4/ 5B6Z1TX1-2$G^%A%2$-)&#1ID\    ODHD_
M                                       !S2J06N=$
M                $^! 0      7$=(I0M0E0/H1LY9/RE#2A69WS[$*+9,T
M$>      +;((1\                    %]E"
MD)>QF@     G9H(A!3!HTRV:;*M)>?L]9TRES1)!"#E8 T"5*1@     L0F)
M10   !M0K8K$G97Q>1099!/"L"Q2J2Y"N#J&?0:!(R5(    7R42?@
M                                      YI5(+7.B
M              "? @(      +B.D5T:!*W) ?LK0^A;13Q?Q6IV#@D++\,U
MG       +;((1\                    %]E"
MD)>QF@     G9/"B :I,M&H#YD</<?D]) RSCEE(D=!H$J4C     !8A,2B@
M   #6)DX%\%<%[D#.V2TK$[![3S'W(&5D6<:'(,9C    +Y*)/P
M                                   <TJD%KG1
M           !/@0$      $]/604T(<,Y1Y2('"+Y/"6$98+\!01:!TBC0
M   "VR"$?                    !?90@  +R)L?4S\1,   '=+H,]
M   %ME>''  )"7L9H        !^S_3YG^GW/.?Z?8^        +$)B44
M   #[GP!Z3S ]!YP      7R42?@
M            YI5(+7.B                            "? @(
M   .N:?/"5X4T         6V00CX                    +[*$  !>Q!#R
MEK'Z/<5F625L=4L$_!29;!'"8'/.8=LZY3Y:YV2+')/R=T@199Q3XDX*D*B
M )"7L9H                    !8A,2B@                 "^2B3\
M                                         '-*I!:YT0
M                  3X$!                      +;((1\
M          %]E"   O8@A_I818A6!'2PCJ%(%\$/(.6$2,RH:M(85L7.0 ^Q
M8!G4T&=LK4^)8AELT^<<H\X8 !(2]C-                     +$)B44
M                7R42?@
M      YI5(+7.B                            "? @(
M        !;9!"/@                    OLH0  %LEA'G*#+4)(5$?Z6 4
M@:$/N4N6"1\LPAYV#KGA*Q.B3 I<N,XA-RMR;E"%\'!/T5   2$O8S0
M               "Q"8E%                  %\E$GX
M                             .:52"USH@
M      GP("                      6V00CX                    +[
M*$           +@($1P         D)>QF@                    %B$Q**
M                  +Y*)/P
M        <TJD%KG1                            !/@0$
M           ML@A'P                    7V4(
M  "0E[&:                     6(3$HH                  ODHD_
M                                          !S2J06N=$
M                   $^! 0                     "VR"$?
M           !?90@                     )"7L9H
M   !8A,2B@                 "^2B3\
M                 '-*I!8![0                            2X$1
M                    +$(F<<                    %ME2
M            [):Y1X                    )D24J@
M  MHJ<_(                                           !XBOP;2)4
M                            "O@6"                      4\3\D
M0                    ,^&@P
M
M              10Q<#^C9.0                            5."V
M                  #/A:I+@                    9.-8@
M
M                                      @I_.4']&R<@
M                 J<%L                      &?"U27
M          R<:Q
M                                                        !\ ?
M(_P]H   (*?SE!_1LG(*I(>     6T2P                     J<%L
M                   &?"U27                     R<7H
M                                            2@ZH
M *,(V>$N(^19      ,]%[E/EW BI%2OSHF@P        4B7<5(>HM$ I8ND
M 'X,DG@-:F5#MFHRFC\DS,QEIG?)J5"6.2 D   !!3^<H/Z-DY!E<J@$E(T3
M8C1VR)DE(T#5!:X                    !4X+8
M  ,^%JDN                    !DX@@
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MM4           SX6J2X                    &3B"
M                                     &FBT@         >8RP:;.J
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M:I+@                    9.((
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M6, &_P KTXIEXU64^5X7P>8H8^)O ZH          ,^%JDN
M       !DX@@
M     !IHM(                 \AZP>,]@/(>L  'F/N?@^H !\S\D/(67*
M?4\Y]3]@ \AZP>8]( /.?8_1YCT'G/L?L  ^)^CZ  \9ZS_0     04_G*#^
MC9.097(<3@K0U06("AS/),#OD(-'EK@'\_S3!'"I#8YCX^!LHQV6@2TR^7@"
MH#8AFHCII8RD:Q."74        "IP6P# I8Q7!8Q^R3$8-9F #?Y69P3.I;9
MUR@RQ2=E-DB+S+-          !GPM4EP                    ,G$$
M                                                  --%I
M                       _)_A^P                       04_G*#^C
M9.097*Q+</\ "WB>@HDH0N4X95AJ0M< I\G)XB.EEE;'X+,*V.\=(KT_1+2-
MEDD()84F6P3$         %3@M@^!5!;Q&R.D4.67H=$I\N  AQ5Q?9 R&%ZE
M0',+S           ,^%JDN!3)$">EL %2'J+1!4A;9&2CSDEBES@
M   R<00
M TT6D              1,_9*0 5N"R "MRR   5N60 "MR9'W/>
M                 04_G*#^C9.097(,>\[A'S0ISC.A\2Q2(GB-)%K@
M                %3@M@                      SX6J2X&0C4I!#ME6D
M_*O+#)@4V0DV$#RF;#3I5!91 2OSRG>/>3 JTGYX"(GI/B:%    !DX@@
M                                                  !IHM(
M     CY(   ?(QV7B6P?X46=4@A9IT2$DA/H3LHXL4\1!"ZR@#39Y"BB8G^E
M;DS/\/ 7.463$L\_)19T">%:G;+(*-+ ! BP2?@                $%/YR
M@_HV3D&5RJ3Z%ED).,2@BQ8!^"#GR-4%K@                    %3@M@
M                     SX6J2X$+*>..>HU&9;/2#YFG#,9I\'E,V&G3,AH
M0I(CI.B9%.GP-1F6S\FHS(I*S2!^@   #)Q!
M                              #31:0         /(8F-DG;  ,[$A/N
M7"5@? ZQ4@.@7,4&?8_9HLAA%R/GT.0:;(.4(6D04EIVB@#N$R(B6D7"5,>L
MB)SRPBK3Q$D*M)@:>,SFH0                ""G\Y0?T;)R#*Y!R9GX(\?
MHF1"SYDW.:5Z:;+7                     *G!;
M   !GPM4EP,>%QE3$D)^5@>H'?.V4V;%!Y3-AITR:3T\!R"8DX*7/J3\K ]1
MI8SN1<TR=P    R<00
M            TT6D          ? ^X  *<*\.B:5("0,^9P3_3H%]&=0=$M0
MKXK NDB9S339#B-%'$L)>?<@9/CHGS*.-CE<D/(V=DZ9 3NEGD((V:;,R&FP
M                ""G\Y0?T;)R#*Y5!ZB>%<EF'U(^0XM4JH&J"UP
M"MR"&@P            5."V 5^<8K\@A=I&C1@,A$Q(R:6,ZG5-(@     %7
M%H@%0%A$'+5    ,^%JDN!YB'DO/00TEYX0=,B!VSJ _PYAU#FG@.B?@^Q]S
MQ'1(:2\\)TS@GX)"    #)Q!
M                  #31:0             !SCY'6!71TSU@^AWR. DA5!8
M!'3_  ZP).?X522P^AV2)GT.662522PE8*Y/>18XQ9Y)RJ";'X).1@DX
M            !!3^<H/Z-DY!E<J@ '0/ >\YX -4%K@&:BOBTSRD0.&:8,S'
M9+J,]'=+H*Y.21@O8C)!3EG=-2&438@       !4X+8!FDTL>4S8:=,L&IP9
M +[*&+2.V0@MXD1F8\!I,SL> M<@1_I996!\"2G<(V2DH$V$4$:7    ,^%J
MDN                    !DX@@
M                    !IHM(                               '$/4
M=$                    $%/YR@_HV3D%8D4     +1)0 8$-]F!"SBY#*I
M8I<9*#)!KDR 7>0TJXW28;/*;X,#FA2IB;&EP       "IP6P#,!I\\IFPTZ
M98-3@QZ6P04TZ9S(<:=.X9W(>6H>X%+FNS/A(29E0@M<IPL@@AIHS :?
M,^%JDN                    !DXLP
M                         L(D8             (Z1DZQ,@ "/'T.R?0
M$>)"          "/'</J #A'9/H #B'!)R1X^!*#X$<)404E)T0        "
M"G\Y0?T;)R        #*Y$2Q3XEMF9S11F,ZY=10QTS0! 2!G)+L.*5Z0,WZ
M?S1/Z,G?        *G!; ,SFF#S&?S1)D<D98! C21GDG941ZC3Q'S-X+R*9
M(T6V1$\Y:!("K#_#O'"/81POLHHTP    9\+5)<                    #
M)QK$
M            &7BT"OR8$I),0TF)G<M8E1R#H$<+!*U)F14G1XB&%C$6.>3<
MY1VS_"%G;(^=XZA7I8)S#LG*,]G%-0$++!/45T2HY)ZB3G^&%CJEVF;3[&SC
M)I("RRIB)&\P        ""G\Y0?T;)R                 9K(0=$GA69LH
M        %3@M@%:G7)F       #Q&:CQFH3V@    X17A<    !GPM4EP
M                 ,G&L0
M                          >0QT:W.R  9>/2<$L<KT[)*2M3O'1.P<XJ
MXO$\A$C@%Y%7$I/F?$J0O@YY$C31XC'9:IX2#DO)(=\K0T(4D<8X9W"7'?+0
M,ZG8.<0LUN#Y&)"]RGB0EF'Y*F+$($4$?TK/V        ""G\Y0?T;)R
M                        "IP6P                      9\+5)<
M                 #)QK$
M                           @I.#]  &7C39]B#D3*^)^14\AT3L$W*?+
M\*C(^#39F0CY8!XSEFFS*I*#01XC/Q[#['$+0(D1@^9?)4)R#_2UR'$8--F=
M3L$W*?--@Q.6 749(.Z:2/F4":+*J* /Z @        $%/YR@_HV3D
M                      %3@M@                      SX6J2X
M               &3C6(
M                            *N+./V<,Y)V"D"8'L/0>P[A#B?$2.<"S
MBLB,GT)(?@LXS$:%.P? K\G90IW2;%5EDD>.*3<\AR#W$.+))\5T>P[A#RS3
MR&8 7400YIHTX1 "QS,9<!:(        !!3^<H/Z-DY
M           !4X+8                      ,^%JDN
M    !DXUB
M                             <(JLO$
M  @I_.4']&R<@                            J<%L
M       &?"U27                     R<:Q
M
M                          !!3^<H-$G;
M    !%02H                      @!*3K                     JHM
M4
M                                                 '$,[ _HV3D
M                           %3@M@                      SX6J2X
M                    &3C6(
M
M             (*?SE!_1LG(                            *G!;
M                  !GPM4EP                    ,G&L0
M
M                                      04_G*#^C9.0>4\8    ![S
M[@                    %3@M@                      SX6J2X
M               &3C6(
M
M        (*?SE!_1LG(,ME2@  '3)20,&IRUP                    "IP
M6P   ?@_8                 !GPM4EP                    ,G%C
M                                         %QGH
M                                                !!3^<H/Z-DY!
ME@J<  $B-&&7CQ U06N                     5."V 8@-)&439ACD^A=I
M6QJ4I\[9ETG1%3=901'"V3/)"#^B9]0          9\+5)<
M       #)Q!                                            #;1T@
M                       9D/V<$LH]1<0    !X3'!L(Z9SRK2X@ #PE#$
MV+1        ,[%H'C+%              !!3^<H/Z-DY!E@J<  Z!L,S"0H
MU06N                     5."V 1D_G.;;(02XN<X)DTU64X=LS$:(*%-
MJ%&G&-<%2D0-$@          &?"U27                     R<00
M                                       VT=(
M  'P,XFA3H  &7BV2NC]$!/H:I,^D8+,.>2\@)ZB;%L$=*'-#'4*^*(.T>TF
MA31-20' /B1,D!89 CU$V+8,Q'2/$>HFI3AWR?$K*A/H=4Y9P#VFD#W@
M        $%/YR@_HV3D&6"IP #2AV3*0 -4%K@                    %3
M@M@%+F4B[#MGM+H*E*E-+E.DN,Q&@RK#:Y!2@37!B4V>>L           SX6
MJ2X           XYS#ZGN.P       9.((
M                  ;:.D                   #YE'%UGJ  ,O%EG?/\
M2'D5+<*9*Z-.%.DR*6+<.J76#/!>9U#C%+G -0&7CV&E3*1(3P'^&BBB"K"W
M#JEUF8C3IB,MPZA'B+E@D\*8.B3X^)&R"FC23@            $%/YR@_HV3
MD&6"IP >\W*9J*@ !J@M< P2=\XQN Z      ,^%P$C ,9&LCM@       %3
M@M@^9C0UZ9)-.F7#CFFP9A/4;),K&OS*1>)T2H#11E$U<           #/A:
MI+@8]):>0U    0TZ9WP "KBT0"G25%?G6+B       ,G$$
M                               -M'2                       !0
MQ>I]"+D;(^3(J$XI8QQ"0'(.<6.60"F2USWGE,S$D.<6@9Q)\661L\8+H*E.
M0<XL<L@HHO4H$YQ8A59]"YBD3SE@$]*D/,?(O<D             !!3^<H/Z
M-DY!E@J@_P! +#-=&,"(@'^&IRUP# !O\S&2 I,^II0R&7&5F>(L(YI<93QV
MBJS0969Y"W2JC1!EX_TV 8X)$2DB)=1XR^0   5."V
M    #/A:I+@9/-*F6"S3BEGE2G^%Q&:BQB?%6'*+I*Z)"<T]1Q2R#AGQ)D0P
MNH       R<00                                            VT=
M(                                    H8OD
M       $%/YR@_HV3D&6"PBSCZ'X*6+_ #/1>0.,4^34M< P ;_,J'L*A+%+
M&*O-"%#GP-#&1"[2.$!.X::,=&Z##QV2:$I.4<\AQ=Y 2!GA-IG4   !4X+8
M                      ,^%JDN!BLMDL8C96)9A#2_#.9ZR9'H(*5H:J*)
M)L1<L(K$MXYY[STG'+9       ,G$$
M              -M'2
M                     !!3^<H/Z-DY!E@L$X!]#YGG-&F2"<G^'4.<24M<
M R <D[1K$R*>4T<5D6^5,?$N4SD28CA_I*S\G$(::!*S+N,O'V-<F3CFD\)B
M44;?    *G!; (B?(F8 !PSED>+1!1 +W!_AFTTF9\."3@@!W#EFG2&E7&AB
MGBX0     #/A:I+@9M-) H$\YWB!'H+:(,2@X!$B,%RD2/V?0]1YSO%T
M     &3B"                                            &VCI
M                                  @9"B\2I#U%H@%+%T@ _!DD\!K4
MRH=LU&4T?DF9F,M,OT              @I_.4']&R<@RP:")* 4F<0L,L0 J
MH_):X             /D8I/0:/,S&E2R    "IP6P#-9I SB<\N\I,_PFA'B
M1%U@RP#4X*[,]FR 9C-%F8#2QFHTJ9]/D:8*Y/46*     #/A:I+@
M             9.((
M ;:.D                       "H"E"SCCG'/>28@YYC49DP^QI0J@DIV2
MC#RERG!*M-!%5D=-3F7CCDW-/&?SW$#(\7:8W-O%"$O-,'/*[*9)8< AAI@R
M\6X=P@Y%3:8             !!3^<H/Z-DY!E@T$24 'S/H "JC\EK@
M               %3@M@&8#2YG8AQ;9\R+EC'F*Z/L6B4X#4X!F0TV<@H4TB
M8N)X<HU&8B)@3PN I T.     #/A:I+@                    9.((
M                                        ;:.D
M       "I"M"OSWFM#%I9!;YE@O,^YRSP$;)L20S:;&,Y$&-W$8,-EJDB(H7
M80 T\9_/<14K<OTSF7"0(C)NX^Y2)4!>97!"C6) "+'J(Z00W
M    04_G*#^C9.098.T=,    B99Y:X                    !4X+8!F4O
M0S>><LT]9%"TRHS_  TV#+ .D=HOLS(:;*9)23TRP:G,OGT+:+",BFA2(%R
M     SX6J2X                    &3B"
M                   &VCI                        QR=8@ITS7AB@L
M4N@RD:X,D@U>8Y.^: ,ZFPC-QXCS%H%-'=-)F0"1DZ-/&?S[&<B4%VF83293
MAWS8)&C^<!<)I(RR?8W>4Z18[92A]#;(             !!3^<H/Z-DY!F<D
MYV0   "%$]+0                     *G!; *C)F=\])_H /F?0
M  %!EZ'H     !GPM4EP                    ,G&B0
M                            "2G[                       !_A\#
MT    ^)_I]3SGH  !XSV'Y/.>H^1^C]@ \Y]C]'F/0><^Q^P #XGZ/H #QGK
M/]              (*?SE!_1LG(                            *G!;
M!Y3U             'E/4      9\+5)<                    #)QK$
M
M                                              $%/YR@_HV3D
M                         %3@M@                      SX6J2X
M                  &3C6(
M
M           (*?SE!KTDP                            (("=@
M               %3DY.^                    "B2]@
M
M                                  1@R&2\]!^@
M            ?@'[                      /F?H_0
M    /D?4
M                                                        'Y/.
M?TE
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                        *]+"(B=(CY-C['.(D3X
M      K8LD%;%D@  ^!RB)%D@    '+(\=(Y!*SW@ 'Y*Y+(   .61XFH  !
M&#ZDB (X2,_PK@L@ K8LD%;'N):>X@I*CG$A    !7IZRK"["-EA A9Q"SR$
MGE/,"R05X3T^Q'"1@      \I"B?@   CA(P
M
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MLM0KTO(@)QSTD8+C,;FR"HB;%A
M
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MN7R0(B9JHK(CI*RNCJ$H*;-CGI
M
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M&:#,S$W.X0(^A91#30)Z
M
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MD)=H
M                                                   *H+7 *X)N
M=                                %8DZ.H                 "J"U
MP"K"SSZ
M
M              '_Q  Z$  ! P(% @0$!@$$ @,! 0 %  0& P<! A46%Q0V
M$"<U4!,@,#01$C(W0& Q(24S<",D(B9'1K#_V@ ( 0$  04"^)F6#UQEPZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYRNN<KKG*ZYR
MNN<KKG*ZYRNN<KKG*ZYRNN<K%ZXS8?$S>#(<VJ--*:K2FJTIJM*:K2FJTIJM
M*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM
M*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM
M*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:J(QX<_/R
MZ/#F!_2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJT
MIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJT
MIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:J"1@64*F@C%L7TIJM*:K2FJTI
MJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTI
MJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTI
MJM*:K2FJCD1$/(GI35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4
MU6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4
MU6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4
MU6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4
MU6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4
MU6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4
MU6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4U6E-5I35:4
MU6E-5I35:4U6E-5I350")""N7,*:?FTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJ
MTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJ
MTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJ
MTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJ
MTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJTIJM*:K2FJ
MTIJM*:K2FJTIJM*:K2FJTIJM*:I\.;4VG@.^Q]Z@O=$Z[H]MMKZU(?7O:HGV
M/_?[8?IS?J_K)'['P'?8^]07NB==T>VVU]:D/KWM43['_O\ ;#].;]7]9(_8
M^ [['WJ"]T3KNCVVVOK4A]>]JB?8_P#?[8?IS?J_K)'['P'?8^]07NB==T>V
MVU]:D/KWM43[']C:14H^;[*-)S&"K3)]3:1;X'\:I3S4LW@R8."-7+ 3&;*1
MCI$5E\*E/-2S>VVP_3F_5_62/V/@.^Q]Z@O=$Z[H]MMKZU(?7O:HGV/['$>V
MWEQLC1X#FK(U7GT;I_ 5.CGK8YZ>:EC\M.A5K+-EQR8K+V^L,/QQJ-:U+#QS
MMJM/+X888YL:M"I067)CGS5:-2CBLN7'-C4;U:/R5&U6E@K>!VE=E-.YO 0P
MH1P)5N=G^*#-4)&/E@G('-6\#M*[*:=S+*R<9LN.&.7%9*>>KFJ4\]+-X4Z.
M>MCGIYJ6/L=L/TYOU?UDC]CX#OL?>H+W1.NZ/;;:^M2'U[VJ)]C^QQ'MLUZR
MWKYFU<G2P=BHL"UXF2+C8@V9$!DS9DV56*2 HVIR&/Y:>;/4HY*4:CT2!;E)
M%Y..C..&47-1A)AG%O\ +V^.85";YH.&1(>PFXLFYFL1HY&ULONS.(P.Z#2D
M?(<TZC=,36MKZ*2)B8F]:.6<F%9WP>"89,64G$YQ-36F[(=#18N8#I!7G$:I
MAZULOLBSH3&GX8XSDK67"J04\(+MS3:725CD:>$9-T#HPA;P<ZS/807%T\:N
M?J!!=N:;2Z2L<C2!#!^1K6N*-I.3XIJ>$!QN<N2QTZ(B\A\/,<9=VW%@6O$R
M1<;$&S(@,F;.0A\093V*V'Z<WZOZR1^Q\!WV/O4%[HG7='R"L*>8IT4<5, (
MK9,P^/9,TO;C\A63 Q[8#_'C$0J2#+(V-(::@3,>Z;3.@V;G/H6U]:D/KWM4
M3[']CB/;9KUFC2S5ZQ&K@T&6QR8?!D(<,0?!6@ $XN(Z:O'-NBG4C*$;_+/;
MD%/A-+<Y,,H P" O203(" 83NLW<G<O;]N<F7,?N=4SX-O\ "R_^R%ME]W<S
M-FU"*9\U.17 RX8QRVOHLYS8YI/;KT"99\<\E@';8G)AFN-(V+ @T9@HVQ=3
M<DP>Q^V7V5PL^.:16QQ_]BY?JUM_09IW,J-'.XK58R8$4&4]*M%&)73D6%QQ
MU-L2MOZ#-.YHY!ZIFAF!Q8)FRYZ6<5;G+AB?N=FS=.-S9LA"7=MVQR8?!D(<
M,0?!6@ $XN(Z:O'/L5L/TYOU?UDC]CX#OL?>H+W1.NZ/FA_;1SUIE]X?9U"
M=E;H?3IRB#X"6M*EFKU!5N*.%%Y;EC7I$1]<6[C,*9FA NW3;\A.,Y=R-K=#
MJ%-U;D=6IDA]44^$P-D_$![<T?@&+<T_@9LN.3-&X'F)T*EO!53+(HVXCU>(
M15K(&LF%4@I>'QQO(<\I T 94($H@6DOBC7/1B$6;2"A)Q%((5C,0K'UEMV)
MRY9+!<PIO\MM?6I#Z][5$^Q_8XCVV]MQ@\> X*T$.9](Z>#> &,@XG,(EG.Y
MP-OJ5*E)F[!F4B132CGY,N&>2$]7,VX,9*6:5PFL5?"8 SH,"^5ID(Y>WXX5
MT8P:$-Y0+'6VJY7<S.TQ(NV7W<ICF2148O!J@E_<<QDQIVU]%F_=%N?0)AW)
M;_MMR1TF;'15*4!PMNZV5[-1 H,K9?97 [CMC]S<OU:VM3#$-+HA7K.E2JYJ
M%4:_:R02ZMEC\:-1>C':<],4R92VM3#$-+HA7K.H]6INX_EMV2SO<K?+D'QP
MIHIDT(;R8:)@] &YEW;< ,9!Q.81+.=S@;?4J5*3-V#,I[%;#].;]7]9(_8^
M [['WJ"]T3KNCYH?VT<]:9?>''F8>(P>5\KHO_YP%NVF5P<F@\F4;P\&9"D;
MFL\OY(%VU+S[S.=8'7[)^]&2.58Q$ Y -;A8?A(HOV\>+5BQ* %:I$5(163/
M.#F1WF$CXK(!KZ:,\KN.VS]/GW<ML/\ DN3ZY;RMGK YFYK;AME]I<#N-ODR
MA0+A\X=.LUQ7>+/Y;:^M2'U[VJ)]C^QM):58-M\&TZE19YD\&,R*CZ;Z9%7]
M/PS3$QGH+#''+BUG)=KD)2HF5IK>!?IT,/OQ"JSTQ5R5Z]1S5ME]W/7[@:<K
M3LQ5I9\^:IG&R,@'HOGM8BZ'24B);O'=5^Y'R<F+;.7-1XX&2$@'PK3TQ5R5
M:V>O4&'WX?(0(N"CD8:>!LQ(L[,51A=V'K/9L5?-_!B1<C:N2X!?)E(2PH2R
M(87=AZSV;%7S<4>?!<7DV+/:3&5%!S84TUTSFC9N.LV]$]("<X<96\;3&9%1
M]-],BK^G[';#].;]7]9(_8^ [['WJ"]T3KNCYH?VT<]:9?>2WMQ$.W[=.\M
MY-GQ090!F9*?K2S$W2R0+MJ1^OVU84JSF<20@*>0"H^=-KA]PQ?MZ0B*P@G;
MX758"CY6GDG1_,\RB&4JD+]X?RR9D.MEFPZ*X;;/2/6V'U6[6Y7KEM_0IG0J
M;DME]I<#N-M4R&0;D:Y:.Z5N:>8=F_#\?DMKZU(?7O:HGV/[O&I'C'*LDD&,
MB=?S*=3-2SC[E5J5.I<VAAE/2-U(*OLUL/TYOU?UDC]CX#OL?>H+W1.NZ/F
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M?S9-(VT6%1D[EDH7Y'DSR,Y?*)GDC)#QE$SR1DA\T8F>22DODE$SR1D@4*M
MK)@\ID6/NLY[0\(-VAX7+[B$$<HUQKF:H_<L_CY )]P =,[ABW%,I<AE0I$'
M]8FZ:-L[QQC6R4\XTOT>4H^U%[;3MWVNZ?8UK.QO;;U]LQ#M3P9$Z,0N@/,L
M2N6O!*>>92R7-(BQR2^:.:,.G#:6TS?[RS&95HR3D<A:Q@6UFTN)411VG([K
M^#K[:Q_V2'3*L]G#VOBU90.5U9>*R76JXO'%QI!'W#R>%2E:%S^J?(RR7-(B
MQR2^:.:,.G#:6TYE.,8F4%3^0%BSFX10N2H7')AR?TKD=[_VVW/H'\7/(!U-
MU\U6KDH4I'4KSRE:SL98X_A@_NLWZV/7):F")O\ >65REF!(S"6TH@R)72I4
MW41N"REE65REF!(DB380RY8J.\8I-6$MI2B?,(S7JW7=,4%--9 .M7W.G;ND
MP;8W6J.\\5G[&45Y7*68$C>$WFP86[DN8H./7,9BR ^Z=#%\Z=T6+7&ZU1WG
MBL_8RBNL<<,N#ZZS?K05SF9(A)C^2,AZMTZ;A1FXC0^^(D6XEGRQ4=YHK-V$
MLPDDS;QDB[NSA^:)3-C+Z'L<Y[0\(-VAX7+[B7PLZ8-LCQ@8:TV1!/ ?2,E%
MJ67-@?I?D;_#S>%M.W?:[I]C6L[&]MO7VS$.U/ D)"3"B0LJV_,&/G81))-D
MP+W<1#)@(O*;_>6Z_<=V<>MD&7+A3RNF5-G>OP=?;6/^R0']XS'I%E.VK9ML
MF><7?RX9H=!:&1O$,</RWODV3 O=Q$,F B\MWJ&#H]ER89,C6C(K8/&]R(Y)
M\^7\/R_1N1WO_;;<^@?Q'>6IG:U*-7)7"4ZU$1\L^-YSA24Y!HRWUK'5'9BN
M4_SCX9;(51'1&1PIE)7AO]Y;K]QWM]!C0ZB*!/*.5G>JZ_<=XZ^=S69,J(YH
MVA3)G)R%"-Q*2&[IAB(^RF;';=J^YU-A-<Y%XO<K+%6(//%Y*?NOW'>#L^D_
MSB[9V]F@6*,9O<$#*0(RBZEUI(O<K+%6(//%Y*?5T2&=A#;<":(N)7A$T7$=
MEC_.4M);L31%1*\3;!A6O&5QK465V8V.:/)4P>W"O$WP=F6S:DS;Q&CE8W8]
MCG/:'A!NT/"Y?<05_3'O*1RC5J$'59BTP)-R.3+'<[C%XPJO*6C46:KFOAY:
M53-GIY9"WRXO*V5RZMIV[[7=/L:UG8WMMZ^V8AVIX-7+FTTGRW8C>-'.ZJW0
MF=R1[H.?HW/CM5E$Z;B:SPW^\MU^X[L 7+QD,NF"=C@YK/(;L>#K[:Q_V2*/
M]F74D=Q!SP;93MJV'=]WNS8;VG4_>^Y(]T'/T;GQVJRB=-Q-9Y=/NBKAFQI1
MFY%1D\N4;"R.B#:56 7Z-R.]_P"VVY] _BXT*>-3YB]JQ!HE*K6" D>M="V.
M(]3L/4.16V<N8U8_+ITXU8U^\EU^X[V^@CO3RW[T77[CO",KYFHF9"2P\-,7
MTDG,9R#WUP95) \>!V3S?_7[5]SJ6E78,"$DX68!7C,=3N7=?N.[^7'-#@CE
MC)X+;"1-!;>93H='6#T\5'PD))PLP"O&8ZG<M7!#5#L5MO,F#D!=*3MRC.;C
M<0]K;<S%@\CL_)4YN>NZ(K9&H65A#3#).\2DQNMW(HY^\/L<Y[0\(-VAX7+[
MB37-AD<R+\,C)"!_14FA)M5='!F%#*J53)H/A;3MWZ]Q'U<=#K0F7QAI_*NG
MV-:SL;PF\FPBX)K'2U.$U(;-*=.)9)7,*46C<D&%M;?\P^&->02"=;(EZ>'I
M5;X@],MF(<57E=P\^4^<@17ZLM&G7I+Q>2YUEN&<&YBPJWTCJF1WT;U]LQ#M
M3P<-J3NEC!@&.=LUHLZ..&&;#-"P6>M2I9*%/.+9U'CL6S?U%5B 2NYTIEU7
MACA^.#$6S&8)^-:%*(Z/#!&+(<U&TVHMFRJNV3<A1HT:;>EI;/KL<,,V&:%@
ML]:E2R4*;H6S?542 CC"&QT8(S?2N1WO_;;<^@?S2 ^@59"Q34*Q\#-OP9UP
M!B F-XUXT-<&2L:&G'!N/#Y'0IT\M*G5C0VN:*QH:<<9\F6KD<VLCCFN*#,@
M;4[!PTCK!(*%C]4+&AL=0J-#0CI8X?C@]M?'7M8'%A<<RE8T-..'K*@1:@X2
M(CCPY# \BSB;= 0SC'#\<'MKXZ]K XL+CF7P,6^!'' *%AX[GNQV2"@P:1Q8
M%%QD;R9\F6ID=VMCCNL%CHZ/42L:&FW*;QH:T,>QSGM#P@W:'A<ON+Y,S]QF
M;)P_KNLGR6T[=\;BW(<"7N<?/Z#2W%Q:D@K7=/D0>9D2F4U&QB<&P4DFTKR1
M(..SS>9Y8I/RX4_/YKA$&##+.I51BUR28<M=+L6Q_P!E-;E/ZY9XWGD>;6\G
M>[&]S;@. -48RGU%J#GA@O,[CG3L:D[ E2?BXQ*#4JF_\&Z?8UK.QO"15-PW
M53K[:Q_V2_\ W3P"%V86Z7(<=5PI31FU2=#:C*V=M'%&O"[UN:.6/Q5QBZC-
M>ME;T1CJ2W&KGV\HM]D:%J+@(P>2.Y+N4.I5!F&$MT2WXH-+)@U:R0W!CUR"
M+D5$P].4SH8.-'H9+KCG'XHY<B5NH\US064X4H"<+&1]<(7RW'#-7+$8\J;;
MN_\ 1O7VS$.U/:KD=[_VVW/H'] ,AFIY@/841;+VJ<]H>$&[0\))",DA?<54
MUQ537%5-<54UQ537%5-<54UQ537%5-<54UQ534=!Y8\/\6/X5+GH-^&2YU\_
MU6XR84X5-\/PN5?+'/\ $MO^39.9X);DKS8Y]UQW+2R@+R9:6$NFV.?&U5EO
MS:7:K"GGF[S+2S-+2XY]Z7!_</#_  .QIXW1N\$U*-B)ATUK;*A?@L/X-T^Q
MK6=C> +_ %O(G7VUC_LE_P#NG@'"LCUT3-IPCYE;4[D#%*]"FYHXVT*AGDZB
MV8)'XPWQ:1MVZI,6K><2:559V/E.4 [_ #\0VG_)LF[/Y-E3?'-QRQPR8,KW
M89-'N/CFQMS \N&6'7-[RNOW'-8=1F _!A/XMA!9YNFH[_>Y7,_TF_T;U]LQ
M#M3VJX?_ ,[C<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%
MQFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&
M;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M
M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7
M&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9
MM%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT
M7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M%QFT7&;1<9M$!"TP++^8
M8D(X!AR-&TPF(0I5^4C(!XER7.,0-')GPJY/DI2 ?6+?QAL@'EW&:KDR9OD+
MG&(&CDSX5<GR%#; +383@$3KHM(!P+*)DXH[F5>MD;40TH%R'.GLX CG# BU
M*-_X<Y[0\(-VA_"N+;IXX)9YG-:[2VEO*X=S>02^*9H(VJM(C,0!-S<&>Q/=
MH845EL'R1F%&)5(;CPC-*V@V0S")-HU BTI-7':5GL+LZ+>#&DPMZ4#&GTIF
M4C:6V@F>+T;G0!P>JBL\^=-HZQTVX;IM3>M2 NLP+@!64&&_@W3[&M9V-X',
MFWKM)SA^+>SHMX,:*24S JYG(<I4/DQ@ZZBHIZWN>KI0^L0P&XUYC#P)\U;]
MME&%[D'%(!F)D)%9$4@C27Y)+-Q<3;=3#&#21VV=SQY() &R1C"4VU$3 Y$F
M> @S<@[<UG7?Q"&4*C6*W#%O'LKN8+>/SUR(X1)Y*=T".6E;Z-$*9>:LRH2=
MQXG6,"".3<=WOHWK[9B':GM5P/W1_P"BKX_;T[;1O&G.;:B6P&WLDQ>PMW-P
M;)HP(MBC1W<*.LJX\FT+-[H]US9F$>L*Y!D'&D)B%%41,A'':.>X<=IN:=3+
M6ILV0'),ZAMC1)U[AQULX:NJ+Z@3,,@U&E<F-UJM.IDK4\9:'RT:,] 5VM"O
MD<T2IQ@$R88_CAFS89,M2:A*8\2:8G6Q*= 1%<4<8'*3ES29T.28W\5LZHO:
M%(ZPKDZE3+1IBS#(W0M=FPR25W*6-:ZM,NRJCN28W\5LZHO:"FS,(]85R#(.
M-(3 ,+H!Y,+D'ACC^&% "5G,QN%;EK%1MMY#4>PL"/K7)F$TC>:WYT8;IO8[
M,[C.I53L?][=@_6#1Z$VO;2,!&W[J!3;^'.>T/"#=H>QW,!G<"#2Z$D9LK<P
MXFZD,_FQF-$[<0]^3D'\*Z?8UK.QO"?1G&2@H@;Q/@OX#VAB[9B9:<A*-D"]
MSLS)ID8,_I'"N0(*MS'ZP]C]&]?;,0[4]JN!^Z/_ $$[JYJ#6H;?U789U4?"
MOEOC]ODO4VRY#<Y+3=G4CVV+86TA# \&N6ZPC0 .!A@MA2KM(;<*Z/==[?0+
MC?MQ;Z$#G,?*QG(VN/(H #RQJS[JHYB ?]YY^QSE+EXVZCV+"S=6JWJNX#5,
MS&5"8?@(LRZJ5XM$8W1DTR+V^&Y(U:0SJ48.?_;[H)]]E:V(M9+EFV>A (=$
M $4'!Y/F'0R17FJU>B&-X,=9P>(5XA2 _O&8](LIVU:W##-)G($=ENY=QOIP
MP8W@QUG!XA7B%)7M] N-^W%OX0.<@)((H1"X/A5JY*%*?S'/-". '&+6RLGA
M_O\ ?/!6[HX/[>'HX.CL(L?][=T'6*QZW]R1H2/2,OB<.Y,?QR?PISVAX0;M
M#WJZ?8UK.QO;;U]LQ#M3VJX'[H_]!U(2(JN\,,,N'RWQ^WH_\*G':%I>RKSM
M/RNFULXJ\;U@D,#2>Z/==[?0+C?MQ!.SR?[U2#T&R_:@?]YY#^\2M/W"W;U[
MFR\G;^-1L)9/MVUO=:H.<D N):,=4J-$^^RLEZ)>AGGKQP!;^+&PTACL)C+F
M2R .'12SX1ZK8OGS"2!ZF#>\\F>TA\>LIVU:ON=Y_I>Z4R,2+J%+/A'JMB^?
M,)(KV^@7&_;B"=GW-[R\+F3O.;>0)O&HM0<UVLH 6F)TA,KO06H/2<)'YA<4
MG/9]C_O9-)*$6&@VL-F%(EDI2R??PYSVAX0;M#WJZ?8UK.QO;;U]LQ#M3VJX
M'[H_]%3F$;SIY,OY<B.#-9$1*.[6"F [4Z/I6U,"L(G;UM''<HA>Y2LVB&\6
M$CC.X(X"%Z*'<POJ)J0:]<PA<6V@*9POI)F0A?7S%1.%[7(&;:YZAIO;JN_K
MPF'9H=1BT+VT55Y6U)[7#C:8<6J]/XU&$0_9S)XSHD&N%L7XBM'K;4QY24Q5
MG+&%.WTBH4HE#6<2;R^WE&2O&=M73JO"HEL\;%87MDG,+>820DX@5,K&*=OI
M%0I1*&LXDW4VB&\6$CC.X(X"%Z*'DT+W&93NEG<-.#%P8H5%-GBY9:=J>>QR
MSK<:]1T9K0>#P'9E8H,;F6#FQ]3X\/M^QB/\2<]H>$&[0]ZNGV-:SL;VV]?;
M,0[4]JN!^Z/_ %"<8UR0F+V[KCS'N\Y[0\(-VA[U=/L:UG8WMMZ^V8AVI[5<
M#]T?^VISVAX!.0-(\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F
M:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S
M5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:
MI1OG1(OOG1/,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F
M:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S
M5YFKS-7F:O,U>9J\S5--WZ:(Y"TOS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5Y
MFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,
MU>9J\S5YFKS-7F:O,U>9J\S5YFH_N7<_F:O,U>9J\S5YFKS-7F:O,U>9J\S5
MYFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O
M,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5Y
MFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,
MU>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YF
MKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U
M>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFK
MS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>
M9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS
M-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9
MJ\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U>9J\S5YFKS-7F:O,U&^0-(\(-VA[
MU=/L:UG8WMMZ^V8AVI[5<#]T?^VISVAX0;M#WJZ?8UK.QO;;U]LQ#M3VJX'[
MH_\ ;4Y[0\(-VAX5W=!JM68K5F*U9BM68K5F*U9BM68K5F*U9BM68K5F*HUZ
M;C)[7=/L:UG8WMMZ^V8AVI[5<#]T?^VISVAX0;M#PN7GS8G_ )QPUP4<R..T
MH_1\+:]N^UW3[&M9V-\^7/ES^S7K[9B':GM5P_\ X7%Y.H+DZ@N3J"Y.H+DZ
M@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"
MY.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+D
MZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J
M"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+
MDZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3J"Y.H+DZ@N3
MJ"Y.H+DZ@F];J&__ $!.>T/"#=H>%RNXOF"!*YQY6P8P,,\=U7SGPMIV[[7=
M/L:UG8WA<<$ZBIR-S9J5BK>J2N+,"I%I#8]\>1W-)%K=GXFWM?.ZY]7F<5:4
MHBN..:,7IJYZ02T%3-5B1WJWTVXJE&"U>1P$R.(4R(VX%S&S=G9&IFSO;D"R
MY45LR=)OG/NC%++CDI?QKU]LQ#M3VJY'>_\ 61GION%[:U2DWR6=S9LAR&&X
M2RW)C);9VGJ9JD-^F]?-QS:X5P:DBIB_3$0<9FC"UYQY(0OROOLK+5<]4'%H
MDZ F?X-Z:N>D%/E*P:(6](."L2_G3GM#P@W:'A<KN+Y6#&J2= PS>.#96=SG
M"GC;3MWVNZ?8UK.QO"1@:$D$5\S@;FMC%\@$#?!WFR,+0L\C>'U:66O2&1P6
M&5ZNZHIVM>WT.SO:!-[D&W#QO8(4E+N;BR5N$Q;19U;-C&8I8_[U7+D^,<C]
MH(Q@R&?Q[U]LQ#M3VJY'>_\ 61GIOM%>ME;T:EQB.+L>\RD6/RWQ^WI7 CV%
M.=7($U@(D+6"6F@D7(2T(?%/+5D2SVJS$!H$_E[:0B7=K']U)$[%L^'FF>A;
MW ]09G2I*:RUW:7$<WMS+*DH$(\!:R-C=L:U$Q,7Z8IN"RG MIXOE)-C),G.
MY8]M-F&MK;RZK)Q9*L8=W+?VEP:M8+*ZTFC5DO0K:N:U:6OW)=Q<PS:C%D/M
MC(7$AC9TJ2FLM=VEQ'-[<RRI*!"NT4="C0>V+ZD4.E24UEKNTN(YO;J65).'
MC[&I=-^ZAAJ&$;IUZE&&0O/FJ1.X;FM1G%[?1+C LI"*VKB^7*-J85[A38M;
MLC%\K"I6K,?Y<Y[0\(-VAX7*[B^6W('!NTN$5S#PWR6T[=]KNGV-:SL;PN=+
M]NB1L,?E(Y:&8*]8[/7#V;,4G,?,%*(49!KDYY6^O92QPD4)=4WD2O>XR8#K
M0TL:<-=MZ;NY4QM8P<C+93;0WRG/9]C_ +U7,=5)!.FC:FR:_P >]?;,0[4_
MCUBS>@2-2H5'4%DHV19&)9N1J_7N1WO_ %D9Z;[14R9:N2I;+\7;5MD9-OEO
MC]O3ME&LU,="08FK-NT;1]EWN]&-'J<:C0O":S%K<:,N0+63!A4A'<<R6/*W
M\T?F'\:!OR\LV!(E;V*TX\X\+V=O"_3$:]'LIVO:C'X4F5J,?C2<%GR9;R*V
M?_F?62]"MCW@'_><EZ=9/M^- WY>6; D2M[%:<><*ZN'YI.HT#?EY9L"1*W\
M7I1RL5MDQ,NW9*8V]5R7N0E;N#X_C$+C9\-_WM]$FO[?VM[%D=OADK(O:4U@
M="-&\LC!_P N<]H>$&[0\+E=Q?(P:YGKQHWR-&URGGQC'R6T[=\;G.:U.<8V
MLE&3!A*)% BX]_1*,?J7/G+Z-U8W6SN([XWF<5:4H!X_B$_@W3[&M9V,JF;'
M)3)P24RF1#Q] 6PD=L2[*0M*%4W'RUK#8)]6B,TD>>#PJC#V,ZAE.8#J$3FD
M=SM+<2:1OQ(RB&&YH$=QGRN#;-X],0O5L@.5L:Q*-VKB96-NDPA!K&XG\B]?
M;,0[4\,SB12";[+FV"%3 [%Y'\\N:$GH,!0=M@WRD1IVK,_&!5-;=#XM3:2+
M-\)U=<[4T&<_7N1WO_61GION%U8R2DE&GA^6FI0RK$8[;L.[!1BZ4=(2,9)8
MYN., WDSC3&4P>425O,8<ZDXFG(IU2I02'.Q#R4PHE0/NR\Z+MH-#\D0%^%T
M8^_D09A3S46*=4,'36("9;$'TFA9-G('I&<GFT*B5*(BB0]^0ND^?SHVWC,2
MR1>.VMCQ"."8)&B0:2#(T2;W-?4\U9E:Z//XZ'E,*)4#[LO.B[:#0_)$!:GT
M:)&CRE,*)4#[LO.B[:$PRE%0[4!)H _)#)7/L348HE(N%S3B*-7,'D3N072C
MI"1BS0?.7C$!;2H$X>Q8]$Y$4WG,FH -2CX?^7.>T/"#=H>%RNXOP7X8K\,5
M^&*@33!U(U+<_P 61_ABOPQ7X8^%M.W?&Z/?:O>TR8L;7%LK:!4ZYRZ9PFP/
M6M?%C.4Q;V-U3IW,/B9*(P^&YSY_,>%%;=F\L;D=R&5JY&^9R2YCD_TN%HC%
M4=:"3OJY2? WH0Y;"+%!.:6S0I*SQ"VD@CK*V$ZK2'+>KNI](<D7@XT9(KFN
MGE*16O(B)(V*QW.^-7/D!\#(("(M53JG 5MC;L5,KM&\PJ-6A8U\@+Z%T^QK
M6=C>VWK[9B':GA$W-)K=;,;'9<)Z2H3*6SR2DJ)E[#94,:P<V].@Z\C-SLZ5
M$2R&-@,DIR6-QLM*YDT+:]%;?"#V=K PS24SQL3?2.VQ&?2?/%H^TATH)LX(
M9.YB)LX_;W/GDE)43+V&RH8UAQA](8Y:;-ALV2R=T^*Q@.,CS2X__E=?7N1W
MO_61GIO])&1XA0NA[M.>T/"#=H>%RNXH\8C^0;D8,:N73&:S#F67+$:63-,E
M :=-^8TQFM,9I]5##<LS+AGPFVG;OC='OM7M*TLR$#*K2S< %F"KDS I(_R:
M&XCEK[(Y,,2\][.L=A_[=[_4H1A^$1AG[F7*N$YCCG+!Y.>9V?[PO;Z_',N;
M/$+65*;:;O:U)LSM)3SYYI>KNJYM//F@%FJU+/%;VUJ6 .'-JV-I;*N*=.07
M7<TJ$*L=]G=(;G 2^?G-YR$6/IBAWT+I]C6L[&]MO7VS$.U/!E&FLJN3A9<%
MAC'X<*C*G$$RRO'&I<"+81N:99?'K)89-#)89,1UG\<VV;(Y,, ]V.R8^8;@
M;=LY5,93DN,PD#9G(8Y0E(+)')Q%,L-N$X+EI%^\,X@F65XXU+@1;"$3.E,6
M(6AC&I6ZMQ'7SH9 0(9]2H8R*;_7N1WO_61GIO\ T!.>T/"#=H>%RNXAL'&$
M@M-I(HGFY(?88]/(Y9GAE#2)>H^-)O7N+R945^67E<&%N<F?/-XVP$@K:=N^
M,]@1TU+-L7"S(!9]\Z>8M:.+5];N014O6A\OFK\C'NFA5K(D5CCV7,:Y.-6J
MBA2-U[IQ(K(WL79UAT=C,%.#YS<Z /#SMD-GAEE!X0<C,ONI"W\ASVW9RAF]
MFMK75<DY#3T[1@<'IQ!I<^&&)$?J@*96+8P661!\UM[)9829,&XL>;M>0;$I
M!#S>6/6/R_\ HW;%TWT2M %U&2?1NGV-:SL;PE4AI1@)$<A' '\ILKD!B8D<
MSR0!%G9]P9\(=*R)B8W1E9&,>/\ A2JYV.4TB16>4R+N1SY@VMM)B\HHUY5*
MB4N_+<99;@R"+D\F?+4R3(]MR.V]FQ$J71H\\C$M^K>OMF(=J>$2%/6USO"=
MA"[8[FN>1K4K:1-U'66E&;;'#$N.S!G&HQA%XO9\:[&![FLZ[^(5HRZ,VPC<
MV(1P7-QTFE;:9Q]U*XFRN06'MHJ#*')@=%O*UU9V$+MCN:YY&M2MG$W4=9?P
M[D=[_P!9&>F_TJ=%G(.+6OE)"3MU<R0O8T"MR=>2*/>+&Y3<S+/DSYL*>4S=
MHF1(M+J2 (_:DF[P<4NJ9+DHE=1YG+*X<[IQEE:^1OY*+ELGHQ,13N#,B^%O
MKDYY*Z_FSGM#P@W:'A<KN*-^A>,Q"NVY-S<%X0;PL#G##_&Y7;EM.W?YE6EE
MKTG=OY'%#!)M.I=3A45VH!+LYS)\('%-IA/HW3[&M9V-X3"IN.XM3/EI9*$M
MDLT=DY%,H3F+FL<D2#3*42UAC,I+#B]TL"N(&U>4]IL)E;\[(?"W7[BWR\9G
M''DG:S:,,8L0\)Z_KRR3#A] 4QB[FDUNOK8Y79D+$U2"M<[ -<NMGD,FN2UQ
MC!YLXIO&]R1>!2'V^,YCD4^I>OMF(=J>U7([W_K(STWW"X,ZVBWPD\^K,K<7
M"KR=Q<B=E8R=?3F5':=OKF/"Y6Y\O(Q7'"X$FD+.)W2*8&RA-N''N;G2.0/A
M]TS@,@5,X98M;.:DY0_N7)GL7%6_..I%''%U20R4EYI-J%&W<WSRYI/[EXQQ
MS6F4Z'-X+-*<P82RZ+S5<T^ET8<"##8V*.75*DRLDE<AR1^QWVBO7VM9WM"0
MW/*/33N<36-57LL?$H, ?$6)UE)JHV%TY[,).XA]SG=8LB++*2812WK*)/[V
M$&U9[7^.%LQ8YKEQSWA;96LO*.7Y""&K>.PL:LEZ'=H$Y, ()<80"C%N!;DW
M-?YLY[0\(-VAX7*[BC?H7R?#RX?+<KMRVG;OM=T^QK6=C> /_P UY7&:GEH4
M;B9?BSLA*2$?J?M+:&GER0V]V'^TSGL.UO8ML>\*UPY1DK0P\2/-K=?N+?+Y
M+M>O(N1RB!=GQF>OD3.-M91<LS9=EBRM4X$TWU>MD;40!\EGE,HDIN3AK0'=
M1CQC)A4$63SXXQ[ZEZ^V8AVI[5<CO?\ K(STWW">2P3'J>673"0-;/\ >-Z>
MZHW0RMH^$RX4KHWS_5;6AEH0J:9<*=RKTUZE.-V::4J47O:UI8A8C7SU;1V1
M]7O;C_L5H^S&]#*YNE-,F%2)61]6;_@_N@\:T7S71F$=&0H@]&')09DTJ%Q-
MN1$6WLI0IYS]UZ%.M";'?:*]?:UG>T"MRV5$S.R$G)C;1]F6X_<2]U;/E$PN
M3'@P.2,I%(S%#-FST%<*X62-4X# G$D=W3I?G@]CL^'3WISX9I3&:6-&-W:[
M+LEZ'=Z2N1 ^'VL&E([&2+N$3G^;.>T/"#=H>%RNXAD3,.F&S#BV8<6S#BV8
M<6S#BV8<6S#BV8<6S#BDT=)"QMM.W?:[I]C6L[&\'^70KQ28?5*Q^!SAC$!L
M\DCN9!:3C*YM#:3LN]WH\K952$,M;-&^1M;'O#PMU^XM\O\ '-[)!;MM#157
M:]>5VW>+:&P-G@QAZA_[MJZD<JCW<MG](G;V A="BJI8[$NI-'^ V*6F&YA\
M/^I>OMF(=J>U7([W_K(STWW"\@1UD,M[J/BPRU^;2YW>GNH)Z*(_=6^?ZK>=
MESC]RYK&]T@ $G,6W<EC!JZ!)E%,@^&QTX]MV>FYXI+QUH^S!_[KS'M.R/J]
MQXH^"2 I=TB6$6HBSP:R>#B=L)0<NF4D2CXXA6C.7 K:Z2R67%IX)L=]HKU]
MK6FI?'@X1^[MU*)M)R$U&V==9*T2HNW4&F1-K6N; (K/GL$I 9#*9E)%)"^A
M L[ZI6?Y;PG<F4%6J3F!B296UYQDR(W.E>7+AERW:[+LEZ'=6)N)",CMTGT9
M%P2/D)7*?YLY[0\(-VAX7%8.7!X/,*P\;OS,M^9EOS,M^9EOS,M^9EOS,M^9
MEOS,I7(',@'V[H5&X#VNZ?8UK.QO"Y,=J&@T8.4Y&$JM:-?'_'R_#RX9_P")
M/L:DG,MZ&1K0^I>OMF(=J>U7!_UN;M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2
MMKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5
MM<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2M
MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M
M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MK
MB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2MKB5M<2LF3"GD]PQPPS846])O\
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M +F( N8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"YB +F(
MN8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"Y
MB *;W($2",PBY B/QGF( N8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"YB
M +F( N8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"YB +F(
MN8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"Y
MB *X\\&2D, NJ$&@^8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"YB +F(
MN8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"Y
MB +F( N8@"YB +F( N8@"YB +F( N8@"YB +F( N8@"YB +F( I5+V!B;<Q
M%S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7
M,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q
M %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$
M7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<
MQ %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$
M 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!
M<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S
M$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0
M!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %
MS$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,
M0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q
M%S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7
M,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q %S$ 7,0!<Q
M %S$ 7,0!<Q %S$ 4FNB%+1];/.K"$'\<-CGUL<^MCGUL<^MCGUL<^MCGUL<
M^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCG
MUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^
MMCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^LT)/
MY<,L)/YL-CGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCG
MUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^
MMCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUL<^MCGUGA1[)AA"#^.&QS
MZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?
M6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZ
MV.?6QSZV.?6QSZV.?6QSZV.?6,+/9<VQSZV.?6QSZV.?6QSZV.?6QSZV.?6Q
MSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.
M?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QS
MZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?
M6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZ
MV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6
MQSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV
M.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6Q
MSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.
M?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QS
MZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?
M6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZ
MV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6QSZV.?6
MQSZV.?6QSZV.?6,(/Y<-GG?_ /"\<RS_ .U*3R5K%A80I@:$RR39XM1HULCB
MBB+S </A\NI3!E]>G-J-28^!>;41$G^:O7IMJ(<RU.M<DVHYYE],J_P%C(E)
MZ<L%[@88F9A*Z<0'L'>#]C\N./X80V:4IC3^<J_P%C(E)Z<L%_/)3N2-AH\9
MRR /X[@88F5CC^&$-FM*8Y/&G-J-29>!>;41$GF$KIQ >P=8/V*F$KIQ <Q>
M97H\2?8G,WTF$LU63R:8CHI2PO*VRH*<9R%C()9MPKX2R34XF+AL[;3'.I;*
M:$2&0Z7TI@TR3:CGF4MFU&)N/"8S&E#VU&I\:BGL@8,"/UG5?I6T.EU*8,_H
M;@88F?\ MH\6R P]IQ^?,,E1BL!"2P"=>"8'V<7&TC RTQBKF9J3]M62]"KS
ML6T-5;TA\E<&>92)CX'KHA@;D%=(.;=N'%-I0>7D#4*\:G8J4YCQNA'19*Z@
M4<UC5RA4E<DKPA6+J.2AA*6=8@W%WCQO.'PKB2[0XR,GPK*4R:4-(HR-W4#!
MJL9N,)D[AZ]H#FKJ\HBG4C=R!$E<W.DC42$M7,F+5ED/A<TU(D6PEI6O0(R5
M8Y+ALII'Y:RC;HO=P*,=1B<#)9X2$]0C0T04HFAI>?# IQ,IP*.L04F$5(T-
MFK!I<&ZQ&D7A&%SQ$?$QJXPF3N?"0RD=&&]*] G-59$FQ8?:^3#XP,:WG#5J
M[=Q3=4)+<(3&*HV[X9XXRYL,^62S87%4TO*'K5I.XINH;9KM(M/AHDO))2UB
MP\M=02-KQF?BI34QQPRX%+NA6#B.W)#R-Q)R#$4$CS]F1"4;I ZHMK><-6KN
MR[=J(&S5@TN"+(TBX['_ $PA1X,<IUYV+:&JMZ0^2N#/,I$QJOJ V\M6](?)
M7!GF4B8F3X5E*;U]M9;H"00R,S\5*:DR,"P@V0RM@#C5KIDQCU,T=91]GS2)
M^("D+"1M#\M91QVYN^&H$I-/Q46J-+QAZU:A7IN:*G1_;D:MF%TB*Y(4])7"
MKMZ3JA;#_P!"<S0)A((W;"0XG8RKR=HQ/_ZG+%<7-C));9'T;(?"YIK>7U//
MGPIY2%X S1S<J6#Y4"8?8Y\WP\A6:L'L_ R!M(A92[H5@XCMR0\C<>!.9#Q)
MUY>8,W<X3\+B":WG#5W-*IEK4Y)<41&:PZ[X9XXR9\M3))YX+BN:C=,0:;62
M]$DLT%Q7*UO*'K5FSJD];NY^*8EH[<T=)"L@N6&C[EK>814KN3#9L'&S5@TN
M"Q,-GXE[>(,WKQF="I5C_P!KWF=XT(M$6V#2+J[O9D#[.0O'3+TJ3]M62]")
MB*1V\=42RK,;/X8M#:GA6H&B=I8ZV:1^;P6C+J5UW3IN.  &D='75#Y #VXC
MK!];>TP!JTC5V!%+"5L@C$>/MG2P'STB#IR&\%48TK,;?_FC<_FO[L7K[:@4
M?:AXY<5C1#S>:1;/+AK,M'(JPEA<20FT\RX8Q"T63+L]O^^-RL]0_,F QJ,9
MS%GD@TYO?ACFK!(^S CG+*D#O$I$+P- K-DL7$?D%"I(JQ:3_EMW%Q.FVGLW
MA^,1"9,O,EZL/PC,!CS0+';D,J(B:^ UKDFUTGPQJ18PJ'UH>SL['VI1[<<4
MV?Q*!%\["V5MR(-I4E\@BDD"V@,YWD9MNQIRZ2R( WD8G)':T6MV#GN,;AMN
M8BU%#[U]M02.MP$>NR-RA']TC^>E#('&VP !=V.T-+DI3.:M#;GL2S@!J3?7
M($MGT2M15S5X4$R9>9,,/PPS_HL=]N3$4CMXZHEE68V?PQ:&R@>D>O%G%,ZC
M&T.&+(]-?W8O7VU!(XV 1^ZPS(!)7@<8.X>/RX9H;9+)ES"C=+>5U,K%OE:T
M*&$(NK>_#',X%PX2,8YB=.'W,?$XU<$;'@F2.B5>QQFSX4*.5O14]G^G*W4-
MQBPY6PQT^;J\G:,J$XN;9A#E,E'(30SE&-D?1F_[XWE]3N^5J#XO!8^W QZ\
MD=;LJC#[%2#)EPO#=PIG&1>!QML  7=CM#2XB4SFHTKF,,"EQ*85C1'VOCS9
M[*+KC6]>'1DOG'VLM" HN6LPC3:2!K0',]>-VN'Y),<F<=;R('97/A3 P\L)
M)28O*HB<8V8*9T2$4SMX:8-BUQCD7%0*K<.4QLL M/GQJPD)DR\R7H+5&HZ/
M2.)1P;/BPBF7;5\'3;_M:]+?&I&8O7P<QM7=[,@?9R9X=?>U2?MJR7H3;]\%
M:ONU7(8YR$,M03I/HA-9;DB NYU1PY:#W]$HRO02R5J<^:XL+96V[(NGW>H#
M^Y^).D+O3FS89,L*S;AN;-?W8O7VU'>W[L]RWE-.FM 7:B/LZ,]RC6<QG79]
MH<?QAK?]\9_FT&XM.IEK4[F5\L@F-Z?O5(?WC\'K_8DRAD:^/;&D8JF8Q)&V
M1G"K-=I!?]+S7K[:CO;]W.X?")U,(_=.I4RT:</FV:7Y['?;3GM"#L<Y.UEJ
MQ(,XQ+Q.+!1L$K!R8FT%? 47*$*0D<WE5670&VD1''8E;PU7BQR]?;44)TB\
M=O*]P=YKKAL].&Q M2,QR\):DUC)EAG&V8MSV)8[[:=]GVA[-"_Z7F6?]%CO
MMVW[X*U?=K;]\%:WO&:_NQ>OMJ*$Z1>.WD?8/*EW6_1PP;V=9#'_ &JM6RQF
M\*(5\LFN]>;U!-9"%FI25VJ#4A=H2;HC&5>JGC2KY,^%3)/IHZROH1;]O%Z?
MA;C#K+A*\G:,>'Y"UOF<FJB80R$:#!+(^C-_WQO+ZG>4?G=1J(%:1B-WM)TN
MF8?8J1?Z7BO.PSN8W$"U(S'+PEJ36,P9AG&Q)33]V%:3N.Z'8L=89R=HK,E:
M58%(2U((%LX*S9@%GG6 U](2=(.$LQ3^-'K;"!=<Q7@T9:T+?/@).JS_ 'ND
M1#.)!6^AS29-YP!C\7B=HNS O^EYKV,L_P"49$(L782BC#HJY;T\M)O_ -K2
MH-N"/VE*XNHXI='-U!@(O1 [YY3'L[3#ZKNJB;+4AL)B&SF-.#_#G"BL'VR6
M6.'XX$+68T2 VUV:J1*"FQEAEM>4%9HS;5L%?RH#N8'&PVW@DI@^Y2Z 0C0Y
M.6M>V-R&K;$RXIQV.,XP/-0?6)9-8GO :.:= /ED'W02EL1:2]@VMY(:%)]9
MYE4;O&60B/!6M<@#%.#_ ))Q((ZSDP^G;,V/R1&WS*+5)I!]WUD0@_7S'PF]
MO,DQ=,&>0>Q$6PHBI478:J*AL7VB)E5LL#ADO :IJ*CFG0#Y=!]TD?"7P1E+
M<,]LS;W(# -(Z,@\)V93.#-:$1"-[4#R&V% B1S6N)%J@X<W$LI7;IK(G>:V
M!0IFJQ]OA'(;%]HB9G :,MK7=I5J$.86Y>9&$6MQ0!OG+:D\;U+5NAKH-:VG
M2(RD#N8'' F@ H/"=F4SHO6@\0C>U0TJME@<,@1U42(QP_'"#0C9E.G!_ASA
M16#[9+4X/\.<*+0?;1@U!]8EDUB6\!M>V+IA5BMN* )]-8GO 8/9="-RVBJL
M2,JA[&6M,+:GLE&)PIA$:$S@^[G"E%MJ)LCGMF8*8!Q#4$/5R06)V*V\,X&H
MF\LW5>/^&*ZB%O*L6*R@QE @+2 \PR.*91C=H@(-T80[M@W=RY\VZUE"(=LU
MG3@_Y)Q,H/NURY;TWE#/:QX,=.;.TW;.A2^!04UMY3E;N.QK.,!5+5NAKH-:
MVG2(^!J#ZO+%$H/M8E* >Y 49";<!G[84GI+"UCTI79,J YI++<MY \;VR>/
MJ\(A^SF4LMRTDCJK;(T2R@0+..#J,'^%-Z]'(YHX6M?"'E&UV1UA#(OGB0N5
M6RP.&6D;R8QK+:XD)J1RV5$82_[8VLZ&37QFX4A(F ]A1%LOZ!<"*N)<)%M<
MS$9[(!BSJ-2;QE\:>2I]DR9:63_O_P#_Q  5$0$!                  "
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M_7Z!B;_H] ?P\DVY/2Z%I; *5. $0LC[1_AICO<^DF+1[X7Z7U7:O][\L?\
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M$SW?](B<_H] 1268PRT-WRE'9.*@(FI$-MUHJA-Y,?1/82=;[!24'HK]2/\
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M3Q?N)CO<^DF+1[X7Z7SRF7FGF <9#;A36+[[JWEY+SBKQA+;4],MH3D2EU0
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M^Y^GZFM'^W^J#_II_P"[JL?=^NY3^OT#$W_1Z ^KICO<^DF+1[X7Z7U7:O\
M>_+'[JSN^&_2$,]\#T5:I[LKU0_W17G@2P<N/-)+2KIQCB,)9=G)A,O>V3XF
M#DY,<--JM68FRX:X!TUH./+ E[U%8'6[G&DTI6$":#>M4JJI05V0Y(8:DT%$
MPK9*3?) 3 [Q3Z BTO[?ZHG?OCS"'?OI\\2O,OT3$EW,^>!WBGT!#\JX;NN
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MUIMQ#2=L6104XHDT\,N$CFI_VB62,I2L>,J$R<U,IF9XXB,(4X^+%")J5*L
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M[PDNW>D?"!:D\A*W"C"U6*W$\G+&L792@7B1A0"#[(EWF4WI91PB$JQ\Z?\
M?' FY5M P='@4)I5/^_-&%<3>:ETWC7)7>_WR1+6;*-H24T2;HILU?[$(<+6
M%>.QO4V:U>H0\VN6N/(RU[)/*#$K*KQJ:FT"O'LA$IW;U09^<1A&JT;;.0\I
M@RJ&5*:2;I4V@7(-HV>E*%A.$^C[%Q/MB?PC:5T*.R%>.'4(EB]-N*+CBD@;
M&N.GPC7,ND!U0JV[2B@>(PE#J JB%52H0B<=E0]-.)NMH2!0 ;_XP'%,T2NH
MQC9H/(839<K*D(OX)3XIC5D\,-3S+8:<*[B[HI>Q9?PC]I3J$N5K@TK[$ ;\
M"25+' +-Q*UI%WHAN9E4W)=XT*/LJB72MM-7$K25W17LC")&5E2EB]<PX Q\
MO+"9YIM+;H7=7=%+P,#6S1;P5&UU2!4T$*E&&%-S#,P;ZR@ &E0?G6?W='GA
MONZ?,KZK8^ZOS19O]S]/U-:/]O\ 5!_TT_\ =U6/N_7<I_7Z!B;_ */0'U=,
M=[GTDQ:/?"_2^J[5_O?ECY]I?V_U1._T>@F)=24[!DX1:N*).6X147#YHPSS
M.N)4,I46TBM1BAM4O8[N'!JFXV*^>)9#;#S+C1-<,D#+#LB]LBSL"#OH/^S$
MVX_E"EK4?Y1D_P!\L2TP\=DZ_>/.8EU6C)JFT%1":)!NF'')*R9A!I1:FFQD
MZ8DYIE"VTJ?9%%Y<1$2G=O5$N&NRN+3X:F"E0HH8B##!?Q ,J4:_9QGS1:'.
MCUQ.W]]5X<U(459%/**>:@AY2>Q)=(B5[CZS">ZJA!_\_P#5".[I\QB65<PC
M88-Y W^,0FY8SA77%1M/MC6HEIAET.!?TR0/7#!_D<])4)YX<[HF)KNWJ$6A
MWPYZ1^=9_=T>>&^[I\ROJMC[J_-%F_W/T_4UH_V_U0?]-/\ W=5C[OUW*?U^
M@8F_Z/0'U=,=[GTDQ:/?"_2^J[5_O?ECY\]KQ[ X2Y=V)-:7N+G@N/:W=<.5
M:Y4DGQ8*9%O"'>0TW@TPN9?.S5O#(D<4"0M(?1I%U+E+PN\1$&;EUH#N]=O*
M/@&] 6$EMAL4;0?/"'7579=8N.<T"5D7\*7%?2;$B@'/"5H-U:34'BC6]K)#
M:^$% W2>,$9(<39_TJU8[C=25'E)ABT)I5/\0EQ9X@#$NW*/X5:7+Q%Q0WN4
M0IA])<E%FNQRH,:[=+!=RF\E6/G&_"I*0!#*NS=(I>'$(M#G1ZX>E;5:2AZ7
M5=2XJNR'.(,I95%+NW4E":);$(?FG,&T$*%ZA/FAAR4=PJ$M72;I&.O+ 8FI
MG!.WR;MQ1\PA#A.P#MZO)6$LRLQA7,*%4N*&*AXQ!E)L$RU:I6G'<^$:_0MH
M/ WA2]B/W80TP"F4;-1>RJ/'#4J],W'PE8*;BCE)Y(!Y86Q*S.$=*TF[<4/.
M(?EYM6"0XJ\E=*BL7Y!3:IU;M]:D XQCK\ZS^[H\\-]W3YE?5;'W5^:+-_N?
MI^IK1_M_J@_Z:?\ NZK'W?KN4_K] Q-_T>@/JZ8[W/I)BT>^%^E]5VK_ 'OR
MQ_$3@FWPS?*;M037+$V\RJ^TM=4JX_X2S^[H\\-]W3YE?5;'W5^:+-_N?I^I
MK1_M_J@_Z:?^[JL?=^NY3^OT#$W_ $>@/JZ8[W/I)BT>^%^E]5VK_>_+'U;9
M_=T>>&^[I\ROJMC[J_-%F_W/T_4UH_V_U0?]-/\ W=5C[OUW*?U^@8F_Z/0'
MU=,=[GTDQ:/?"_2^J[5_O?ECZML_NZ//#?=T^97U6Q]U?FBS?[GZ?J:T?[?Z
MH/\ II_[NJTA3E%!./8F-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4
MQMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-
MM\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMO
MBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4
MQMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF)>8F)C!LIO55<4>">2)
MB8EYC",JNT5<4.".2-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMO
MBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4
MQMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-
MM\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4P\[-S.";4R4@X-1QU'$(G
M'FG[S;CRE)-PY*QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4Q
MMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M
M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOB
MF-M\4QMOBF-M\4QMOBF-M\4Q/R;TW<F'<)<3@EFM44&]&V^*8VWQ3&V^*8VW
MQ3&V^*8VWQ3&V^*8VWQ3&V^*8VWQ3&V^*8VWQ3&V^*8VWQ3&V^*8VWQ3&V^*
M8VWQ3&V^*8VWQ3&V^*8VWQ3&V^*8VWQ3&V^*8VWQ3&V^*8VWQ3&V^*8VWQ3&
MV^*8VWQ3&V^*8VWQ3&V^*8VWQ3&V^*8VWQ3&V^*8VWQ3&V^*8VWQ3&V^*8VW
MQ3$F\Z_=;;=2I1N')6$,RL[A' Z%4P2QBH>,1MOBF-M\4QMOBF-M\4QMOBF-
MM\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMO
MBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4
MQMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4QMOBF-M\4PU,3,Q@V@E557%'
M>YHDM9S>%P=^]]&H4K3C$;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;X
MIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,
M;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;
M?%,;;XIB=UY-X+"7+OT2C6E>(0?I?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;
MXIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%
M,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC
M;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;
MXIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%
M,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC
M;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;XIC;?%,;;
MXIC;?%,;;XIAU"7*J(Q;$ZMG34Q(E;[K(4M6&6*GIC<XZ=SWHW..G<]Z-SCI
MW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<
M]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SW
MHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C
M<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-S
MCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..
MG<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=
MSWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHG)R3D\%,-W+J\
M*LY5@;YB3G)R3PLPY?O+PJQD61O&-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<X
MZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCI
MW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<
M]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SW
MHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C
M<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z)>
M8L^5P#JY@(*L(I6*ZKC/)%FS+\B5O/2[:UJPRQ4E./?C<XZ=SWHW..G<]Z-S
MCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..
MG<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=
MSWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/
M>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z
M-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>C<XZ=SWHW..G<]Z-SCIW/>BR+.EI?!R
M;^!PC=]1K5P@XZ\4;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T
M;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N
M<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQ
MT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3
MN>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y
M[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO
M1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&
MYQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G
M'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=
M.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[
MGO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>
M]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T
M;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N
M<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQ
MT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3
MN>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y
M[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO
M1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&
MYQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G
M'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=
M.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[
MGO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>
M]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T
M;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N
M<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQ
MT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3
MN>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1N<=.Y[T;G'3N>]&YQT[GO1:,U+R
M);?:9*D*PRS0].K9'>Z?KNT.=O\ ,3%G\[GYBOJZ4[['H+BQ^]&O1'U78/\
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MSY,+7)H-$JI=0/ !0=,2;EMRDO),WS@FVC55:;^,Q)JEG0S.RNR;*LAK2H_
M12T[+U\PC*[<_4C%TPZ)9G6DRC9.,'S@[\6W-V5(-S\T7%AS"GL05\XXH_\
M#TKUO_?%J:_D]:-/W5(%X$5Q\1Y=62[Z_2J)3N*/-%DI<%4X(*\("R/Q&I;;
M36)M:7"H#G2?/!.5BR9?P7S_ /\ 7BZG['L).N[56;A4@5#9]9\T*GIU>N;6
M?[-PFMRN4#EY=2UE(RX CIQ&&%)&R<<<4OGK3S 1:J7!4!DJ'.,8B>"LB&GT
MIYHE5)&R=6XI?/>(\P$+4KLD/(*>?)ZX^3843L[E[EHC%$LS+_)^5P#;:4HV
M6]3%PXE=<6&VPN7)*%LK%<?.KDBS2L47AQ4<MPQ)MI%$I90 /!%G4WVQZ"HL
M\2K"9J89;;++*^Q4:DQ_X>E>O_[XEK:GK+3)I5L7BVM-VER[]H\D6FMW&II"
MKE>9*?-J?*9IOL&W4I3S7G-25[\3Z"X_ZA?J@M6'8K<_.@E F0C&K[M!4PP]
M;,FB2DL+]&@) -ZAY;V2L,]U7YXE/O/>@J+.:'8*>*CX!\3"&;.L!4Y+E:E8
M=+:S>/@C]HJL&:EGJ)VIA>4;\-J4+JBD$CBU#)29#EIK'.&1QGEY(%L6M>,H
M57P'.RF#[(G[O!+9\<1:Z=\*;/I1+#[,HGTEQ93:LJ91H'J")CNC?I1/]\?I
M$2LE*.*97-WBMQ.(W13%X:PQ.3ZWE3$RF^,&N@0-Z/V5AR[**F=;N(WC4T"J
M<>2+*^4+:2=8.7)@#_@JQ$^" I)"DG&"-^)ZU4+=,Q.)2E:5$71=%,6+DA<I
M+"].SYUJRCE5E/@%8E9%O&EAL(KQ\O[BU^]U:MD=[IU1W!/G,-/70JX:T,$W
M9G'Q+$3#C"'74W:/M.8R4\8C!2RDR<I="EOKVQ5>2/HY779_XDR3ZHG7+EQ+
MF"N\1RY(O-.*0>2%O3:,$MJGTK?^9R4XX;PX<0Y=HAADTN)Y8O!$R2.-8AUZ
MZ$WU7J#>A7=U>8?,M#[[?H)A4Y.7@R"$[ 5..-?E]8;*RVENY](HCB'AA$J@
MO2SRS1 F$@!1XJ@F%2]YZ;6DT499((!YR1"GI!V_=Q+0H44CG$:QFR]AZ [!
M%1CA4L5NS;J#1>MD@A)YR1#MHIFPVPSM@=%%).\*>R,$==-)K3#+;%W\#7\(
M2\A06TI-X*3C!$)DI0O%Y0*MFW08H<G9N]@$$ W!4XS2'G9$N%+2KJL(FD+L
MO".)F$+6VHK11 *:UQ^""TG7,R :81EL7?Q(@34B\'FJT.\4GB(A4S./IEV$
MY5+BX&YQQ/\ Q$MBGI5@NR$P';O9)R*3SC^%M#G;_,3%G\[GYBM68FWMK807
M%>"+5GP+ZVTJFWNMC\_X1-V2XK9-'#-?=/9?C3IB>4P2DJNH4H;R2H ^SPQ,
M"UEI7,@C!,..7 H<?+"7;!E,'.)5C9#FQ6G^HQ,25J-8- 7>9%\*Q'*,7^\<
M9HYIE>V$6<M),H9TLW:\&]3+"'$RK@4@WA],K5,E?V"7TR;?\N.A_&L"=L]I
M3+C"DAPE95?!Q=-:0Y*NJO*DW+J:_8.,>N E]:L#,/*R;S2:FG0(DYRSFBPV
MM>"<1>*A6E0<?,8:>KA)MA"FL>^4]C^%(6W:A+HP:GKA53"*J/:3$G^SDX##
M(*ELA5;M,A\/JBS'9BN'7+H*R<I-/X>4[['H+BQ^]&O1'U6WW@GTU?ZN7W=7
MF'\;9'WG?TPCF&I:_>R_-#'=7//%G=W/HPY+R@*W@E"PV.'2F*)>SYYMZ6F)
M8%!2ENM['$O:"9!V5L9E>#:6\**<4K?YL463;-BOO+EVTI<=8:.):<1!(&4<
M<7W&9IMZF-D(!Q\]8M/Y0NRID9>9O!IHBE;R@?5#]MR\LJ:LJ;J7@C@UQGFQ
MXQ!%G2\P_.K%&VUHH >7'YH<?MJ9?<??-4,OJJ6T^TZLEWU^E42G<4>:))RS
MV\-.-L)<0W]J[>)'0#!*92:U]DULI.17/%I?*.V 69F:"EW5"A2CLE$\7PBU
M+9='TMH32E> ?$F F65<FII6#2L<$;Y_WQP2;->F)]S;)B\.@<D ?LU_KC4F
M91W:WVRV?"(?LBVI5TR965LS#0J/!QCS1^Q?D_*/O8<C"NJ33%ZN<Q.2 5?4
MU*+O*&^HXS"6K2EGC9KRRIB9;36AWTQ+658\NZB00Y?>F710?[R\\)LV4HER
M5"3+U_E%*=$-V9;TK,RTW*IP=ZYV0&2L2S5B&:L^RV3]+,=C7CKZA$AWS^DQ
M+=R3YHLWN8]!42-OV4@NS<G2\VD5) -0:;^_%Z9EYEF: V3*4@X^0UA^V)E;
M\G9'^5*E6Q7BH,7XUXX9^5-GL&99I29;3O8J'P$;_' :LJ3FIFTG=BVR49%<
ML?*!M_;DJ;"^>JZZDKWXGT%P\W6[?><37BQ""N;D[SC8+:VU8J@[Z3 F6K.7
M+61**J7%8ZJ.++&"!V;+Z@H<^.%/KE[STLZOZ->*\#4>8PS,H:2S/!:G6VZX
MJ@D4KRB'K,G;/4Z@**@VLX-:#T9(+LD^[)22EB_07FFD^$9=2=GZ5++=4@[Z
ML@_&#-OTF75+PB\+C"SRP$I1)I2,0 :/M@&>NI<G6W$*+8Q#9* /X")A#\I>
MOBZI"\27!O*28UTZU<ERH85:>P;0-ZO'  % -Z)CNC?I1/\ ?'Z1#$Q)HPLS
M*$_1#*M)RTY<4?LUV13,%FJ6RM104<A&_";:FT$2R'M<+=(H%KK4!/AA2%I"
MT*%"DY#"6VT!MM(HE*10 :C;JFD*=;K<64XTURT/[FU^]U:MD=[IU1W!/G.H
M$C*<4-2<NNZI.S=6G?,7 HJ^TM600,,5/JXR:1=E9AQ%WL6UFJ86P^FXXF%H
M:(HKC%<<&9..:E]L/VD\>JKNZO,/F6A]]OT$P]W5'GB<G9]D3(:4&VVU=CQD
MP\S)HP+*D)<"!P8*%RJ5SAEKYF#V5^[7%#R =BN654>%,*[@B%(7*I7-F6OJ
MF#V5^[6HAB5F:F6 +CB0:7J;T2$Q(RR94J46UA&0XL42MXUNX1(YKQAGN2_-
M$Y]YOTQ%I=V3YHFI.\4!^T5ME0W@7#6)U4M))9>EF2XAT$WL6/'QQ:;-=@II
M*J<H/QC]G))P,M=;0C>*R*D_C3P0F7?EM<OW=F^5D$GDXH+3;I4AAT)5_.TJ
MAQ^ PTQ.X:^XF^,&BN*&)-C7&&>5=3>;H//_  =H<[?YB8L_G<_,5JL6<A7T
MDVJJ_N)^-.B)AR<G)5#LZHA3;CJ0;@Q4(ZW3"5H>#LNP^6U.(-0MHXJ]&.'9
M9](=EWDW5#C$*59CB)UC>0LW'!ZH2%+G)).\EW&V>G%#F%0&IUBF$2G(:Y%#
M4:_^I'T]1IB=PU]Q-\8-%<4,2;&N,,\JZF\W0>>$7LO[4/YD6G_;_,3%O4^R
MU^N)/[CGH&)?OQ/H+B===5<:1-+45'>%Q%8=5\G9$RI)*\2Z?UG[,2S_ ,H)
M/]H(4;VS=J':?S>HQ+SDJ:L.IO)]G\/*=]CT%Q8_>C7HCZK;[P3Z:O\ 5R^[
MJ\P^I,(IEM2_M%(KJX3 -X3[5T5U;Z&6T*^TE(!^?A<$C"?;NXX*5 *2<1!@
M(;0EM R)2*#YUU:0M/$H5BZVA+:>)(I%K][+\T,I6D+27%XE"N_%U"0A/$D4
MU/I6D.4^VFL!*0$I&\/FWU,MJ7]HI%=4J;:0A1RE*:5^:,*VARGVTUB@%!Q:
M@PC2'*9+R:ZGTK2'/OIK 2D!*1O#YUUQ"7$\2A6 E"0E(WA\V\XPVXKC4@']
M]:_>ZM6R.]TZH[@GSF*NW=D"D*4F\$GCA+X2&GVOI%MC(NF,%,.NEM>R43DA
MI5-F[LB=67G$BBZW5:F!+:\&^DI5BY*QLPA4SE6I8JAH>V'7&4W6R<6*D*[N
MKS#YEH??;]!,/=U1YXGN^?TB#W!'KA?>WZ85WLOSB%=P1"^]SZ,'O9?G$6=W
M<^C$N.-3GI&)=R=5@&Q?:6I7!--_PQ^SY2;:FWWEI)P"KP2D8\9$6EW9/FC_
M .Z+],Q;'>COHF+0[@/2A4Z!]',77FU;U0 "/P_&$S3D\W+*NU6RYV:3Q4W_
M  05L-JP<P\#]UM-!4^ 0S,3;TPTMI%P!E20,O*#$O.LS,XIUA5](6I-/1_@
M[0YV_P Q,6?SN?F*U5,RYO)+HE&.*E:5Z:F-UT:#XQ+OJF1-M.J*"I*+MT[W
MKZ(9F)":>9F[-7@YC K*5%L#+T7>@PY)6W-.UOWVYEVJ_P"DQ-24L\)Y]\70
M$I-$\M8M&=H0Q<#0/&K+_OGU&O\ ZD?3U&9B;>F&EM(N ,J2!EY08EYUF9G%
M.L*OI"U)IZ,+FE(-P329Q/\ ,";WM$:TD9M$RY,J35*."D&N/BR")B;6FFNG
M=CRI3B\]83KH%#4L^IM1IP""+W0:Q)24C,HFJ.89:F\@Q4'G,3$LE)$S.,.N
MA'WAL>D4B91/+$NB8;NAU>1)!R&)&3DGT32FU%Q;C9JD<E8LY#P*5J"G*'>"
ME$C\/X>4[['H+BQ^]&O1'U6WW@GTU?ZN7W=7F'UW0BHBB4A(XA]8VOWNK5LC
MO=.J.X)\YA+;:;RU9!#+ ?(UM52ICBQ=@F&'S,3+R70K8*R<6/'""FB5(-TI
MXM67E =F3>(Y(;=4F^$FM(E;LY--F:"E) X-*\L:U0[5147$.#(_S\L%*A10
MWH5W=7F'S'K1??G$O.D$I;6F[B%/L\D*D9I;B&E*"JM$ XN<0[+R;CSB'%X0
MEX@FM*;P$:]FGYIMVZ$494D#%SI,&7J;A1<KOTI&O95Z:<=N%%'E)(H>9(@S
MLT_--NW0BC*D@8N=)@L5-PHN<M(U[*O33CMPHH\I)%#S)$,LSCCS:6E7Q@"!
MYP8;D)9;BV4$D%T@JQFN]"YL+=DWW#5>"I=4>.D3,K],M;Z;JIDJ%\"M=CBH
M,D/LR;C[B757CAR#Y@(_; ?F]<X<S%TK3<O$U^SDB9DW2I+;[:FU%&6A%(>?
MDWIEQ3J+APZDD?@!!EIYA+[67'E!XP8JB=FT-_9V)_&D*1(LT4KLW5FJU>'^
M%M#G;_,3%G\[GYBM1QN^IN\DIOHRCE$-3[#LTZ\W6Z'E)*<8IO)U')&;OAI1
M!O-]DDCBB8UH_,NI? "VWU)*?P A3K!>D%*X+)%SH,!3\W,S ' Q)!AN6E&4
ML,([%"=1-JI?G#,!_#W2M-V]6OV?F):G6S>1V#K9HM$!;\S,S*!_EDA(//2$
M--(#;2!=2A(H (2N:2IJ82*!]DT53B/'"7GW'IZZ:AMR@1X1OZBIGZ22F%XU
M*8I11XR(2^^MV?4G&$.T".C?_B)3OL>@N+'[T:]$:J;,L^45:-IG_+&1/$,6
M4\D895@LEO[ ;->B]6')5QDR5H-BJF5'+S>SYDG826&BP\D*+AK>&(^R+,EY
M23$RW,JHXLI4;F,<7/JR]@!AK6[B;Q=QWNP*O5J3$Q9\KKR;1=N,T)O;(5R<
MD$GY,D ?^2Y"S)6&W-!'9%I"U4_&$L6E8AD9:Z3A<&L8_#_$M]X)]-7^KE]W
M5YA_'+G9C9<%#8RK5Q1+VBEHL!V]L":THHCU?-EK!,JI2WTWL-?Q#+O>"+.E
M52JGS.*NA072[C ]?S+.E52JGS.*NA072[C ]?S[1E$RJF#)JNE176]C(]7S
M;.E52JGS.*NA072[C ]<+FIUX,,)RJ,2\VU7!/MI<3>RT(K];6OWNK5LCO=.
MJ.X)\YA2UMEQ*DE) -#$NJF"EFS0-C>&_$S)?YB3AV/Y@<=/QC"-8T'LT'?@
M%TJ97O@B"),*>=Y<0A<P^J\M4(:1E48F)A.U2C>!:Y5[_K@M.HPTN36Y6E#Q
MB''[MR]O0KNZO,/JRT.=O\Q,6?SN?F*^KI3OL>@N+'[T:]$:MJO6N"AM\KP;
MUVMT*-4GHQ1>DYQF9'_EK!ANWVIHL+3V3*6^S-*''7?$!^8JXZO$TRG*L^R-
M>,_)QK6AV02JN$(ZU?PAQ&#,K/,[9+J/XB+*[F/,J+*E6I=#R9Q5U2E'L<8'
MKA<[-$W1L4H3E6KB$:^E/DZVJSSC )-]0Y,>/HBS9U#2V*H*5M+RI4&U5&J]
M]PQ:W=&_,=2<L(RZ$M,)*@Z#C.3VP^\!4MMJ73F$/S3S"&%-O%JZ@UW@?7%H
MR8LW7$ZV_@95AFM7,:JD\U!TPRJW;$0Q)NFEYK+TU(KR0XGY,63^T)=HT5-O
M8D*/)C$/V7:,IK&T6@3=%:&F44.0P'YBKCJ\33*<JS[(UXS\G&M:'9!*JX0C
MK5_"'$8,RL\SMDNH_B(LQA3*%2\R?I7%5JA-14CIB5N6"4V5,N!*75(7V/VK
MV2)B5^35E)GDL&BIAX[$_B//#$I\I;*$B'C0/M'8C\37I_=M]X)]-7^KE]W5
MYA_#:V5.-!ZM+M[?^>MQQ00V@7E*.0"+6MHE3=D6<@HE4_\ $5Q_[Y(L[^Y^
M8K4J<0A<K9%FS%LN(REG$/!B,?LZ;E'K*GSB2T_OGBYXLKN8\RHLV7F9'72Y
MI5$+Q;#&./GAF9=87,!QS!T0:;U8=9LJRYFV T:+=:Q(Z:&%RZ6URDX@7BRY
MCJ.0Q9LO,R.NES2J(7BV&,<?/#LW-NAEAL54HPM=G?)Z=GI5.5X5]23"];WF
MIAO;&'.R'+RB$2JD.3D\O)+L#'X8"Y[Y,SLI+G_,63ZTB&IV37?97QXB#Q&/
ME-W3]:M1V8?6&F6DWEK.\(4;+^3T[:$NDTPR:CS),+E0VY)SJ!4L/?C2+-EY
MF1UTN:51"\6PQCCYX_9>LWKI*'==4^CW\7/$K(&SYB6$M*-C#N#8.4 &*#9\
ME*O6M.I-%-L9 >*O'")2U[-F+%<7V)?['PXA2')E]P-L-IOJ6=X0HV7\GIVT
M)=)IADU'F287*AMR3G4"I8>_&FH230#?A<K9%FS-LK1E4SB'@Q$P)">E7K)G
M5&B4/Y">*L.S[C2GDH(%Q)H<9I#2+*LJ:M:8+27'$,Y&ZC)4 P9!^7=LVT1_
MD/[_ "<\.S4VZ&6&Q52S"U6;\GIV?EDG&\*^I)A:&+S$TWC7+N]D.7EBSI68
M:)$XJF%O );Q@5/3#B[.L6;GY1&69QI3YC#BI:\T\UMC+F4<O*/J2U^]U:MD
M=[IU1W!/G.IV)B7UZAS"A5UD-FBEB'66B;J>/>U,/APM2:7T7>QKJ32@A3CJ
M4]BD\'?B71*))DLH5OE7+'8G45W=7F'U9:'.W^8F+/YW/S%?5TIWV/07%C]Z
M->B-4MOAB>P?";7LD>$9(OV=:+TLL8P'1>_$4B6L>VWC-R<P0E#BE7J5- H*
MR^ Q94F_LF&DIV!R9"O4DU2^P$TD%Q(W[P(/FK%E=S'F5'R:[I^M,?)ZSU[0
MXO9?U* @)2 E(Q #>B2+8"<,@ND#CP:AZM5[[ABUNZ-^8ZEK=S5YD1.]P7Z,
M3G?9]!,?*%XBJVU+"3Q5</LA9(R/H(BR4H% 9=*_"<9\\)IBO-X]#%E2;^R8
M:2G8')D*]235+[ 3207$C?O @^:L?)]E78N$H/A4F E(HD"@ B;1+R'[1LQQ
M5Z^$DXN/%V)YX98MJS\ I*MCK@!QM)Y_A N]CO4_=-]X)]-7^KE]W5YA_"O!
MHT=*#</+O06EH4'JT*2,=8DT3&W):2%5^<S\EI%]+-\UG'R:!"<M/]\@B=D)
M)YG!ML74I"P2<<6<SA487Z387MEV:M[4M!39NK< :KR*-#^%8DUH2 [,C"N+
MWU<7X1)S3RW6'Y;L7&" H[XWHLKN8\RH^37=/UIB1[Y_28D99E 0E+2:TWS3
M&8E"T+F%3>53?);5'R:[I^M,6)9B576WW"I7/B \YAJ6ET!MEI-U*1#MN,K=
M;F'*WFDD!LU&/>\,.VU/3RA:#X-&UF_3E"0*CBB:DI>6FIY3S2D4#6+)$X-X
M39]!,?*;NGZU:D_)2VWN)!2..B@:?A#-D6M9CS"I?8WFQ0Y=])C]L2+M^U$C
ML;Q0K)2MW?Q1\FNZ?K3![NCUPQ--FCC5F(*#Q'!BD/F;9F%S[R]DZA .QWA6
ML.RJ&)G70HIE:VQL3T\4"6;5>F[F#34]E<7B'0*0S9%K68\PJ7V-YL4.7?28
M_;$B[?M1([&\4*R4K=W\6I-X,W5/%+->0G'^$2);0 Y,(#SB]]1/PA,_= F9
M9Q-'-^Z<5(8F73>=<0S>/&;PK$A@T@+F&P^XK?458XLFV)?Z.;;=NWQOTQI]
M<6-+54B7=J^X!X*><PU+2\M-M,M)NI2&DXO&BR[4LE#K%]:$3 6D)O5-">@Q
M8#!Q!PJ1TJ3#;#* VTV+J4)R 1;3#(N-8-S8C)E2?J2U^]U:MD=[IU1W!/G,
M81Q)4+I&+*.6$H$U,U4:=BCW8><#A6^7<'A3E":0$3Z2'!DF$9?# ,I,,S"?
MOA)Z#%H2S=TNIP505 9*Q6=FT)_D9-\GPB U(HULT,=>$KGA$SA52Z5,85P-
M@8S>IOQ77$RKDNHQ_A#KJ$8-*U5">*%=W5YA]66ASM_F)BS^=S\Q7U=*=]CT
M%Q8_>C7HC5FD/2ZWK(FSL5(WQO4Y17)%_7;B5?\ #+*J^:D2+DK+K:LN1(*G
M%\5:])XHL[Y3RC1=0Q1+P&]0[_.#2-<&>P9IC94@WQR0Y\HE,J:L^7Q-7]_%
M0#UQ97<QYE1\FNZ?K3$G:LDDJ?D%7E!.6[Q^ B$OS$UK1\)^D84DD@\G'$C/
MEI;++H5@ O+<#:@#Y]5[[ABUNZ-^8ZCL_.(4)*:3M@%<12/,1#LC8ZU6C:$V
M@M-H:0=C4936)SOL^@F/E-W0_F*ASNR(L?O5OT8;[G_Z)BSOE/*-%U#%$O ;
MU#O\X-(UP9[!FF-E2#?')#GRB4RIJSY?$U?W\5 /7'R9[I^M,+"#=738D[QB
M<L_Y4.ZVFVW-BY@Z)YL737EB6E;*0F>M1;HHXRWCIQ5WXD)9XWGF6$-K/*$_
MNF^\$^FK_5R^[J\P_AL)@TX3[5,?SYB=?=FPZ\J\H(6FGHQ.SS#LV7F47DA:
MTTR_=BS;?OOZ]^DV-X7,JD9*<6I/2K(O/70M XRDUI#%GS,PW+3DK5!0ZJ[>
M%<5(L^RODX^W,3CB_I"D!:1R>LQ9-<9P2?15'R:[I^M,2/?/Z3$MW)/FBS>Y
MCT%1\FNZ?K3%G6LPF]K)S9\@-*'I'XPB:1/,-"[5:'7 E2.0P[+V<L+L-A/T
MB[F7%O'E/FBU_P#XAP:G[Z\$B:["M[EY,D33$LJ7UT\V6VI>6I4DXL@B>3OB
M:KXJ8^4W=/UJU)B>DV$S#K.R*%_9WS#*YXR1?N_32[]-BK?H%;T62CY-T("T
M*>P"JH&/9>+'R:[I^M,+/$\@F&[)EIMI<T;.#2FPK9((33&.>'[#M6Y)S;+I
MNX?%7C37CKYX_P (J5G)]1%QD;(#C*J0+5U@T)X(#CDMCHE-?9CAE<\9(OW?
MII=^FQ5OT"MZ+)1\FZ$!:%/8!54#'LO%U)R783??31U"1OD')T5B7D)F9;EI
MR53@RAU5V\!D(AFP[-<$[-/NIOA@W@.(<]81)'&IE+*%4XZBL2LH],M2\W*H
MP2D.JNU R$>"+,L*RUB9"%DNNMXTCP\@K%F6I*HJ)%5U0XABNGI'XPB91,2S
M1ILVG5)2I!Y89LJQY67FY3_.F:9/M$'B]<?)KNGZTZEL]S7^CZDM?O=6K9'>
MZ=4=P3YSJ-*.0*!@"^DEQ[""Z:XJ:C;_ /GN)OX178M)X^>,'+_1/#L7G#MO
M(J!--I+:5JNJ;/!5J82^F@ERW2N.M_55W=7F'\!/S$JZIA]&#NN(-"/I$Q:2
MIV:=FBA: DNJK3$?XNT.=O\ ,3%G\[GYBM5R83CFG/HV$\:OA&LV[0<1;#U'
M%S+KA-U502*\V*%*/RD&Q%=N7[(F%RUO.,A@@'"NJQUYH2_:=LB=E;I!:PBC
MC\(C]GZ[=UC_ /+WMAM%<G/JVK9DE;+TFEI;BD@K-T &E/QC_P 4'K+B7_:T
MP+3L]TY<M>.AI4&'+36NLJEK"U&^-Z'9QFT/V-9H5=1@]_UGGB6EK=F!:-ES
M!NIFZ;)'[ZS%V3,%F6;5_B$AV[>%1T[_ ,R2L%M"$2Q25.+RJ5]&H^")F50\
MN7<<3L'6U%)2K>.*'92=Q6G(*P+X.4\1_#\/W4IWV/07%C]Z->B-4M/M(>;.
M5#B;P,7_ -D2M?N8NB TPTAAH9$-IN@0014'>C"FR92]W(4Z(2AM"6T)Q!*1
M0"$S:Y1A4VGL7RV+X\,-N3,HQ,+:[!3K844\U=3#KLJ54[E)P0QPW-:S8URV
M+J'L&+Z1Q ZM#C$*$G*,2@5V08;"*]&I@IR6:F6_LNIO0HR<BQ+J5B*D(QGP
MP6Y269E6R;Q2RV$ GP0X[+RC##KO9K:;"2KGXXP4TPU,M9;CJ H=!A#32$M-
MH%$H0* "->ZT8UY_\Q@QA.+LLL$$5!WHPILF4O=R%.B$H;0EM"<02D4 AMR9
ME&)AQKL%NMA13S:@U[),3)&13B 2/#%Z2D&)=?VT(%[I_=M]X)]-7^KE]W5Y
MA_'.RDTC"R[HHM%2*]$-R<FU@99NMU%XFE37?U2_,2=U]79.-**">>"J1E V
MZK$75&\KI,-6JY+WI]H40[?5B\%:;\2S\[+X9V6-6E7U"[T'DA#-H,:X;0J^
MD7U)Q^ PE"11*10"&[67+UM!L42[?5B\%:;\2S\[+X9V6-6E7U"[T'DA2%I"
MT*%"DY#!<UFIJN,I;<(3T1K>1ET2[7$G?YSOQAIR5J_DPK:BE1Y^.,-*28P^
M\ZX2M0YJY(?_ &?+ZWPQ!6+ZB#TF)F8DI? O3)JZJ^HWM_?/+J4.,07=9%E1
MQD,K*1T0K6$HEE2L2G.R4?"8EGYV7PSLL:M*OJ%WH/)#DM,M)>8<%%(5D,+F
M9"74R\I-PG"*5B\)Y(PD[)I6]_Q4$I5TC+"7V9.^\G&E;RBNGJBAQB"[K(LJ
M.,AE92.B%:PE$LJ5B4YV2CX3JJ?F).Z^KLG&E%!//2,))2:4O?\ %6;RNDY(
MF_OM^D(LA^<E?I];I^E;44J//QPI,A*I9*NR7E4?"84A:0I*A0I.0P7-9EDG
M*&G"!T06[/E42X5V1&-2N<F)9^=E\,[+&K2KZA=Z#R:CUJ-2]V?>%%NWU8_!
M6F]]26OWNK5LCO=.J.X)\Y^:&"ZK!#@UU$I==4M*<@)^:KNZO,/F*LNRB$S"
M=M?I6Z?LB/VB7YZZ!?*-<5('W*Q^S;2NZ]I5MT"F$XQ3CBRM83;DKA,+?N;]
M+M//#7[.696590$*?PEQ3RP,9KEZ(;L^U'W7VB]@'FY@WE(-:5!@S-T.S"S<
M9;.^>7DAR<E9Q]#(-*H>P*:\0I";*MU:W6RY@E8;LVE<==\0@-)2[//UP259
M$C[1@S\M-36!/8E+^!2KF&*!9OR@*EMW\&I;HHXR>7C$6E_;_,3%J]T1YC"[
M*L(E 2O!%UL7EN+XDQ^T'YF<P2<:JS&%N\Z:F'&)E*6[09%57<CB?M"$V;9R
M@B:4F^Z]2MP;P'+";5;F'W4TPFMWWKY4G[A_[Q)I5-NM2K\RD&6KL0.*/\/:
M#R91Y(=:1P1QCI\\,3R31EUH.U.\*5A+;<^\W(%U3Q:&1+0WO,/#_!6ASM_F
M)BS^=S\Q6K95FG'+R/TBD_S4O^Z-1[[ABUNZ-^8ZG@__ (VK;;\Z^F79)=3>
M5QWA&ZK/X^R)&Q[%0N<5A;]\)(J:4Q5YS"Y-!OF6990JF^$E,6>&2/HP4+ W
ME5-8DV"1AUS-](WZ!)J?Q$64ZK&I4JW4\MT0XZOL$)*CS1-/R]HFQ+,;7<2&
MQLJ_[Y8:M!-N.6I*WPA27ZGI!)_ PS::OHF%L"8->"+M8F'Y2?78MDM*N)+?
M9'HRGPPIIRTE3\I,42W.?YC2JU_$ Q)6M-DS$PME% 3C<<,)M&9MURR6GMDT
MTP"-CO8@1BB7LZWW]?6?,;7-[XY:^<&)F8E'E,/I4BBTY>RB7?3:ALF22@-I
M6BN$>4!12S3EK$I9%K3AM&3FR$H<6:G&: U./+O18+4I-+8;?71Q*>%LDQ)R
MTA1,[.K*$.*X %/:(PZ?E6\9NE<%LL'7I]43<O:K#C,W+FZ'U-W0OU5%(8D3
M;!5:1143UW)]&3DYL4,,3<SKR80-F^12]#*D[%FTVP%CE.+TDCI_=2G?8]!<
M6/WHUZ(^JV^\$^FK_5R^[J\P_P! KDYQ!<8602D*IDAF4ETW6&DW4 FN+ZKM
M?O=6K9'>Z=43)FBP;@10(KZXW15HOC&Z*M%\8W15HOC&Z*M%\8W15HOC&Z*M
M%\8W15HOC&Z*M%\8W15HOC&Z*M%\8W15HOC&M4NE[9E=XBGS!KK_ /J9O7N.
M_B_'4;$IM8M%01=^Q?/JBQ?[WZ(LL#[!/C&)BG_S#7F3%CC@4=Z=C%EW,EQ7
M3>-8<2IZ3:G\5X%20YDQ<L,WNQUJF[UE19H9I@M;MW:<5T0G!TO&61A.>I]5
M(47=LUO+WJ\=Y$6S<[.\FG/0Q*X7&JZX4U^U=/QAX/TP)0;]>*F.)>YV.#<O
M\U/;2)S#]AA6ZU^S=3&+)"2S3!?M-5VG%?,"<0FKLDJ__0<2O4?!$_)W_P#$
MMKULW]US'[\3=J+&R>5@6_NC+^/F_@K0YV_S$Q9_.Y^8K5M2_EN*IT)U'ON&
M+6[HWYCJ>#_^-JVW+SS F&075W22,=X<4+1)L:QF:;!U*U$5Y03#OR?M&49E
M)X&XA]+825G[*CO\AAQEU(<:<24J2<A$.._)RV=:L.96W2<7GK"IZU9]=IVM
M,.I:2M78MIRF[T19;*L2D2S8//=$/3#RKC+22M:N("'3\G[+:1)I5=PTQE\]
M/!C@S%MVBPN7PB0)5@;_ $"!<R_LY'105_")6[EON7N>\?52)J]EOMW>>][*
MQ\EAP*"O/<_[Q+AO:\&F[3BI%G$[9AS3FNX_5!*^SHS7GJ(LFG_ $?)CNB?S
M!'R:[I^M,(:4Y@)ADWFG:5IQ@Q1AX6K+(X-<)B\.RZ(?DYJ6UI:# JI R$5H
M>;'O1)]S_P#15J?)HIVR^C\P?NI3OL>@N+'[T:]$?5=F,;TPRTR3Q!3IC/'N
M@1GCW0(SQ[H$9X]T",\>Z!&>/= C/'N@1GCW0(SQ[H$9X]T",\>Z!&>/= C/
M'N@1GCW0(SQ[H$9X]T",\>Z!&>/= C/'N@1GCW0(SQ[H$9X]T",\>Z!&>/=
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MGD\-83+2,HTZRXR%AU3:E$*J1QTWH3:]HLN(8:7AKSPH77-[\<=?X.T.=O\
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MA:6L:G)-Q5Y'+D$.6;:"K\VTF^V[ON)Y>6)8(<6@:S3B2:<-<602:DR;./\
MH$2!0M2#KC@FG!,56HJ.N%XR>:)^49>4%O6@MI%5D"I<H(SAG_\ (/L@,OON
MI6BBBPXY?;<3$O.HV+3S0=%=X$5AZSK*=$Q,N"XM]!V+8WZ'?,6K>43]&C*>
M4Q+-V-A,.EZ\O!O!O8T/*(R3?_YR??@68U.32YPKP=Q,R2*[^,&D(2K&0*'^
M'E.^QZ"XL?O1KT1]5M]X)]-7^FI3N2?-]8V3<6I%5.=B:?9@']O/XQ_P_P#W
M0JT[-MM]]#.-Q&-.+CI4@Q/3^UOZW<0X$[RP-[SPP5J*CA%XR>7]XN8FGD,,
MHRK6:"#*V<EQ%F(6+[]*856]S")3N2/-J3+R:%3;:EBO((G)N>>PSNNU ;P2
M+B<0^=,=S5YHGBM:EG7'"->"(M2<>G!,-S:B4(%=ALB?X*0*%J1_B.":<$P_
M.L7<.TP"F^*BN*)*:FW2],.%PJ6K?^D5_'VOWNK5LCO=.J.XI]?SFY=A-YQ9
MH(NBE0+SCAA:J_0HV+8Y/F*[NKS#ZLM#G;_,3%G\[GYBM5^1?Q!8V*_L*WC$
MW(8:B+]UU+:MBLI/XPB95=5-SJ0XI0QT3P4Q9<M78N.+</\ 2![T-N@;-]U:
MU'F-WU0MM:;R%BZH'?$5DI!B75]M*-ETY8E>\T^FN+'[S9] 1(=\?I,?]0OU
M1-3;@*D,6FIU03E(#M8Q24[T)]Z&C)R:KUP,M-#&:5RGIA-E)6+XE-;W]ZMV
ME8M2:>7KV>$NJCBA1*.8>N+5[FCSG44&579R:^B:/V?M*_WQPJUWD_XB:Q-5
MX+?Q/J_B)3OL>@N+'[T:]$?5;?>"?35_IJ4[DGS?5+CJ^Q0DJ,7T(:2Q7:B-
M[GAB90*)=2%4.]\ZR/O._IA(_:K.3EB:D9!_7DQ,HP>Q2;J0<N,Q:")A)0\\
MRZ\4'*FHQ?@!&"?M!V3L=E92EIG*XK*:],2,Y9\\\]).JHIIPY:;QWC$Q,RK
M"IIY+=YMI(J5'>@S_P I)^>:<<4;LJ-A<',<G-2)&<LVT'G9-U5%,N'+3>.\
M:Q9\I)OZTU\HA<P#2ZD4W][LOPC"MVO.&<(J)BHND\?'^,3,K;C:S@E?0/N*
M!*QO\O3QP[\G[,FE24C+5UP\C*:9?QQ4A4Q8UJSC=HH%X7UXEGBQ4I"]=9]*
MJN.XJ7N)7GZ-36DY?+%\+(0:5I%GRTFPB793-8D('\JHE.XH\VHX#,O2V "G
M?H32]1)Q'D@6H9R8:5+S=, A6P50)./IA^PK.FE2-G2M0^ZC*JF(_CBI"IFQ
M;4FV[00+POK[,\6*E(=1-Y_*D)<-*7AO'\#%IV=9LTMA4S]$5U-&D4221Q9(
M5,V9:DX+50+P<6OLSX,8B=1-XYZ424.'[0H:'S]$3_?/Z1'RD2XZM:4N&@4J
MM-F8M.S[-FE,+F?HKY)HTFB5%0Y<7XP]/2=K32[1907+SA[.GXB+\VO"3##A
M9+ARJQ @_C#OR?LR:5)2,M77#R,IIE_'%2%3%C6K.-VB@7A?7B6>+%2D+UUG
MTJJX[BI>XE>?HU+">EEJ"D57<!Q*(4G+$G:T[;+BYP.!U]"0<?\ +>K#OR?L
MR:5)2,M77#R,IIE_'%2%3%C6K.-VB@7A?7B6>+%2D.:ZSZ55<=H.RXCY^B)^
M8M.TWF66E?1R;*J71$I,?)R8F9^7*OI95Q8_'>A];:E-+OMXTFARQ92EJ*E&
M734GFCY-(0ZM"%.(O)2J@/T@BS^^/TF!/&9>:,I+XFD'8KK3+$A;.O)B\H.#
M6U[Z/LE)BTK-FK1<DI&3*D(EFC0KNFGQAJ<^3,]-N.I6+S"E#'Y@>8Q+KF6L
M!,*0"XW6MU5,8_C+7[W5JV1WNG5'<4^OYW[0=3]([B17>$8)"BER8-VHXM_Y
MJN[J\P^K+0YV_P Q,6?SN?F*U=:RZZ3\T*)IE0G?5_OU1.6PTGZ&7.)%,;@X
M1'-'[#FE\:I91_%'KZ8D9Q(J)=TI5R!7_80NS[XUQ+.$W/Y#CKTUB8G7U!+;
M*+W/Q"-9.V?@G@@K+K:JHIS;T23F\J5">A2O;%DJ;4%!,LALTXTBA\T6:Q>&
M$+JEW>0#XPV3PWEJ'F]4.L.IOM.6L4+2=\%W'#CUD2VMIUH7@VDFCO)SPFS9
MP(3*/*NAR[13:N4\6I:_>ZHM7N:/.=1JS6CB:N2R/O*R^?\ "&9=H76FD!"1
MR#^(E.^QZ"XL?O1KT1_$2\@5$S3R2M*$BM$C?/%"!:$XEA:\:44*E'P"%*L^
M;1,7.R3C"AX#$TTTHX65<P;J%"A2?9_ -]X)]-7^FI3N2?-]4J0H52H4(C83
ME):N0IV0$-,-"C;:0E/SK(^\[^F$DV8*T_XSGO0'9:S64.)R+5LR.F+7[V7Y
MH8[JYYXL[NY]&%3[B<)@VTW4?:4<@A,\FTF;+DW>P0A..G)BKTF))V=MA^U)
MAY:A]+6B0.+&8EY*T7T,N*I@%7PE=[)BKE@JL2VK[8R-%117P8TQ-V1:[01:
M$L";P%*T-#7EQ[T6Y+RMK.63,H<65%%:KV>/?$?^,)KH5[T3[K=KLVIA[M[!
M;Q%<N,\>K)=]?I5$IW%'FU)_N"_1,3??BO01'RC9<SB]DYEJKYQJ?*-YK:"K
M%3E6JD6P%95,D)YZ(]5=3Y5OM[00:>$KI$_WS^D1\I^Z'\Q46GW,^BF)KN2O
M-$]WU^E,6Y+RMK.63,H<65%%:KV>/?$?^,)KH5[T3[K=KLVIA[M[!;Q%<N,\
M>I\F@<F$_6G4MR7E;6<LF90XLJ**U7L\>^(_\8370KWHM!]%L,6D'@+Y;IL:
M5QG&8=M"PK4$J[?-X-*OH"^<'8PT[//IM*S[UVJE7_Q[(1KMK:W\"XFO$2#%
MD=[ICY,IWPML_P#[L6?WQ^DQ/=[)]46;_<_,5#TY9]HIEK030NX(A8KO$@'$
M<4&:,\FT9!OLKRL( .6N,>")6T$HP>&3C1Q$&A\W\9:_>ZM6R.]TZH[BGU_-
M981V3BJ"&V6TW4(% (;92JJ6T8QQ'YJN[J\P^9:24NK2GZ/$%?\ EIBH?:)Y
M)@P)>>4\I">SE9A5X%/\I]8AB;EU7F7D!:3^]9D9$);<>;OF8.,IQTQ"++==
M47'%RK2E*5E)NCYDL$.+0-9IQ)-.&N+/)QG6[?HC^"M#G;_,3%G\[GYBM12@
MDK(%0D;\&:M"4ULV\NA7AD*#2.0 PS)RZ+C#2;B4PJ8L*7ORUX.M%+J4%H\6
M,[T!BV9,-.NMW'V;P(KQBG3&N+%=5,-@U0MMS!NH_P!\D(;G4S"T)WYI[8IY
M<L*3?P\X]MKOJ')"$!89FV22RX<G*#R0M$FW,MI)QZU>%U7+E@.VF5LI/9/S
M3EY5.05K$O)2XHRRFZ*^>/VCK'_!_M+#X3"H[#"5K2M<FIKZQI<.IF-D\U?2
MFZOCQG?AIBV9<LS;.PO%:581.\<1BT9661A'W62E":TJ8M!=HRNMTNH2$?2)
M57+Q'4_:DS)4DM>+>PF%0<53=Q5KQ?Q,IWV/07%C]Z->B-6UK,D+8=E0TXXI
M(4X0D)"J4Q<\8OE(GPO+]D,V1\HU)F&7B E_%BKB"@=\<_[AYJR7<#.DINK"
M[N_CQQ*-3Z\).); =5>K4\_SI.:EY@IL=*1A6L+2IQ[W1\RU[>7C,P_@&?Y6
MD9(M"V'7=<S$S=#=Y&TI&\/PB7-G@5EY90GUMY#EH#RUN_[$6//(Q-6D#)/C
MC/ /X_P#?>"?35_IJ4[DGS?6-G"SI;7!:4N_LTII6G&82#EIJ6C*RZ,(^ZPI
M"$UI4TAJ4GFL#,!:R47@K?Y(DVK.E]<.-NWE"^E-!3E,+LXJP3I2DI4<@4(1
M9G[#1.H:V+3N$&3GK";0FRT[/7@E$@RH!+2-_&3EK2+.F6/\):\HD$)4KFJF
MHY=^ PNP&79@8L-7$>7LJ1.6M:KB7+4FZU",B 34P+?^3KB4SG^:PHTO^K'Q
M0J3;L=N16X+JY@*I3FJ84T5AV;>-YYP9.0#D&K*L6>QKAU#]\IOI3BNGC,2[
M:Q1:6TI(\&H\R30.(*.F!9Z9)IZS7)@*==O ['$"H8^*/V_\G%IUTK;991I?
MX^3'"I%%DM6;A!=<F+U*#DQQK<+PLPX;[SO&>3DBTOV8\&)YGZ9HJR&B4XH5
M9XLIF0+@N.3(5O<F/S5AR2:.&F' 5..9+RJ>:)MFT)?6[BWKR1?2K%0<1BW9
MJ<E\"Q,K):5?2;VS)WC$]:SDO=D'$$)=OIQXD[U:[T3"$"JE-J '@B:8M!C6
M[JW[Z1?2K%='$8%O_)UQ*9S_ #6%&E_U8^*%2;=CMR*W!=7,!5*<U3"FBL.S
M;QO/.#)R <@U+#F)*7PS,LNKJKZ1=V0.^=06_P#)UQ*9S_-84:7_ %8^*%2;
M=CMR*W!=7,!5*<U3#DNX4OS$QC?6,A_E')$S^QF$6I9CRKV#4<8_'+#,K/RC
M5CV:E=]9K51_&%V,@X)L-);:5]F[2[YH%F-66S/,H/T3A54#PWABYXLBUIRD
MW,F82Y,A"TA+"$J30#CW\D2;5G2^N'$/7E"^E-!3E,3%G5#;KK%P$Y JD2UE
M3D@A-DH*ZO522G*<6/CY-^)FU/DZVW-RTR:N2JCDW^3P4@V<NS&;*E'",*ZI
M6]T^J):SV3>0RFEX[YRD]/\ &6OWNK5LCO=.J.XI]>IDC)&2&:_Y0+G1J3Q&
M/9QDC)&345W=7F'S+3_M_E)U+-FJ?2)<4W7D(KZH=?F%?0R2W:_= O>N'&4S
M& ED[/!WC@VD^LQ+.M3N%EW,ETG!JIE2I,3=HRY+>%DU+%#C2:8QTP_9$A,.
M*,S13BEN'$E-=_BV7FCY2+G'J.*;HU@G24T^U_OBB8LJ0G5,H=HX^^M9JE(W
MJ^&&;D\<(I.$0\T3LN0B#:LS/-R[*ZZWEC6[T;W/#=DO.K7+/7DX-9K<4 3B
MZ(9EK%EY@MK!+S\OV7W1OQKUR<;3-W,)@%5O<U>.'++F7UORY:*V\(:E!%,G
M)"A.OI?+]YUNZLJNI*CBQPBT)J:;=DYF43@FTN*)36Z1B(ID@V39#CB);"8)
M"630O'C)XH5:34TA:VA?6)9Q06GEY8<L^?5?G&DWT._\1/+RQ*]YI]-<2T\H
M7UB7;2VC[2RG%#[RYOZ%!V2W5$-IY$I$,_XFK*\:;JBIESC!$(M<?1LX,N.#
M[%.R'X09=MTH:-5):O4;:1QF'0F?UU9LQ]$NZ3]&=X\G/%O2KTPZ<)=0%E9J
MG$<8C6$Z\X<->EU)<63=6,GXBGA@,-+*'YMP(!2:$)&,^KIAV?F77'%32]AA
M%$[!.+SU_<VASM_F)BS^=S\Q7U=*=]CT%Q8_>C7HC5MU;SJ&4_3"\M5!M@BI
MGY4#E>3%DR%EK$R6S=+S>3&<?0!%GV!9+B9::FP%*F%<$$D#S&')N5^4\Q-S
M#8OX!=:'D%21^$)>M"67+3:%7%7D%%_^81,2%@S&L+.E\2YH95<M>7> @VE+
M6XY:S+6R>:?!.+F).*/V@R,&NXH+1]A8$+L^3GU-EM>$>G%KND @74U&/>5$
MVJ<M-3UH)?3<>2JM$7@,IQ\<2]JS95,.)EL(KC68-HN6TJR)1:B&FY=)]1'G
MB37-6FJUK.>50X6I/+ER'PP9IA(4^ZL--7L@)!-?PAJ=>^53[#[J0L--UN"O
M,0/PB=LFVVENJE^PG,'L58\E=_C$679[<TM$FXA)6R,A[*+/L"R7$RTU-@*5
M,*X()('F,.3<K\IYB;F&Q?P"ZT/(*DC\(*YZ77+3@JV;R"B_BQ*$,HR+;=<2
MH<M8-@6,ZAB8I_BIY9Q,#B'\W^^82LFZAQU>R<=*P5NJXS'R:83MJ[101X,O
MG_@&^\$^FK_34IW)/F_T5/VFN6*9%Q!"7JBAV*?K>U^]U:MD=[IU1W%/KB58
M<,OAPFAOM[_1 4B6EU).^$",T8T8@DRK '<Q%I.-TN K NY,NI:JGVT.Y.S3
M7?,9HQHQ&:,:,1>F4RK8^X(P<C@L/A =@W3%"N[J\P^9:?\ ;_*3J6?9Z%!3
MJ27G .#O#UQ.XB%OH6_3^6H]0B;18]HIL]U*05WE$7AX!#3-I_*"3<3>JVA]
MY67DV,6A(3+C;JT,.F\T24T-3%HKWPP!XWPBUNX&+6/\C?G,69W)7GBR.]D>
M:&.^7?,J&[/LZZF94B^MY0K=X@!&'MBWE,,J1?+(458N48A">X+]42/>WZC%
MF!&)1D6J:,1*A[8J(6A-[>52'W7R RA!4NO%3'#!1V*&G"OFI3SD1*]YI]-<
M6&H=@DM7M&8<;01A$3"KX\ I$@T2,,J8O)'\H2:^<1:HH?I$OE'*+OP,3;2B
M XY+[#EH16)M#A%]Y2$-CC-X'S Q:WWV_,8:M*7V F*/H/$XG+ZCX8LYB2V:
M,$VE"?YUT)\X'@B6DVMK8;#8\'[FT.=O\Q,6?SN?F*^KI3OL>@N+'[T:]$:M
MMR<VMU#25O.59(!K?'&.6-OGC_<3[L%4C+775"A=6;RX8F6)C6EH,"B'-XC+
M2*K M:61_=]BXM!UMK6\XPV0ML&N.Z:$=$3Y&V:XQ\UT4]<30<VO!*O5XJ1;
M X&$-.>Y_P!HM%6^7P/%B;^^WZ0B0GIDG!-2R3093Q",/9-FRTI)$[!UX^TX
M^B)-VW+1:FKZR$,LB@1BYA&L7U%%:*0X,J%<<!%G3B9^51V+=X'%]U63P0;'
MM:3UE:(!I0$ T%:4.3%CBQ^YI_7#$RQ,:TM!@40YO$9:158%K2R/[OL7#KF"
MP$RP0'6ZU&/(1^,3\@122M(F;ECO!S_,3ZX=F'[/OO.J*UJP[F,G+PH:G).1
MP4PW6ZO"K-,5-\P9PBLC9"2RT=Y;Y[+H&+G_ (!OO!/IJ_TU*=R3YO\ D#:_
M>ZM6R.]TZH[BGUPPXI"D/+1V85OQ@Y8:\E,O'0>J*?LH5YS[(^EK)2AQ\6+U
MQ-2)55*0H G?U)MRS7PRIM6RJHB]CB@9O\MP1@7/\,D\*EWS1A;3F5S+ARI!
M]<!V69N+PB4UK"N[J\P^9/3DG(X:6<N75X5 K1"1OGDBA=GZ<MHCWX$Q;;R4
M-5O*:2N\M?.=Z-;8-. N8/![UW)2#.?)]9>;X"D*%\#B4#EAI=K_ $#:,6$>
MN@(&_1(B9L>SF[Y$LIIM)(%X_$Q/.6C*ZW2XVD).$2JN/D,6A*RR,(^ZT4H3
M4"I\,6BJT976X=2@(^D2JM*\1B1<LZ5UPEMM04<(E-,?*8LZ6F$8-]IA*%IK
M6AI#5H3$E<E \XLN85!Q$*IBK7?ANTK-2'7@C!N,5H33(1";+F%F2DKN#6\[
M="KO%BQF$/NR=Z2%]LOAU'8[RJ5KQ1*3EGMX=QI);6U6AIE!'XQ@[52\BS6I
M?!M(<4G8FHIBRY*PY:5B$7UJPBI>]=(5QI,"1FA,*E]_"K2E/A._"RM8?GGM
ML<&0#[(AB9L^3UPRF62V581"<=Y1WSRPU9<\F@,NA"J94J &3F,+<LA:GD'%
MA9=0V0Y4F$S%N.*8;R%QY0*J<24C)#<HR@-RS*+H!XH,Y\G'DOL7K[8;>"5M
M>&)RUOE!.K<=8"0RP7+^5:0:[W1%JG>PB/,8<F%$)<E%I<23RFA'X_A!G%BK
M4DB]_6<0]?1^ZM#G;_,3%G\[GYBM5^><V2AL6T?;7O"&'+5?+TZ]]*H$ 7*Y
M$_.F9]Q"G$,)O%*<IB7M%;09+Q7L$FM*+(]46HBU6BB20HZV)0!47CZM6V;/
MF74JEI;"8-(0!2CE!%F?L]U+>'PE^\@*R7:>?YDG9]C/)4G#)2^_0*"L?8CV
MZDTF4LUE<J'5!I1NXT5Q<+BAR8F+/EFF6Q>4M5W$.M$W,6@VVF720EI:$7;Q
MX7JBTK*LIYGZ!:[J5H3V(-,L=G*>)#,O\I9)&MW/\UL8Z<8IB/-"5I-Y*A4$
M;\3<ZDC# 76J_;.3V^"'[.MA2<.IE+S&P"<5*^8@ZDH9IXN6)/C!B\!] YS\
M7QXOWTIWV/07%C]Z->B-6VIIV3?:EG,-<>6T0A6S&0ZLE\H+'2J96P*.2PQ^
M&F_4&D%J7^3,YKTX@E0)2#T1-3$_1,Y.J"E-_8 K[3$U,V;)*M.QYDU+3>5/
MLIQPNS+*L.9E0^+CK[V\G?%:4$&12<*\4J6XI/"61O?@(GD3DJ]*K4_4)>;*
M"=CRQ-,RS#DP\5(HVTDJ5V0WA$K9H0IF=2RA0;=%W9#>,,V5._)Z=6]+BX@M
M(.R'1#5I/V:MAAM6#9D&P5N@'*LCP");6M]F<0E+H97L"K%C0>7V0B6M+Y.S
MCDX@7;Z$D7^7)"_E-:DJ;/0D49EU=EV-WS194VB4?7*H0F\^ELE [+?B2^4%
MCI5,K8%')88_#3?J#2"U+_)F<UZ<02H$I!Z(FIB?V,Y.*"E-C@ 5_'&?X1OO
M!/IJ_P!-2G<D^;_1<[.RB@B8:N7217*M(]<6@JT'$N%I2 FZ@)RUU&)F0<#;
MJID-DJ2%8KJCZHUW.K#CV&4BH33%B^9+61(,E;*BL.3#F+(DG8CP;_S2I1NI
M&,DP96P9;85HA6#PCCG+2$M6U*WT<)MQG!.4XQ#<\VX-:K;PH6?LPJ7L"7HW
MP+K6$=7RTA%FVXTE!6K!AVY<4A7$H:AEY1U)M5SL4Y<&.,Q-O6@\'G&WKB2$
M!.*G)"IQU.%63<;:KV2H<F9*7)ET9<!*WDCPXX_9\^VAN<NWFUMY'*913C_C
MK7[W5JV1WNG5'<4^N)+[GS&;8L]%]Q'9I$:VEI$HF'-C4&L%3^</&\KD^9_>
M3ZX5W=7F'\:MM8JA8ND0)JR4*F4MJJT^S0FG*F$RDW*NABM;JD):3SF-:80*
MF7"7'7$Y+W)S0B3G9:8<;2JMW!I;17CKB@,.%*YMU6$>4G)7B\'[JT.=O\Q,
M6?SN?F*U;&L3++2_TKJ>,TO'Q0.F%+6;J4BI)WHF!\GFV)*195=UQ,#&?/YH
M:F+55+6E)*5=*D #P8@*=$3%JR9QZUUPT5#DJ(:9LIAE+[==<SKHHD&IH .:
MD2S'RB#4S)OG;FP!BWR*4R<1$.F34S^S\&==!?9'&*4B0)5+_L.CE$_YE;RO
MU1;4I-*06959#=U-.$1J_*/G>_-BQ.=[]&K+RDO/&28OU?(KLT\5-^/DW+R2
M#LG"5N*QJ6;R,NK*_):171I*@J96./+^ _&&9261@V&4W4B+<6\ZAE'TPO+5
M0=F(S^6TR8D;,L]Q,],X:\2QLJ8J7:\M?PB0EG<;C+"&U<X2!%D?)QA6(J#C
MM-ZOL34^&+%M^41=0W1E:4_RY!X4U'@AI]I5YIU(6E7&#$\*56PG7"#Q7<OX
M5B2?<-YY P+AY4_"G[V4[['H+BQ^]&O1'U6WW@GTU?Z:E.Y)\WUBTU+MI=GG
M\:0OL4)XS'[00EW6EV_42R*7>/)6D.R,\V@32$81+K>(+&_4<>.&I616VEI4
MNEPWT5QWE#U0N8L*0<:D&_\ .#(6I?'E\PANS+4N.*=K@WTINFN6ABS=8*;3
MA\)?OHO9+M//#2;$D5*4VV-<3(:K5=,=*XA#5GVS1U#CF!*RW<6VK)CIRP_.
M32[C#*;RC"F;$EL$G>0TUA5TXS6!+V]+%Q/#"FL&Z!QC>B;M21<2NDLIYI>]
MV-1$XU/*;4AIL*3<13?B5?D5(2XX]<-]-<5##<Y.%)>*U)V(H,43C$S<<D&'
MW48-"-D0*A(KT1^T%2RK/D2<0UN"!Q5KCA]$RA+<Y+TO7,BP=^/V?9Z$.SH%
M7%N=BWR4XX$],MN)E/\ S95(3X<586I2 S.,XG6QDY".2%698#06M*L'AKE]
M2U<21#1MF6PK*^"ZT$5YE)WX9GY=7T#B;VRX/&#&M/D^BZW>NMJ#=]QWEH8F
MK*^4$D4F9"<%,7+N,+!WL1R1:WWV_,=25[\3Z"X_ZA?JA5G?)YH&BBA*PB^M
MP\8Y(:5::=@O(E]A(2KPIANU[&EE*G%D# I;PA&RHK%#4S9S2G;0!5=;2W?.
M0UV/-6&[6MQ"F9D)-]JY<43>( IT0ZJQV+C*. RT%4YU*WX395NLAI]2L&EV
M[<(7Q*&I,2BU*0A]M3:E(R@$4Q0]-2[SKZUHN#"TV(BSY1!"IED*4Y3@@TH/
MP@)75+JF*>!QSW51:TR1LP&VP>3&3YA"7$"Z7I=#A(XZE/Z1&N+/PFOWY9M:
M,%V554B9M:U'ZSA6FC(5>I4XRH\<3_?'Z1#3DJA3RY9R^IM.4II#4C.81J8E
MRK$A%<)4D^O?A5L(8+,DVXXZ3O556B1T_P =:_>ZM6R.]TZH[BGUQ)?<^;V(
MZ/F_WD^N%=W5YA]66ASM_F)BS^=S\Q6K::EY4H53H2(<+UW A)OW\E-^L.RO
MR7^3BIED*J5M(N)KQT \\*7:DA+R$AA$[%)JLG>WS'_VL>A#9 QK>63YO5%F
MG?PY\T6AW >J+-_N?F*CY3]T/YBH6E/R9=4D$@' NXXF%VE9RK.6VH!*5(4F
M\/#'RCYWOS8L3G>_1\SY-=T/I(U)N=7V+#:G*<=-Z+0MV9V<Q-.% 4>E1\)\
MVI;4G.%Q+04ZY]$:&MX>V%FS)E],T!5*7U I5R9,4+D9BSD2MN-5 <74E5,M
M*]B>:''7%76VTE2E'>$3WR@8L68M4N%24X-*B&Z\H!X.*'I!WY)3K5ZBDN!#
MAND;_80J1<55Z25=_H.3UB)Y)R%A8/5B=3P1-8NJG][*=]CT%Q8_>C7HCZK;
M[P3Z:O\ 34IW)/F^L6VIV31:,RX*HEU)!Q<9KDBEEV*W*2BD[%PHQ7>0JQ?A
M">X+]42_>:?37%FMH%$IEV_1A"4X@FT%@=8Q8O\ >_1%FW12\E2SRF\8F+N+
M_$-'\$Q*MIQ(<F1>ZIAU](&&=?5?5OXJ4'^^.)"9H,.F8P8._=*23YA%K)7D
M;1,)1S7:^<F+1[@/2B0'_P#<_I,,]U7YX+:Q>2;454'NABUP<?\ AEG\(M+N
M(\\?XC9!5I&H/W\0AV7F$!QAQ)2M)WQ$Z[9LFS+.!E1O-IV1H..!,R$@;2FD
MH51NZ54Y<7^\<&2F/DR\VF\%A:&%U!$?*!F:EGI5:4NJ;#J"DT*-Z)UQ0!<1
M+['DJ16)Q:P+S2VU(Y[X'F)BUOOM^8ZDKWXGT%Q_U"_5!:L.Q6Y^=!*!,A&-
M7W:"IAAZV9-$E)87Z- 2 ;U#RWLE89[JOSQ*?>>]!46<T.P4\5'P#XF$,V=8
M"IR7*U*PZ6UF\?!'[158,U+/43M3"\HWX;4H75%()'%J&2DR'+36.<,CC/+R
M0+8M:\90JO@.=E,'V1/W>"6SXXBUT[X4V?2B6'V91/I+BRFU94RC0/4$3'=&
M_2B?[X_2(E9*4<4RN;O%;B<1NBF+PUAB<GUO*F)E-\8-= @;T?LK#EV45,ZW
M<1O&IH%4X\G\=:_>ZM6R.]TZH[BGUPRZU:.#;4FH3Q1NI&ZD;J1NI&ZD;J1N
MI&ZD;J1AIN=P[5\"[RPKNZO,/JRT.=O\Q,6?SN?F*U9685B9GT 5Y2F[YP.F
M+0E&#1YYE24\_%#UE6K+O2DPVZ5$X/+S\L+79\B^BQI50<=F712^<@ITP5(-
M0+.*/"!0^:&.ZN>>+.[N?1B=8807'52^Q2,IWXD?DZXPZB:!<HO%=X2X^4_=
M#^8K5^4?.]^;%B_WOT1N;,=<1*R*)!YM3Z[@45#%J?)KNA])&H\@?Y[J&_QK
M^F+*; I5@.=;9>O4MSF>]-.HS\I;.JVZVI.&N;QX*_5T0VXPH(FIXX!QL<"G
M9^KK1),*%'EIPSGWE8_8/!J*1V$C/'P75^Q46H^33Z!2!SJV(\\-+4**F7%/
M>#(/-^]E.^QZ"XL?O1KT1]5M]X)]-7^FI3N2?-]8MVD$*7*+:""L<!0WC#=F
MV=9*EVFMO!7D*JD8J7@(1+S'T;A#C!!WE<7X1+]YI]-<2'>[?HB!_P#4G/2,
M6+_>_1%E=S]9B8[NSZ*8>DP0EX'"-*.0+'^R/##\G,21+:S53#VQQ\:3###$
MI1MOL6V^Q17A*5#EB-KJ5RZVRYQK4#4])AXOR9*[N"=8<V.+C!AFT79+6-E,
MN8-H$UOK._7?R0SW5?GC_P"Z+],Q;'>CGHF+2[@/2A=MR*%JEUN8?"-BN"<R
MX_#CAR13)M,O/)P:WD$FH.6@WHF)NT XV)A-QN6<WD[Y(Y8UXTR7)4*.#<(V
M#B#P2>.)>5LF6=D7;U?H5WUK/%DR1K:W7S,S,PA0=%!L4D4NXH+F"O#&@*4-
M@^C_ '2'L#(:TLV5&%?5>O5.]CI^$6M]]OS'4E>_$^@N'FZW;[SB:\6(05S<
MG><;!;6VK%4'?28$RU9RY:R)152XK'51Q98P0.S9?4%#GQPI]<O>>EG5_1KQ
M7@:CS&&9E#269X+4ZVW7%4$BE>40]9D[9ZG4!14&UG!K0>C)!=DGW9*24L7Z
M"\TTGPC+J3L_2I9;JD'?5D'XP9M^DRZI>$7A<86>6 E*)-*1B #1]L SUU+D
MZVXA1;&(;)0!_ 1,(?E+U\75(7B2X-Y23&NG6KDN5#"K3V#:!O5XX  H!O1,
M=T;]*)_OC](AB8DT869E"?HAE6DY:<N*/V:[(IF"S5+96HH*.0C?A-M3:")9
M#VN%ND4"UUJ GP_QUK][JU;([W3JI6U+NNHP*15"">.&)=RR)Q:VTTJE&*-Q
MI[J1N-/=2-QI[J1N-/=2-QI[J1N-/=2-QI[J1N-/=2-QI[J0F5:LJ::%Z\2M
MLPI+K:FE896)8IO#ZLM#G;_,3%G\[GYBM5,U* _M"05AFKN4\8]?@B6GD4JM
M.S3]E>^(!<90X1D*DU^=>NB]QT_A;/\ DQ*G$5:XG%C@(WO]_=AMEI-QMM(0
ME(W@/WLIWV/07%C]Z->B/JNQ6SV#B6$+'&"Z:B,P8ZL9@QU8S!CJQF#'5C,&
M.K&8,=6,P8ZL9@QU8S!CJQF#'5C,&.K&8,=6,P8ZL9@QU8S!CJQF#'5C,&.K
M&8,=6,P8ZL9@QU8S!CJQF#'5C,&.K&8,=6,P8ZL9@QU8S!CJQF#'5C,&.K&8
M,=6,P8ZL9@QU8S!CJQF#'5C,&.K&8,=6,P8ZL9@QU8S!CJQF#'5C,&.K&8,=
M6,P8ZL9@QU8S!CJQF#'5C,&.K&8,=6,P8ZL9@QU8S!CJQF#'5C,&.K&8,=6,
MP8ZL9@QU8S!CJQF#'5C,&.K&8,=6,P8ZL9@QU8S!CJQF#'5C,&.K&8,=6,P8
MZL9@QU8S!CJQF#'5C,&.K&8,=6,P8ZL9@QU8S!CJQF#'5C,&.K&8,=6,P8ZL
M9@QU8S!CJQF#'5C,&.K&8,=6,P8ZL9@QU8S!CJQF#'5C,&.K"4I%$@4 ^L:'
M&(.":0W7[":?N;KB$N)XE"L74("$\2134&$:0Y3)>37Y]]++:5_:"174H14'
M>,'!-(;KEN)IJ77$)6GB4*P$I2$I&\/FC"MH<I]M-8H!0<6H,(TARF2\FNI]
M*TAS[Z:P$I 2D;P^==<0EQ/$H5@)0D)2-X?-O.,-N*XU(!_C[7[W5JV1WNGZ
M[M#G;_,3%G\[GYBOF*##+;(4;Q#::5/'_&+>0RVAUSLUA.-7.?WTIWV/07%C
M]Z->B/JNP?\ I_SC_P V[7[W5JV1WNGZ[M#G;_,3%G\[GYBOJZ4[['H+BQ^]
M&O1'U78/_3_G'_FW:_>ZM60DW]<89EH(5=;Q5Z8[:T7QCMK1?&.VM%\8[:T7
MQCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.V
MM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7Q
MCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM
M%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QC
MMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%
M\8[:T7QB;D97#X=RY2^W08E \?)$I(S6'P[=^MQNHQJ)X^6.VM%\8[:T7QCM
MK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\
M8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK
M1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8
M[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1
M?&&):2PV$0^'#A$4%+JAZXL^4=USA6&$-JNMXJ@4XX[:T7QCMK1?&.VM%\8[
M:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?
M&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:
MT7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&
M.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8LNU9?"ZUEL%?O)HK8N%1
MCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM
M%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QC
MMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%
M\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCM
MK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\
M8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK
M1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8
M[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1
M?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[
M:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?
M&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:
MT7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&
M.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T
M7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.
MVM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7
MQCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.V
MM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7Q
MCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM
M%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QC
MMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%
M\8[:T7QCMK1?&.VM%\8[:T7QCMK1?&.VM%\8GY-C7&&>:*$WF\5>G4W'GO\
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MP#(JKP\43,JI+TD\MI01AP+JC3)6+0[X_2(3KQTEY0JEAH5682A^7FY5"O\
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M(10_X#'O2@,UMHS#[AA&HX)P](9M.B$L&N#_ !5@$2Q4T==$&$_%_.^OQO\
M!@U';:$-+FFJX.EZ7NL)Y:)Q](B8"$&!-Z*()6S[*EQQG'/+&D)C X1]!CW<
M2)X3C3P)S3^:?2,%*NA20+LGWNE,ZL<7AK&,4S9T 2K1V2:_[4H,$)QP.=(
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M_P#"&NAW)+^BYU-NV!02D 1>WZH0R$B;:<82EE.> ,'N3;A15BR*$D%PQBU
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MQHZ%H2QG#;+VJXB<BX2JX)^FDS+,N+*#/>],W/!I$:L[N.L^D@NEN\H!S&L
M1HH))Q;>F0.HP\T@<FBW)C]CY1&I1%23+:6[+0B+(<@$$_=7V]+MT*?#.1^E
M+5RR,V"35:=B=:8DPS)!$MI(<JO1P8<+X?DUWW7Z#(<G&!AXD<MZ'#(P'6'9
MBWL5$@%&."6#WH44R"8%[YL305<B$(FY7)IHC5?T9TVB2H:!G]_Q^#1^#_02
M0@,HB8)^Q[\&?-*%VPEO:U7S0DV0:M@*EFM^4X,CWUH7K/?"QP7^&APB"24H
M9-7'H[ ;R=;WXT$D@=-=CL].T:Z>+@ZK)[$Y34JY5AC]#:I,I."*0D9;XZ36
M/WXU\1^OHX'^7%8S-MR]M(K4K" Q;B)TJ+,[F;F^[1D10,0I-"%H*N1"$3<K
MDTT1JOZ,Z;1)4- S^Z'NI-G8.2IS3':AAO;"M5=;J%^3WH$$>LV \[.]0B')
M4+29CC2 "DL?JX_52VPP:"'[<OZ<'8=7].).\W:[WJKL>NL"N9SC!0*MTK6^
MP>XJYZK?:OC+5;*1$3(/1G:]Z 9!908+LRG*K0388V"23CKG5A"P@&QD>]26
M)R.NB\>U!5R(0B;E<FFB-5_1G3:)*AH&?W0]U)L[!R5.:8[4,-[85>1;X\'I
MZ./Q1,@9F[49[*@%VNM$)(6A\XR7,O\ P5*4(8P&$\97WKO-VN]ZJ['KKLFO
M_!P4D*&382^:\YH9;$!U:+&1EDAL_P!(B1BI,(N3O6I^/W10502B%@X>_P#
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MBW=Q,* 3Z10=<E?^*V$1.'H@S@(<1G3--LW+C'K'%X:76!H&80+@TE]!KXE
MR1RHTK0\-$6I(W*%@B)P];)0.0 X5"1ZXY' P]&^-7C5+&,!$X#*IA+KM DX
M?Q^#1^#_ $$8:*%EBR\)FC<P9:/T],-(C^84E$$#8;QC4<6AI=8&DJBBN1,+
MKT=C(XZ OI)FY0L$1.'IV!#8PIH:B>0N2R]JOJ_%9K"T0GY$#1BB'_"0-I:2
M Z40C3([6,7V4\-!>:8F&^+SI*@$+&]VF^-7C5+&,!$X#*IA+KM DX4D!THA
M&M@L3YE)?-3E6:M;STWU5O/#?532).>D1UJSX&-I3'S_ $X.PZOYN(>!"U8:
MM+^Z0:2T?!H/#8&G((E7%J_R )O8:>/R4#5<Z0HF*WN:T8![^'49+(S%C%DQ
M$94L(I<C42KB/F]W!?04'8,3P5JSV7(^KT;XU>-4L8P$3@,JF$NNT"3A20'2
MB$:V"Q/F5K!HEYNC>B'_  D#:7T"B]B*.$X4-S +V#+T/@T'AL#3D$2KBU?Y
M $WL-/'Y*!JN?^%@H<1RD&1'P5AH,_UB#,:% F#.5E\-,!V;5M'W4+N%D&Z2
M'V:(!#'A9;WTJ6QO'_(?JL6FC/))F5+I<6!=#5H\];;F2_502@D)UAIZ#.9S
M%WZH>=1"*(XG"]-P +;@LEP"*3:YB&?NZ45J_%2K!-*/<EMTGPM69I0K3],8
MF/O-&<#8$C^A\TO&#+P6_P!4V9="1SJVJF13HF3Z7>^:_P"GM^G\8Z[UKKX'
MX;^?1\_\+NGX_54>[B?,I6R2N5]_0 .2 9(<6]7HZ.\0M"1T@5@VFD5Q,+#E
MFFH8- HZPM/;*$ON:TZ><8#XA9I]QRMP"4\59"$5]R]% JDSC>&H1OR<8@E:
MW)XG\5@3;1>=8T*E;W?PGSOK\;_BQ[.0"1F@)P*:Q&WL_"_!H_!_'G!V'5^6
MP4(<$.7$+R7BAK](RV+RH,-M66"09!+CTKNVE-]FE%@UC/&D0^5V$R[VA[5$
MW<D22Z(B-JBNY,F3G1$ (UC&\/NIQ@3(S"[M44,:DK\15PL9>@S!Z?TAI([&
M *;Q-3QN."B#?.U"C7H['_I]!AXEHTN?T4[1TPS!5&<K2,V*D:2X1>,_>E#A
M2HTQ"#WH%CQ'NF 8-IITI=1\G7TN]\U_T]OT_C'7>M=? _#?SZ/G_P"M?.^O
MQOYOX-'X/X\X.PZOS."B[W;2G=-5)4L0#9C]G'4:.$;C#K%T[15^[BX&?BL6
MUTI;D8!@((<(:BL'E\;@,;[Q205=$5C.+^O09@_E_31*H8$V26:?Y"Y5-RL(
MP SQ+35[$;9X+#0PH=T.5')'6LI3P^Y:913W(+<,.OI=[YK_ *>WZ?QCKO6N
MO@?AOY]'S_\ 6OG?7XW\W\&C\'^XHCC,] F;X10M.E6A[5FD?PE--.K-7MH_
MNGR!QT2C?))5R%W3 8?WX.PZORN%I&CC(D8=ZC4=:D"3(9+ZH)X\VMT<J:*2
M35:M@8FQ-'4XU8*T>FCXI>A3++61X5=AHF#[TM#FWTJD=K=PXU<SCT\0$W8;
MU^WJ\C ZJF,2R2>!:IAW%BQA<&KQFEJ20V1,&I%D)9CP%7,X]/$!-V&]&$09
M$Q* H) ]='WIG79C/9+>]&DB" CNK-1QS!<&Z7I3(4Y&1F9%YJ=1UZ4!,ID%
M2H+A1*LO]/;]/]KI5MVA, N;A5OE^ZWHEJ?Q'<IJ-YF!"QBMRW.@^)$"1EO8
M_N@A(3[0&NE3#T!6 W?[.]:Z^!_5X;!#'NM3.+5OW11*"X38,F)-N5:D-*.+
MAP4J\*4 @X_V1:C7PEBJ$L-12MDG6A]MH['GA<9_J^?1\_\ UKYWU^-_-_!H
M_!_O/;;:^)0_AN8+4XD)$V#!GVBF0QA&@^XU%0[#A8Q1J25'?3$(@YK6K=A"
M2-=8UFQ&%3YHD&+ P,[T/1I0;)8O\4F3B#V)D>/Q1$S(ZN%X.M(BBG^^%11_
M,3X4^]!D)(VUD).-ZC]W87X8J^BP!4JZ UJS1>(F7"7S_?@[#J_UC#M^G^YU
MB785]RM]@IFSQ:SI]4!\;T0N_=&AT*G>I0>3R&D(C@LTLM.F44D.EG'K0J"W
MX4Q5R,N=3VZ02UM@?:K#R'+$BYXE#18;R9A=6V&M.&)%G#4,7*I&:,)+KO9J
MS>YQ Z5HK=0^C*3,<J+%((P&2;)?TN3KS69CKA>K=)922,OTKN.O]G>M=? _
MJT=-@$TPC_DXK6<N->RP,J I\JN\+)I(!+&S8J 4@DPEA99C"])I8($H9!N_
M=&QH$Q![@%2L 3<D),<RC( ^Q'E)R"3G110@Q?N4QQ)J<?CF8TY@]?= T#6B
M+C,'P8Q*IVJ=(RDA8QW"W/T2 5 4!1M"7M200J4!I/&IA%B:=#D</;^KY]'S
M_P#6OG?7XW\W\&C\'^\]MMKXE Y14B P8;4%0$ PZ20> RJ=0J1(M.!9ASPH
MW* [>WHT)*C9WUXVBB#'5E8.52*.U\*1/NARH("*;EA$KXZH0R_:7-#!RN+*
MS(MX(^:L6"\;9 VD7E4DFZ.&>)Y/)13(G.7?HP]@4B'%O[\'8=7^L8=OT_W.
ML=FLUF),I1SH(-^)I09!RS'W3X.94A+AMMUG&A.S^VF:NG2F 2V4M"(>%9.V
M"U]6N[:*()YE@@9;9&.=1! YD<9MP2HQ[*18DC)O\T569A47,C*?:A-O0D=8
M]J,WB:,F)&</KVS1KN.O]G>M=? _J\&H1R@S<:'=FD/6@$([(:RZ5\JN01@F
M@5-B'PH:,^ "P,L,7&U+0MS#?12FI2O9GB+X1C3E[<5"@,&&!?C08^^B?!/P
MIA&O./"7,WJWOKL8C)M*TM&!SADJ 3U=0-C*YZ@: 9:,>/MEQPT!TYC(V?/]
M7SZ/G_ZU\[Z_&_F_@T?@_P!Y[;;7Q*"/+@!-!S**B$E% WCV"]$4SF 56&*7
MXKVDO2TYVZ@C1.NJ$YH/>L;4HPKP9MBU)* :,*83BN%?'5 H"+4)/VH71*0,
MK(JL2/FHYA$N=$*](2Y%L3:<U.>#5EA4)P2XY_WX.PZO]8P[?I_N=8X/X<Y\
M%7>=:'["8$S9Q''6D42M[UUV8T*D *73 _5'FV$B;4NR/<M3/B)P@CA400DV
MN24LXA>GH&""#E9]#6&':(^J5>F8<#JEG>M/Z/7MFC7<=?[.]:Z^!_;@_*K^
M&]($OOE<62/%MQJ+^GXR"8CCA04I(I[ HEG3#D;(FT-.&]0"*U<>@/E04F9@
M1+<HM0:(R4:HUNVTJ&V!<#<7/:FOB+XZ&_N]M_0R(I>"G'R7V*5>0W<Z-L*\
M-_J?/H^?_K7SOK\;^;^#1^#_ 'F-9.8F#FFE-D=QTP8A:JAL>[AP=G"K;S&/
M":G$J:- C+8=IC-: #,CG$8>2U.\A'1 S&E 20"%I,ETJ>$X)9EY(TB:#]TN
M=X(?>E<8*6(L"8XS0L<^:"KA+EDZCLT82B"?7?%-QXM/7?%75=&1H&Q4_0:[
M#=1QEDUH=["I0699PG+^_!V'5^2PP9UMZ*[R4J ,]$J9ZB,VHX^Y4QV==HNY
MWC_2!00D:$=AQD9_\+&,&H0,K'/"@Z*[ "@/Y=OT_P"(Z.E."0E<>VI]$)$,
M$K?M:3T,(A@E!@482P_P>]:Z^!_@^!VY:'J1,\-Z.7JS!MQ\/[_GT?/_ -:^
M=]?C?S?P:/P?\<WK#-80/<6HW9"-?!3!S*:3MFMY8IG1 )$.&H3>=C_%P=AU
M?E,'B3 6C4(J/]T795_6L*$<$4D-1^XHF^;P?=U05HM:S>G$Z47( LEE\-F:
M1(N$93L'Y:.$.!R0@8T/DU-#)"6%>[V;U!BF"7L!]ZE,'P#+#[D-=IOHB /'
MTQU#*.-6VGG7 FYV36%OOQ!E8V7K!TU'"VNI H D\).%FPH*GL"#U[?)1[ ,
ME<*UI;*DT&['YJ.VA0AVH,P 1B+G.[/E4-R/$DD1KU5#X*"G%&9W''2@<II"
M6Q.4:F6 ;#&MLDVV:O=]@,C,U!'QWC,2S&[RHI[TB2+NXQ?>F\/!)9FRS62&
MLJ01EOK_ "[?I_&.N]:Z^!^&_GT?/_UKYWU^-_-_!H_!_'G!V'5^4P>)?#:"
MT"W-B@.B1: 0YR\J%* HL\C''VK$QT\I>T53!/@ &BZ5B034C'1RJRWG693G
M"2LQYGN$?*5A)#& U3'I5Q%0<;HVTO P82!DNE=IOI3X(R,OOT_AN8#1"\2\
ME\BNWZ5,0R2.:$4/B31L?V-9>O&DL4T>5+L.U(LW0SZ,*D*)&6,\RY0D@$6*
MY14"?A"D";LZ0ZR-0XX:N\Z_T;>.WZ?QCKO6NO@?AOY]'S_]:^=]?C?S?P:/
MP?QYP=AU?DL.IE^,#HJSL]CX@E=%)QQ+N;R'Z:+\V#A ;4RB9VXWQ32Z.!)Q
M$HH0F.1FMVW(I%""@L+!@T0^:5D#+/J+#%CE2+0CXHP:#,02H&Z?"H(/8"&2
M.XH4918H;@8P!\5D,[1)&12?NF=#4V[9/$R"5P;O9JU@J::!D<:[?I5[8;9Q
M-7V;4F*Y4UPG%X5.TPQ5+6"UE#Z3D<AK4=@RZL1="H(@%#<J+NJPU<D#,I(T
M9DDXB9YK5@1(G&& ?:CR=T,'(RVXM84]QRLN0S*!K #433#!1O<"F'@3P0A&
M,,J= '@G7%MBC_+M^G\8Z[UKKX'X;^?1\_\ UKYWU^-_-_!H_!_'G!V'5_H>
M"2AN!%V ZE"/B )"#7_$[?I_&.N]:Z^!^&_GT?/_ -:^=]?C?S?P:/P?QYP=
MAU?ZQAV_3^,==ZUU\#\-_/H^?_K7SOK\;^;^#1^#^/.#L.K_ %C#M^G\8Z[U
MKKX'X;^?1\__ %KYWU@YD#_PKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=
M[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?1
M7>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[W
MT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN
M]]%=[Z*6^'!20+$L6EOAQ4@&S+$KO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]
M]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHK
MO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z
M*[WT5WOHKO?17>^BN]]%*UN".7%S1IMD)K*:,)7>^BN]]%=[Z*[WT5WOHKO?
M17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[
MWT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^B
MN]]%=[Z*[WT5WOHKO?12^]%0+A#$KO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN
M]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOH
MKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[
MZ*[WT5WOHKO?17>^BEN2NL *P%*^=\-#,CJ5WOHKO?17>^BN]]%=[Z*[WT5W
MOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%
M=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?
M17>^BN]]%=[Z*[WT4UD9F1!8E4@G+><#1KO?17>^BN]]%=[Z*[WT5WOHKO?1
M7>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[W
MT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?104DG%
M9Q-2D,9^RU=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*
M[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^
MBN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5W
MOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%
M=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?
M17>^BN]]%=[Z*[WT5WOHKO?17>^BN]]%=[Z*[WT5WOHKO?17>^BI.9@_\/6Z
MB5J"[!$_-I$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$
MB1(D2)$B1(D2)$B1(O\ =A+)64P6E_NQE@K"8!^.2)$B1(D2)$B1(D2)$B1(
MD2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$C256G-(AC$582E3(J")=_%I$B1(D
M2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2-&XD3LDD&#_P=(D2)
M$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(
MD2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$
MB1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D_P!42)$B1(D2)$B1(D2)$B1(D2)$
MB1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D2)$B1(D
M2)$B1(D2)$B1(DM-A:C!AB^O:]/_ )QZ=+AHWO&GKVO3_P"9>G2X:-1]-2!$
MJM#.'P!"1HGFR%&"X@:O_!V&*=R#^GO&GKVO3U7P*,Y79TKR^OE]?+Z^7U\O
MKY?7R^OE]?+Z^7U\OJL@@@Y09QO_ ,'Z=+AK)K74=;^W^W,&#!@P8,&#!@P8
M,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!
M@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,$$+:PU&
M0-3_ #;B!,"$<>*HB,2=VCQRF<LZ?!6$-OE(R&$@2AD9V,0%C^VQR6P1C?9?
MQQI!I0Q$J%IS8,1*<3)ZO?V!W$J:1+,$8 E$TC<T@4CJ%Q0%/JX##*)0R3:2
M(<33_",R-Q)%PQ](9GL2;B'<4KLZ,8$+''^$QDTI6[BB_)G_ !&Z%0@ SH*5
M^=A9,(;0M2!:&(^$#F7I(X%B"$RZ1G3E14*E,UP&T6UJ)$<RE@P<3:8(SVJ
M8D :X\,,!UFK-@ *%R&M-=!-">4)R(%7:G/.\=X4+#>D$M@T*Y%A"^C#A%W6
M3@.(-FBF<P Q!F<0(-<&@L^3"LVT+#8*6]R?$XP>]&F$!X?M!/;^CO&GKVO3
M^341%!<&P?D]&2B(@.<BXTHGB^@:UH+!; 4"ZFY?T9&"6:FY''_X-0].EPTZ
MPN4 E7 I0*217W,44)0W $N/\N[:4[-I0/*GB3D;/LBB#1[L/VHL?Y%.R)MA
MLMC.'XBT) DW2%H3&Z5S 8&[1&%!T3&[/&H"KMBKD"28ND,7*:D.4PQ*C' C
M>E<(_:%9WO4V/0@F8 W+@F4;U!7Z%,A,1(3%U6#?*T+E\\<6QLM(7)*2CB3F
M7$='TL_#H).TQ7TM4*,/#YH&IES6N^::8"Z=UB<TI%&UXDQQ8MKJA+!,8L)K
MPPVR2K/M-J!?W5,:;U(@N6O\%2$ZS( 3O:HK6<=)(/$K0?1%YDH 8K5I6#78
ML$)R":.3)4/02!VN:T9C$F%B).E,W8#"K7#+DO#.)=@&ZEQ$W0=*EH@.);[A
M5*1M5;HCJMXP*5K8""+$HLBVDB'$TDC!X=UTH58&"]>S' -W&CX7 G8(73(:
M&]30@F68QVB3=7W"\%01'B<>]1)R(A!,*#@C$FXFT',D,"RS-7;V"[2<F1!H
M#@MG@:!5'S$"OJ?QNZU2^$:]8@V+'+ FKQ<PB,2 _=2:MT:0(%RS?2EHNLHI
M6KMU%\RLX$;P4ZJF*VX<Y &>".%0MIW*1EY;21>+9^B6\)!DI(WO5O".SD%A
M Q@IM7[BN=S,<-:L9-%Q,)0$ESQBB>_PUAA'9)E<J#2)]47%ARLMZ@R-FBWS
MX.;7Q=$7\<RA"AG%O::%&^-M+#DX,&%1COS! JS3XFY0T5;_ 'O4@2&!>Z2F
MKU))/MWG^CO&GKVO3^#5P!2P%"$D/%3:3"$)3"Y\<K4G\R:THO6-T[1&8SE,
M-/@# GM>%(I$A*BJ)%*V4(J89RI$8;/\4*?(.<@(8Y#\;TZ$U=TFHA*+PE6#
M[C R1W$1X4H%6 Q6F3A)!>$GC*I9JB$.,S\5!U?#$I'/U%"L&C <K'K./NQ4
MZ!=H10X1O<ICBT?D1*0:E1V],8-88&[!5L7CM"@H>\>G[%! %@[3->W_ ./
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M(+N>X4_% !S>+-Q]Z-7 !%][4R"6R<OY(;#--QNR@M0-ZKL079LNP5I9];4
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M8-,Z.ID/$5-I6-HJ&O"K/#7U)UOA#1U11D8B6, &!,K*U#,%[@6&W=)QBAS
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M3_ @/;T& ' !#G5H& ,!_$8=Y]S>N&=U%Q/\1 +< 0YT9,! " ]&VQC%#A-
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M$IUH#/)(;/$ C26.]LRS%@!XX*1(&- 3B%B,-6-ZM/Z0NQ1C(A&5]*M 4ZO
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M,1,(+5B<1)9V-FUT"EI7"PMDJQ1?I/.B'P?UKU7L+'BP4FC!F[78+*N(9?\
M.;AHW=;9 )"E&&A)&P8!M5DAL(E3'WQ_EW;2D^> [BHKH(5,\)@.JN%1RK'$
M4L;%CVH_2/[J22,>^T\TI]D!)2RDKLZU"5<SG*2Y"FQ2'->,BXH)O"E?'^L>
M-"!\#C"EK!^LJDX\$7>Q,J(&3#-Q./!>:$/FSE&/F_0.I,?,)P/>*)"]O,'F
M32&"PX$E^_Q4TO1@G$& S$-W:G%,F<Y%]T69H 0$N/&/<>]*^P^) 0OA@]:
M8>22<@4IF>^KJJ&.,[E$P&#^,$<]F]_3LFJBBBD4=^0X<?VI"S\**H)F81I)
MI41PPV)F(N1K4,J2+)) L ML!"4A6Z;B4<[!I;MAE+D)WEHT94S*2+,W4NMZ
M/'9=7I%%>0$<RET9 F;^P!HXY>4#<=)AA2W;#*7(3O+1HRIF4D69NI=;^ \:
M2TJ.?%+6_0J_\>F,Q#0P'J^Z$4+%7*HNLDIMD<BZ'%794#(O76<"@W+(]_"@
MC8*O1<.AG;>U;+O1>;=].K$TDRR@SA=PFD%4' I&V$EC;"]3G5_$;>Z IL8
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M )1P08M*M;:K&]'4Y4$!5)""(WOA " ""9@2&:X3!44UK6@'@L'"A@X-1"X
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M0NA%%;$5SV?PP>^W^<0S )U0D-)DLI-6ALX8;)4;R6EIF6F-/BKP'08@ 2R
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MKEJ:5^URHOAQ(3RFD=#Q4W"\ACF7C6@UO3E1(GHY!2$(>'Q4PS J4)6X_P"
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M<&5Z[(3Q"-ZM&2!GT!1=K/K90-B9FUG J)=YW% %]XHLI>U.>]$7F*@LZ-U
M1CA-#X.C*"1&L"BE\94#A,[4\\<#AXJ4Y11H&+R#@C4&>4Q&LD!Q:C7/L0X
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MQ"*!XV#XT?*)>"J/8I ="V9&6\53%Y3X]$C0B 1L-3EIEEJ2, +93.?P1"N
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M17R/I.GGF%9E+MQJ+6$&XRO<Y13X&S-QN.-#MVCT0Y0.-PJLV*&;2^'WIN8
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M./JUL'-TZ*%U4^!#)#]4%X=E3M%^?T"N>D7=B28G":^->\(C]BL%7X@BX"*
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M)R_"S! 1EQD0XC@G\%H2T4&8,,(SG-H49%!\ , _^ /_V@ , P$  @ #
M$ ))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))(())))))))))))))))))))))))))))))))))))))))))))))))))))
M)!))))))))))))))))))))()))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))()))))))))))))))))))))))))))))))))
M)))))))))))))())))))))))))))))))))))))))))) ))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))(!))))))))))))))))))))))))))
M)))))))))))))))))))())))))))))))))))))))))))))))) ))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))(!))))))))))))))))))))
M)))))))))))))))))))))))))())))))))))))))))))))))))))))) ))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))(!))))))))))))))
M)))))))))))))))))))))))))))))))())))))))))))))))))))))))))))
M) ))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))(!)))))))))))))))))))!!)))))))))))))))))))))))(!))))))))
M)))))))))))))))))))))))))))))))))))))())))))))))))))))))))))
M))))))) ))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))!)!))()!()()!!)!(! )!( (!()!)))))))))))))))))(!))
M)))))))))))))))))))))))))))))))))))))))))))())))))))))))))))
M))))))))))))) ))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))! ! ()!!) !((!(() ))( )))!(!!))))))))))))))
M))(!)))))))))))))))))))))))))))))))))))))))))))))())))))))))
M))))))))))))))))))) ))!(!)))))))))))((!)))))))))))))))))))))
M)))))))))))))))))))))))!)(! !)  )!)  )(!((()!())!!(!))))))))
M))))))))(!)))))))))))))))))))))))))))))))))))))))))))))())))
M))))))))))))))))))))))))) ))))())) )!!)() !)!)))))))))))))))
M)))))))))))))))))))))))))))))( ) )))! !)!!(() ) )!)  )  )!))
M))))))))))))))(!))))))))))))))))))))))))))))))))))))))))))))
M)())))))))))))))))))))))))))))) ))))((! )) ()! !)!! ))))))))
M)))))))))))))))))))))))))))))))))))))()!!)!))!)()   (!)(!!((
M()()))))))))))))))))(!))))))))))))))))))))))))))))))))))))))
M)))))))())))))))))))))))))))))))))))) ))))((  ( () !!  !! !)
M))))))))))))))))))))))))))))))))))))))))))))))))))(!))))))))
M)))))(()))))))))))))))))))(!))))))))))))))))))))))))))))))))
M)))))))))))))())))))))))))))))))))))))))))) )))!(( ))! )! ))
M)))())))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))(!))))))))))))))))))))))))))
M)))))))))))))))))))())))))))))))))))))))))))))))) ))))))))))
M)!))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))(!))))))))))))))))))))
M)))))))))))))))))))))))))())))))))))))))))))))))))))))) ))))
M)))))))))))))))))))))))))))))))))))))))))
M   (                     )                   )))))))))))))))
M)))))))))))))))))))))))))))))))()(  !)))))))))))!!))) ))))))
M) )))( !))))(()())!)))))))))))))(!))))!!))))))()))))))))))))
M)))))))))!))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))) ())())))))))))))))))))))))()) !(!!((!( (!)!!!()()
M()!) )) )))(  !!!)())!(   )))))))))(()())!( !))(()))))))))))
M))))))))))))))))))))))))))))))))))))) ))))))))))))))))))(!))
M))))))))))))))) )!)! (! )))))))))))))))))))()) )! !!)((!)! )
M) !)))(! !))) )))())(  ((!( )) ()!)))))))( )!!! )) ()( !))))
M))))))))))))))))))))))))))))))))))))))))))) ))))))))))))))))
M))(!))))))))))))))))) )!()!)!()))))))))))))))))))()) ))!! ))
M))(!  ! )! (((!!))) )))!)))))! !()))) )))))))))(())!!())((!(
M(!))))))))))))))))))))))))))))))))))))))))))))))) ))))))))))
M))))))))(!))))))))))))))))))( )! )))!))))))))))))))))))()) )
M! ) ( !!  !((! )() (!(!)) ))))!  )(! ! ) (!  ))))))))()! !(
M (!))()!)))))))(())))( )()))!)))))))))))))))))))))))))) ))))
M))))))))))))))(!)))))))))))))))))( (()(((!))))))))))))))))))
M)()) ))(( ((()))) )))) )!)!) )) )))))(( ))  (((!()))))))))(
M!( ))!(!)!((!))))))))) ()!!))!(!  ))))))))))))))))))))))))))
M) ))))))))))))))))))(!))))))))))))))))))!) !  ( ))))))))))))
M)))))))())))))))))!)))))))))))))))))) ))))))))))))))))))))))
M))))))))))))))))))))))))))))! (!)!!)) ( ))))))))))))))))))))
M))))))) ))))))))))))))))))(!))))))))))))))))))))))))))))))))
M)))))))))))))())))))))))))))))))))))))))))) ))))))))))))))))
M)))))))))))))))))))))))))))))))))))(() )!)!!)!))))))))))))))
M))))))))))))) ))))))))))))))))))(!))))))))))))))))))))))))))
M)))))))))))))))))))())))))))))))))))))))))))))))) ))))))(())
M)))))!)))))))))))))))))))))))))))))))))))(( ))  )( !))))))))
M)))(())))))))!))))) )))))!))))))) ))))(!))))))))))))))))))))
M)))))))))))))))))))))))))())))))))))))))))))))))))))))) ))))
M))) )( !)!! ))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))()))!   )))))))) )))))!!(!!(!)())))(!))))))))))))))
M)))))))))))))))))))))))))))))))())))))))))))))))))))))))))))
M) ))))))) !( !))(!))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))(())  !!)()))))) )))))) )())()!))))(!))))))))
M)))))))))))))))))))))))))))))))))))))())))))))))))))))))))))
M))))))) )))))))   !(!)!)))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))(!(( !  !()))))) ))))))!!  ) (())))(!))
M)))))))))))))))))))))))))))))))))))))))))))())))))))))))))))
M))))))))))))) ))))))))(( ()! ())))))))))))))))))))))))))))))
M))! )))) ))))))))()))))))))))))!))()))))))) ))))))))!)))))))
M))(!)))))))))))))))))))))))))))))))))))))))))))))())))))))))
M))))))))))))))))))) )))))))))))) )))))))))))))))))))))))))))
M)))))))))))( !!!)))!)()!))))))))))))))))))))))))) ))))))))))
M))))))))(!)))))))))))))))))))))))))))))))))))))))))))))())))
M))))))))))))))))))))))))) ))))))))))))))))))))))))))))))))))
M)))))))))))))))((  (!! ) !!)(!))))))))))))))))))))))))) ))))
M))))))))))))))(!))))))))))))))))))))))))))))))))))))))))))))
M)())))))))))))))))))))))))))))) ))))))))))))))))))))))))))))
M))))))))))))))))))))!)))))() (!)( )!!)))))))))))))))))))))))
M) ))))))))))))))))))(!))))))))))))))))))))))))))))))))))))))
M)))))))())))))))))))))))))))))))))))) ))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))(!))))))))))))))))))))))))
M))))))) ))))))))))))))))))(!))))))))))))))))))))))))))))))))
M)))))))))))))())))))))))))))))))))))))))))) ))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))) ))))))))))))))))))(!))))))))))))))))))))))))))
M)))))))))))))))))))())))))))))))))))))))))))))))) ))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))) ))))))))))))))))))(!))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))) ))))
M))))))))))))))))))(!))))))))))))))))))))))))))))))))))))))))
M)))!)))))))))))))))))))))())))))))))))))))))()))))))))))))))
M)))))))))))))))))))))))))))))))())))))))))))))))))))))))))))
M) ))))))))))))))))))))))))))))))))))))))))))))()))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))) ))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))) ))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))()))))))      !))
M))))))))))))))))))) ))))))))))))))))))))))))))))))))))))))))
M)))))
M))))))))))))))!)!)))))) )(!))))))))))!))))() ( ()!))))))))()
M)))!))))))))))))))))))))) ))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))()))))))))) )))!(!!!)!!!()!!))((() !))! )!)   (!!!())))
M)))(( )(!!))))))))))))))))))))) ))!( !) !) )))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))()))))))))) ))) )     )(())(( (! )((!!! )  (!!(!(
M)!!))))))) ) !)!)())!!!  (!)))))))))) ))(!(!)(!()!))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))())))))))))))))!)((!)))((()!))(((!)!(! )! !
M))!( (!()))))))) )!! !))((((( )(()))))))))) )! ()!)(!) !))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))()))))))))))))))))))) )))(!)) ))!))!(
M))!)))))!))!))))))))))!)( )!)))(! !  )(())))))))) ))) !!(  !
M!!))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))()))))))))))))))))))))))))))))(
M)))))))))))))))))))))))))))()))  !))( ) ! !!!)))))))))) )!)(
M)))!)! !))))))))))))(!))!)) ))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))())))))))))))))))))))))))
M))())))))))))))))))))))))))))))))( ((((!))))))))))))))))))))
M) ))))))))))))))))))))))))(! ))!))(! ! ((!))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))())))))))))))))() !
M))( (!( ()) ))!()()))))))))))))))))))))()!) !!))))))))))))))
M))))))) )))))))))))))))))))))))) ())!))))  !))( ))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))())))))))))))
M)))! !!    ))! )(!)!   (!))))))))))))))))))))) )   !))))))))
M))))))))))))) )))))))))))))))))))))))) !)! ())) !()  !))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))())))))
M))))))))!!)(!)!)))) !() ))( (!)))))))))))))))))))))) )(()!))
M))))))))))))))))))) )))))) )!)))))()( )))))))!)(! )!(   )()!
M)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))(
M)))))))))))))))))!)!(! !(()( ())! ))))))))))))))))))))))))))
M ))!) !)!!!( ! !!)))))))) )!)))(((!(   !!)))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))())))))))))))))))))))))))))))))))!)))))))))))))))))))))
M)))))))))))!)(( !(  )())))))))) )!)))()(()! ) (((())))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))()))))))))))))) )))())())))))))))))))!))!)!()!)))
M))))))))))))))))))!!!!!!(!  !)))))))) )!()() )!    !!!))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))) !) (((!!(!((((! (!(()! (!((
M!))))))))))))))))))))))))))))))) ())))))))) ) ))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))(!))  ()(((  ( ()((( ! ) !
M! )! !))()))))))))))))))))))))))))))))))))))))))) ))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))()))!))((( (!))!((
M!  (!!!!)  ())!)))))))))))))))))))))))))))))))))))))))) ))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))!()!)
M()))((!!)!)!) ())!))))))))))))))))))))))))))))))))))))))))))
M) ))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))(!)))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))) ))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))())))))))))))))))
M))))))))))))) ))))))))))))))))))))))))))))))))))))))))))))()
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))!)))))))))))
M))))))))))))))))))) ))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))) ))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))!))))))))))))))))))))))))))) ))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))    ( )))))))))))))))))))))) ))) ))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))())))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))!)))!)!))))))))))))))))))))) )( !( ! )!(!))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))()))))))))))))))))))))))) ))))))))!())(()))))))
M)) ))))))))))))))))))!)))))!))))))))))))))))))))) )  ) ())))
M )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))())))))))))))))))))))(!))!( )() !!)!( ) !
M  ((!() ( !))))))))))))))))!)))))!))))))))))))))))))))) ) )(
M !! ))!)))))))))))))))))))))))) ()))))))))))))))))))))))))))
M)))))))))))))))))))))))))())))))))))))))))))))(!)) ) )()))()
M! !  !))))( )( !)))))))))))))))))!))())!)( ))))))))(!)))))))
M) )()! (!(())))))))))))))))()))(!))!((()))))))))))))))))))))
M)))))))))))))))))))))))))))))))()))))))))))))))))))))))) ( !
M!) )))! ! !((!)( ( !) !))))))))))))))))!)))))!)))(((!!   (
M))))))) ))))))))))))))))))))))))()) !!(  )) ()))))))))))))))
M)))))))))))))))))))))))))))))))))))))())))))))))))))))))))))
M))))))))))))))()))))))))))))))))))))))))))))) )))) !)) !)))(
M()  !(( !)))) )))))))))))))))))))))))))(  !))(  ! ))))))))))
M)))))))))))))))))))))))))))))))))))))))))))())))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))) ! !((!)
M    !!!! )!))!!)))) )!))(())))(!)(!())))))))() ) !)))(!)))))
M)))))))))))))))))))))))))))))))))))))))))))))))))())))))))))
M)))))))))))))))))))))))))))!()))))!(! !!))))))))))))))))) )(
M!)(!)))))))))))))(!(!)))) ))))  ))) ) )!(!!)))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))))())))
M)))))))))))))))))))) (!))!(((  (((((!()(  ! ()))))))))))))))
M))) )(!)(!))))))))))))))))))))) )!())  ))(()))!)!)))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)())))))))))))))))))))))))( !)((!! )((  ((!( ! () )!))))))))
M))))))))) ))))(!))))))))))))))))))))) )()!  )()()!) !(!)))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))()))))))))))))))))))))))) ()((()!( (!(((!(( ))() !!))
M)))))))))))))))!))))()))))))))))))))))))))) )!)))!)))))))))(
M)))))))))))))))))))))))))))))
M              )))))))))))))))))))))))) ))))!(!))))(!)()))))(
M))()))))))))))))))))))))))))))))))))))))))))))))) )())))))))
M)))))())))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))) ))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))(
M                        !(
M
M                                    ))
M       )                      !(
M
M                                          ))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))()))))))()!)))()))))()!)))))))!)))()
M))!)()!! !)))))!!!)) !)!))))))))!)))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))  !!( !() (  !! !( )())   !))(((
M)((( ! !!  ) ( ) ! !( )) ( )((! )! ) ( !!) )))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))) (!)()!((!(! ((! (!) !))!)()
M( ((( ((!(!!!( ) (()!)(!(!))))  !))(( !!(()(!()()! )))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))) (!)())!! !! !(!()! !)
M)()) )( ( ( ) )()!!) )))(! ( ) ) !))!!!(!)(!))!!((!!) )! )))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))) ( !)!!(  !) )!(
M(( ) ()!) )!(! )()(() ( !!)! (!  ) !(!( )) !(!(! !)!)!!!(!!!
M )))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))()))))))))
M)))))))))))))))))))))))))())))))))))))))))))()()))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))))))))))))/_\0
M%1$! 0                  @.#_V@ ( 0,! 3\0O_\ *O\ _\0 %1$! 0
M                @.#_V@ ( 0(! 3\0O_\ *O\ _\0 +Q ! 0 " 0,# P,%
M 0$! 0$! 1$ (3%!46$0P?!Q@:$@D?$P4&!PL4#1@.&0L/_:  @! 0 !/Q#^
M284WX,'8!U_H?]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?O
MW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^
M_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_T-^_?OW[]^
M_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW
M[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_
M?OW[]^_?OW[]^_?OW[]^_?OW[]^_?Y)^_?OW[]^_?OW[]^_?OW[]^_?OW[]^
M_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW[]^_?OW
M[]^_?OW[]^_?OW[]^_?OW[]^_?OQ#?@@=D7>?R3T9+!*).><^:^^?-??/FOO
MGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\
MU]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-?
M?/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WS
MYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WQ=J@;:Y Z!Y
MZ8NU1-I<J=H\]<^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y
M\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-
M??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7W
MSYK[Y\U]\^:^^?-??/FOO@YG*0":+P'WQ:''X$%K0!GS7WSYK[Y\U]\^:^^?
M-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7
MWSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\
M^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOFNL^6M $TEV=<^:^^?-??/F
MOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[
MY\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?
M-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7
MWSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\
M^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/F
MOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[
MY\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?
M-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7
MWSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^*@ O6.N//6[8*A! >7ZY\
MU]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-?
M?/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WS
MYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:
M^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOO
MGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\
MU]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-??/FOOGS7WSYK[Y\U]\^:^^?-?
M?/FOOGS7WP$L$HCKSZ_ ]O\ \+3)A8*3\OVS^1_[_C7S/;U^![?_ (6F3"P4
MGY?MG\C_ -_QKYGMZ_ ]O_PM,F%@I/R_;/Y'_O\ C7S/;U^![?ZZF3"P4F$3
M9&R6 FQY/1B.;HY/5;@\N)&//]00%<M/LVW=)?\ SI$( 8"([VA.XCZCI#1Q
M^R'E!@5S+[I#\XN:HI084"NFGJD0@!@(CO:$[B/]N^7[9_(_]_QKYGMZ_ ]O
M]=S)A8*3[?AUE$%PW:7!&852 50W L!>EP0\$IX2Z4".2GDN)@4J,?8.+3,J
MK]IW^HQE^\B&8SA8E]0/I^ ]+XP@ZKV# K%PF?=)Z\Y*U.V[B(CZJ\>&J=@.
M<6+VW[407&UG'T> VX/=*H)X >B>YB".P'.<\A1S](/5"!1@'+GXOFA"A?0E
M FQ?7I;X4A)^A&+2?KINID0= #.E7/JR=*>W#NY,'U>Q*F0Q&%V((F6/WK=Z
M_2*\!<)0)L7UZ6^%(2>J,,ZE& ^H3'>/%@/9'T).I1C'T"XI#BK!^R7U3 I4
M8^P<6F957[3O^R?+]L_D?^_XU\SV]?@>W^O)DPL%)]C&8/BB,G[A@Q"83C0?
MJ*/VSB5$&* G14/ +<F18QXO@E!*E15>8S1R*P@T#+&7:W.,UJ(D4H1^R132
M.4C9(4E;MH'ZIA29G-UA'>ZP"$O #4?*IY&(E>D6":..4&R.XJ:!AO*FB,"O
M5 1=K'"- R+':@H=\>P6 AJ2.@@>'/P&24(0.H?&!/ X(JX,_J"#L\:?'+E6
M&=':""'@!KCE#!T-S$=#JR@@TZ1P% /<P"E6(J;VA=UI "E< .9+O"H*79;X
MF\%L0Z1H.TR.AEI )L#WS)P_XXD"XV #6*CSAC(6=I %B[$[(Y>IO313AHG9
M5-TTL0<1>]*2FDHIO$.C)A28<05V+AQDCF-'4V\+ V\."A_ @*F!H+U)I<22
M:#0C1VR#I+B 50/=^K.4C"J+!R[0BA0@85B:)=!@HWU4)G*V-X7P,(#H Z8D
MX!:PM/2;L,D0)3,_IH]9L9_8!7YY1V;5L<;&S$->O"^@0Z&.E7&G.70IP([&
M/F\2?:N1&Z[XDX!:PM/2;L,D0)3,_IHQ&+JEP!*P*BT";J"TL<V3!>4'QG/X
M@@X$5U"M1XH)I(1O0,/6(#JPZX:5E P:%TP+M@#P:. 0$$4>&%J$3E,-$<.F
M/$J(,4!.BH> 6Y,BQCQ?!*"5*BJ\QFCD5A!H&6,NUN<8'/ Z5:?(B35<U_8_
ME^V?R/\ W_&OF>WK\#V_P&9,@^*6D9O7);J7/@'O@;@H0V4 CL>,2.6+9B"T
M1(CFY&1S2@TNW/3->W\T5 H[?_0BL@73 ;3M%T;87H81ZPG*H]MZ UC&APPL
M=FSC =]$CV!K;S_C98*3[&(/'4J,'[I@7E5>S ^K)@'!4O4"GY7[8^L@&"8'
M9V<.*E,I#MAP)W>%[Y,XTW#6TNN]G.-(Y;51.^EX QT3'L:(NA*AVQJFKS8T
M0[4?KD "QG-!'[!^^'SJ;E!'L![X <F*@1I%N\\';&M_ !.E2-'F)GX#(4ES
M>C;,9-ATY#5YG[CCD$4#$<0+(2.>J_=]*%V2AP0,\S]HQ)Q9V:?TP&^-O..B
M] N1\@+T:G[I^^.-:#/W/?&;*RZ #\8HUH$\%/OARE)/B?\ $X>W@Q(4*;"&
M\&_H-9@ "J1*:7&P[$P"*K'L.+GQ/=C,@6]!(_N_WP0G<CR3_P"N#]&))&WL
MGP@@*AM0VX$=P6(E##8OBY'-9*S]1GRG :2"^>&$C*C41=R2/M0<7ZD+WVY7
MU)(TT)=0S$%"U!59T17!GI1=!G[8#A!;%8.D+3IQ@!C<_LF!(X6.)=^9^7%+
M"ESEH^\S\)B!P5+U I^5^V/K(!@F!V=G#BI3*0[8<"=WA>^3.--PUM+KO9_L
M?R_;/Y'_ +_C7S/;U^![?X-,F"%3 AD$9K170 5^G7-[E+M]-@[JWL<9LLJ8
MJ 0 H(E#=2RUP;"H!U50P;3;X3D(SJPO<VSCELEV$/"FG9R;J *IOHPV/V8B
M8,/UA&$%<'?"Z&G@,04@%(%DQIG%431:M?%KR93^L2N^!(?5Y5SRE>B@4^AP
MLLW:P%NX"[WN.'^*]*%@4R^7"NI=;%UU+K0#0ZL;P<Q!V2[6PNKRQW/T@3$1
MX1Z8)V  CA B=-E-Z)17!%\=*)]M8IMZ&7FYG1E1-B[C8K0X-5+>TQH;[*DJ
M@Y>V.I%D4A]#9)RXMN6Y.$:0.SE<(%K.-P32#IU=X+\. 81T$'U87ZM.(KRF
MNDPF$E]J103[8[!1ZOY:$.%Z'0(08%8E/S!_#"!_8.J  771&]E3_%BP4GVH
M/VK/)LTL+.,H61])Y"D=%@YE!&C_  8 +.D$= CV37;,<13P"[NXN&)(Y0 U
M<A$39-Q_$,JU-N#6P#K=&#/L&NHX.1=,<L5ZP. O OX6<("N4RB>PI]W'3>K
M=&[.VC];RX#[ G,]PQUP8Y&PC$ FP*FRUL#"X8((1$16#<X*ZY#%@ ,&U/H9
M^ R4Q,=4*AU:"=4&$\+"7P,$B42G3J&%_C H;8@>J5*$Y+U"61Y!P(=T30S*
M!'G=B*)M$TABH.\H;%YF="@P#E&ZF!8XJ0(\RK.07K^I<CJ-#NL@,TPAU=;S
M,--YAQ0:;23-E&*3*.H06(($2BMNI-TD:D"4=B2#P)VSXGN]5N7X+,^K>VPY
M?=_;PKDFNN.--VWKQKT:P#'1D^R&"EFL(CK3ECJD3$7Z6^S,7USZ,$D "5DI
M8K555G$ UM>::6NHVNK#4P^K>VPY?=_;PKDFNN.--VWKQK"A&HD+X'_2=<:'
MFO6FQSLZ,+]V%V4$=)135-'R.&:3 H)><K1'5G%/G+&J.XZ"4H\B"(&)Y(#U
M-!$\CQGX3&:[9CB*> 7=W%PQ)'* &KD(B;)N/XAE6IMP:V =;HP9]@UU'!R+
MI_8WR_;/Y'_O^-?,]O7X'M_@TR8(5,&: Z44J.L0SQDU!EC?:;5^N(RJCH%<
M_9P^@=%BE]ONID&[X9$/1L:;*5P8;"*4L:"704'"NL0, H;<@_4?O>E(350.
M-O2G,\$.F4=+:ZD([Z Z#(4+!H56-Q!>@0-UGPV@ ,$K5P?7<#0$'NZ?\#/E
M.V/^JRH#BA@*G+7%D5*HZ-J@UZ1TP<(L0C#^J^HP)#;:UD 1H:1DXPK@S<6>
MG"B/? 8GU-C*/JON,^<[?5]Q9@@HCL<PU49 &"I9MUYS3L&:RJ;R7?'K@CK'
MA!!1WR"?*S:S^A52QT.@0.F;XBG'=HG)2IO%JZGC_%2P4GOSA&EE:VO*^GC5
MH:3'4=D\8JE6KROH\0Q>DX M3@-#IE_^*TO(GB\)H]?5R;9IJA&^=W=;OT,A
M!P T1.$R#.1$/,'U$N$B^#EVD#X2>/02($?XC!;?/IHGXZ'5BA>X#YQB.*$^
MQ /J&4+\F'E-?2AO(!)-DBZ1H31K!8RP$=8AKR![3$V?7N-4;5>KEJJ;D44@
MT4&:S;I_M_I$!H..^4G^[H ] -%FLC]704%1!H. S@'UV2KDCYSDQP=%6 -]
M #'9<;)>4-$]6%[Y);*&CPB/J1QGUT"'5-KG%\IS$&L-=IG+.C@$' #QG((F
M#%$FBO$SOM;^&@3M-2[P*J)AN S"L92L3%9_F#(!2BG!]:&D"(!NK3X"88)D
MCKSQ?C#)(HK<H0'LD] JHF&X#,*QE*Q,5G^8,@%**<'&BQKAQ4D& 1'7.22J
M2'M%/W&+J-["O6(CSUPWQ?-!HQ1(('#MAN2YB13-94&V:K##AK7XNMH,A7!B
MV'"\8#Z.]#Q#%Z3@"U. T.F7_P"*TO(GB\)H]?[)\OVS^1_[_C7S/;U^![?X
M3,F"%3#5,F(MW@KXFLVU&0C5@T,Z*UR8K6+9:"H;&$X%Z877<.\8&2-(WN>E
M)FO:_;* =#VM,=( >SW8* ]%!(E <!U+$PW),\%"H6#H5=L"7(,L_*=L2L&W
M6+X%!!.B)B4+)A6C92P>D>N20'C03]U?48J!=M:$B=1%6!SCF=!N6=#%5T!R
ME/0MI ;6#J_:X3@]: *#^7[97XF6M9XB%.8'J8^N&1'8#RD@]:[>D,ACL3A/
M:-HU.\FPEXH^N".BE-U2-\H'R.)SFA"P8-7D:$=8K<CA3@%D:=MCO$8&BX%T
MS<^G^4E@I+F5QNR;=UOC&*$7D-:NB3I_[4OB&55!PB#<(_A:ZZHA=41XQ2BM
M67ZB?C%+!$17E*JX&WV 9_9_E^V?R/\ W_&OF>WK\#V_P.9,;O%4G8*2#D,*
MCD8!$!08+%+U<!0#HH*RS>LV(5C(;*#70?05:T!6%1NSS+.F*.<&(4/N8:9N
ML%M,5[(\],V5DC7D-/J)XP DE"16GZJKM5<>F.[A$6<.]8=(Y2( "@QW%^N1
M",VYM1T:RZB.M.#>#$]*B^<#+6=H0<=BC&;Z)".5@NPKK;..73Y3MAO1@%0*
M1[T(M3HRS:S6'=*730&/9CN?I$FJKRKUP+XU@I%P$- "!)@/[#*40#]\,EZ)
MD(&TH+!JG;SG,/A=%Z-:+I U:&1(#/'EW^<*+LWMR3V$#0LWMQ)L3DQ0/IU+
M1UA'A!AB6 !6Z<!N!B40%$26B%@NL4XV%"#P[OI<TD78=-#3[X^H&\GDM1Y7
M!=BEIZ.W9+VJ?EAE/D'5!$?KLC6BC_K$L%)^7[9_(_\ ?\:^9[>OP/;_ !.9
M,'L^N1M%#]<*P\"B*B?["+!2?E^V?R/_ '_&OF>WK\#V_P!+3)A8*J3"$>"!
M8+N#K^VL&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#2
MM-HR'TQ0TW#*?47]K8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8
M,&#!@P.G7:Q^TY]8)HOV?]F8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,&#!@P8,
M&#!@P8+MF?EG-$EX<53D&OK_ (U\SV]?@>WZ%\16R>474XZ?H[]^Z^\.U5)"
M>FM81\<6 %X(C_Z##FGKKE. [H/0$;?L )K9TO/7]?.=-)V & P%B5W@>4:6
MB5=5R/41_P#1,F;F]4P=4X"[2!U</?E^@#_C+"N1HR>$/H2^,3M)P$Q$>$>G
M](FF'8(78%#79QB!<LQFD)IZX0G*L$-&AKB+?D@*5@;ZAE(DD";1,;I=*4D5
M./'Z>FD)O(.^B9&ZOZ7&"/4A(FX(_; ]1H;@PZNGU?URP4A*1:+@*B.=\Q,#
MFU+MT_79:B&@T36SI>>N)260"XH%#[.//6;<9I":[_T>FD)O(.^B9&ZN$)RK
M!#1H:XBWY("E8&_URTOL*0L!6!=?VU<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N
M7+ERY<N7+ERY<N7+ERY<N5ROP"H0%4-N%0RIH"&>$XZ?VM<N7+ERY<N7+ERY
M<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7+ERY9@-D(E$T"\XB%_L 74G6[_P!F
M7+ERY<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7+ERY<N7"@4']P67I=L(AHL/W
M?[(8GS1)@ ;5>F$\ (D/%^P$)VPZF6O !47ZIA3^A#V#7RDG3T$83G\A>RB4
M)%OZ:,J+3X#_ +TQW"-HK5!1B)K^U_,]O7X'M^A523]/M#FK>QFWIJK(M,OU
MP^)G/"6AT-YY/2KF;D.%0>-XXX" JO!AI6BQ9W&5]C$&L8G<B.Q\.<X<,XC/
M< 1Y,(EE8KW@&>< L%$LP VJL Q[5B E@( 5UA M=8]?!$;LDWA4(.$- !RY
M! J*J?27!)BI.[(3['#D_:), #:KTQ$H R:PI J@;ZX?S88'=LC[L^W\FP4!
M]%)T[974HV\7!&EK-[#*? ^GEWHK1$3R8D!4"(G(F*%%%3%&,&(CODRO3M;-
M@0PTFHW(WW<(JLJR38XU)B H&(%1%6=L,"B?UH^#J6>D]LRN^%"#ZS"$#&#W
MV1Y<X]>,O1+6(O"KX6.@$C;E'T_+X<XX@S08)^P/0T^?'_:<A.MF2*RA=IE/
MD.)/\T"8B.Q'IA+]BR[@#[+EOU\7^5"#R7T'H0JQ[P8>7&@R6+^8?QE4L%#V
M (_7^K,F'*6;4, .ZX.Z0EM ]@4#B"\KB))@U'I(O9KR<9H<J82L$98K06DF
M%1J'M3MU2H-CVX="#A#H .7((%153Z2X),5)W9"?8X"!AJH8 '*Y*:I5M!2!
M5 KRF%050GUR'V+BX!-L#N *>37IOA*%0G(,$^!Q4F82([AIY-9\!VRG^ P)
M1B#>MX_&O0MH$,=:PU/FR6@ VKVQX&:\,[Z_\8/D<XH5$Z.?-]N#T(58]X,/
M+C09+%_,/XRJ6"A[ $?KB/<D2&"D-.9%Y-%@P038*I8R]G' (= ,1'A'%)T[
M974HV\7!&EK-[#*? ^FYPL^ _%QOC-WC4_8'V_KE@OS79GQ_./-CYBBHGD<Y
MP-NT$"?<F(N?PTA-/BWT)Z(ST\*"#RS%D"!S>W>\6^G)C13!X(%7P8S_ "EC
M.P=KWZ>AEFT?9Q OWPNL)MYVTV\7T'H0JQ[P8>7&@R6+^8?QE4L%#V (_7$>
MY(D,%(:<R+R:+!@@FP52QE[.'_ 98&@39-F/QKT+:!#'6O0"]U >Z!'TN7US
M^]< ^R^GFQ\Q143R.<X&W:"!/N3$7/X:0FGQ;_H@DV:I,?+]L_D?^_V0]LIJ
M.,>0!V\YG/4>QURALJP'1N,[!J3 ]@J4@RMU%8Y- PCNI-W(NA@L[QY%7OUS
MNA-XBD,J(S%@H=MF>&<*K "/AS:#DWYVTV\7#6%'+W5P\N%ZZD1T %5[&0F]
MN1@8 )DXZS=P0SX9>P"C9'?3%:X9-.004Q'%4P'* 1.SFNCGUQI0,1GDSG;(
M\P$0E$2G".0MQ4O.Z!AY<;+$L3]I7\8A(J4>P!/O_9/F>WK\#V_HH'"P!+A!
M7>=*K6P1O34:HQMWLH'=20R,]Q@L;O:@]IZ$(TP%P\W3LIU'*(B],JG11E5%
M9L2/.+4AH^,43J,>8A=.$A)+C5'BF"/8HJ:BZBT=QA^P?M)W5:-/L=8&\:4@
MK(JA;0!JJN:JMPQ &UE--S <"B"0%>ZH(Z$F)5+>Y.OQB I;3**>@E>J1HS
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M!+T"NK1MUOH&B<O/J8H"[M%G9R&K/5B@KO@,^?\ .?+=\ 9<KF8NI$'71TN
MT&&I*:2U!P-S5004;Z@(-!$)-\B[@[=-1CPF&VN3BA8@U:)DB*L8=HQ %EZF
M%*"@HDO#@!:\A<$ZA0O&YRX_!]8XT#8Z<]G%33K=1;Y3^V+97YH0#^_HN<8
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MY86 (.BH1^P0WF;<&"L38):_<?O_ (]^IFS5)CY?MG\C_P!_QKYGMZ_ ]O\
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M(>SIW<534;;N[TZPV[G.-2U3@2"Z  '8,,EN;1HT904Z)UPM]<FW#D $6W_
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M$8'"$X,(7.\X6*3=@AH F\.3;9VV+;IT-+%'@%YH9D^*P*I$$4P=#F5<Z*:
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M=+.L@-7%P9"TZCQ-M1ELI56,QL"1< J4"J&/?L#\Q&DZV!$M)CI5F"E"<"#
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M4-';N8=,%:*:DTM! =?3.?6N1&-$"I9(*I5IQ0!I"+5PA.F#GR+>P*AOH/\
MSTZ=!>085K.]?_#T'R<080V-:9Q*[XI*L8ARQ IY?1D;A XG Z@'26"W799>
MIH.X5#0*D/D-(Z9=6QV\WZ/ZTXH TA%JX0G3!SY%O8%0WT&0_2J KOQ^LL5;
M)LC((="+9UIQER<2M?0H_P#^LI%$(#$"PN%20NL&>N_:+Q55#?)*81;D"?7
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MX&B@'@B[9R8]H> (.<#SCWZ?_P 3?_W>LQMBS[C>$Z:R&Q7H,O\ F*0@T@E
MXI5_0HS0TK20++%&;&*4%MR0MB@W(!H8B1\H%"$<!.]F< )!"B-$_JL)&@+
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M%D;;S3 J)T:N0OJ4LB;=I0H2:PIL*E@RB*$*%/,PW8)EXB!A'J EHY#C!UA
M0-Z*JE 8(6&B^FG0RICR"1GJ10H!!6$&.WNJ@[FNHF &:)12AR%P0H:P4/E
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M,LZU#@-/P%_4=CC0!1(&EM.<FV!AJ@,M'VPI@!&C"M]Q/TN@@5"2JZBUU?\
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M).N'43LALZ$1'1#EG14=IDW3OR[&$[4,FY&U0JHG,U_^3U@*=-].9(R8JM1
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M$>13KC,>$DL@#0%JD@!,+$" 2:0 " $),,$0.^L:804>!)7#1-H#"I)!#5
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M(R)]13-6Z:ZG7L37#OV8U-46H8*]757J_KYM-G.=07 'B&Z<*I=X<^;[\!(
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MDDSCB$2RY1(6SQ=P(H61D,3&UB6Z2-OA],F"BVE! ?HN#DCHZT.>&H:,1,>
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MCD9?6%R(QU+75^!:)3H/KLTMN<01D1: F^8O"Q11X4OHS8@MW72*K".G9W&
M&87%>"OT'XP=OIRH)I$1$Y'"-2-:2@LTCLA'1*?_ ,K1XEEUMERH;P.'%R5
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M<0MD>@06E 4*QT[QJ%XOU&;0*I$QB;H@[;8'>Q>=@^A..I]:1*W40?6?HTD
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8G'4@= **$M+8]HA!0 -   >/_P  ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ast008breastcancer.jpg
<TEXT>
begin 644 ast008breastcancer.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +)!:<# 2(  A$! Q$!_\0
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M* "BBB@ HKQ[XO?M;?"7X"^)K;P_X\\80^']8N+1;^*UDL[F8M SNBOF*-E
M+1N,$Y^7I7$_\/)/V;_^BFVW_@LOO_C% 'TO17S1_P /)/V;_P#HIMM_X++[
M_P",4?\ #R3]F_\ Z*;;?^"R^_\ C% 'TO17S1_P\D_9O_Z*;;?^"R^_^,4?
M\/)/V;_^BFVW_@LOO_C% 'TO17S1_P /)/V;_P#HIMM_X++[_P",4?\ #R3]
MF_\ Z*;;?^"R^_\ C% 'TO17S1_P\D_9O_Z*;;?^"R^_^,4?\/)/V;_^BFVW
M_@LOO_C% 'TO17S1_P /)/V;_P#HIMM_X++[_P",4?\ #R3]F_\ Z*;;?^"R
M^_\ C% 'TO17S1_P\D_9O_Z*;;?^"R^_^,4?\/)/V;_^BFVW_@LOO_C% 'TO
M17S1_P /)/V;_P#HIMM_X++[_P",4?\ #R3]F_\ Z*;;?^"R^_\ C% 'TO17
MS1_P\D_9O_Z*;;?^"R^_^,4?\/)/V;_^BFVW_@LOO_C% 'TO17S1_P /)/V;
M_P#HIMM_X++[_P",4?\ #R3]F_\ Z*;;?^"R^_\ C% 'TO17S1_P\D_9O_Z*
M;;?^"R^_^,4?\/)/V;_^BFVW_@LOO_C% 'TO17S1_P /)/V;_P#HIMM_X++[
M_P",4?\ #R3]F_\ Z*;;?^"R^_\ C% 'TO17S1_P\D_9O_Z*;;?^"R^_^,4?
M\/)/V;_^BFVW_@LOO_C% 'TO17S1_P /)/V;_P#HIMM_X++[_P",4?\ #R3]
MF_\ Z*;;?^"R^_\ C% 'TO17S1_P\D_9O_Z*;;?^"R^_^,4?\/)/V;_^BFVW
M_@LOO_C% 'TO17S1_P /)/V;_P#HIMM_X++[_P",4?\ #R3]F_\ Z*;;?^"R
M^_\ C% 'TO17S1_P\D_9O_Z*;;?^"R^_^,4?\/)/V;_^BFVW_@LOO_C% 'TO
M17S1_P /)/V;_P#HIMM_X++[_P",4?\ #R3]F_\ Z*;;?^"R^_\ C% 'TO17
MS1_P\D_9O_Z*;;?^"R^_^,4?\/)/V;_^BFVW_@LOO_C% 'TO17S1_P /)/V;
M_P#HIMM_X++[_P",4?\ #R3]F_\ Z*;;?^"R^_\ C% 'TO17BGPM_;,^#'QJ
M\71>%_!OCRQU?7YHGGAL&@GMY)E09<1^;&@=@N6VJ2VU6;&%)'M= !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 45X1\0OVXO@=\*O&.I>%?%'CZUTS7]-94N[/[
M%=3&)F17 +1Q,I.UUZ'C.#SD5S__  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?
M\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\
MZ*;;?^"R^_\ C%'_  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?\/)/V;_^BFVW
M_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\ Z*;;?^"R^_\
MC%'_  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?\/)/V;_^BFVW_@LOO_C%'_#R
M3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\ Z*;;?^"R^_\ C%'_  \D_9O_
M .BFVW_@LOO_ (Q0!]+T5\T?\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X+
M+[_XQ0!]+T5\T?\ #R3]F_\ Z*;;?^"R^_\ C%'_  \D_9O_ .BFVW_@LOO_
M (Q0!]+T5\T?\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\
MT?\ #R3]F_\ Z*;;?^"R^_\ C%'_  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?
M\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\
MZ*;;?^"R^_\ C%'_  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?\/)/V;_^BFVW
M_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\ Z*;;?^"R^_\
MC%'_  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?\/)/V;_^BFVW_@LOO_C%'_#R
M3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\ Z*;;?^"R^_\ C%'_  \D_9O_
M .BFVW_@LOO_ (Q0!]+T5\T?\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X+
M+[_XQ0!]+T5\T?\ #R3]F_\ Z*;;?^"R^_\ C%'_  \D_9O_ .BFVW_@LOO_
M (Q0!]+T5\T?\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\
MT?\ #R3]F_\ Z*;;?^"R^_\ C%'_  \D_9O_ .BFVW_@LOO_ (Q0!]+T5\T?
M\/)/V;_^BFVW_@LOO_C%'_#R3]F__HIMM_X++[_XQ0!]+T5\T?\ #R3]F_\
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M3:K#8RR+E[:X8AXSG!!X_7N,4[,#O**R]!\2:;XFM7N=+O(KZ!'\MI(CD!L
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MP)I7BR/PM?>-O#MGXFD=8TT6XU6".\9FP540EP^3N7''.X>M '-?\)%\;_\
MHGOP_P#_  O+[_Y34?\ "1?&_P#Z)[\/_P#PO+[_ .4U>JTM 'E/_"1?&_\
MZ)[\/_\ PO+[_P"4U'_"1?&__HGOP_\ _"\OO_E-7?:CXLT/1]>TC1+_ %G3
M[+6=8\[^S=.N+I([F]\E-\ODQD[I-BD,VT':#DXK8H \I_X2+XW_ /1/?A__
M .%Y??\ RFH_X2+XW_\ 1/?A_P#^%Y??_*:O5JR->\5:+X7.G#6=8L-(.I7D
M>G6(OKE(/M5U)DQP1;B-\C!6PBY8[3@<4 <!_P )%\;_ /HGOP__ /"\OO\
MY34?\)%\;_\ HGOP_P#_  O+[_Y35Z!H?BC1O$[:BNCZM8ZL=-NY-/OA8W*3
M&UN4"EX)-I.R10RDHV"-PR.:UJ /*?\ A(OC?_T3WX?_ /A>7W_RFH_X2+XW
M_P#1/?A__P"%Y??_ "FKU:B@#RG_ (2+XW_]$]^'_P#X7E]_\IJ/^$B^-_\
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MG!'TC0!Y+\9O^2F? ;_L<;K_ -1[5Z]:KR;XS?\ )3/@-_V.%U_ZCVL5ZS0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'E7AS_ ).F^(?_ &)GAG_TNUZO5:\J
M\.?\G3?$/_L3/#/_ *7:]7JM &?KNC6_B+1[O3;O=]FNHS')L;#8/H:\\_X9
MO\'^E_\ ^!'_ -:O4Z*+V ^3=7_9]\7V.J7$%E8)J-FCGRKI;B) Z=B59@0<
M=1ZYZ]:].T']FO08=)MEU>:XN-1VYGDMI2D>[/101G '&>^,\9Q7LE%.[ Y[
MP7X(TWP%ILMAI8F$$LQG;SGW'<54'G'3"BNAHHI <W\1O ^F_$SP%XB\):NI
M?3-<T^?3KC;]X)*A0E?]H9R/<"OS3_9EUSQ!^T-\6/@M\&?%-I=1K\!'O[OQ
M)DA+>XO+*?[+IB(8R06A CY;[X$O49K]3Z,8H ^)OVR/ ,>B_M!^#/BAK^K_
M ! T?P"WAZY\.:MJW@*^N()M(E%PMQ#-,ML#*8)<NC;5(W10[L87.-^SK8_#
MWXF?M%>$?$OP]U;XJ?$W2O#NGWUPWC3QAK=\VEV$D\?D&T@CNX0TTLBG<P78
MJA(VRY&%^\J,8H ^=/\ @G?C_ABWX5?]@U__ $HEKYA^#_\ R9K^Q3_V4RU_
M]#U6OTJI-M 'Q3\/?C7X9_8S\6_%7PS\7)+[PW_PDGCK4?$N@ZM;Z5>7MEJE
MM?,LB1QR00MB>,J4>-@"#C:6!S5N3XEZ[\7/B]^S?XFUKPC=^#;:Y\6>(5TB
MSU$E;NXT]=(N1!<3Q,H,+N-Q\LEN I!PU?96VG4 ?F5#I_@OX$^*/&OAWXR_
M$3XQ?#2YD\3W]UH=QH.LZJ-)UBSNIWGBE@%I$Z+-F0K(G7=SDEB!]5_L2>';
M72OASXAU6PT3Q9I%CK_B"XU&WN/&VHO=ZGJ<0CBA2]E$B*\7F+$,1OD[55LD
M,*^BJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ^9_CY_R>7^RQ_UV\4?^FL5],5\S_'S_D\O]EC_ *[>*/\ TUBOIB@
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M0!\O?MO>$==\6:E^SX^B:+J.LKI?Q3T74+]M/M9)Q:6L;2>9/+L4[(UR,NV
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M./VEM$\%_$[X@_"@ZQHWAG7;^:'X9PW+0:Q/H-S!''YDK+*%-ZLD23_9U89
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M7O$/AK7OAWXT\*>,-*T6?Q!!X?O+.&>?5K6+AA9/!*\<TNXHOE[@=S@<@$@
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M2^(/#EAXO^%_CSX<Z=XDF2VTK6?$=A"+4SR;1%!<&*:1K661G"JDJC)R.QP
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MPA%KYTA58H;GR9I&M9)'=5595&2<<8./H6@!:*** /)OC-_R4SX#?]CA=?\
MJ/:Q7K->3?&;_DIGP&_['"Z_]1[6*]9H **** "BBB@ HHHH **** "BBB@
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ML[CX?VOAM=7N$DM[C[4MVT893(1AAY>>%([!ASSSSG%\/_LT_P!A:_IFI_\
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MO@S^UA\._B+XQO&M? %YX=U#PN-2FA_T31M1DN+>=)IY?^6:SI$T08\ Q\D
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MM:/)X3T.32=;NWO]4L&TV$P7]R[*SS3Q[=LLC%$)9P22JG/ H ^?=6^(&A_
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M8K#TCP/X>\/:OJ6JZ5H.F:;JFI,'OKZSLXXI[H@8!E=5#.>!]XFMV@ HHHH
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M2I79Y;220]461Y)$9V^10BEBN.?>_CO\<?#GP'^$VM^-]<O;9;:SM7>RMWE
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M?#?49?"'CF;X<7EGX/\ '_B"-)UUQ[6.99;J)%2(SJZ.K(4C6)CL)"$E>0*
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MUWX*N-<U>2\AU  VK:A'ISG3PRM\ID\PR;,\[AQS7T3X/\)Z;X$\)Z+X:T6
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M=-ND.8+2598S&P-O_JUPK''EJG)YS7NE !1110 4444 %%%% !1110 4444
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M^2%=I/* 'UA\.?VG/A1\6M<ET7PA\0= U_6(V<?8+2]0SR;!EFC0D&10.=R
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M#N]3T3PM\&=5M_%6H:F_B&7Q:;W^T]1N6O9Q.E^D4+1L02P"'(V%>.37U/\
ML1Z#K/A7X$V^C:MK/A;6[>QU6_BTV;PAJ4U_8P6IN'9;99945OW+M)"%YVI$
M@SV ![]7FW[3'_)N'Q6_[%/5O_2.6O2:\V_:8_Y-P^*W_8IZM_Z1RT 0_LN?
M\FS?"/\ [%#2/_2*&O3Z\P_9<_Y-F^$?_8H:1_Z10UZ?0 4444 %%%% !111
M0 4444 %%%% !1110 4444 >'_LU_P#(W?'W_LH<W_IHTNO<*\/_ &:_^1N^
M/O\ V4.;_P!-&EU[A0 4444 %%%% !1110 44E&: %HHI-U "T4E+0 44E%
M"T44E "T4FZEH **** "BBB@ HHI* %HI,TM !1110 4444 %%-W"G4 %%%%
M !1110 44F:* %HHHH **** "BBB@ HHHH \F^,W_)3/@-_V.%U_ZCVL5ZS7
MDWQF_P"2F? ;_L<+K_U'M8KUF@ HHHH **** "BBB@ HHHH 1J_&F3X4Z?\
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M/_\ PJ+'_P".T >JT5Y5_P -8_!#_HLGP_\ _"HL?_CM'_#6/P0_Z+)\/_\
MPJ+'_P".T >JUQ'BCX1Z%XO^)?@?QU?_ &K^W/!ZWZ:9Y4H6'%Y$L4WF+CYO
ME1<8(P?6L'_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=H
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MT85HT9"IW*0"&R!5/X=_LF>!OAYXRMO%?G^(/%7B&P66'2K[Q9KESJC:3#(
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MS]H'CCQ]XI^$WP6NOA9I5V_B?P?;2?:[S6%2V"V;W,4$SPHL(,@VA-VYP2W
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M_P#0?_EI1_PO/Q5_T0?XC?\ ?_0?_EI7KU% 'D/_  O/Q5_T0?XC?]_]!_\
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M0?\ P60__$T?\*L\%_\ 0H:#_P""R'_XFNIHH Y;_A5G@O\ Z%#0?_!9#_\
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M'7Q,E\._#[P[XLT7Q-XD;7;6]O/%C:=*BM96EN8VB%G+R#;%L[_XNG'/1?\
M"Q/C]_T1;PI_X<!__E;7N-% 'AW_  L3X_?]$6\*?^' ?_Y6T?\ "Q/C]_T1
M;PI_X<!__E;7N-% 'AW_  L3X_?]$6\*?^' ?_Y6T?\ "Q/C]_T1;PI_X<!_
M_E;7N-% 'AW_  L3X_?]$6\*?^' ?_Y6T?\ "Q/C]_T1;PI_X<!__E;7N-%
M'AW_  L/X_?]$6\*?^'!?_Y6T?\ "P_C]_T1;PI_X<%__E;7N-% 'AW_  L+
MX_#_ )HMX4_\."__ ,K:/^%B?'[_ *(MX4_\. __ ,K:]QHH \._X6)\?O\
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MZ4 >6?\ "POC]_T1?PI_X<!__E;1_P +#^/W_1%O"G_AP7_^5M>XT4 >'?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH *\I_:Q_Y-9^,G_8F:S_Z0S5ZM7E/[6/_ ":S\9/^Q,UG_P!(9J /,_\
M@F/_ ,F-_##_ *Y7W_IPN:^HJ^7?^"8__)C?PP_ZY7W_ *<+FOJ*@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -@RQ_\ 1MW0!T%%%% "$XKY-TVUB_:'_:3N[V:)+[PIX>7RQE0T,RHQ"*6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%8OB2'4&LWGL=1-@T$;NP$*R!\#C.[IC';UH VJ*Y_P>-1FT>VO
M-0U$WSW4$4H7R5C$9*Y(&.N<CZ8KH* "N?L_^1^UG_L&6/\ Z-NZZ"N?L_\
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M]J;P'^RIX/M]>\;7L^^]E,&GZ5I\:RWM\Z@%_+0LHVH""SLP4949W,H;YO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !5/6/^03>_]<)/_035RJ>L?\@F]_ZX2?\ H)H J^$_^15T;_KRA_\
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M8'RR2;QOQ\Q?=SNR=.;_ ((@^*AX@2&+XI:.^A;?FO7TJ9;H')X$&\KC&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSQ7S%\;_ -H+0]3T77H?"U^U^^M65KIQG$,D7EHDEPTX(D3G*2(O_;4D'Y:
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M !1110 4444 %>4_M8_\FL_&3_L3-9_](9J]6KRG]K'_ )-9^,G_ &)FL_\
MI#-0!YG_ ,$Q_P#DQOX8?]<K[_TX7-?45?+O_!,?_DQOX8?]<K[_ -.%S7U%
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '/?$+_D0?$O_ &#+K_T4U=!7GWQ,^'GA6_T#Q'KEUX9T
M>YUI;":5=2FL(FN0Z0D(PD*[LJ%7!SQM&*Z#P_\ #SPMX3O7O-#\-:/HUV\9
MA:?3["*!V0D$J6102N54X]AZ4 =%1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !116)XJ\8:/X)T^.^UN]6QM))
M1"LC(S9<J2!A03T4_E0!MT5YO:_M$?#F^N)X+?Q3:S302"&6-$D)CD*JX5AM
M^5MKHV#V8'H:](H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "J>L?\ ()O?^N$G_H)JY5/6/^03>_\
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M*^_].%S7U%7R[_P3'_Y,;^&'_7*^_P#3A<U]14 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %4]8_Y!-[_P!<)/\ T$U<JGK'_()O?^N$G_H)H J^$_\
MD5=&_P"O*'_T6M:U9/A/_D5=&_Z\H?\ T6M:U 'AW[7WB$Z1\(WLE +ZI>0V
MQ^?!"J3*6QCD9C4=L;OP.Y\#?#?_  B>DV.F-'-!+'X?TZ6:*<8=)9);N213
MP,8=V&#SP.IKR[]HK_BX7QS\#>"D@^U00,KW*HK!MLKJTH)R.%BA#?+TR>?3
MH_A9XBU/Q9\;];O+?59)=+V3,492$EMU?;"@4CY2-ZMT!X;U.7W ^@Z***0!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% "5^?'[4__  56N_V;OCUXG^',7PUA\01Z+]EQJ+ZT;<R^=:PS_P"K\AL8
M\W;]XYVY[XK]!Z\^\4?L]_"SQSKUSK?B/X:>#_$&LW6WS]1U30;6YN)=JJB[
MY'C+-A551D\!0.U 'YP_\/R=0_Z(Y;?^%&W_ ,BUZQ^RO_P55O/VD?CSX8^'
M,GPU@T"/6OM6=136C<&+R;66?_5^0N<^5M^\,;L]L5]6W7[)OP,\EO-^#_@"
M./'S,/#5DF/Q$5?GY\ =:^&_P/\ ^"HFK^ O VD:!JOA#5F:'3[Z.&&[GT:_
M-EYDJVUV5:15W>="T:O@>80?N8H _5ZBBB@ HHHH **** "BBB@ HHHH *\I
M_:Q_Y-9^,G_8F:S_ .D,U>K5Y3^UC_R:S\9/^Q,UG_TAFH \S_X)C_\ )C?P
MP_ZY7W_IPN:^HJ^7?^"8_P#R8W\,/^N5]_Z<+FOJ*@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB=)_Y+1XI_[%
M_1__ $IU.NMO)I8+=Y(;=KF08Q$C!2>>Q) ]ZX339]3C^*/B"^.CS$3Z-IL/
ME">+<NR>^;<?FQ@^9V.?E/MD ]$KS?\ : ^+2?!?X9ZCXA5(;C4<K;:?;3DA
M9;AR=H..2%4,Y&1D(1D$YKT*W9Y(D=XS"[*"T;$$J3U!(/4>U?$WC"Z7]KW]
MIS3/#]E_I'@?PJ'-U,'5HKE%D7SW1D(.)6$<2[7;Y5\P=Q0!T_[-/PEN/#/P
M4\7^.M=\Z?Q'XGTRYF6:Y;?(+4QLRL6(W%I6/F,=Q! C/!S7UQ7,^.K>.U^'
M?B&&&-8HH]*N$2.-0JJHA8  =@/2NFH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /+/@[_R43XY_P#8
MY6__ *CVCUZG7EGP=_Y*)\<_^QRM_P#U'M'KU.@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4=>PN5&>^!ZU]D_\$U-6MM%_X)_> ]0NI4AM;*#5IYY'8!45=1NV8D]@ ,T
M?.W_  1&^(M_>:#\3/ ]U=&33[">SU:PMRO,;2B2.X.[T/E6^%Z [CW-?=O[
M6'_)K/QD_P"Q,UG_ -(9J_-7_@B-X6EO/BE\2O$@DQ#I^C6^G.F.K7$YD4YS
MV^RMV[U]$_M6?"7]J!?A[\8M8;XY:.?A[_9>L79\-_\ "/6HF.F>5,WV3SO)
MW;O)_=^9NSGG.>: /5?^"8__ "8W\,/^N5]_Z<+FOJ*OEW_@F/\ \F-_##_K
ME??^G"YKZBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRHHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /+/@[_ ,E$^.?_ &.5O_ZCVCUZG7EGP=_Y*)\<_P#L<K?_
M -1[1Z]3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "JVI?\@^[_P"N3?\ H)JS5;4O^0?=_P#7)O\
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M&?$GX.^"/C%H_P#9?C?PMI7B>R 81KJ5JDC0[AAFB?&Z-L?Q(0?>OA_XS_\
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MT>O4Z\L^#O\ R43XY_\ 8Y6__J/:/7J= !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55U+_ )!MW_UR
M;_T$U:KXL_;)N99/BII<#2N8(],B9(RQ*JQEDW$#/!(5<_04 7/V=]52W\4?
M$/X@7D2F/3[9D2!B<EYI,H@(3@_NPN['&_H>:^EOA?\ $ _$C0;C4OL']G>5
M=-;^5YWFYPB-G.T?W\=.U?!O@>:__MO5+2S><Q7,6VXAB!(D42H5##V?;^.*
M^[_A#X>N/#/P]TBSNHWBN2C321R+M92[%MI'8@$#GGKFF!VE%%%( HHHH *P
MO$GA^^US[-]B\2ZIX>\K=O\ [-CM7\[.,;O/AEQC!QMQ]XYSQC=HH X#X+_V
MOJ7@#0->UGQ%?ZY=ZQI=G>R1W<5M''!(\0=Q&(88S@E_XRW"CWSW]<3\$/\
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M\N_\$Q_^3&_AA_UROO\ TX7-?45 !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \\^/'_(@0?]A[0_\ T[6E>AUYY\>/^1 @_P"P]H?_ *=K2O0Z
M "BBB@#RSX._\E$^.?\ V.5O_P"H]H]>IUY9\'?^2B?'/_L<K?\ ]1[1Z]3H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OC_\ :HL(O&7QF\/:#HT FULVJ17,J.SA0SLRJZ@'9L3=
M(3_=<'M7UMJ5_;Z7I]U>W<RV]I;1---*Y^5$4%F8^P /Y5\M?L]Z?<_$;XB>
M-?B-?Q2&%?.BM#/\Q1Y <*K8ZQPA4XYPX[4 >G?"?X,^#O .N6^J:?=SR^(+
MJP$IM[FZ4LL;X+.L8 .TD8R<U[#7S!\)9)O&'QJ74EEWQVD4DF[ !,21B!!C
M'HR=??ZU]/TWH 4444@"BBB@ HHHH XGX(?\D7\ _P#8OZ?_ .DT==M7$_!#
M_DB_@'_L7]/_ /2:.NVH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OQ)_X*--X6^'G[?+>-QK5EXMN;?4M'OM;\'/:W$$UN(+>
MV(A:5HS#)'+#'&=RN2#*5*?+D_MM7QS\?O\ @E_\,_VB/BUKOQ"\0^(_%EAJ
M^L?9_/M]-N;9;=?*MXX%VA[=FY6)2<L>2>@XH G\._\ !5S]FW6=+@NKSQE?
M:#/(NYK+4-$O'EB/]UC#%(A/^ZQ%=]\+?V]/@5\9_'6F>#?!OCG^V?$FI>;]
MDLO[(OX/,\N)Y7^>6!4&$C<\L,XP.2!7SS_PY3^#/_0W^.O_  +LO_D6O0?@
M#_P2_P#AG^SO\6M!^(7A[Q'XLO\ 6-'^T>1;ZE<VKV[>;;R0-N"6ZL<+*Q&&
M'(';B@#[&HHHH **** "BBB@ HHHH **** "O*?VL?\ DUGXR?\ 8F:S_P"D
M,U>K5Y3^UC_R:S\9/^Q,UG_TAFH \S_X)C_\F-_##_KE??\ IPN:^HJ^7?\
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M.FQO,\@7S9C,Y)\Q@"P SA0#_"/3N22>HI %%075PMG;RSR"1DB1G811M(Y
M&3A5!9C[ $GH!7&6OQE\.7>IG3H8?$!OE6-W@;PSJ2M&LC,J.^;?Y58HX#-@
M?(W/!H [JBDI: "BBB@#B?@A_P D7\ _]B_I_P#Z31UVU<3\$/\ DB_@'_L7
M]/\ _2:.NVH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(_X*4?L9^#?V4?#/P\\>?"N&\\-M%J(TZ[D_M&:69KH1F:WN49V)1P892=A
M!V;57F@#]CJ\#\1_MX? 'PGXP_X1G4_BAHL6K"0Q.L1DF@B=3AEDG1#$A!X.
MYQ@@^AKPW]JO]JC5[3_@FKHOCRPNFL_$_CC3-/TTW=BH58+BXBW7A7/W?DCN
M4!7E2RD8QFOGG]E/_@G7X$^-?["^H>-KRVGO/B+KMOJ,^BWS7LD$5A);R2PP
MQ%%)1T>2#+LR$[9"%P0#0!^L^E:M9:]IMKJ.FWD&H:?=1K-;W=K*LL4T; %7
M1U)#*0<@@X.:\V_:Q_Y-9^,G_8F:S_Z0S5\3_P#!%+XL:GKW@/Q[\/\ 4+KS
M[#P_<VVH:6DC,SQI<^:)HU!.!&'B5P !\TSGO7VQ^UC_ ,FL_&3_ +$S6?\
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M&K=-50B@*  .@ IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ?T__P!)HZ[:N)^"'_)%_ /_ &+^G_\ I-'7;4 %%%% !1110 4444 %%%%
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M3,%UXH\*W,.2<+&/L<9'M\T;GCUKZ8_X+57"+^S#X3ASB1_&-NX'L+*]!/\
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M/^N5]_Z<+FOJ*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***RM?\
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MCG*[<8W-GZCI*6D 4444 %%%% !115/4([R2$"RFA@FSR\\)E7'T#KST[]J
M+E%<GI=WXBU"^U:#[=IB?8;I;<-_9\AWYABEW?Z_CF0C'M75T +1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU^T)XTNOVEOBW->^"_#^J:M::;8K91?8[62:2:))9&\\HJ[D4M+@9YQMS@G
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M_P#D->*_^PFG_I';5T%<_P"&_P#D->*_^PFG_I';5T% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >>_M"?\D/\<?]@FX_] ->A5Y[^T)_R0_QQ_V";C_T UZ%
M0 4444 >5?!O_DHOQV_['.V_]1[1J]5KRKX-_P#)1?CM_P!CG;?^H]HU>JT
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M(^AJ** "BBB@ HHHH Y_XA?\B#XE_P"P9<_^BFKH*Y_XA?\ (@^)?^P9=?\
MHIJZ"@ HHHH Y_PW_P AKQ7_ -A-/_2.VKH*Y_PW_P AKQ7_ -A-/_2.VKH*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;A=0TS1=57FX; V7%Q'C"Q* JQ08"[57Y0@4']/Z2EH **** "BBB@ HHHH
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MV0<#)[DD]=X;\-Z;X1T.RT;1K*/3]+LHQ%!;Q X11[DY))R23R223DDFM6D
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M69A.EI,QW&5W)/F3 _Q#@')!8X8?4-%%( HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _*W_@I=\9/'_@/]M+
MX::'X:\<>)/#NBW>CZ9+<Z;I.KW%K;S.^HW2.SQQN%8LJJI)'(4#M7ZI5^,?
M_!8^.^F_:^\$1Z9YHU)_"EBMJ8&*R>:=0O=FT@\-NQ@^M<7_ ,*N_;W_ .?S
MXN_^%/=?_)% '[H45^%__"KOV]_^?SXN_P#A3W7_ ,D5[G^Q'X"_:XT7]J#P
M7>?$^Y^(TG@:/[;_ &BNO:[/<V9S93B+S(VF8']Z8\9!PVT]J /U=HHHH **
M** "BBB@ HHHH ***X6\^.?PXT[Q/_PC=W\0/"UMXB\T0?V1-K5LEWYA( 3R
M2^[<20,8SR* .ZKRG]K'_DUGXR?]B9K/_I#-7JM>5?M8_P#)K/QD_P"Q,UG_
M -(9J /,_P#@F/\ \F-_##_KE??^G"YKZBKY=_X)C_\ )C?PP_ZY7W_IPN:^
MHJ "BBB@ HHHH ***2@!:X_XE?$O3_A?I>GWVI6=]>QWMZMBB6"(S*S1R2;F
MWNH"A8VZ'/3@U)XP^)WAWP.K#4K]?M8&19P_O)CQD#:/NY[%B![U\Q?'/]H>
MP\3V,%I=V\.FZ9;W2SQ&3,MPSXD16(7[H*%N #T/S&G8#TC3?VDM(T>^\07<
M^BZG/!=W"74*6GE-,<0QQ%2K.J@_N\\,?O8QQSY[\4?VA/&WCI9M-\*X\$Z-
M(&1[Z4B74I%*D?*%.R$$GJKEQM!# \5Y-J_CS1=(TZ2Z_M"VN2%)CB@F5VD8
M#@ #/!..?>N[C_:\T"PM].T[X8_#5[[Q1(A'FW</FE'"C=Y:QEI9E*^9U:/'
M!P>15.R H?#7]FGQ FL/JT6DW-_J#KO>^UZ%"F]@29565>6).0PW$'!R.M=[
MXUT_PQX-N6E^)WQ+CEOX"=^E6,CW5Y\R!E !RR9ROWH\8QR,\<T?!_[3'QR_
M>ZKJG_"$://^_CMVF^P@*3CR_+B#3< GY9CVZ]*[OP!^P1X&\,R077B&]O?%
METF=T4G^C6K'=E3Y:$MD #@R$'GCD 3<#YW^(7QZ\$F\@A\&^'=5-O"BI)>:
ME>(AG8%@6\L*V"?EY##_ '!5OX6^*_C1XG:_U3X9:0D5L66REG6.UE9& #%=
M\XX'S*> !PN>E=)\2? W@>]\<:K]B\)6=E:02"VCAC>:$?NU"$[8W5<DJ6SC
M))YR:]!_99CTGP;XZN--TS3A81ZQ;F-Q#+*ZM)$"ZE@[G@+Y@! ZM]:K6VH'
M--\/_P!JSQ<Y;4O$4FBF0B$XU&"W"KQ\^+4' Y/(&[@]>*Y'XJ?LS_&31_"-
MWJ.L^*;KQB9)8XWTNPNKZ_EF!(PVUH^0NT'D<;17Z$5YK\9/BA=_#>WTL6-I
M#<W%Z\GS7&XHJIMR, @Y.\=^QJ /S[^$/@?Q-X1^)6BZQK/PTU_7-,T^Z'VR
MQ;29VQE.&*^7]Y ZR!2.<+ZYK]3:^6K']HG7["ZU&=+#36>^G%PX9),*PB2/
M ^?IB,?CFOH[PKKR^*/#NG:JL)MQ=PK+Y3-NVDCD9QSSGGCZ4VK ;%%%%( K
M)U;3[JXWSP:M>6 2/_50)"5)&3D[XV.?H1TK6K UKQ?H>E_:;2\UK3[.Z5#F
M">ZC1QD9'RDYY!H /"]K>RZ?87UUJ]W>&>W21H9$A5,LH)^[&#P3ZUOUR?@_
MQ=H=YI.CV-OK6GSWIM8E%M'=1M+D(,C:#G(P>/:NLH *Y^S_ .1^UG_L&6/_
M *-NZYWXV>--1\#>$H+W2S$ES-=I;[Y4W;5*NQP.F?D YSU->#1_'3Q;#J4]
M^MW;_:)HHX';[,N-J,[*,>N9&_,4TK@?7=)7CGA?]H;0U\)VDVNWC-K05_/M
M[2U?DJS!<'[N64+WQDGI5>]_:>TV1X8M)T*_O[B1P@BG=(B<\ +MWY)/&*+,
M#1^(GQH\,?V/XCT)+F:6^:VN+,;(3L\PHRXW>@)QFN&^+^@^$_VNO^$:\'2^
M*]6TK1;;58]3U30XK=5@UZ"$%_LLK<,%W*K<-C"ME2VQD\EUR[>_UK4+F2$V
M\DUQ)(T+9)0LQ)4Y'4$^G:M+P'H^IZ]XLL+'1KW^SM3E\SR;H2O%LQ&S-\RC
M</E##@=ZKE ]Y^!?[/\ IW[.,GCE=)\0W1\':OJ;ZM8>'YTCBLM 5EW3QP$<
MA&DWMC(55V@+D,[\M^TEXLL-:BT&UTO5[>_A5YI+B*TN%D4-\@0L%/7[^/J:
MWH_V:UU"]-QKOBJ^U0[-H*Q!9 <C'SNS_+UXQU(K)\>?LXM;VFG#PHC7,B,X
MNC>W #N#@H1P%X^8<>HZ\TE:^X'@YZ5]I?#"ZGOOA_H,]Q+)/.]JI:21BS-[
MD]S7SM_PSWXU_P"?"#_P*C_QK?L_"OQ/^%-LL^FN-0L %>2SMV-Q&O))7RR
MP.>I3L>M4[/0#Z4HKQOP;^TEHNJK'!KEN^CW7"F9<R0,< ?[RDDG@@@#^*O6
M[*^M]2M8[FTGBN;>092:%PZ,.F01P14 6:*2EI %%%% !1110 4444 %%%%
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M/0CX'D\&? [Q*;_6=3W0ZGXDM898A8V^WE+9V"_O7SCS5SL4-M(<JR0>%?\
M@DWX\^,FN6WB[]H3XM7VH:O,2)]-TQS>7*0E2ZQ+=S?)"4ED?,:0O& #M;YL
MK]>_#3]@/X"_"W1;G3M/^'&CZN;M=MQ>>((!J4\@Y& TP;RQ@](PH. 3D\T
M?@)\/?$?C#P]XBCC\#:IK>FZ]JJ_V8B>'[B:*ZNUE90+<"(AI [!!LYR0O'2
MOV=_8W_X)D_#SX0^%M!\3^.=$/BSX@7>GPS7MGKT4,]EI=PPWM%# -RETW*A
MD9GR8]R; Q6O0OV>?^"=OPF_9M^)6H^-_#L&HZCJ\V]=.75YUG328W+;UM_D
M!R4;9O<L^T$;OF?=]14 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E
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MM#9VR9VPV\8C1<DDX4# R2?SKQW6/BG\8;'X-Z'XCL/@:=1\?7EZT&H>"?\
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MR.#GB@#]9Z2ORL_X;Z_;>_Z-R_\ +&US_P"/T?\ #?7[;W_1N7_EC:Y_\?H
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MQ:^.,-XZ6OA&26# *L=(E)Y X^]ZTVK ?3MU=0V-O+<W$R6]O"C222RL%5%
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MV>_#.H_&7Q-JMOI[JFGV\:SWNHN0$@=B1'&(^&9G <Y P!"V2"5#-6Z@>L?
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M9)GD*@A06D9FP 3@9P-S$#DUV=% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IK=.*=10!X5\'?VO?"'QN^,/C_X<
M:'IFMVFM^"[F>VU"XU""%+:5HKAH&,3)*S$%U)&Y5XQT/%>ZU^:7_!/C_E(!
M^U/_ -A;4O\ T[2U^EM !1110 4C=*6F29(P#@T ?D7^PCHW[16I:?\ $YO@
MOKO@;2=&7Q3.+Y/%<<[3/<8&"ACB<;=NWJ0<YKZ2_:BT_P"*^F_\$]?BU%\8
MM4\.:KXI+1M#-X765;46OVBT"*PD1#O#B3/'0KS571?^"7][X0O-8E\*?M ?
M$+PC;ZI>27UQ::%<M:1/(Q)W,L<@#$# R><"O1+']B'4)O@G\0/AUXG^,/C+
MQO;>+%ME&H>(;EKN;3Q#()"(A([ !R!D<=!0!^<W_"PIOV6? /Q(\*VL$%G:
M_%+X4^&=3TSEE:2>6WM[6Y" #&YUN-0D)]817U)_P3Y^&J?!_P#;&^+G@P10
M13Z-X1\/VUU]F4JCW(LK0W$@!_ORF1_JU>T>/_\ @G=X0^(-_P#!:[O]9OA+
M\-M.L=*4K!&1JMO:F(QI,"?E!V/G:/\ EJ?2O4? O[.%CX'_ &B/B!\6H-8N
MKC4/&%K:VMQITD:"* 01QQJ48<G(B'7UH ^8_AF/^-R7Q9_[$Z#_ -$:97T7
M^TA^UUX>_9EO]"M=<\)^+_$KZO%-)$WA?38[M8A&4!$A>5-I.\8QGH:?X?\
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MK'B#5W$EY?W#=6=L9VYW$ D\NQ))8D@'LU%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M()VM*]KY1/'\+L.G- 'Z33_\$1?!#>*DN(?B5X@C\-!,-ITEE UX6R>1<@A
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M,6PHD3 )W1A0!O)KS3X9_M;?MI?&'P/I?C#PA\#_  9JWAW4U=K2]_M*.#S
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M4/&&I? KP9;^';#3I-6N;W^U(F\NUCB,KR;%ORYP@)VA2W;&>* /T-HK\]/
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M]+\7^$?@=X,U;P[JBN]I>?VE'#Y@61HV^22^5QAD8<J.GIBLKX-_MM_M@?M
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MFN],\+VEFMA<J@+".&2_CE\QXU5BI4*!M+!!'D8^TU&%Q7YS?%#]KO\ ;/\
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M6O,[;X">'[7]H2[^,:7FI'Q/<^'QX;>U:6/[$+83+-O">7O\S<@&2^,$\=Z
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M9)^$=WX*F\1IXH:?5IM3^VI9FU"^9'$FS9O?IY6<Y_BZ<5[_ $4 ?"G[ O\
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M%% !1110 4444 %%%% !7B_[0/[7OPL_9ECMD\=^)%LM3NX6GM=(M(7N;R=
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MG8^/M>'@OP5)J]SINHZM]KB@,*Z?9& %9) R R26J@ J>9  ,D"@#]0?"?\
MP4<_9W\<>*M&\-Z)\0OMNM:Q>PZ?8VW]B:C'YL\LBQQIN>W"KEF498@#/) K
MV?XI?%CPC\%?!]UXH\;:]:^'M#MV"-=76XEF.2$1%!:1R 2%0%C@\<&O@_\
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M^ST?65B2XGTR1$N%$<R2KL9T=1\T:@Y4\$_6@#Q+_AZ/^S%_T4S_ ,H.J?\
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M,KE@,+N&2,BO2:_''_@JQI%S'^VIX!O/'ZW"?#6ZL["&*YMXY0@LTN6^W(&
MYF7>S'9R%DASU% 'W'\*_P#@IE\!/BUXI@\/67BBYT/5;JY^S6<>NV3VT5TV
M,J5EYC7=C $C(22 !D@'ZEGN([6&2::188HU+O([!550,DD]@/6OQ6_X*A:3
M\$KK6OA=;? Z'P;=ZA<)?6^HP>!#;RB0[K86JR+;$J9"6F S\Q]^*^KOVZ_B
M#XL^$/\ P35\)Z/K1O8O%_B'3]'\,ZO<2W :>*8VAEO/,<$[R_V::)CDY\TG
M)H ](U[_ (*G?LZ^'_&!T)O&-U?1I(\4VK6&F3SV43*V#\X7=(IYPT2NI'(.
M"*^H/"?BS1O'7AW3M?\ #VIVVLZ+J$0FM;ZSD$D4J'N"/?(/<$$'D5^97[)O
M[$'PS^*7_!/"^\2ZCH$-[XX\0V6JW=OK5P6,MC/;S3PVXBVD80&W5BO\1=P2
M00!K_P#!$KXD:CJG@SXC>!KNX:73]'N[74K"-R3Y?V@2I,H.>%S!&P4<9=SU
M8T ?IO1110 4444 %%%% $%S<PV=O+/<2K!!$IDDED8*J*.223P  .2?2ODO
MQ!_P50_9U\/^,%T)O%]W?QK))%/J]AID\UE RDC[X7=(I(X:)74\$''-9?\
MP5J\:ZMX/_8_U*WTKSXUUS5;72KV: [3';L))7W'^ZQB6,^HDP>":\7_ &&?
MV'?@]\9OV(;36?$N@PW7B/Q']O:;76E87&GM%<RPQ&%@1L"B)'*\AMQW9!Q0
M!^CWA'Q=HOCSPWI^O^'=4M=:T6_C\VVO[*4212KDCAAZ$$$=000>17E/[0G[
M9/PI_9C>WM?''B/[/K-U US;:-8P/<WDL8. VQ1B,,00K2,H8JV"=K8^(O\
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ML3_\%(/ >K^ [;^P]$NVT_6&TVVR(H89II;6ZA0$\*Z1RG&<#S"!@  ?M)0
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M 5"L$2W#S"-%F=51I HW%025!/H-S?\ ?1]:FHH _%7]FG_E,EJ__8Y^+/\
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ML LD8W')'WI)"."* /IVBBB@ HHHH **** $K\N?VWOVN/%7[2WCZ3]F_P"
M<,VJ_:Y7LM>U>T; N]IVRVZ2=$MDP?-E)P^-H.S/F_=?[5UK\0M2_9]\9Z?\
M+;*2_P#'-_:+96"1745JZ"214ED661T562)I&4[@<@8YK\?O!/\ P3]_;&^&
MNJ3:EX0\,ZQX5U&:$V\EYHGBZQLYGB+*QC9X[M25+*IVDXRH/84 ?JG^Q/\
ML@Z3^R'\,'T>.ZBUCQ5JLBW.M:Q'$8UF=<^7%&"21'&K$#/4L[87?M'Y[_\
M!.K3QX/_ ."DWC[0[J7-Q;C7; %AM+R1W2YXR><1L<9/2OH/_@GW\(?VJO 7
MQLU/4?C;?^*+GPD^A3P01ZUXMCU6'[69X"A$2W,N&V++\VW@$C/.#S/[6G[$
M?Q:\"_M,#X^_L^117VJW%PU]=Z6C0K-:W+Q-'.ZI*0LL<RL^Y0=VZ1\#&, '
MAW_!:"WEN_VK/"4,,;RSR>#K1$CC4LS,;^^   Y))[5^TJU^67P!_8Y^.WQ^
M_:@T;XT?M#0G1[719K>]MK*=XA-<O =UO!'!$Q$$22 .^\ L2PVDR,R_J=0
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M9P:?>6LR:A;:=*83/=74<:QVS&*$E84A"(PW$/NC3@Y8U^GE !1110 4444
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M&D08001E@-P7?(Q;:,M(PZ 4 ?'?_!#V\BC\8_%>T9@)Y;#3YD3/)5))PQ_
MNOYUQ'[1EM+>?\%E-*CAB>5QXO\ "TA6-23M6WT]F./0!23Z &O0OB)^QG\?
M/V1?V@M=^(_[.=A%K/A_5EG1;.W6"26S@FD61K1X)2"Z*ZH4:/)Q&N<<Y] _
M8=_8I^*B?M#:G\??CNWV;Q07GEL=/DN(YKB2XF0QM/)Y3&..)(F:-(AR,CA!
M&H8 _2*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEG(.'QG:<>G_ !0_X(I>-X_%]VWP\\:>'KKPO(2]NOB22>VO(,LV(F\J&19
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M&<<_/C 'DVA?\$4/BW<:M:Q:SXT\%V&EL^+BYL9KNZGC7U2)K>-7/3@NOUH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWE% 'A7[&O[,-E^R?\%+'P='=1ZGK$\S:AJ^H1*52>[<*#L!Y"(B(B],[-Q
M+$5[K110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image95.jpg
<TEXT>
begin 644 image95.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P@ 1" .<#OD# 1$  A$! Q$!_\0
M'0 !  (" P$!              <(!08! P0""?_$ !H! 0 # 0$!
M       #! 4! @;_V@ , P$  A #$    ;4@
M                                                        &IR^
M(&NUXTLQ83WS(^>R)7DG&G/(M>4
M
M
M
M                      07=KUHT:W6X  )NISV=S;78Z
M
M
M
M                                       !#EN"JFG4X   !.]*Q9C.
MM
M
M
M                                                      #'^N44
MVJ&+]>0   /IV[6/>W.'V
M
M
M
M             !#5N"JNG4     G6E8LUG6@
M
M
M
M                            *O:52$;D     &\PR76Q[P
M
M
M
M                                          %4].I#EN     #;HO=
MX<:^
M
M
M                                                        !76_
M6KU?K     2A6FM_E7
M
M
M
M           -'FCI1L40    +19MN;:<X
M
M
M
M                          I_K4HPL1    ;'X]WDQ;WHYT
M
M
M
M                                           8CUYI?L4M7D\   9'
MG;DY%W=89
M
M
M
M   !B_7FLFE6B&U#\N "0X);19MK:HO8
M
M
M
M                           & ]^8ULQ83WYR7GLAUY=OB]@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                             #5Y/'>[EO'?7SH
M
M
M                                                   '1WF,]<\O
M>='7UQWN^[RR/GU]@
M                 JWI5(4N0<F?\>I @EERI+*-:;Z
M                /'WF']^<1[YX.\Z.NCO/OCO=]_GN6\]S<?KW<Z
M
M      //WF&]\\O>>OSW-^.]KH                    '3WF+]<\O>='7U
MQWN^WRR7GU]@                           &/]<T&>/2)H].E\:S+YUV
M3QC^\X  !].YCSW8H_6T1>]RA][Q#)O,/OT<Z
M                                  -9D\48VJ/RX -RBDM5F6MSAD
M                           '!J4OC19X]&FCU*7SJ\OC#^O/     ,KY
M];1'ZW&'WO,,F_02;5%[
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MB.U#%MF'19_'6X        /0[O\ 7DE*M++56;.>/0
M  ZW(GM109=@T">+@           '8[)E:2<J=B3*TO(            !\E.
MM:E&]B(   "18);CY%W[                *H:E2'[4    &XQ276Q[OHYT
M            5OT*T 7JP  S7GU>3%OY'ST
M#3Y?$'7:\1VHL;Z\@            9GSZEVI-,E2;=89              !5
M+3J0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M        _/G=SO-W@  &R1^[UXM\   0S;@K9HUL3Z\@     #V<[>S$OY?S
MZ            ^"*[4,%W8(]GB^0           ?;LDUY)QI6)0K2_0
M            !\$.VX*\WZ^MR>              !MT7NQ%"S+%6;D
M      &$]^:0[-'$^O(   %BZ%FPE"R               (<MP53TZ@   'J
MYV[&/>VV+V            !$MJ&I6I3   L-0LV)H60
M       (\GBKSH5XZGBX               !(,$L]T9Y1K3?0
M !5+3J0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5
M<          _/G=SO-W@  &R1^[UXM\  8WURJNG4BRS"       +*9]J>Z-
M@           ?)$-N&O%^MJ\G@              ;5'[L-0LR[4F^@
M          :#/'6+2JZ7+&                -ZADLYFVMYAD
M  $7V8J@ZM+@   ':[<S(N[]!(              -:D\4DV:/@[P   "T&;;
MF^G.             -'FCI3LT0.0<@V#QZO9AZ
M  &ES1UKT*T<6(@                 -OB]V2S[4G5I0           !5+3
MJ0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M      _/G=SO-W@  &R1^[UXM\ #59?%/]6GK4G@       ;G%)=C&N]CH
M        &C31UBTJNC31@               #=89+.9UK?H)
M   /-WE<="M!-V#Y<                 'V[.U*>QN?9]/.@
M5ET:L%7:X   &P^/=W<:]D?/0            !U.4PV*6B31@   2I6FMWE7
M              -?D\T5W,\#D'/1SDO%AZ&RQ>P
M!C?7*WZ%6%;D/PX                   ))KRV=S;6TQ^P          !5+
M3J0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M       _/G=SO-W@  &R1^[UXM\ :3-'3O6IXKUY       'V[=/'N[S#(
M        .CO*[7Z\"7J_6X                 /HG&E8LCGV?7SH
M      UJ3Q4G5J:7+&                   -OB]VVR[FU1>P
M!Y^\I7L4M,EC    EJK-;7+N             "N6A6K[>K    9WQZN[C7LK
MY]              8?WYHCOYP.<@Y ZMGCW91J3@
M 1C9BJWI5,%[\@                    >KG;'9]F=:5CZ          !5+
M3J0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M       _/G=SO-W@  &R1^[UXM\#2YHZ;:U/&^O(       $YTK%G,ZT
M      ->]^:E:M/1IHP                  !M4?NVV5<V^+V
M  (]GCJ+JT\9Z\@                   #W<[;#+N2C6E           &J2
M^*3[%'Q]X   !:/-MS93G            $>3Q4VUZ?PX   /MVXN3<D>O*
M            ,3[\T2^@S>0''7(.2R^5<FFA9                     ZW
M*W:-:!KM?@                      $I5IK9Y=OU<Z         !5+3J0[
M;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M   _/G=SO-W@  &R1^[UXM\:W)XI;L4L-Z\@       9SQZO)C7_ '^>@
M      :'/'4/5IXCUY                    'KYVUF9;EBK,
M (IM0U.U*GG<      'T[M4?K?()-QA][''ZS_CU[O/?7SH\O>8KUS7Y/.K2
M^-+F\:!/'AO7D      #L=LYFVIOIS@          "%;D%6M*H   !Z^=NOC
MWMMB]@          #&>N4BV:& ]^0   )_HV+(9]H              #7Y/%
M(/H<T<N <CKDL?DW)MS[0                    Q?KE1]6G'D\0
MR/.[Q!)N47O:8O>P1^LSX]9#G?1Q]'0>/US%^N8+WYUR3SJ,OC2YH]3E\_+@
M       WZ&2WV3=R?GH         JEIU(=MP   #]",+1[^=
M       &B31TKV*(   E.M-;S*N          ?GSNYWF[P  #9(_=Z\6_P"#
MUREFO1U*7P   !DN>I(K2;M#)G?'1K<GF/YXX]L1]#EMLNY+-68
M",+,52=2GY>\      ')M,?O>X)-SA][''ZS_CU[_/?7SO)Y>\Q/KF D\ZO)
MXTN;QH$\>$]^0      /IVRV=9G>E8          $36H:G:E3J<     ')(,
M$LNU)I5K2YOQZ      X-/E\17:AA^W#JLG@     #DLIGVIZHV
M  !4O4IQ):A    W"+W=;'O>GG0          *DZE.)K4(   &\0R71Q[O<Z
M              !J,\=,M_,'/0'+@Y+%Y-V;<ZV                   !K
M_OS3S7I:G)X      &UQ^Y<J32A6EW6&3[       ,5Z\QS8CBRU%%EF'P]X
M      -WADN3D7??SH        %4M.I#MN    ?H1A:/?SH
M      T2:.E>Q1   $IUIK>95P         #\^=W.\W>   ;)'[O5BWZD:M.
M*+,(   VB/W8.A8ERK-Z.=  &,]>8WL1RW5F          BZS%4C5I]#@
M  Y-]@DEZK-*U6;.^/0      U&7Q%=J&'[4.I2^      .2Q="S8.A9
M     $;6(J@:U/H<     ['9CJ33Q1L;A%[         $?3QP3>KQ39B^7
M   .2SF=:G*E8           QWKE(]FCKOOP   !.-.Q9[-M          "%
M;D%6M*H   ![N=NUC7MGC]@              "/+<%2MW.Y!ST#G(++8U^7\
M^T                   -=D\TRUZ.O^_(     ['9<JS3G2GWR"0
M   >/O(EM0P1>@TV6,     "1();A9-ST\Z        *I:=2';<    _0C"T
M>_G0                  !HDT=*]BB   )3K36\RK@         'Y\[N=YN
M\   V2/W/%*>L>C5   [';!4+%@J-COYT              1[/%3O6I^;O
M   /MV7ZDT\4I]UAD         &A3QP3=KQ-:B^'     !9//M3Y1L
M  #4)?%+=BCX>\     DVO+97.M;;%[           &G2^*V:-6-+$0    '
MT[;'+MRY5F           T&>.F6O2ZW   !R6YRKDJUI@        !JLGBDV
MS1\?>    6JS+<RU)P               (BT*M:-J@.0'.1T+3X.E)=*P
M               !@O?FF.O2UN3P    !R2[5FL7GV=FC]@           #@
MBZS%7/0K:=+&     )BJ3VMS+8        JEIU(=MP   #]",+1[^=
M             &B31TKV*(   E.M-;S*N          ?GSNYWF[P  #W\[U'
ME[P  9+SZMMEVY'KR@              :M)XI5LTL=WR    !(]>6RV=:W*+
MV           -2E\5NT*T7680    .2U69;F2I.       ,9ZY2?8HZW)X
M  &0YVS&;:F>I.             (HM0UATJN%]>0   !ZN=N;D7=XAD
M      KU?K5UOU@   ,IY]7=QKV>\>@       !T=Y2S7I:5-&   !+U6:V.
M7<                $"ZU*"-6ER.\Y .06]^<U=QK3
M #Q]Y3#8I:7+&    !M,?NTF9;D*"0              ?!!UVO7+0K>'O
M  +.YUJ<J5@       "J6G4AVW    /T(PM'OYT                   :)
M-'2O8H@  "4ZTUO,JX         !^?.[G>;O      !E?/JX^3=W.'V
M         !X.\I3LT=5D\    #V\[93.M3;3GY             (NLQ5?TJF
M!]^0   !WNW)R+N_P2       5(U:<3V80   !MT7NW>5<V:/V
M    ,3Z\U6U*D7V(@   !GO'J[F->ROGT          /@IMKTH\GB    D*"
M6Y61=^P       "M>C5@2[7    V+Q[N[C7LAYZ                *R;N;
M%NA5Y .>AR"[7RFUD/'H                 #@J1JTXHLP@    3;3GLQG6
MO5SH               &MR>*I:=309XP   !W.W5Q[NZ0R       "J6G4AV
MW    /T(PM'OYT                   :)-'2O8H@  "4ZTUO,JX
M  !^?.[G>;O      /0[<C(N[_!(               *HZE2'K4     VB/W
M;S*N;7%[              &,]<JSIU(ILP@   #,^?5W,:]FO'H     "%+D
M%6]*H    ),KRVURKGNYT               ?)7+0K0!>K<    $HUIK?95P
M          # ^_-(MFCB_7D   "Q-"S8:A9       $;6(J=ZU/Y<   '8[<
MW(N[]!(                !4+Z7(U.S"Z'( ,EX]76^3V\7ZC]//7KYZ
M              @J[7K+HU0   !W.VAS;4T4YP                !U.5HT
MJT&7*X    W.*2Z^-=[70      *I:=2';<    _0C"T>_G0
M      !HDT=*]BB   )3K36\RK@         'Y\[N=YN\      LWG6ITI6
M              !#MN&J6G3    $BP2VXRKF2\]               '!7F_6
MKQ?K<    $D5Y;C9-WD     UN3Q2#9H^/O    )2K36VR[??SH
M       $$7:]:-&KP    6GS;<T4YP          (JM0U&U*?    .QVY>1=
MD""0      8GUYI#LT<)[\@   6)H6;#4+(                '5WE(_K</
MI]<'(!SW@WNE8M5\WK\$'7,S>(;.]0V@               -/E\4HV:/G<
M  ]O.VYRKDDUY0                  ()NUZT:-;Y<    M7F6YDJ3@
M  52TZD.VX   !^A&%H]_.@                  #1)HZ5[%$   2G6FMYE
M7          /SYW<[S=X     )$@EN5D7>0              # ^_-'=JAX.
M\    DJO+;O*N>KG0                (1N05@TJGR    6=SK4Y4K
M%/-:E&=B(   #>X9+E9%WU<Z                 ! -ZO6[0J@   9/SZO-
MBWLMY]           5@TJL'W*X   &P>/5W,:_D_/0    !P5#U:<6V80
M) @EN9D7?L                 U6S#47ZG&.#D Y'4R9%Z?L/2'4Y5K1P]O
MBL3Q3U/MT              ?!2W8HZ+-&   ![>=N%DW9 @D
M        A>Y!5O2J_#@  R_GU9;.M3%4F       %4M.I#MN    ?H1A:/?S
MH                   T2:.E>Q1   $IUIK>95P         #\^=W.\W>
M   =CMW<:]MT7L               5&U:<4V80   -TBDN=CW?;SH
M          $%7:]9=&J   ![^=O)BW\YX]    1;9BJ%JT@   ,QY]7=QKV:
M\>@                  *MZ52%+D    $X4[%G\VT          !YN\I1L4
M=0E\    2O6FMQE7     !!MVO6+1J@   9+SV[F-?V'QZ
M   $5:=.N?T&6.7 Z'(+'?/:LHYEP#%>HZA:/S^SQS6;H[>0Y[
M    @V[7K%HU0   .]VX&3<DBO*                    !"%R"L&E4X /H
MF>I/9/.M9/ST       "J6G4AVW    /T(PM'OYT                   :
M)-'2O8H@  "4ZTUO,JX         !^?.[G>;O     )CJ3VLS+8
M      C:Q%3G6I    9/SZN[C7L_X]                   5DT:L%W:X
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MVW    /T(PM'OYT                   :)-'2O8H@  "4ZTUO,JX
M   !^?.[G>;O    !R7@QK^W1>P              ."DVS1TJ6,   "V^7<E
MBK,                   .EREVQ2T>:,   ?;MX,:]MD7L  "'[<-4-.F
M !+U6:V.7<                    &D31TJV*7PX   )KISVDS;8
M    A"Y!5_2J    >KG;K8][;XO8   \W>4IV*.GR^    )HJ3VGS+8
M             JO]3B:7=K\CHX.09*/W<CXSZ$  5AN8<;2T\_XEM?3WLSYE
M            %=[]:O%^L   !.-.Q9[-M                      #Y*EZ
ME/<8O<_4;'?SH         JEIU(=MP   #]",+1[^=
M &B31TKV*(   E.M-;S*N          ?GSNYWF[P    2-!+<G(N@
M       "*+4-1]2F   !*E::W>5<                    &GR^*2[-'J<
M  $Q5)[6YEL  "D.S1TZ6,   >OG;TXM_-^/0                    %6M
M.I"MN    >GG;WXE_+^?0           J-JTXILP@   ;=%[NOCWO5SH  %9
M-&K!=VN   !M$?N[>->]G.@                 =?>4R^U^=\_K@'([P<DA
MYMNRGS&T  -=]0T]N_.=;FS>)[9U/H/?SV           /'WE#]NAC/7D
M;;%[NSCWO3SH                                  JEIU(=MP   #]"
M,+1[^=                   &B31TKV*(   E.M-;S*N          ?GSNY
MWF[P    6LS+<QU)P              !2K8HZ+-&   /0[>;%O[#'Z
M               K'HU8,NUP  !W.WLQ+^=\>@ ([L14TUJ0   $_P!&S9#/
ML@                    # >_-%MNAT.   "R>?:GRC8           &,]>
M:1;-' >_(   $W4Y[0YML  1?9BJ#JTN    =[MTL>[NT,@
M     U2W7JG]=A<] X.0.IV^>U9?Q=$  "M5C$BN6AP2!'<M16W?IT
M    ""KM>LNC5   'T70R+V^P2
M 52TZD.VX   !^A&%H]_.@                  #1)HZ5[%$   2G6FMYE7
M          /SYW<[S=X   !Z>=OSAZ'MYT              #1)HZ5[%$
M"=*5BS>=:                     &&]^:)[5#R]X   +$T+-AJ%D "I^I3
MB"U"   /5SM\,2_E?/H                     "JVG4AFW    -NB]WAQK
MX           $>3Q4VUZ?PX   .2VV7<EBK, ,+[\TAV:.(]>0   +)Y]J?*
M-@                  ")=G/@7Z+)'(< #BU/R._M5.P  !J7JO4&U\Z!.\
M.K.D.J          !1O:H:I)X   $R5)[5YEL
M            52TZD.VX   !^A&%H]_.@                  #1)HZ5[%$
M   2G6FMYE7          /SYW<[S=X   !)]>:X&3<               %6=
M.I"UN    =[M[,2_G/'H                     "K^E5A"Y7   &RQ^[TX
MM_D \7>4'W,_R]X   )MISVBS;8                      TB:.D^Q1
M O#C7]NB]@           5UOUJ]7ZP   &3\^KN8U[8/'H<%/-:E&EB(   "
M2:\MQ,F[]                   %=OI<:--2B' <#CCW>/=Q?C/H_IT   5
M#L_/:AVL.QVW%?Z';_-@         #0YXZ6:]$   =SMYL6_L<?H
M                           52TZD.VX   !^A&%H]_.@
M      #1)HZ5[%$   2G6FMYE7          /SYW<[S=X   !9K.M3K2L
M            >;O*$;F?X.\   $QU)[69EL                      :E+
MXH]LT.    77Q[V\0R 1':AJ9J4P   +NXU_<HO8
M  %(-FAI\O@   6/S[5@*-@           #K*9Z]'0)XP   ) @DN7D7>QV!
MKM>M.C5    RWGU=[&O9OQZ                   %1OKOG<'/$X XX D//
MN63^<VP   (5DS*^RY#@;CYL6ZA^AY=         %8]&K!EVN   )BJ3VMS+
M8                                   %4M.I#MN    ?H1A:/?SH
M                T2:.E>Q1   $IUIK>95P         #\^=W.\W>    78
MQ[V[PR               1;9AJ%JTP   +IY%[?()
M    *5;%'19HP  !86A9L50L@54TZD-VX   !N<4EW,:\
M        *_WJ]<-"J   )%@EN5D70           !KTGFD>Q1QOKR   !8:A
M9E6M+2S8I>=P   <EO,JY*5:8                   8N2.GOUWS@X'  <3
MWAZTN9>B   !KO8::3?- .+,Q[DJ>;X         HCMY^O>_(   NED7M]@D
M                                    JEIU(=MP   #]",+1[^=
M               &B31TKV*(   E.M-;S*N          ?GSNYWF[P   ?;O
MZ!X6AZ>=               J[I5(2N0   #:H_=Y<6^
M      ()NUZS:-4   ;W#)=3'O 4,V\_!^_(   LEGVI]HV
M          !JLOBC6S0   'IYW] ,+0[G0           !$MJ&I>I3X   !]
MNYWQW7_?D   "<J=BSN;:                    CN_3K9]!B . ' MG\S]
M!LD$X    I?+\U@47 -EY-<B/Z/Z=        &GR^*0;-    ;/'[O1BWP
M                                 !5+3J0[;@   'Z$86CW\Z
M             -$FCI7L40  !*=::WF5<          _/G=SO-W@   V6/W>
MK%O@              "BNU0UJ3P   +$T+-AJ%D
M  :])YHEM9_   !VNW_PM#U\[K<GBBFU0    O/BW]HC]@
M         43VJ&N2>   !=S'O[G#[             JWI5(4N0        #;
MXO=U\>]Z>=                    @O8RH<U,T#C@ 96*2X/S/T6-YXP_(\
M-YBPW(\/R+#<CP_(\-R+#>8\1R+/7)L%)%P 6F\;TE<N@       "#[L%8-&
MH   )]HV+)9]H                                    52TZD.VX
M!^A&%H]_.@                  #1)HZ5[%$   2G6FMYE7          /S
MYW<[S=X   )(KRW'R;H              &$]^:&;>?P   "[V-?W&+V
M                  !1W9H:E+X   %T\B]OD$D26H:EZE,   >SG9\HV
M                     !$EJ'4I?    M1F6YGJ3@            >3O*3;
M-'5)/        ]/.W7Q[VWQ>P                   !5GZ#!TVU6<< #@>
M?-\XKYV/I<    ';-Z[['0."1>7+6<WP       !5#4J0_:@   %Q\F[)%>4
M                                    52TZD.VX   !^A&%H]_.@
M               #1)HZ5[%$   2G6FMYE7          /SYW<[S=X   )GJ
M3VHS+8              $768J@ZM(   >AV?Z%CD
M    BFU%ILL8   L_FVYPISUUOUJ]7ZP
M     G>E8LQG6@            !ILWBE6Q1\[@      %G<ZU.5*P
M             .KO*9?2_-='>!P<X' Q6#X\69X     ^_??1:Z X^W;LOI\
MJD        H_LT-0E\   =CM_L+0]O.@
M       "J6G4AVW    /T(PM'OYT                   :)-'2O8H@  "4
MZTUO,JX         !^?.[G>;O   !8*C9L;GV0              *_7J]<="
MJ                                 )MISVBS;=3=2G$5J$
M                        2K6FMUE7              (*NUZRZ-4
M 2E6FMYE7.0                    :A8K54W, !P '&"^7BZH>     ?7>
M^BWT.!P64;<O]T0      !UN?GWO9_0X  !M4?N\N+?
M                    JEIU(=MP   #]",+1[^=                   &
MB31TKV*(   E.M-;S*N          ?GSNYWF[P   68SK4[TK
M    %5].I#%N                                  297EN'DW:6[%'0
MIHP                                !NT,EV<>\             !P5
M"U:<7680    !F_'J[V->RWGT                    !$=[.@#3R  X ZX
M>8+YF(     <GHM>N !Q*G;]H/6Z       -=D\T2VL\   2G6FMYE7
M                                *I:=2';<    _0C"T>_G0
M           !HDT=*]BB   )3K36\RK@         'Y\[N=YN\   %K<RW,5
M2<              "F^M2CBQ$                                 -M
MB]WBQK]$]JAKDG@                                 9CSZOOAZ
M           Q/KS2+9HX/WY    'T[<3)N237E                     %
M==/&BZY0X' .!QX\_F+QHP!['K,=ES'J3,=ES'9,SV3,=ES'9,QZDI_Y^=Z7
M '&9[)=R3Z@       :%/'2W7H@  "<Z5BSF=:
M               JEIU(=MP   #]",+1[^=                   &B31TK
MV*(   E.M-;S*N          ?GSNYWF[P   6^RKLHUI0              *
M.[-#4I?                                  ]_._H!A:- MS/QOKR
M                               .]W]",'1               BZS%4'
M5I    "9JD]J<RV                     !4C8^=UJ6 .!P!Q*67?W:I:S
M'9<QV3,=D]O?8   %((OE\2C <"Z\OTV>[,      !%5F&HNK3   %B*%FP]
M"R                                    !5+3J0[;@   'Z#X6CZ.=
M                  &ASQTLUZ(   E.M-;S*N          ?GSNYWF[P
M7-R+TA02               4,V\_!^_(
M     Y+YXFA1+;H=#@                                 'Z%8.CVN@
M             "K.G4A:W     ,KY]7=QKV=\>@                    /
M)WS2_9^8^7!P!P!<?(^ER_F4     "E$/S& 0N. "U\OT$D>KH      $/VX
M:H:=,   64S[4]T;                                     %4].I#E
MN    ?H'A:/LYT                   1]/'3'7H@  "4ZTUO,JX
M  !^?.[G>;O   !=S'O[G#[               H!NYV/[P
M                   "S6=;K/HU?EP
M    "_V'HY'ST             ")+4-3-2GP     2+!+<?(N_8
M           -)FJU7TOG^  .!L7B>WN7]&      *30?+X#D0 %B9-F;Y-0
M     "%[D%6-*H   +,9UJ=Z5@
M  "JVG4AFW    +_ .'HY#ST                   1U8BIKK4@  !*M::W
M65<          _/G=SO-W@   O1BW]GC]@              ?GWNYWD[P
M                              #?89='FCZG   !=W&O]P
M                   -HB]=CH             U_P!^:1;-'&^O(     %C
M*%FP="R                    (=M9D!7<@<< #@EFMHV(I;(      I-7^
M7P'(> .!-,FI9";:       A>Y!5C2J   "R&?:G^C8
M                    JUI5(5N0   "_>'H93SZ                   $
M;6(J<ZU(   2S5FMMEW          /SYW<[S=X   +XXFAGO'H
M    #\_]W.\'>   "ZN/>]W.@                            #DI1L4?
M%W@   OUAZ&5\^@                                          !\%
M-->E'T\0      [7;FY%W?8)                    *Z7<6*;&>X #C@L?
M3VI3@T      !1^M\MA>1. !*DFA::?>       AVW!5+3J   "P=&S8S/L@
M                                    5>TJD(W(   !??$T,QX]
M               ",;,5/M6D   )=JS6RR[@         'Y\[N=YN\   %^\
M/0RGGT              !0?<S\1Z\@  "^&)H9_QZ
M           H=MY^!]^0  !>K%O[+'[
M              %>;]:NU^L       -B\>[NXU[(>>@
M "IE_P">U#W6 X' %QJ'TF=\S      "A]3Y/R/+@ ;_ .[EO+/T0      $
M668:AZM,   334GM-F6P                                    *T:-
M6![M<   7RQ-#.^/0                   BVS#4+5I@  "9*D]J\RV
M     !^?.[G>;O   !^@>%H^SG0              *+[5#6)/    O!C7]OB
M]@                             4DV:.ERQ@  "Z&1>W^"0
M                                 #09XZ9:]+K<        ERK-;/+N
M                   <%)]#Y;RO( <<&6Y)<ZC].      .MR@]/Y(  ;IZ
MLW(M?2@      :!/'2_7H@  "1H);DY%T
M         "NFA6KW>K   "\V+?VF/V                   (DM0U+U*8
M G"G8L_FV@         /SYW<[S=X   /T'PM'T<Z              !2[7HZ
M#/&   +C9-V2:\H                             %0M6G%MF$   6IS+
M<S5)P                                         !C_7*1;-'7??@
M       "T^;;FBG.                  ,-V*FEWYD .. 2/'=L]6W@
M !BN1T9J?*@ .MN]6;FV?I0      ->D\T1VL\   9KSZOKAZ
M                          $ WJ];M"J   +L8][=X9
M     !"MR"K6E4   $^T;%DL^T         !^?.[G>;O   !^A6#H]KH
M          %3=2G$5J$   6@S;<WTYP
M*TZ-6!KM<   6"HV;&Y]D
M   5-U*<16H0   )*KR[A%[@6[7    ]G.W9Q[VU1>P
M-#]U*K6?G^  .!/,.O-L6H      -/\ -:FE;YH  ;3ZL72L_3       =;G
MY][V?T.   "^&)H9_P >@                                   !"-R
M"KVE4   %R<F[(U>4                   0-=KUIT:H   L70LV$H60
M      /SYW<[S=X   /T-P=+Z               *YZ%:OEZL   )XI6++YU
MH                             "%KD%6=*H   )+KRW$R;H
M                                $,VX*K:=0   #+^?5WL:]E/':7;%
M+1YHP   -TBDNICW>_G0                !$DF=7.?% < "U-??W[S<
M  'RYB^>(MCH5LAQ  !MWJS<VS]*       *0;-#3Y?    M?F7)@J3
M                               "*+4-1]2F   +=Y5R5*TP
M           KO?K5XOU@  !:'-MS=3G          _/G=SO-W@  'T?H;@Z0
M               A^W#5#3I@  "0H);FY%T
M    #3)HZ1[%$   >_G;^X6C]@
M      &L2>*2;-'Q=X   .2WN5=E&M*-8D\4EV:/A[P   "=Z5BS&=:
M            $$2Y,'291P <#BZ]?ZC))!Y^></R/#<CP_(L/R/#\BP_F/#\
MCPW(L/R/$\CZW.1Z#ET ;KZLW%L?2       "JFG4ANW    )@JSVOR[8
M                                 CZ>.F.O1   %J,RW,]2<
M            5HT:L#W:X   MQEW)7JS          ?GSNYWF[P  #M=_0K!
MT0              !JLOBC6S0   'JYV_P!AZ'?SH
M          ZW*![N?X.\   %V<>]NT,@
M            Z7*6[%+2)HP   )SI6+.9UH 0W;@JIIU    .2W^5=D^M*
M              !6V7$BCWG!P. ?7EME&UA^1X?D6/YX     'UWO/0.<CH[
MOWJW;J?Z(       0C<@J]I5   !D>>KZX=_T\Z
M              !K,GBBVU0   %C\^U8"C8                   %4=2I#
MUJ    71R+V_02          ?GSNYWF[P  #T._H/@Z(               X
M*#[F?B?7D   70R+V_P2                              5 U:<7V80
M !8>A9L10L@                                       "MNA5@*]7
M   W"+W=;'O>GG0 *HZE2'K4    &7\^KO8U[->/0                JM)
M\_'WJF.!P!U1<\=/@      'WZ[STZ Y!)_J]:B;?       &L2>*+[5
M"V.7<EZK,                                   !TN?GSO9_P .   3
MA3L6?S;0                   IMKTHYGB   %\\30SGCT         !^?.
M[G>;O   /7SOZ"86B               !4G4IQ-:A   $^T;%DL^T
M                      !!]R"L&E4   &TQ^[S8M\
M      #Y/H               C>Q%3K6I_+@   ]7.W7Q[VW1>P !X.\I)LT
M=:D\    237EN)DW?H                J'[^<U#M8<  Z*_/-7X      !
MV^SH  3'[T[*2[8       %&-JAJ\G@   2#!+<[(N@
M                  "A^WGX#WY   DRO+</)N@                  "BF
MU0UN3P  !Z>=_03"T?H          _/G=SO-W@  'NYW] <+1
M     AFW!5;3J   #8/'J]N)H?0                       /D^@    #"
M>_-#MNA\.   "YF1=D."4                      #P>N4HV*,LU9I\HV,
MCYZ             ,3Z\TBV:.#]^0   +/9UN<:4X   T::.E^Q2Z7    +(
MY]J?J-@               "F'OYC H@' 'FK<Z8N       =LKD  $\>]:?I
M-@       "N.A6K]>K    73R+V^02
M      4XUJ4;V(@  ,_X]7PQ-                   #H[S\_-W/ZG   -N
MB]WAQKX          _/G=SO-W@  'NYW] <+1                Q7KS0O<
MH=+@   N'DW9,KR@                      >/O*4[%&4*TL_4;&4\^@
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MZ                  &DS1TFV*(   E^K-;#+N          #\^=W.\W>
M >[G?T!PM$                5"U:<6V80  !)=>6XF3=
M         K3HU8&NUQD.=GFC8GBC8]W.@  "([4-3-2F   /IV[6/>W.'V
M                   !H$\=,=>E\N #,^?5@J%B;:<_?SH          $&W
M:]8M&J   !G/'J[V->ROGT    /DIUK4HWL1    ;+'[NYC7O=SH
M      %''ROC>> !P)@BTM@39CU)F.R9GLN8[)[^^P   (9\YE<?&*!ST +7
M>_H)%[=        %,]>E'D\0   %P,J[)]:4
M           0S;@JMIU   !:S,MS'4G                  $#W:]:-&J
M +(9]J?Z-@          ?GSNYWF[P  #W<[^@.%H@               "++,
M-0]6F   .2Z61>WR"0                     #2)HZ5[%+K< &6\^K 4;$
MX4I_3SH  Z7*)[=#!>_(   DFO+<;)N@                    #Q=Y239H
MZQ)X   V'QZLOG6I7JS          :A+XI1L4?-W@   ^G;BY-R2*\H
MPGOS2+9HXCUY    F&I/:[,M@              45Y\ITN. .#Z+U>OJ^UT
M     5J\X<0^<T<]Z !<SU]-LW9P       !%EF&H>K3    V/Q[O#BWO7SH
M                                  &K2>*,[5    2?7EN!DW0
M            !2[7HZ#/&   +F9%V0X)0         !^?.[G>;O   /=SOZ
MX6B                .LHOM4-<D\   "0();G9%WD
M   \O>4GV*.I2^   ,]X]63SK4O59@ ! =ZO6S0J@   6QR[DO59@
M             *K:=2&;<    %KLRY,-28         >;O*4;%'4)?    $^
MT;%DL^T      (OLQ5!U:7    !:O,MS)4G              %%O/RGGYSAP
M 9=)=OW]2      !3;S\UJ_('0 '87H]?5]KH        ^2DNS1TR6,   ";
MZ=BT&;:                       KEH5M\@DE&M*          ."A.YGX?
MUY   ^W;T8M[9(_8                 U*7Q1[9H<   'H=O]A:'IYT
M      ?GSNYWF[P  #W<[^@.%H@                0;=KUBT:H   %J,VW
M,].<                    "L&E5@^Y7    M)FVYKIS@ #Q]Y17;H8;UY
M  &5\^KOXU[-^/0                   $06X:GZ=,   #<XI+M8U[Z
M     !6+2JP;<K@   ;O#)=+'N]SH      %9M&K!-VN   ![N=NUC7MGC]@
M             4;\?*>#G@'0-L6+CR?2@     #PO%'^?+?(  -B[-<Y],
M       (PLQ4_P!6D   !R6TR[DM59@                     ((NUZSZ-
M7DF*I/9G.M9/ST         "J6G4AVW    )NISVAS;8
M JIIU(;MP   "2*\MQ\FZ          !^?.[G>;O   /=SOZ X6B
M        !Y^\HOM4,![\@  #(\[=W%O[#X]                    13:AJ
M/J4^    ;7'[O!BWNQT  "#[L%8-&H   !(4$MR,BYVN@
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M           ?GSNYWF[P  #W<[^@.%H@                "&+<%5].H
M!O<,ES<B[W\Z                  !J,OBENQ1\'>    7"RKLFUI0  !UE
M)-FCI\L8   $V4Y[1YML                  8?WYI1L4=?]^0   )?JS6P
MR[@         PGOS2'9HXGUY    M1FVYGIS@       #5)?%)]BCX^\
MGRE8LGG6@            !36+YG5.5W X!)7J]:R7Z       0/W)@ED\]
M"<N:L]\UP         -<D\4@V:/B[P   #,^?5S<>[M,?L
M     "(+<-5-.IU.  "8*L]F\VSE//H        >3O*%[F?C^\   &]0R71Q
M[O8Z               .ERE>Q2TJ:,   =KM[\2_F_'H          #\^=W.
M\W>   >[G?T!PM$                 ?)2K8HZ/-&   !,=2>U>9;Y
M             ,7Z\TJV*6LR>    )5K36ZRK@    T.>.E^O2^'    +!4;
M-C<^R                 ,;ZY377I:9+&   !E//J\>->S'CT        !\
ME.M:E&]B(   "7*LUL\NX         (5N05:TJ@   'T[<+)N277E
M      J1%\[H'FGP "5?6A:*7>      %3_7SVA=J <] "S?C=E'E\
M    0E<@J[I5    !G?'JXF3=VZ+V                  !"%R"L>E5ZW
M !F?/JV67;D2O*        *P:56#[E<   ">*5BR^=:               %9
M-&K!=VN   !*]::W&5<           'Y\[N=YN\   ]W._H#A:(
M        &ES1TIV*74X   !/-*Q9;.M                 #P=Y3C7I:--&
M   ![^=O%BW\]X]     5JT:L"W:X    GFE8LKG6N0               #%
M>O-0-:GHDT8    MEEW)=JS         " KU>MNA5    V'Q[N[C7LCYZ
M      !4O4IQ):A    S/GU=[&O9CQZ            %8XL*)/&< =$J^[]H
MI=X     #J<I%)\MYGET  +D1_2['R<          "I6I3B6U"    ,GY]6W
MR[<BUY0                !UN5MT:T#W:_    !D.=NYC7MCC]@       #
M59/%'=JC\.   #DLQG6IVI6              ! ]VO6C1J@   "Y^1>D""0
M          ?GSNYWF[P  #W<[^@.%H@                 "NFA6KW>K
M "<*=BSN;:^@               #&^N5#U:<?3Q    "U&9;F>I.     //W
ME*MBEILL8    F6I/:/-M=_.@              :+-'4K5IZ_P"_(    F2I
M/:O,M@        #2)HZ6[%+I<   '8[<O(NR!!(          ,=ZY2/9HZ[[
M\    2;7EN#DW>0           ""8\JOL6. !*ON_:.;>      TGM6I<OSH
M#H#D]SW=J#ZGD           \/>4MV*.H2^    !VNV-S[,]T;'T
M        :_[\U3U*D>3Q    #DM=F7)@J3         "I^I4B"U    !R60S
M[4_4;              @&]7K?H5>    "2:\MQLFZ           !^?.[G>;
MO   /=SOZ X6B                  .IRE^Q2T6:,    2[5FM1F6_5SH
M            &E31U)U*FMR>    !+=6:VF7<      &L2>*3[-'']X    -
MZADMCEV]DC]@            #S=Y7F_7@6]7Z7    !N$7NZF/>]?.@
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M  #W<[^@.%H@                  :[)YI+L4<9Z\@   #=(I+8Y5O:H_8
M            Z.\K]>KU_OU^AP    ;5'[NMC7O?SH      $7V8JAZM/X<
M   'NYVQV?9G"E8^P           ?)$5N&NM^MK,G@    #+^?5U<>]L<?H
M        56TZD,VX    -_@DN9D7>QT           "O5^M76_6    [W;I8
M]W=H9           !A>14?K?+\.. )#]W+<6/HNMS%<CPWF/#\BP_(\-R/#\
MBP_(\/YCPW(L/R/SO/OT/7;,'+H =39%J3W#K@           #3)HZ:ZU/&^
MO(    'H=GJC8GNC8R7GH            $>3Q5NT:VB31@    "5:TUM\JY]
M@          KY?K5SOU@    -IC]VAS;4BUY0         !'<\57M.KJLG@
M   ">:5BRV=:            'Y\[N=YN\   ]W._H#A:(
M    C>Q%3W6I]3@    ]7.V)H69VHS]SH           X(FM0UTT*VJR>
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MQ;9AX     -OB]W7Q[WIYT            ?GSNYWF[P  #W<[^@.%H@
M              0G<@J[I5.     #:8_=B,^S+=6;[         !YN\B2U#
M]Z#3)8P    !Z^=N-DW=^@D         KIH5J]WJP     &UQ^YLI3R]5FS7
MCT      !\FASQQ!;AA^U#C?7D     #W<[<#)NR#!(         -=D\TCV:
M&.[P   "V67<EVK,             ,#[\TBV:.+]>0   )FJ3VIS+8
M     K+!AP]'F@ <<     #NF[D=+T'0'(Z%R:7TV;Y*             -,F
M\4\UJ6&]>0     .QV2*\DNU)I.KRYCQZ       'R:/-'%-J*'[<& ]^0
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M      #+^?5OLFYO4,@         ZRF6O1T&>,   "9JD]J<RV
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M)-OB][%'Z]'.@ ?)A/?G6I/.E31Z#/'']B/"^O(      &3\^K>95R0()
M        (.NUZRZ-;K<        ^G<CY[[./5SO3UY.\QWKG0X        !M
M\7NW65<V:/V         !7:_6KS?K    ;/'[NWC7O;SH              %
M8-*K!]RN   !D.=NWC7MDC]@         #HYYHW5^6QW/  V_P!6=0\U@
M ,IK>^V?H =<@DJ&]9BGN               8_URJNG4BJS"         !Z>
M=]#O9QT=YY>NMP         >KG;-9UJ:Z<X              C*S%475I^=P
M                   =SMLLNW*]68             #\^=W.\W>   >[G?T
M!PM$                     0M<@J]I5>IP       #Z=]_'M\]]?.]1X_7
M,?ZYYW         -JC]V[RKFU1>P           (WL15/U*F(]>0
M           )CJ3V?S;7MYT         "/IXZ:Z]+K<   '<[=''N[Q#(
M            /+WE*=BCJ$O@   #>X9+GX]WM=          %<(,6$X\L 6$
MEV( AR>EY'+N2[[S'9,SV7,]DS'9,SV7V>_5?]7'=#D= "?*FO,M;3
M         '!!=VO6_0K>7O                     -UADM=F6]LB]@
M          ".[$51=6GCN\                  'MYVVV5<DRO*
M      /SYW<[S=X  ![N=_0'"T0                     (]GCJ9JT\+Z\
M@                   2Y5FM)FV_?YZ            !A/?FK.G4C&Q$
M               ,OY]6<S;4N59@         !C?7*1[-#7O?D   "R&?:G^
MC8                &H2^*4[%'R]X   !8"C9L?GV0         !K?F"EE?
MYGX<Y!-LFI*?N_\ 3N8[)F.R]_>@ ".YJ58K^$'7(!R.K6YOT.Y160
M         !JTGBK^G5CF>(                   >_G;$9]F=*4_8Z
M           -4E\5)U*>HR^                 !LL?NW&5<W*+V
M       !^?.[G>;O   /=SOZ X6B                      ,/Z\U<TZL5
MV80                 !E//JS&=9F.I.              !#]N&M>A5PGOR
M                .QV:J<UC,^SE?/H          "I>I3B2U"   !(\$MQL
MB[]                 $'W(*P:50   #[=N+DW)'KR@         "KT.#%'
MB@!MWJQ<J?Z4    0%=R(=M9@#H =[U=+'^G[G0                !$EJ&
MN.A6UF3P                 /0[-M*>P-&QF?'H                 #Q]
MY6_1K0=<@^7                )@JSV=S;62\]               'Y\[N=
MYN\   ]W._H#A:(                       B6U#6G1JX#WY
M      'V[,U2:Q^=9R_GT               !X^\@J[! ]ZOB?7D
M      ?3LK5I;%9]G;8O8           A:Y!5G2J    97SZN]C7LYX]
M              5%U:<5680   ,YX]7=QKV6\^@         -=Y#3"'YGH<'
M)=V;ZC-=E    J1J?.ZQ+7 =#D&Y16K5Y7T                   Z7(>MP
MP%?KZI)X               &1YV;*4\Z4K&>\>@                   -"
MGCK3HU=#FC              &U1^[)YUJ4JTH                _/G=SO-
MW@  'NYW] <+1                        \O>0;=@@2]7P_KR
M      /HE*M-8K/L[C%[                  \O>0W;AA.Y!I4T8
M     ]G.S%4FG:E8VN+V           !JTGBDNS1\?>   #DMUE7)4K3
M              #%^O-(MFC@??D   "4:TUO<JYR          0#XR('\9(%
MB_>S-?O4   &,]1TVV?FN!T.0.A,=+3GG/U@                  !P1Q8B
MA6Y!%MF+R=X            .QV0H))EIS2Q5F]G.@
M #@BZS% UZO'D\7            !N44D\T9Y@J3=CH                'Y
M\[N=YN\   ]W._H#A:(                        'F[R'K<,)W(-&FC
M          'KYV7ZLT[4;&WQ>P                   !J,OB)[4,8V8M(F
M\=;@        &2\^I)KR2I6FE2K+[.=             B>U#J$O@   #/^/4
MT4YP                  !HTT<8V8@   !,M2?8H_0         '0Y3R/YS
M5.5QMW;%QY/I   !&EJC6[3Q'0!T.N2RF5MR/5N@
M>+O(SLQ1?9BCJQ'KWOP         ,YX]2%!))=:64*TN6\^@
M           !JDOB'K<,568=2E\<         &P^/<IU99AJ3;U#(
M           (3N0=8  !W$U4YP                         !JDOB)[4,
M868M'F\=3@        &0YV2*TLJ5I95JS>[G0                      ,
M=ZYHTT>D31ZE+YU>7Q@)/.']<^7   /0[FX_6R1^MIC][G#[WF'WN$,GV
M                                                      :OR"GW
MGYSR/(MWZ^BWGMH  "O^ECQ)>SP'0 YZN)@?29;Q(
M   !@/?G29H].F\:M+YUR3Q@_?,5Z\^3O.  <F0YW*>/6<\>MCC];+'ZW&'W
MN<4FQ1^@                           ,#[\Q]8CT>:/3I?&LR^<#[\_#
M@   Y,QY];-%ZV^+WN\,F_P2;7%[
M                     \'>:-/'H\WC4Y?&K2^,![\X?WSX<   ]#N:\>MD
MC];1%ZW.&3>8?>Y0R?8                           /@Q_KGA]<Z'/CK
MMX]'.Y#SWV\[R
M             ",N4:M\POGJ1URUG=\  "I>Y\]K,\ #H 9N.6W_ ,_]&
M                       !TN>;TZG/IWOX]''VZ
M              !UN8KWS%>N>7O.CKY._CT\[E//<KY[Z.=
M                                             'P>#USP>N=+G7UV
M\>CG??Y[[N=Y
M                                                !#3,KFQA;=]#
MO2V !X/7BFOT?S7 ZY#KH"2J5VQ^+M
M
M
M
M                    "%V97?N/MBQ<#GT78Z -!MTZR;N('0Y'0$ZY&K,>
M9I
M
M
M                                                     13W/K9Z
MQ9TYJSKYU0!".MEPKJY@'/0 =6>^>W=YIV@
M
M
M
M                         !I7:M9/>)9?QM[SRT!6;Z##T&]4 =!T.2XW
MR7TF0\>P
M
M
M                                                           ,
M:\0-[R9M\Z>>Y,*>_6?.8J6,.N0!UFH9;>?)?1
M
M
M
M                               #2O57;_-GQ2>*>?7_ #CKD#H.A(>=
M<LE\UM@
M
M
M
M#3+M6KWU6$Z#H<]!U,F'I3?@:H
M
M
M
M                    B[6H5]^EQSHX ..!8;YK8D_*O
M
M
M
M                                       "$]W,A7=S#HXX X!:7Y/<
MW.E9
M
M
M                                                          $
M_0Y42:]  <#@<%P/C]_-P2@
M
M
M
M                "N'TF1&>G3<< .CC@78^+^A[>=
M
M
M
M                                    %;OH\F,M*F#O' '!Z?'JZ_QV
M^
M
M
M                                                       !6[Z'
M*B_2J#@ XX&5B]W.^2W0
M
M
M
M              *^;F;#VM2XX ''.C+Q>[G_ "FV
M
M
M
M                                  !#FI2KWN9PXX.@<&5C]W4^4V@
M
M
M
M                                                     -0LPU%^
MER.'1P!QP=G.WG^3V^0
M
M
M
M             <%,_IL?7IO X .!SMW/E]C*>/0
M
M
M
M                                 $0Z-6M>UGCC@Z. 6TP-*0*DX
M
M
M
M                                                   '!5;<SHTN
MU^'1QP!/^5<GC,N
M
M
M
M          #S=Y6?9H1-=@ XX&XUY;E8.D
M
M
M
M                              (YM0P;HU8\LQ=?0XXN-AZ&]5Y0
M
M
M
M                                                    /#ZYI<\6
MB6(XCN0;C!):C)N@
M
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M<O:4-C$3#0=8;E)[P,.&6#5+CI)"%"Z*D8@^MGU33$%Y13(3;IG@(3+A(ZC
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M=+[%@ _@VA\_5,%MOM.E,?(PLHGP+8U]QU+@6YA9*5REN[>]4KE+BP6H4?\
M5^MT#_$KN!H)7.'!N%UDWS X& >X%T:I>105]-4" R6=PVW=7A#K<5#<3!QZ
MS(V#_,,1K<B(;0J&N"3<%NR?D)87$1YBB=C 6^8)ND<"CS9:P,A)Y0WOPFZ7
MV+ !_!M#Y^J8+;?:=*8^1@IIG746!D6+:^Z9_P!96P-A*YRN;A=5-]0C@9![
M@'/^JV>YDKX+4IOD+;@Z4WFJ!@+CU%3 (LAPM4_VMSDEAHKJ#K65PVO&,-N6
MMQH^TOLUZ"%@;A/@43$O$^ 6?U;JM-%5J:I5TZ)W'^7-S VDWFZ[^%72^Q8
M/X-H?/U3!;;[3I3'R,#:+\6X-@<A[F2]@M0F_MN#A3N;(N ,2H(0H8D;*0Y#
MO+T'"V$WE*#N+B(<L7,#--\8V-7<1J\N,Z)KM\1Q*98L&3+[3<8UXF.]+*<>
MI?M3(54) 0*[$<&!7^B!P+<U,H@6Z84H%ND;G MR5<2!7RMBP*Y%4:!#@XLU
M91YL)V,%5Y@B:*ZIWTDO!:A/\YG\*NE]BP ?P;0^?JF"VWVG2F/D8+>@^LZ]
M>MG>7)&%H)O*V[N+K(<M<6!C&^+:T7-->@V\!,:@N;ZN1U<CJY'5R.KD=7(Z
MN1U<CJY'5R.KD=7(ZN1U<CJY'5R.KD=7(ZN1U<CJY'5R.KD=7(ZN1U<CJY'5
MR.KD=7(ZN1U<CJY'5R.KD=7(ZN1U<CJY'5R.KD=7(ZN1U<CJY'5R.KD=7(ZN
M1U<ASKE+B4L%K#?JH>K-E0CQ9RH K=4] 6+B&QVNW@VXF;4[S7%.#O%'K @0
M806>(/M8BGR]>T5SSGKN#!;XAP+8_"KI?8L '\&T/GZI@MM]ITICY&"U8/G7
MM?<@UP[7P 5TAC]6XZN1U<CJY'5R.KD=7(ZN1U<CJY'5R.KD=7(ZN1U<CJY'
M5R.KD=7(ZN1U<CJY'5R.KD=7(ZN1U<CJY'5R.KD=7(ZN1U<CJY'5R.KD=7(Z
MN1U<CJY'5R.KD=7(ZN1U<CJY'5R.KD=7(ZN0Z7!2Y%#!:DWZB5%V3/\ K_!+
M3F?*H:QU-T-QIA@ 0J/GMRUN# VH420(0XTS _>:J\:\=/\ GLHKF'6E'I*2
M;H7<9XMR]]%$Q*R1:1(G^%72^Q8 /X-H?/U3!;;[3I3'R,%I0_$77W9,^ /X
M):HSY%B+GF/5<?X);0;TG1K;C-7BP<S$:_/3_P#C:W8:X1OX!*O-7CE_GMML
MH>NE: 02008XLQQN]K%N+<?X7=+[%@ _@VA\_5,%MOM.E,?(P6G#\"&ONF8]
M1=_!+=#>DZX?0OK.O\$90WH.G6SEXR?36Y"?R(R2,MJ"4F HY#:[C&?(0[Q*
MO+1HK<G.'7M XQ?00,%M0/5='X7=+[%@ _@VA\_5,%MOM.E,?(P6M#\C=U]P
MA?5=GX(TQO0<L.,3U7!^"(XW#J^N54P%8(+*2,B*.*4IU39#8DWT_;+A&?56
M.\S/PH[ B8X\!-M5&@)C+8L!6V5Q("M:;G 5JPY0%;%,I@*WR*' 311P8%H]
M,7L13G+U;0/L7T6I@M0#XJGX7=+[%@ _@VA\_5,%MOM.E,?(P6WH\K6U[L$]
M5R_@A$;AST*5?J*/X(#5Y!M?<!"!4T;%;)+*G57;7(9XM=[V^Q@5Q/"MLD!P
M$Q40* FTE P$2+@8E>CTE;M037&HN>Y=?E;&"T@?X9=+[%@+_N7VA]?LT\%M
MOM.E,?(P,"CR-+7KE?J+7X+S&4#3\1OP4*KSA:ZXCIYD:Q)BD,D'D18!74[:
MS8\BI6JJ==7>D%. 3,K@_P"^[;?&/7;.>Z,_!N8+32_]/\+NG]BP$_W)[0_I
M^#2P6V^TZ4Q\C S:/(U]>H3\3_X+S2)_Y_!4ZKSI^M?[IY,2R,MSS;RC35(2
MG:GD9X9N][>*<<MYG!_WW;:XQYB>>ZL_]AP6G^!^%W5^P8$[]T_:+@S_ .(X
M+:?:-*8^1@;%/E;FO-_*_!>9P)+P$P!-9&$"]IHT>TT:/::-'M-&CVFC1[31
MH]IHT>TT:/::-'M-&CVFC1[31H]IHT>TT:/::-'M-&CVFC1[31H]IHT>TT:/
M::-'M-&CVFC1[31H]IHT>TT:/::-'M-&CVFC1[31H]IHT>TT:/::-'M-&CVF
MC1[31H]IHT>TT:/::-'M-&CVFC1[31H]IHT>TT:/::-'M-&CVFC1[31H]IHT
M>TT:/::-'M-&CVFC1[31H]IHT>TT:/::-'M-&CVFC1[31H#HI"HUBZL@H*:H
MGQE0[EMNZO-+:KD&?*3[[=%/55,S@_[[MM>)X*>>ZLO]AP6EG_Z_X7=7_O<"
M5/Q3-HN)/_B>"V4O^3:4Q\C @4^5"UYZ7@=P$6PCC$O::-'M-&CVFC1[31H]
MIHT>TT:/::-'M-&CVFC1[31H]IHT>TT:/::-'M-&CVFC1[31H]IHT>TT:/::
M-'M-&CVFC1[31H]IHT>TT:/::-'M-&CVFC1[31H]IHT>TT:/::-'M-&CVFC1
M[31H]IHT>TT:/::-'M-&CVFC1[31H]IHT>TT:/::-'M-&CVFC1[31H]IHT>T
MT:/::-'M-&CVFC1[31H]IHT>TT:/::-'M-&CVFC1[31H]IHT>TT:/:B/!VCT
MSF!)K]1*_&*ZZ0J'DYJG$I9@Q*@1&>Y:7&F[3<4QZBOWV\*>BC9ENOU%GMML
M)Y'%GNG+Q;N"THO@+^%W6E_O.!&_=(VBX\_^*X+7R_Y)I3'R,"53Y4O7J]'I
MJN!OU^H@[ZO4>DN8&S7ZC=_&+D.G0H*T,@*2>?!4R>T.TQQ+B[T(IP*/F-U^
MH:[6&)Z;ISW*#\[7P6K%\J[^%W8I_P#?P(,_,A[1<F?_ !;!:RGQ<.E,?(P$
MY>!37N>CTW'@:-?J-G?7F#Z#HP,,QQ#5_%WBY:6ZFB"5"UZ%@.GDQS9YS\)&
MAN(,]R25XU3S"5>F'W,V?@Y\[\"]5IX+?&>&=7X7=NG_ %X&M7YVWM%SJ_*V
ML%J*?]WTICY& O\ L7U[[!]!UX+>&/7:N^W)!])TX+6&/40?Q90/@IA->6AE
M]2T=O'5S(MLRT/PR1WL$KQ#@S*POH)7<TI^#DSN$'B$' BF>"5_PN[5/_K8&
M37YVKM%U:_!#P6FI_P#:TICY& +]@M?<\'TG)@M28\R3OMV"WE/8+3&/ 7\6
MN Z><',+(:\W H7&:DBU6$H;%(&6VO!.),V5[C^@V^^VA7P!S.\;T&UW-;[%
MG$HD*&,%, ; @'>8HGX5=8/Q1L%O:_,TMHNS7X$<%I*/]&E,?(P4_M3K[LE_
M_)@M.8\I_?;J%/51<%NSO!NC\5N&Z>6%<*4F#+!]'2041/&!H,!.UN5MQ3PM
M1Q"-Q3 '#- [)<D7RI/>QBW#MS)55*F0JN1 A\N$@:0>YI2\SDT#N+<(YL%L
M#_$('X5<P+SMC!;6OS-?:+MUX;4A>"/I3'R.^7[SV"Z!3UF]@81W@G1OKR*<
M:V<! U,B>HKD)1^)N)=";R8=."J!K!_F&(U^1$/T<2$$X4PZ3%3S>&W#JX47
M9+FB_P"KO32W!IWZ"& @8%<*8# KV1 H%N.CAP+=$E*!;J50+<]1J@6X:T)
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MD0 .&:!U[F=Q1N!+*X;7C6*WS4YJ:TCM<=#<3!AJS N"BBH6MFMFENINF4"
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M1+B(C)9BU#=(RM.-1M,;2.*<VDVFFH3W#FU!:6H;IY&VYU(6MJ&V6?#=4?Y
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M[1.)Q.)Q.)_5]5]PFN=(T+RP*+BKJ2?TNS=%$[2S]P4;1T:8947#)!V%L74
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M2</ZPTWB'1OM7Q,9[2/63(:9.>@8^X*+XFV?TRR_-%WK.TV;KHVKI&F&5$[
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MV;_2"".1U;+=P3.=)]RX)#.G9W/P-+.'6\,[0O/UR,73%PQAF,.,,1<$71!
MH#1-JN*!I/(OI_2K*>1%%8NJ(V=D36*-I,D:<94#EL=G5>11?1>3N%G;E[S]
M2D*Y&%V;_2""GD:-G5)4N])U%Q4MN9;Q%>I20O.%V8CI@B6>HL[<_<:2U! F
M84HJ,S49<OCS26@+$H(*3([/<G&'%P1<$71$J1H#1LKO(I/MW%3_ $FS'W2H
MVE,E3V>RIYDT;4<AIQE0.6QV=5U<N])Y%Q6W--XBO4I(5R,+LQ_""",_6.4(
M5?3.B\W?3MH!49"&T!"94%(2O.'6</F-,VC$5* )<A2><OGQ50HH,Q"5!0F*
M3[=X7ANQU=G7=5+O26B^F4$2,C^D-FZL&B^F\C9V4W447S-9TXRH'+9&U7TS
MHO(OIVT"9D(;1AIE04A*\X=8N<QZ[,O\:3[=TWAMC#=T7C2M"[RKNE GR$-H
MPTRI6AS\!79<N&1RIOMW3>'ZBTN^F=*T-S]PW!I@2FN'&"CF,M0DWD@T7$W%
M2V5I%]4J)Y03,STXRH'+9+,N1NTK0W=-X;99VY>XTK0N9N^L&1F(2J^)T5)"
MA(PM)09':F&KQO'*DZNXF>FL[<O<:3KF&F,]!9W9^PTB H2,.(+9E^H,+N*I
MOM7#,9;<PU/W*^KEG"N:84DI,CIK,J:94;0B8O#9;.BZF]1?5=1J!E0.6R R
MYPA5],Z*@%"1A:"@R.U,-7S,Y4G%W$SHV=<C=-)UO$'F,MH:;+A@"0D*3SE]
M6E8;OF9RI$A(F8<7B*GH09<Q#3F(F=)UO$$9;&,]M8<OID:1 (D8<;+9VQEF
M_P"XY>E2 L2,.,%',9:6SJDN5)Q&&J6QM(OJE2M*N=W4#*@<MEL[ETW32=;Q
M!!$N1VAMLN&4 !(D*3[E]5)I>(F=)]J][D[.E)69"$("!(4GW+HNC2H25F0A
M*0D2%)]R\;HT;:\-4X!F)BE:&I^\:T^I.>G.F0NXJ< WA,4E)"Q(PXV6S([4
MRS?YG*@XP%<TPI)29'1@R,X2;PG1=;Q$[%G#3>&F5):KRIZ@94#ELS2[Z:3[
M5_W#/9TI*C(0A 0)"D^Y<$A3:<PU4WF?R3LJ4E1D(;;#8I*4$B9A2BLS.E9;
MN#S2?<N"0STK#MTW33>;N'EEK#GZDYZ<Z>SN73=--: L2,.-EL\]H:8O>Y5)
M20L2,.M8>CLRIB[2?:G[QL+#4O<:5H5=1+OJ1E0.6S-+PU3IO,S]R=E *C(0
MTV&Q2)"1,PM5\S-2SN3]AIO,3]R=C2DJ,A#38;%-]R\;HTMG;_,TEK"!,PI1
M49G3,.7Q(YTE)"Q(PI)09'5J]2<].=0P[?$CG34D*$C#C);_ .;,TQ+FNF2$
MB9A:RLS.C;7<5.F^S+W)U[+,_<JF\N^K4C*@<MGL[GX&F\S>]R=C2DJ,A#30
M;'FG:'+QNBJ#+F(;<Q!.FZQ>YIS@B7([ VT7(0@($A3?=NBZ-*TWB*C*DZYB
M'3I44F8A"PL3%)YN^.6>K5ZDYUAL()29B&W X)U';/\ *-C0@K,A#;0;_P"U
M'W;YNC+2V==Y,J;S'Y(UK+'Y*IOKN)U0RH'+9\H:<Q!3=9O\QG!$N1V!MHN0
MA 0)"F^[<$AG7;66S. 0H3%-QH.0M!09'6@$\A#=G^5QE3<<#8G!,S,Z0 J,
MA#: V)4K0Y^ U+3F&:=H:E[QJE9>I.=6<(YT%9:I"R@S$)4%B8J.,AS_ +"V
MU(SV!NSD\U0$A(D*C[LO8-,A=Q4X!F)BFZP%<TP01R.I )Y"&F+O-51U>(J>
MJ&5 Y;0A909B$J"A,4W&@YG"VU-YZT">4-V?Y7$I4W%AL3@DJ,SH&7;AD<JA
M 5R,.6<CFC5HLZE9PAM*,JBE! F86LK,SI6&[HO&DZYAC5V=W\#2(G#K>&K4
MGU)S^LQ%X1?$8@C$C$,7S%XQ,_5H2307JVW"V82H*$Q4(GG"[-\H@I*>1UB&
M5+A#2457G;G(9ZBSN?@:BVTKSAQE2-.VRI<(;2WE4M#DO8-6,J!RVEEW#/BH
M0#R,.6?Y1&6J19U*SY0AM*,JBE!(F8<67#/1,/2]JJJVDKSA;"DY<], 3E";
M,H]4(:2C*J2$B9AUPN'2L-WS,Y4E$)$S"UE9F=8RYB#S2<0'!*""DR.I.?JF
M:@YQ*5!>>L;<+9A*@H3%4I"N1A=F_P!84A2,]0AA:L^4(90BLZ[ACS!,^9U+
M3F(FJMA*LH6RM&C0RM<(82G.JXO#3."9\SJQE0.6U,/7?:JJMM*\X79U)RYZ
M8 G*$V91SA#249520!,PZZ7#XTC#WXJK*;2O.%68_C"D*3F-"EE:OB$V8#J@
M)"<JQ(2)F'72X?&E0@K,A"0$B0I/N7C=&6M0LH,Q"5!0F*3[5X7AJ5YZ)D37
M1/,ZUMPMF$J"Q,5U,(5"K,H904*3F-$EE:OB$V7_ &,)0E&0KNO7.0S@F?,Z
MI"R@S$)4%B8K*:0O.%64_B8+2TYBJ&UJR$)LQ_(PEE",JRE!(F8<67#/6#*@
M<MK8>_%593:5YPJS?ZF%(4G,:%+*U?$)LP_*$I"<JQ( F8==+G_-,R]^*M I
ME"OB#9>Q@V=8@M+'Q$B,_6$*/Q 8</Q LI^3 LZ! 2E.0T"E! F8<=+ATS3>
M&*3[ET71KV'+AD<J;[5TWAJ%Y:*SIS- \AKT+*#,0AP.#EH2TA7Q!LR?B#9E
M?!@L.#XC#6/B)$>JZKM :6?B!9UP++W,"SH$!(3EH77[O).M:=PSX@&?,: I
M2K,0;.V8-E'P8X4]XX9<<,N.&7'#+CA3W@64?)@6=L0$)3D- 3*'G<0\LM:,
MJ!RVQE[\5:!32%?$&RCX,&S+$%I8^(E+UA"C\0&'#\0+*?DP+.@9P$)3D- I
M02)F'72Y_P U#+\O:K271VBXGM&&CM&&CM%U/:)2TCC@;'.%K+AF=-9V_P S
M2<6$)G!)49G8+.Y/VFD0%"1A:"@RU!Y>DCYJ,ID@4'>2=@2HI,Q#3P7R.>FE
M%T1=3VB0TQ,N9AU^]R3KV7</D<H!GS&TY0\]?Y#+7#*@<MM:?N^U6DNCM%Q/
M:,-':,-':+J>T2EI%N!L<X6X7#SU3;Q;_P"0E06)C:G7PGDF"2HS.F9;Q#XI
M90ZYB*V$&1F(;7B)G2=;Q!&6G6/GTCFF7IE%TQ<,7#&'&' ;!,HE0?SEL3=H
MER7 (/,;8XZEO.%N*<SV%ITM_P#("@H3&SD@"9AUXN<AEKQE0.6W-NEO_D)4
M%B8VIQ\(Y#."2HS.L2LH,Q#;P7R^=G4H)$S#CY5R&G2DJ,A"$! D*5H<_ ;&
MVO#5. 9\Q2M#?YC3D3'I1%T&+HB0H-":J+IFH[&AQ3>4-O)7M)(3S,.6B?)&
MR(<+9Y0AP.#ELJUA F8<<+F>P#*@<MO2HH,Q#;X7R.>SJ4$B9ART%7).P-V@
MIY*A*POF-D<M '),*45&9U##=P3.=)YS#'G9;.Y+VFF\WAGQIU#T#.FP.4Z&
M49[*BT*3R,(<2O+9299PNT@=,*45Y[,"09B&[0#R5L;CX3R3"E%1F=A&5 Y;
MBV^4\C"5I7ELCEH">284HKYG8@2.8A%I^%PE05EL"[0E.7.%N*7GJ6&KQO&D
MI02)F%J*S,[,PY?$CG26D+$C"DE)D=,1.NVF210>,D'9\H1:%#JA#B5Y;"5!
M/,PNT_ZPI:EY[4V\I$(>2O7K<2C.''U+Y#8QE0.6Y D<Q"+3\+A*@K+8%OI3
MESA;JEY[,"1S$(M)'5"74+RU9(&<+M('3"W%+SU3:,14H D)"D^Y?,AELZ5%
M)F(0H+$Q2>;OB8STZAZ$T4B\94;2>0&U)?6F$VA)S@$'+6*?0F%6E1R@DG/;
MD/J3G"'D+U:W4HSA=H4>G91E0.6Z D90BTJ'5"7D+U9(&<+M*1TPMU2\]K2Z
MM.1A-J_V$)>0KYTI4$YPJT(&4*M*CE!).>L;>#8E*.*\1Q7B.*\1Q7B.*\1Q
M7B.*\1Q7B.*\0NT%0D!M+;I;,<5XCBO$<5XCBO$<5XCBO$<5XCBO$<5XCBO$
M+4%&8&G(^HHV<37.C:3-<ML!*<H3:%C.$VE)S@+2K(Z4K2G,P;2@90JTJ.4%
M15GN:7%(R,)M7^PA+J%9'2J6E.9A5I'XPIY:OG9^)5VCBE=HXI7:.*5VCBE=
MHXI7:.*5VCBE=HXE7;=TNK3D83:O]A >0KYTI4!G"K0@90JTJ.4$E6>X!13E
M ?6(%J[B!:40'FS\Q?2?FC.48B!\P7VQ\P;4GX$&TJ^!!=6KY_\  ;*GVDT5
MF\HG< M2<C M"Q M7<0+2B,9L_,8B3\Q,>N\(Q$=X+[8^8-I1!M780;0LP7%
M',[TE:DY&!:5C.!:A\B ^V?F XD_-,K2,S!?;'S!M*?@0;2KXA3JU9G]L"B,
MH#ZQ M7<0+2B \V?F+Z3\T9RC$0/F"^V/F#:4_ @VE7P(+RU?.]WCWC$7WC$
M7WC%7WC$7WB^KO$S_P"#LINH H.&Z@G>;QB\KO%X]XF?TB^KO&*OO&,YWC'<
M[QCN=XQG.\8J^\7U=XG^\7CWC$7WC$7WC%7WC$7WB^KO%X_^FH%Y0$2H6LR;
ME_:]E3>=HVX\PG^TCZ;"G-5&UF;I_M,CT6-,FA$HE$HE$HE]5JO**O[3G.#R
M^K2;J *#RKC:C_:L^_T:3>6$_242B42B42B46\W6?^_VO8TWGTQ*)1*)1*)1
M+Z?Y,\DI_M?_ !J9ND^*/^25-T#Q_:_^,'6:-M,WU?VO_C>A1HOF\ZH^?[7_
M ,?]G_[1)F9_VO8/LT%&0/\ ;%@^U_\ :#O0K^V/\>?810=^VK^V+ KW$4'.
M@_VQ9EW'0:!Y_P!LM.8B J@X)+(_MBQNW57#\T+4).G^V;._B"1S]=M3DK^V
M02DS$,VD+Y*S]3Z;[9']MMVA:.6<(M+:HGZ'T7%_VX%%.4"T.#YA-I68"R8M
M(FW/^*__Q !4$  ! @(""! +!0@" @,! 0$! @, !!$P!1(A(C% 05$3(R0U
M0E!287%R@9&AL<'1%" R0V)SDJ2RX>(T4V!C=! 5,X""DZ+P@_%DPD14<-*$
ML/_:  @! 0 &/P+_ /(]4O:;D91=68*9-EN41D4;]7=!+\\^Y3DMS1S13;&F
M-(FWVN(X1 #^ASB/S!0KG$);MO!9D^:=.'@.7^=ER2L:JVF!>K?R(WAOPI:U
M%:U72I1NGQT2EDE%V5P)>PJ;[Q"5H4%(4*0H9?YUO 955$VZF^6/-I[ZI%BI
MI5+*S0RL[$[G^=5Z:=_AM)*C#\V]_$=53P;U4"#01EAI\_QDZ6[QA_.HW*@W
MTRN[Q4W>NBLFI)1N.HMT\(_[Z/YU)1K(EBVYU'NK+'JSKM><$?SJ,G/+)^)5
M98WUR?YU)"; O;K1/2.VL:<HO6$*</-1V_SJ3+2$VSJ-,0-\?*FL?G5IH5,*
MH3Q1\Z>;^=53S:*)28-LDC E65-4U*M@T$TK5N4Y3#;+2;1MM(2D9A_.JY*S
M*;9M?.#G$%F832@_PW1@6*A$O+-%UU6!(@-BA<RNZZYG.;@_G75+338=:5GR
M;XA3LEJV7S#^(.3+R00101D\5+EIX-+'SSHP\ RQH<NFEP^6\KRE?SM:JE&G
M3NJ*%<^&"6)A^7WKBA&NAH]1]4:?.ON\0!/? +$DW;C9N7ZNG_\ [?)2JR,N
ME0N$%=%$7MDI0_\ ,F-*>;<XBJ?Y7+]Q*.,:(OY^51QGDQKG*?WDQKE+?W!&
MN<K_ '1&N<G_ 'T]\7DXPOBN Q2D@C>_':+(-)H:F;B]Y?S[_P!HT&?F$49-
M$-'- $PEJ;3EI%JKH[H2AU2I)T_?>3[4!232#@(_ FFOMM\90$7UDI7^Z#%V
MR"#Q4J/4(^UJ/_$KNC^*Z?\ B,87_P"W'EO#_CB[,+3PM*BY/CE;4.R+VR4M
M_4X$]<:5,-.\18/_ .)TN.(;'I&B+ZR4H#ZY,:Y2W]P10BR,JHYM&3%*%I6,
MZ33M9?K2CC&+^?ED<9Y(C7.4_OIC7*6_N"-<Y7^Z(USD_P"^GOB\G)=?%=!B
ME)"AO;=4S,PTP/S%@10EY<RK,RCOHBB6L>>,ZYV"-++$OQ&Z>NF+ZR+PXAM.
MJ-.F7G>.X344@T'>C2IZ8;XKI$7)]:N.D*ZQ&G-2[XXI28U3(.M^J6%=T >%
MAA69\6O3@BW9<0ZC=(52/QK,RM%*RFEOC#!%!N'Q1H#ENQE87=2>Z*6CH<PG
MRV%&Z.\;?$/3[5L-B@VYZ(HEV'Y@Y[B1&IY5A@>E2L]D?;2@9FT)3&G3LP[Q
MW2:S29M]KB.$1<GE.#,Z J-42K#P]&E![8 F&'Y8YQ?B &)]DJ.Q4;4\Q_\
MPHN/.(:;&%2S0(*6"N=<_+%"><P1+--2B<_EJZ;G1&G60?4,P7:CF$4DTGQ+
M9M:FU9TFB+R><<3N7K_K@)GY,*&[ES1T'O@"7FDZ*?-.7JMH[:8F&F!G<6$P
M0E]<RK,RCM,42UCR?2=<HZ!&EZ!+\1%/7%]9%X<2\ZHTZ:>=X[A-12#1&DSL
MPUQ72(O;(+5QP%=8C3FY>8&^FU/1&J9!QO?:6%=T >%Z K,^FUZ<$6[+J'D;
MI"J1MB?"IM"%_=BZKF@ID9(J]-\T= [X(7.*91N&+SYP5*)43E.)V[+JVE[I
M"J# "GQ-(W+XIZ<,!,[*N2YW3=^F+:4F6W]Y)NCDQ]<WH"YA"/*#>$#/'V.8
MZ(^QS'1'V.8Z(^QS'1'V.8Z(^QS'1'V.8Z(^QS'1'V.8Z(^QS'1#<W+F\5A2
M<*3F.T;LR^JT:;%),?8YCHC[',=$?8YCHC[',=$?8YCHC[',=$?8YCHC[',=
M$?8YCHC[',=$&91+.,-4T)+FRQN;2!0APZ*GE^=/C(?8<+3J#2E28OJ&YQK^
M(WVC;DN/.):0,*EF@04LJ5.N9FA>\\$2K34HG/Y:NFYT1JJ;=>&Y4JYS8L/!
M9QYH;D*O>: F<8;FD[I-XKN@)4\91PY'Q0.?! 6A06@X%)-(VA3*O2[KJB@+
MI11O]T?8YCHC[',=$?8YCHC[',=$?8YCHC[',=$?8YCHC[',=$!6<4[4O3CB
M2M#0I*4X<,?8YCHC[',=$?8YCHC[',=$?8YCHC[',=$?8YCHC[',=$)E&I9U
MM9!5;+HHN8LI/@<Q<-&2/L<QT1]CF.B/L<QT1]CF.B/L<QT1]CF.B/L<QT1+
MRR91]*GG V":+E)JB]-/(8;&R684W8MFY]^\.H1HDW,+?5Z1N#@%8$%SPN7^
M[>/482A+G@\P?,NW#R'+CVJYI#:MQA5S04R,F5^F^:.@00J;+"-PQ>?."I:B
MI1RG$[=IQ32]T@T& #,>%(W,P+;IPP$SLHM@[MHVPBF4FFWO1!ON;:LK6H(0
M,*E&@""B5IGG?0N(Y^Z"#,>#-'S;%[TX<:"T**%# 4F@P$NN"=:W+V'VH"'%
M^!/'8O8/:BD71CA2H4@W"#%LT-1/76SN?1JJ'"? GKCHS>E 4DA23=!&7:+P
M*77J-@W2-FJJ2P*4L)OG5YDPVRTD(:0+5*1D&-R$UNDJ;/)='6?':FV#?H-T
M9%#-#,TR:6G4VPVV(F)@%T>9;OE_+E@HD&DRB-VJ^7W1;S4PX^KTU4XY;2DR
MXQO)-P\D!,_+)F$_>-7JN;!U0$LS(0Z?-.WJL?:_3)^)52WQ1M39#BCXA4M>
MK7U8L[QC46,_4M_$*E3%CP)N8%PK\VGO@O3;RGE[^ <%>U+LIMW7%6J1$O+%
MU3RFTT%:S22<:*E*"4C"3!1+TSSWY?D>UW01H_@K1\VQ>].&*3=.,A224J&
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M"QS=#^%UA.SWQOU?[OF%4S# O"=DCY8QX3+IU:P+E&S3FJDK02E232",D7Y
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MY](NI.@K/2.WGJ96DT)>I9/+@Z:,;<E'KE-U"]RK(8=E9A-JZV:#5"Q,TO\
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M,LC4SQTQ(V"NXXFEA-*64WSKFY3#;#* AIL6J4C(-JI27W*2L\O_ %42TO\
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M;WP!X8OY5A?&;$7;&2?]A/=&MDK_ &A&MLM_;$:V2G]D1>V.E$\#"8O)=I/
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M#9G35CG9$TO1 TSR;*)I^J+P<08;:3P8ZP!,E'@=R>(\?H+*9\<B$)PR5/\
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MP8S&TYOPPW!B3!%Q8C!,!2?+[*;&L/F:9#&-!N"\<-9N^0&3)E([K%7BIF5
M5."(Q$0TDJ<)#GL."BVG@F\EW\X'/),&)#GI* P<6>L=4Q/PKW *?O,ZR@<-
MC&Z+D)?0N:I]2YP24FW@P93L[^A(]Z&D<Q.AND'G )[-" O!!N:"5)-35Z.
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M$6>=/Z(_?1^1RD&P2<)R +R:#%.*8C?\?5R&SSW1#,6YU9S(O<@V)7$;$,%
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M 0]7'=F"0P/-,2.S+4Y$(I0:YS0P1U3>,^!ASV5@?-1]2O02.6O'--2F;W=
MAKM9B0@LYCKO.[0"^TU=-/!03'RP3LK+FE[:HABQV1U28ZQ;F5_*NO2<U_8Z
MJ8P: (!@P@-S'P$F@'U7H?HO0_1>A^B]#]%Z'Z+T/T7H?H@U1B"*2]V]ZM1
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ME1M1,5X-"C>M=!Z\#B#DFA1F#BR_,6GR*<W+Y,F4(W86 N>0/^U2ENRZY%N
MX31"1<47>DTA8,S!-\V3)]@X_P!KIPF6 /47Y.F^+)OPX0)*<R2>@_VNTAB$
MZ#N-^73ITZ=.G8$6QP .K_[7C.7HY>Z=.G3ITZ=.F'43:FZ-_M=Z^'&:.G3I
MTZ=.G4+F+G-K_P"US"FB'%[ITZ=.G3ITZ )D'@'^UX/$BCITZ=.G3KW'Q_VP
M)Q9$NG3ITZ=.A!>07+_MB#<'#41TZ=.G3IUX;1_M@XX.\FZ,KITZ=.G3H!"
M(/#_ +8/Q.1/L!&J=.G3_D=&'3#P% $$08C_ &N @(<&!!1?@AP7E'DZ?D=/
M^#IT9)QQ8/\ ;!H-H G_ &1R)_(Z=.G3IL$OI X<P_VP< ! Q!D4:;$XK5X7
M)TZ=.G3H9- *]_HX_P#;+>B%P!3IK"-4*C'C>G_!T_X=LIO?0L=/]MDOQ9'$
MX)T8HX/#4\+!U,J0T(T^ #7[YB0EJ#'-_P#;GC7"NG$N+_'.W)'U[N04^0!>
M'TC*KS)PF;CF?\5__]H # ,!  (  P   !"2222222222222222222222222
M222222222222222222222222222222222222222222222222222222223E;V
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222222222222222222222222222220S_\
M_?DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDC?\
M_P#_ *DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MF_\ _P#_ .DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDD?_\ _P#_ /TDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDD?_\ _P#_ /<DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD7_\ _P#_ /<DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDW_\ _P#_ /TDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDD_P#_ /\ _P#]))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))?_ /\ _P"#))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))U__P#\F22222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222223C?\ X$DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDUIPDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDG%DDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDE)OCTDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDC_L:DDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDB(Z+D*DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDHB\DDDDDDDDDDDDDDDDDDDDD-,X:DDDD
MDDDDDDDDDDDDDDDDDDDDDDDD@%XK_P#_ /$[:R2222222222222222222222
M22222222222222222222222222222222222-?_@R22222222222222222222
M22222222226H/_\ _P#_ /7FB22222222222222222222222222222222222
M222222222222222222222222222222222D)?\:*22222222222222223(L9_
M_P#^!49DDDDDDDDDDDDDDDDDDDDDDDDYN_\ _P#_ /\ _P#_ /7MDDDDDDDD
MDDDDDDD0    !DDDDDDDDDDDDDDDDD@    'DDDDDDDDDDDDDO\ _P!Z2222
M222222222222222222222220N?\ _P#_ /\ _P#_ /\ _P#WG)))))))))))
M))))(0   %))))))))))))))))))))0   ))))))))))),   !)))))]_P#_
M /\ ^])))))))))))))))%U__P#_ /\ _P#_ /XW$DDDDDDDDDDDDDDDDDDD
MDCV__P#_ /\ _P#_ /\ _P#_ /Q@22222222222221/_ /\ _P#C22222222
M222222220?\ _P#_ .&2222222222223?_\ ]$DDDDDDDDDDDDDDDDDDDDDD
MDDDDS7__ /\ _P#_ /\ _P#_ /\ _P#&,DDDDDDDDDDDDDDB_P#_ /\ ,DDD
MDDDDDDDDDDDDDDDDC_\ _P#]22222222221__P#_ -))) ]__P#_ /\ _P#]
MR222222222221&/_ /\ _P#_ /\ _P#_ /\ _P#'"222222222222222222)
M[_\ _P#_ /\ _P#_ /\ _P#_ /\ _P"1))))))))))))()__ /\ _LDDDDDD
MDDDDDDDDDG__ /\ _P#$DDDDDDDDDDDDDO\ _P#]R2222222222222222222
M222221Q__P#_ /\ _P#_ /\ _P#_ /\ _P#_ /O)))))))))))))(O\ _P#_
M #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#222#?_P#_ /\
M_P#_ /)))))))))))) )_P#_ /\ _P#_ /\ _P#_ /\ _P#_ -BDDDDDDDDD
MDDDDDDDD@_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /ODDDDDDDDDDDDD'_\
M_P#\"222222222222222G_\ _P#^I)))))))))))))&;7WZ)))))))))))))
M)))))))))))*O_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ ^22222222222
M22+_ /\ _P R2222222222222222222/_P#_ /U))))))))))'__ /\ TDDN
M_P#_ /\ _P#_ /\ CDDDDDDDDDDDG?\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ I)))))))))))))))+=__ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#^J9))
M))))))))))O_ /\ _P#!))))))))))))))S_ /\ _P#\))))))))))))))(=
MMA69)))))))))))))))))))))))]_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /[\DDDDDDDDDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]2222
M2222221__P#_ -)(5_\ _P#_ /\ _P#^<DDDDDDDDDDA2_\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ VG))))))))))))))1_\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#[LDDDDDDDDDDDE'__ /\ ]B22222222222223_P#_ /\
MOR22222222222222 5]*&2222222222222222222222!_P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ )))))))))))(O\ _P#_ #))))))))))
M)))))))))(__ /\ _4DDDDDDDDDD?_\ _P#22K__ /\ _P#_ /\ ^I))))))
M))))-_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ +I))))))))))))-
MO_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ "))))))))))))*__P#_
M /ZDDDDDDDDDDDDD>_\ _P#]6222222222222220Q+T]6222222222222222
M222222,O_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ ,9)))))
M))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#2
M4_\ _P#_ /\ _P#_ /B22222222220?_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#\R22222222222$?\ _P#_ /\ _P"B6[[:C3/_ /\ _P#_ /\
MZ4DDDDDDDDDDDD__ /\ _N2222222222220__P#_ /W)))))))))))))))&(
M?W Y)))))))))))))))))))))/\ _P#_ /\ _P#_ "[,H3@,DU__ /\ _P#_
M /\ Y$DDDDDDDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222
M221__P#_ - __P#_ /X^)K'LDDDDDDDDDDG_ /\ _P#_ /\ _G-UDGWO_P#_
M /\ _P#_ /\ .22222222222S_\ _P#_ /\ >5DDDDDDDUO_ /\ _P#_ /V)
M))))))))))('_P#_ /\ [9)))))))))) _\ _P#_ /O))))))))))))))) ^
M9GVY)))))))))))))))))))(C_\ _P#_ /\ _P!?TDDDDDDD^E__ /\ _P#_
M /\ :222222222+_ /\ _P R2222222222222222222/_P#_ /U)))))))))
M)'__ /\ TG__ /\ IF220^2222222222"?\ _P#_ /\ [Y4DDDDDD&O_ /\
M_P#_ /\ LR222222222,?_\ _P#_ -!2222222220:[_ /\ _P#_ +,DDDDD
MDDDDDD __P#_ /B22222222220?_ /\ _P ^2222222222222220Y8"GV222
M22222222222222222'__ /\ _P#^""2222222222=C__ /\ _P#_ (,DDDDD
MDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222221__P#_ -?_
M /\ ^UDDDDDDDDDDDDDDD>__ /\ _P#Z5DDDDDDDDD@G7_\ _P#_ /\ ))))
M)))))$?_ /\ _P#^1))))))))))))K__ /\ _P#]I))))))))))()_\ _P#[
M\DDDDDDDDDG_ /\ _P#_ '))))))))))))))))"(!W;I))))))))))))))))
M)))M_P#_ /\ _P#GR2222222222221#_ /\ _P#_ /PDDDDDDDDB_P#_ /\
M,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222221__P#_ "__ /\ QDDDDDDD
MDDDDDDDDCG__ /\ _P#VDDDDDDDDDDDDF_\ _P#_ /\ W)))))))(-__ /\
M_P#>)))))))))))))(;_ /\ _P#^W)))))))))))+_\ _P#_ $I))))))))+
MO_\ _P#YDDDDDDDDDDDDDDDDDF5-BUDDDDDDDDDDDDDDDDDDDT__ /\ _P#]
M4DDDDDDDDDDDDDDB-_\ _P#_ /YDDDDDDDDB_P#_ /\ ,DDDDDDDDDDDDDDD
MDDDDC_\ _P#]22222222221__P#_ /\ _P#ZDDDDDDDDDDDDDDDD1_\ _P#_
M /NDDDDDDDDDDDDDDG__ /\ _P#@DDDDDDD!_P#_ /\ _?DDDDDDDDDDDDDD
MDY__ /\ _P#[DDDDDDDDDDDT_P#_ /\ ^4DDDDDDDD/_ /\ _P#@DDDDDDDD
MDDDDDDDDD5/X@4DDDDDDDDDDDDDDDDDDDO\ _P#_ /\ V9))))))))))))))
M))?_ /\ _P#_ "R2222222+_ /\ _P R2222222222222222222/_P#_ /U)
M)))))))))'__ /\ _P#_ ,"2222222222222220?_P#_ /\ R22222222222
M22220?\ _P#_ /TR222220?_ /\ _P#E2222222222222222)/\ _P#_ /H2
M2222222222)?_P#_ /S)))))))(]_P#_ /\ !))))))))))))))))),[0MI'
MI)))))))))))))))))__ /\ _P#Y9)))))))))))))))))'/_P#_ /\ XY))
M))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#_
M /\ S))))))))))))))))/\ _P#_ /Q)))))))))))))))) W_\ _P#_ &))
M))))7_\ _P#_ ,9))))))))))))))))(W_\ _P#_ #)))))))))))"__ /\
M_P I))))))&__P#_ /[DDDDDDDDDDDDDDDDDE]Z6)4F4DDDDDDDDDDDDDDDD
M4_\ _P#_ +\DDDDDDDDDDDDDDDDDDD>__P#_ /N2222222+_ /\ _P R2222
M222222222222222/_P#_ /U))))))))))'__ /\ _P#_ "22222222222222
M237_ /\ _P#^R22222222222222221/_ /\ _P#F222227__ /\ _;))))))
M))))))))))))%_\ _P#_ ,Y))))))))))(/_ /\ _P"9))))))%__P#_ /RD
MDDDDDDDDDDDDDDDD@!I?8TF$<DDDDDDDDDDDDDDFO_\ _P#]J22222222222
M2222222225?_ /\ ()))))))(O\ _P#_ #)))))))))))))))))))(__ /\
M_4DDDDDDDDDD?_\ _P#_ /2DDDDDDDDDDDDDDDD'_P#_ /\ FDDDDDDDDDDD
MDDDDDDDG_P#_ /\ YDDDDD7_ /\ _P#!DDDDDDDDDDDDDDDDDDDC_P#_ /\
M\DDDDDDDDDDDA_\ _P#_ / DDDDDE_\ _P#_ +TDDDDDDDDDDDDDDDDDB&;L
M6DDN^DDDDDDDDDDDDDDE_P#_ /\ XLDDDDDDDDDDDDDDDDDDDDDS_P"R))))
M))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#_
M /TDDDDDDDDDDDDDDDG_ /\ _P#^4DDDDDDDDDDDDDDDDDDDW_\ _P#\2222
M9_\ _P#^Q)))))))))))))))))))(1__ /\ \,DDDDDDDDDDDS__ /\ _P"D
MDDDD3_\ _P#_ *DDDDDDDDDDDDDDDDDDD-+^ 4DAF,DDDDDDDDDDDDD0_P#_
M /\ ;DDDDDDDDDDDDDDDDDDDDDDD_JDDDDDDDDDB_P#_ /\ ,DDDDDDDDDDD
MDDDDDDDDC_\ _P#]22222222221__P#_ /\ ^2222222222222220#__ /\
M^9))))))))))))))))))).O_ /\ _P!)))(/_P#_ /\ 9)))))))))))))))
M)))))'O_ /\ _P#)))))))))))(O_P#_ /[TDDDE_P#_ /\ _,DDDDDDDDDD
MDDDDDDDDCZ![2$DD,1DDDDDDDDDDDDD__P#_ /\ $DDDDDDDDDDDDDDDDDDD
MDDDDYLDDDDDDDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222
M221__P#_ /\ R2222222222222222_\ _P#_ .222222222222222222222:
M?_\ _P"I))!/_P#_ /XDDDDDDDDDDDDDDDDDDDDDA_\ _P#]>22222222222
M ?\ _P#_ /V222+_ /\ _P#Q2222222222222222222T;*TN221&NR222222
M22222+?_ /\ ^[))))))))))))))))))))))))))))))))))(O\ _P#_ #))
M)))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#_ /DDDDDDDDDDDDDD
MDDO_ /\ _@2222222222222222222223?_\ _P"-))#_ /\ _P#U))))))))
M)))))))))))))(A__P#_ (DDDDDDDDDDDD+_ /\ _P#_ ))))_\ _P#_  9)
M)))))))))))))))))'@+7[))))WT9)))))))))))_P#_ /\ W)))))))))))
M))))))))))))))))))))))))(O\ _P#_ #)))))))))))))))))))(__ /\
M_4DDDDDDDDDD?_\ _P#]:222222222222222?_\ _P#_ *22222222222222
M22222220O_\ _P#[))+_ /\ _P#_ "2222222222222222222222?_\ _P#Y
M))))))))))))]_\ _P#[LDEG_P#_ /\ $DDDDDDDDDDDDDDDDDDDD@))8DDD
MB]IDDDDDDDDDDD%__P#_ -222222222222222222222222222222222222+_
M /\ _P R2222222222222222222/_P#_ /U))))))))))'__ /\ _DDDDDDD
MDDDDDDDDDA__ /\ \622222222222222222222223_\ _P#])(O_ /\ _P"Y
M))))))))))))))))))))))+_ /\ _P#U))))))))))))-_\ _P#_ %I!?_\
M_P#[DDDDDDDDDDDDDDDDDDDDWK+/#DDDDC8DDDDDDDDDDD'_ /\ _B222222
M222222222222222222222222222222+_ /\ _P R2222222222222222222/
M_P#_ /U))))))))))'__ /\ _<DDDDDDDDDDDDDDDM__ /\ ]22222222222
M222222222222!_\ _P#_ .2;_P#_ /\ J22222222222222222222222?_\
M_P#U)))))))))))),_\ _P#_ ._/_P#_ /\ X9)))))))))))))))))))&63
M[3))))"6F9)))))))))-_P#_ /ZDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222221__P#_ /W)
M))))))))))))))'_ /\ _P#Y)))))))))))))))))))))))#_P#_ /\ I(O_
M /\ _$DDDDDDDDDDDDDDDDDDDDDDDF__ /\ \2222222222222!?_P#_ /U1
M_P#_ /\ _))))))))))))))))))))V;_ &_R2220$EJ222222222 _\ _P#_
M "222222222222222222222222222222222222+_ /\ _P R222222222222
M2222222/_P#_ /U))))))))))'__ /\ ^,DDDDDDDDDDDDDDD_\ _P#_ )$D
MDDDDDDDDDDDDDDDDDDDDDD?_ /\ _P!D#_\ _P#^22222222222222222222
M2222'_\ _P#UY))))))))))))$__ /\ _P ?_P#_ /XDDDDDDDDDDDDDDDDD
MDDDD]OM]\DDDD@6R,DDDDDDDDF__ /\ _"22222222222222222222222222
M2222222222+_ /\ _P R2222222222222222222/_P#_ /U))))))))))'__
M /\ ^DDDDDDDDDDDDDDDDW__ /\ F222222222222222222222220/\ _P#^
M'+__ /\ _P#))))))))))))))))))))))))-_P#_ /\ )))))))))))))(__
M /\ _P#_ /\ _P#^9)))))))))))))))))))(&S_ .JT?."YM^T222222222
M#_\ _P#_ "222222222222222222222222222222222222+_ /\ _P R2222
M222222222222222/_P#_ /U))))))))))'__ /\ ZDDDDDDDDDDDDDDDE?\
M_P#_ *DDDDDDDDDDDDDDDDDDDDDDDDC_ /\ _P#$W_\ _P#]MMMMMMMMMMMM
MMMMMMMMMMMMMO_\ _P#_ .2222222222222._P#_ /\ _P#_ /\ Y2222222
M222222222222228+286VVVVVYLWR222222223_\ _P#[))))))))))))))))
M))))))))))))))))))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DD
MDDDDDDDD?_\ _P#B222222222222222+_P#_ /QVVVVVVVVVVVVVVVVVVVVV
MVVVV/_\ _P#47_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /[DDDDDDDDDDDDDD$__ /\ _P#_ /\ F22222222222
M2222222220$!._2VVVVV\DO"22222222/_\ _P"M))))))))))))))))))))
M))))))))))))))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDD
MDDDD?_\ _P#R222222222222222;_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#\O_\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ )))))))))))))))_
M_P#_ /\ _P#]2222222222222222222222[!(!&VVVVVJ!OZ22222221S_\
M_P#9))))))))))))))))))))))))))))))))))))(O\ _P#_ #))))))))))
M)))))))))(__ /\ _4DDDDDDDDDD?_\ _P#N222222222222222#_P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#,
MO_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ I))))))))))))))%_P#_ /\ _P#]R222222222222222222221;2
M:0VVVVVVLVW:22222220?_\ _P#I))))))))))))))))))))))))))))))))
M))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#V
M222222222222222+_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#<W_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ )))))))))))))))._P#_ /\ _P#.
M2222222222222222222223":6]6VM61K5:!422222222?_\ _P"I))))))))
M))))))))))))))))))))))))))))(O\ _P#_ #)))))))))))))))))))(__
M /\ _4DDDDDDDDDD?_\ _P#R222222222222222/_P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#,7_\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /XDDDDD
MDDDDDDDDDD@__P#_ /\ $DDDDDDDDDDDDDDDDDDDDDD=+=FI%\DDDDP 2<DD
MDDDDD_\ _P#_ +DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDB_P#_ /\
M,DDDDDDDDDDDDDDDDDDD@_\ _P#]22222222221__P#_ /I)))))))))))))
M)(__ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ -L?_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#<DDDDDDDDDDDDDDA__P#_ /\ 2DDDDDDDDDDDDDDD
MDDDDDDFS=O\ ?))))))$7^Y))))))))__P#_ ,DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDB_P#_ /\ 4DDDDDDDDDDDDDDDDDDDF_\ _P#]22222222
M221__P#_ /))))))))))))))))?_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /A?_P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#DDDDDDDDDDDDDDDS_
M /\ _P#_ .-))))))))))))))))))))('_;_ "2222223[:322222220_P#_
M /\ N22222222222222222222222222222222222223_ /\ _P 222222222
M222222222227_P#_ /Y))))))))))'__ /\ _DDDDDDDDDDDDDDDG_\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_!__ /\ ^                              \DDDDDDDDDDDDDB7_ /\
M_P#_ /[))))))))))))))))))))(2?R:)))))))&;?\ 22222220_P#_ /\
MZ2222222222222222222222222222222222222?_ /\ _P!R222222222222
M2222222/_P#_ /\ R2222222221__P#_ /I))))))))))))))(?_ /\ _P"
M                             7__ /\ [DDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDD2__ /\ _P#_ /Q))))))))))))))))))))(2V2_
M9))))))+>VQ)))))))#_ /\ _P")))))))))))))))))))))))))))))))))
M)))))_\ _P#_ #))))))))))))))))))))/_ /\ _LDDDDDDDDDD?_\ _P#N
M222222222222222#_P#_ /\ 2222222222222222222222222222221__P#_
M .Y)))))))))))))))))))))))))))))))))))))))))))'_ /\ _P#_ /\
M_P#!)))))))))))))))))))($!-L9))))))/6VQ)))))))/_ /\ _P"9))))
M))))))))))))))))))))))))))))))))(?\ _P#_ -))))))))))))))))))
M))__ /\ _4DDDDDDDDDD?_\ _P#^222222222222222;_P#_ /\ 22222222
M22222222222222222222222?_P#_ .))))))))))))))))))))))))))))))
M)))))))))))))()__P#_ /\ _P#_ /XDDDDDDDDDDDDDDDDDDDA[)?(DDDDD
MD@MDD<DDDDDDDG__ /\ R22222222222222222222222222222222222223_
M /\ _P!R2222222222222222222;_P#_ /Q))))))))))'__ /\ YDDDDDDD
MDDDDDDDDG_\ _P#_ ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDW_\ _P#^2222
M2222222222222222222222222222222222222203_P#_ /\ _P#_ /\ _F22
M22222222222222221<DOVR222222 ?\ ]DDDDDDDDG__ /\ F22222222222
M22222222222222222222222222+_ /\ _P!R22222222222222222223_P#_
M /\ R2222222221__P#_ /Y))))))))))))))(__ /\ _4DDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDD/_\ _P#B222222222222222222222222222222222222
M2222222__P#_ /\ W_\ _P#_ .R222222222222222223/VEO2222222#_\
M_DDDDDDDD8__ /\ ]2222222222222222222222222222222222222;_ /\
M_P"R2222222222222222222?_P#_ /[))))))))))'__ /\ \DDDDDDDDDDD
MDDDDD_\ _P#^R222222222222222222222222222220__P#_ /9)))))))))
M))))))))))))))))))))))))))))))))(_\ _P#_ ."U_P#_ /\ P9))))))
M)))))))))))%),D/)))))(1__P#_ $DDDDDDDC__ /\ \222222222222222
M2222222222222222222222'_ /\ _P#R2222222222222222222?_P#_ /\
M22222222221__P#_ '))))))))))))))))/_ /\ _4DDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD/_\ _P#W2222222222222222222222222222222222222222
M21W_ /\ _P#R3G__ /\ ^Y))))))))))))))))))N2;W(UK*U[:[0EO)))))
M)))O_P#_ /$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDF_P#_ /\ \DDD
MDDDDDDDDDDDDDDDDA_\ _P#^R2222222221__P#_ !))))))))))))))))?_
M /\ _=DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDY_\ _P#^R222222222222222
M2222222222222222222222222??_ /\ _P#22?\ _P#_ /\ $DDDDDDDDDDD
MDDDDDD!+?IDMMMMMMJV[(4DDDDDDDB__ /\ ^62222222222222222222222
M22222222222222?_ /\ _P!222222222222222222223_P#_ /Y)))))))))
M)'__ /\ $DDDDDDDDDDDDDDD@7__ /\ B222222222222222222222222222
M222+_P#_ /W)))))))))))))))))))))))))))))))))))))))))_P#_ /\
M_P"R22?_ /\ _P"&22222222222222221DW:6VVVVVVVKVP#R2222222?_\
M_P#_ *222222222222222222222222222222222222-?_P#_ )))))))))))
M))))))))))/_ /\ _4DDDDDDDDDD?_\ _P!R2222222222222223_P#_ /\
M^222222222222222222222222222222;_P#_ /R)))))))))))))))))))))
M)))%)))))))))))))))+O_\ _P#:DDDV_P#_ /\ [DDDDDDDDDDDDDDDDDR6
MP#MMMMMMMKM__P!))))))))!_P#_ /ZDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDD?_\ _P"R2222222222222222222;_P#_ .I))))))))))'__ /\
M,DDDDDDDDDDDDDDDD?\ _P#_ -DDDDDDDDDDDDDDDDDDDDDDDDBDDDDD@W__
M /\ ^22222222222222222222222"@22222222222222=_\ _P#_ .2222,?
M_P#_ /\ 22222222222222220X!)*VVVVVVVUM__ ,DDDDDDDDG_ /\ _P#D
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD?_\ _P!R2222222222222222
M220C_P#_ /Y))))))))))'__ /\ LDDDDDDDDDDDDDDDDX__ /\ ]2222222
M22222222222222223MN22223_P#_ /\ B22222222222222222222222#_;2
M222222222222;_\ _P#^I))))%__ /\ _#DDDDDDDDDDDDDDDD>V2DMMO>A"
M>Y)OT$DDDDDDDDC_ /\ _P#TDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
M/_\ _P!F2222222222222222220__P#_ .9))))))))))'__ /\ LDDDDDDD
MDDDDDDDDDB__ /\ ^R22222222222222222222222_FZ2221?_\ _P"I))))
M))))))))))))))))))!O_P ,R22222222222_P#_ /\ ]N22222?_P#_ /\
MY2222222222222221+2;+2A"2220KX$"222222222#__ /\ ^)))))))))))
M)))))))))))))))))))))))))'__ /\ [DDDDDDDDDDDDDDDDDDD?_\ _P#J
M22222222221__P#_ +)))))))))))))))))__P#_ /<DDDDDDDDDDDDDDDDD
MDDDDDC7_ / 9))&__P#_ /8DDDDDDDDDDDDDDDDDDDDDBW__ /R9))))))))
M)(O_ /\ _P#K))))))1__P#_ /TDDDDDDDDDDDDDDD 26XDDDDDDD'X 7TDD
MDDDDDDG_ /\ _P#\LDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD_P#_ /\
MYDDDDDDDDDDDDDDDDDDD_P#_ /\ _DDDDDDDDDDD?_\ _P"R222222222222
M2222;?\ _P#^I)))))))))))))))))))))+_ /\ _P"])))/_P#_ /\ I)))
M))))))))))))))))))/_ /\ _P#))))))))))#__ /\ _P#Y)))))))__P#_
M /\ Y))))))))))))))*O^O))))))) @)MQ)))))))))!_\ _P#_ )))))))
M)))))))))))))))))())))))))))))/_ /\ ^LDDDDDDDDDDDDDDDDD@_P#_
M /\ !DDDDDDDDDDD?_\ _P"R22222222222222220_\ _P#_ ,R222222222
M222222222220?_\ _P#Y)))A_P#_ /\ C)))))))))))))))))))))__ /\
M_BDDDDDDDDDD'_\ _P#_ #DDDDDDDB__ /\ _GR22222222222222_Z!2222
M222423;22222222222?_ /\ _P!V2222222222222222222222?M22222222
M222;_P#_ /\ R22222222222222222+_ /\ _P!222222222221__P#_ +))
M)))))))))))))))"_P#_ /\ SI))))))))))))))))))))7_ /\ _P#7)))!
M_P#_ /\ XY)))))))))))))))))))?\ _P#_ .W)))))))))(_\ _P#_ ._)
M)))))))9_P#_ /\ \Y)))))))))))))+V!+)))))))$A(E9)))))))))(?\
M_P#_ .S)))))))))))))))))))))!O\ GR222222222'_P#_ /Q)))))))))
M))))))))"O\ _P#_ +)))))))))))'__ /\ LDDDDDDDDDDDDDDDDDG_ /\
M_P#],DDDDDDDDDDDDDDDDDDDA_\ _P#_ (DDDDV__P#_ /\ $DDDDDDDDDDD
MDDDDDDD-_P#_ /\ YDDDDDDDDDD*_P#_ /\ YDDDDDDDDDK_ /\ _P#YDDDD
MDDDDDDDDDD);_P#))))))(, $DI))))))))));__ /\ _#DDDDDDDDDDDDDD
MDDDDDDD'_P#_ !R22222222,_P#_ /\ ER222222222222222??_ /\ _+))
M)))))))))'__ /\ LDDDDDDDDDDDDDDDDDD__P#_ /\ TDDDDDDDDDDDDDDD
MDDDC7_\ _P#^222221?_ /\ _P "222222222222222220?_ /\ _P!&2222
M222223__ /\ _P#R2222222227__ /\ ^M)))))))))))))*[;1))))))(]L
M -I))))))))))%__ /\ _P"]))))))))))))))))))),O_\ _P#MDDDDDDDD
MD'__ /\ \R222222222222222;__ /\ _))))))))))))'__ /\ LDDDDDDD
MDDDDDDDDDDD(_P#_ /\ Y$DDDDDDDDDDDDDDDDDS_P#_ /\ ]TDDDDD/_P#_
M /\ YDDDDDDDDDDDDDDDDD=__P#_ /\ 4DDDDDDDDDB__P#_ /P222222222
M2!__ /\ _P"62222222222222VT R222222923;F22222222220/_P#_ /\
M_&222222222222222221E_\ _P#_ ,V222222223[_\ _P#VY)))))))))))
M)))/_P#_ /\ _I)))))))))))'__ /\ LDDDDDDDDDDDDDDDDDD@_P#_ /\
M_$DDDDDDDDDDDDDDDD@W_P#_ /\ _DDDDDDL_P#_ /\ _P 9))))))))))))
M))(C_P#_ /\ ^I)))))))))'/_\ _P#6DDDDDDDDDDD _P#_ /\ Y$DDDDDD
MDDDDDDG_ ,+))))))$7[>X))))))))))))G_ /\ _P#^))))))))))))))))
M))A__P#_ /[DDDDDDDDDDD__ /\ _P#TDDDDDDDDDDDDD&__ /\ _P#<DDDD
MDDDDDDDD?_\ _P"R222222222222222222,__P#_ /\ VR22222222222222
M2K__ /\ _P!B222222,__P#_ /\ FR2222222222222&#_\ _P#_ -N22222
M2222)?\ _P#_ -R22222222222"?_P#_ /W))))))))))))+LME))))) .?[
M21))))))))))))!?_P#_ /\ ^')))))))))))))))(?_ /\ _P#^9)))))))
M)))/_P#_ /\ ^')))))))))))(S_ /\ _P#_ )2222222222221__P#_ +))
M))))))))))))))))))O_ /\ _P#QY)))))))))))))"I_P#_ /\ ^=))))))
M))O_ /\ _P#S5)))))))))))(HO_ /\ _P#_ "22222222223_\ _P#^_)))
M)))))))))+__ /\ _EDDDDDDDDDDDD O_,IW<H7UEH"4DDDDDDDDDDDDDEW_
M /\ _P#_ ()))))))))))))).?\ _P#_ /\ ^*22222222222_\ _P#_ /\
M)DDDDDDDDDDDY_\ _P#_ /YDDDDDDDDDDDDD?_\ _P"R2222222222222222
M222$?_\ _P#_ .>2222222222200_P#_ /\ _P#3DDDDDDDDC_\ _P#_ /\
M_P 2222222222&__ /\ _P#_ /ODDDDDDDDDD7__ /\ \R22222222222233
M_P#_ /\ C2222222222223_]&6VVVVE9MFV22222222222221S__ /\ _P#\
MQ2222222222283__ /\ _P#_ /LDDDDDDDDDDD=__P#_ /\ [0DDDDDDDDD>
M_P#_ /\ _P#W9))))))))))))'__ /\ LDDDDDDDDDDDDDDDDDDDD3__ /\
M_P#X2DDDDDDDDDDOG_\ _P#_ /\ Q)))))))))!__P#_ /\ _P \R2222221
M2;__ /\ _P#_ )4DDDDDDDDDD/\ _P#_ /4DDDDDDDDDDDDDB7__ /\ ^222
M222222222;_VVVVVVV]^WLE222222222222220?_ /\ _P#_ /Q9DDDDDDDD
M33__ /\ _P#_ /\ 6222222222222 ?_ /\ _P#_ /D,DDDDD#.__P#_ /\
M_P";)))))))))))))'__ /\ LDDDDDDDDDDDDDDDDDDDDE__ /\ _P#_ .DI
M))))))),M_\ _P#_ /\ _F2222222222+_\ _P#_ /\ _1'!DDBWG'__ /\
M_P#_ /PY)))))))))-__ /\ _P")))))))))))))))&__P#_ /\ ))))))))
M)))(N  +;;;;:/;V7)))))))))))))))+_\ _P#_ /\ _P#Z#Q%DDCWNW_\
M_P#_ /\ _P#AR2222222222223?_ /\ _P#_ /\ ^*I1'#;_ /\ _P#_ /\
M_CDDDDDDDDDDDDDD?_\ _P"R222222222222222222221O\ _P#_ /\ _P#Y
M3;))(M^?_P#_ /\ _P#_ .4DDDDDDDDDDD*__P#_ /\ _P#_ /Y.P3__ /\
M_P#_ /\ _P#OR2222222223_ /\ _P#_ "DDDDDDDDDDDDDDD@__ /\ _FR2
M222222222>VVBVVVVVJ3: *222222222222222 ?_P#_ /\ _P#_ /\ _P#0
M57__ /\ _P#_ /\ _P#[DDDDDDDDDDDDDDD@G_\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#BR22222222222221__P#_ +)))))))))))))))))))))(
M9_\ _P#_ /\ _P#_ %75!_\ _P#_ /\ _P#_ /R9))))))))))))1_\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ -I))))))))))E__ /\ \<DDDDDD
MDDDDDDDDDE?_ /\ _P#ODDDDDDDDDDDUM[UH%#Z"G9+?DDDDDDDDDDDDDDDD
MG_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ \)))))))))))))))
M)"?_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ :DDDDDDDDDDDDDDD?_\
M_P"R22222222222222222222237_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#\22222222222220W_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
MPI))))))))))(?\ _P#_ /I)))))))))))))))),_P#_ /\ _)))))))))))
M'*6^OI))/_3^S)))))))))))))))))&/_P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ //<DDDDDDDDDDDDDDDDE?\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ ^E)))))))))))))))'__ /\ LDDDDDDDDDDDDDDDDDDDDDDGG_\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ ^K))))))))))))))()__ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#U?))))))))))('_\ _P#_  I)))))))))))))))))
MO_\ _P#ZLDDDDDDDDDDE"0DDDDD'_M_&DDDDDDDDDDDDDDDDD@6__P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _"LDDDDDDDDDDDDDDDDDDPW_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#DDDDDDDDDDDDDDDDD?_\ _P"R2222222222222222
M22222205_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _HN2222222222222222?
M+_\ _P#_ /\ _P#_ /\ _P#_ /\ _P!9))))))))))))?_\ _P#^$DDDDDDD
MDDDDDDDDDD@G_P#_ /\ ?DDDDDDDDDDD,E<DDDDQ_M;$DDDDDDDDDDDDDDDD
MDDG]_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ KTDDDDDDDDDDDDDDDDDDDD!_
M_P#_ /\ _P#_ /\ _P#_ /\ _P#[I))))))))))))))))'__ /\ LDDDDDDD
MDDDDDDDDDDDDDDDDDLG_ /\ _P#_ /\ _P#_ /\ _P#_ /\ M:2222222222
M22222222%;__ /\ _P#_ /\ _P#_ /\ _P#\2222222222221_\ _P#_ -N2
M222222222222222223__ /\ _P#Z22222222220F]R222.:ULV2222222222
M2222222222"U_P#_ /\ _P#_ /\ _P#_ /\ _H?222222222222222222222
M23!__P#_ /\ _P#_ /\ _P#_ /QW)))))))))))))))))'__ /\ LDDDDDDD
MDDDDDDDDDDDDDDDDDDH__P#_ /\ _P#_ /\ _P#_ /\ [.DDDDDDDDDDDDDD
MDDDDDDDQ*_\ _P#_ /\ _P#_ /Z\4DDDDDDDDDDDDDK;;;;,DDDDDDDDDDDD
MDDDDDDDG;;;;;DDDDDDDDDDDD 4DDDD]MV@$DDDDDDDDDDDDDDDDDDDDD1D_
M_P#_ /\ _P#_ /\ _P#7Y))))))))))))))))))))))))!&__P#_ /\ _P#_
M /\ _$Q))))))))))))))))))%MMMA)))))))))))))))))))))))))));1_
M_P#_ /\ _P#_ /\ S^I))))))))))))))))))))))),][O\ _P#\V".DDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDF &DDDC$
MTFP4DDDDDDDDDDDDDDDDDDDDDDD3(L;_ /\ E)7@22222222222222222222
M22222222871?_P#_ .[W:)))))))))))))))))))))))))))))))))))))))
M))))))))))))))%<KU__ /\ $%14DDDDDDDDDDDDDDDDDDDDDDDDDDDF@]>4
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MD2'DDDB 0&RDDDDDDDDDDDDDDDDDDDDDDDDDDDGCC<DDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDD=C6Z5DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDP#K6DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDE ,DD5]:"5DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDD_0DD:TR"2DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDEHDDO_ "W[))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))+E)'?[[7I)))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))F9-_2W;))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))(0_2S[_ "2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222-EWEFR2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222<@0'M22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222@;&UR2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222238")\R2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222220+T#>22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222"T;*Z22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222+" _^22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222228;$Y*22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222,GY*"22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222229X0/R22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222223Y2FI22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222204_"0R2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222221(P;+R2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222228Z'O22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222*X#&2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222UZ2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222222223_Q  N$0 ! P($! 4%
M 0$!       ! !$Q(3! 05!A(%%Q\!!@D;'!@(&AT>'Q<+#_V@ ( 0,! 3\0
M_P"1RQ%09213H"@J2JJ-!^MG<*)>IXR<B@7J/K68YEIH_6K  DC&*W4?K48W
MKC1?6H.D7#8/K4CZ?7 (KAYW+ZU'\7&2+/ZU:D(-HH 0  8?6J,7(@QL$-D&
MUG]:X!9*I4.*K0$$8?6U!D7!\ 9Q4&/_ &^=] N1 @P?I<) E-R0MIX#:+;(
M&@^?*!S\1"*!FJIQIY%("2B/(B+-;_!!O+=0,@ P?^)D@2F<G@ 6"$"#&F$@
M2FY*VG@-HML@:#K9D%!9NCRA$D41(A))L@<% 6: Y" YA9@@0:CSJ_\ $@$-
MI.O2!0<!$T!$F:)I-P"@H S0%(1<AE#'_A1( <J.JB>12QX02(6:+DE%G0R$
MBLT=$<@B2*(FS1))L@4% 6: 90',+,$"#&HSY!R+-%.#!(J%FCHJ"E6/CCK:
M6TMI;2VEM+:6TMI;2&PT, .6TMI;2VEM+:6TMI;2VDP8,6\<1"<(([ZR2!4J
M.JB>12+#29!0=9HR!>-!=0+:6TMI;2VEM+:6UI0C$MI;2VEM+:6TMI;28 88
MBR6TMI;2VEM+:6TB 9-H .2R115RN;F%1L\=-D'(LT3O.#!(A9@Z*@I%I9+2
MN?%GK8H%H4]54LTQU<$&U.0IT)VR!:,T@  PQ8U'&.T0! :M-%&<BJ!8R5(X
M@HLX_P!JR(TF;'ADV/S+(Z*BBKE? DP30,5"IPJLY;%0IBJIYIH\*@5*88^.
M*H]!Q@W",\M?':"S9)M $F"$QC =W*Q.>J4:2MK&A9^X5/-,;[5D1I,V/#)L
M?F<8!=*0*# LA^*HE14XQ\\5$H.B43-2$:' 0H"<77!(M M4+JV/ X1"<VFS
MYQHN5AGU)(2J' T:&*H9H<7[5D1I,V/#)L?F<0!RB#G T#) -08B0E2$:' 0
MNJ: 2 <HYIH\XHH(!QBFRVT5@@"S&DM4KHEITY@8ZKI>#\+ITT'3P"Y(E%*G
M2:%(01\2]JR(TF;'ADV/S.$8[HIO@4J@9X<D .4]19T8]"@@'&- .AVL:25H
M@CC$D ABC-96G;H.-^>M'8(33'2]$Z=.G3\!OIVD"I1QRTP$DX0S3$?:LB-)
MFQX9-C\S@&+YHAN<$Z7X<0Z&:QI)1P@M,6(=T0WTL0G"#09Q(F"@),;39\XN
M,E3:G)./EZ<+ITZ=%6-],):I3NH):#"! .,-[5D1I,V/#)L?F>('"CF[!' "
M ###"'='-]+ DG"#1+$CH2B22YP$ $7)9#.* D )M%MA;(3^1$V2)$1R* BJ
MA& A;QQ+;.M DG"$YB0"Y%<6G] C;H%/XNG3IT^F  NE(RP(@! V2!YE#/*
MLDPC.1;:VELD2(2Y(DA$<BB&%(#!&/9 %\*]JR(TF;'ADV/S/  .49XVJ "(
MFB YE=9'>7-+('1!%#X59)PP082B23G 0P1,T0SB@! 62VB9R"VPG\B)LD2(
MCD4!%5 -(COA$O4WLI9!2=0J_)A<TI\7WL2NV0;1GD""'&(=L@6BM9(!@PT
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M]E65.3]:$)Q$DES:(3! !S.D;QME0(I@/:LB-)FQX9-V8@:"$A(A.;1#<P@
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MOCM+;YLOZ?[8V!'O?_*>_%]I?. CZV8>3$?2S%I,^/#)LP]- D;)0!UT
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M</3)**7#I?BS)L2&DM'$HAJ&V"2<(1HH((<8JC5&Z@AL0&!@MU7894<T.&)
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MOK9YL$W%1^[];( 8PCYD)DR9,F3(?K;K H5&ATQ%#X-X,#R/K<@#HER5<#H
M*(L#/Z*__\0 +A$  0(#!0<% 0$! 0       0 1(3 Q0$%046%QD:&QT>'P
M$"!@@<& \7"P_]H " $" 0$_$/\ D96&&:BAOP5/$P5%"LE*/5&?]LP]')
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MG"40"&*+!JI/$:Q03*OW>F"$ %Z$(+O1DR9,F3+;EAQZ>MY*XJ-5&!%!<O0
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MBF,RF=^:X4QY!/Y^^\!TZV[MNA+!<)_4'%D\PI\4MK;>DFHXE*^T6:A)<NF
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M!G?BDHXI%&9V<AX('$>U@ +YFTT4R9,F3)DR*!G@#B6*N4YK,PW+1"TFY:2
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M&;@9<*<V+5R96]7H-0*N'+[)P$$A!-7$:(UCT%O:[60PAN)A,*$2R)2JV^L
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M:".*NF,U]HRP<*"71U$3.$(1,(TY.SX!%>743EJ$7H98\,0X@=6 -TI1=X1
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M>&('2>?WH1QP5;A-@@!$1N)KU+ "-@2TC!9V[:=%TA'DBM *= :)4)M P\I
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M>XB#=C!M$'=/U.+8K(6DR>=^V/16TV\)2//(V2S5B1V+@70SKFTDRNBQ%?X
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MGL^EB,W4G'97C[L]OU,L+(OAW"GH+BF0K& XCW5VU/-245 *["6!W+ ,[F@
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M'6XH$(W1=2_#L#VN(8P!L!GY_''0&:8I[15\?SUV?8P):EI_S;EP_>OH)?\
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M_P#Q('CULTEW!-L?5 '>\ M2Z(+"#X)\LK=>EBD*T)>#@\;=\.@2C[)B%QM
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M<B:4>ZZLHINW<9:QTA((3UR*NKHO8M$R" HA(CA'V::H LZ<:JP?T2TD*[*
M/<.NHJV(#HP_]8L,D(BV ].8O,$#!?=@#8#:(YRD"84-Q&T=+3FYL80Q@/C*
MT1GV3-OC"^65@96FB,/-G@@'@"P=*+L\G(;H!3L-1IS,@V_+"\3!8/2)OL4"
M)56P!K28LX2&,V\(E@&'I& &,L>(.MO=FX*,>DXB#@IL,A*:LB\'2- QU ,B
M)A*$R$)!QFYQ'&P#UD('RV%_*J?M(HF'.N:]9?%T4H?L$*[*[*M.[V#,\?)?
M3I^3)B@&3GEGL/2U[8R5'5B.XPB(-"!!!5>O,S"7PPB'LY DL-N'2+5R[R*.
M/&ZZE"ZJJKT2Z:!T"YWA);)#>I^IR,F);IDY@PW/H\0 A8 $^$=*LYXRD9'7
M>Q1CV$VDW<S,9%=T-I=)G?#$J;N!BY]3_<[_ &Z!,?>PQ&3H5VA-R%.F*\H0
M#A$1.DKB4LC0,^9Q<&H$@A(C9/9&L[=P: RC "ZH%))MAAQ:L+.@L:KT5R!G
MB7*: *= 72A',05PY6 T 8#J6WQ6TR(#"0=ENN.EK_EC16SI'Q=50@*(2(X1
M]BL^T%F+8-WBP<N!:,H+FPTLV%X%C5Z;*U4<R(&D9M181GTELH-T,2":F.4%
MY!T45*;28>$(!:4-:-(1DZBM4*=5?2I)#BLL:<Z3P;VS&@GHW^V,1-CZA;BR
M7!J_D91!L?1)'>R2(^KL.;B$/Z:_2:D^HYZRG,Q+T3X&FXG5V]?Y7Z(*@J/L
MERT#P8_3I (DC9&G*D$NA+P7MG@3TI@JKGL"756J_=[&Q='<=Q,A+V0,3E R
M5%@#5J?G4D'#K/JX6D+TST@3/?$N4T 4Z NE ,+@AB?X - :>C2.F'A*IT+F
MTI+=W#0HT1$Z(HB,)J44&B82++:<)Q?7I K<86PVO <3+I\? C0>DVMB;M_J
M?W._V^!EOMA 1LVY=Q=-871%T0F78YJ'/\42)$2R)K[$'O;B^D:[Q8%:'BD8
MK M,*)@N%@F5TT;!_2F1C2TM2"TCJE]?^0(3PT%2@2T^3%T#LQ Z8EN@9!M&
M2\#410H5"C>$+/L$"9SA3B\[B2Z&&">J95=U]C$K*BZO32!G;PTA&JPZ&%Q
M])E^>NS<MI%W6Q=4D3$C%1JJKT6@D$50 NJH!4$T4F47G*RF4L1'IC2,8.HK
M0 '1"G%21).?*A$T TZ5H5 IP#.+$<W70H#YDY W$=3U5D3E2)^/ROW/K*6<
MM$Q@/Y/%0_8(5!447"FHTN'YH_!0%@,'J'\VU(<(Z!!!<03%7;->$G#H2!H,
M. O2>FY MD!<1O)0K9$1H@)\"[@5.?XHD2(ED37V(2L)'*W4Z)6!)*5D,VI0
MV)&X&Q!-W2!0!*X"HHB%RT(S2RZ@+#=Z1T,P;R6T8$Y79TD@,(0B81K3G;&@
MEC2*VPW]86"DH(E#2"SI1;<;T<LB5,J[])%M+9"M[2S*.?5/]SO]O@0HR0,0
M-1%*8NEY3*YY@=QL3!TEF7X4QR?.YF=5 J%%>(=]$R(C<]@4@2$<+7N:B\,$
M)2-T))1W.<2I4$MB.D)2&XRA.=K=DU(   @-.L$@)O QAW6-1.&$6@3"3HFH
M($LB.O3-7C8$N;[O@CH8((A,6C6DN-A*BRP^M@ 1J#E?@-6IYC,'/6%;QY60
M&GM_1+Y0JKN],C$A<G@6S"@WEPH! <EC_M;JMU5;OI-'K48T#5, %U0+M:M'
M\EGOJ5-4T@.C,MAJ@W%'S_ZCU(@&BA:N. )T"P(NJ>0J0#<1$3I7$&M\-*UR
M(NXI:,^I:14Z&!5^H[OJ:J.\/\"ZB@50#*U.[@L_P47SY4P:J3%OMO45#4OJ
M0J"K*OR,3+X]4YA#;"43<%X=!2UDE56XKUWR#N(C"(=-$JN22MTS+7)7L+"$
M-L-Y-<TD>7KWH0, $JK@-Z$FT27=(NSLPNN4SW,U!H!8IL &AU+I^%)V)UBS
M0G ],LQ:268EK V8R#6LX35V@<DF=2_3B7".U!Q;K&2!2/!EI_\ $PC<1$'U
M,?#/3_ZK8"ZH M+5,2&-3G\#(%Z:7Z,90 ,JH!6I%=81(=1 [R<KU7[G?[A
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MXL-'P"X+)U;'/)L6QCB$=J$.$!G?835>!0B;0$3VI.8C9?3M-41.RJV"IJB
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M&G*2(M( O"=].6V8$+IB/ #K'5$===5< 2J@ 58*M&R*5@W[@0ELLE@/2A_
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M[?)^UL#9$#RU+V+-H^"N;:F_HG228P?F2@^(@^3:VOZ03'O(>85?*<#N@$[
M/0S&6YAY-1=L&(0H;W&EH L $ >L0$:> RJ7FP\A9"FI<>+H[[B61$L^@@0K
M,L]RR\E:!=?+$7FAH!R(?%/=FUY+;ZA3S"H[S*_IU^(]?V*'=K1#^5=B1>:8
M!HDH[@G\U!\H&VX$O#-130+CM*'@] ]8*+: #*M'\&1; FH)A#(-!ZW]SO\
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MSW+)<Z5H1-@(RBZ*>ZN@/3,H&+V03H*2:!D]F@3"C1$BH*CZ6U7HVO8<I/\
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M>O#O1PA8 +JU8MM>4D/<H9AJ7AVKN<8+LCCU/C>\ 9& D-23:3I1V&1G7MT
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MT:8T"NTK<&JV=DPJA#A.4(.HB/VW:9IF\#R;S4-0_8(*@^EYV8-)2._XS_M
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AJ%]B3[-FBNRD!C@S_-8SSKW\"LFT_$?(B @.Q:_\5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>smainvivogreyscale.jpg
<TEXT>
begin 644 smainvivogreyscale.jpg
M_]C_X  02D9)1@ ! 0$ 70!=  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P@ 1" *2!$(# 1$  A$! Q$!_\0
M'@ !  (# 0$! 0$           @)!@<*!00# @'_Q  : 0$  P$! 0
M         P0% @$&_]H # ,!  (0 Q    &_P
M
M
M
M      '\<=4&9]Z:GTN!&_"VHFWJ%N]6Q3E-Q;KI9U@N=H#69Y1N$
M                                                       ^>&2H
M6G>V1]+\[7KE:DO<S3@YL9-R$D=:.C1Z \?1C,0J(7$RP 66&S0
M                                                  "O+)UL1^I^
M9A?@[6CIJUE_DE;<D5CFMF6J9>GJD@T40EXI[8*PBY$G,
M                                             >3SU^?<?J<=XU)S
ME?/N'>LQ\ 0,*.#J1,I!1H3E)S
M                               @84<'4B92"C0G*3F
M                                                   ! PHX.I$R
MD%)Y5R;'/Y+."WD
M                  @84<'4B92  :_.<TZ<@
M           0/)<$5"<8 !!8G2       1+()ELI!(G.:>,E-9DR0
M    ?F5QE,IU(F4@ &OSG-.G(                              UN?D
M #)S)CFW,P/))LDA3'"#!840S/*,!+7BI\LS*IB5YI$M+*I2R4K;/1+TP<R!
M+ G@<G)T5F-$:S4IT^@           ^,J3*O3J1,I  -?G.:=.0
M                    !7 >8  "3))DYP3<Y"$W83@/((,EAI!H\0D0:1-P
M'J&.DF2O$W0? ;8(KGL'2""K<U8:]-$$;"S<J5/8.E<E6   ?QY["RO)'RW#
M+J2&3\,X     $#"C@ZD3*0 #7YSFG3D
M      "KPLM*>3:!HHFF0A)T&H#YC9!M$K$+&#$3T2$Y965@E@1H\^DM#!6^
M0/+<2+9O$BN2M-VD3"Q,   @_7M:JNY^\H)8X1R2WT:4FZEH     0,*.#J1
M,I  -?G.:=.0
M      ,7,GX49Q3R>T,^R^O9      @84<G0H9   824+'0^   >F;R
M                                             !$RM9@/;J: BFMM
MNTY>U;   J8I68D:=*XRI8I3FXN3N4I5TK@@85$%G!]P !BA3:7>@  $,2_(
M                                                  %;]6Y!B_1L
M0CZ^6U7L!J6  !S_ -*W$S1I3MHVIMWJM=VG0O\ ,C1$#"K@O9/6!_1L4_0Q
MPX_SH:+"0  4L%TX
M      (6TYXW:F?;#!8^/B3#Y(L^YZ  YGX)<M@L;*O5/L1YMK9MS^3J0.(L
M'D$Z #41,TV^"G0W 65@  I8+IP                              <W!
M:*5ZEXA[!ZIHTD 5)EF!X1N0T0;G-2&9&NS?YHPW8:Q/R-M YVCHE(Q&L"2Q
M]IEIKPVL1W-[&K3:![H!&JK9J4EAQ.:/9??%PTD>VZ]@ #5D,D?[=:9D$T&?
M?9M20^GQ((&&L"T( B&;=-O@IT-P%E8  *6"Z<
M    @@>>  #?Y( YNS!S-S]28)K$KD+\"KDT$9.3((*$SR'QN<U$6=E51.4K
MR,Z.J<'-"=+Q! A 1(/Z,E-$%S!3^3.(BG3.;"         ! PU@6A $0S;I
MM\%.AN LK  !2P73@                              YP2W\YX20)\18
M 5W$L#19YYN SDB:6#&L#;14J3U(G%II7 >@='P.64EX;#,,!H\]H\8VP:$,
M]-YEV  !2_1M;,U<ZS..3(>.P     (&&L"T( B&;=-O@IT-P%E8  *6"Z<
M                               ^0_4_8QTR(  \0]L'\G@F0'B'M@
M   \0]<\X]4   A)3L4)=\^M9BO5T<Z;N=H     "!AK M" (AFW3;X*=#<!
M96  "E@NG                                                  !
MA4?5"?O=LWD6F)^9H=<;2BE     $#35Y:$ 1#-NFWP4Z&X"RL  %+!=.
M                                               #2-6S0K:K2)>6
M26H)5U;      ^0IJ-O%H0!$,VZ;?!3H:B+Z   4L%TX
M                                  *XEB,U/V,=RM9?>IV1T;@
M$##6!:$ 1#-NFWP:1.4L[(@  4LETP
M,9*.S;Y<6  :@/H-K@ K.+,0           "M2G=K?N4A99>IV/T;@     $
M##6!:$ 1#-NFWP#E-.K(  %8AI0              &IB_H_4          J8
M/'  !, E^4LDN3Z#(2J4GN0-/$,^-Q$)2QPAF3W*Z#H^            *X5B
M,U/V,-RM9C>IV24;@     $##6!:$ 1#-NFWP#E-.K(
M I?+F#Z          ""!YX  -_D@"GDV&:F-;%E93:?H;)-I$J2MDV>60E-I
M]QT?             J'HVH3W:MU]VI*&G;  &B:LM?E^M:?!+4]U[:A/6SN"
M<0,-8%H0!$,VZ;? .4TZL@                 "E\N8/H
M!\148;U)GE299N:'/:-DD9S81* J3+-S0Y.D            U+')0/+S:MGV
M8G?1XMUN7?  ',I4LR NT]A4+VR;]'1VIGWHY.F(&&L"T( B&;=-O@'*:=60
M                 !2^7,'T                                   A
M56M0MLU?D)CVZTZZED  <M,,TNZ<\?=.C:9WY"73S[X\C2@819-OEH0!'PBZ
M?4 4(E^)B!9>>P                "E\N8/H
M            .9NI<C'U%;'O8]SN5H@ "%U.U7AHY]OM>Q37UY<9:J[KK61
MPU@6A    Y33JR(&$RS*                 4OES!]
M                  !3$:IS;\E?I,&U[-O@     0,-8%H0   .4TZLB!A,
MLR@                %+Y<P?0
M 434;,>K4%M^GGSOH7@     (&&L"T(   '*:=61 PF690
M  "E\N8/H                                  !%*"Q0S/#8-3EQWZ#
M*NOR[P     $##6!:$   #E-.K(@83+,H                !2^7,'T
M                               C]%-"3E#JU7N7F@D56L@     0,-8
M%H0   .4TZLB!A,LR@                %+Y<P?0
M                <XD4\]X.]2[^/<]F7@    !YY36;B+0@   <IIU9$#"9
M9E                 *F37A_)(XL=
M    *0Z5N*UJK<+IT)P9]X     "!AK M"   !RFG5D0,)EF4
M       QLJ@+@P                                 #GTXEM6D@V_WS
MM:.0     "!AK M"   !RFG5D0,)EF4                  QLJ@+@P
M                             "JRC;A1?HVN689G5;(     $##6!:$
M  #E-.JL@F3+,H                 !C95 7!@
M            '-C5M[P1;9WLJX7+O@  1\\;_>Q!]]EQU%]7/8@8:P+0@
M47D2BY(F690                 #&RJ N#
M         .;VC<UO/#@MZG?;/%->C;  TE2M<G6QFWW_ #^W$/5RMS:V;<SD
MZ@@8:P+0@   8^<PY=*3+,H                 !C95 7!@
M                          YI*EG3MNI+VCH6-Z>=7)I4;^LC1@B13-O%
MH0   ,?.8<NM,%/L ,@)\@               QLJ@+@P
M                 0@K6H56:HF_:K35JV0 !%^+NJ/KRSN*:G.Q!<?=HR^I
M71 PU@6A    Q\YASJ7/\ !7.6-                QLJ@+@P
M                       :NX[C!XU))Q)*Q!+FO.     ! PU@6A    Q\
MYASJ8  *Y2QH               &-E4!<&
M        <R\%G"8_+!-_'N:R]      "!AK M"   !CYS#G4P  5REC0
M           ,;*H"X,                                  JH-0T+LH
M]_$L2S[P     $##6!:$   #'SF'.I@  KE+&@               >&4%$C0
M#<19$                                4OT[FB;^?;Q-')ZM8
M@8:P+0@   8^<A!U8FY@ 5REC0               !X)^0!3P75
M                       %.U.Y&"[0MILPR_JV0    !\A3:;;+0@   ?X
M<\Y,TM, !7*6-                  %*Y=0
M       "OY/%6IUI*W6L1N5+!Z=L     "!1K(M"    *FCV2TP %<I8T
M               4KEU                                /#>U.5YY@
MW\^4,,_N^>@     0,-8%H0   !4T>R6F  KE+&@                 "E<
MNH                                (VU;'+T]NYWL:U[+T      (&&
ML"T(    JC*TCIS/6 *Y2QH                  I7+J
M                 #G[@LVQ7LZ44%@      0,-8%H0   !C!S$G1T;C *Y
M2QH                  I7+J                                #ER
MI7=H7J%E%RM8K2M@ "B2G:C#8@M*]57=<6X:6?8AG: @8:P+0@    <V1?4;
MC *Y2QH                  I7+J
M "KFK:T/:JSDMUIM5+(  Q^.3G6YZW'QU8;H5*T-&AT!8^E%(B&9:6A
MYLB^HW& 5NF_P9P;K                !2N74
M          $88I-#5IXY_1XUT>5>  '-+E:>/;V'8GG:5=LU:S#5S+1\S3UP
M0C/#+0@    <Z1]QT/@&LC% 16+(0                4KEU
M                     !332N1MOTK?K->552R  ,.\]^/WS,??/*\]R$ @
M8:P+0@    #E(.K<  %<I8T                "B@GR           #>)NT
M                   K\SKT;]&A6'S[=WJ9]BF;H      0,-8%H0    !R
MD'5N  "N4L:                !%LQH           PXTZ6N
M        %&%/0CAW4M9M5H@:->\3-N      0,-8%H0    !RD'5N  "N4L:
M                            !K4KL+70                  #7,,L+
MKM3,J%V4-^CL2"<     "!AK M"     .4@ZMP  5REC0
M             -:E=A:Z                           ?D5KGE%H0
M!RD'5N  "N4L:                            !K4KL+70
M               #Y"J R@M"     .4@ZMP  5REC0
M          -:E=A:Z                           "!AK M"     .4@Z
MMP  5REC0                            -:E=A:Z
M           "!AK M"     .4@ZMP  5REC0
M    -:E=A:Z                           "!AK M"     .4@ZMP  5R
MEC0                            -:E=A:Z
M   :>JV:/[,%RURE(NI;$##6!:$     <I!U;@  KE+&@
M             :U*["UT                         IFR]*4&QEP#TZ%^
M61HZQ(2F@B?X    !S>G2$  ?X1;)2@                            P
MHAP3\ /9)'G^@                      J7RM/!=;*\/5SKN,G3BV:=(3&
MV@ #"CRS9(!_IKLP(D  #_#?) @W^  #0!O\  &@#?X  - F_@  : -_@  T
M ;_  /'-8&YP #51E9E0 !IPV*>\?L9D8."/Q($N%/V
M     !YL?=;4G-BDD.1QRC61IPE@  >"?$96  0%)]   UL;)  ! <GP  #6
MQLD  $"">X  -;&R0  0')\  'Q&$&Q  "+!M4VD  8*96?>  0$)]@
M                    'RG\'V@     \<]@      \<]@      \ ]\
M  \<]@     'E'U'U@     \<]@
M
M '.?5L_5JYG1-4M    "$V;?IYT:$W+U6%.9H;BT,^_>K:    _'CKDVCM=-
M\V?SV^RS1NT;H:5T   "CJE8TQI4[%L^Y4K<K727Z$W,_0   'RUY>97INK2
MHR-Q=:!5^AT%7*NZ*5P  ##ZTG,#%9Z6]_!HDQ-K]=7,E;C:\"K^?T$W*VZ*
M5P  :;JS<RFA6Z;<J]S[Z-*05FOC65I8)IY_2-7F_KSH
M       ?G5ZYQ-6NI7NCSNE_?DH   'X^*F\^_\ )HY\;]G,P'+TND.+H
M"H:A<KCT:MR53K46_CP=R-GI"]B    Y-Z\^[IH,RK6K4[4,"M;*O*RM$
M?A%WRQ<R[>U,S^:NC93DWOG^K^:LGQ]$  #7\,E$="[>#O?/4-=6OZI7?BGA
MLLQ]/YOJ_FK*,?1  &GX^Z!9>NE?F&"M&]#G=Q8TU=+*Z=J_?5PLGI7@
M                   \<S%>?[-'/Z6Z]D    0&R[_.[N9=\T?56$,VT[5/
MHQKV0   *E:EJG*3F\>W4JQY29M5KY:=P   #G@J6=03PSIX]@U/#;1IY]B6
M9I   #'ZECF"OU,RGAE-BZ\4+E"^O3HR)S[X   H4Q=6Y+ZOYCGRQ=GZ='/D
MSD:\3[E"^K3HR*S[X  '-MS/>=2EY.=.C>!8@AODZ.)Z%'IPC[_7GL
M                 #S?/7?/I<^@   #PN?<<Z\]WWSZ^>OL[Y^SGT    8]
MY[[_ %SX'G7O>\_WYZ   !^7/OB=\9!YUC?K)/     \;Q]?7GW<^XYTR/P
M  !X'/OL]\_)SU_/?/I\>XYTR/P   ,;/1\]Q+WSTO?,AYZ^7OGU^?0
M
M
M                                                      *RZ-^"
MVGF;(GBO5IV<.\9A[Y_KT>3S[^'?/N^>@
M                                   4P9FK.7Z;YFHGYGZ*TO6R*6:E
MV5=VO]%REJ[/O1NHW)5[>+T'4;O^O0
M                               !3!F:N4_0_.USY^A/ZE-7+>JSQUJ,
M4?EOH)G_ $WSVIL+9K5NP=?=BGD%6T
M                                -)Q2QCEAE))%FM:U'B:'[XY:#N.^
MDW2S<+S=/%+=.544H
M                      _'CW7,D>S/.P
M
M
M                          !__\0 -1   0,# @0&  4$ @,!    !P4&
M"  #! (7 1@V-Q @,#508!$5%C0X$A0S0'" $R$Q,O_:  @! 0 !!0+_ +2:
MM7#1ID%)C S4R*BBH*@BDJ57AC.ERXQJC0J%8OVV@),!CGQP,6.14SBBR/!W
MNU'9""R'P@D!&^^W;>F]:-PU98[!<1>S3P_&Y,V:FG1Q&Q=NW]<9V'HM\O\
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M#GC(6P>X</\ RECCKMRY]&2Y&4=52(828-6T>]?X@"&_#AP$HJXZK<O/1?\
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M[/FW3KAP#OV2S)?#_P#FY&CYWY_Q_<%TG_[R_P#9.;_\*>L/_*>J_P#;9?\
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MA7[<E)\6:;L0_$WC\5,R:A^'IXHD_!JFB&0TWX5@>+< K<2RAAO?H * J@
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M5_\  ?\ 20)&]$C8T='6Q\]'\1L#Q^SUH#?CY^3^T_B?T>SHKL\202N_!(V
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MA)7[O'E77$4<EW"[)XJSDE5\^0N@?K\O4ZTD29MQY*4;Y%60_-75@5=3X]K
MC8!UL#T !D3R?]+&DK2W[ISM%S25%B=R#HYV&X;\+_9'J.'\=U&)0)\;E,,1
M:,>"M\192JOQ]O'N^5/$]OD_'0=MY.?'$Z2\CR=OB!E-L#PZ3K&6/CCR[URC
M0<]:Y,L$5&*D^L"#X^)*=?-CRKD'QYR+NUKG8\$=VCZ/X:]#(J$$R0Z*'"+1
M$H)\_+=OF&[>S[O9Q]WN^?GTT9NZNXY%""H))167EIPF^',<CI]<AXT? _<*
MK%6#*2K*0RLITRD>001Y!!\@CY>C-&IWBBFH'$4(!< G9 ;Y_,G_ +KO_\0
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MPQ+ QS:@IP6Y%?DY$@1(GDK,@;>]J&%,[\!))9) 7551KC"&G3H!LR1O/;M
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M8-EY"J@,ZR]VV&3$OBE&94567\[3;#:=KECNR"RMSU]N,*WJ7EIIITD<DBD
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M/5X(8P/%+U@DDSM\),87/*X'I.W'K]*SN#)&D>E6Y ,XL24J<;.[#P@'4*7
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MS:1)1:+VJ\2QQ0S#BQQS22JS+*3Q%E (SVMV)DKS2@-.\,,DD<62=[1Q^%%
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M+3L['QF3+-XB2/3%&KI.D.(WTFI4D@:,;!S5JL4L\I ]KO+F<S!L\B3,AZ8
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M=ASLEDM0E(^>47*,>JQ'%$"L@A+(*:9(</5'[GC$@NWJ,IY?"L^WR-%JI4$
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M%TD@FD1)T)(W*A&Q6ADN,N]S-?R_MO"=#YVC8F?K!/W \4_@NO\ )!>BS+X
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M@VN4[.37&RQ=I<@8<&6[\<[F'L (87.&^!PMJO4J(_=M0;=W2)9JQJG?(R[
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MGS34^@I/UR5Y.F*;]"?RR1]G+GCM#\QWV*3PKF#SH?T9O"&5OW-;[O\ 1]X
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M9)A&<*LR^HG%BF> CAJ_,['*-7,56*YC'*W35K5ZL?@#/_Q7EW_>K'X S_\
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MU<"'5#CBE2N4!OX\N7..G;[=Z\5C5>P0D:G2#$KK:K9=]'T^17S*8W,I(LB
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M&/\ 7KO]W-]V\T>+UQYOD8S)X*KO*C^[-MX3H?.T;%]XV2?--3ZHS^D#//\
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M<5)+O:X3G"3V]^$USY+7K1=%R]']I=?_ !IAC.[L:UNOO[4T]SY$&='#,A3
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M %@7GF7Q)KAK!A&EHU(SJF*C^)PMGLS=J+NT733!.DH5))L<IWDN9.XL=JH
M@[<2MMZYTG:X4:>"4]TF.P^B%9P7)JU7JS+"4E!-K<K4+(PIDB4B&2% ;*2;
M9RI\@7W,P\K1L6%$81SWJT76NXG#:-B:,8UK&I[S6IHB?Y$]TG1IT6/,CNT5
MP)01R N5JZM5PBM>Q=%ZTU3J7"1X,6-#CM55:"* 4<**[URH(+6,15]M=.OU
M,;;*N@V#1*KA-G1 2VC<[J<HT.-Z,5R(B*K=-=.O'>U0?$U=]'P]];5UU>\J
M(TCH,*-$<1J+JC7J ;%>B+UHCM41<(&PA1)X4=O04R,&4-'IU(Y&'8]J.ZU[
M;37#(\4 8T<2;1  -@0C;W=K!C1K&)K[341/4QK95E?8*'7A+-AQY2BW:;N'
MQQOV;M$UVZ:Z)KW,(B(B(B:(B=2(B=Q$3WL#=8UE?/<+7A.FPHTIPM>M>&IQ
MO5FJ]W;IA&M1&M:B-:UJ:(U$ZD1$3J1$3J1$[GJ3AD:U['M5KV/1'->UR:.:
MYJZHYJIU*B]2IAZUU; @*7V584./%XFG\?@#9O\ _:U^QV1[%UW9#7=S_(QN
M<W:;=W-<+C:[>K7?KIU>IM%8P8<\35W-'-BAE,:[^,UAV/:B_G1-<,CQ(X(L
M<?4,$<3 A8GO,&-K6-_R)]@DB#5UT.075"GBPHT<Q-R[G<0HA,>_<[MEW*NJ
M]:]?J0TLJV!8(+<HDG0X\OA[M-W#XXR;-VB;MNFNB:]S#!B8T8QM:P8V-1C&
M,:FC6,:W1K6M3J:U$T1.I,.C38L>9'?IO!*".0%VU=4W"*U[%T7K35.I<)'@
MQ8T*.U55 1 "CA17>N5!!:QB*OMKIU_8))@U==#D%UXIXL*-',3<NYW$*(;'
MOW.[9=RKJO6O7ZBR7,JJV7*%LX<F3!C'D#X;MS-ABB<1NQW;,VN3:[K3KPL:
M=$C38[E1S@2P"D!56KJU5$9KV*K5ZT73J7N8[VJ#XFKOH^&R8-)4PY#$<C3Q
M*V'',U')M<C2A"QZ(YJZ.T7K3J7#X\L 9,<J;2@D"88)&]W1XB(YCTU]IR+C
M@5\*)!"KE>H8<<,86]>Z[AA8QNY=$U737_U:J"SR?:)539M_R4DJPH$[B1N0
MDFX>R?&DC9Z8-KMS&(_JTW::IBOS%2R03*FTBMF09'!Z/0N/'=KM=RYQ#D,5
M=J]H\37_ )L Z/NF:J' F2I0:]EIR25<N#.D:)$[(QF+R9X4MSF,9,B,"T>]
MAO3@JYS<+#->4X9;7;'12V<(<A']S8H7&0B.UZMNW7T''L)L2"#7;QID@,86
MOO<0SV,U_-KASZVP@V#&+H]\&6"6UBKW$<X!"(U5T[B_]0&5?&K_ .US<='O
MB[&_MEQD>X"C1S9-781BD9VI7-@2PEC/73K]+661&.UU]KVL5<3(UE%K\Q7M
M%1EG3I<LT(SH<BM$>>.'* $G!ERWJT7%7A-:%YM",<J+B;=YEZ2X,;I$C0%G
M%R]SU;)$>=KQ$K C81;4YBL]*9-3TKF%1[F('KQGW)=G8RI+X4DL'+TD\DRG
M@D?!%/KQ-D;N,D>/8C:YK-RHP1'C:G#T9C.71_<G.Z; D-N88Y97O*/:Y*VV
MC)Q55R<$PX;]B=QSS.T[N#M'*EKEK*<W<5@3'9&6!E71C&N:QR,VV-WZ[7K<
M([^[MQFBJZ6<TW&6LN5EE/K:Y8L0LQD*+&(@ZH08NA!Q@2PO2<>?RQN+O4BI
MH5KV5.8>AGIOJ)$.)LDRXIG<>X-P#(DJ)*J(98;9=7)$J"*LID?9O[5'N1A$
M_+_*OC5_]KFXR91W6<HL&UK*4$:=#=7717 .UQ%<-7@K2A>J:IUC(]OY\98R
M[D:-,-5PQ)6!FF"\:N$:1S%M<% O7%A10HFU3;7O0*:M:\K!XRK1Y7DS:RIE
M2V4UC+A$>$O)5]<U(5>^2+0@ARN&YQ$:]O'2/PG:L5[5)(B)99@Z3+.@=#;%
MFMME/ OY U8^6@T0-0*/"-N( C"22$"T7:O*1R-SJ/<F]N883W-]M&NKD1J_
MR*K'(G\U<2\XT\9SH69*VQM(X?8PF+;Q)$2>'<B:?<UNC)RMZW(BB_C)B^SY
M8->L_-ED^/&*5%WDKJY[N*=%7K5)=D63N7\;E6KB=E'I9Z.)67UK7'KC9O+(
M*RV":.5JPW.93@Y@U5+!Z:"1QIF@B"V 41'.;EU_09FK,5W-+(XF[A2!%@6#
MI 6UD>KE<E6S)!2JY[7C< BIH+[H+QG,96K9(C;%8$-9[4TT2:L<?-(FG5U'
MW]SJ][\OXE9G"L6TA0I?.QA-FSX/#D\)X>)Q($F,1WI9'-VO<K.O7;JB+CO/
M)\H<R_6V"!RGEVMI>,UK3FC"W2Y#6>M21-,XLLZ(O7H0SDUZ],2*;,%9#MZN
M5MX\*<%I@O5CD>QVB];2#>B.&1BM(QR:L<BX)8464(0)I&%%S,L\ZS*%AF.&
M5L5UE*E<KQ!O<QSH_#=M7;NTQF2\RO32JX+J\L^V "QL[!9(:H4B6G C6,\P
M&G:U3-%LX6N_8Y^WN9+RYD3+]F\T:1(C@D3XPF6<J5:OBCY<8(LB6P4&.D=#
MF*0JZKZ8[@C"Y7Y?RS%TX-)51(&YJ:(4@1(AS?\ ZY^(5?;U?@;LVY9@6L@3
M>&*;Z=$L!CUUX;;"$6/,X?\ YM3*SWFX99Y<RE!BV0E503Y)IEG+C*J*BK&-
M9R9;X[M%5-P58[3JU_ZA7B*QI!D8X9!O:CF/8]-KV/:[5'-<U51S531471<$
ME4&5\OTLHR*A9%53U\ Y$7NHXL8 WJB^VF[1?_5=_\0 +A ! 0 " 0(%! (!
M! ,!     1$ (3$@01 P46!A0'!Q@5"1@*&Q\/&0P='A_]H " $!  $_(?\
M*1)YP@]6: *KH"Y+;Q8 )A5/8XF7,$$*9K:'85QT@:LK"F*__-(ZJ[:3UH.4
MGB-@*207IUER1>!V 41#H9("5Q(5E5U4&8N/%!;5!XK7(KT1<Y3HW,-KJK<
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M1++AAZ%X6F D&BR"K0YGFI?;I==I4RFDB>;DQ =HK@3:WFD;OX!5B.\'P[U
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MO:\DG(\CX-2-=\A.4$83I#;S%39BJ=X!EA9<L=AD7:6L#L)#:,>T-,C]*VZ
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M(%5A>@4*%(U)+P0X?4F39[GHKZWP"^ T7;-#BWQ!0O<1;_TIGH!MHZQ_;IZ
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M+\0Y36]DT2$28#"&_ )8N%RDP$C_ (9>FD3B=7)VM3:]!\^?)L:]V5$@<P
M>PA22XS):1,&2!F])"&511VP(>(+>53*XWZQYK#FG<J+JA0!&#E:Y5*'8%+W
MUY/%!$01(CL1Y$[CEWE1!%J2.#)[MB>OEP@)80!P"5HEHY(RR !D>(-H9Y ?
MDN%+UF7$A\ZL[ /+%W?<N_?'$5/7RV((U4-1#9MI6ZKG-W1/ [BND%N5PT=B
M"ANI,(8"- )[8I?J#JOV&+\14]?+EK/X4&LL9\,:-N=Y72_#N2Q!CTE!A!$]
M&V2!]07XIRC'>:!TS'@<SVS^>^35L-0P^#5ZOB#I?T4]V+Y?'S;B24HSC8B7
M.75C:PW+H1A^I+\8[XURKBLHRP%!2S"N]4+JT;ONW6OEIS)661[UJ*@Y8N Z
MP(8T&B2F5@H3/TP3]SP8HZT8_9MI"]^DS%RA\11832>;.CQMV)19=TB%H([V
MY&W;;K%AS2F9^#)\\KDM[\2_%?K7RT"X[0)DGU 0)F4F\XHC!.AX77Q*<L!
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MG9HEV165\LP $O&@GE/S.Y& F<, (!H!H#0:,&)X(1@"P!"I!=F!_J ;!X"
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MCP-P+IX=SE*DY2.]]SG4Z'ZU(3JBTSLF:Q7V?K#N. $E2T=_\]4G=]#-#T"
M?#F/T1V[=GUX6>!-O$6C6&?R=O:II3V+NP-J1E;D"_,8>XZ,!#LI">AV>_ZM
M==."E_Q5A 2/$CM#7J,IZCIPRXSJRZ* "8%! 6&)AH^(K$+7!$W-7_P9R[P2
M8/\ _P B:D:5Y$G#R!%[C<R1(+"Z]P>H);NI=R+O-J@S"CE*E".X5QDZENRX
M6XVX=?85/'@GH$O$E@13$^X<+5_^M_4#_B[_ /_:  P# 0 "  ,    0
M
M
M
M                          4D+M $
M                                  'Z8=@D@ $
M                                           %V=PD$$D
M                                                    G[% $  @
M
M     @ $
M             $  D$
M                      @   D
M  D@          DD $            $   $@
M      DDD@  @@@ @      $ D@            @   D
M                   @D $@ DD @$ @D$D@   RF      $   $@
M                           $ $DD@$   $@ DD$D   ""]      @
MD                                                       ?6
M    $DDDD$DDD@
M     MP  "B% DDDD DDD@
M             !D   N& $  @$$   @
M                     &LC  !&Y D $@$@  $
M           D @D$@D@ $  $@DDD  '"@  C>H$  D D   @
M                 $$D$D$@$D D$@$  DD$D          @ $@$@  $
M                           @DD D D D$D @@$$$   #?      $  D
MD   @                                 $  $ $$      D@   P)
M    @ $@$@  $
M    >S0        D D   @
M             ^       @ $@$   $
M                     $%      $  D @
M         $D  $               #DH      @ $@ @  $
M             $DDD  D@ @D@             IE      $  D $
M           @             $$D $@                EH  '=- @ $@
M@                  $               @D$ $$$             4E
M258$  D $                   @
M   ",H  &4E$@ $$D$                  $
M            $2   LR $    $$@                 @
M                     ^P      @    @D                 $
M                             #_      $    $$@
M  @                                  "50      @    @D
M          $                                   %Q      $    $
M$@                 @                                   E0
M        @D                 $$
M   %<      $    $$@                 $
M            AX      @    @D
M                    !1      $     D@
M                             U    <P @    @D
M                                     &/@  JJH$     D@
M                                                  &.N@@    $
M@ $                                                   @#   <
M$X$     DDD@
M  %\8      @    $  $
M           %O      $     @  @
M                    )@      @    $  $                @
M                            'K      $     $  @
M                                     WH      @    $  $
M            $                                ,'      $     @
M  @                  @                                YP
M  @    $  $                  $
M  !,      $      @ @                  @
M           \       @    $  $                  $
M                   &N   .3P$        @                  @
M                            DH  "EID@        D@
M   $                                $)   ?2\D        D@
M            @                                =    B8 @     $
M                                 @                   $\
M $                           $DDDDDDDDDDDD
M $88      @                                       @
M          >H      $                                       $
M                           @
M       @                           D
M               $                            @
M                        @                           $
M                                $
M @                                       @
M       6P$                                       $
M               $DDD     @   @
M                        *\$DDD@D@ DD DDDDDDD$DD@DDDDDD@DD@DD
MD DD@D@D@@                      "( D   @         @         $
M      D  $   @                                    $      $
M           $      $      @
M
M!     !@/     C-    '3W    >UT   '(-+   %"BO(
M        '@0    ])     Y0     ?VX    ')H   B@8T   D92O
M                 "0    'SD     ]5    %O<    J#=    >:+@   -$
MFP                        A     45(    $$(    T%     )"    '
M@J0   !LP@
M
M
M          (@/ >
M                  &9W0)>
M                           U+^&YP
M                                   %Z'9R8
M                                              #P
M
M
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MI[5<.+)&!N*U4HLCBD?@-W_\]'_<_P#"I^MN_P#"/]D<,C\@>*578@2\5G,
M1(A<*9!67%KG315G4W02(NIE8-ER=Z5^AKYU;6X,19U:_ <WZ? E>Z-$VH%&
M8"/1@)& 2'HER (SD$.X@(>$1Q2P82P90BN$B6*"[#Z-0J9:%124J (L"_[*
M03, 4$ JI0 %5AO 3NZ+P%%CB1+>\0D2(-L0B%-*KLHZ92*@4/2):5(C,07P
M-"8Q';'L2S =<E4OI824@"XBX"! B"[W!5J)MU6"0 !?0$ ,9%>A(#A$<((]
M6 E!);N!\"RE$VU:4PEH!.D *@=4#^[K/.AJ^?0$"@3C+.JW[R(K%?@9C@HT
MQNQ?"[L2)A$6^GZ!#B,L,&PE$% #U(D*!(]\B40HY7B;K8Q?O:";H_LNZ*IW
MBT4.U#CWD"AQ0> 'RCE=.)>A*(SAGD:D-;M'X2+,_P"!#VC0VTE^=RYRGE&:
M>V&:$$RW'W;J10.Q+ML$5P=0+E&_1D8I,69M+$SK#55;3[Z\F(!(&1D=%@).
MY<V9:,ACC%BNH55V?H3S"@>&))O+V&>13;J+556Y@H(&F;T3L"7>_P Z+$M3
MIA$81!",R'8U* &2L1&PH.@YX<        AA"7(X,%#* (JP,:K@?@9BCW$^
MY:&;F)'7"Z0H#,!O2.D2<GO8A$ -HZBQ"CSK#C-*6"6QO H&+.1B!8ZM%*@*
MF:DU/SLA!.C0**F)LB=&/00AN2T4EZTBF@(- T%V(\%(7J=P\FKU!WRLG?<C
MGLNSP[(TM>J@A^TB+<)<T$;0 0F'C?F$>#."A$:E3"""_P" B7@<( !$3%D@
MVH0J6(QJ@+0<V*0#!5*JKE* $?P$G^HWC5L'8NR09CB)$#B#4C(JHWB:@SEM
MPEBPT")\#P.3!!1%V5:XWN53 4G '<UJ%Z!3$)L]*4K /&> X907'=;2PO?
MJWD\0[\ AWS!T-N)1IQU/(DP!%/P)&0E>4@=@)5M"3^P,)(SPM:(*Q^ K;BA
M!;0IK_ H24FX.%&A-4&5+>3QH3Z(%$M,5&/: 8HJ*A@$0I A * -B4 '?65
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M0)/P,4  *J *X@3< 8E)Y1A3(H3D\6DLB/Z=-'8_G@+SZ22AM2H-H@=6Q-M
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M[1!$&-Z*M/02SM7)WYYF7(VGVH/H[0BK1YFTG0AC:"H /W!"%58=YP8B-.V
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MU=]N"H)<(@9%X))G;BB"<EMMAUC<%!F$Z>E614U3[J$]+ 9]_P"V)E_(H9G
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MP"WC!4F3*-Y<+2RK3, =)'VCG!^PO_K.$RET*@5=I@L^K,AQM!0::WZPS14
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M<0 >SZZ#48(SRA@D[/;/@W I4*^$G9DJL^G&K?-5W=7H^\JSBA6TF51]G>=
M^6"_<,B&J^W^]CZ/FDTDBV[6POR"Z!6M#&RI@R9RZ@5!5"JJJJK>?H(6948
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MBK2O:S042O,05PYXD>@D,';\#7#6/TD6Z9P'8H :N -$\-U((! F $*08KU
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M]C/P@%EI/-WP-F>*"(,1!:4"TL01"@"D\BE4(((<YRI@A8%E*0#$5/P.NAN
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M.7O=9I&5@>0\P[/D3HF$YPUPGYEY&E!9_J4L]G'Z@*W1T9P$<[ <<!Q9&<V
M:/ZA,'+WNGD<0-'"D=)+C#C)<  4( 5%>57G+7J4(6>^96""U?YM^X+X-B>D
M/:Y>KVZQ&!%S%(N;D^&RUIU"(PTKX 3'P=GV^@Y>]TT841!.$22/LGP?&[ I
M;?!--.?T-87:@]2&(0T/'6ZE &:HSGK#\#_0<O>Z+<P$[E2*U(^0CU&5.XE*
M#2E)A4V.D% <4D)R/ZA]!H4 *H '5$ #E5 .5F*WAM4AT'(04YD^7;W1;F;O
MP3:U@]Q:@Q&&3%UW_H.@U_\ H7IC"X/GH>!!Y#54-.B5"C/A_-\S:S ,*+V:
MJ!'K?OBO&1Z*]+ WP(=CU/H,D-("/R7^7C5$Q "=!;U%&%VWNBW.DN@%BHU9
MLMC6U.GI*#^M7[3K_?5L9'W:WCFTU*0,]!'=>0+2.^"465B[>8BXHI)<5S3-
M(JS4C;5%D53 8<4IF&/HP'D9RI_Z*,UYOX%8MOT'2V[W1;F!L[&0TA><8#3V
MR"$OYD6@Y#,W" B.1'!5R!08.,O.D$ 13 8RVG"[(>:82<]M1?V7-WV3RLP>
M$*I M&#]$;UZ>RW!:\ .O3!TMIE>?!;$P+OP.?;) Q?WXKWP@ZT*% ;;'B6
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M$?1& !PMYE)N+2@\*_\ 8/>P'ZD2&9>@A#@4AP'?>K/&,4#YDKGTP! EAR$
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($E;(?\7?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>twosnasa04.jpg
<TEXT>
begin 644 twosnasa04.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P@ 1" -5!_(# 1$  A$! Q$!_\0
M'0 !  (# 0$! 0            8'! 4( P(!"?_$ !0! 0
M      #_V@ , P$  A #$    >J0
M
M
M
M
M
M
M
M
M
M                               5@2(EH       !\$-((:8Z)
M                                !4!$BP"PC*
M                                                        *L*:
M+4+D       /$I<JDDI[&R.AP
M  #\.<2H#]-L7F7&?H
M                              *H(@8)T*9X      -(<BGN2@L@^RS#
M/                                      !3A418I7Q(C,.C#Z
M
M      -444:TE!>!Z       QCF<DQ,2.GT6:;TP2*FC/$E1,
M                        #\*U*\)02$I,NPILDYT$
M                                                      "/%"D(
M+//0N WX      *K!IS4FR)X9YRZ0\L@C1/2Z27
M              &$<TDY)$5>9ID%=E=G]"P
M                                            #3E;'.98)8)L"RS8
M    %>D0+))0"A36$H)\1XRBO"-$U,LF)[$O
M            !""FBY#>%9G@<U'] 3[
M                                        !I"BB&%W'B;,F1M@   0
MXJ0AA<);P*0(B2PP2W"1E/$/-L6$?I.
M        "M3*-J<]E@%*F =T
M                                  \CG(@1+"R2/%@DZ   *Y*'-&;D
MZ/)D 0<JX^"TR:'J8)S4:LN\L@
M    AI5Q=1S(00O O\                                $%)R?I$"6G
MT   1 EX (@2\   @9.3[ !IP;@$0)>                  #F4P#/)P:(M
MPRC<@  % D8,@DA;1OP#Y*1- 2$M4W((R488QTP90
M                  (L;@@11)@'7!NP                  "-F0;P^3Q,
M@          '!)=IT2<<'8![@  ''!V. "J2U@  81P"=5%P@ B@)6#CD[&
M                 (8<H%WF000L@T)NRVSV  !XE2E;&A-F7P3P Q"@2*$[
M+R/<'-)!B4G4I^@$.*U(Z:@^#JDS@
M "-E&%4E_EW                    H(RC9GN:8B!T\?8         .,3].
MHSF(Z_.4#K<Y'.E#E<]2^RA"_2@P=*G/!TL<JGL7N6>"@B1%%':!1) 31%VF
M05F>93!_1,ITB1AF&>0!Y%GEPGZ          ?)0)N2YP0LJ<UQKCZ/<]#:F
M])Z3(   TI2!IS3%QEK@$=*$(*7R6\"!E5E8E\%S&B.>3[,DP3/)"7>>P
M                             !'SFLRCJ(R                   ",
M&<1TC)$B:'-1W>          <8G6AQZ;0[ .03L8XX)R6@3@P#DTQB3& ;DC
M!/BQB?&N-L#@HN,H<[C.6CLPU!5Q]E-'91QV=B&B!F&8>H *C*>+(+Q/0
M      JXIPLXN8'B08A! #[, R3#,<D1+25DN)$?0 *F(B2HJTO\F !H#G8J
M\N(Z/-&5Z8)49T^467H:8KHG9K"T#;
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MQI"7DI              !KSEHI@\2PR+DS/H]":$#)$:0^37F 3,N0MD
M                                TAST81T&2H  ^2.DD!R22<WI)"S@
M    14J,UYH#*(T=@&P!K" F.0\U)FD?+/.<B5$^/PFA(2MRO".GV6R8AN#3
MES&J)^ :LY:-8=&DJ-J                             #0'"1<A(#?$H
M+"              !2A #>& 8)9!7!J37&:>1BDR*/)N=)%D
M                          &N.?2/%]DY!YE*DO)F?1Q27<99L"R3.
M!\E=&2<WFX/TN\L8 Y/, 'T:TQ#*(T602LBY 3),@W1O2UBPRD36$I,\GAM
M "H2@SJ\E8                             !'CD\O KTM<@9^$B+G
M          !2A"2=E9%_E6DW/TYG.V3"*'(X7X3D
M                    QBA"$EWF><V%H&268<O%HGV;<N     &L.=2GRP"
M='08 (@0XA17IBF4;4FQ8Q7)6Q(2>'H6>2,^@5F5H>QMR^@ ##.?"$DZ.BP
M                            #".>#"++( 3HWY]$L,D]0
M 5J5F8AO29DL*#.>33'41KSH,E8
M        !\%'G,A.22',A?A@DS->3HMTD@   !7!S"; O\DA,@#'*?*M->3T
MV1 B5&^-,:<SC?FP+=/< &L.>#4DO.@#] !XE!FF("=L@
M               J KP^P>)C&&81@GR9A*RPRU#)          / Y](H2\E)
M.3^?Q#P=2'6                                            ,<YL(
M05010R2\"=GV2\I8ZG)@   5J4 5T=9D5)P6: 444(6<"YR)E7F:3,L@U11!
MORU"R   4F5.?9TB3  Q"(FL->4.=J
M &M(N5F91Z%:&K,PTYAF,?9,3K V@         !2Q79%SJ@X-(49IOR1'7I9
M(                                           (:5T<5&.#,+U+$-H
M:0CIU*;,  T1Q"6R:TNHQR=&X (.4281\%R&O*[,HE1MBY#F4CI>I8X /DUA
MH3G(PSI G@!B%:$:,,B1UH   :\K\K UI*2=E@&:
M      "FC&,\@I*S1&*>QA'3@         !0!!34%G%H$@-D
M                                  5H1DT)H2"&F.D"$&S-$=#DC/4^
MS\*;*G/DWIFFX)(2@F( (T5Z4N:HVI+37&46V6<>9RT1$ZC/ UI5)5Y\EC&$
M1DWIT\2<TA4)B&X)004OX  $$*'-V1@V)'33%OE_&8
M         4J;XV9S^3 R3GL[H-X #S-*9A\D8-*6J    #5E/E.E_%L
M                                            &N.?B($P,@K<L$VY
M%";%9D!)J3@@I[DV,H%]GV #\.;3$*^-&6 2@LXL4\SF,C)&#X,PGI*C>$+/
M$T9 SQ.A#**Y(T6"1 M4NX_0 :PYY/HRS7'X;8VA%3>'00
M  !&CE Z$+./H        U)0Y:Q5Q8)S$=5$[ ! S\(D:HW159UR    8!2Y
M-#G(]#LD^P                                         5"998IG
M    TY1I#S)(@;\C1B& ;$W)*C$,<\33GT3<G9)RP@ :XY>-6:\TQ+R.E\&*
M2<@1I#3$Q-0>Y(S7D)-J"/FF,@T9DF 2<LXZ%/0 %6E4$W(68YD%AF.;\SB?
M                 %=G%1T^2PLX        _#&(L5P0$KD[O,\ %:$?(\3,
MW94ITP    >91!A%=D9.J"R@
M    #!*9*A+8+Z    !J2M35FF-60HL D!FF@*Z-26T?)]$:+5*A(H:\\#Q+
M5.I"L"KSZ(H:XWY9AN"CC,+8+/*<-&:0]C,/TO0VARJ?A:A:AZF8?9SH0X\3
MH\G8 !19#RQ2 $:)V99)RTS[                 !49S"=T%)EGGF00M,W8
M      -,5Z8I0!8YTZ:0AAJ3W(^?AJC**^+F+D    !$C2&P.32PCJ@
M                                    C!3I69=1=8   !7I2!C$Y).1
MP@@.DR2G.I6I+22D?!KB9F4"G##-&8YYGZ9Y(#8&A)V;HL(P3G$DY8!B&8>Q
ML2O"RR0%DG-)5AT^64 0@@YIB'G7   .?C[-<2 TI=!(#]
M    !2)5ITP5F9!NB?%0EXGZ      "%%.D3.FS/.="V2L26%:FI+=-.4N=O
MFQ    !2Q S((<: [L/T
MPRJ#.*&-V=9'Z   :(YC)">9Y&Z-,1$ML@!U6<&$K)^;LC1J2]"-'Z1TVA61
M/S2E<& >99I'#((P:<Z<( ? - ;PW9\&";PNLK0N B1Q^=!EU Q"#$!)L5H=
M+@ 'R<U'P2XJ\SSJT                   %'D;+T*U,DWY&#4%E$V
M /DY[*J+]+>*"(6:DV)H3?&>:0B)TJ6V    "*F<:(JLWYS<=Y&:
M                               "O",GT:PB9YG4I6Q5!JR3DG+K!K2A
M2VR7&L-<<:%G&N-$2\JTE)OB2$^-86^1H@IB&B*X),9!'S!(L>99A+#.-2>Q
M S+-\:T]#9'B?!OC--B7"<_%0'N=L@B)"CU/@C9;)OS- -4<VFJ+N*S(N=A
M                   J$I0GQCEJD2-H3XJ O4^P     1@YL,DO4GA41S>3
M8\C[/8C9I"7'7)E@   'P14KHKPL<^BB3N$_0
M                4>08F9(BF21GB0(F!LB4%%G2Y9H  (><KF^,0\C'(Z3\
MWYMR/&T.C 5@:,PR0GR5"14^CW)230UQYF8:TK$R#+/$FA&S#):2TRRTR)',
MQMR$';)$S0F05Z0$T)C&V+=+[)$#GDB18!79X'7P                   (
M,5(3@K8\BZ#4'H4V6J6L9P !7I3!EEHEFF.<KGL6&7(?8*>*6-";8QR3$K)6
M:DO0TA S4F8;8WYMC+*?/@RR.DP*L)R7>           #1'.1U4"G2?$D
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M)F5Z4^?!%3MXBQ2Q-S5D,)"7B1DQS.(J:8]2J#=%\EQ
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M!6Y"#9$>-&2DBI^&N-X91^EC&>2LL,]P  1,K(RBQR&E:D0+.)L2$HPZ(-R
M  #5%3E<F_-87,;<BQ!2M"/%JDK,XSC.,XSC-,XSC* !I#B<FAM27EG'$!<)
MN"^3E,V!;)59AGD=3G.1U0<L'112!HSH,J$W!7!C'7!]G(9UT?14)K2%'4IR
MN=$'+A]'1)1YU0<KG19RL9Y;Y7)TH90   /,H<KPA1T41TF!KC9D9*[(D6^8
MYI"*'4A)BEREB9'5!]FO*H*<,PFY&"2D-)(1XUAA&(30R2)%LGR0,WYZD /8
MDI]D5) 9!\&N(L8)KB;&\(>3 P#K4@Q49*C0%5':)(P  #",T
M           TISB;@OLVI5!"3:FW*^-:1PWY@&O(^>QUN5@2<JTM WA #H0^
MP "I#S*H+E*9,TT1TH4X=%&G-V9(  !#BF39%VE#&<6\24A!S<;,FI7I>Q9@
M        ..#L<  ')QTV;8                      'B4 5B6H;<TA"34D
M:+7)>6B4P5B6B5&899A$R2'4H-0<^D!/ W9K20&V->08Q#8'H;4VIO#T-::P
MBA8Q%#<&010Q3]/<Q37&E-@2,UQOB?E<G:94!1I=9&RC#MHD8 !7QS$=4DU
M            /DC!O#-       !$2A3 ):0<FAFE[E&$,*W+ (6:\RSHXN,@
MQS\725T3\D1HC'-6:\V9N2MC+) 5R2,\B'F].ES:    $'*?*P.LR6G,Q8A)
MBL"E2T#HXV)"#G,MPN<        CQ(0  :$W1Z
M  CIS"0 F)-RP#F O\L4A!"B&F<1HO,A!DE.G?![D+(@04C9YF(>YCGR1TBY
M<YCGV2<SS",,RB#F(28^SP!XF@(\>AI#-/<\B?F_/@DQT.5B4"6*:<I0[:)@
M  1 Y'+..F0  #FP@!TX38        A)S43PZ/        (^461@QP20^R+F
MJ-48A\$S+?,,O8^"AB+&":LT9L3#)0:,S37&>2TM(YA.U2BBO2R2XS> ^# !
ML#Z!&RF30$R,4MTJ(QB#DS,\FA71<9X%;E-G0A;H
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MC9S 6Z=,E%F4>)L#1GD;8TIG$ ,XZZ/L
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M/'N52>Q=YM3U)"        <_&R*U)V34LD  _"I"H#V,@^#,+H.6C='7YD
M K@YY.M2+D0/<B);Q-3[ *V.126FJ,HN,VY+"I3%*3.MBPBKBEC'+#+D*2+!
M/PQS%-,8A&2"D1.D##+K)&5H6F>H/$JHQC0&](^:TAA,#IL
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ML<WE/F23DUY8YT.    #"*1-80PUIVF
M #X*5( ?)91@FD)&4V=&DZ.9#S+;/$C!' 0 EY&S:E4GP2HV1) 91$3<$L/T
MQ"ER^2N#2%A$9*M+D( :LV)BE@&G/H^CS,0\3!/HQ#)-B>)!RQC)(^>AIC=F
MT)&9YY$.+5-^4T2(KDW!:1J3;E('50-08I&B*F07P1@LDE         !I#E\
MVY/"=FS-D?I595ACDE*W.G"BSH JLVY1A*#KD   I<CAL3+*[/D\#1$Y)48A
M$#'(H;4T9AFT)V0<V9/R'D/-V=.$;,8T!ZETG/Y(CT(@4V28W1NB G0Y;P
M  -.<_&X*H/$[>                              !5A2Y9A%S8D@/(EA
M3YI#JDYF+++ .:B3F(;T^2C23DI/<SRICV.B#GD@1T60LU1BEMGX8IZ%5'J:
M(^0:8DQNS5'J1<R"Q",$>,DCY-C2E>E@$@/ TYZD@(V>YL"=D),@LLAQ<I#B
MM#&-.2DF1#SJ(IXJ(O,PC1$C(,6V>QYEKGJ         #G\KPMLT!=QS23TK
MPUY81-2ISI(@9/RGR7'-YX'0);(  /(Y9)H4R?IE&>;@U1LC-(T?IHCX-$30
MUQ(2+DZ,,T!GFM-R8I*#,)>:@GI(3F0L@B) B?$2(L62=7     \2D#U(^:T
MZB                              /PI$_38&8?)L2P35$'.:SJ4U1/#F
MDP"1&^-^1$@Q""=ET$K-Z0PYU*5-$6.="'X;@I$WY89ED1-^1,V!6Y^FX,$_
M#.(X?!,B*GP5Z:LL$A9*B9D'/4FAK#P/0U18!BGZ;<E!'3Z-8?1HS,+I-F:L
MYZ.L2/%*DN(B?9(C<DT/LM(          AAQZ7:?)("+$?,$_#H4V)5Y?@,<
MHTM<I4K\F)TD90  -:<HFK)L1PUY*3%/ _24$7(D: WA99'S)(P2LTY@FS-R
M:<W1N3H\$<*=(R6\; IPCY*2*F&:@[C/T    $<*]*\.@R2@
M                   %!E4'7QM0:<YI-\24C16A<!IRURJ3%(X1@M\Z'!\D
M..;3G  M<MDU)41U:0<E1%"G#U+3-2:\Q39GR1DP"<GR?9HS5F.2@B9*CP(@
M7T:,P#0D--F38V1)" GR;XBY-3S*[+<-\1,VYN"B3L4@I4IOC0EP$8) ;\GX
M         !\'$I(B:@CQ'BYRX0   #".7C&) =(GL #'*<*D->6"5J30^3J0
MY&,@FI2AK38FB.AC6F">Y@&C,8V9O##-&7V6F0<YT+U*H*\-P8QDF6>QD$&.
MZ#(    (P0H]RQS.                                !09419IT8 5L
M<^%I%:$P+?)D>ARF1DVI]&J.L3?D8((5:4H?9@FJ)V8!@%J&:6@10@!8!K"
MDI*S+?($2 \BLBWB*FK-29!*#Y-81@L@W)FGL0LA)>AX&<0(BY:1XF^/T^BD
MCHHD9KCP(H81[F,1\O CA;P/(W)[@          ILYP.BB)$8-N=3     '*
MYIC[.FR!%M&D,0YV->;H^#?$)-<?AG&C,$_#W)^;TPB4'F3@FQ1Q5)A&^(N;
M4WIU6<W&:=!G+A"RVC1D(-@>Q-"-&E.U    #3'*YJR,'6)98
M                    !\'/!#S:G0A(01PY9-\>YT\>P,(X_,0LLT!#2Z3<
MD6+&*L*W-T>1\D^*(-8;TO(BIE$W/T]#DLEYL#(/4QB1$(-N?)[$!)N:<UIF
M$F/L^SZ,LQ30EI&65>2,R#X,XTAK2*%J$E)H9Q@E>GD:DU1-B[3?
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MTJ8KDZ9+()2   #Y.="MS#)B:@KDZP+=
M    *P(\0@^B:$N)\5N3(W9'3W*W*N(H1\O@Q2&FJ-R6*3D@!SR=!E?D7,8V
MYE&@-V91HS9%>FV(X6,?1XF:8AO31&>;DB!G$0-X:@V9)#/-J1HUIBD^)"5X
M2<_31&^-L3 U10IM3Z.KB5 $?.=B%';A]                       YO*0
M.EC",LK<T)L2R3"+!(V0$NDIDAI'C>DE(X6F:\TAYG3I6Q'RIS#,$IT^09I8
M)N#V/PWY8I=13!8ISX5X=2%O@  'B1,V)R^1PS2XR/%9&[.QP
M                    #4F,<^FN)8;(WY\FY/0IXM$I,@A>!3!<9JSX-*8Y
ML25E5D;+A(X?1!27F40HL(C!%36FG)0?!)")DA-H8I*"&'P995QJ3\+R-.>!
M-CT/DUY##<FU)H>A@&R(T1 &K.@RHP?I<I>P!YG,A69TZ6<
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M0(F!0YK3 (J;LWIT ;@P"C"D2]BY38D1)40PWI5Y-R<
M            %='-9T"08FYIC(!7!#3M '&!9Q]&(?1[&B,X_"*DD-(:XR"2
M&L)<5"99D$+(H;8MTP#0D;)V5B3,W1DF0:0]R!$L(434W9O#P-(:0QSX+*,$
MDAAD%-6:@EYC%GET%?E\ _"*'(AOB7E?F^.O    "HBCCJ EP
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M0U!\$Y*=(67"7D  "+'&I,"\#Y/(RC6'V:4E1/39@
M         &$5>:HUAH#?D2)>8)"33%BFS.ABE2('X:HUY,B&D2,HDQ/B+$/-
M4>)&RR@5&1DO<T!NS7GB99MC!,PU1H"Y23GR5<00VYAF8;4QR-FC+!-8?!CG
M0) BGRQ3S.@C>D8*J, UAOSX-B7"<YEZES&(98!I2)% &N.CBR0
M       ")GD5<9Y#B+GN1PW!V<?0!%SE8AALS'+C+G)8<YF.3TK\\"!'L=*D
MO./3;GF9!)B:G/1TH2XCI)"0@'R<XE8EXF4:$VI&"O2='3)]   %"%5FS+P-
M>;P@);111^$3.O#*                          /D^#U   !S\8IJ24&,
M5D>1;I'S<%ME*&A/0PBO2/%[D6,LC)L22DB*S-X;,UQ6I[%Q$S,(YT-8>)DF
M>:PG9+C?%8F*:TAA[DS-D99XFN- >9F&V+Y(Z4B7V<]EOE@E3&$:8M F9*BJ
M#+,PA)=YJ2T#$(21(K4U199T<?H                 *X/<F911)#G\]3%.
MO23 %$E+F"8I[':QN@<X&W!!"VR'E3EA%^G/)>9 2%&M-"6<1LBQ]&&7B7>
M8YRL:@WIT24T5,66=''N   #%.7"/EFDV(X1@W)OSGXZ$+9
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MJ>I'2VSKDY4-499J#H,GYE %+DK*R-,5^=K',IHRVS!*7)(9ABEIDJ)V
M               #6%!FG+K)X "!%)&Y-T547Z6>  :4YU-J:H]2%%O%9G7!
MS$>9&CV-H:LV!?1$RT#>
MPCF,RS(-J2LV1LB&%%%V&>>10IT(4T9A:Y7!'C6EU&F*P,P\RX2B")&87438
MP#4&K*0+4):91KCS(B:PVQ%"&&U,(]#4DB-&;(G!'B=&K-6:@K LDVYJSQ-L
M9ICFJ-@:,[(+&*H*0,,M0OX  ^#[($00JDN@L8AI'C#(2;@SR>FL+4-@
M                   #!.:#2EIEJ'P;L  AAS06V1TDI3)9A:!3QLB>E+'Z
M9Q!BZC\- =(@                                       %;E)$H!,S
M;EA@^3G$C)(C,*R.H#EPFA;A.C0')1*C++;*S)P5P5L6(10L8L<T9%S=D5(^
M;@J$WA:AI3%/LCQJ#7&(;TB)(#7$M) ;,UIBFK(21TE))#U-464?!5A+S1$<
M.TRQ31G'Q+CJL]",$E/H 'B4R1,\2U#,-(5:;0L D! RV#=@
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M3,Z0  !$#2$!(\?9.2-%<E\ENF 4P0\DY^$8)>7B9(
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M:ITR  8)4!;)5!ORE31&>>!KS%/4RBT2XR1
M                 'B<K&06(38K R2IRXB(D_-,;\U)0QT*6X 14Y_,,RSR
M(\5P;<V!41."Z2:$=,(DA1Y'B\S:FO(X>I&#<%>$P-P1DWA@'J89FF:: ]3>
MF:>IA$2-T1\R3]/4^"RCP*_(N3\WAIC<E>@F1(""G8)O0 "M32EE&Z
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M,>Q"32E7&H+E-:?!BFO/<M@KHCAU4<A'0!9 /DJ @YH"3E=F^.MP
M                                  1TPB7@ A)S.8Y;9E%''4)8(!$3
MF,JTWQ<ATP8QSR0@]CJ I\L,G9SX:,HHDYXEYD</(U1'#]-*>YN3?D4/(VYI
M25D0/<U9NSY)P>AL2($9/HDI[FQ-H:(T9K3H8N,QC'-B#D,FA,#G8NXLD^"6
M@ &C*4+6)B                     " %:E;'N;HF!LR/EE$&-8;H^RG"3F
M28!Y'V>IZ&J,@^C4DL.HP >1'R+E5D=->=I@
M                     '@00U0)L2$ JTYR(L6";PZ$).#4'*AF'4YG@BI#
MBG"KB>&23,RC6FN-81TU1)37'L;4TYO#1$/-X;,UIK2QB6&0#5&&>ITL<SD)
M+Q(B5>?!U"6D  0@K$Z$..25EHFC++-J1@]#2%'&D.NS;
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M817A&BV32FS,PV)!C2DL(\7R7& #$*W*=*Q+I.F@
M                          #S.8#,*^,,L0Q2/%CD),8ZV!S230R2T2/'
MD0PAAC ]C'(:3$V1\ B!MB,&"2PQ"*FV,,RC (T9YOB6DE- ;X^CY/$UYX$=
M/@D9,""FN/D[3    -><5EUF_(<2,CI59(3J0W(
M*>*K+#*N.J3]*J+N  , TQEF](V<IE<FK-L2PLTRC&)<5:1LZW)6 0XYQ,4W
MYU2?H                !RT=2@B)%2V            <S'3(-<<KGX>IU@>
MH          /PYV*H/LMPDIO",$9(>9)KCL,H<IP\C")V:@LL@9J3<$L-<;
M^36F 99X&$1XRC5$M-B14^C8&J!!S<FP+,(@20\3]-@:PD!5QOR.%WDM.?3$
M-N6T6*: C1"R(FE)87B6 14YH+6(H;$B);9;                       *
M#).1TWA5!(R^S:     &A(V?AZ%?&\-"9)81S62HZA!ISGL@A-SIX^@
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ME:F0;PFY"RZC\,@@161MS./ FI-B8%>D\*M-Z;$A)?YLP
M          4B58;TVAE'0P       !%BKB?$1*])L5$="&_.1"1EM%U'H
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M\E<G0!("6        UY31=A2)8Y4IT408Y!)27.1HE):QF@
M       KXL$                                T1[%+%-%CF_+@-^ #
MQ,(CI3)"SH\HXUQ R?&M)$=$$H!^%1%?D:*M+4)22$R"1G-!:I?ALC%*0/LG
MI%3<%;GL1D_3<$H)(:<D!2I#2X"#EB%[                          P#
MF<UQ)SHH]P       ?) BI":GR1XU99)RX6:6224UI'BZCT
M                                        (6:HT1SX;,W1T$3H  %>
M%6%>& 6,;HG!!#:F@+<)R?A69&"E2+$A,0NLLL@Q2I,R:%IDD *_(N>1\$!.
MJS[  *S,0IDRSU(\=#%D                          QSG@BYJ#H\GX
M     /PJ$D!#RSRDC5FV,0%M%'&<38Q 7D?0
M                          ,4@QOS7D,-*5$;(D);9:   -<4N5R0TZ-)
MZ2 YH)":0D9;I695!%#")":<Z>(\8!$R&$L)&?)AG30(21LQ";% G3AL0  5
M,4$=,F.<^'59M3(                         (.0\ILT9U<3H       T
MA]E"END9,8N,KDH0ZX.?BT2L"4F":XVQ=(
M                     !7YS(34RBYC7F]*P):5N20RCGDGAJ#JHW@ !C&L
M*#,0A);I;YO2OSG8Q#P,PBQM3=GZ2LZ"-T?A3!7I!39&"8QNSLX%0&:: \2M
M3L _0  4>0@Z4.:CQ+9/DL@PS=@                   &.:X^3='B?AHS7
M'X08AA69=IT"      #!*2-*9AH37G0)-CG,F);9#"D#7&W-86(>!DEN&:
M                                             <Y&A/,T)D&H)Z?I
M,R/$U(01(F16Q:!T$  5T:<BY@$4/4ZX*R.;"?$4-4;8UI]&.= %S  &J.4S
M1F\,DFQ/BQ#R*C/,P2O3K4   H CQT*<XGF7X:,UAKS4%]F8
M     #\*&*[*U-@;$W!NR4'F;TT9K23E*&].R     ?)J#<@J@KLS#Q,HT1:
M!J2L#KH^P1 J(T9]$8)80\LHEYE%E'H
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M_+W)& <C%C'Z>)I"OS#->2,\R5%<'<AD@  '$!?9E%'D@/ SR;DO)X
M            #\/$J(^#6%FG@5@6Z1<A97A'C,).=$DJ    .;C'/LUQOC7D
M:-F6^24YB(\=:DP   !^&F(.4@:\TA@GV=&%U@
M                      I$K4O,Q2P#D8LTUA:)HBU#$-408UI8Y*@8I###
M(P8!-S7'.Y8)B%E@]BV3]*B/DK<W!JB,FK.J"; XV.@2%$F+7/@UI11Y&H(Z
M7:6V   #B(Z$,TCAA&83LFH                     *\*[)N6@  ?!@&R
M    *$*"+@!"R7GD89&"&ENG29MP     10C1$R'E6'39<@
M                               (D1LC);1J#%(@2D@)9A-@#X(R1D\S
M<E3$Y*Q)(:DD1J"2E,$M)D?1N2UP1DYV,XLTC)*BNRL3LTVIRJ6:?1^DH)D"
MOBJS!/(L0PB9&<2 V( .5"6GH20A!DG@666                      #Y-
M:;0        &B.."+&Y-L:8UQDEKEY$V      !7Y59&B*$B.NC(
M                                     !^'X5\4^2 \B<EDGL :HY^(
M*;@_#[/$R34D=+8.BSP.=RNC-+C-J6@>X*L*@(T3$^R?D'-D=%%.'T:XE!.3
M8GF4Z0D]CZ/,\3S-63DOT &N*&-P>A%2/G@>!UV98
M            /$KTAQCFW)@3(R        8!ST5D30ZC,H
M                                 @A31*3V+-)( #R*>(81,DAYGH;4
MEI8IN2,&D*.,0@!=1T490 (>4N:H^2>&U( =.GP4V>I9QM 1<YR)06$?)"S:
MFM-<7,2D  &B(68!G$E).>P
M     !6A3)YDB.CST
M    !%2A"S3Y+,,X  \2GBO#[+%+B!YE,%5F(;\Q3:FO+G+)  !YE9E4&"?1
M,3H(&.5B6L 4 0<NTLH @IH2;$B
M                !SL5P?9TN38
M               \2/DF    -&4:2<LXW)@G()*#8%FFT)F#X/L   %8E8&C
M(P20ZX/0  PSA0Z0/8M\^@
M             544Z2XNHWX
M                 / C)X$T.8#2%K$A-Z28     KDTIHRO"(DA.O#8  $)
M.;RW28D0+;,P
M  &I.5C2%[&A+Q-B
M            <?EK&O,$L(L8     BQ31J"G3<$[.M   1TY1+K(>2XSBV0
M                                                 <XE;%JFQ+1)
M                                                         "H@
M:,W981O     5R5F1$K<D1+SI\W   !RZ3XPS0&838LT
M                                  Y4)D3DL
M                                       %#FI)&1LO\V    ,(K,K0
MT1K20EQEG@   &"4B3 @9@$Y+>
M                / _#(
M                   *S( 8Q.2R39   &E.;2"FX,DDIT@;      \BJRK2
M/F0=4&[
M                                                        ,0Y^
M)V6B    5\<SD@/<DA;!*#.      !I#0$Q,D
M
M                          &A-X?0   !Y%%&@-*;4DY;1O0
M
M                                                      #5'.QL
M3!-87"6:
M
M            "EC3&2:DG9:!Z
M
M                             $3*.,D^2RBR3[
M
M                                              ! "GRSRT
M
M
M"-DA/L
M
M
M
M
M
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M71YG8E,>9VI+'F=P18YG=D&.9WS7\<SU#UW',]2=;QS/4_6<<%)K-&^NR?\
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M%T_VMU,"*CAI!$F^OMUA\/6M4Z+E6U?OQ-;7;1LY6U,_IT=V02G]LD0S8/6
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ME\/UCYMFY!ZA4M.@S7\ZRO/$2Z[T@#8I/\$U/-NUZ73S8@#ZVBWHC_S/+/\
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M5ZP!;I[D>Z:P3*,L^DM;E[]?^W?+B*=75GDTU:FZRY6_W<I8A@O9EP? C*6
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MNU:M>4T*4#EU*U52JN:,6PFFBL>O^VZ@(/D!TQ-VM.=K*[YS)G:PNNLQ'"A
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MM_0+J*R(.A24TQW5B5+1ODB%Q 5@PNLMCDY^R66Q.0:/ADM:I"DA'I?35J&
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MB5$%+C53NAKR]P$-?N22)@O\XMZPOSUW-YVF(N3O;BK5413RX<:H2K]%1?\
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M66P[#U-U.W9D^N=5K=?"V;>3-_IT_6\:[KAREMTNV"WK>+XVJZJTW#8^J/\
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M%T"84Y ES3MA(F?_ &#DN88@A1;N=:8]=-:1!0Q;5P]WQ"]YP@(<JO<!X82
MM?B:-<L$[8:<A6A4$4Z\D.W"/<\(@PH(?Q!/TG:O_<%X=!68QQ#'/]^5KQ:9
M_2\,<OE(]0\?I!<+79]\HXG&E>*-/[LXQ+&%(.)_7*X65OVR6!SL_N\Y],;V
MNA"@F7IE1<:!DS5S0H:\V+#+^S=5\R00V-FU&;(%34POK_CIKJAFK^A;88.Y
MP?)T3L+4(><BZ6O&;61\T2*;ES]+K<45%/;S:'"FRZ;@,Y401>-X</Y:-45
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M54TB?D&%1#H.WH?,&_=./)R->94JR26NUV+F2'0PU<OR3 ZCQ_'+TAB2Y6;
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MBC5%M5H<15SU?M8\3J[(VU__ 'G85GGC5###D7;#V"@1S"&OX:(+:1CB$?\
M[T^U_)&2\9'EH898J[_[ZTU\-OR$,5P__LR__\0 %!$!
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MH/+^Y<T14GNX+=!7'U12,%TA5.KF*]*UM+<E-.3L!XX%/*,:^2Y\:O1+PO2
M=2S'VB#S_CSKAO)ZI8L$@[$YK1"=2[4H\!_[C5[N6;EX5<%Y@\R#=?JBHKF\
M5F0$NOAJ\34LUI*A5&.4?8Y\*6>5(WF3&E(]]-1^D21EP/9/3XTL,?Q8^)_H
M3$[ @>\&'.@J^C0\0]]R,M]O_*I(D9[F0G,8C&YJ6_G<Q\9-/H_[_IN/CJ^V
MKB.4I;W)?7%,^<$=5-+;\=Q.._(T6.^*E$5F\FD9$D*<Q4<EPI5_VA@X^AI!
M^JE)(/@:D0!9-8Y.,_/XT;61=$3=]M(]ZEDL62UW.62+G\:>UNE+11+CB:<
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MXW'XU<7;7JRKG*(-AC]] QN891U'6MUBBN(X@N3&.+J_.K>XC6,M=+WIM6-
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MVSH!\%7K\Z;M/LOM5Y5A[TG#!C8#QQDY%<28 7D!T38Z^#?/Z8[!&Q+>/O\
MX%W/WXJ*&=,M>J99E/4,.7_AQ5QV3.V(IG-N<]3[A_CZWT16%ACT^==1?&>&
MO[Z%UVOVN\-Q)WN&X,K#X[BH8;BX:][.DW"Y)5UZXS[+4]U:S,H<Q,DD9QL3
M5N\LC2OQ'[SG)]JO_P"'NPF96#<-WB.&=NHST KTA>W-':'/NJV,_P"/.?NJ
MWM^V!_/;," L>;#.0?OY_1-V?/;74DT6,F-5T[C/CYUW>S[H_$J*[O94I^,H
M'Y5W>QB?C<__ (UZOL3_ .L3_P"FO5]@_<YKU?\ T?\ _P"WE-<>Y[!$=LOM
MDVLJC'Q)I8YG_DZY/N3GNGX-_P JR/\ 1B2< <R:]&M'>, ]W0<$FDL;[O2-
MW4E'4^!^E7QD)(,_#E3V\,C6\3G45CP,FO5R9<G):4:JDC$ZNC'WL[4G$EUN
M?+&*PP##SJ.UBEX<46= QXTL4W?T;:U3)(J*6.TG:-_8>-.>_7PJ0]I1\(Y[
M@//^@DXH9E7O84U'=]GK$\<+%/YWN/.IXGABL9D95[@TQXH.X.G/=FCH6ET?
MYV!W6^N/W_H#C:ACZIQ0!<2Q-R8?F*!&S+N#26E[B&[Y*WNR?N/TLYBB2Z;=
M6T;FH 9RSP=QT*]?CX5&SIB.9=<;>(H]GS'UEN/5GZR_Y?1Q)VWZ(.9HV_9T
M+%!TCV4?$UJO[R. >"]\U+;"620MIS(^,CX;;4PCM+B]Z?7T^'*DD9+H7*'>
M-F71G[*?0!!:ME'E7VOE21K[*#2/[B/+C4_)5'C6MW;C7$F=_CSJ%90K0#&O
M2,%MZC:+]45!7'A_9#)I=B.HY4SH=.DZ2&KTCC2218P(PVP^8K^41>LK0;QZ
M$W^9IYY\.Z\AG&/E5[,5Q-+JDU8WT@[?A3>)/^C0?[5:_@E3V-RNJ*5<?#P-
M3=G7YQ:2-HE/3]F05V>1N#;?^HTG^&NT/]G_ /4/H_\ V@?_ &ZL(0>Z\^H_
M(?YUV4J# , ?YMO^=/%*H>-P593R(HK96D-JK<^"@7/QKM+_ &>3_P"XE6D'
MNI; @>98_N%)$G_1U@B *!K;E_X:NK*3L!@L\;1YUMMD<_9KM:"6-T3U;KJ7
M'UL_E4?^T0?\"U90@[27&3\E/[Z[*5![46L_$[T\<BAXW&EE/44RV5I#:AO:
MX*!<_'Z7:75)8VKB#2G55/>Q\\T .S;D >:U'VE90RVDH4!M1'M#D?X\*L[Y
M><J=\#HW)OOI$E[R+<Q@ _LJ#^7T1^F6D-UPSE1,@;%31QJ$17C"JHP ,U;G
MP>3_ (JOKN7O2\!FR?%F&3]'9TX&&EB ;Y-]#3S]G6L\S<Y)(59C\Z[O9UHO
MPA6N[:PK\(Q7=4+\!^BTB1^@7)_K;<;'XKRK5:O_ "CV:ONKWTQ_AYK\J6*^
M'\FW'BYS&?\ >Z?.E=&#HVX93D'_ $22PBFTZ1E\=:DM@':ZS^L(Y_#PKTTR
M"XOMP<<H_M_'Z6CD4.C;$&OYM-I'U)-_OKBRA''_ &1_?40$,HXC!4RO,GE2
M>D030ZN6N,C-%D)8+[6W*N8^C,;%3Y5IXPE'_:+F@+JT#_M1MC[J 9)XO,J,
M?C7JKV(GP8Z3]]94@CQ'Z-S?)=R@R]W0@P"/.C(MTL]Q+NR!LE!T%7LG:,WI
M%JK"+0XR<]:,_97%"(O%9#S3?F/*A+MQU[LBCQ\?T/6.Z=W3W<<J"6\CS#(7
M##?_ #HAU*L.AI+7M F2W&RR#VD_?2RQ.)(V&0R]:96+*^G *G%-; ^DIK+1
MQYR14Z=HW"1S7('"3.T;?&DXH[]O)W@.HZ_=0,3!W==8/0#QJ\[6FE,=O'^K
M5AO*<C[J$7#CM#& -"GN?[M,D+-]7U?C4$,H;1*^)8]7+&:*=GQEQJY =S'G
M7#NB\.LDNW(@XI8(22O/+<S_ '$+NP5!S)J:7BZ0#IT!M\5;6EC$[3N="@=/
M\J]'N8)X($]J1A^!J.)/810H^']D-<6DKL,_JE3.WYT9+NV8!W+*YV/P(IYH
MM/HQ(U(<'-=_7PV'>RGL_&M5G:H8&<:TQEI*8 ADD3;'7-6L.,AI 3\!S_2W
M=1\ZWGC'^^*WNX!_\05O?VH_^,M;]IV8_P#VA?WUOVO8#_\ :4_?7_MBQ_\
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M.T4<0BP>&=R,U8:RLEDTXCT9YYVHV:G28AC2B[#RI98FU(W6AD@9\?HR=A7
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MV&#'-8IK-_UEMR\U_C\O[R/"_7D? ^-:7)CFB.4D7;YBN(9S+EBVPPV]6]C
MC]T M(\>G21X5<]K&YEM97]1@J"&4X_CY4R0W#(R[I(N^DB@T=C<Q1R[O<2^
MT%ZGR-1V_9Z-#$C'OO+O)\_.H(Y)]$S80RG=8Q06VA,A'O2=::/B<&%O<CVK
M/6HVN2H6895$8%E^/A4$4KQPV]NFF-(L C;'44T,5N5'+B,V2?CM4,9+FW5N
MXR<TZ_C5E<)?IQ_;C0]Y\_5^=37*RPO;XP%D7&_RH\0\>X=NY$J9:@2-)QN/
MTDBNE6UMIFQQXE&P-6<5C<274,7=T2L3M^R?#X43 _&8$AHP.\**@X!YK0(W
M!I+5[:.YBC(T%QG2/A4':8:%+V7?!FWU?#/T:G8(OBQQ3E)'?+=P1;$^-0FW
MLO18YFT+)(.=-$TQ+ XPHK1!//*V-^)@5Q=2PP]&8_E4BWT;R6Z1[0C/>/CG
M-(/1H98TMVTZD!5>1%2RO;121^YW /\ G4!0"-U8L1IV^RO6(LID/O-@*:L[
M=XD6X.PX?(#PIHI-F% J<8\*,=]F6)!^N]Y?CXT@MKU;6=VU\9\Z/F#RIY]=
MM-H&E)(I%;/\>=+$VZ]<]*:.WG1[4'44V!.WPJ7T)FA9^XVG?._XT4ET'TCO
M-<Y[N<9"ZJR-Q^C)*>8V7XT\DC:F.Y8U<R7H;@J@(3..?L_G]U3P1JVVGAY.
M>G_.I&1E,A).#27ET=F!7UG/4,9ICGAZ6;0N>G3[JFA6X]$NE0,A #9^->BN
M>.4;1)*OCU/PH+:<2-8OUKYR''A_8DC(VEFPH(KA_P H7$<6O'ZP[4R]I7/I
M&6]7*%]WSH$;@_Z%(\7M#KX5Z"+C TG5,>]@5.3-QI9B-1 P!BHHHPRQ!P)B
MK].N!1@$*, .'"'&2&/7\333:AD[Z179P?GH)^TD_HR*5SJ7.:T2%;B:;UA=
M]GY=.H%36_8S:[=9"3Q')B0&I4[5+.(/;@24@9/F*MKV*T6WL(@)0<C"Q@9^
M-6S/OO*W_E/]$\V-6GI47HDN;C6!P5SIQUR*>-UD59$(U$# H/C /C5O<Y(0
M'$@'5>M*RG*L,@_W5.+'4@_[3?\ "AZ0DEMY^T*6>VD$L3<F7^ET2CO#V7'-
M::31Q(!_6)^?A7> >M+W$SI]5I"11;A=[XT./,T@48%*I/=7D/"MSFL("Q\!
M6=./ 9WKAX6ZN3S!&<'^#3]]+""/VBQY;9Y5PQ?&Y'^M48%11:B&4;OU>N&1
ME>6]>I;;GI/3X4OI$O""[X/>I95]'N7'=$DL0U8^(P:<RVT"%?V^=!&F6"X)
MQPVVS\/T>-+#'(T0)5G7.*FN'@[GLH4. N^^U2W"IHMO;>3/LYY TTUI$+9H
M@ 8E;5GSWH0S$QAO'IX&BK#!KN%0">;#E4DUXZR6CCU&F35K/EX?.C#;'1$O
MMR>Y'^\T'L+=KBYY//HURD5<132%HEEU!9?;&U2SWI R<1[XS4TL'#FMM1#Z
MF[R>51Q("JGN#3M27"YEDY')V-7:MJ13R1>G3\JBL,;Q1"/??;QJ&V@:0ZET
ME4YL,?Y46A[ZLN^JN"T+O<\/3 B^\=C^&^:DAOE$4RL=FW9:L[T2:TN 3I(Q
MI\-Z]+)Q:/W,Q/L3]4TK06#R$=UI(8B1GXXJ9)X)0[; XKU/KC(N^WLT05P1
MSZ8HE8TXP<,LN-ZN!%=\/2RDJPY_QO2HNRJ,#]&WMA_WA_ ?G4*3MB%Y%5S^
MSG?[JE[1[-O8S"HV$#]X^"UA@<D:RW4T5;DR_G21R:EBD G1=7M?'[ZEBFTJ
MCQZ$R.1VY5HC9)QKX+ZML[]*N)+5F&3KX9&?LJ8+&JPELA@/:/7^Q(QTU9^Z
MF/B:LDG .JWC./#:HK"39O91O]#8Q0QQEN91<9J2(:VE/<72.M+-VNG!M<$8
M5N\6^5%8KN6XBC/JN(<X%+9J&9Y'"H#YU;VR[K#&L8^0_11);9+@/L R9)/@
M*Q(Z62QKZO!UD_&II+=$,6O0^1G,GRI+_M%U>1AK:UT[ GQ\:N1R,H$2CX_Y
M9J23I%!]Y/\ S_HBKJ&4\P:XG9<,\;R8T^CDXSYU*6@T.^S)YU+G4S"0]_.Q
M^A8V_66WJOET_NH&D.,^%1M<KPK=\J7A]KR)\:N#;MQ@96T,<YT5?6SYPD@<
M9\QC_P!/]'B5^_\ 47G6B)$3.P![S5E4FC4_ZQ^']U27$DL2(@R?7'-+?W6F
M6V9>X8FR2?"M)7#9]@]*%R\ZVK%B.&4R=OG6_:"8_P"Z_P Z]=>R-_W:!?WU
M)<75PT[?U<?3YU+<,&A?.F./EM_!KT.VWN'PLCK^5'M:\*R7+CU&^=!W^^CZ
M/+C6/6 G;XXH@KK"]UNE:MFR1W6WJ*>]2V-S/F(!>7/'+H:98LR1Y.G'/:L<
MZU*3&?V367F;3Y#>@"RHOU\T+:[<W%EG&K<E/A221L'C<:E8=11M;=^'I U,
M.>:.;N0^9D-,J7<C1D8(9LBN$TF(5U2:2=L_P*CCM>ZHWDU;!S\*:WCP][.G
M$ ?DGC0[4@7^<V^.)CWDJQN&'"N>&0)%',CN[_97HLD927SKT:'VSS-6EG);
M"(2>S*OO'S'YTI"ZF;QJ26"&.U:++85<:CYGK3R\%)=0*$,/9WYBKL8 A]W]
MIOW5$9<\?NM)H]WE4,$B=W7WO.I)(_402#NQ$[9I)>!'&9URQC%#AIE_]8^[
M5="V8O#KR,U'+&VG3WB<^Z.?W4O;G9!FN)B^)(QOMC'+[*CCOXAJDCQ)'1MX
M8_5'F&WS7#@B2%.>E!@4\K^RHS5U?"4-;S[+'N&R-M_EM5R+F+T6])5XT(YK
M_P L4\*2B.<1DH']EJDCN'5YY)#(=)SCR_CQ_2?]E5%3-*,XMY J^)/=_,U=
MJ692?58'08J7+@<'(1OK4SMN(X\_>!5LQ1N,LGM_]GX?;3VX(1T4MJHM=.T.
M#N>9>@OAM_8L(\G-6=N?9DE /PZUHE'P(YBEDYR6[95_.EDERDF-U YT>"YX
MC;?X:!5B4_K1Y4L:R=YN61C^GD$.=7@O.O2+Q3#%%)ZN(KAFQU-0VT2%IU;.
M>@%9][Q\:DNYCEHDU1+Y\L_1ZQLO]1-S7J;7YNU?]7A^^O76>WBCTG"234-@
MK[;YY\Z]%N9-$C#&V,%?'-))V9VGZ1-/L\:1=.8_.INUE[0M^(D9E,8W<[9*
MD5!!<O\ JSD+IQSJYNF&./)A?@O\'^C6W99!J..)C8?&L2!S<1@/H.P8"C$8
MN&-^&L*@8-&A;Y[ERI4_$;C^ZA.^5\*O-*L(9)%S-TP,[8^=1V^K0O0J.57;
M-D<&-$\ <Y_=_1-' X7&S2_NHZ)-*9QGWF--:I$&B8ZG4#437#2.2YM4491C
MO'\*FM;A4LS<JKVID]X9\:T L3H:/2/9,GC^>:;1$/3QSQ[(Z5!VK;7'%CE
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MMA8L\2,^UBK;AW,MO;'N.PZ>?WBDM[B6U[3M)7V<[Z3U'WUHCOY;TZLA<:4
M'2G>U:6$/_JF84\C:E7.23UKO:6^(KB0226TGUH7(I([M1>Q?7]F0?OHFTFU
M,/:0C#+\OI/#]B0:\8Y>56T5PNJ*3*$?+:E]#1M\.!J[RG?D3N*:2X+.5GTY
M+:M/E5GY:F/_ (3_ &2[#G&=5=IV_5XU?[#_ /E4$MG '>*34ZQKWV%2W#6T
MB6KL$;B[?/%6D5S"3#KTX^M33*#'C;AKC1]E16,L?J4C[K)SVI^">'%CPWI(
MUBDDE9L@*I.WC6\:1E3AD*FHIUV#KG])DAQ+(.I]D?OHZII,>"' KU-TS8_J
MY>\*$5X/1I\XS[A_=]#RR'"(,FE=@S0H3A5&=(J2RM+?B32Y/$SX>/E4&;L#
M'ZT!/PH*HP!T'TO<VI%K=G_P-\:FEOK-V71A)8QK7/RIKBX76"I ..7G4DAR
M8H0=6_3I5U<EFCTMG4NQ)//\JM;&1XXYISQ%<MDA,9WJ6PMH515SJE;>0_&H
M+=,NZ!VC8[=_4?NS4_9<Q.1WH@?O'\>?T9N9UC/1>;'Y5MQI#Y*/WU^IF^ZN
M\MPG^Z/WU^O=?BE=R_B_WCI_&BHN$R-^>U/P6!+*=+ T+U]4(A/=PXP_QK@S
M*DMOO[(P1MM4J+9NDJ<V/>51XFK2[5D](238!<:CRW^VC&L(2-NZS2'E4T5F
MTEW=/@RW+'"C'11]M'M*=/62#$6>B^/^D]HLI*L+>0@C_":[4$]Q+-A$QQ'+
M8W/TVB=CAS*DI+\.41[8^(JPAN\^E1PJLFIM1U?'^D,'I$O!](8</6=/L'I]
M-['!GCO"ZI@X[V-J[1_ED2 R&/A<282?6SR)\J[/CBN)8D,$>51R!^L:NT(;
M7/I,EO(L>#CO:3C>KY>V!('=U,?$F$FWR)_3N&C?1<7'J(R.>_,_9FNS6[0N
M)6MKR,;22$C0_)OM']%V@DUQ+*@MW(5W)'ZQ?Z>U/@GYFH8%D3C2*HDE'LIM
M7 E58^%ZM)X]]?R\:%[VO/Z-;JP(B.&9_E^^KAY+?6MP/5@#EWN51P<,Q2D;
M*IJW@N83<VRCUF-@-N9-26]M"W#P",'V=LYJY9AZ1P&,:J1C;;;[ZCM9$D D
M5]11O8ZCY=*LAV3&"SP:-!&KB'4<Y^ZC_*3+QU [D&ZBIT+9MYUT*Q/O9V']
M 9P\ENS>T(\8-.5FE$BG.N1L_+:DX"K)>KZQV=O/85:QW"312C494?'7ZM=H
M3@9S<: S#? 7_.H7*ZE6XU%?'E79]V)%873<5DT^P/"B82!#S(8;T#,H-J\F
M#U;% O*W"T8+^]IQM5M!8N,Z6++UY<SY\OHQ[3> KVN&O[-9)58_CWFKB,%!
M\:U)HBBSG!&[5 0\6O6/59/*A#"&FGQOII4N".*Y.<;X\JD:+5(^/?;9:+QR
M1A_JZMJX"HMN$9LR.?:_?3*XXLI]J35W:CM5TAWY,W*CPY1K\/&DN'0=PZF5
M7!(I\'O!1FB9.31T9HX<ACU-1V\GJY<>U]6DD!3/CBLCA@D\^M+*5U:3FD>T
M""-?#;<U*9;D6ZNK+JZY(Q4-C_*'IKYU-;,NP\/^6:/;=]&BO+O!&%P%\\?A
M]$]KQ1#K]XC(IHX6:>/FS'K035ICQTK4Q+-@#)^P4@UG@:^1ZCKBI.UK)I+L
M&0JG!!UQGIGY;5)<7L<TC%C'PT3(/Q_=1AL(7D9R>&)2"W+F:>6V*D(V4GN>
M;\ML#ID4\I(U.V2<5F[*LD6G5&Z^'0_QUI9X[;@6>@,R+L<^6](ZS!$SWM7A
MXBK<07&N64[!ZCADU%U/.(\OF*C24LZAMAK]I?.I+FU9K<<L,=UK2[F543VS
M2OOW6!VYU(EQ$C7,295XF*_;79YBB,/%EUE3SS@YJ:Z]R&/'S/\ !_LF:+ZZ
ME:M21I61C"P/G_GCZ,1#45.=/C1OWA9'P4031\O.FL=:*B]\OC&!^=7$\MPW
M$T81Y.2_94B3SKZ''SC'MG_*DC0:448 IKAXBL+D:L<VJ-8AB(*-('A^@2=@
M*>"W;$?(GJW^5>.>0%0W=W'P("=6A_;9?A3]H&:>.?B,NA<!5^[Z'[/D;**N
MJ/R\17H$)Y>W\:E292HN -+L,#;SJ]=8U:=V $SGF/"O56LENG)I<]W/@#5I
M:PM//WPISN,9Z_HXDC5_\0S5S(]WI5UTJ@'/XU ELVN13@"3U@4=:M)8YI[J
MY UHJQ8U-X\Z1+SB:)YE:X#9U8J-;956#'<"<L5%>@>K9Q+^_P#.O4',[KE3
MT IR6)R=R>OT-("(US@,_(TAD>-]7^K.<4+MI6XS*'51RQ33WWZOW%#5*9RH
MEC/+.#RIYFU.@&H,DG.FADUZ3[)9M506_$UK[6#R%7"12&'6>]@<Z:YN)&69
MMD;E15YF>+]JN+("MBI&MCMK\A2H@"JHP .G^D]I?[-)_P )KM7_ +M/Q/TV
MLUI%#*TLF@\8'P\C5C>RA5DGB61@G+)KM%;^VATPY$"0 AG;5C<DFO38NQU6
MU.X3@D[?#.JO0[F(6G:&,A0>[)XX_=3RRN(XT&IF;D!1M/\ HYV=Z1X2.A9F
M\](Y?.EE[6[*4VQ.Y,97_P PVKTFT)!&TD3>TAJQ6TA@EXX<MQ@3RQX'SJ6W
M_P"C'9WI$46S7#KG/Y#YTEM_TC[-X:-[R+I8#Q\&J*X@<20RJ&1QU%7-]<YX
M,,SL=(R?8HW'978Q2S]T\$N3\^ORI.S>V;9;>9VX:RH"N&\&!J\N4 +PPO(
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MU0Q1$@7DH!_PXS^ZK:<(/2+L<61^I\!]E203QB6&0:61N1%7'9:L3"[20'S
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M*CN4&G5S'@?Z'5,VYY*.9HZ&]%B'U3O]M".!&GE;D%&2:!NY(NSHCR,KC)^
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M4=_V]&UG9)[C#0=/U57G\S2H@TJHP .GT*9;&XC[-6181*R$+PUYG/GO]M
M8 Z?1_-XC+=VSB2-5&[#D1_'A4W9_:-G/;<!LPF5",J>GVY^VKY[VRGM4:'
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M(, "N$I+O]2.A$-"RM[HW-.DCR #E4B<;N@[9I5?OJ>M+'+'P)6&>[6NY/$
M.0G[ZU/B-1R K$(Q'U(]JH4N7=P[8VYDU*J9QGJ:4#]2C=[S-16C3($UC03S
M0>&>M:9)HT91M,X]K V7 \:CBFDX<;9.KQ-=M7\I7T>*W,%OKY9T[X_CK3K<
M,3!<X,".V= ZG\*M_16XTQ(1H-!SJY9SRWQFC'/,EI(S>M*)J"^'6A86*<&X
MMT,L#'?5\3YYI67,4\+\CX^!I+A<!^4B?5:DMHVR$W;XT6-6?:?K-<I]8)6'
MW4P$NAS,J LNVGZU6%OJ>4Q( SCF4_C-37-K*5MH3PE<G&%Q[.*NV9#(X&D(
MG(G/C4LY3^<:CDCD/A_HQ4[@C!J3(P,XJSC[-,23I&&D+^R0,;>=1PW,,9=>
MX((UPI^%6US<36_"7?@[DL?A1K-7-U/!PY)#I5FYZ?Z*> \I$*[U)(J:21PR
MG@14D+?_ *XA49Y:AN/S^VI/2IU20R8,IW'/>D4'4 H&?T2BR(S#FH.]&SMV
M]6/;8>\:R:*N,]/C20C3=6J;!&V8#R-2:5]23JT\S26?:EPR6\*F;0BA=1Y?
MG0C$>8KAO1^]NZ[[??4LK^PBEC7%C*@-_5*.0HW,QX5LJ,#MNWE7!MXRJ9SE
MN9HY.WA6PS1X@U2'D!RI(XOUC':E2M4,9DX,>I\=!08=:ENI>Y;1#G]8^5,Y
M7,40SY9HL>=#Z!$=!8R.[?6!)Q5I'V;9NG"C"",)DYWSRY\ZU-WL#EX&GA*G
M@P^P_P"7T9NY<S$=RWCW=OW44A7T#L?._P!3YGWS33C#SJO?NYO:^7A1BBS%
M9 [)U;X_1=7]JJR"WYQ;ZS\*;5[2MBLCF-Z@5V(DD;AQ#W?G2KT\1SKLZT1=
M$T#MJ\\]:\JC!YA1_1#BY>1N4:<Z>"YAE@60:=0[P%<3T[TI.@BV^VA%!&(U
M\NO]PY9;>X9Y3WC'L<5.7+1HH[C X/SIO5\0N0N>I'@/T$N@FMHVT_(C_(5)
M<3,$2[73CK5I8VKF2.%3B0G.O.]<&-T21L]Z0X I6D*PE?5H)LKW1Y8JXQ<-
M.92.8QBB^D:S[V-_HNL#D<?9M4TEK)PB(N^<X)7(Y5PUD4(_?VSM4\;N)RZZ
M0>6*M>YD+JV'+D:BNBG#UYV^!Q]$EFLF9M.<>6<'\:N;36Z=P/ZML9I>'<W*
M9BXFK4I'3RKA02-<'. NC<UJ>2WB;ZCR;UJ$2RKXQN#7=M97_P *$UZ!VCKB
MN$&(9CMJ_9-2"Y=F8^SIV%6]TA+HC;^:]:XD$FL-R'6F[5[11HRGZB)^8\21
M4;$_K/X%:]('[3T)+F;AQ<RJ#<UH]"1AXMDG[:CFMRQBME_5\S@4&<\MQ1U'
MNT)X_=.<9I;B#.EAUZ4[P31P@>T6ZTSW+M>7 &5U>S]E-ZM8_ J,489=#E-M
M1%6\MU))*\B:M.< 9KA=GD(AW9)#M3&2WXPT_P!5TH^ID5_!QBI4.2S[C HZ
M4.?C2#/>WU?&B,F@KQ''+6>5>DLV"03GXUP1)PXO+FU/&D:\!3R'/XU %;@/
M*.Y)YU*Q]:/:[O2KBY5E"Q^T6J.X6(&!(^&N?:;I1N9N?]7']2M3;O[JUQ96
M]9[0WV%*%1V93DB,9-)?0MI@CRI!)!QUIIH(],)P-9V^=16UN(GR>Z6 SGXU
MJO9DUXPN3L*1M4:27$38+L#W",&H8G=5CU8U-R I7CNHDAYKI;4K^=%)#&Z6
MJXTD>UTI&12<'45'+C>[4T]S )9HE4IJV"_*D-M"BI[&/$5)<,DB.X77H.5V
MVJSC@33;+WVTC)9:FE7(5F) /04J#V5[Q)J&.0\()*7AR/=_@FN#,C)$K=YU
M&Q'QI$8$:%TJP.X%,L9)U'))HRNI;.YC/LFM$2!%\!_H_''^$_'H:M[@@KPW
M[PQTZ_=5G<6LBAX,21R^T#FC)*V?R^BU:2RD2-)%;UJ=W'/^D9M_1Y&6;1T;
MQ_.I?1\K=<XM\'_*K6WN4XRH"THR=]_&HKW:W$B=T2'&]1VVMYA(I+[YT^?\
M>--(_LJ,U+%'M+'N5/A3K(QU8QD=*-ZDG"3240+U%;UALBRA.96^M^S3^B6R
MQ0:3$< 8^(\*X[DVL^LZ.(NSKT-20S#O1MI/A7*@ZY5P<A@>1K2UU.X.Q!D.
M*VP*W:FX<9?3S(Z5WS\A5Q"H16P/B:2$_K$'=>C(Y$DY][P%%CL!5\>C1;?(
MBD97X=OJU/&/RKT?AKP NG1TQ5P8E"0+W(U4;:11H.&&W2C3R7<YMH$!)94U
M,WD*BO&CXN[#0.8%!9/5(SER/OQ322-';6\8R2>ZJU_)O_1F!YI7[OI&C)/^
M%?S->G_](I3>73'48-61G]INM.RJL<,*9"KW0 *T2-B!3D(!U^B?M7M:,RIP
MM:0*2"!YTL=M;M=6S.2;>-<N=O&KR2&)K*.0[VTIW0]?O^A)+J+C1C>/O8"/
MXT8Q,L(1=1TKJU?"A#Z0;B:1=>=.-&]6]I&/UC ?+J?Z)[B3?&RKXFGGG<O(
MW,U*((VE,:&1@O11UI986:)UY%3124@7D0[W[7G_ '".GVL;43HRN>_$VQ-3
MVZ1E)4.64>]21-:/)VJ)<Y7+,5&2,5%+=QM%,<[,,''P^F\BQG,9(^6]6\<Y
M:2>WDQ&OE_E6K957P&*%C-#+ 926EDTX8)C*C?E_G21K[*#2/I/$E16 U:2V
M]32MS9B:5L<2ZFQHC\*E@FG:6?)X<D(]4U2I(O#D3PY&CMHQ4<$<,D+PP@<3
M&1_!HS]I2B>2?+1Z"-DZ;TVCOW#AC))R[G3;XXHB0ZM1.?AX5_,%3T2'NOQ-
ME \*DX2AKQ_>&^@5Z=VCB>=QJ6-NE320IKBY,V-@U)/$^&V.5\:EU?K47$@_
M.B#339X-NNVH^]\*B:>!IK: EC(/9#8[N?GBKTN=L#:H+:?F,\(^?3-)%<.%
MA9^;<A0/UMZ5"ZAFY GG1%3QIMB38>5+H)#4TER-?#P55O&C%GVN0\Z9F&"W
MN]:CG& HZMUIV1A&@.G>I9S<L-\<J6SO7R4&%EQL17I"9(?EMTJZ)Y[?G6?>
M!VI9BB\9M]76N=7)8Y4>[6%V\=Z&V8%VQXU,ENWZOFHYMY5P,:9/:HPATU-M
MC/.GAF221_<8;JOA7\IW#*T8+,['IM4\X@/!D'0=ZE6Z7+J^H=!Y4TC=*DNI
M$)C/LDC8>53F0'3G4H\*FOD&8I4QI ZYIT"\/7D,NK-7%D /5+E32M&Y6)3E
MP?RJ6S6REO6QIX:YSGY5')<OK8*(P3@:5'2NT(>T98)Q)&K02Q;G..AYCI3]
MG3,0#DJC=&ZUZ7:3D,K' 5<M@UZ;?1LUX93(.(>7AM3713,./;\/C5W+='U<
M<9"Y]LOX_"E]&X<7%V#XY\Z#0+^I.EV^/T-+'+'JXA!5Q]E);NX=AG<?Z8R.
MNI6Y@UQ(8!>Q>&.\O[ZT^SCIX4L<2F61O95>9I+R_ :;FD/2/X^?]+%<JN6B
M."?(U,7CU:QC4.8J>[NHA/-JX9C;DHJ"WCE!X2D<%>0%2W'""NTK#B=6%+WM
M*-G/G5YVI=QND]P<A6YZ>GPWJ;/JH%?+*/>^= #8#8"A&#@GF? 5+;3!+:*#
M=7']9GQ\ZDDMRR1MOI/C4,,/)$"ZN'DG'7>I+BY3$AZE=.:6*[[)LY@@QW5T
M'[14MS;PFU&=HM9;'SJ.[DNG,6D9=9!IS]E$6W99GQR>XF;\*:(]CV00]4#!
MA\\U<R9]ML?0LJ=.8\:!XHC;ZKUGC*?\)S1BBN8K2+JK',C?*GE$[3S,NG)&
MD8^'T3QVYQ,PP/SK@SQF)O!J*].E!P<;[T:X2GU*G;SIHCXYH&UN8NT)D;6#
M%R&/K4EWVC-Z'V7G* #N_P"XO7XFN%8P!"?:E;=W^)II9G$<:\V:C!!F.S7[
M7\_H665!+"I[T;;:A2VD$TB0R=U5>0D!?"IKM9(=$GJF,?>X>^QY?+YT+J.'
MTN5$"2&., GGN:E/"9-!Q]$LHMTGXBZ3DX/VU+<SMEY&SM^%&_NE*3,-,<9Z
M#Q_H1W-6VK)-1E5:*%5]@GKUI(8EU2R-I45)_-C=JXX;X]KY"KR6V!6%F)CC
M?8H/"H+I=PI[R^(ZTDB'*,-0/]PIFSIN&'<8<\"@[#UDZIQ#G[:=X&;C!?:Z
MXK7*LOLY*3 [_"H0_J;A_P"K/C]#*>1&*FDD1LMR;1A?D:;UGH]JG.73G4?
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M!<70YR3>MQ]O6H_4&=<ZC%&G3Y=*FU!4 ^J*DT -H]EFSFI;C@R21(Q!D49
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MP)%[G=TX\?X\Z6*(?J^Z *C:6X6XD1N]$YSMX9JRNKF-$XDRHREL#34$]LL
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M.HY9%94Z@>1'6E<QD*-LFI.S[IQ%H.J-CUSS%<5M7#P=PAI9EW#<J*'FA-
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M2117.*]H-7*B-1K7G)-#K3'Y5@[BE[*BMC,9-4:R<3V2QVV^=+%)JC](C!S
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M"][/SJ2.1DBXK@0L^U-WUETG&M*W%+$Q)7EMSJ;CXXDSZ^>HXZ9-2QKCB%2
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M*M9(AHXZ=]%;V3X5<=H7@61)B83'+[(&?O/*H^ [-9S]^%_J^56]R-N(@./
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MLLAA25^&S#I42V^_H^Q)YG/7[?QJ7LZ631+&-:E^]MUQ]U1".TBU1C <KO\
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MJI%_JWYFFN%[V/:^=1RQQA(BND_&@%AQ'+K]:WO;?Q]M6$J2M)Z."Z,/>/O
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M!P7. 2=LT+3M-M:QP>^=.ILC[:4VH")%DLJ; -X"H[93@.=3MX+UI40:548
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M=$LZ,!L!X5V=;P8>X.IYYL=[.?9J1;XK9SO$OHVD#=>OY5#:]E-,5M@$:9L
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MYY),:M(SBG>Y3DV,Q>%)( .\VG+<A5U%-I7W1H/M*13E"Q#;1R [U;ZKF4L
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MI(T?+.I0A#[%1VL$GK$]XTEUVC<MB+G'PSF0_NJ5( PC.PV%.EXDKY/=$0!
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M<TR+:0@2<F08T41W93KSU!QX5QH@_%*:3J;/Z9::W4N??&QKU5U+'Y. U?\
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M* -XBH985#O$<ZD R>7[J>22X?0AU$ZM(7[*[MS&LBG.#SQXT^AF=W]IF_\
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M%5Y9K+<L_FSW_0L4".5X?9CT_2*E5>!!*)UGQ(+[9\: ^V?$L'[$DALSDKT
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M ++UB?7 "9@Z(_"I^P,)ME2IX,ELKU+4#U\F)$^V#2M1;B7KFZIU%+A4N=8
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M-E:RFK3TAA.<4P.X&2AF.\=\039,$V>1NG%_#MGC-S<T$_."UTN]?,HR(_\
M$[=00+Z$=\26>S=/PX9X$<@]FO23W_P[=+<1\WI[Y+5%P7;^2?.3#+M ['S7
MW,2F26I_#J_6]F"D!GFL[#_;(OTBB?7PN>^0U7B5#TR7W;?!BKR--7+V,;P5
M%(2.(HG?7SE50PZ5HDU4"[WC&0)55([GJP&O57K_ $6F"(.C$&DGI'8G=?,8
MN8BAE%AWQ]!T([%YI( !31RW[87!F%3D,&]5W[X$,$]56B]>W[$]QSLG4>9G
MUP=J2 \;6C_>&F'CM'K<XN(5=X3JW?QDZ9Y"9LZCMA.H88%?1B\TX *[?\7$
M&278;0Z9Y]V3QQ&Q1ICGY(XQCFCPB4D@=*RD6#5<!N>'%7UC>L[]"L2&R2,=
M^)XP&#Z"4^^ 7=Q = :OC"K.'D:,4<X,BL%-X!6#G2(8],-M0[@A^>F3$*AT
M!E.O9S&"FU#2=P]?AP';S9E-$0WWP[1)=J65_<J%)+,1-=,D)89V8Y62] )]
MY'U_OVH!#[!P)PJC5CWUZ,KC0Q]R0K(F 1X2QY57K>6=A@(G/_3# 'Z!'?IZ
M9,B_66/)@R')'I(A'?C_ -KQ$0]^=_,Y!#2SSBE>@#N01O9EI<W(T>2T9/=(
M.DU;.JUWP6"!",R+-2,Y/2 4&\\!\<8>L!+@:A]4B#G%0/%K?Q[Y<310O7.3
MIG0]6^\[?ER_.1(WM?/[LG73: ['R7V<&&2&X_#4#_$BV#!INXX'.LTMV?9G
MQCZ,DACL?2;VSAG=:O=]%GM@QA%>[X_G *(CS+@/R<C/O@#W2+[Y!\$@18)5
MM!7'RS 8@'O+\&5-1,)#3#G7&L 6LX3L#&[)O=9!+U+1LY/.0F]1M2GLY_I@
M"Y"@'1<<@GU(=!J"[Y?3!S1I<!+MR@H)+Y<MK^;P?L\.*1Q,'[0<9D#S/A]1
MR;S9QXX,-8\^,XZ.&3TU.*7@H*@.CBC^I6%"V=]><31W7B:;>-.+S3G$%SS%
M<1;@=#B@CHVA8Q5(TP\@!!].SC26.^)A=?7ME_8U5)ZEPRT*KI:M[,FGR9.+
M9*2^;@B2==,'NN*/F%/YS3*Y>*/O//. F% -!^H293\W#U7R4(^J<*$B]Z%0
MG3!QTCOY(?G]S22NMK'&(.I&@F0B7"R/]^ 5:GIBT3#>FSW/I_?J6E#\IF_.
MBCC<4L1N5'JQMQA@(D7C1+;.1I\HRE, F!&G9G295UW79YR."E8.HVAWSMDR
M$]^AWG/@ _DSX\!_]9C*#N;*SEA< FBHK/:<CCBC>JER'LG)&!$FX.7:'WPB
M1;$"[?SCQB#*/![WD,0L?P&WG#?@GJB8^,&7I8_Y+7IBP98$3H<?B?&3ULCW
MF=^FO\6,0\'(=$QZ:E,CY^X/&1^MJ N$V/ICY#R75A*^G#VR8'7>J =DICZH
MX9(W&8Z+%XPY/P00!5^?G'V0*LA9@ULWC2D@Z;&DCF<,&E!R>L&-3G"(0_-]
MW]*87SJSC\\>!B<15^><E-PN?+P&HK)VN!J=XDZOC*Z7+!F2"8@J*X_86$I]
M^&+C?<3]1+[>N=.9Z"4.UZPXRZ1"I-B@(9KK@;<\$\UC7\\8/N:PD)^5(+P#
MKE2K.Z)<33K'I>#K_#DI$19H(=M&YC62SO53 E-'$7>/6!.TA.SN<<)^X3R+
M)R:Y=<(0&*I!?4"1Z.,6#0#YU'"SOMB@E&2M+]'[>XB> LQB*E'#R9MV4H='
M'3BZPTAR(YHF2<7@ 1D=)^UEA@<@UD2I(UU%A9U6&!M#I!(%W<#'XM XZ+_?
MTO:[D6X.2^,)3=E>,MSC>%,TJLBO(*UBKAZXS,#^!.%%DX%]EC/QCPN&)'?#
M^(D^<)/THD?_ #&]D!D:"-?)P^I&$?*N,FAW(8B&NVYP3TZ[W1:]>>F:+J\(
MGRN-EL?XCJ]7GX_5=*9^L=Q39/C@G_&-0?(8M,V4DT#LG65)I-IWY_&<&A1#
MLTOHG]' Z@^F)YAW%-(FYC)I/PE!M?*G)4Q6O:Y:(Z7UQPB0?7D#,=G =23*
M936=A5VPI##-P?V2'U[?T%EDF=C,HN)X,73E<';HE<3S&7$%HJ\D;HWRX6\#
M+5E EGB?O+.RUA0).  G[)(1;?L#'.L>:W2*>,)Q4@S)J&D=0U&$9+"]I5MV
M[[R2%"&+M_C6.(* <8D#>YD!"</7K/9/J#-B%4F >M)3MCTCU>-_% ZF.Z^:
M1=-5VS3:+2.!\/7$*:24EWX.2'4D;X;H-3<#TR9<D,/Y_P!\@*-=?[-^9Q?.
M'0I,/LH*1],\'L#<?8_L^O 3P9$JL*# U,:G&^K@ B4,3Z],*ZK(MDHT*V=&
M*06G.K["?X ,(O ^6\BI.X/C@[3"K[N:C_F&&W% \;^,)I^F"E3E#@.^3""X
MB,^<6V@HHZSK"Q&&B!Q3V<J2$KU'@R"3]$Y,+R1T-ZKQ]\1ZJUOF7_FA,)5L
MBSUMQRAQ)SBE4C3C^ A(4&OJ]..=9:4$N^]7GEX@_2.O/P0R)C7E[@F*1X22
MZTXXM![,H;>Q].?\9V+JVO.C;SD=XY4%""WY>>.<GZB5_5#<(LOW(%=E#?36
M7D*(Q46&WG.Z<VT@&=)&!M)F3 RQH.N27IP 6G7UQ4T@^LCU_<\Y%WZ9DEKC
M0!D+X$M%9EO<XC,!<PH">%WZ.K,C5'C8JXF(]<4P*&-3%\SYP+IK8E.O7]AB
MM*Y"9OGU^,G[=W5V>G?&*8MS&'0!J43K_N7/'!*@2W(+QD0"C4%-28_C$M^
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MXG.DM)I1+YPSIPH.54K/G#UQ_D=O. $B$5!>" +-,9$#6-%?TMN$ ;,8-;W
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M58C)OQW,-JX9JNN[J9>!G.DVG$?<QQ!D<!3E ='$'@($INWJOZ?VL;X!1/\
MH+],1:$AQ/\ $Z>WC)>P\V-)-!'F>V'KJT-HZD>V.0)"T*2Q9I]L%BV;K&'K
MKCC)HK7?DLO73"1TM05%\"/G&UYEQ:UDE>IQ/=9I(B5X-G7"1&SI S$>V:%]
M74"JCG6+%2T0'M62[J)- ]9/IBQQ.A*P#GIOC%!CHMCU.M1B5![%1QK*BL[
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M#"$EE,WA%8>]]0DJR=TI]]/=R! A-L3*I//R1AD1#H :/T.'$<-5ZD\,-L*
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M13(I=X\08ZAQ);&B40]-X+/BF.6.N6A,",)##CGG(YVSP<3%Q+WQ> 8IG9"
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MRN-W!I;=JX.W?$:G0DRL=0#*Z3&(T7YPX-UW8,OM&A;#;WQ)NP(R=G3OD<0
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MX8H]9Q6U3>@.ZC>4<P,YZ+YY[SDB+:VQ20L((W[M>N!%:XQA<*9.;QR-STT
MUZY(V\5C>T3A1*L>)DU*"/&":D"T#FDG)&((T.G& -)1+3;[7@$N"+RO+@EF
MX/J],(GJ#?6:#WR>T;43A/5*39A%P9I6,VC1"-FO-ZS0$BTX6KT!^QEYD[##
MKD,H4G9KT\9#$B8DN/\ >'"(@\P*5TJWOB100U18Z*]=B(PP.>P\L%$3W[8J
M)J:L&B<0#2,I'2\T$]<7BUX0SV!F!D5Q7DBRZ+Y&+B2PP>%)8]/:W?0SD)LZ
M"MWAXC$WODA ;#IPF<*KCY#QTRZBQA[?B_?-C.AU<%WG5,@F#I,6QXR>N8J#
MF9=F,K>B2UL[\,8/E7;!R:KYR.'B77E[/NX!01:DPP-'_F$>6#J8XUER]?XC
M"<:3H):6[1UQ"J%ZG .M96 910Y*1!YZ8C+7!BI>V1KE,2*TAXF//I_2%$8'
MI9&(FE14I&7S.5LG>1_98M-5:!55P7$9&-(ZZW^W2#(T>F7@/:]#QDHD1SA5
M0;/T=<+8*7Z$?81PRE7,P2S&L42B2@@)Z_SQO?6DO)71.!S(2$T$N"D"QR#7
MYTP$P("9= \P^F0YB1AJU!1\XV1*X9"D7;'1A<PSWYP.5@0X[X1C*%N6Q%GC
M$5@3I553"P=DQ.%(6-=AHR]Q.3AS)FUR4D!I@(.E!\93!*-$D61*OOA&93L8
M<*"8$.JKW?IO]SX"X=VL@:45*?6=@KQO :4,3R.GV+[N.Y,&KN1^F'=Q'+03
M!Y1%P7OAPB1+@=&_YQ.<X8 *X-2UIS/NY+BS61$EG_DT8TT*UBZ8#[?TI7\<
MV/5Z&-YRX0)$]?AR*#M@_67Z8,*\;+JO+_@;_J:2NDB1@$8=2+A9T]LDS:--
M*DYF?V24(.&(=/SA'Q(%@NX8_P".1A.$L6K#QA1!P*R^D'=,?F<FD1$#5N^<
MZ,+C!,5+=[P$#"$6'G]'ZJ7Y OIGE5,0A=:]AQ(^B04_8L]O. I.XZ^]SB4-
MJL%-S'%Y-/(PTRR/,8L$M&$/.0:8('#*VPL?))QVQ@]<0^@MSUPV;X+Z)P$[
M=8_$?.-#G?Q>9QE$C=3[8(H=\AW]IP^F/KE=T=^^41A#:4/9<"EK!RZ1UR5Z
M0Y)QZ+34^>F1!U,+QQB  0S4;UG3!!RZ3QD2\PZ?=@@$XG!HA> /C'DP6'KE
M.KX-N-HD4LAO 8<ZL2Z/?#@;:GPB,GXF2!3<?RQ=W)*4Y GD;+T9G&G#/6DQ
M!DN4J!\^V//E4A]S&&F= [!P33UQ0(Z$?SENQ]"3.(<IZ<9PY<&+XZ%6EO;*
M96IX'!P8Y-B</N><7H0DFL3Z+6!; "YTC7SC:QEJ2O!6+F L2))1HE'G%1"\
M\ =OGZ9;!]'+D'D]:@Z1C99\@@WK('8(DA!'3('_ )4'EX[8$5:0*-K"?PS4
M4ZL3I\7E>NPKI$U3O&B)W1-M8O %5)QFFG;*9A)DD@@] ^3 ]:TC93U8]7-K
M-DNY>I@+XQ^ST :W7!BCUTM-DQN ]L0/S(3D9OG>$!M[$:/;$2"P *EZ]G!#
M7*]'9Y2<7*:P/ 31D^O;->NI?<>N.^:DR?(E$6>I&$B?1P?^<@,T=G\![9'0
MI39T/664JX8"$SW(<F>&@*!T#)BN3+,*D2)76N/ZD29P+['NF'@3))S]NHZX
M<= (MP<N>,!S-B"6@OQEC7?$ D72X,*I$AB?I2'F7.;,(0PWOEBM8E:E<5EV
MZY1=$)CMIRF^AFV@9@U1X<96K<,0Q3DM;YC N3%+D=\>FPHZ*-/4'KB$Q2>C
MI$X5!]#)2:.F5ZA)*\G M!A*E!,4V7^<XK<0^@[UTQ>8$B,= Q<84JY'?,\!
M??!@4RON+B<.D+A@^?L:!T(ZLOKBF8UO"OF&?!RWFK4FCD)>[AS02&$U[Y0_
ML]3JO/KDY#C@/H9,F4/63:/^'.<_97\R?8KNXN680(T<&1Q87X=W7 D<!OUO
MJ)1%M1T^@1*Z!5#2:CQB8:S'>IUM7$YL,25)&7"/M_WC)]<PD/<ZV9:C+1"@
M-O3$/2K''V!+_2Z9 -OHQ$"RF=-%^!+AF^3:8=:$2"/2?7S_ (%+*B27?!XS
MA9+\YPQ2EPF>>,:#:Z(@&DZ 48W=>KZEX?J-R N]'TR%\Q Z5)R(]L"4S0#V
M*,(K%(%J%%N>89)?!D98"#]8BHX08$M>F)M7?5G"TFA+0FEQ'C0A1Q9/5F?3
M'+4"=L3$XM3L+D3(3+--2#T=KP*%[^ @\G?O'&"=@G?>#9B.EU>.]/<B#KJ_
M[F_B.P.REK[\9*4[ >A[N"ED R3!)X6\G>,=$4D]=5@8#>@0D<'2: I8KU0X
M*R.^*PH@<J[.G?(%#(@LOL'VG(A<2;<W>1*RW:02.[IEJ7# G=Z.)%;:]9S7
M";!\# )6)K&N)T?$L5*CCG(_XVP4M^D?.+:BG\G.7W29:'<Q,D[U0I,ZS00^
MV2HM)'8;^F.$&%#NNCD:9RF"]",8$SU#$_I5'1XG(G"O*B".B8O&Q(CIPR!0
M,#)*:],#!$-U^@.ASB2&XKL:OO@(#27 6GIBS$T1(:3Y?;$SH7)J)[RF; /0
M232FL,9'I0'$(S2<)CKVR1^05@N9>V! AE7<*.^!'[[!W(\'YQE/)" BX<?)
M3B.5UAGGE].*;MQ?B8A%60%7C([4\"B0*(O\<-9A6^>H<C3[X Q>">AY)KMD
MDPDO;-[]N_&%R-%!M;4GF]87F)(BD1 WOG UQ2HE"3[)+IGMC(]=;%4OO'IA
MP9J-A2/&,S!$I+)(C8_C%F*G1;K_ -@YC1I.,68NWS'U'MG01K6/9BQ+@<IX
MRB)C;3<]7Q._]6W S?AL^<8)1<+]G[8!X,VI"(=_M@$*\04$_$9=0-!"B+Z%
MGI@5 &S<B#)KXSH>CJ3\88-.6E6T^'OA!0T#0=,;^5P3D,L9:;)AS3??B,^_
M+ T.^*00DPHB3*\3\D$;$%H!-<]LBX"6O/PUBJR @5.6[OUP<WP^4+C;?&\
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MC>)A@98C"/EB""F+:,@36L5CH^\9L TR7D!BGD'$N##D$\];QO#)&=0;9)C
M8X02$NSO@ HV,1+P8IZU-FZ^^,DRL/GS3ZYQ-B)$C_QZ8JC"(B%9X<X&#,..
MK?MA!@B  TG3.0*O1\#]7]DAY090XGC)CR-R)X9*D^F/9*(+10)=]L52F,HL
M7;7J>_\ []C1#3^K$%9$"!W=O]8MQ". Q3Z,.,#52X3"Z+$396&3M],9!4Z
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MSD2[D%):M1#TS9(-0G[T],ZJ.EM2C(W%8O+TH:K)/OTCD.Y]GKB74I@-)=Y
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M#X/]."BN6YN 1]O\2)3(0SV;-8%8H. "5VV_&&#G2B\/T(P\)H0D<4%4;N$
M<RUXP7$;R]5"/WQ*2&K UT0XP;U15:OVQDE@:&*6.F0GULL.=H?-QP''B$0
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MPF"Z; ::7[86."EDO.D<MF&@'8UBBIT)<L\B@82XQFGSFF!] QT0"U3V.G?
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MYY%!02=8^ZH>SUQ%!U<OH9H"]. C.:(WL","251L4GP2CYPC*!;RMP';._\
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M^_.(]&.X#I16(JKW4$2;)1OICV#VUQ0?V&TOJ8[9TEOT';09Q@7+ML]<7A_
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MR6$9A[AG,2^XXQ@%7?C:!HK67+R>Y5GT,AE7/8YUT_<X.*82>Q.N\E@?=/G
M'SC)U7X?WG:%.F8"[56-UK+  _QG'3D(93V&S7/3/B3&B=?4O)\LLS%M(#%
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M.!(/!)^9R44=$>PL]!ED=001U,OB2]9R:#WP"=98>1"7UP]K*6Y,%W5R,O%
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M PGMQ/[83ZX!Q7.8?]$5G;#M_P CWQ7HPA<S@-B6?$?&Q#U8W C5Y=!HOPF
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M7Q#=.J>V5Y[.0/"E0_8RY9L7W@&-WAV@BE.V%6@QT[80QD:V_$##2Y*P4S?
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MQE%$5<"%?L]\2EDE5Z)]<*#9):>_^/3&],D%8<0?R<'%*V/J;CWQ%QDF</7
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MQ/.:HM'RB]5^']"/!5;%\ >F0#&P3+I/)?2&"$8**I].^$W$@Q$Z*?G $5J
M75N=:.F*"XLV'+XS9)9N).T#[^V*()'<,@N%HYFYN]\83(V,#9!_97F2,KH@
M?B<,('; =XIF=Y0+2,243UYT8+WLRAV5#F,,UQ/@M>E,S&!N)E;N9B):QZ1>
M]/3%PY11O=D9N9$FN["XPNM_SA0DH"J,62[#E:L:R'&&@^<Z<"U:"#&C*[7T
MXRFY :M G=[G!_7NL9?2/7^DJI4@TNP]"/? G5@DAZECKOAQDNXDZ;=QXPO)
M=:,K(UK)AHHFV2/MBR;C$,#)#T,"!\QB%[]<=:,G%Z(?3-XY#$U]?XX-JCM%
MQ?,9'8T6#?@X90';0#NC;CZ2$D*\=4^KD:FU@ZA^AV_:!]8'(G<QCN!5_1[1
MB[W(?4KYQ.#>N7L5DM9/D'C!6')Y'@@VJ%(\Q/SDK1I03OR>^$CXI'D3C_&M
MH:7C.4(EW-Y%3!&$29?SC(./9K<A%SASVR"D7>^H>9PGCPINFF#",AY0 %[O
MYQD]J?NR*)EAJ#;##U#3;XG#I4JMI.I$_5PTX-7.[-,8G2ZTNK"9H!,DZSUC
M H?+=J1%7BNF$);3R7M%[QGU%*!,TBZ#3Q@IG(;7K"8)W^M@<E61Q^=,E]1K
MBHMT8X;RXBDIEWDC7%?.,T>AL\P-D#HNLCT)L0I+\QZYTN>E-D*Q2UJG/4OM
MO63:T5;=]W-R08;^I,7$]2L+M2!)-HAXCBLLUOR[$=X(&<2T(E$-+:5ZP_K(
M(2<Z09I,H!2%.4,'-\QBX0PW84*]S_UCN@BL/PGMB TR#E2QWRN_#\8JRBZ$
M[_L8+5HP@K\G(?R))L1X**T)RF"2B8 M0]QB;$5%!;[#60RNXWU0SXSO&YOY
MP(N],J0],5HP!!Q,>^=\MT9U)UR9#K46R@\DX5U4@N3X9.&L,#P'] 9D -SR
M0/!KF,(5)FU7;DD;.^/*Y]*1,#B(,^V4,4'P*::D^N(4)*(E,[V7TR-'6WOG
M&AGYC0]<@%G7SCH^<A+:0H[XF)_LZ 1)'8YMR4#+TQZ>.YX!P>F4Z1$O<68]
M\ZGI6.1&P_&!1>)CIF#9WR<6TR1[D?3+A)($'IT3MCTQP_U69R?H_P"3SAVW
MR!7N2/QB4V/\,O%4?W0F"DBLN3.BEZ!6XZNQA-0KNWV.W]+KJ;^DH^V2LRCF
M))(GFP\8T:;$I TULOQGUVNJC9V9\YXURT$01VS3>M%ZSO-X'7OE<$-LCD,$
M808=MA?Q@$!Y]@ON:Q:V*_MNIX*\Y$STE8Y2O!C&JZCL.G9_10")(\.>$E'N
M%X- )T3VG)/G)_EQTEFD!CKM'?6/"GC$3C+,;#3G1 ?I_P ;0("#=1_W.1^!
M![BK[^F%RD>B/4Z7.32LA]C#,"GY=Q]8R>".>$VE#(X>,6J(,DHHI]3C#"KB
MR2<J+>1TQLI25)38[^<N%BY";LLS:30,Y_F@>\[P<6>&?T3ZXH.R0^P?5B(@
MRL7VG)*UT"^.B^/UA_GB86_3!E=#3.O99VR?<I%))F>?KD=(--#)5G(W\8CV
M$%U#Y8'KVSB$539/9D?UO0_7:?\ 62#7QR,:,7"!IHLM3SV<G,F4"KLP[?&=
MM;W2YV5>KO@D; 8A@@HJT\]<W-&-@@ !LNNF%"*BWK^E-RQ?*:^,Z:P%"6FQ
MYW$.<M68,\E6*9[Y8\MZ\22'MXP16FIU-NT^T83Y'=+P\X.0#$T=#DQ$6L=)
MYZE'I^K1BTATIKJYQ(40D!+Y-$X<1ZN1WP'$0DR_B(+N7$#/#P>IC=IV$F'A
M55=\89?D,O*0BXX/M@X\E@Q:RT>9YO J7M%5)TAQ^0Z,J$43[YH3:.^>KOV_
MH\4K(1#\!>0;%>(\^30)3B,E@G>"-GC?P&"E&5*HWJK")^F<]\AQ63 E^V$0
M$5:<W7+7?"4P%+I[']M2\!><>#>L@'&Y74(^F2D-'!Y@_<I<>&3.14PE^F!!
M!_363 9>(?B,0(= 1GR*5OG-F\.FZJ>J(QBG>36*ZV8WTK);12AYR&,5+IVW
MCHL@ITAE .^\$^&)2\]>@Q8L2E1@H++2@>#Y?G!R&R;ZI<O]66\9B^B8]LM9
M.5] >N."J_$ISS 9 DD>92]"_-9-)*  > H],65(;<F_$H]/\;CIQHUZ/^L"
MCJI4YHO.'_&/.AP*S)4E<F,[$TN@)?H>^2X!)1(?Y8LUVW$A//BY],32VD47
M9;3^=,?7(>OKEZHXQ)&M0EK&N:_8[L&I[8Q+^HWBD^F#K!Q"]G&!,NS#A,SO
MMVQ@5$E2YUT5TQ]CY'9T:,-&"K[716UQ7*NJ]6F_SG)E]U'AI:[VF<! _(E>
M]9.3E5S[5VZT7UR=G0(BY+TMFGRWP%/W9=W Q:Y4:;-E.T9#57<K8\@7&6%'
M'TP!<,<3Q.%:K KH16D7Z?KH_O9!D]EPW&!@*0?SEQ4@2]VGQ,N'548\E+D+
M@V3U/8RZ].)S,AF6:;(D](>EG)EPU32I!S&M]<Y1OU#E=G'>I62\R[C7Z3I$
M5=$K[3D#XUH J%*Q%X_HI"B7CK _*R\*0TIYH!OSD.I/@&5>GZ;RI%!>\+YY
MJ3YSLJ603->F&<%AN2=L\;QRQBQ%9Q!KYPI/VDQ'F<GO >N#HS\8MV630^BO
MS$9(A(E$@[F_V\E,S7_2_7$Z0%((3M=$AU3S4FD"X<WQ?C&2M@UAU6\! )%N
M2^WY62'[SH.XX&VIP>@4 XH:GB)QQZ B-*W7M/\ ;1[ @/)@V+2E'2VO_&GM
M4PWPN!UL) ^WV;_317!TA+.PY!2^PD^^"))AT0:"T>F$7DI@PYVFXCZL3B[L
M\/X:]7*>[W3J&O0?UX/-+EC2HAN&"U%UDO(DD[R\T+XZYZ0@S&%A$77.UZ]^
M,(6?H ?XZ# *I'#9BH" SL0?2/OBB9J E*!LE._3*02E9I #$G>L)F)X0!NR
M<8BIQL2!$DZ5.ZO"@:I 2>O[/%C[D8DE([F&'@"2P*AX5@Q7P*[L=>?OB:LJ
MJCA34.0$B8$\)&<6YL5$U26,T=BCW( ,S/;62,QAFEEOZ$8P!)+AP/L8)UM)
M[!Z?GQD'#A0#%"[L7UR5@$INOR.F\DY/GH.39?-/:G"B'NG$DO*9P"@)D5EW
M$LY3S8.*W]9'.^4\H^V%#&(,@DAO *QP.K)0F)UD9X=L13*4[C6!&YA9X> G
M6$?8/..JZ=^#!4)9)9$S6OQR6<%%=:/J7^@SP"HFBQ]_J=,0:L\]$$Q/'#$,
MTS+$()T%#)/RL=HGP[YQY6A&V?O^@^CE< 9$<[(@_+Z9--""C)TQ(!/0,9=!
MG(8=+6-J9R:4KKDEQJSQ/[6Z7#AX$[Y,5$(*<] ]L)$5; 31(["IR&+Z(6TG
M2[@J\248$ ]";?L8!P##>)!98K6(P8Z0-!T,M&X)">M8\G>>82>_^ TN7&3T
M<*7LN?*3%79P?2, W+(TQ/!)^' 8,YX^[&$2S0R]#_P+!+1B(0DPEYQ@5N"R
M<I#BT<VE@4<O;?!;(/2YG 5*@4'^0&!L/X/XP0J%:!O$73+UR_ 35ZQZ)YQ@
ME);EI&P5YYQQJ?2,R_3]LYYNL'>;2_ZUW^N-NX<969)*W[C&$1QCW4&C[X.&
M,9F.*_'UQ;+A"1I= XQ*?XDX$KCB)YV_..%HBY'RO 9("U<B 9#ZT,WP'LGA
M(WVR)VG$=+[.5O"]Z#C$:#)&"#U09AF ] 8P P1J>P']IS!2LA>S[_7)0 FS
MI0_CA4!52[Q)'H<!\6VLJY1>\#$13#J9+C7*YU6< O!"..B1Q@$R@/<^G]!^
M"J.3"6S':>IVD^'Q-<1<2(YF[YO"#\/Y"/UBIRWAV$]!A^@=:3JLO"!?1!)]
M1C2\T$_G^&1,T3SU<&#@R1;-KIRKAR5H A%Z,$'7>,3@GT)OFY*QG $.2")#
M]N<@O3YZ,+7D/WBXF'ZN8B3.@#Z8/F9@J,+Q$?KA<0&9 ^[@01T8/0_QB$IB
MCCT[3A21(HI.KJ2?&,/KI1AJ^26GF.G?SQ@W\I Z!_D,3_\ 0,:6)S@T^C#D
M%J,,*/=W^,+P<,C"Z+G)X%6_]PV"1I.)8_#5'J_G-@N4XN<:3J3KXZXDG2+,
MKSV'P?J9>*0.JY3A\L_%2XM6B&8W;N>\Y%*X-]]HV4%\.!R4))2J23U\X(4+
M"#[P'G!E.C0#U1A\ +.'1K*0ZL$GR"'_ )^^F',@>F:=1WEJVO&L&' ;@\!2
M\?)L!U<@4QS@(HI$Y1),S&XP-JE5;OK^H'(X_!OOC-@$Y6(X'\#]AM(F(0D)
M[/?)+\*09MI!%/\ F2D-%"^/H8]/V-@ A\B7)!.MBR^^L 5'D0_#:/\ )1)X
M)8766DG/J;'US9T20"?)B9P1L*!_+_(I\I<6[SHM8O"<>@/Z1QR9%!'?TR*!
MJ)Q )],E E$T"2!VR+3/;[HU/ZUR->X5(,TR;_!C&0E("QS9GHZ8^)6Q=B!'
MSA/L2#T(-)WOSB-0^)>Y_48!1F!-_P!&)J=%#M?++Q3<!.^SGC(:X9.6=0OV
MQ:)$$F+:\U)OKFSAKJHGN5ZWC7P;=1L_= >*IU2<:D=$,RWO6;(5X!4AQR[C
M6)]$F"YI#VWSG&J=B?\ *0;18-@_+B^R$+T3O@DY0!0)W-8H"*P"7MT_R\^:
M6!CYQ4,YF7MCTT AE(_=[_HKLTO+'T/OE^SHR/T^G.#2@$. 0T._=SC:DPB$
M\4PZUQC=12J!H_W_ %)P20X&=>KZN1Z"V;7*/LUFG21Z6+?B"LA*1-[&1#PZ
M8R%2,35J'0-^^%&<"FC95@15'L'[MMKWA.#".:!)%\%-K?G)?U'.E&U?#[Y3
MEA$M&QI;^,C$7O3*> U3FBRHB4<_Y.BQKXH#''EE/H'HQXDE]'4.KH_UA3\I
M8=M&YZLZ<]?P":CUCID&ED-S'^9+Y66I%)]; R:6<2E/$6(X,62;"4+2&-K)
MV,J$B!$)A^41YPD:*$52RY+_ *BE/%X8]QDW<Y"L\QMLYQ7) W2F5^V/%'+;
M8H0=LHD$G9R*!(Z;!\C7G]Z$6D'5_P!& Z(&3!:CP5Q&\2%6=C#*UQ)(9P2"
M 5P@A[FL+&1+="=.I>BX0@Q)8'*D2;\?Y.GD3%9]^C7IWP*\!X?]F1V<M2$T
M-\+Z=\@?)D0;Z?Q><2X%/@[_ ,SC+H'Q)]#!<>0(>+8VZX_]6+JQF#R=.V#H
M);51'Y),MAV"*(HEC7].(8TBZ&Q^-X2C)0-):(>['46822SL^3%/ZIC'D],T
MG2^N*Z8;$?-YU@F2B?C1)U_>@D-F.]7Y$R%^,>,54A3I-/-OD9*M?(:MH-3,
M$&$C0,4@IN2$!Z8JIU06R)3^!GI@0>@.*8C_ ":P>).8+CSUR81%H&-0Z.O?
M!D@R%&33P?YKLVME10_5T7!"1D6:8#(64=WKDYBVVG; 53$Y3:RFOW+">V=8
M7IM#M*SYG^B/J*&Q<%W.A"HX7<Y=9CO<B]&;\<QB>TBX5]W('D2)-70<ZOM@
MO?3@[B^F\M%KMKW)ON_&:_HG_)%EKJ='*+&+B8N(=1[.*\@00>X1LWSE/GSH
MFR.4>#&#>' -:;]_!S.'O>K-((96(U_DVZ.@A[.&PJ! ]#_-E5)J?/\ L\9&
M=T9)!(NS7H>N#*O]C4[&_5FU#7E@,I8-&@R?JG799^_]!DX$#*M!EF<+^K7(
M,^.V2QSZ\XXE],7H3<"N#*9+=*R08GA6(L;W:08&*I1"24?U!&[$@."L-+*_
MX//OB?B@5O K'A+H0>PCZY1QT*? 1D?Q(0+UC_ZY)$2";.^6S#!U_*/AQSU.
M6U5/57]+3,E' U]8QBD),MA?O@SU2<0@XK+:Y">F\;$TV@J8WP888-^S?\SQ
M)DE&=Q+' ?QBI,H)L_KR*RV?@+QJ2WDP>^ M"-Z!'_UT=J: ."%QAE@0 @#^
MD/M)W([Q\#!HH[8CS7U/)SD/N0C8)(N'$>>RLFB2$6],"@6MR_ZY7%DO<< :
M-_\ WHJTT)+.@=\@O5BUP%N;^N,<)A.S%@/4C.LM'*#B^'6.[(M#8'3?'_WM
MM7 "M&0AL0G6#! ,()8,1M1R<Y?[W&QA>"[9=^*@B9&5F7!ZX94BQT$-!Q+V
MC(%V=<.O_O2VL!#S8!=E6'5SORL)\#UT,F[;9Q<K)2'+$SYR<B:5>" &'X*
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MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$D$DDDDDDD@
M@ D@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD DD$$DDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$$ DD
MDD@ DDD  @ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD D@DDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDD  $DDDDDDDD$D $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@D DD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDD@$DDD  DD@ D@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDD@@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$$DDD@DD$DDD$DDDD$DD
MDDDDDDDDDDDDDDDD@D@ DDDDD DD $D@DDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDD $$DDDDDDDDDDDDDDDDDDD@$DDDDDDDDDDDD$D$DDD$D@DDD$
MDD@DDDDDDDDDDDDDDDDDDDD@ DD@DDDDD@D@D DD@D @DDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDD$$DDDDDDDDDDDDDDDDDDDD $DDDDDDDDDDDDD@$ @
M@@ $@$D@@@$DDDDD@DDDDDDDDDDD@ D$D$ DDDDD DDD$D@@$$ @DDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDD$$DDDDDDDDDDDDDDDDDDDD$ @DDDDDDDD
MDDD@$@D  @@D D@ D@ @DDDD  $DDDDDDDDD$DD$$@ $D$DD@$D@DD@D @ @
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$DDDDDDDDDDDDDDDDDDDDD  DD
MD$     $DDD@DD$@D  @$D$$$@ DDDDDDD@DDDDDDDD$DDDD $DD $D@D$D$
M@ @D$ $@ $$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$$DDDDDDDDDDDDDDDDD
MDDD@D $@$      $D$@@$DD@ $  D$D@$D$DDDDDDDD$DDDDDD@@DDDDD$@
MDD@@$DDDD@ D @$@D DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$@ DDDDDDDDD
MDDDDDD@D$D@$@@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$DDDDDD$D
MDDD@@ $@DD@D$$DD$@$  $@@ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ DDD
MDDDDDDDDDDDDDD$D@D$  D$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$
MDDDDDDDDDDDD@ D$D $ $D$@ DDD$DDD$DDDDDDDDDDDDDDDDDDDDDDDDDDD
MDD@D@$DDDDDDDDDDDDDDD@ D@@@@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDD@ D@D@$$DDDD$ @$D @@DD$$@@$@$DDD$DDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDD$$ DDDDDDDDDDDDDDD$D$ @$DDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDD $$D DDDDD@@$D@D@D@ $ D@@DDD DDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDD@DDD$DDDDDDDDDDDDD@$D@$$DDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDD  @ D@DDDDD$@DDD@$$DD$DD@@DD@$DDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDD@@@   $DDDDDDDDDD@D$$DDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD DD  $DDD@D@DD$$ D@$@DDD @D@
M$$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ $$D  $DDDDDDDDDDD@$D$DDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$D@$ DDDD@D D@@@ @@@
M$DDDD$D @$DDD $DDDDDDDDDDDDDDDDDDDDDDDDDDDDD$ $@DDDDDDDDDDD$
M@ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ @   D D @$
MD@  $DD$@$ @@D $$DDDD  DDDDDDDDDDDDDDDDDDDDDDDDDDDDD @ @DD D
M@DDDDDD$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD D
M$D  @ DDDD D@$ @D$@  $@D@DD D D$DDDDDDDDDDDDDDDDD@@$DDDDDDDD
MDD DD@@$$DDDD @ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ D
MDDDDD@  $@@$@@ DDD @ @  @@@DD@  $D@$ DD$DDDDDDDDDDDDDDDDD $D
MDDDDDDDD $DDD$$ DDDDD@ $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDD@DDDDD $ @D@ @$@@   D@D@ D@$@$$$ DDD$@@DDDDDDDDDDDDDDD
MDDDDD @@DDDDDDD@$$@@@D@$DDDDD @DDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD@ DDDDD$$  D@@  DD@ @@D@  @$ @DDD$$DD@D DDDDDDDD
MDDDDDDDDDDDDD@$DDDDDDDDD$   D$DDDDDD@$ DDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDD@@ $DDD@$ D$@@@ @D D $$@D D$@$ $@$$DD@$$D
MDDDDDDDDDDDDDDDDDDDDD   DDDDDDDDD@$$@DDDDDDDD $DDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDD@D DD$@$  DD  @D $$ $$$D @@D@@DDD
M$ $DDD$DDDDDDDDDDDDDDDDDDDDDD @DDDDDDDDDD @@$DDDDDD  DDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD   @$$DDDDDD$  @@$DDD@@@$$
M @D @$@ D@D@ DDDDDDDDDDDDDDDDDDDDD@@ DD DDDD@ DDD $@@@$@D @
M@DDDDDDDDDDDD$DDDDDDD@D@$$DD@$DDDD$DDDDDDD$ @D@ DDD@$@$D$@$D
M$@ $$ D$@$D@D$D$DDDD@@DDDDDDDDDDDDDDDDDDDDD@D$$$D   D$@DD $D
M$@$ @ @D$DDDDDDDDDDDD$@D @@@$DD@@$DD D$$DD  $@DDDD$@$D$$DDD@
M@@D@$@  @D@D$$ D$@@$DD$ @D$@@$DDDDDDDDDDDDDDDDDDDD D$  D@ @
M$$DDD D$$ $ @D DDDDDDDDDDDDD@D@D$@ $@ D$ DDD$@D@DD$ $$DDD@@D
M$ D $DDDDDD$ @D$ @@@$@DD$$ DD@ DD@@D$DDDDDDDDDDDDDDDDDDDD@$
M$D$$  D @@DD@@@@$DD DDDD@ @$$  DD@$D$D$D$$ D$ @@$$@ D$ $ @D@
M@D   DDD @@@$$@  @ D  D@@D@ $  D$ @ $$ DD@DDDDDDDDDDDDDDDDDD
MDDDDD $$$@D@ $DD@DDDDD$$$DDDDDD@@D@$$D $D$DD$@$$D@D@@D D $$@
M@@@D$$@D$DDD@@$$$D$@@ DD$@$  DD@ D D@  $@D@$@ $DD@$DDDDDDDDD
MDDDDDDDDDDDDDD@@@DD$@$$ @$DD$@ @D$DDDDD@$D $DDDDDDDDD@DDD$DD
MDDDDDDDDDDDDDDDDDDDDDD@@@D@@ @@D @$$ @D@$ $@DDDD$D $$$DDD DD
MDDDDDDDDDDD@@DDDDDDDD@$$D DDDD@ @$@   $ DDDDDD @DDD @DDDDDDD
MD$DDDDDDDDDDDDDDDDDDDDDDDDDDD@D@$ @ @D$$$@@@$@@ $@$D  D$  D$
M$DDD@$DDD $DDDDDDDD$$DDDDDDDDD@D  @$DDD@@$ @D@@$D$$@D@@$$@ D
M$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$$@$ D @ $@ $ @$  $$D
M@@D $D@ $DDD@@DD $DDDDDDDDD@$DDDDDDDD@  @@D@D @$@DDD$D $$D$$
M@@ D$@D $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@@D@@D@@@$@D$@
M$DD$ D$@$D$$D@D DDD$@DD@D DDDDDDDD$ DDDDD$ DDDD $@ DDD@DD@
MDDD$D@@$@$$ @  $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD @DD@D
M$$D@@@$D DDD $@@D$$@D  DD$$  D D$$DDDDDDD@$@DDD@ D@ DDDD$D@D
MDD@@@DDD@@@@$@ $@ D@$@$@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DD
MD@ D $$$@D$ DD@@$$@  $$ @D$@ @   DDDD@@ $DDDDDDDD@$@DDD@@ DD
MDDD$D$DDD@D@@DDD$$DD @ $ @D D $$DDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDD $$$DDD$$DD$@ @D$ D@D $$  $@ $D@@D@@D$D   DD@DDDDDDDDD$$D
MDD@D D@$DD@$$@$D@$$@$@@$$$$ @@ DDDDD@@$DDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDD$$$ @  DD    $@D D $@D@$D$D$$  @D$ DD@@DD    DDDDD
MDDDDD @$ D @DDDDDDD$$$DD  @@ $$@@@$@$D$DDDDD  DDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDD@$ $ $ DD$      D$@D@@   D@$  $ $$@ D@@@$D$
M@$$DDDDDDDDDD@D@ @$D$@$DDD@$@ $DD @ D  @$$ $$$DDDDD@ DDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDD@@$ $D$$D@@$DD @$$DD$  @ $$$@D$$ @$$
M@ $  $$DD@DDDDDDDDDDDD@@$D$@@D DDD@D$$D@$D$$$@ $@$DD@@$DDDD$
M@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD $@@D@D$DDD@D@DDD$ D@DD $D
MD$$ D$ D@  @D D$ $DDDDDDDDDDD @ DDDDD@ DD$ D @   @@$$  @$@@
M@$DDDD@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$DDD $D   @$$ $D$
MD@D@ $D  $ DD DD $DD@D$@ DDDDDDDDDDD$@ DDDDDDD$ $$$ @D@@$$DD
M@ $ @DD@ DDDDD$$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ DD@D@ $@$
M@D@$ D$ $D D$ $ D@ $D $@@@ $  DDDDDDDDDDDDDD$@DDDDDDD$ @@DD$
MD @$D@   D$$$$ D$DDD@$ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ D@
M@$D  $ $$DD$$@D@D$  @D DD$D@$  $@D@@$DDDDDDDDDDDDDDDDDDDDDD@
M$D   $$$$@$@D @$@@D@ D$$DDD@@D$$DDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDD@@$@$ DD@ $$D$@$$  DD $@@$$@D@@$@$@D@@$DDDDDDDDDDDDDDD
MDDDDDDDD $ $  $@$$@@$D$D@D@$D@DDDD $ D@DDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD@ @ D@D$D$$$@D @$ $DD@ D$ $$@@DDDDDD@D DDDDDDDDD
MDDDDDDDDDDDDDDDDD@@$ $$@ @   @ @D$$D D$DD$D@D $DDD$DDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDD D @$ @$$@$@D$ $ $D@@$$@$   D$@D@$DD$D
MDDDDD$DDDDDDDDDDDDDDDDDD  @  D  D D$$D$ DDD@D@@D DD $ D @$$D
MDDDDDDDDDDDDDDDDDDDDDDDDDDDD D@@  @$D$$D@$D$$$@@@D$$$@@D D@$
M D@D$ $DDDDDDDDDDDDDDDDDDDDDDD@$@@@$D  @DD D @$ D@DD@$@@@$$D
M@D@DD@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$@@@ @ D$D$$D @D$  D@$@$
M@@@DD   @$D@D@$$DDDDDDDDDDDDDDDDDDDDD@D @D$$DD@@ $DD$$DD@DDD
M@$$@ DDDD@@$ @$DDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDD$$    @ $D
M@$@ $D $@DD$$@@DD$ $ $@DDD@ DDDDDDDDDDDDDDDDD@@$@@DD $@$$ $
M $@DD$D@$D$$DDDD@D@@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@@@D$@
M @$D DD$  @ $ D@$$@ @ @ DD $$ @$ D DDDDDDDDDDDDDDDDDD@$ D$DD
MD$$DD$@ D$DD @D@$D$ DDDDD@  $DDDDDDDDDDDDDDDDDDDDDDDDDDD$ $D
MD@DDD  @@$D @$@@ @@$@@$@@$DD$@$ @$$$ D @$ DDDDDDDDDDDDDDDDDD
MDDD$DDD $D$ $$@ $D$@@@DD$$$DDDDD$D@ DDDDDDDDDDDDDDDDDDDDDDDD
MDD@@ $DDD$ @   @@D$D$  $@ D$D $  D$ @$D$D$@$    DD@DDDDDDDDD
MDDDDDDDDDDD@$D@D$DDD$D D@D @ $DDDDDDDDDD DD$DDDDDDDDDDDDDDDD
MDDDDDDDDDD  D @D$$D $@ @$ DD$@@@$@D@$@$@$   D@ $$D DD @@ DDD
MDDDDDDDDDDDDDDDDDD@$DD@D DD@@$ D$ D$$DDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDD$@DD@ @$$@  $@ $D@@ $$D    @$ @D  D@ DD@@$
MD@@D $DDDDDDDDDDDDDDDDDDDDDDD@D $DD$$@$$DD@$DDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDD@@$$D DD@D$$$ D $ $@D$D@ @  @D @@ D
M@DD$DD@$@ $@DDDDDDDDDDDDDDDDDDDDDDDDDD DDDD@ @ D D$DDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD  $$@$DD$DDD$$D  D$DDD DD$@
M$D$@ $ @DD @DD@@$$DDDDDDDDDDDDDDDDDDDDDDDDDDDD$DD@$D D$$D $D
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$DD$@ DD$@D$DD   $
M@ $ @$D @D $DDD@$ $ DD@@ DDDDDDDDDDDDDDDDDDDDDDDDDDDD $DD@@@
M$$ $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@@DD@@ @DDDD$
M@DD $  $@$@  D D $ @ $$ @@$$D@DDDDDDDDDDDDDDDDDDDDDDDDDDDDD@
M$$DD@$$ @$$$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$$@$
M@DDD@D @$ $D D$DDDD@ DD$D $DD DD$$DDD@DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDD $$D@ D  DD$@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDD@$$$@$$$DDD$DDD@ $$ D@@D  $ D@D $$ @@$@@$DDDDDDDDDDDDDDDDD
MDDDDDDDDDDD@D@  D$ D @ DD$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDD DDDDDD D$$D$@$D$@@D@DD $@ D@D @ D@$DDD@DDDDDD
MDDDDDDDDDDDDDDDDD$ @@ D @D@@$@DD$  DDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDD@  D @DDD$D@$$$D$@ $@$ @ $D @@ $DD$ $ @
M@@$DDDDDDDDDDDDDDDDDDDDD @ @D@$D$D  $DD@ D$DDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$ $@@DD@ DD$$D$D@DD$  $D$$  @D
MDDDD @$$DDDDDDDDDDDDDDDDDDDDDDD@D$DD @ $@  @$DD$  DDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$$ $@@ D@D@ @@$ @  D@$D
M  $ D@$DDDDD $  $DDDDDDDDDDDDDDDDDDDDD@@D@DDDD@$D$@@DDDD DDD
MDDDDDDDDDDDDDD@DDDDDDDDDDDDDD$@@$DDDDDDDDDDD @ $DD@@D@  D$DD
M$ $@@D$D@@$@@    D@@$$@$DDDDDDDDDDDDDDDDDDDDDD DDDDDDDD@@DD@
MDD@ DDDDDDDDDDDDDDDDDD$@D$@$@ @$D$$@@DD@$D @$DDDDD@ D$@@@$D
M@$@$D@ $@  $@ $D$$D @@@$D$ D$$DDDDDDDDDDDDDDDDDDDDDDDD@$DDDD
MDDDD$ @$D@@DDDDDDDDDDDDDDDDDD@D$  $$@@$@D@ D$@D@$ $D @    DD
M$DDD@@ D$  $$@@@D$$D@  $   $$ D $DDDDDDDDDDDDDDDDDDDDDDDDDDD
MD $DDDDDDDDD $$ @@$DDDDDDDDDDDDDDDDDD$@@@@@@@D D  $ D$D@@D $
MDDDDDD@$@DDDD@@ $  $$D$$$D  D$ $ D@$$@DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDD@$@DDDDDDDDD@$DD@D$DDDDDDDDDDDDDDDDDD $D $$DDD@@ $$$
MDDD  $@@DDDDDD$ DDDDD$D DD $D D@D   @$@DD$ $@@DD@@DDDDDDDDDD
MDDDDDDDDDDDDDDDD@D$DDDDDDD@ $@D$D$DDDDDDDDDDDDDDDDDDDD@@DD@D
M DDD@DDDD D DD DDDDDDDDDDDDD@@@DD$$$@$$$@D$$D@$$DD DD@D D$DD
MDDDDDDDDDDDDDDDDDDDDDDDD@DDDDDDDDDD$ D $DDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DD@D$  $DD  $ @ DD@@$$
M @$D$DDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDDDDDD@D$ $$  DDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ DDDD  $$D$ D@ $
MD$D@@@$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$DDDDDDDD$  @@@DD$DD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@   D$DDD@$@
M @$@$$@@@$D  DDDD@ D$DDDDDDDDDDDDDDDDDDDDDDDDD D$DDDDDDD@D D
M $@$$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD $D$@
M DD@$ @D   DD@@@@$@$$DDDD@$$ DDDDDDDDDDDDDDDDDDDD@ D @$@DDDD
MDDD$$$DD@$DD DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
M @@@ @ D$DD$D@ @$DDDDDD$$$$$$DDD@D@ D$DDDDDDDDDDDDDDDDD@D@$$
M@ DDDDDD$$@$D@D$@ DDD DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDD$$D D@D$DDD$D$ D@D$DDD$D$ @$DDD@@ D @DDDDDDDDDDDDDDD
MDDD$@D@@D$$DDDDD D$D@ $DDD$@ $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDD $$D $  DD@$ @  D D@$D$@ D$ $DDD$$@$DDDDDDDDD
MDDDDDDDDDDD$  $D$@DDDDD$ $DD$DDDDD@DD@DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDD$$@$@@$D$D$$$ @D@@ $DD@@D@DDDDD$ DDD
MDDDDDDDDDDDDDDDDDDDD $DD $DDDD@@$@DD$DDDDDD @DDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD DDDDD@$@$$DD@@@$$ DD$ $@D
MDD@$@$DDDDDDDDDDDDDDDDDDDDDD DDDDDDDDD@@  DDDDDDDDD$@DDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$@DD@@@@@@ $DDDDDD$D
M@ @@D$@DD@ $  DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD$ DDDDDDDDD$D
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@  DDDDD$D@@D
MDDDDDD$D@DD$D$$DDD@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDD$ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MD@$@$D$@DDD $ D$DD D@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDD@$DDDD@DDD $DDDDD$@ DDD$ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDD$ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDD$$D$DDDDDD$D@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDD@$@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDD@$$DDDDDD D$DD@$D$DDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$$DDDDDD $DDD$$ $DDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@@DDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDDDD $@ DDDD@@ DD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$DDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@D$DDDD@ DDD
MDDD$@ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDD
MD@  $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDD@$$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDD@$ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDD$D DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD  DDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@DDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDG_Q  4$0$
M      #@_]H " $# 0$_$%4K_\0 %!$!                    X/_:  @!
M @$!/Q!5*__$ "X0 0$  P " @$# P4  P$! 0$1 "$Q05%A<8$0D:$@,+%
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MUS<C_OE=&$5]!2)"()I31%W3J6XZ1(:_@"6-#6DO4?8C1-;NXF-^&]L;& I
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M5YDD$,_ ?7^G25[N40-JJ '<^I&&0W>ZCY6F[]2?_C>G]TH7$.TJ\< K]O\
M7[EG /E[8H>7$*!?7^H1'CX&:^#!4(_3K?E_I&W@E0R!IN3$QAU1F)II9_M.
M5^$+T-J"<J5A&IA]I!J0D%0%EF,8^!%:)U:(HI,1)H5XR5X#8T?6 [>8'#XS
MQ@XDMRNAMVKD2MH*+A'/"E3XPF"5',U<<;3.*A8ATYB*RHW@?<ROW_7,9H*"
MT^D01-B"8Y!\'RHQ2E<*W:S1;!B^8B0BKL#0F5-<F.PH^(B;F\_EJ'L:--4B
M>$RI?-D,5$WH6] >@O\ 02" GE\-X#L<:T9"FWB#AY/VHBL/$;0L/M<*M:PJ
M&>BC8.<U3\OD_,70$!/<?U9J:T,P"@<#T34S:032D&K(CPLN*[H O7XU.ITW
MM(G_ !)T#Q'R?JH%6!U< #W1ZG./OT>L.26)#[=/X'\N)%D__;*'[XY^X_ZU
MCZ(*L0JCP/-UB^UIDWS^5_X(CY0D90(H*>E.N PK%+2RD,5IYCG52!1@-#SJ
MF E/J9%(],C;)X5_VBUT%&Z3JL8EOOF"MU!!02E:LJ[, W5+0)9U!:217++,
M0I2(4 3K/&*MM.7JH.A5$YZP@2:W'4#WNU5?@Q)[MOM-_P"F$";[%E!-:EPC
M, JC\6QS\113+Y#]">O_ *-<FP>IHH,#//Z',M4ZUZ"[D[BQ.=B,#XJ"QA7Q
MBL!3<PI\V-IN4T%MZ6(B@#^/!M0(%PJO0O+@YX":#]"E02NT0B$4*!M#H5-I
M^W34O3G$II"*/4[Q@#.$,!':.'5 #12+Y0EW:C3'WER*C!H55)M7#N;AQX<\
M(E\"KH<:J(L8!T,#:>Q9@6-E'I0%-I6J4!0'S[9/0 6GB,"?KT(*(AP\I\@G
MW@[PYX7E#0IX7&P 98,_LI\'Z3"D7%!UI,4(&IO!YJVO% 8OB'*2&M9<"%0H
M412MK8T/XMN"" /WP>^IP !1=&7(])"*-$8"1MV-E6#UJ;H WX_ACF$%"9"V
MH0>8JJXO/4G?2R -&QZ;:/Q__796?BO^JPJ'JDOX#SW7Y_\ 2<]D^?\ UG/9
M?G_UG(%6++RK?M"'IYEU(8IOC4]P"QXL" 80HCQ'_3/.LQ %5? &4YF)?I*$
M^#QWMQ24I\S)&KI)FR(K?U5%,TH;-CU2PF%I55\G(28@%EZH(252%/37:R4T
MC%XEZWS\XT:B9S)LD57U)N]RP1J($3&,6@P:"(I:BU*W-8%XL423>-$K'9WR
MN24&:&(:MD(!!ZM_$FS)<+*TN^^)_8-?EJT1V,(JQAOQCBI334&*H@)M=]<E
M8$]DFV#9&QNN'OK5DGP;G$&/JQRB0E4+JJZQ/!-GG^C3C8.DM.E5-^>--9Y%
MQ)>2CU8U&>&@:4T@8E'?S[QZ2UM'0>S1Y'A3]2->8AEMFTJO*V+@,\-M)]<P
M5HFBQ.G8X-5]\IX_977VJ=U%>U(OT-ER1M.)TR%T4E=8HG =&TK@6/D'HQ7>
M!/YFN[V+ZQ>'H%$MAH8CM#"7<?T$&1B(0^-.1]Z&,5->B?#8PXKC.N0'?2NK
M[F=B1NL0OS#_ (()7:+J(NHE?P><,"')=/L@[/G\9N@Y,&=MEO2?$R.[%,BD
M\"C7C_:'GG W&:5?QC5F;QU.EL;OG'@4.(A; """^K<W4PUI/"P10DM$Q*LW
M=Y;)*K)/ UD.>B3XGDG T_)<,VN;V57 @#A_IA%D!"'FK>&!][4ID99=8;J_
M"O*5$00^Q>@L(G3/_)]?Z-QSATUR4'\IGQ\9-<)O(=^:8*'(2,,]%(GIQ/H*
M[JI$LJ-.W]"E$'F/=S[ Q(!]T4'T ,'X]TT (U:#?1A6"/78H@M/V3]-\EWC
M@R#\4,]AZQRB$-IE]M9] >,H?UXL,]$43YS? V.ZI$LT-2OO]0O@"EC9=D#T
M^.&@8?@( <&,\+6.KUT[L&&*G%7#X"'V1\Y7H(=!"7R93S7O]#@1F2 0*; N
MO!AN_H$8X   " 8!!1P58NLO,.=PD'RB;Z?Z-Z#!)%/;'Z#U^A<J -!0U !7
M0!DW4<_Z[,#5<_ZK$+7?^P/Z 8!"(\<O+703YU[:K4]PD*5!UO<\=JQY>+3+
M?TJ >SJ.7@4JAD. 41]G^D=H@ 8-KQ=UT]%Q,Z &TA94!;9VG6@J<Z;H]Z0C
M$:$TOZ)/&/5?^[X[C0;'^'@@?8N[]22*"("ECX<&Y7$OPP "V)T\^<NQDT T
MR[//W^<AXIM)Z<V^\"%1+AM O'/45UF(P@#2C39\@_9@Q!@*X^(?8G!+F#:?
MF 7\,@ZFW3\YA;R?-_1I^V$L>E ]B:?Z6<D[U ,K(9\"(L>$VR%J1Q2J*#2+
M&9(9.VPXL-;(3<L,B  ,*4(H3NMG,ZH(&AT#OX0>/Z-ZQ32,K$-Y9X<RDM([
M(A38FLCU\V_Y'9DS2=*+KS$3X#7AABC'7>(F>:VS?:%%"K3>6*!(,[Q$8,/M
ME3*100 DLR CBL1?/'L "U2 \T<$/>X(-B.RC\NNW,<!V2NH,1"Z326Q6TVC
MK2@5=E';<T9$2A"(^A0MVW1X@/%M)+T!2-!TRKL,G6":8@4W UCE J+@$*$
M")#$!,4HU2 -AXY/^")J5-!BDDP>H /(5OE6.B%%3LY[BRA< 5FX-D^U0 K$
MELBN)F00@0*]T&_]H1/"F8> H# BAMIALKAA@/+M(!'5X/\ '/.RU5848CKJ
M8^E9<&Z%I2.V4Q@?I[&,0I5L#?MPFS=E4$32(],HN39=G]/E!5A[<_AMW^7/
M!7ZG^7/X:Y_G'\%/S_";<?P&'/1?_HT\Z*_]VESKC[_\!SIG_P!FEG1/_HTL
MZH_]6L<&Y/?E"@,02[#^H1YJSL&Z6]@][@=Y= 35^07N+Z#Q4@GC_B87&2'G
M(\HCRQU,;C$Z;U&@P-@N( L>*Q/"X-P#:A4#M%Z1XRJ2G&PCTM>!!XQ6XBBD
M/.'=Z"=#A>2H^H,H' ZO7Z%-0A_U\;B)?? ";S1CS1*B] TXO:-P' -[JG [
MJ4,M0YT 426THU7Z;SGAFM&A\DOA7C#43VCL["[/I>L3(U$I1TE'G"K 7)X'
M5VK90G)WX?H R%>1X^0-'\#'UD#XT0D$G6N]_1BTXC-Z"3I!S\<U_%5\85]D
M0]GO!Q\9:SN:M/'SX=I0K?$?X3HB.S.=/;X%&@$D#@*)5I?W5,IKY']+$3%.
M_.W B> CU@)!B$J+;ZP]YLY 30-II4BB/]P0ZC[#9/BJT:!B4SN/<OI<K\F+
M_?-P8ZE[J(2-&2:0UGM2/[_Z'<,T0#*:6RP#:=)F@P_>=(501L=:6RM[RJ=H
M5'6Q@TXC[1]@_D05W\?TI4Q$UIQ@F""%! 2(Q:%YFKI!M3-#I/WX2J@ E"4
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M;IV/1AXB;%@NUP;R4<!NJ#\XP;_HYF]GR<%T8B2Z:A%#M*@OKQP_WQWAWZP
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M/'E>#!XV+!O)6!M*?G#79XVO4$R/*B>_U'.D<#Y7-J,7,@!>*H4I=^L.H/\
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MJQOTQ^$W.^,C7B:F[*$40KMT8 U:]16H7P=9K'@$BW'5!88PZ&<7X8Y$&7"
M";>4?!]#9_&7DVJ$FI/(_OIXG^F-B<8"T!^6WR3T8<FGDGG"' PZ5 FD(-TP
M^<G7D76"4K7:0+ D6=0HJ\.:0L5!P!B(\:W'[F7'(FS\4_G"#O$(T"@1WK>"
M#@<LXND/D:M5?\86:6 8WQ"JI[O#6)>Q<^AA!5HJ'9T9]09#1 #P  'H_4A*
M]UL>)Q'B.G'D/#@A*LU6BZG8IMX(?7MMT82@WME(Z2"/QT$(*<CDEWH@X!5!
M5)W 4U44T#RT5V=+W A>2BB2?$,_J98F1*?]^WX' [/-=U@KH* ?)G3GUAX
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M.ERI0$PCP"J?3L?.;+ +>W0F\T)K-1L:0)/$TT$ :T.ED!$=F1@E+R4#L0L
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MUK;>*12C-J<C@0*Z0H*'0!61T00;0;"\T"RA"<!$^F(:T])H+'[_ &']J<2
M1^D>XM7LXP[,QC6H)SSC]Z/U'& 0-"-7XQ.T[DX:G6CC0G$7 1KIBMV=N87^
M/\WS_P 4MWIE+S^V$\@881WFX@H)WKT?Z91I$M .3N/=!S"Z#? G\W^V\*C
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M4PC%I)1QV14A=A$YL;.GNJ07)P0/D-PVN,%HF_'^T^U&X.>17_O)%T]^&/\
M'.D6JH;6>1_"=N S:9C8%$2'>=6U;3*$@P-J 6/S+D4C5I@)(:2OH#Y18^'@
M- TK&;_.7]J.#9>MI>X1#K0!*TA9M=O[?[V_%WD%.F-0ETWH=!KH67NL._T6
MIA2DV>/\X78Z(\Q0NR(UV'EFIK\98*_1?W</E7L(HH2)HJ1[RZHUE'+J,1'A
M+6\71EJ+:=0FU,=%F62(0AJ FM4O*$4N.],7H5?H =2^4<..C(FG8# +H8UB
MHS%T&TH1=1\)<+\&*NH":)H ]3"H")*6U][F0\&_VEY] ">@3<=+[]X5R3\E
M161$3A'W0%[*5/ #4>XNM8C_ )&6K4'9"&<$ZA!D<8M 2&HD/3"_DP$:^P79
M?^(I)WN@D! M7K4_.M;"*L4FDHH:H\&=X4U"W4-4AIPH;(L26%V* &K4I>X>
M1YXX#%*<:-^+B/"I_L@GH "@4"Y'@@Y_E<:L9HS=1(#W]BYYJ[ 3T,?DJ_.-
MXYI$66GZ6\EKDLCX=2?E/WP[DC!: AIMTJ/::OZ-C4B6"*/((3SBVRA;FGN2
MBC3HD93TFF2"^ . *?EY>I7[@Z<=W$$@H4-A8;"ZR/H6RD.H!$8\7&Z)$&&>
M4 @ 7AZQB$ L4!1%,1)+L,69C]:-"*40U/RE.%/T!H6CUN[,8*5I-" +**NV
MXR2_&SV#[#1\,WTN545#L5&7?\#&2/5Y4(OX)KWN!H:1DC2)6K[7K*H=E&F@
M H[[^# #F($@%'0QUSYGZ($,^5HW1T=^#O,(HL=]P$&D&PD?.! V+VAQ/D %
M35TT>6?#8! B^MV+B+AA]JL=(WNH%<TKJ!? DYPCI5KC"7H8U5E2(>"/-RV$
M-$Q3I Z0$KT'VI]G"T.R-+I/. 4T]$6E"0Y-8J;?!!70&@VX28@HC( DGI>N
M"0VV;"NT]O?ED]H@@K0+7\^\C7!&O*(Z?D&N8\XI7MG 1$\<7N SS!&;&^",
M/F8Z^A:N8 U[G@]X'Z^TM(H=L=[I\%BFGM4 NH2-7)<;$ =:CN*3JSQDIM%2
M(J:6($[?+B.)U;-3D G8$:8?AC:TA =/PH ' G,C$Y7"!%L 2B ?=\DS0"KM
M8"B<,;PIA[,>=1^@=[A1'Z%%5JB:KU35MJNXC5C$>)@_+7E(;X4?<_KMCCD=
M[ZV 397MPV,UJ*+ )76,&IEOP@)$#+-$:\CA0'Q4*@'6E3*O*N4G#&*1@Q]=
M\93L^7_]9['\;7IIC\/]!>4B /D:\A_%FY@KH3[2>_09YD8B*J72WS26F18[
MC0[L$VBF0?*#)B8@]$:AAD;>>15^]!_S_M+UI7'G_"3]V)QI9-4(6 U.T\S
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MXB"E,0+SU"A/,TN'%1.F24<1$/@OF!W^, ' #]29:3.T5 NEL:VE7$)5E]8
MVG4(7W@UB?C@ ?0KR"_(UFLP'">=(&@PNJT4"M99Z+M[S8?]!Q)*4(WQL*XO
M^ 8U,92D 996K_NJ@N?08._([-+1<*U+WYP$'3S^D>9C0;V4C3L37<L!X'^!
M#_&-JCPF3R"ZCOR7_&0/(LG[2O[8$(;[O\&.^50%!5G0Z<VJYWN@+:LV8IK
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MU4L0T"-*>\JOF2!*H3(RH(8S'>%+J "N@._/HQ"BA3CZS>99&.L.5NP.OO\
ML'+6M/B)J?F8,LZ-H]\'\GXPL=L'TNR?QF@_%*/WP"MWA_*#DR\X,_9_RX^
M(E'%!\513]O0?,QW/PP15+H W<JZ/O\ VN*F@_\ *F4M%_XTRIH/_"N4]/Z%
MP5?P)O[L5_PZN"G\)_T&%'X;_HL5?A/^BP5(YXO^,9[4\U_A,]B>?_3<2Z\J
M//& D=DW_64Z*$5#[6W _P"C=)E%JDR^E]!D_DWBV0^*"^Q[PX #=N6'A3Z
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M#YQ@4!CSQB]7TP3;LY_""*'H8A!!9V=M0 >W (G*P$ 4%/WQT2XE4.%P;6Q
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M/(\%_P#:S31]3H4@!0#3!^,6WZD@1 @:*)K4W5:&=5#X-K:V5T2").)QMO\
M%R<Q&7S-?S@(=S"$])*&[$PPR_>54C:((]$^\5Z:GXL#=';35V;P6%V)#8Z/
ML$S0G,\Y&7I I%TW6W;@HXHQT$#"*M'X0P,7E5$ -$U1J!Y<JGZEP8DWH"WK
M2_K=!=R'1HQB6PA1QEX/&U;"!J:;!I-O;%T#HSD&/ I&3.5)*0 K=8+X,Y@!
MP$3H)6NG0OGH<ZZ7[* :.M&+$$-G$J3US0SK@;J"FI03@H[*:PD@0M9$_@_
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MB9*$5&AZ27!M>_E@-B"!0[.XEJD]EHU5FAOV%"#K50  N"=C*7Y0J1W=U;@
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MZ"&#)/3U#9CL-9N$-(-%= U8$JEGIYQ]4F: %6T JN+=8W 1&'GPXQXQJH4
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MJ& 6B,5U ]$1K8\OZ!Z6Q;8M/+*'0CI,(EJSXC?!4"_*Y3L6T2-F.DO/>'?
MFT-^"-/@P*&E31(^,"SJ&PA[;K7[>\-*I0#50>2ZGP>,V_A'#[%X8;)?*H"T
MAV"/%(K3!"KI96O .O"ZP=\3R^YX"3Y-JKDM)J&ZG3U79DFG3 @ @$X364^:
MW4(_P'SB7-CQ%EMY:T?/<4K/#DE1<4[7/1@,'!U!38"Z=N3*,*F>C[ADF #
M+ K Q\R2+<H&_1_&)\/3U5]%3OX,*GK.\]O[8'3V+B&K9WS?>;[E-91 O[N"
MP %.D\F$:-/!$W;O64[(/$?28UP 0?0F(O" #%M.P5[UG*;A ^?*>KM7N>BC
M. 87Q>RLWXQ[F;\J+;T:\M.!ZA N)W0_YS31&18"*^]Y? X5=</?[_C)"3NQ
M)&&H!=DIRX_D8^?3>^-"<WZPK/01!X P2ER8!]I ^?&;TT\DE4+L(Z9NL&5P
MM[_Y<L)66V!L,Z>!&&-)#+4$:!HVC#6$E+5!3T":5V6]7OZ$W2P@J 4_>ACM
MG ].X&H!U(*0 $-A%3>RCHVZL62L("D,JK50W>N=>VG?A:1E>%T;.$KX!HK=
MJ%%T@HL:U(BD,1%2/D%'(0@$S('9NK5Y'V.44 8O,%>QX:VWZ;E.NZV@#Y<:
M24.40);;T KQ(-M\@:&UDNWB_8I0]/G--6C'/:ZQ#ZH@05::4>?;%'MK(%Z+
MOPN%R*Q'JWEO"EED_P!,,M9?(1/V<IRX6ZBCPTT/O&O1:YMJ=D=#*T+@OU;$
M6JC-FO>@LR:L,5!LY;-^?RR02W987F*WS@Z_$QZG"H ^&U0V/,?VFX[?8]OW
MR%X("65EX?Y,?\G(@)*]D_98H $6D0%X1T0)#%-+%X@#\I?Z:>WT.Z:&F"$>
M'@'E.E_=/@ID VK(O2 P^^VFLHFTS0Q1@>-!HF0C%4I(:4+KZ<*B<MQ,!H@4
M8<;7-_++1\6@X!AK<H&/&&(2X(Z=#W"_.#)8@2&A/!K"1+- 9YK2C \MF0L2
MR$0)D*WM(<Q4#U<5??O'DW5#8>5RQ), A*^8?5-=<%:AFGV)P#:Y#!0OEF+B
M3XU5!7WK<-P?6$D1T_+BAE\/@C1#MZT;XVH8VTU^'>T^/G;P+2O<$5B_,9L+
M@//.O&#W61TE7376RLA1NYQ0$55%4H+5J5@B118]U^<=\:%K:'R%IZ&>OT='
M>:/5=Y6[S1E=8NC<+@=D@OJ"A3(8MEJ)H<38;5!680D0UP'<CNIP:ZEP2D_.
M#';I ".P(HA2 L'X2C&0'?R_MS:H/%DGJ;P=AIZMJ"JC>E-NU(+J I#.R1<'
M?080"RVUV#)H-&OF:'O+?;.]A'^ULG)Y >Z%25VW0QE,0KYDT@2W65;R<&&A
ML)^(A,V860X)5MIU5_X&@4GBRJD$O!'5KR^#V%70Y#X5P0H4!Z$)!T"VT(3?
MZP^CN\A8\\7$9H/;H' W4WY/1C9'-/"#H%KKPAXPY[]UM/HO1T'G#;: 8!-%
M'9%"MHML$%'6R*;;7@U[/DHP"X/2?'Z:XC_]45X+Q5*,?3=A@BP63+V(7G!F
M_ #MH(C>'V."P5$:%3]O-Q),JPB+ 0TFJ>3.@=LC#EH;8[+YZ@R %5=!B'AP
M'N0Z(_E+'*V=C%J)L:2\(AS'?1H(>P,-OTQC-=Q!\"5UX,7]"K/O1X,L.!!^
M'^+ M33 >V6<RI0$HFE1Q;NQ397YS-(?-;5ZX?/A[O$X&O?%9+JSUDIIAR]+
M[*U)@Q00P AZD0U8(EATQ+2(?#6>>X9M\%!$()5[XR)D2X"P+2=/%!-&%C$B
MZ^ZH_$^,FH(-3]A=H*J"/L:^P NH7\*_C#>X4UB=#XQ!E> "M7CFI_[6&FC
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M"EE2255IV\L^,52ZA@O77GY_TYR%5#9+3X1OZ]LN06S>B'M#^<4+[>$T&B.
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MIA 8*"@II/DOAB&Y1)C'CB94?2/J ?O?!7%'*3<P-PM:-MBHG]Q#$$&PM7X
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MR:1919=5X.2R85AM;_$^\+@!\%@"NBJ;7+Z#;'\T8_"Y-HO7A^N/W'! J\
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M$QPG83X,G"YXHK=I1 ^W+ 8JU6D1U=\8O\2R@USZ>/G$(*,-B:L16:95E"1
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MWD*!*1(;K5:PUDZ<= DA-@!YHV#A8J8F]@"A/#;29 NC9225T;=P/&"_85L
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M FCW>1@!L-Q:83/B/$GY)QU:>$.^:2AH"=!H(3F*?$KJ%K'R39T=[@0R$\]
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M 9B!WLB- W,&Z0O'HZP!@#1/*Y,T W>E)X2'T#RR"++5]\=S\AB J&=K_/\
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M?$)]H><TUI('BD-!#XZ;!%C @@D2@:8%Z&I7 -5PDS5[HE71^3"%-L&SY0/
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MD& BJ^C "\3+COK:Z:\+W_=4&N(G=5=!\N--=%0NP17W:35B1Q[V- /=,F^
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M$4&@+7!P4GX\QP>01C\#."'X\^6RX@ML!$MV[UC)!.?D%PFM'.&,B(@&'80
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MC7QW(8TN2<NV#K&#M5?&+@5L -7QK";F1\JNA*ESA#@E' GV1VX%=NWV_P!
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M=<%@EKJ5.H/SER)E7I(B^589!EZR'AJ(D&.X$<,1VY<@511"76^A/-A=MD+
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M4_0Q59S&W /I#'O9!B!@(B/.3'TPK)4L 'EZ[?ZC?(4"-2(57YUB,M;/);P
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M2S?Z?[?SK*PG=W6&NEX$J&0PO@1TQ4S3#Y:&%"#2$KX4*N:JH)870^#%X^4
MK#.A093I;^H,;D5ROX!]>+=8J?$C<4&\"O[IQ<=<03=B\]S8Q=4P(A$AH385
MK795N'<K]M:+MK!ZI@A#'M0.W=O<^"]HVO/ 7)4 <202HI5\"/'](@1.E0V+
M:\WH&;.X@):I/8Z/E\;XP&0C]^6[K8_&S(=V)1Z0:G#UXPLQQ40HI!@ KAHV
M%J*)2!32[8/&&42=PJ!N!CJL1*S^AP=T":*>V*? [*X7N\ 4M>H'T&WO"!7!
M0C:&; _#J:P '/9B4=1:!1G&9:5[MY@.)V)X/-..=\<L47(5A5=#>TK2DA%H
M0';MU,09T@D* C946_&3U?  !&^\S1O>M9LU SA1?R(F$^41*1'9 04A>W#\
M,;'+2&E#S3^,:6PD65H<#SRI@B $P%TITU>:U287: C9?0]XW:Q<V>GKA3Y8
M<B@60HSQHWY<6\\;&W#PDT(&W!RIP&_4;B?_ '@VX5;/H+#5?/,%8YT#&?SF
MHP3(R3X"5-QWA<RP*R6K+LGD9]L 0F@Z VH;)X=#=R<BRAQG?2-'W\8"?J^:
M$*T 2B?EX!D_%U$%4T\95M(<!06?:J_>%< -"0[(K)XW/>L4Z6!H8L5/6_KX
MP-KZ>$U]I4#\8<W1;*OPF:,_-!5K[UOXF$KD$$\FMNC<AM)0(XC5@$.3GK1<
M:OP!!Y$"[@.S8N6%2("AL72ZT731=#%18-L 0$$7627&+JKS^-_.0,IR*00
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M-S[CBW"0.*B_QBPTG!DES5T^4;H18:2,SJ=AQL\:3B,C3VX\?4TKPAUW%M:
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M%%&,)K9T$P34H@*G1("V\ B!P#FRO_ Y1\Y6 4XB^$(H]FJ1P:-@\A:T 4K
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MQKV@H3A0#X!6S3PRO-C.R%,0-TM@;-.RFFC)'$:" UWB4[#'RZ8>TV-PITG
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M9/R;S.6C3+@'Y!PBX3FAK;XH_'Z!31L(P04TZFM/ETH>0!2RE=M"E[7$+34
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M[(WZN36X;9M)YA==JL$^*<.H%)OSA1@TN3\@2M7\8"C098 Z)G!$.94DT%
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M6\4D*"Q:'%,$XC-(E1AD8*%V@(MT8Y!I-8ACX$CY/K-^.H$AT+04YX\/,I8
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M"*+78@G\?K76[,%0UV=H,E]?H*\1/W^<N[>.YX DC #5&U'H 9C-/6B0& H
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M5"6Z81>@J*70+KA"V$2,5V+C6(&-?J@#= %E.3')<;.VLFH>#Y$8 ;X2Y@<
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M6M='M_W2[8$G5<J$".T]8J*&%B@% ""'\S#D&@Z"R^2)!V1D[CZQ0W%Y 0*
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M1$X1VAP:3#_$[N#/JF7UEU'C1AX$3"#+:H@<82UT&I$8\"[!%XSAYL\AB;_
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MKP"PJ=H1,4.A#>ZW>@^@ @3^Z'6)W,MFK*; 8FJP6B4"5 '36T[#+RYEH0H
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M?1A& <2^3W_9&CB!EP/&V("[$/>(Z%'U5BKH.VIO)J0$^H6(1/#=\9K<4P,
ML*32Z9J;?BJIM@4.^(U::YJ?(A/V3^IEFH\2[3ZQW[[M]26&;2,R&E ##2/0
MX?DNP<0O0I0H**AZ0>8DP,8KAN7Q?^4ZWJ$,0ENM4UHKI1QG=+!>1+J!2=VR
MX#!^(&G@70S5/>3,Y&%*J3CP'_+VU/#)]@'-N?B!!%A NKKHN[G'4$ 1" 0
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18"DC6 %<) (!]!__ *9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>xcur17preclinicalresults.jpg
<TEXT>
begin 644 xcur17preclinicalresults.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" F1"[(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY]/YTV33?B3M.=3P1ZDCG .#S_D _C^/B_M_?%U0H_MPX7IR>/U^OYFI+?\
MX*!?%J&X1WUDNJD9525R!V]AU[=S0!^N4J?%..0JKSNO9AGFHUC^*C$;FN 3
MC)R0./:LK]B?]M32?CWX?T_1)B&U^"("<ACR>.V/?OBOKEFVX]2< 4 ?+^WX
MJ<8:8_F.V>_^>*/+^*OK-V_B]:^H&8+USTSP":=0!\N;?BKC/[_IGK[XI?+^
M*OK-W_B]*^HJ* /EWR_BKZS=OXO6DV_%7&?W_3/7WQ7U'10!\N^7\5?6;O\
MQ>E'E_%7UF[?Q>M?45% 'RYM^*N,_O\ IGK[XI?+^*OK-W_B]*^HJ* /EWR_
MBKZS=OXO6DV_%7&?W_3/7WQ7U'10!\N^7\5?6;O_ !>E'E_%7UF[?Q>M?45%
M 'RYM^*N,_O^F>OOBE\OXJ^LW?\ B]*^HJ* /EWR_BKZS=OXO6DV_%7&?W_3
M/7WQ7U'10!\N^7\5?6;O_%Z4>7\5?6;M_%ZU]144 ?+FWXJXS^_Z9Z^^*7R_
MBKZS=_XO2OJ*B@#Y=\OXJ^LW;^+UI-OQ5QG]_P!,]??%?4=% 'R[Y?Q5]9N_
M\7I1Y?Q5]9NW\7K7U%10!\N;?BKC/[_IGK[XI?+^*OK-W_B]*^HJ* /EWR_B
MKZS=OXO6DV_%7&?W_3/7WQ7U'10!\N^7\5?6;O\ Q>E'E_%7UF[?Q>M?45%
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M0 !<;01QV/0?KUJ1E+9!"]01GFO+?CE\?O#OP1\'WFKWUY;^=#DB MR>^?\
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MWXNERK+_ +O\(!Q],?XU]2_\%/F*_LZW+<\,YXZ_='N/YT ?@O1110 4444
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M&\[NAV].G?./\_2@!]%-=BN,#/L!UX_2J&H^(-.T>(/?WT%LN,[I&V@\9XH
MT:*R]-\3Z7K+,EA?0WCKU6%LFM'<5;DY^BGN>/\ /\J 'T55NM2MK&/=<S)"
M.Y8\9QGK63_PL#PWNQ_;5F3TP)1[_P#Q)_*@#H**YW_A8?AG<!_;EEZ_ZT8_
MSW^G/2E_X6%X:_Z#=F/K*/\ /_ZCZ&@#H:*YX?$+PT6 _MNSSZ>:/4#^9Q^?
MI2'XA^&@H)UNSYQC]X.<]/\ /U]#0!T5%9^G:]I^L1EK"[ANQS@QMD'\:NNQ
M!P#C(_ND\\4 /HJ.20J"0<#!^\O3GKVX_G3VSM.!D]LT +13<D!CC..@!Y-&
MXE6QM+#C&?RS^E #J*S-2\3:5HYQ?7\-KU_UC8Z#/]*L6.J6VJ1^99S)<Q_\
M]$;*_G0!;HHJ,RA>25"Y(SN]!S_(T 245A3>.O#]O,8I=7M8Y <%6D /8?U%
M1K\0O#38QK=GSC'[T=\?_%#\Z .AHKGE^(7AIL8UNSYQC]Z.^/\ XH?G0OQ"
M\--C&MV?.,?O1WQ_\4/SH Z&BN>7XA>&FQC6[/G&/WH[X_\ BA^=2V_CC0+R
M0)#JUK*Y 8*KY.#C'\Z -=E/.1][(_O+V R/\CK4.H.&TNY?.T&%CD'I\I[C
M-3>8&7<.@RRG) .!W/\ GUJ/4/ETVYP<8B;DGV/?/]: /@[]GWY?VIM3'RK^
M]/R[>>W3T'MGTZU][OG. 1G&0N<$XQW]/\:^"?V>\C]J34QL./-/S8X'3CI_
MATZ>GWPRAE((R#P0:  <=\TM%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4A[<X_K2TQF.Y0..>Y&#UX_K0 FW<JE<,%&5.<Y
MX(Z_UKF_B.';P+JH@.7\AMO.<\9]>?UKH@ R]=Q(RN3R>,9!'3/'3UILUNM[
M#+#,!)"X*GH0>3Q_+C'YT ?SG?M9)J,?Q*U!;Y7'[]\!SRIR<CJ?4=STKQ"O
MO;_@K!X)L_!_Q*L3:H%:Y;>S>ORD_P!<?A7P30!]T?L%?L7O\7-2LO$M]N?3
MT(.W@CMT[$>OY5^O&C?L]^!=)TV&U'A^SD,:[2[1@Y_#_/6OG#_@E39B/]G^
M*?9AF*[GVD9SDXY^GZ@=02?M1E&&+_,N#Q@]/IWH X7_ (45X%W$_P#".V?/
M0;!@<_\ U_\ .!3_ /A1_@;G_BF['\8P?7_/X"NXVMW;GC.!Q2JH50 , < "
M@#AO^%'^!N?^*:L1_P!LA[_X_I1_PH_P-S_Q35B/^V0]_P#']*[JB@#A?^%'
M^!N?^*:L1_VR'O\ X_I1_P */\#;<?\ ".67_?L''3I_GN:[JHT8\<[LX)R"
M,<=O\/>@#C[#X-^#=+NDN+;0+.*9#E6$8R#G-=>D?DH%7[HV@$Y)].E+(QVO
MD84 \EL=OT^OM3FP^5^4CHP(SVZ4 (J[OF*!3G/OTQ^?:GU& @;^\V[KCH<?
MX5)0 4444 -8G( &??/%-4ABNUN,[ASG<,=1STY_SQ2LQW*!QSW(P>O']:9R
MD;X#;B"=V!G(&.P[_3_"@!2Q3 _B/(7DGU/-4]4U[3M%0RWUY';)C[TC8'7%
M6X]S2%NHR1UXZD>I]!^OTKY$_P""AFL:EI/PSOI;"Y:VE\MAN5]O7 '?_./P
MH X']I3_ (*?:1\)_%D^AZ-&NHKM9?-BPVTCCMSZ@^F/R_+O]H3]I;Q)\<O%
M-Y>75_<+ILN<6S,2IR23P>GI7DVK:C>:I?RSWT[7-R6(:1CR>3_7-4Z "C^$
MG/X5ZC\%?@'K_P 9-0F33[25K6%"S2!>/S[#FN8^)?@V;P!XLNM#GW"2W/*L
M"/QY[Y'Z"@#E:ZGX6\_$3P^,9_TQ.V>_T/\ *N6KJ?A;S\1/#XQG_3$[9[_0
M_P J /Z4?A+_ ,DU\.<D_P"AIU&.U==7(_"7_DFOASDG_0TZC':NNH ****
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M /YZZ="=LJ$@,-P^5C@&EG_UTG&/F/7/K[TR@#]T?^"=?QZTWQ9\.-.\-1R
MW5J%4COT  ^G/UR#7VF[?,5/0J3\O7CK[]^U?BK_ ,$C[Z\_X7-) )6:#Y?E
MR3CIG\.?U)K]K=PW$9YZXH :P*G(&YNV<#''\N*1L/N&U68#&&QR#_3_  HY
M9,;=VX'J,#V!HV^6>",MG"GC)Y/^/:@!RC!;@#)[=^.].HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSZ=N^: %V[_F9=O0]B3]?H:X3XP_%_0OA'X4OM6U2\BAG@C+11.0&8]ASV/
MK9^(7B?_ (0GP7J>LA0&M(=X4'Y1CZ\>OZ5^#/[8G[6WB#X_>.+F.*>:VL+>
M1XEBA8@-ACVR?T]* /H#]H+_ (*I7WCWP[J6AZ' UA(SM&MQ&".A."#^7?\
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MU5JVO?$<:;X8UF6*PCW9:)R1P<<\\YZ\BOT#_P"";NN:KXB^ ME>ZQ<O=7C
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MQ7V-OPQ!]N!R>?\ )_*OFO\ :S^%^H?$[P[<:9;([1R @LH) R6&>/KVZ>E
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M^5 ']*/PE_Y)KX<Y)_T-.HQVKKJY'X2_\DU\.<D_Z&G48[5UC_=;DCCJHR:
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M* "BBB@#] ?^"0?_ "6"\X].V>PZ\<?IU/6OVE89;^(<'Y@>E?BU_P $@_\
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M'K7XG?LYDM^TAHX'S%M1;O\ [>??/3UK]L?VV3CX5ZH,]87X! _@[C//Y?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y->.OF_P""A5K\
MQ8_:U)Q\Y'W?8Y/?I^76OJ7_ (*@'_C'.[!) 9G& <9X'!.>/\\5\M>.N?\
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M\U^^7A+/_".V&?\ GDH'X#'\\T :]%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSGISCVQ0!^>?_!3+]E_2]:\(7?BO1['.KL&+^6A9NGMV_GGVK\JOA#\4-?\
M@CX^M]1TR=[:XBF5)55B.C5_29XF\*V'BW29+#48%FB964!CGJ,=?RK\2OV]
M/V*M4^#'B"_\6609M)NI#(J(.$^; .<GL/Y4 ?K5^S+\8K7XK_#O2KI9E>\\
MK,J@YP><_P!/UKV%O]8IXS@\=\<?_6_.OPL_8)_;,;X$>*OL.OR>9IUU((@'
MS\I(QDCUSZ8Z\U^VW@WQOI7C?0+/5=-NH[B&XC$@$9R1QG&/6@#P3]MSX$:9
M\3/AKJ6I3VR3WEI"SQC9D[ATP,\Y]._-?AS\+?$B?#'XR6&J:A&T4=A>%G24
M8X#]\CVK^E?4=.AU>PEM+M-\,R[9$SP0>HK\>?\ @I#^R/\ \(SX@_MOPKIK
M?9BS.\<*=SSZ]3D?I0!^F'[-O[0?A_X\> ['4])N(]PB1#'GG( 'YUZ\OIM8
M=>ISWK^<_P#9K_:4\2?LZ^.+*3SYH=+C<BXM&!&03U_2OT\\'_\ !6+P/XFU
M*WL'@$,L@P9,$<XSGO\ R[].#0!][45\R+^W5X,,8?[1"?EW$<_EUP#PW'T_
M'R#Q=_P5E\%>';ZZL4MEDGC5E5ER1NP<'OQT[4 =;_P4B^.UY\)OAFIT:^5+
MR=2I6.3#8((]1ZCD5^)_AMK_ ,:?$6PGD62[O+J^21RJ[B3NSZ>@_2O1?V@?
MC]XH_:*\>:A*C3W5E-+M@MHU8D#=QW/^2:^^O^"=O[!\>C*/%WB^S:5Y0&AC
ME0#;P<<$<?T_D ??WP'M#IOPC\-PN"@CM%'S#!&!CG@<\5A?M0^&[/6OA!X@
MEGC4R1V[,"W . >I_K7JMC8Q:=:Q6UNOEP1#"H , 8Z?UKG?B7X;D\8>!=5T
MB,MYMU"T8*@@YZ9'.1S0!_.E\*_$UOX&^/%IJLY\RWM=1D8D\Y&\^O\ 7^=?
MT)_!'XKZ7\5_!]EJ.ER"2)8$RP/M@?R]J_!G]K#]F/Q#\ /'UU#=6\TEK<3/
M(DB*3MR=PY&>.?TKW7]B?]OZS_9_\.G2=93[1&3M.X')'KT]AW]>F: /VR"E
M0V,$\X7H.I-+M^;)Y/;V]OTKY \!_P#!1SP1XXTU;R-UA7N@R3G."._?'Y^O
M2WXN_P""B'@GPMIK7;2Q3;0/E7)R2,^OZ?K0!]6:A/';6%Q)/(D:!&)9CM &
M#Z^U?S__ +>OQ(N_%'QFUG2S<^?:6TI P^X=>G4]P?SZ5]/_ +3_ /P5,M?'
M7@.?2?!RFQOI"RM(K$$ C'W@3Z_0^U?GAHMGKOQ0\;6SM#<:E=W-POFLBD\9
MR>>>V: /OG_@CG8W</CC6)I+9DMVR!(PQV'J.^,9S_#[U^P'.X<<5X%^R+\$
M=!^&?PQT>:RLE@OY(LRL !STQT''3\NIKWI6#X;;D]/<#KSZ=N* /G3]MKGX
M5ZG\V,0OQD9/R].O^>..]?B7^SF!_P -':+@# U%L<9_C^O%?MG^VY)M^%.I
MY8 >4RG)(ZKQWQG..,=_QK\2_P!G&3'[1VAG=DMJ+ %ARWST ?T9Z"N[0--
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MG).!P>G)..N* 'T444 %%%% !1110!7U!MEC<L.,1L>?H:_G5_;:(_X:)\3
M'<!*0/FSQN;C\\U_17?9%E<;>6\ML?D:_G4_;88']HCQ*%;*B4XY)[GG_/I0
M!U/[!N?^%FP]QYF>G3@>W'7U]/Q_?+PG_P B_9G@YC7E1@'@>P_S^5?@;^P;
M_P E-BXZR=>>P^F._MU/K7[Y>$_^1?LSP<QKRHP#P/8?Y_*@#7HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R:\=<_\%"K4
M88%;M<_+DC[I^[@X^F/RZU]2_P#!3YMO[.EUC=RS#:O\7 X_SGZ&OEKQSD_\
M%"+/CY1=+MV+GC(Y P?U'Y=:^I?^"GW_ ";I=#.-S,,<X/ X."#0!^"]%%%
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MV1]W!'/KW]:;M^7=C)ZA6/0\]_QH7.#MQR2.,$ Y//;\:!+W(P,@ GCJ/?\
M*@ Y5<#@#@9!;/3!ZUP'QJ^%-C\7O!MUH]]$)8G0[4<'J0>W'M^7:N_9CTXR
M",J"<]>#Q^- W/&#DJV,$8Q]3WH _%;X@_\ !,GQ OBS4)=)DDCM6D9XT3G!
MY/4C]21T/3M]Q_L$?!OQE\)[&2R\1W$TT$2%(Q(3M QV! [GOUS7V(]G#(VY
MHU9O4_6FQVMO;*PC2./:H[= .GX<?I0!(P^<$;=V.!G!./Z<_K63XB\'Z1XJ
MA,6J64=TA&"&'7_/^>U:[-]X9V#IN]S]?PI%78WRKQP,\# ]!_GO0!^</[4O
M_!+^/XC>*FUKPNRZ? =Q:.,#)RW/?C'^>^/B7XR?L#^-OA!I;:E;K/?/$00%
MVC'J!ZFOWZ5PV.5YY&#G(]?Y5F:QH.DZ]"8]1LH;M67E9$^8C!_'IG]: /YI
MGTSX@_<:RU<[?ESY+']<>U?0WP)_X)V^,?C5IJW\[36#OR48;3STZJ>,8K]L
M%^"?@7=N3PUIXP>-L?0@UT^CZ#IWA^/R-/M8[2,CB.,8[\GU[T ?!?[)G_!,
M^Q^#OBR35O$^W5L8,:R $#!XSQ^/'K7WWING6NCV<-E:1+!!&N$C7C@58W#&
M2<#..>.^*C;<S="><[6 Q[<^F1GUY% #FC+GD#G@]#Q^7?C-.QM88W8Y[\=:
M$78JJ.@&*:KEL?=/L,X&#SS_ )Z4 >9_'3X%Z!\:_"-[8:A8PW%W+%MBF;].
M_I7YI^(/^"/.NK)>3VNJF- S,J( 0 3G '/ &1_G(_7AI&P,+G/3.?UXXY-.
MW#:3S@>QS0!_-[\3?@7X\^#'BJYT2*TU"1!DAX$+;ADCG ^O_P!8\5QUSX9\
M=:PJ6\^EZI.K80*\# =>.WKCFOZ3=8^&WA77KMKK4=%M+N?<,O(,D'MWX/2J
M*_!?P0I'_%-V/'^Q],?E@?E0!^,?P+_X)G^+/BUHL.HW,LNGAP"R,-H /?D<
MCK^E?HA^R_\ L"^'O@S;QOJ=K'>W"#*L^"RG''..O)S[D^@KZUTO2+'0;4P6
M-M':6X^8K&,"K9;G Y/' Z_6@"&WMH+*W2U@B"PHN!&N, $^Y^OY&IMQX 7G
MW],TSY-N&;Y>>'/8#!^H^OK3F)4G&>1@<9 /\^_Z4 >0_M'?#RX^(G@F\TRW
MWB29&0!22<'.1P>^..GX5^;/PA_X)V^(_#7Q@T_6KIF-M;W1GV[2??H1S_3/
MTK]@VV21MYB_+_$'''K4:V]M"3B- 5Y+8SC '?MVH BTNW^SZ3:V_!:&%$.X
M9P0HZU<W#<!GGKBHRAC4;>.>,9P.,#C\OYT*2V3AL$CCD'Z\^V./KUH >555
MQC SGY?7/M2+C*_,2V".>"?4XIC2?>#':/N\N!CU]P<<_AVIVW:N6;:HR3\W
M'7.<T >&?M:_L\K^T-X'.C$[656 /4\^V1Z]?>OR]U3_ ()=^*-)UHI'<.\4
M3Y'TR""3CGOZ<<\<U^V^-H4* %Z>F!4<EK#,Q9XU9B,$XYH ^;/V._!NO^!?
M#T6EZL[.D,82-23M  XQD>F>/\CZ5E P>O*G(P6!_#\?QID-C!;DF.)5)ZG'
M)_S_ $'I3SC=P?FW<]3CCI[<4 *0-V-W7G&3GC'Z?XT+]Y@N %/(]S@_UIJ
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M7X1_&+X/Z[\'O%E[I.KV4END4[112/R' Y'/^>E?TU,H92",@\$&OF_]J_\
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M_=%:GB3PSJ/A'5IM-U2V:UO(3M>-NQK+H ***7:VW=M.WUQQ_GD?G0 E%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444J*9
M&55&68X% 'Z ?\$@_P#DL%YQZ=L]AUXX_3J>M?M*<[AUQT[8^O\ GUK\B/\
M@E'\&_%GAKXA-XBU'3VMM)N,+'(RCYL<D@D=_P"A[U^NN]?,''S9VYR/3- #
MH\;0 %&W@JO0<=*'3=]>V>1]<4A8[=X)Q@'!7^G7-/H C;'*CIW5>#R>O7ZT
M[ 7)/)/&<<]>!^M.HH C"B3EMK<;2."!ZC_/I1Y0W$@X8Y^; SSCV]A4E% $
M>[<2&7CC VY[]?Y?2AL1\@8ZXYP,D_U-244 , \L$GD8R>.2?7CKVH5"H7YL
M  #:H '^?\*?10 SE\,",=B#D$<4G*L H)&<G  ZGZ?7WX]ZDHH CVDL"PZX
MR%)XQD_YXH,9;[QSD8;C@_@?QJ2B@!K)NSWSP0W(Q]*#EE'&#P<$XQ^5.HH
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MQ0 Y5"J !@#@ 4M%% !1110 4444 %1RP1SKB2-9!TPR@U)2%@O)..U %/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/KVH_P"'=/Q>;&-)'/3@]\8_F,_48S0!\O45]0_\.Z?BZ<8TG(_W3GM^O(_
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M.01^O3T[T >RJIR23D_I3JB7+."?4GD$]..O;M^O6I: "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX[COVK]7=6!'A3P'GOX?@QQC_EK-^= &-12MG<<XSGMC'Z4E !1110 4444
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MT )O(?:<#GCGKQ].O'2EW<X((YP/RIJD=>02<G"$9SP,_I^5*R%H]N[/&#N
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MY[9X&.>/3WI5)QW8=.F#UP322*>N6P#GCL,=,8Y_^O0NZ-><L!U/X=NI/XT
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M$^0V/-(!/3[QX'Y_K0!U/[!B[OB="<  2@;L9QE>I/8<?J:_?'PGG_A'[(D
M$QKT ],>GM7X&_L'#_BYT!X)W_B.![?U_P#K_OEX3P/#]D !CRUP0#R,<=O3
M^7X4 :]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!^3?CI6D_P""A-HK#S?]*7&X9W<CD_>_/_\ 77U)_P %0#_QCG=@D@,S
MC .,\#@G/'^>*^6O'*;O^"A%FOE@_P"E+\I.Y3R.G7C_ /7[U]2_\%/FV_LZ
M76-W+,-J_P 7 X_SGZ&@#\(-+S_:=IC.?.3&W&?O#UK]7-6Q_P (KX$QU_X1
M^#/_ ']EK\H]-_Y"5KD9'FIU&>X[=Z_5W5O^14\!_+C_ (I^#\?WLU &2&QD
MC &<@,,_ATIK8R<<CMFE9GRP8MG.6!]?>D9BQ))R3R2: $HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $\<G;^SW\0F\PI\]
MF,*?^NW/4?YS^/Y9U^I?CIE7]GWX@\LK[K/YAZ?ON.H_S^OY:4 ?H%_P2"_Y
M+!?<?W>WM]/\*_:1N6V[MN0?K]:_%O\ X)!?\E@ON/[O;V^G^%?M'(1R&P5V
MG*XR3_G^M "_>49!7OC//Z4WR^H)8C^]N().,=J=DJHW<GH<"J&L:I%H^ERW
M\S*B1J&9P1C YZ]QU_\ K=: /DC]N[]L:#X#^&[W0H,KJ]U%MBD3AAD8R.>F
M3^E?C5HMKXD_:0^)]O:7-S)=:C?2G#MEBH+=,_CU/I7T+_P4T^+%C\3?BE$;
M)LBW8JP5L@$9!]^X]*]E_P""7?[,\/BBWB\<./WMN<HW&!SUZ8)Z ?0]Q0!]
M5?LM?L ^%/AW\/8;7Q3IB:CJ<J@LTH!(R 3VZ?7-?1FB_ WP9X?M_)L=&AAC
M[  <?3CBNY7]VB*5Z #Y>@Z#_/%'EG=G/&<@YY'Y_4T <1KWP3\'^)K7[/J.
MDQ3P_P!T@?X?YQ7R[^UY_P $^O#7Q&\"L/"&FPZ7J%NK./*098X)S^@K[89B
MQ(SA<CD@COT]\\_IUIX7*E6&0<Y!.: /YD-6T'6/@Q\1C;7T<MO<Z=<@,V"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR?SISE5R#N.[).#SC'4?IT]:_%'P7_P5&^).K>+]+LY\&"XF6-U4^N<_S^F
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7U!MEC<L.,1L>?H:_
MG5_;:(_X:)\3 '<!*0/FSQN;C\\U_17?9%E<;>6\ML?D:_G4_;88']HCQ*%;
M*B4XY)[GG_/I0!U7[!B[OB="<  2@;L9QE>I/8<?J:_?'PGG_A'[(D $QKT
M],>GM7X&_L'#_BYT!X)W_B.![?U_^O\ OEX3P/#]D !CRUP0#R,<=O3^7X4
M:]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !3?N*269L#T_7BD92S'MT[GL?2D5=RG(9<Y_B.>: #)?H<?>&5
M(('/\_\ Z].^\& )!Z9Q32P$@XZ_*>,'ID?UI NX  ;5'*G;C'&./0_A0!(.
M_.?Z4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/^"7/B6X\?3S^!X%_LYP?E5,J".@ZCMCGVKRG_AUC\7=W$<./>-O;_']#[9
M/TPF_P""DGPE2-RNI*S!2P'F*>G;ZY[>GY5^=O[3W_!1CQ-XTUZ_T[PW=F/1
MW. 58J<=NG?OWZY]*P/^'67Q=ZF*'W C;/;W]S^1]L^B?!7_ ()8^,5\512>
M*XE:S1L%5C.,=SR#U]_6@#Y/^#?P7\5_M*>/'BTV"2=I)E>>8J6503]#7[H_
MLL_LOZ%^S[X4LTL(O+OY(AYYP,Y(Z9'U_P FMOX%_LR^$O@7;%M$LHXKR51Y
MCJ@ SCG_ #FO6Y"=IW !.AW 8 YR3ST(H HZYI%OXBTR:PNE;R)EPW!&1C].
MOL>*_'C_ (*,?L5OX'\1#Q%X6M&:PD&955<CH3U'.?8]/7U_994VDX^7YL]<
MYX[_ .>PK#\8^"=+\=:-)IFK6Z7-O(-K;U!)&.: /P=_8]_;(UWX!Z_8Z1+)
MCP\\F+A&)X'N,'T__57ZGV?_  4F^$\EG"\VI!964;AO ^;'IC(''\NM?(G[
M6'_!,#6M4\>-??#ZW5-/E.701Y R<^O88[]_<5X6W_!+3XNKN)B@VC=\VQL<
M#K^/_P"O% 'WC\=O^"F/@BP\"W7_  BMZ)=38$+A\D<''(Z="?RZ5^1/Q5^,
M'B+XU>)I;W4Y9)WGD_=PY+'KQ^/2OHE?^"6/Q<##='"5SSMC;)'/3\OU'OC[
MN_9I_P"";GA/PKX3LI/%EA'<ZK&P9MR _,,?F./?GKZ  X?_ ()A_LRZAX"2
M#Q;>VTB&\4.NY=N  .3D9[_K7Z$^.I O@S6'SM'V5SE@>F/T_I5OP[X=L?"^
MBV^EV$*Q6D*[0H P>.2?K4/BBS?6/#FHV48S)/ 57:<]>A_S^!H _FW^/&'^
M,FO !,?:\84[E'.,=>1^-?KG_P $O5*^ B>S+D>G0>W]3VKX\^)G_!,WXF>(
MOB)K&IVL>^RN[HN&$?.#C)Z].WY_C^@G[#'P&USX&^$39ZT"&*XW,,8P!@>W
M'KZ4 ?5;*&()'([]_P#/%"KM&..I/ QWH5BV<KM[T+G))R.V#C\Z /PC_P""
MI3A_VAI2H^7$A# \'A/\_C7Z+_\ !,@JWP-LR%R_DH"V0??]?J>GTKYU_;C_
M &$?'?QJ^,$GB#0!YEI)&V<J6QTP,Y]!^.>W6OL']AWX*ZS\#_A7:Z'K.\7"
M1JOSJ1N[YZ>_\Z /HC4%W6-R,9S&PP,>A]>*_G[_ &^/"UYI?QHU.^F1O*DD
M8!F.3U) SGTQ7]!3+ECZ$8/S$5\1_M^?L;3_ !L\-QS>&H%&K YX'WL$G& ?
M<<X_+F@#X;_X)I_M)>'/@5X@U ^))A#;39568@=0<X__ %U^M/P7_:6\(?':
M6X3PS<BX,&=_S@G@<]/J/SK\?&_X)8_%K<NV./!XYB/''4\_RSWZ\9^V?^";
M?[)7C#]G?6-6N_$JLOVP$! #L&%(_K[T >)?\%EL)XBT-<8)(/4_W1_CZ=SS
MUJS_ ,$FV5+68?*29&X!'O[>_P#GK7L7_!1[]DOQ5^T5KVDWGAQ6?[+MW*0>
MZX/'T]<5-^P#^R/XI^!*O_PD"L))&+E1P!G&>V1Z<T ??J_<79\HXP,=OI38
MP>".%Q@9)S^O3O0T96,!.O/.<<X//3UIH5BP[@,<$CIR?7VXX]>F* /E7]O+
M]G%_C!\+KJ'1+?\ XFW+*5ZC"GG&>>3U[5^+GAOQ-XN_9>^(TOE*UEJ]JX#J
M1CH>>H__ %BOZ3U;:H^5MO8\D]NO?_\ 57Q-^V_^PCI7QBT&YU7PY:1P>))&
M8EE0GU(X!Z9;T]/P .$_9O\ ^"G?AZ^\/HOC.Y6*\8 EBW)P0#U^IY/OTZ5[
M)J7_  4H^%$-C<O!J2M.D99%:08)XXST[_3]:_-5O^"6?Q;_ (8HSP3\T1'X
M'G_/'O@/_!+'XN< 1Q'G&?*;';GKTZ^_'3F@"/\ :F_;R\1_$[6[[3M+G*Z0
MV1G<=K CTSD\>O\ ]>N,_8[^ ?B?XR?$ZPURUM))[.SN?/G<IG=W.,@C')Z@
M_P!1]0_LT_\ !+?6K;Q ;CQS"&A&%V[" N3^(QP>_I]*_2WX/_ OPM\#=)>S
M\/6J6\;?>98PN3]!WZ4 =IX9L3IOA[3K4KM,4"J1D'G'7BOQ[_X*Y/\ \7#C
M!;+%\X!/;(/&2.OT_'FOV3+A7YX)XY(_/KZG%?G#_P %!OV,?&7QZ\:QZIX?
M1G1)"VW!(Y&/7K^7&/6@#XK_ .";\B?\+TLU(W,&4A?KT['T-?ODN#$F%4CC
M 7!'X5^3W['/_!/_ ,>?"GXJV6O:Y$4BB8#:HQD;>3T/O^E?K"&,<: C+8Q@
MGD\=N>OXT "MMR,*/4+S\QZ]O?\ 6I*8JJV&!W#J._KR/SI] !1110 4444
M%%%% "'/;BJ^H9;3;G(Y\IL@<]C[?TJ=NG0GD=#CO5>^7_B6W*A<#RF 7'L?
MK_*@#X0_9[7=^U)J;X!_>D;N2><=^1V]?ZU]\U\#?L]@M^U)J;<%?-.>,GMW
MY]^_/OBOOF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ;)]W/3;SW/Z"D"C;L;YA@]02,>]+MYR"1SD_E2+)GMCH".I!/8X_"@#
MRWQA^S/X$\=7SWFL:1#=3L<[V4$YSG/^?_K5S/\ PQ%\)O\ H6[<XZ?(O/!Z
M\?3ICI7O*J%Z# QC';\J4=^<_P!* /"K']BWX7Z;?0W=MH,,4L+;D;RUS^8'
M\O6O;+&QATRSBLK8;(HEVJHQE1SBK&3CD<Y['WI,,H/\74X[GGCJ?\^U 'G?
MQ(_9_P#!GQ5NDN/$.FK>2KT+ $=#CJ/4YKB_^&(?A-_T+D'_ 'PO^'^1^=>[
MLOSC[N2V[WX&/Q]/H:>6 P"<9X% '@I_8A^$O./#< ZX^1>^<=NW'Z_@O_#$
M?PER2/#4'7.-B^AXZ?3\J]YW#<1GGKBAF"J23@#DDT >"_\ #$/PE_Z%N#M_
M OO[?3\NU!_8A^$O./#< ZX^1>^<=NW'Z_A[W10!X+_PQ'\)<DCPU!USC8OH
M>.GT_*D_X8A^$O\ T+<';^!??V^GY=J][HH \%_X8C^$NX'_ (1J C/0HO3/
MT],4B_L1_"=<8\.0#C!(1<GCD]/\^]>],VU23V]!FD7=WP>.H]?I0!XQX=_9
M#^&OA;5H=1T_0H8+F(Y4JH'/Y>G\Z]DCC%K"D:ABB# X'  ]!_2GB0;2?3JO
M4CC..*:RC!+X"\D\GCMD'MQ_.@!RONS[>G(ZD=?PIU%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7U$XT^Z.<?NF[X['W
M'\Z_G6_;<R?VBO$^0V/-(!/3[QX'Y_K7]%.H?\>-SEMH\MOF/;@\U_.K^VUD
M_M$^)F*X)E.>,<[FXZGL10!U/[!O_)3(AC_EH#D9[+CGC_:]OY5^^7A/_D7[
M,\',:\J, \#V'^?RK\#OV#%W?$Z$X  E W8SC*]2>PX_4U^^/A//_"/V1( )
MC7H!Z8]/:@#7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HIH=2<!@3SW].M*6 P"<9X% ",I9@?EXP1D=/7]*#G9R
M.>N%/?TI&!W< G./XL#@U\W?M4_MF:+^R_<V4.JQ?:'N2"JY&<>F!SW_ "'Y
M@'TAMVXRS$<9ZY)XQTIBIM)#,">AVCG![C'(Y_E7A/[+/[5FE_M-:3-J&F0&
M".+<"I]00.OK[?7VKWIE8GJ/4'GCCN._>@!]%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY_VNV?Z\YQ2G]NCX6!N/"2;1_=N9AZ=/FXZ?^@^^ #MO'7_)O7Q#PVT[K/\
MB '_ "VYZCD?Y]_RTK[A^-G[97@[Q/\ #W4-!\*:,NDF_56N#'+(^]ESM'SD
MD8);IC@CIV^'J /T"_X)!?\ )8+[C^[V]OI_A7[2'.X=<=.V/K_GUK\6O^"0
M7_)8KT8R?E/3V^G^%?M*WWU]>><=OKV[?E0 )]U>2>.K#!IJMMX.X?+G:>3Q
MU]R>GZ4Y/NKR3QU88-,/WPJ\#/\ ".AZG.#W!_SQ0 &01_*!A5XVC ^G?\*?
MRJGJQZ]L_2F[@S+_  MT[9'0[?R_E2*NU<A6&!TPO/7"_A0!(&#<@Y[4@D#-
M@']1ZX/Y4A)8[EPV 1][C/I2_?52.5/.0: $WG^X?NY([_3T_6G$].,_TJ)8
MVSDC<>^[@9R.<#^OH/>I/FST&,^O;'^- #=VX@;<^JXR0>._3BE^;GG!/ XR
M!UYH;#+N93C;RO7\,=Z3=N<J3C';G)Z'-  5+'..-P.UO;OW]C^%-93'@YRQ
M/; +<?D3Q[<4YFWJ5^4AOE!QD9YSD4#*L>,[F[CK[Y'MQSZ4 *DF_I@CU4Y'
MM^AI5;</0]QW'M2;=XR"0&'/4'']#2;F4\Y(&2<#/KC^73Z4 .^;:.!N[C/'
MO31-G&0 "<=>G;'IG/&*:8SNXZ@ !N,^G4Y.1S^=2$A7'&"W&>.W;^?ZT -&
M5PQ4CGIN)//_ -?\J5%/7[HZ[<#OZ^^<_G1&=X#%<-C^>/\ /X4*HC4DD* /
MH !0 +)N&0I_,>N".O:E9OF"@_-QVS_GH:;'@-C;CL#SD@>I/XTNUN QSW)'
M'/'3VH 1?NG;]XC.YEZ\=3T]*1CCY$&-O.T<'C' Z4C1[F.!@MD\CW'/IVR,
MU)NV8R>/[QQZ\#]: #=M&6PO..OOQ0V1DG@+S\O.1CZ4BY;#8Z^I/3G''K2J
MJE5(7'\0XQU__70 P?,2?F(S_"W'7'Z8Y'N>M2#COFF[6RW. W?N.!38U;=D
M\=^G/4\$Y/3- $@/7C']:;YA;&%//(W#'''^/>F*PC(X &".%P>.@'X9J14V
MY_('OCW/?O0 C-Y:C))P.6/ZD]J<S!5))P!R2:;(=HR#\^"%'J?IGVI$?<Q^
M]CL""/Z>_P"GUH :JG@%EW<J2H)(SSU[=C3WDV^A/<9P>>GYFEW$Y(Y'3!!'
M?FHUR3A3T"D<D''N#]/_ -76@!Z?.JEAR.02,=NH';K35D5%_P!DY(88Y[\8
MZ]_RI0HVY5 !M&WJIXZ \<#_ !-.7!)8#GIG&#Q0 ZD# Y .<<&HUC.6R>O!
M8]2,>H/'/^>]+RGS,V1SG)P /\C^?TH <[%<87=]/I3=O0N22.!CKUZ\#OQG
MM2,OF?>&_'!XQU(]^GKZ_I2G,A(((3D=!@].N1]?PH 1,ME=^",]/?O@].<X
M[4]6W=L9Y'!Z<=?2DW;QM(YQAMIZ'T]>](1^\^7&>,_XGGVQ0 JRJR[L@#;N
M/(X%(7#;E/3IQG/)(_R:1HVW*!R%Z>W3N<G.,_G3MI6,+DDXQD=?KS0 F]5;
MC;\W7'7.0/\ /I4E(#GMBEH **** "BBB@ HHHH :V,<G R.^.]5[[YM-N.K
M9A;[PY/RGMC^GX588[1U"\CK]:@U '^S[H'G]V_;V/UH ^#_ -GO)_:DU,\D
M>:>=N1V_BR?_ *_X5]\U\#?L]DG]J34SM)'FGY^H[<9YZ_7MWK[YH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DQ\P/]:6B@ I
MK;NP!X[G'-.IK;NP!X[G'- ",RJPSC=TSQQG_$BC:N0&PS8[XR<=_P Z7:=W
M7"]>N<]>*9MRNT!AT^7.W:,8QD?C_G% "[FSW&<$Y&<=../Q[\4OWL%3\K<[
M@<^G3VIEQ<10(SRNJ1KC+9[]?\*\(_:&_:T\,_!7PY/=B]AN+U Q$(().!V&
M>?\ ]5 'N-QJ5G:R>1-.JNW\#').:L+(LRYC<$CH>W<?B.M?BKJ'_!2#6_'?
MQ'M+DO+:V32@^6IP",C Z=<$]NU?K#^S_P".8_'W@.TU))?.WHIW+D@Y&<_C
MGCOC% 'I/#94\KDJ5//O^ Q_,4VXFCMX2\[JJ 8;(X-2##'<#G&1P>*^*?V\
MOVQM/^$?AFXTO2;Q7U5TPT:N"1G/8=_Q[T ?56M?%;PKHEI=2SZW:*UNC.R;
MQGBO@[QQ_P %<-%\,^*;W2[6Q^UPV[,HF &#C@?T/^/;\L_%'QN\8^)-8O+V
M77;I5N&.8U<[,?0^U<)-,\\C22,7=CDL>IH _H%_9C_;@\+?'[3+B:XO(=,E
MC7[DC[>^/0<G_(KZ.TCQ!INO1N^F7D-VH/S-%R.U?S :+XLUCPWN_LO4KBQW
M=?)<KFOL[]AO]O#5_A/K\&B:_<R7ME=R;/.E?U/&<]>2: /W <-R1SUQM.".
M/?@G-)N+D;3D?PL <=./J.M8'@GQOI?Q \/6>JZ/>1W<,T8?<K=,CT'7FNA9
M0?[W)YPQ&./K0 JXQN QNYZ8-.IB*1]X L/XOKU^G/:GT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %?4/^/&YRVT>6WS'M
MP>:_G5_;:_Y.)\3$C#&4Y'_ FQGD\_X5_15J!"V-R3T\MLX..Q[U_.M^VUG_
M (:)\39Y_>G)VX&=QS_3\Z .H_8.'_%SH#P3O_$<#V_K_P#7_?+PG@>'[( #
M'EK@@'D8X[>G\OPK\#?V#?\ DID0Q_RT!R,]EQSQ_M>W\J_?+PG_ ,B_9G@Y
MC7E1@'@>P_S^5 &O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 -8;AT#<CK]:%PN 0JY)P!W[TI..V:8N'Z%0V<N%/X=?J/T
MH .1R=PR<>IZ\<>E87C/QQI/@/1+K4M8O(;.*&)I/WK8!QGN:W?-7 PX)ST8
MX/)'^(_2O#/VJ?V?=0^/WAE-)LM2.GJ!\S!MN[VH \3^&O\ P4Z\'^-?B=+X
M9GEAM[996C2Z?A6PV/O#CT^I/TS\V_\ !7KQ/X>\67F@SZ1J4-_,ORMY;\*<
M@'OQQCM74-_P1]?1HY-0M?$#QW<*F0-YO<#)YS^/UKX*_:0\'WO@#Q,VD7.M
M-J;0MY8_>;@J@$8X)% 'Z3?\$_\ Q1X(^!?P!O-<O-1AM[L0%W21E5MW4]N>
M#GTR3T)J_P##S_@JUH_COXFV?A=+ 0QW5RUO',5QN^8 $$\=,GO_ $'P%^RE
M\'[SX^3MH4OB%K.*4F);8M]XYQP/^!=![U]R_#?_ ())V?@;QEINNMJQG:SD
M\U$+ @,#D=<X/3D4 ?H[87"7EG#/&5*2+O!48!SUJQ69X=TUM'T>VLWY:)%7
M(]@!_P#6_#\3IT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 PJN[YMI+$8XYXY_P 32LVU2>,]
MLG SVH*]<,PS_G-!(C7IA>23P .^30 FWYL[%^]G/?IC/3KVJKJFL66AVWVB
M_N8[6'.-\AP*L22&.W=^K*I/0@9%?C__ ,%#/V[-7UK5=1^'^B336?V.0K)<
M1$#OV(Z\#'].] 'ZM_\ "U/")7(\0V!'7/FCW_P/Y4G_  M7P@"P/B&Q&WKF
M7'M_/BOYKE^+/C%6!'B34./68F@_%GQB<?\ %2:AQ_TV- ']*3?%3PBN<^(;
M 8Y.91ZX_G2GXI>$AG/B"Q&/^FH]_P# _D:_FL_X6QXP/!\1Z@><C]\<C_.:
M/^%L>,/^ACU#/KYQS^= ']*?_"T/"9; \06)/3'FCW_P/Y5OV5];:I;I<VLD
M=Q"_21>AQR/UK^9&V^,'C.UF61?$5\Q7D!Y217Z'?L)?\%!-5FUK2_ VLA[B
M6[*HLCC(SPO7'TY//3K0!^L^ L?(V_Q$+GKU[=:16*D*!P.,*N!VQ^0--MW5
M[>.8\;D#9?J,@?E3E=]VT@$XY[=^O4]>WTH DHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **:Q*J2.W/3-"D\@]0?3% 'Y.>--I_X*!6BM^\!NXR5P6Z
M8[<_R[]NM?5O_!3+2-2UK]GJ[ATNVDN;A2[;8C\W1:^5/BEH>KZ?^W=;ZLUN
MS6*SJSR/AEX)SR<\YY]@!7Z5:GXP\-:Q9V]OJ0CO(9%#%9%!^8C_ /7QWY],
M$ _FW_X5CXLZCP_?L/\ 9A)]/3ZC\Z3_ (5GXJ_Z -Z/K$1GZ5_18MG\,6QG
M1[)\\Y:#<>N!W[G]>O-*+/X8G&-*M>?2!N>G/UY'/T]J /YTO^%9^*O^@%>?
M]^Z/^%9^*O\ H!7G_?NOZ+19_#$XQI5K[8@;VQ_,?^.^@H%G\,3C&E6OMB!O
M;'\Q_P".^@H _G2_X5GXJ_Z 5Y_W[H_X5GXJ_P"@%>?]^Z_HM%G\,3C&E6OM
MB!O;'\Q_X[Z"@6?PQ.,:5:^V(&]L?S'_ ([Z"@#^=+_A6?BK_H!7G_?NC_A6
M?BK_ * 5Y_W[K^BT6?PQ.,:5:^V(&]L?S'_COH*!9_#$XQI5K[8@;VQ_,?\
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M?BK_ * 5Y_W[K^BT6?PQ.,:5:^V(&]L?S'_COH*!9_#$XQI5K[8@;VQ_,?\
MCOH* /YTO^%9^*O^@%>?]^Z<OPN\6,P4>'[XL>0HB.?6OZ*Q9_#$XQI5K[8@
M;VQ_,?\ COH*3[)\,!@C2;/C##]R0.Q'L.H_/WH _//_ ()5_ GQ!X0\9/X@
MU>TEM$D 95=#P"..W0\?CCKV_6*O/],\4>$=&_=Z7%!:@8(\M2O7!^O.,?BO
M7-3R?%#34_Y;\#!)7!X]?;[PQGT^M '; MG'!.!G@@>__P"JG$9Q[>]<5_PL
MS3509G4;5.1G!X[\^YQSW!Z\4K?$S34SNN.G)VCV;V]1^G/>@#M:*XIOB9IJ
MYS<9P2"5'L3CIU[_ )9[T-\3--7.;C."02H]B<=.O?\ +/>@#M:*XIOB9IJY
MS<9P2"5'L3CIU[_EGO0WQ,TU<YN,X)!*CV)QTZ]_RSWH [6FE5)R5!/';TZ5
MQC?$S35SFXS@D$J/8G'3KW_+/>AOB9IJYS<9P2"5'L3CIU[_ )9[T =K2*-J
M@#MZG-<6WQ,TU<YN,X)!*CV)QTZ]_P L]Z&^)FFKG-QG!()4>Q..G7O^6>]
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M_BYT!X)W_B.![?U_^O\ OEX3P/#]D !CRUP0#R,<=O3^7X4 :]%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSSTX_(>G.7_PHT%N;V7!Z_/CTS_-OR'M7KG\0.?PIDK,JDCC ))/3I]1_D4
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M_B?\*+C_ (;QEP/EW$#'H.!TX ([\_CZW10!Y)_PHN/^&\9<#Y=Q QZ#@=.
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M'&#GG''-&X<=>3CH::9(W_C'(QPV.N/\1^='F1D@AP><_>]@/ZC\Z '9^5F
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5^:/_!9#/_"'Z3RW&!@>[#)ZY[ ?CS7Z75^:/_!9+GP=HXZ]
M\=?XD^O\OQ] #\A:_7+_ ((UJ3X8UHGIN;# 9!YY&[&?[O&>U?D;7ZX_\$:U
M_P"*9UIB WS%0V"2,<]<8[GOQT[B@#]-Z*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-\>/VVO!GP,N/)OKF&Z?.#L<''7/?_/YU^3O[4'[>GBWXH^.KV?P_JCV>AR
MJL2$@$;O0-[?K0!]@?MT?\%"],L_#=WX9\(W6=2;*N\;CIG'!SGL.W?/;C\E
M_$&OWOB;59M1OYFGNIN7=J@U34[G6+Z6\NY6FN)3N=V).356@ KJ/A?_ ,E"
M\/X7=_I:?*._/2N7KJ?A;S\1/#XQG_3$[9[_ $/\J /Z4OA.,?#?P[_UZ*>
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MC'';T_E^%?@;^P;_ ,E,B&/^6@.1GLN.>/\ :]OY5^^7A/\ Y%^S/!S&O*C
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MZI,I5B",$<$&@#Z1_P"'@'Q?Y_XGK#\6]_?W_2E'_!0#XO;N==;'LS>_O_G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?:MK[S;E.>Q[],_UH C52Q ;HP.5()X/4'G'I^1J:F Y;[QSDG:>.G'Y4^@
MHHHH :S%>BEN,\8_*D<[3G.T 9+'H!QGO2LH;KGIC@D4)SDXP#R,Y]/0]* $
M_P"6F2#G&!QQ[\_YZ5\G?M[^--;\&_#J]NM'N&M;@(<,K!<\<#KZ#O[<5]9*
MQ89Q@=O7_P"M7QY_P42.WX7ZAA<9C;C@=NO7\?Z4 ?A_XT^(&O\ CO4)+G6[
M^:[E+$XE8G'MSSQP/PKG*EN_^/J;_?;^===\/OA+XD^)&I6]OI6FW$T,KA3.
MJ$J 3CCUZ4 <I:Z?<7\S1VL+W+CM&I/XTVZLY[&4QW$30R#@JPQ7[!?L6_\
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M1110 4444 %%%% !1110 4444 (1N_\ UTS=M( P6S\^T>P_+M^%/9@JDDX
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M(XP /TK8VYQNP2#D<=/\BA2>0>H/IBG4 %%%% !1110 4444 %%%% !1110
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M&?4E?Z5?L_\ @DKXNFO(HVO9MC$9.T'_ -ES7Z\_",D_#3PYG_GS3_/2NNH
M^?/V/?V;A^SEX)_L@C,DB@,203GC/OV_(#ZU]!U&DA;C\>>#@]#C].?0U)0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ/YMQ.& STSU[?ET-24 %%%% !4>?,V\KR"58')] 1QZ&I*;MSG/S#.<'M0
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M ,;O0GMWK\T_^".)_P"*0U3YE/#<#D_>/?'Z=L&OTM(W?_KH 6BBB@ HHHH
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M\1M;\;>)K_6;S4+H3W<A=AYS<=L=?<_F:Y]M1NV8,;J8L#D$R'.?7K["J]%
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M1/#XQG_3$[9[_0_RKEJZGX6\_$3P^,9_TQ.V>_T/\J /Z4?A*-OPU\.<!?\
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M?A;^P1X,?QA\58HDB\UHW4X(X/?.<8X..OK7[W>$=.?1O#]M:RA@T2X((.>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXRT[2?@;JVGRSQI=RC*(S 9^@[\_R- 'X SDF:0GKN.<_7Z4RAL;C@8';-%
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M[XY_,_A7Z6U^:7_!')<>$-6.W&2><=>G?'/YG\*_2V@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5^:/_  62Y\':..O?'7^)/K_+\?3]+J_-'_@LESX.
MT<=>^.O\2?7^7X^@!^0M?KC_ ,$:P?\ A%]9)7=RP\SMUSC..HRHQ7Y'5^N/
M_!&J,CPSK3$-G+#<5.#\V<9/L5_SS0!^F]%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5S'Q+D9/ ^K;#AC"P&.3TSTQS^E=*ZEL8"Y[%NW'
M6LSQ!IZZQH%W:  "2,H!NP%[<X/;^E '\ZO[54D\OQ*U%IBQ_?OU)(^\>_?O
MZ?CV\712[*HZDXKZQ_X*%?#^3P3\37+IY9GE+%<GN#SR3W#?YZ_)M '[R?\
M!,F"*W^!D"PA0& )X /4XR,>A]3T]J^H?'7C*S\#:#/J=[*L4,:$Y8@=,?X_
MYZ'XW_X)>>,M'L_@/$E_JMO;W0VY260#C&2>1[^I^]UKI_\ @HA\5M(T_P"
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M%% !1110 4444 %%%% !1110 54U?_D$WO\ UP?_ -!-6ZJ:O_R";W_K@_\
MZ": /YTOVR3_ ,7VU_[W^M;ACG'/KD\_C^5>9_#<X\>Z#SC_ $M.^.]>E_MD
M'/QTU[#[QYIYZCKU!R?Y_E7FGPW_ .1]T'G'^EIV/K[4 ?TI_"3Y?AAX>W-M
M_P!#4[L8QUYKL:X[X0_\DQ\.[0I/V1?7&>:[&@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *_-'_@LESX.T<=>^.O\ $GU_E^/I^EU?FC_P62Y\':..O?'7^)/K_+\?
M0 _(6OUP_P""-2_\4SK7RKD,23M /).#TST_F3WK\CZ_7'_@C6#_ ,(OK)*[
MN6'F=NN<9QU&5&* /TWHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-6.W&2><=>G?'/YG\*_2V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YH
M_P#!9+GP=HXZ]\=?XD^O\OQ]/TNK\T?^"R7/@[1QU[XZ_P 2?7^7X^@!^0M?
MKC_P1JC(\,ZTQ#9RPW%3@_-G&3[%?\\U^1U?KA_P1J7_ (IG6OE7(8DG: >2
M<'IGI_,GO0!^G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36."O
M(&3W[\=J=2%L8]_:@!D>5 &#P -H  ZXR/\ ]=*I;)S^/L<#@<<BF*IDX;D8
MPP)!)XZ$=._;VI[%MR]AN[>F._'K_GM0 UE2:,QRKN#<%) .>^/0_P#UJ^0?
MVK_^"?OAOX]:B^O0[+.^B0MY<:XW';^1Z#\_:OK]MQC5LX(&?NGT],_I0I.X
M@ENI XZ]_3\/_KT ?SV_%C]A_P ?^#/%=Q8Z5HLU]9AB(VCW,>N!]:XG_AE'
MXGA<GPO=@>\;#T]O<5_2"VEV,_S/9P.3@Y>(9]NHIG]BZ;N ^P6N>2!Y*^H)
M/3UQ0!^#G[-W[ WC#XE^.8[#Q'I4^FV .UC*"GUY(ZXS7ZV_LY_L>^&_V>U!
MTS;+)C:6VCG'X>O^<U[W;Z;9V; V]K! 1P#'&%_D*L'GOB@!DN<KV'0G=@<X
M'Y_Y[UR7Q:\IOAIK\LZ+M6S9N>W3UQ_2NO\ NAB22.O2LWQ+HL/B70K[2IRP
MBNHS$Q /<9_R: /YLM:\"ZU\1OB=XAM_#NG37Q^V2 "-2<<].,^E?;W[!?\
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M3DB4CO\ WF/?ZU_15J!"V-R3T\MLX..Q[U_.M^VT"/VB/$H.6_>GYCG&=S'
MYZ<_K0!U'[!O_)3(AC_EH#D9[+CGC_:]OY5^^7A/_D7[,\',:\J, \#V'^?R
MK\#?V#?^2FQ<=9.O/8?3'?VZGUK]\O"?_(OV9X.8UY48!X'L/\_E0!KT444
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MUQWPDPWPP\/<>8/L:C'7/7CFNQH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS1_X+
M)<^#M''7OCK_ !)]?Y?CZ?I=7YH_\%DN?!VCCKWQU_B3Z_R_'T /R%K]<?\
M@C6#_P (OK)*[N6'F=NN<9QU&5&*_(ZOUQ_X(U1D>&=:8ALY8;BIP?FSC)]B
MO^>: /TWHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIWI]1JK;CGO_ !#&>#T_(^GKS4E !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-'_ (+)<^#M
M''7OCK_$GU_E^/I^EU?FC_P62Y\':..O?'7^)/K_ "_'T /R%K]</^"-2_\
M%,ZU\JY#$D[0#R3@],]/YD]Z_(^OUQ_X(U@_\(OK)*[N6'F=NN<9QU&5&* /
MTWHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY:KEFW= !C./8?SY[ 'N*J<DG@]\  ,<#FGT44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% %?4,FQN0.OEMC'T/N*_G5_;9
M8-^T1XF8=#*?3^\?3MC%?T5:A_QXW.6VCRV^8]N#S7\ZW[;3%OVBO$V<@^9T
M)!P-S<>W.: .H_8-_P"2F1#'_+0'(SV7'/'^U[?RK]\O"?\ R+]F>#F->5&
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M110 4444 %%%% !1110 4444 %5-7_Y!-[_UP?\ ]!-6ZJ:O_P @F]_ZX/\
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MV@'DG!Z9Z?S)[T ?IQ1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?FE_P1R7'A#5CMQDGG'7IWQS^9_"OTMH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "JFK_\@F]_ZX/_ .@FK=5-7_Y!-[_UP?\
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MZ'IW[5QW_"YO!(S_ ,5'8X'4^9T'/)].011'\9O!4F?^*BLP1U&__#WR/PH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5BH9CDG!(Y/K[>W;I7]+EPS+:S'[K!6Q@^W%?SL_MPL6_:(\1%B6.\C)] S
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MP;@#R<;N_((Q^7Z=*D^;=V*_K_GK0 JYVC(P>^*6BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *_-'_@LESX.T<=>^.O\2?7^7X^GZ75^:/\ P62Y\':..O?'7^)/
MK_+\?0 _(6OUP_X(U+_Q3.M?*N0Q).T \DX/3/3^9/>OR/K]<?\ @C6#_P (
MOK)*[N6'F=NN<9QU&5&* /TWHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'//S''.WD\ ]OT8>ARZS_P""KNMG6+2)\+;MM#[@>P_'HW/X&OS,HH _I%^
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M([=?;/T_+G%?FS_P4&^*$GQ&^)SF1MQM963&[IR>V3QUQ7RA0!_1;\(?VR?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCDG'&2,&@!U%%% !1110 4444 %%%% !1110!S'Q,_Y$'7?^O5J_FK^+6?\
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M:#^/L<9_.C.0IR<AN1U(SVX^H_SS0 [YAC!W?7ZTWE\%2I'56&?3CZ]Z% 4
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M%?T1VG_'K#_N+_*@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% ',?$S_D0==_Z]6K^:KXLG/Q*\2<8_TV3^=?TJ_$S_ )$'7?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-'_@LESX.T<=>^.O\2?7^
M7X^GZ75^:/\ P62Y\':..O?'7^)/K_+\?0 _(6OUP_X(U+_Q3.M?*N0Q).T
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M =@GQ@\:1QB-?$5Z$& %WCMT[4O_  N+QI_T,5Y_WT/\*XZB@#L?^%Q>-/\
MH8KS_OH?X4?\+B\:?]#%>?\ ?0_PKCJ* .Q_X7%XT_Z&*\_[Z'^%'_"XO&G_
M $,5Y_WT/\*XZB@#Z+_98^*GC#4/C=X=@FURYGB:4!A(00!D9/3TK^@SP[*T
MV@V#N,,85R/3BOYS/V1/^2]>&SC.).^/4>H(_P _A7]&/AH!?#^G =H$'(P>
MGI_G\: +X4;@ .%XQC 7CJ./?%24@SWYI: "BBB@ HII8 XSSQP.3S0SJO5@
M.,\GMZT .HHI"P7DG':@!:*0,&Y!SVHW?,!_2@!:*0,#D YQP:Q/%'C31_!M
MH;G6+R.SAQG=(0 >"3U^GZB@#<HKR_\ X:6^'/;Q+:G_ (&/\?I^?L<2VO[1
MOP]O+A(8?$=J\CG"@..?U^GY^QP >ET5#:74=];1SPMNBD7<I]JE+!>2<=J
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M":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5.N=HSR>^* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$@3+,!QZ9[\ <\5\,4NWY<D_2@#]P/V6_P#@HMH/Q(TN)/%-Y':7T@"_,_\
M'^7'?_(K[4T?6K/Q-I<=_ITJS6\PP&(X(]#^>:_EQL[^YT^:.6VGDADC8.K(
MQ&".]?K)_P $T?VKKWQ1):>"+ZXWF/;M+G!/0;>.G3\?PP0#].4<,%8C)QP0
M.Q/K4E,,?S;@<?J>WY#BGT %%%% !1110 4444 5]0R;&Y Z^6V,?0^XK^=7
M]ME@W[1'B9AT,I]/[Q].V,5_15J'_'C<Y;:/+;YCVX/-?SK?MM,6_:*\39R#
MYG0D' W-Q[<YH ZG]@Q=WQ.A.  )0-V,XRO4GL./U-?OCX3S_P (_9$@ F->
M@'ICT]J_ W]@X?\ %SH#P3O_ !' ]OZ__7_?+PG@>'[( #'EK@@'D8X[>G\O
MPH UZ*** "BBB@ HHHH **** &M]]?7GC/;UQW[?G7 ?'S=_PJ7Q&4.'^RMC
MG'.#Q_\ 6[^U=^WWE';VSUZ]:\_^/V/^%1^),G:/LK_-Z<'GZ"@#^;7QQC_A
M,=9QR/M4F,_[QK]B?^"0:_\ %H;T[1T'S=^OT_SC\OQV\<'/C'62!C_2I.!_
MO&OV)_X)!K_Q:&].T=!\W?K]/\X_( _0.BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#F/B9_R(.N_]>K5_-7\6L_\+*\1Y.3]L?OGO7]*GQ,_Y$'7?^O5
MJ_FJ^+./^%E>),<_Z;)_.@#]3_\ @CDN/"&K';C)/..O3OCG\S^%?I;7YI?\
M$<EQX0U8[<9)YQUZ=\<_F?PK]+: "BBB@ HHHH **** "BBB@ HHHH ****
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M.6K<@<-U_#_]??@'BOY_: /U$_X)1K_Q/$;8O!"[NXY7CI_7L.!7ZR5^3?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OS1_X+)<^#M''7OCK_$GU_E^/I^EU?FC_ ,%DN?!VCCKWQU_B
M3Z_R_'T /R%K]<?^"-8/_"+ZR2N[EAYG;KG&<=1E1BOR.K]<?^"-49'AG6F(
M;.6&XJ<'YLXR?8K_ )YH _3>BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KR_]H@_\6YO^?\ EF_'K\O3K_G]1ZA7E_[16/\ A7%_GM&Y&>_R].N>
MGI_+- '\\WQT.?B1J7.?F/?_ &F]_P#/M7V)_P $@1_Q=^^X!X']/\]NIZXK
MX\^.C;OB/J??YC_Z$1_2OL/_ () C_B[]]P#P/Z?Y[=3UQ0!^TM%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% "!0O &.]'.X\<4M-XW'GYL#(S]>U
M'XF?\%<6!^-T//\ >]NY[=_K_C7P97WI_P %<L_\+OA!)SAOO'!ZGMZ>_P!/
M6O@N@#]^O^";*[?V=-.^7:3M.=N,C'T'O7U:,]^:^4O^";*[?V=-.^7:3M.=
MN,C'T'O7U8O3A=O)X_'K0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD^\S?T]* .E^)WQ6U[XL:_+JVMW+RSR'<5+EAD_6N/\ EVCGYNO'\J:JEF
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M<?L3_!74OB5\3],OK:-GM[2=68*N>,\_7IC\:_H&\.V[V6@:? RC?% D9"C
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M_;)/_%]M?^]_K6X8YQSZY//X_E7F?PW)'CW0<=?M:?S^E ']*GPCW+\,?#O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/'?]?Y4 ?EY_P5E^&<_B.:'5XU/^CKNR#TX]">X'\O2OR>=2C,IZ@XK^@?\
M;M\&1ZQ\*=2O2OS)&V,8'(!/J/3.>/TK\ =64+JEX , 3. !_O&@"K7[9_\
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MZG^=>9?#?'_">:#GI]LC]/7WH _I4^$F5^&'A[)Q_H:G*KSW[8KL:X[X0_\
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M+PD<8\06)S_TU'M_B/S% ^*7A(XQX@L3G_IJ/;_$?F*_FN_X6YXR_P"ACO\
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M&2J-WZ@@C\,>N:_(.@#]1/\ @E#&6UQ2$!(P-V.1R..G3CUXQT%?K)7XC_\
M!/\ ^/>F_"74HY;^<1(!WX[#G'T[ ]_2OO\ ;_@H!X25MOVV$]>001Q^% 'U
MS17R*?\ @H%X2'_+Y$>Y_P XI/\ AX%X3_Y^X_S'X]O_ -?;- 'UW17R)_P\
M"\)_\_<?YC\.W_ZN^*/^'@?A+_G[CQ^'^'^?I0!]=T5\BC_@H#X3/_+U'^A_
MD/K^7TS&W_!0;PH'4"YCVGOQZ_3V].XZ4 ?7U%>8?"GX_>%OBE!''IVHQ27A
MQF+<-V3GL.E>FG(4#/S'C.TXSB@!U%(K;E!'?U&*6@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBF(Q.WY@P*Y!4<?7- #Z*:S'=@%<X)"GO
M_G^M(T@52P(/7G/''J>W2@!]%5+[4H-)LY;J\E6"VCY:21@,#/\ +]:^?/B9
M^VEX-\$ZC]EMM2AN77*L%8'Y@>1[=1_G@@'T=17R)_P\#\)9_P"/N,<9[?X>
M]/;]O_PDO6]B'7'OC\* /KBBOD3_ (>!^$PV#<H.H.<#H?I_GZ\4?\/ O"?_
M #]Q_F/P[?\ ZN^* /KNBOD3_AX'X2_Y^X\?A_A_GZ4?\/ _"7>[C'Y'^0H
M]Q_:.)7X,^)B&9,6Q.Y.H]QR/YU_-IXHR/$FI@]1<R Y_P!X^_\ GVK]J?C5
M^W%X9\0?"W7+&VNXVN+F!D" @$J1Z8'^3^?XI:_<?:M<U&8'<)+B1@?7+'F@
M#W+]A9&D_:(\/!5W$N <+DXW#GH>G7UX]J_HBM5*VT0(P0@!!^E?S=?LJ^,;
M7P+\9-'U:[*K#"P)+8QC<.,D']/S&*_9)/V^O"26]N/MD>YD''')SC@ ?3CZ
MT ?7%%?(G_#P/PEVNXSZ=!G]./QH_P"'@?A+M=QGTZ#/Z<?C0!]=T5\B?\/
M_"7:[C/IT&?TX_&C_AX)X1_Y_(\>N/\ ZU 'UW17R)_P\"\)_P#/W'CUR/\
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M*^1/^'@7A/\ Y^X_S'X=O_U=\4A_X*">$\$BY1NOH,XQZ_7]* /KRBOD4?\
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M58Y"X'5N@H =14>_;DG@#D[N !_D?K4E !1110 4444 %%%% !1110 4444
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MR;_OH^N:HU]T? ?]ESX;:Q\+='\2^,%U&235"ZP+IZ)(1LV[BV]EQ]\8Q_\
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MP1R7'A#5CMQDGG'7IWQS^9_"OTMK\TO^".2X\(:L=N,D\XZ].^.?S/X5^EM
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MS\O( QGXEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]#?\
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M_P!-O7'Y?C0!^<_]N:@,?Z9-_P!]GV_P_P YIRZ_J*J!]LEX]3FOT6_X9;^
MG_/OXBZ?\^L'IC/^N]>:7_AEWX"=K;Q%^-K!ZC_IMZ#]30!^<W]N:AC'VR;I
MC[Y_SVIW]O:CG/VR7KG[WMBOT6_X9<^ I7_CV\1!N?\ EU@/8?\ 37GO^?X4
M[_AEWX![L_9?$6W.<?98/7I_KO3C\: /SG_M[40H7[;-MSGES[?X"K>C>)-7
MM=0M_LVH7".95QB0YSGWKZK_ &F_V6_"OP[\%VOB7PZ\PLKL,T23C;)A6V\A
M2>X/3/7FOD/2^=3M 5WCSD^7U^8<4 ?T:?L=75Q=_L_^&)+J5IIO)7+MU^ZO
ML*]F1F+ $,.O#?@?3MG'6O&/V../V?\ PT,Y_=+R?]Q:]H;;M.!@@\?+G!/?
M]?YT *S 'YB%QR/F[8Y)_.GTT-\Q!]<#Y3Z4JMN4$=_48H 6BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *0L%Y)QVI:* &;CM)!/S=,KT_"O*_V
MG/'4_P .OA#K.MVS;9H(V*^OW3SU^O\ CZ^IJI5N!@XQGKP#Z]<D'_/?P;]N
M#/\ PSWXA'\/E-D^^QO_ *_OQ]: /P6^+/QCUOXG>++K5;J\G4.S;5\PGN??
MW[5Q7]N:@<_Z9-_WV??_ !_SBJ]W_P ?4W^^W\Z]H_9-^$>C_&+XC/I>N3&#
M3H(&N)I-K-A%5F8X4$GA>G_ZJ /'_P"W-0.?],F_[[/O_C_G%']N:@<_Z9-_
MWV??_'_.*_1G_AEWX"?\^WB+'M:P>^?^6WO^G>D/[+GP%P?]'\1 X_Y](>N3
M_P!-O0_H* /SG_MS4#G_ $R;_OL^_P#C_G%+_;NH!L_;)O\ OH^_^-?HPW[+
MOP$YQ;>(@.<?Z+!QUQ_RV[9_04?\,N_ 3_GV\18]K6#WS_RV]_T[T ?G-_;F
MH#'^F3?]]GV_P_SFG?V]J.<_;)>N?O>V*_19OV7?@+VM?$./^O:'GKQ_K>/U
M[>^1?V7?@+WMO$.>Q^RP\].?]=]?S_  'YO37$MRVZ:5Y6]78D_K4=?1G[9'
MP+T+X+^(=''A\R_V=JEK'>0+.%$@C= RA@"0#Z_7VY^<Z +=OJU[:J%ANI8@
M!@!6(Q_]?WJ1M?U%E(^V2\^AQ7W7\(_V4?AA=?"_0=>\6IJLEUJRN\(L8%D4
M*H .6=E&<L#@$D=^H)ZH_LM_ 7=_Q[>(@N1_R[09Q_W]_P ]?:@#\Z/[<U Y
M_P!,F_[[/O\ X_YQ1_;FH'/^F3?]]GW_ ,?\XK]&%_9<^ NT VWB+/(S]E@]
M#@_ZW\?P'U(?V6_@)@XM_$0/./\ 18/;'_+;Z_G^% 'YS_VYJ!S_ *9-_P!]
MGW_Q_P XH_MS4#G_ $R;_OL^_P#C_G%?HR?V7/@'D_Z-XC /_3K!D<_]=?3C
M\:!^R[\!,@FV\1>X^RP8ZY_Y[>F!0!^<_P#;NH<?Z9-_WT?7-+_;VH[L_;)<
M_P"]Q_GBOT(U[]DCX.:GX=U4:"=5M]6M[5[F%K^!$1RBDLN4=N<<\@#"^O7\
M[]0MQ:WUS .1'*R#'L2* /T$_P"";O[66NZ/XSTWP+.\DUO<?*KN-P X_7_'
MZY_9H*"J;0 HY *]..WI7\]__!/J(2?M&:(2I8JPP1GCGV!].^*_H/556--P
MQMP!NQP>G;^E !N.X#DX.2,C/7 _#_"I*8N5VC 5>@51^7TXI] !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4A;&/?VI::V%^8G  ]>* &MF11@,!P?3(/ZBE0J_P P
M*N1_$OH>?Y8I&9CD [2>@[]>3W]J<K!NF>F>010!^=__  4*_;,\6?L\^-+#
M3_#LG#D%CN!_VL=<CH1TKX;^)G_!1#QM\4_"=QH6KVT;P3(4+;N?\_7//->U
M_P#!8PJ?B'I1)4G "^O0Y'Z?Y[_G%0 Z20R2,YZL23BI[/5+O3V5K:YE@*G(
MV.0/RJM10!]&?"S]N/Q[\*[80V%T[JHPI9^>_M[G\^<CBO36_P""JWQ1)SN0
M'!Z$=^G&.V?\<U\344 ?6GCS_@HY\1O'FDO8W$[6Z, ,QO\ KZY_'_&OES4O
M$6I:M=S7-U>SR22G+9D;'7('7H*SJ* !F+,23DGDDUO^"/%4W@GQ)9:U;IOE
MMWW*K %21@\YX/TK H+;O_U4 ?;</_!53XF6=O;P6JK#%"JKM5L X Z@>XS_
M )-1K_P53^*"X^8'@ Y;K@$9_7MW KXHHH ^V?\ AZM\4>,LK>O(&>,=A[Y^
MM _X*K?%'C+*0!@\CGKD]/Y=,<8KXFHH ^X--_X*G?$Z?4+6-V#(\J*PW=<G
MG_(]/KG]A_@3XON_'WPNT77+W*W5W&)'^IP>XK^:70_^0WI^<$?:(_O=/O"O
MZ0/V54V? KPN NU?LRXXP,;10!ZT&W?_ *J6FKRH(;<#R#3J "BBB@ HII;/
M&6!SCI^--#X8*>I/\7'KT]>GY4 0WWRZ=='E?W;]3['W_K^5?SJ?MJ$']H?Q
M+W/F=<Y[G_/4U_17?973KK/'[MS][V/?(K^=;]M96'[0WB7/_/4CISG)[_\
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M\'GC+$=:S?#ZC_A&]-#' -M%U.<Y4<<^M:E $8(9AN*[NFW(.&QV_ U)110
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M_P D?T3_ *XK_(?Y]/UH ]93[J\D\=6&#3J** "BBB@ HHHH **** "BBB@
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M.XY.?K7ZH>&_^/B^X4_Z!=##-@']RW!.1_.ORO\ $QSXBU+G/^D/_P"A'WH
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M_E5O!^Z0#SD Y/?KG\N*J:+AM'M.V8U/R\<]>Q_S^E72JJF-ORKV ]/:@!C
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MI7$=SXATM;Z1<%?, X]^1D&N.'[%?PIY_P"*<AR?8=>N?SR?QH _G1^R3_\
M/&3_ +X-'V2?_GC)_P!\&OZ+O^&*OA-SM\-1#CCIP?R]A^5'_#%7PFYV^&HA
MQQTX/Y>P_*@#^='[)/\ \\9/^^#1]DG_ .>,G_?!K^B[_ABKX3<[?#40XXZ<
M'\O8?E1_PQ5\)N=OAJ(<<=.#^7L/RH _G1^R3_\ /&3_ +X-'V2?_GC)_P!\
M&OZ+O^&*OA-SM\-1#CCIP?R]A^5'_#%7PFYV^&HAQQTX/Y>P_*@#^='[)/\
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M!X'CC0<'C[?#@GC_ ):#W_S[UAIW.,XY]ASWK<\!_+XXT'G/^GPC([_O!]*
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ML3XZTD?,<  ]<=#CO_O<8[]>E?L)7X]?\%CN?'>D#>3T;;V'!!.,^Z\_AZT
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MD?ZT ?TB>'-O_".Z9Q@?9X_N>N!Z?K^-:E9GAS=_PCNF<9/V:/[WIM'I6G0
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MV<]>FYL9)VKG+?FW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6WAI5/RKHUL N?N\,<8W';USC"=<X.=[ '/4444 %%%% !7>?"MML/BP]/\
MB4288=CYB8Y[?_7QWK@Z[SX5MMA\6'I_Q*),,.Q\Q,<]O_KX[T ?EM\=,_\
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M4 %,;&6.X@@ D#DX^GYT^F28X8G '4[B,#K_ $H 0$J-J@<9 7:0/4<^F/\
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M_"=Z2"6/(P/X1\I_4X_3KVK]AJ_'O_@L:Q/CK21\QP #UQT.._\ O<8[]>E
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MOS2_X(Y+CPAJQVXR3SCKT[XY_,_A7Z6T %%%% !1110 4444 %%%% !1110
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M9%:L,]O7_P"O_3_ZWE'P&4_\+!L" N=Z_,>O7I7J_P#P4./_ !D5JPSV]?\
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M1/\ BQ9;;_= ;!'89YQ@]NYZ4 ?=M%%% !1110 4444 %%%% !1110 4444
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M/<>Q_E0!_1I^QR,? 'PWC@>4.  /X5.?UKVI/NKR3QU88->+?L<_\D!\-_\
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M ."?*EOVC-$X8@'^[D?7H?\ .>17]"$?^K7C' ZY_K0 ZBBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]_I0 H/7C']:6H>!G:N,   *5Z$X&?3_ #WIZ9#$'/KCJ.I[_P"<4 /HHHH
M**** &1MNP=V[Y0>!Q]13Z9&V[!W;OE!X''U%/H ^8/V]F_XLWJ@S_!TS[#W
M_I_]?^?W4/\ C^N>,?O&Z8]3Z<5_0%^WLW_%F]4&?X.F?8>_]/\ Z_\ /[J!
M!OKDCIYC8Q]3["@#],OA&!_PS7\/\<CS+KG_ (##[?Y]ZU^B]-N1_$.O/;C_
M #@UD_"7_DVOX?G;M_>77;_9A]O\^]:W1>FW(_B'7GMQ_G!H 91110 4444
M:WAO_CXON%/^@70PS8!_<MP3D?SK\K_$QSXBU+G/^D/_ .A'WK]4/#?_ !\7
MW"G_ $"Z&&; /[EN"<C^=?E?XF.?$6I<Y_TA_P#T(^] 'MO[# )_:(\/ #.9
M%7[N>K >A[XXZ\<=*^TKK_CZF_WV_G7Q;^PRH;]H;P\"I.9 !CUW @=">H'M
M^E?:5U_Q]3?[[?SH BHHHH **** "O$_V^-G_"N?A]M&UO*ER,8_Y;2<X^N>
M>^/:O;*\4_;Y9C\-_AZ& P(I<$-G_EL_'L?\10!\.U^W?_!)1?\ BQ9.W'W>
M=O7@=\>WJ>OM7XB5^W?_  24'_%BR=O]W)P/08[9['N>E 'W;1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]\0FV^"-;.<?
MZ*_.<=OJ/YU_-9\9^/BGXE&,?Z8W;'8>PK^E/XA-M\$:V<X_T5^<X[?4?SK^
M:SXS\?%/Q*,8_P!,;MCL/84 :O[.8+?&?PN 2I-VOS#J.:_1_P <;/\ A,=;
M\O[GVR7&"3_$?6OS?_9UV_\ "Y?#&]=R?:ERN,Y&>F.]?I%X\+-XTUPN"K?;
M)<@D$_>/I0!A4444 %%%% !7FO[8G/[..FCK_P 32<XZ]H/K_+\?3TJO-?VQ
M.?V<=-'7_B:3G'7M!]?Y?CZ 'Y^5^@/[%Z[OV=->/DPL5U&([I'"LF2PR@XW
M$^GS<$G'!8?G]7W[^QG"TO[/.M.NU!%J<+,I8+G(< @'!)Y' SW/09 !ZA11
M10 4444 *IP&Y(R.W?FM[P+\OCK0>B_Z?#T/'^L'O_GWK!4X#<D9';OS6]X%
M^7QUH/1?]/AZ'C_6#W_S[T ?F]^TAC_A=7BG'3[6W\Z^A/\ @F_&LWQ(MHV)
M4-*,^V,X.>G<]P>/QKY\_:2)/QJ\4Y_Y^F[YKW[_ ()SR/'\0864<K(#D>G/
M7/ISW'7\: /O[]K3]M"Y_9M\:^'=)Q)_9USM5Y%''OC'IZ8Q^>:T/CQ^V+\-
M/''P&UBVMM626_O+/ MR1N5F1@0>1C\NYP*]%^.W[(?AO]HO1K2XU>0_;EB#
M1.R'Y6Q]?TZ5^-W[7_[-6H?L\^+)+,WTL]FYP$<],Y';CL/TH P?V5?%&D^$
MOVAM)U?5MD>G0SLY,F %^<'T/;CZ$U^O/Q[_ ."@O@/P+\/9;WPYJZ7FIHVQ
M8HVSM '0X.>GMU%?@RKM&P96*MZ@X-?5_P"R?^Q3XJ^/>JV6H73-_P (X,&3
MYF.\$GY0>GL?K0!^M?['O[3UM^T!X$AOYG/]H%PC+SSD$DC/^)JG^W%^T5J'
M[.?@6VUO3]YD=\$#G/7CKZ _B!ZUU7P*_9;T'X'6]N-+?,JJOF?*,%NY_/\
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M\-ZE=-(H)!5W+#''3VZ__6JM\.O"'B3XG:Y!H&BS2O/(?]7YA P<_GW_ %H
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M)FW*.<G)) Z#\/P_E7R__P %'%$?QGM$V;"MDB[=NW;A5&-NU<?3:N,8VKT
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MZ?KU_'KC\+;OQ]K]]JRZQ+,S7*X(E"D#C'O[5]+_  ;_ &!?&_[0.DVWB?\
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M=?>TDGDFN--EV*W7!&>3CKU_SS0!^S7P?_:&^'7[,OPPT6QUBZAAN)H$&U7
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M3?[[?SKXM_894M^T-X>.PN%D5L 9Z.O/0]L_K7VE=?\ 'U-_OM_.@"*BBB@
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MF\(IIEZF;:: 1R(O';!S7C6C_L1_#KP[XG37=/TZ.*]60R?-&",D[O?OWZT
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M$T,/(XQP,?\ UNU '4KG<>./4GZ=*^,?V\/VSM-^"WAN^\.VT'VC69T<*IY
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MW^<?UKH_B/IL6E^.-2AC*B&0I<*L:[%C$L:R!0/1=^. .!T'0<RQR2<8]A0
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M1#[+P.0W\7.:%^^I;;^F/3D4#G:%&2>-N,GH/:@!74QR!3P.FYEQ[$_GGWI
MVT9'&>,+UZ8Z_C2[2N2#M^7(QW['K^-"/F3>>-N",'IR/?)_.@!%(+%CP<YZ
M#'Y=Z:3GMBE(YVD;"N0<YI&.23C'L* $HHHH Z;PG_R+WCP%MH/AV<9_[:PU
M^3.MDMK5^3U^T29P<_Q'O7ZS>$6V^'_'?(7_ (IZ?K_UVAK\E]8Q_:]]@8'G
MOC/^\: /HO\ X)\C=^T9HG&><_\ U\8/Y\8]>:_H0C.8U.=W Y!SFOY[O^"?
M*AOVCM#X!.<]"3_(_P!/K7]",9S&ISNX'(.<T .HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "D8X4G&?84M1R+N;(7)Z]L''0'\3F@ CQN W X! ^8^O/'MQS3E
MP>0V[J.OOTIJDL"G)'0L<@X]>G7/I]:$5@Q)&3T+=/R]NO6@#\=?^"Q<:?\
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M9)P?0'((YIU1E26R5!/'8 'GCWR/Z_E)0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 5]0R;&Y Z^6V,?0^XK^=7]ME@W[1'
MB9AT,I]/[Q].V,5_15J'_'C<Y;:/+;YCVX/-?SK?MM,6_:*\39R#YG0D' W-
MQ[<YH ZC]@T?\7.A/!)?GN1@?3CKZ_\ U_WR\)X'A^RP!CRUY //'T_#\*_
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M8@]"#\O'7X3_ +-O.?\ 19_3_5GUQZ>M?K+I_B[;8PZ9J^FVNO:/'P+2[7E
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MI45TC>4P8(B!\D#!R.V.IX]J]G_;L_9-LO@[\+=#O?#.G,=7M?+=I(URQ^8
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M:9XEN(_,BM2&*]>=P(P#Q^E?7R_M>_!WRQNLM9\S:<XN5QGM_P L^G3\O?@
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MO.,KI%XP]HB: /V+'_!7OP!NYM%(X[D'^9Z<_G2_\/??A_C_ (\>V?OG\O\
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M]4&?X.F?8>_]/_K_ ,_VHY&H76<D^:WWNO4T ?IC\(P/^&:_A_CD>9=<_P#
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MOD _\%AO&:@XTT$\@8Q[8/)Z?X?7/9?\%F%#:KHOJ-K=?15'3/O_ )XK\NJ
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M(Y+CPAJQVXR3SCKT[XY_,_A7Z6T %%%% !1110 4444 %%%% !1110 4444
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M$!7;M7'TVICIM7H #Y\^%V3XVTX ')D'W1D]1Q]/P-?T1?LN?\D=T7_KFO\
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MW[.8+?&?PN 2I-VOS#J.:_1_QQL_X3'6_+^Y]LEQ@D_Q'UH Q**** "BBB@
MKS7]L3G]G'31U_XFDYQU[0?7^7X^GI5>:_MB<_LXZ:.O_$TG..O:#Z_R_'T
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M@Q^G:@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_A7Z6U^:7_!')<>$-6.W&2><=>G?'/YG\*_2V@ HHHH **** "BBB@ HHHH
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M4,>9LY.(AQG9SUZ;FQDG:N<M^;= !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?H=_P1[7=\4-2(&XCM@GC"Y/3MQWK\\:_0[_ ((^_P#)4-2/
M'!Z8S_<'I[^W:@#]FJ*** "BBB@ I >O&/ZTM(,\Y_"@#^?3_@H<?^,BM6&>
MWK_]?^G_ -;RCX#*?^%@V! 7.]?F/7KTKU?_ (*''_C(K5AGMZ__ %_Z?_6\
MH^ RG_A8-@0%SO7YCUZ]* /TX^*%XMSK6GQJ6/V?3K>$JV<+\I.%^8C&&'0*
M.3P3EFX^NP^*%XMSK6GQJ6/V?3K>$JV<+\I.%^8C&&'0*.3P3EFX^@ HHHH
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M1@\>G?CBE5@Q!&<D?4#';TS2A=RG<,ANJMCCCI31E<X'S'. 22.OKVZ_YQ0
M[ 9MPX/0\=<9XKXR_P""CQ;_ (59?;6P-I^923CU[Y_ ?2OLU01D=L\<YKXS
M_P""CS-_PJ^\RVT[#\O<CCG&><<?CCZ4 ?A/)_K&XQR>F/Z5_0'_ ,$Z?^3=
M-([<#C&,=>,=J_G\D):1B>N3G!S^M?T"_P#!.L@_L[:25&%PN ,>_I0!]/;1
M'EB0JC)] .YS2#<"0H.%&!D\'@=3U_G0ZG;A!@\GKCG!YZ>M*L8SDJ-V>O4]
M^_XG\Z !P2>,],]<#/&,]_\ )IPX[YIC;B5(4CH<>GKGGT/Z4Z-=B@9_ # '
M':@!U%%% !1110 4444 %%%% #(VW8.[=\H/ X^HI],C;=@[MWR@\#CZBGT
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MLG;C[O.WKP.^/;U/7VK\1*_;O_@DH/\ BQ9.W^[DX'H,=L]CW/2@#[MHHHH
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MF$ CN,J&Y[@'T-? -?H#^Q>N[]G37CY,+%=1B.Z1PK)DL,H.-Q/I\W!)QP6
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M1[4 :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(1N_\
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M.(AQG9SUZ;FQDG:N<M^;= !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?H?_P1[!;XH:EC(.<AA]%R.G<9]*_/"OT._P""/J[OBAJ7'.>"3Q_
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MI]K;^=>_?\$Y^?B##@EMLN=JC)]_<' &.GK[UX%^TD2?C5XIS_S]-WS7OO\
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M[LYP >QZ\'^5=M7%_&#'_"O]4W*2-AY7J.#SZ_EZT ?ST?M/'=\3[X\'+O\
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MCAGTH1)(<;C'@#]#C]?KVK[C^"'[3GA3XP:'#<P:E!'>2#=]GW<]NV/>@#V
MO][^+G.5W>IXX],?B?K4B].%V\GC\>M-\L<@C([$L2>F/PX_G3@0J[B-F[&<
MXZ]* '44UG5>K <9Y/;UI0P.0#G'!H 6FLQ';'3G&>]*&#<@Y[5A>+/&6C>"
M-.DOM7O8K2-%+ RM@MWP": -E(RIX^4=.,< '@=/0_YZTYD.<C&>HW#.#C&>
MM?GA\8_^"K6D_#_Q!)I^F6ZWZ(Q7>JAPV.XQ]?TKS\?\%F%.?^)+CCC,/>@#
M]4-HSGGKGJ?3%#*6&,X'?U_^M7Y7M_P66"G TE6]Q ?2M#P]_P %A[?5-5@M
MKG31;Q2,%+M'C&?3@_E[]: /T]W.O'5CWV\=!R,>_J?6E;E03^[&,DYP5X_+
MUKS/X/\ Q^\,?%C0K6ZLM3MS=S#/D;_F.1G_ .M7IC+MW,.._ /7'?'7MQ[4
M .7NO?KC.>I-.IFTY'' ;/WCZ?X]J?0 4444 %%%% !1110!7U A;&Y)Z>6V
M<''8]Z_G5_;:S_PT3XF!.2)2._\ >8]_K7]%6H$+8W)/3RVS@X['O7\ZW[;0
M(_:(\2@Y;]Z?F.<9W,<#GIS^M '4?L&_\E-BXZR=>>P^F._MU/K7[Y>$_P#D
M7[(]C&,9.?KVYYSSWZU^!O[!JY^)L1V_=DX;'7(]?;C\^O8_OEX4&/#]GD8/
MEC(VX[?3_/3M0!KU^/?_  6-8GQUI(^8X !ZXZ''?_>XQWZ]*_82OQZ_X+'<
M^.](&\GHVWL.""<9]UY_#UH _-ROTP^#(Q^SGX,XQF6?MU^6/V_Q_H/S/K],
M/@R,?LY^#.,9EG[=?EC]O\?Z  W:*** "BBB@ HHHH **** "BBB@ HHHH *
M>YW<_>RQ^8]3]>:93W.[G[V6/S'J?KS0!Y!^WDO_ !9?X>DX/-P1QG_EXD_+
M_/K7POIVI7.DWD5W:2M!<1G<DB]0:^Y_V\?^2,?#[GO<=C_S\2?YYKX/H ]+
MC_:.^(<42QIXDNT11@*LA &!@8YXIQ_:2^(G/_%2W@_[:M[^_O\ H*\RHH ]
M-_X:2^(O'_%2WF/3S&]?K^% _:2^(G'_ !4MX?\ MJWM[^WZFO,J* /31^TE
M\1./^*EO#_VU;V]_;]30/VDOB)Q_Q4MX?^VK>WO[?J:\RHH ](N?VBOB#>6[
MP3^([J6%UVM&SD@\=_SKSR[NYKZYDN)W,LTC;G=NK$]ZBHH ZOPC\4_$_@6(
MQZ+JDMDIS]PUT0_:2^(G'_%2WA_[:M[>_M^IKS*B@#TW_AI+XBELGQ+>?3S&
M'IQU]OUH'[27Q$X_XJ6\/_;5O;W]OU->944 >FC]I+XB<?\ %2WA_P"VK>WO
M[?J:!^TE\1./^*EO#_VU;V]_;]37F5% 'IH_:2^(G'_%2WA_[:M[>_M^IH'[
M27Q%"X_X26\/3_EHW^/U_/Z8\RHH ^P?V3_VRO&'A[XA:;8:QJT][;7,ZH-[
M,Q/7CN3S@\>IK]U/#-Y_:6@V%W@AIH%8[AST^E?S0?!.(3?%3PT" P%XIPPR
M#]?2OZ4OA^H7P3HH P/LR8RN.WI@?RH Z"BBB@ HHHH *_/?_@KRV/A5:\L/
ME/4^NX9'/?H:_0BOSW_X*\MCX56O+#Y3U/KN&1SWZ&@#\7Z_0/\ 8+R?V??B
M)SP'MQC _P"?F*OS\K] _P!@WG]GWXA'KAH!D]O]*BX'M0!Z51110 4444 %
M=!\._P#DH'AG_L)VO_HU:Y^N@^'?_)0/#/\ V$[7_P!&K0!\!?MDMN^.VOG?
MO_>MR/N]>HY/\_RKS/X;G'CW0><?Z6G?'>O3/VR3_P 7VU_[W^M;ACG'/KD\
M_C^5>9_#?_D?=!XS_I:>OK[4 ?JE\1MP\7/CY6^RV>#C;_RZQ?YS7+5T_P 1
ML?\ "629^8?9;/.WC_EVB]JYB@ HHHH **** .6_:0CQ^RSKLFS&=0QYFSDX
MB'&=G/7IN;&2=JYRWYMU^DG[2$>/V6==DV8SJ&/,V<G$0XSLYZ]-S8R3M7.6
M_-N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OT._X(]X_P"%
MH:D#T^G(X7!S@]^.W45^>-?H=_P1]'_%SM2)&5R,D+G'W<<]OS[]Z /V:HHH
MH **** "D&><_A2TU<9;!R<\\].* /Y]?^"AQ_XR*U89[>O_ -?^G_UO*/@,
MI_X6#8$!<[U^8]>O2O5_^"AQ_P",BM6&>WK_ /7_ *?_ %O*/@,I_P"%@V!
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M_P :_HB_9=_Y([HO_7)3_P".C_/]>P /6Z*** "BBB@!N/F)P.@Y[]Z^,_\
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MMQ_G!K(^$8'_  S7\/\ '(\RZY_X##[?Y]ZU^B]-N1_$.O/;C_.#0 RBBB@
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MEYV[?XCV[5^;W[.8+?&?PN 2I-VOS#J.:_1_QQL_X3'6_+^Y]LEQ@D_Q'UH
MQ**** "BBB@ KS7]L3G]G'31U_XFDYQU[0?7^7X^GI5>:_MB<_LXZ:.O_$TG
M..O:#Z_R_'T /S\K] ?V+9/*_9UU]?.DA,FHPJ5B08FY9@KG@[0!N[_,!QSD
M?G]7W[^QFL3?L\ZT9';>NIP^7M4-DD/D$Y&!C/KR /< 'J%%%% !1110 JG
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MT+DM\H7YMP.T=<^M1W&19S@]=C<^O';F@#\-/^"C>?\ A8MX >-_(&<CY?\
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MBM%2(LI=@I8@' Y]P:_$O]MS]N+6_C9XAFTG2KJ2STRSF,:M$Q7*CIWY/O\
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M<1#C.SGKTW-C).U<Y;\VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_0[_@CW_R5#4FVY X)QD#(7V/^0:_/&OT._P""/:[OBAJ1 W$=L$\8
M7)Z=N.] '[-4444 %%%% !2!@<@'..#2T@/7C']: /Y]/^"AQ_XR*U89[>O_
M -?^G_UO*/@,I_X6#8$!<[U^8]>O2O5_^"AQ_P",BM6&>WK_ /7_ *?_ %O*
M/@,I_P"%@V! 7.]?F/7KTH _3CXH7BW.M:?&I8_9].MX2K9PORDX7YB,88=
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M_KU]?U\@_P#!/C/_  KVVXP-GYGGGI]/7I7U]0 4444 %%%% !1110 4444
M%%%% !1110 C,%4DG '))K\@O^"H3LMY+']TX)*[\8ZCUQ^@ST!]/U^K\?\
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M<ZA:C&?WJ]L]Q['^5 ']&O['/_) ?#?_ %R7_P! 6O:E;<H([^HQ7BO['/\
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M9S&ISNX'(.<U_/?_ ,$^1N_:,T3C/.?_ *^,'\^,>O-?T(1G,:G.[@<@YS0
MZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "FLVT9. O<DXP*=2'/&/QH 8JG;LX48Z*",#'0'Z
MTVZ;=:3?[C=O8T[R_ESA0W4#&0&YR?UI9(P\;K_>&#G)'3% 'X3?\%'KY?\
MA95U$.2TH'8@$#Z__7Z?A\9U_0_\4_V(? ?Q;U22_P!;A::9\YR,^AS^?^>*
MX#_AUS\)%;(LO<?+_0D\9^O^(!^#XQSD?2BOW?\ ^'7?PFV@?8>>G3MUZXIQ
M_P""7_PG'W;$8.,_*![XZ=,_R% 'X/45^\7_  Z]^$NT@V0/N(P,Y!S].?\
M/%!_X)>_"7G_ $'U_@'OC^?X<4 ?@[2_+CH<X]>^?\*_>'_AU[\)O^?)1T)_
M=@_Q9_E_ATIJ_P#!+OX3#&;($]?NCMG _EF@#\'RV[_]5%?O"/\ @EY\)E _
MT($X_N <Y''Y#K_C2+_P2Z^$RG/V0$_]<QV'U]0/S/X@'X/T!L9]_:OWA/\
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M'YGU^F'P9&/V<_!G&,RS]NORQ^W^/]  ;M%%% !1110 4444 %%%% !1110
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MK67)7]\O3ZBOV4_X+ -M^$VG_CQU[G_/3_ZWXUZ,=NK67)7]\O3ZB@#]WO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3B(<9V<]>FYL9)VKG+?FW0 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2-E<8R&'H?\ /Z5_+[X#\97G@3Q-9ZQ9.4F@<,,$CH0?Z5^_/[$OQBMOB?\
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M<?@3I<WABT79J=]'A)%'('.#^@S7Y!W7[27Q%NKEYCXFO5+.7"B0X7.>GYT
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MX_#H#^5?K@W*D9Q[B@!BL6893G&,^G7/4=.*DI-HW$XYZ9I: "BBB@ HHHH
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MF#_@HTHC^-%LF-I2S1?+";=N%7@C:N,>FQ<?W5QB@#Y1HHHH **** "BBB@
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MV2XP2?XCZT 8PPW&.<>O^>U)N.W'0=_?WI** 'KNCVR#@@@@_P"?I7)_M-?
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M,\?_ *ZS_AS\-="^%?A]-)T2UCM+2/GY5"] !S^5=264A0PY.#M/)ZC^1Q0
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M_)38N.LG7GL/ICO[=3ZU^^7A/_D7[,\',:\J, \#V'^?RK\#OV#%W?$Z$X
ME W8SC*]2>PX_4U^^/A//_"/V1( )C7H!Z8]/:@#7K\>?^"QS#_A.])!+'D8
M'\(^4_J<?IU[5^PU?CW_ ,%C6)\=:2/F.  >N.AQW_WN,=^O2@#\VZ_3#X,C
M'[.?@SC&99^W7Y8_;_'^@_,^OTP^#(Q^SGX,XQF6?MU^6/V_Q_H #=HHHH *
M*** "BBB@ HHHH **** "BBB@ I[G=S][+'YCU/UYIE/<[N?O98_,>I^O- '
MD'[>&?\ A2_P_P 9ZW&<8_Y^).M?!U?>/[>2_P#%E_AZ3@\W!'&?^7B3\O\
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MVZ_+'[?X_P!!^9]?IA\&1C]G/P9QC,L_;K\L?M_C_0 &[1110 4444 %%%%
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M/!P10!]/4444 %%%% !1110 4444 %%%% !1110 4444 =-X1;;X?\=\A?\
MBGI^O_7:&OR8UK(UB_!7:?/D^7T^8\5^L_A%MOA_QWR%_P"*>GZ_]=H:_)?6
M,?VO?8Y'GOC/^\: /HK_ ()\KN_:.T/Y0<'KU(_0_G^HK^A&/_5KQC@=<_UK
M^>[_ ()\\_M':&,9.<_=S^N#C]/K7]",9S&ISNX'(.<T .HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAYZ"OSLK]$?^"2N/^$PO<G^(_>'';]?_ *U '[+T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5]0;98W+
M#C$;'GZ&OYU?VV@!^T5XG [2XZDG[S<G/^>*_HJU#)L;D#KY;8Q]#[BOYU?V
MVF#?M$^)B.092>W]YAU'T_6@#J?V#?\ DIL7'63KSV'TQW]NI]:_?+PG_P B
M_9G@YC7E1@'@>P_S^5?@=^P8N[XG0G  $H&[&<97J3V''ZFOWQ\)Y_X1^R)
M!,:] /3'I[4 :]?CW_P6-8GQUI(^8X !ZXZ''?\ WN,=^O2OV$K\>O\ @L=S
MX[T@;R>C;>PX()QGW7G\/6@#\W*_3#X,C'[.?@SC&99^W7Y8_;_'^@_,^OTP
M^#(Q^SGX,XQF6?MU^6/V_P ?Z  W:*** "BBB@ HHHH **** "BBB@ HHHH
M*>YW<_>RQ^8]3]>:93W.[G[V6/S'J?KS0!Y!^WDW_%E_AZ.G-P.._P#I$AYS
M_3T^M?!U?>/[>&?^%+_#_&>MQG&/^?B3K7P=0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '<?!'/\ PMCPQ@X'VQ,\]:_I0\ +M\$Z(-H7_1(^
M!]/H/Y5_-=\$3_Q=CPOQG_34_"OZ4? "[?!.B#:%_P!$CX'T^@_E0!T%%%%
M!1110 5^>_\ P5Y;'PJM>6'RGJ?7<,CGOT-?H17Y[_\ !7EL?"JUY8?*>I]=
MPR.>_0T ?B_7Z!_L&\?L^_$+AAEH#TX/^E1<]/\ /-?GY7Z!?L%_\F_?$/YL
MY:#@#C_CZBZ\?YS0!Z71110 4444 %%%% !1110 4444 %%%% !1110!RW[2
M$>/V6==DV8SJ&/,V<G$0XSLYZ]-S8R3M7.6_-NOTD_:0CQ^RSKLFS&=0QYFS
MDXB'&=G/7IN;&2=JYRWYMT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_D7O'@+;0?#LXS_ -M8:_)G6R6UJ_)Z_:),X.?XCWK]9O"+;?#_ ([Y"_\
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M:8M^T5XFSD'S.A(.!N;CVYS0!U'[!P_XN= >"=_XC@>W]?\ Z_[Y>$\#P_9
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M>)/R_P ^M?!U?>'[>/\ R1CX?<][CL?^?B3_ #S7P?0 4444 %%%% !1110
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MVKC^ZO0?3U?,'_!1M?+^-%HFSR]EDJ[=NW&%7C&U<8Z8VKC'W5Z  ^4:***
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M)G=@;3W"Y(/'^11D[>=S\\8&"<>OY>PIP^4X))/)Z4UH]W!Y'.2<9QGITZ4
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M.;@<=_\ 2)#SG^GI]:^#J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM2)&5R,D+G'W<<]OS[]Z_/&OT._X(]_\E0U)MN0."<9 R%]C_D&@#]FJ***
M"BBB@ IJXRV#DYYYZ<4ZD!Z\8_K0!_/I_P %#C_QD5JPSV]?_K_T_P#K>4?
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MZ_>QCOTSCKU[U5TO']DV6<_ZF/IGT%7: "BBB@ HHHH **** "BBB@ HHHH
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M-_\ 7)?_ $!:]J7A0,Y]S0 M%%% !1110 4444 %%%% !1110 4444 %%%%
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M-1C& !@X_I7\]_\ P3Y&[]HS1.,\Y_\ KXP?SXQZ\U_0A&NV-1C& !@X_I0
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M]EQSQ_M>W\J_?+PG_P B_9G@YC7E1@'@>P_S^5 &O7X]_P#!8UB?'6DCYC@
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M\J_3+]OPG_A5?AL-RW]DVX^]G),*_IC/&.2?PK\S=.YU"U&,_O5[9[CV/\J
M/Z-?V.?^2 ^&_P#KDO\ Z M>U*H50 , < "O%?V.?^2 ^&_^N2_^@+7M2\*!
MG/N: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\%_;<_Y-\\0\ _NR/F. ?E/&>/Y_XCWJO!?VW&Q^SUXC!)"F)@?^^2?SX_SU
M !_.M=_\?4W^^W\Z^IO^"<LT5O\ ',RS[_)2W+/Y<HB; 5B<.2-I_P!K(Q@_
M,*^6;O\ X^IO]]OYU]7?\$U7:/\ :!@=(9+AEBW"*,C<Y 8[1D@9XZD@=>10
M!]-4444 %%%% !1110 4444 %%%% !1110 4444 =-X1;;X?\=\A?^*>GZ_]
M=H:_)?6,?VO?8&!Y[XS_ +QK]:/";;?#WCPC_H79_P ?WL/%?DSK?_(:O^=W
M^D2?,>_S'F@#Z(_X)\J&_:.T/@$YST)/\C_3ZU_0C& L:@=,#&1C]*_GO_X)
M\J6_:,T3AB ?[N1]>A_SGD5_0A'_ *M<<<#H,?IVH =1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !368J.!DGIZ?\ UJ=368JI(&<4 ,VDL/E8<Y!.#CD\_P"?6E?[PP>3CY<]
M@?K[T-E4 "@ = I/KQT'2A9 J$\#^([F/ )ZG/2@!5^>,9.=PSE3Z^A%*&+'
M@<<]>#6!J'CKPYH\@2]U>VMG4=)I,$=N_?FJ?_"UO!^X'_A(+$GH/GY^GX_K
M0!UM%<G_ ,+8\']O$5B?3$N<^P]3[4?\+8\']O$5B?3$N<^P]3[4 =917)_\
M+8\']O$5B?3$N<^P]3[4?\+8\']O$5B?3$N<^P]3[4 =917)_P#"V/!_;Q%8
MGTQ+G/L/4^U'_"V/!_;Q%8GTQ+G/L/4^U '64Q5*G&X[1TYSVQC^M<M_PMCP
M?V\16)],2YS[#U/M3?\ A:G@OI_PD.F]A_K1VZ4 =5M#2 @8P<DX[XQZ>G?V
MI58[0""S# /^/:N6_P"%K^$/^AAL?^_GY_EW].](WQ6\',I!\0V!![>9G(_J
M/_KT =2LN>HPO8GCT]?K7-^,?AUX=\>JL>MV,5Z%^4!@/K47_"UO!V[/_"1:
M>">YE S_ (]_UI#\5O!I.?\ A(]/SQR)P#Q0!R]C^S'\/M)OHKW3]#AM+J,Y
M615''3V]OYUZ/IUL;*$1@A44A>H]\#]5]_?&*Q['XD>%+ZX2"UUNRFF;A4C?
M)('I[?\ UZZ..3S5#+TZ]#R,<?TH =M^;.2/Y4ZFQXV@@[L\[N.>.M.H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *^H9-C
M<@=?+;&/H?<5_.K^VTP;]HGQ,1R#*3V_O,.H^GZU_15J&38W('7RVQCZ'W%?
MSJ_MLL&_:(\3,.AE/I_>/IVQB@#J?V#?^2FQ<=9.O/8?3'?VZGUK]\O"?_(O
MV9X.8UY48!X'L/\ /Y5^!W[!B[OB="<  2@;L9QE>I/8<?J:_?'PGG_A'[(D
M $QKT ],>GM0!KU^//\ P6.8?\)WI()8\C _A'RG]3C].O:OV&K\>_\ @L:Q
M/CK21\QP #UQT.._^]QCOUZ4 ?FW7Z8?!D8_9S\&<8S+/VZ_+'[?X_T'YGU^
MF'P9&/V<_!G&,RS]NORQ^W^/]  ;M%%% !1110 4444 %%%% !1110 4444
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MS[#W_I_]?^?W4/\ C^N>,?O&Z8]3Z<5_0%^WLW_%F]4&?X.F?8>_]/\ Z_\
M/[J!!OKDCIYC8Q]3["@#],_A+_R;7\/SMV_O+KM_LP^W^?>M;HO3;D?Q#KSV
MX_S@UD_"52/V:_A_D?\ +2Z[8_AA]O\ /O6MT7IMR/XAUY[<?YP: &4444 %
M%%% !1110 4444 %%%% !1110 5XI^WRS'X;_#T,!@12X(;/_+9^/8_XBO:Z
M\4_;Y!'PW^'OSEAY4O!QP?.?].GZ^M 'P[7[=_\ !)0?\6+)V_W<G ]!CMGL
M>YZ5^(E?MW_P25P/@7TP3CMUX'?;_6@#[MHHHH **** &L3QV'J.O4>U<?\
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M?'2E?&>M@G.+R7G;M_B/;M0!A4444 %%%% !1110 4444 %%%% !1110 JG
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M /0A7ZN^+FS;^&UW[]FC6R\MG'#'IN..N<83KG!SO8 YZBBB@ HHHH ****
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M64*,]2!UZ>O<4ETQ6VE(."$)!'TI_P V.P.?KQG_  J.X51:S#[J[6S@>W-
M'XC?\%"?'7BG1?B1.EAJT]K;JY 6-L$#';GWR3[]J^0/^%J>+OF_XJ"^.[KF
M7_/J?S-?5/\ P4=(_P"%C78W Y<':3Z 8/7W/Y"OBR@#JF^*OB]NOB&^/&#^
M]ZY]?7_ZU#?%7Q>W7Q#?'C!_>]<^OK_]:N5HH ZIOBKXO;KXAOCQ@_O>N?7U
M_P#K4-\5?%[=?$-\>,'][USZ^O\ ]:N5HH ZIOBKXO;KXAOCQ@_O>N?7U_\
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M>/V6==DV8SJ&/,V<G$0XSLYZ]-S8R3M7.6_-N@ HHHH **** "BBB@ HHHH
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M\#>!/!UU'X6>WO\ 6$S'M5 1'TQC'OCZ<5^8GQ^_;.\3?'[1AIVKVL=O$/\
MGB<9^OK0!\\ ;O\ ]=#8W''([9HI5;;GJ#C P<?YXH &SGD8.!VQVHXV]B<^
M^1_G^E(&*\@X[5[E\ OV4?&'QLU&TEL=/D&EF3]Y,ZD+MR._XT 4/V1WV_'G
MPTH&2TP ^7=SD>QK^C+PZOD^'[ -\H6!>HQ@8^@KY ^ _P#P3A\&_#F[TCQ!
M+$HU:!58KC.#D$] .01D?7-?9<"B&-(5*J$"J!]!T^N!Z=Z )2RE@-W(.,9[
MXZ?E3JCC8X&XGYNA;'/\N>,_C4E !1110 4444 %%%% !1110 4444 %%%%
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M_@,/M_GWK7Z+TVY'\0Z\]N/\X- #**** "BBB@ HHHH **** "BBB@ HHHH
M*\4_;Y!'PW^'OSEAY4O!QP?.?].GZ^M>UUXG^WQL_P"%<_#[:-K>5+D8Q_RV
MDYQ]<\]\>U 'P]7[=_\ !)1?^+%D[<?=YV]>!WQ[>IZ^U?B)7[@?\$E;?;\
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MO>+FS;^&UW[]FC6R\MG'#'IN..N<83KG!SO8 YZBBB@ HHHH **** "BBB@
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MAEBW"*,C<Y 8[1D@9XZD@=>10!]-4444 %%%% !1110 4444 %%%% !1110
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MS/!S&O*C / ]A_G\J ->OQY_X+',/^$[TD$L>1@?PCY3^IQ^G7M7[#5^/?\
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M^#IGV'O_ $_^O_/[J!!OKDCIYC8Q]3["OZ OV]F_XLWJ@S_!TS[#W_I_]?\
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M-10!]60_\%)/BW#&D8U!=J!5&&(X'X4\?\%*/BZ,?\3!<@8^^?\ /0U\H44
M?5__  \G^+G(_M#Y<_\ /0YQC&,_Y]:/^'E'Q=.<Z@O((.'/Z>G;]?6OE"B@
M#ZO/_!2CXN]M04'K]\_4_K_A1_P\H^+F3C4!US]\_4=O7\^E?*%% 'U>/^"E
M'Q=&/^)@N0,??/\ GH:U_"'_  4M^)MMXBT]]3O/-LED E <GCIT_+OZ^M?'
M-% '](?[,G[0&F?'SP3!J>GN&DCC'G;>0&X&!^.[^G%>Q%26/)'!PP[=/S/X
M5^=G_!'BW\KX9:BQ_B);[O?([X]/\\\_HF_/!&5Z'(SG/&* #!9L\KZ\^A]/
M>GU#&Q52>&/5BH]L=AR<BIJ "BBB@#GOB$VWP1K9SC_17YSCM]1_.OYK/C/Q
M\4_$HQC_ $QNV.P]A7]*?Q";;X(ULYQ_HK\YQV^H_G7\UGQGX^*?B48Q_IC=
ML=A["@#4_9UV_P#"Y?#&]=R?:ERN,Y&>F.]?I%X\+-XTUPN"K?;)<@D$_>/I
M7YO?LYY_X7/X7V@%OM:X!.!UK](?'2E?&>M@G.+R7G;M_B/;M0!A4444 %%%
M% !1110 4444 %%%% !1110 JG ;DC([=^:WO OR^.M!Z+_I\/0\?ZP>_P#G
MWK!4X#<D9';OS6]X%^7QUH/1?]/AZ'C_ %@]_P#/O0!^;_[21)^-7BG/_/TW
M?->^_P#!.?'_  L*'YCQ,N=I'RXSUXXQUY]3^'@7[27_ "6KQ3SN_P!*;_\
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M2OKZ@ HHHH **** "BBB@ HHHH **** "BBB@!&Y4C./<5^0/_!4-E^VW !
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M?\$Y9HK?XYF6??Y*6Y9_+E$38"L3AR1M/^UD8P?F% 'U%1110 4444 %%%%
M!1110 4444 %%%% !1110!TWA%MOA_QWR%_XIZ?K_P!=H:_)?6,?VO?8Y'GO
MC/\ O&OUH\)_\B]X\!;:#X=G&?\ MK#7Y,ZV2VM7Y/7[1)G!S_$>] 'T1_P3
MYY_:.T,8R<Y^[G]<''Z?6OZ$8SF-3G=P.0<YK^>__@GR-W[1FB<9YS_]?&#^
M?&/7FOZ$(SF-3G=P.0<YH =1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A4-P1GO06QCW
M]JC#;I,#GG)(?IQCI]<\>WK2RCH<[>V22![<=^<4 &"Q!QAB"PW#.#@#UXH7
M P47*X&-I&,>U5K_ %2RT6W\V\N8[:+).Z0@=_\ Z_ZU\Y_M0?MK>%OV?]'6
M1+J'4;J4$!8G#!2??/7L/\X /H+6O$^EZ#I]U>W=];0I#&68M(,\#(XS7PE\
M;?\ @J1X3T&RU[0M+56U2-'CBE##&[''?_/;OC\^/V@/VW_&'Q2URZ.G:G-:
M:?(3E5)4$9X&,_YSQ7S/=W4M]=2W$[F2:5B[L3DDDY- 'J/Q,_:4\;_$RZO1
MJ>KS2VDTC%8]QR <CKGT_D*\IHI\,,EQ((XD:1SP%49H ;D;<$<]CG_/^33H
M8);B39%&TK]=J*2:],^$O[/?BWXJ>+K'1[/2+N-+@Y,[1':%]:_2S]F7_@E>
MW@#QC;ZQXLD6]M5 ;RG*D@@9P5]>WXG\ #X7^ ?[#WC/XX+%+:V\EI&2"?,4
M\@D^W!_SZ5^N'P%_85\#?#_P7ID&K:2EUJ\.UVF95W;@!U)&>N:^A?"G@/0_
M!-OY.CV$=G'C&$ %;S+GD8#8P"1G% %>QL[?2;*&SM8_+AA0(D2]ACC^53?=
M9B7(  ))[<D_2@*=P/S8ST+?7GW^E."E4P O'0=!["@!C-N'*LN.AVY(.#[>
MG^%2TT+ALX^ASD\GD?RH;+9!'!XX)!QB@!U%-*XYPQ.<]?PIH/E@\_*O4L>@
MQZ]__P!= $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-
M9]N/S([X]AW[4,VU2>,]LG SVIDUPEK&TDS+&@_B)H -N.7&!M.6S]WUY_ST
MJC<>(-*LF=IK^VB9<E@90#TY.,\]/Z5\K?M(?\% ?#/P3:YL8GCN;T!U3!&0
MP' Z^X_R:_(KXD?M@_$#Q=XNU34K/7[JTL[ER4A1V  ]<?YZ"@#]A/C9_P %
M!O!'P;U)[.XD2[=202IZ>G?KC_(KRMO^"O?P_&<6F?H3Z?7\,^_3CG\;?$'B
MC4_%-T+G4[N2ZF_O.2?QK*H _H"^"'[?G@KXT7HM[:2.S)Z%B3P#@_Y]J^E;
M77-+O<);W]M(7Z+',N3GTP?>OY@/#?B[5O"-T;G2KR2TF/\ $A_6O:?A-^V7
MX^\"^.-+U2_UVYOK"W8>9;R.2I7CJ.?0]NYZ]* /Z(]QCR"% ^]GH.O.?\\\
MU)7SY^S%^UQX>_:$\/Q7%M+'#=[1NB).>!S@=^?YFOH.@ HIH=2<!@3SW].M
M.H :S%>BEN,\8_*@MMR3PH&=QZ57OKJ'3;66YG=42,%V;.T<#O\ A_*OA+]H
M_P#X*5:%\.UU?0+'RY=1V/$KQD':<8(&#G/X=_R /MC6/&VB:%9R2SZC;1B,
M8"[QU[#VKY7^*_\ P4J\"?"[6&L)@EXZDJ2K8Y SZU^/7B[]J'X@>*-6U"X;
M7[E(+F5F$08XVD\#\L?3%>8ZQK5YKUXUU?3--.W5F)H _:C1/^"LW@'6M0BM
M$MU0N<>82<#GJ1G.._&:^F?AW^TEX2^($<;0:A;P&09"N^".,X/OR/I7\V*.
MT;*RL593D,IP0?6NRT7XP>+?#Q4V&L36^W&-IP!@8''MC- ']-MM?6MY\T%Q
M'-NX&QP>E2"/GD*!_=Z]\@U^(G[,7_!2#7?AK-'%XFN9+].$9I#QMS][Z\GK
M7Z]_!GXSZ-\9/"%MK6FW$:M,<>5NR5/)Q[]/_P!?6@#T$2?, 1@X!QU(Z]?R
MI]-4;5 P% X '3':G4 %%%% !1110 4444 5]0R;&Y Z^6V,?0^XK^=7]ME@
MW[1'B9AT,I]/[Q].V,5_15J'_'C<Y;:/+;YCVX/-?SK?MM,6_:*\39R#YG0D
M' W-Q[<YH ZC]@W_ )*;%QUDZ\]A],=_;J?6OWR\)_\ (OV9X.8UY48!X'L/
M\_E7X'?L&+N^)T)P !*!NQG&5ZD]AQ^IK]\?">?^$?LB0 3&O0#TQZ>U &O7
MX]?\%CN?'>D#>3T;;V'!!.,^Z\_AZU^PM?CS_P %CF'_  G>D@ECR,#^$?*?
MU./TZ]J /S=K],/@R,?LY^#.,9EG[=?EC]O\?Z#\SZ_3#X,C'[.?@SC&99^W
M7Y8_;_'^@ -VBBB@ HHHH **** "BBB@ HHHH **** "GN=W/WLL?F/4_7FF
M4]SNY^]EC\QZGZ\T >0?MX9_X4O\/\9ZW&<8_P"?B3K7P=7WC^WDO_%E_AZ3
M@\W!'&?^7B3\O\^M?!U !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 =O\$3_P 78\+\9_TU/PK^E'P NWP3H@VA?]$CX'T^@_E7\U_P1./BQX8Y
M(S>)T[_6OZ4/ "[?!.B#:%_T2/@?3Z#^5 '04444 %%%% !7Y[_\%>6Q\*K7
MEA\IZGUW#(Y[]#7Z$5^>_P#P5Y;'PJM>6'RGJ?7<,CGOT- 'XOU^@?[!N3^S
M[\0CPV&@&>Z_Z5%Q_6OS\K] _P!@U3_PS[\0B5&-T&&Q@_\ 'U%^?_UJ /2J
M*** "BBB@ HHHH **** "BBB@ HHHH **** .6_:0CQ^RSKLFS&=0QYFSDXB
M'&=G/7IN;&2=JYRWYMU^DG[2$>/V6==DV8SJ&/,V<G$0XSLYZ]-S8R3M7.6_
M-N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OT._X(^KN^*&I
M<<YX)/'\!QTZ\>W2OSQK]#O^"/>/^%H:D#T^G(X7!S@]^.W44 ?LU1110 44
M44 %(#UXQ_6EI!GG/X4 ?SZ?\%#C_P 9%:L,]O7_ .O_ $_^MY1\!E/_  L&
MP("YWK\QZ]>E>K_\%#C_ ,9%:L,]O7_Z_P#3_P"MY1\!E/\ PL&P("YWK\QZ
M]>E 'Z<?%"\6YUK3XU+'[/IUO"5;.%^4G"_,1C##H%')X)RS<?78?%"\6YUK
M3XU+'[/IUO"5;.%^4G"_,1C##H%')X)RS<?0 4444 %%%% !1110 4444 %%
M%% !1110 5\P_P#!1M-GQHM5"[!'9HA7;MV':ORXVKCZ;5Q_=7H/IZOF#_@H
MVOE_&BT39Y>RR5=NW;C"KQC:N,=,;5QC[J]  ?*-%%% !1110 4444 %%%%
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M+TVY'\0Z\]N/\X-9/PE_Y-K^'YV[?WEUV_V8?;_/O6MT7IMR/XAUY[<?YP:
M&4444 %%%% !1110 4444 %%%% !1110 5XG^WQL_P"%<_#[:-K>5+D8Q_RV
MDYQ]<\]\>U>V5XI^WRS'X;_#T,!@12X(;/\ RV?CV/\ B* /AVBBB@ HHHH
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MN=0M1C/[U>V>X]C_ "H _HU_8Y_Y(#X;_P"N2_\ H"U[4O"@9S[FO%?V.?\
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M_P")H_X?*VO_ $"/_(9_^)K\H** /U?_ .'RMK_T"/\ R&?_ (FC_A\K:_\
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MB@ HHHH **** "BBB@ I[G=S][+'YCU/UYIE/<[N?O98_,>I^O- 'C_[>/\
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M110 4444 %%%% !1110 4444 *IP&Y(R.W?FM[P+\OCK0>B_Z?#T/'^L'O\
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MV2C9MV[<*HQMVKMQCIM7']U>@ /E&BBB@ HHHH **** "BBB@ HHHH ****
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M^&'V_P ^]:W1>FW(_B'7GMQ_G!H 91110 4444 %%%% !1110 4444 %%%%
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M$\@!X/SFB&SGN6410R2%NFU2<UI2^#]9AMQ.^G3A",_<.>^?Y?J* ,S[7/\
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M444 %/<[N?O98_,>I^O-,I[G=S][+'YCU/UYH \@_;R7_BR_P])P>;@CC/\
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MA\W' QT_E0 ^BBB@!D;;L'=N^4'@<?44^F1MNP=V[Y0>!Q]13Z /F#]O9O\
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MX2#3,\?Z3'_Z$*_5WQ=(6M_#8+9*Z-; J'W;>&./O''7/1.N<'.]ORA\._\
M(P:9_P!?47_H8K]7O%S9M_#:[]^S1K9>6SCACTW''7.,)US@YWL <]1110 4
M444 %%%% !1110 4444 %%%/7[HX4]>I]OK0 RBBB@#,_;\)_P"%5^&PW+?V
M3;C[V<DPK^F,\8Y)_"OS-T[G4+48S^]7MGN/8_RK],OV^@1\*?#2@G;_ &1;
MX! ''DIDX]^!G'?&.U?F;IW.H6HQG]ZO;/<>Q_E0!_1K^QS_ ,D!\-_]<E_]
M 6O:ESM&>3WQ7BO['/\ R0'PW_UR7_T!:]J7A0,Y]S0 M%%% !1110 4444
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M_G^HK^A&/_5KCC@=!C].U #J*** "BBB@ HHHH **** "BBB@ HHHH ****
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MP^]R!_%QGI['/TK\AOC-^TQXO^+6O:E->:K*=/FFWQ1 GY5SGO0!]B_MD?\
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MQ)^=?!]?>/[>3?\ %E_AZ.G-P.._^D2'G/\ 3T^M?!U !1110 4444 %%%%
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MXQM7&.F-JXQ]U>@^GZ^8?^"C:>7\:+5-OE[+-%V;=N/E7C&U<8Z8VIC^ZO0
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M\3_;XV?\*Y^'VT;6\J7(QC_EM)SCZYY[X]J /AZBBB@ HHHH **** "BBB@
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MY5^F7[?A/_"J_#8;EO[)MQ][.285_3&>,<D_A7YFZ=SJ%J,9_>KVSW'L?Y4
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MKR* /IJBBB@ HHHH **** "BBB@ HHHH **** "BBB@#IO"+;?#_ ([Y"_\
M%/3]?^NT-?DOK&/[7OL<CSWQG_>-?K1X3_Y%[QX"VT'P[.,_]M8:_)G6R6UJ
M_)Z_:),X.?XCWH ^B/\ @GSS^T=H8QDYS]W/ZX./T^M?T(Q_ZM<<<#H,?IVK
M^>__ ()\C=^T9HG&><__ %\8/Y\8]>:_H0C_ -6N%V\#Y1VH =1110 4444
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MSD_X9I^'';PU:CT^4'^?O_G'%>F-(5/( '<Y. /KCT!_R:4L<_+Z'@@CD>]
M'EUQ^S3\-Q;RD^&;7&TY^7/;_/U[U^"_[8OA_3O#?QY\066E1"&RCDVJJ]."
M?<^W^>!_1I?#%A<Y;'[MOF/&.#Z8K^=7]MC)_:&\2,><RG/ ^]N8$<$T =7^
MP8P_X69 &7($N1P>F!GG'!Z?K[5^]WA'_D7;'I_JEZ?[HZU^!W[""[OB9 <E
M3YO4 >@..AZX/IWQWK]\?">?^$;L<'GR5QD' ^4?YXH UT;<JGCD9^4Y%?CW
M_P %CF'_  G>D@ECR,#^$?*?U./TZ]J_8:OQ[_X+&L3XZTD?,<  ]<=#CO\
M[W&._7I0!^;=?IA\&1C]G/P9QC,L_;K\L?M_C_0?F?7Z8?!D8_9S\&<8S+/V
MZ_+'[?X_T !NT444 %%%% !1110 4444 %%%% !1110 4]SNY^]EC\QZGZ\T
MRGN=W/WLL?F/4_7F@#R#]O#/_"E_A_C/6XSC'_/Q)UKX.K[Q_;R7_BR_P])P
M>;@CC/\ R\2?E_GUKX.H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#M_@B?^+L>%^,_P"FI^%?TH^ %V^"=$&T+_HD? ^GT'\J_FO^")Q\6/#'
M)&;Q.G?ZU_2AX 7;X)T0;0O^B1\#Z?0?RH Z"BBB@ HHHH *_/?_ (*\MCX5
M6O+#Y3U/KN&1SWZ&OT(K\]_^"O+8^%5KRP^4]3Z[AD<]^AH _%^OT#_8-X_9
M]^(7##+0'IP?]*BYZ?YYK\_*_0+]@O\ Y-^^(?S9RT' ''_'U%UX_P YH ]+
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH Y;]I"/'[+.NR;,9U#'F;.3B
M(<9V<]>FYL9)VKG+?FW7Z2?M(1X_99UV39C.H8\S9R<1#C.SGKTW-C).U<Y;
M\VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_0[_ ((]_P#)
M4-2;;D#@G&0,A?8_Y!K\\:_0[_@CVN[XH:D0-Q';!/&%R>G;CO0!^S5%%% !
M1110 4U<9;!R<\\].*=2 ]>,?UH _GT_X*''_C(K5AGMZ_\ U_Z?_6\H^ RG
M_A8-@0%SO7YCUZ]*]7_X*''_ (R*U89[>O\ ]?\ I_\ 6\H^ RG_ (6#8$!<
M[U^8]>O2@#]./BA>+<ZUI\:EC]GTZWA*MG"_*3A?F(QAAT"CD\$Y9N/KL/BA
M>+<ZUI\:EC]GTZWA*MG"_*3A?F(QAAT"CD\$Y9N/H **** "BBB@ HHHH **
M** "BBB@ HHHH *^8/\ @HVAC^-%HA79MLE4)LV[<*HQC:N,>FU<=-J]!]/U
M\P_\%&T\OXT6J%=A6S10NW9M 51C;M7'TVICIM7H #Y0HHHH **** "BBB@
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M7DIRV,9^][<__7KZ_KY!_P""?&?^%>VW&!L_,\\]/IZ]*^OJ "BBB@ HHHH
M**** "BBB@ HHHH **** $8X4G&?85^0/_!4+/VV91GY0>1P?^^<\ ]^.W>O
MU^8X4G&?85^0'_!4/ OIE)Y4$#<, ^^ >/R'Z4 ?G1X<&[Q!IG_7S'W_ -H5
M^KOBZ3S+?PV V=NC6PVEONY#'&-QV]<XPG7.#G>WY1>',?\ "0:9GC_28_\
MT(5^KOBZ0M;^&P6R5T:V!4/NV\,<?>..N>B=<X.=[ '/4444 %%%% !1110
M4444 %%%% !113U;"@;F'7@?3^M #**** ,S]OH$?"GPTH)V_P!D6^ 0!QY*
M9./?@9QWQCM7YFZ=SJ%J,9_>KVSW'L?Y5^F'[?6W_A5/AP !?^)3;;E ./\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36.T=0O(Z_6G44
M,&"W\6<D]\<<?Y_.F2;4AE8'("D;AR< =,YYYS4F[YB!R.AQV[\_I45RI6UG
MYR-K$?E0!^-'_!3CQ?)?>(;BQ:X\U02N-_ .<],X[K^ K\]1CG/X5]J?\%'I
M&;XD7F6+'?G:#SR!ENOMZ=S7Q70!W/P1T\:E\3]!C.,+.K?,,CKC^M?TD?#-
M/+\ Z$NW;MM5&W&,>U?SE?LZ6WVCXL:)\NX"91@9SRPZ<'L#VK^C?X<+Y/@/
M1 <X%JO;DC\* -\1[E*N.2N!_%@8&1DCU]>M2*NW=V&<C_/US0RCD[=W^S].
M10N<MG/7C./3M0!^*G_!5SPG=M\5CK 5I(\'+Y)R,<GVX&?QZ5\"5^OW_!3W
M0;672)[@JK,"2&1AGD9&!G@>V#VZ]_R"1MK*>>#GY3@T &T[<\8^HS_GBDHK
MO_A1\&/$/Q8UZTL-)LI9EE<!F52<#(_+/3- ',^&O".L^,[X6FCV,VH7.!^[
MB4L>PK[;_8__ ."<^K_$V^CU+Q5:2V%O;NLOE297=T.,$8XK[G_8Y_8+\/\
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MW&1WR/;U'?UK][_"F4\.V>_Y<1 G=QVR>WKFOP-_8-&[XGQ8ZK(,\#IC\_\
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MI]=PR.>_0T ?B_7Z!_L%_P#)OOQ$QR-]OGZ_:8J_/ROT#_8-R?V??B$>&PT
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MW'UV'Q0O%N=:T^-2Q^SZ=;PE6SA?E)POS$8PPZ!1R>"<LW'T %%%% !1110
M4444 %%%% !1110 4444 %?,'_!1N/ROC1:)MV;;)1LV[=N%48V[5VXQTVKC
M^ZO0?3]?,'_!1I1'\:+:,+LVV: IMV[2%48QM7;]-J_[J]  ?*-%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5]0_P#!.L$_M&:/W&1QC/K_ )Z&
MOEZOJ#_@G7@_M&Z./XLC"^O7MW_*@#^@9L97.>O&,^G>G4UNJ\D<]A[=Z=0
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MMNCD (QR/7T]_P"5:A8+R3CM0 M%1JYZE@1G:3D 9]OQXQ3E8MGE2/4?4\4
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M."* /IZBBB@ HHHH **** "BBB@ HHHH **** "BBB@#IO"+;?#_ ([Y"_\
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M'XTH5B1G('&23R<9].!VH?<V0 W<=<#IUSU]J4?-Y@897.,$<8P/:@!-V_&
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M (LO\/1TYN!QW_TB0\Y_IZ?6O@ZOO']O#/\ PI?X?XSUN,XQ_P _$G6O@Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .X^".?^%L>&,' ^V)G
MGK7]*'@!=O@G1!M"_P"B1\#Z?0?RK^:[X(G_ (NQX7XS_IJ?A7]*/@!=O@G1
M!M"_Z)'P/I]!_*@#H**** "BBB@ K\]_^"O+8^%5KRP^4]3Z[AD<]^AK]"*_
M/?\ X*\MCX56O+#Y3U/KN&1SWZ&@#\7Z_0/]@U3_ ,,^_$(E1C=!AL8/_'U%
M^?\ ]:OS\K] OV"U _9^^(9(^8M!@^WVJ+\J /2Z*** "BBB@ HHHH ****
M"BBB@ HHHH **** .6_:0CQ^RSKLFS&=0QYFSDXB'&=G/7IN;&2=JYRWYMU^
MDG[2$>/V6==DV8SJ&/,V<G$0XSLYZ]-S8R3M7.6_-N@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OT._X(^KN^*&I<<YX)/'\!QTZ\>W2OSQK
M]#O^"/>/^%H:D#T^G(X7!S@]^.W44 ?LU1110 4444 %-7&6P<G///3BG4@/
M7C']: /Y]/\ @H<?^,BM6&>WK_\ 7_I_];RCX#*?^%@V! 7.]?F/7KTKU?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** &9RW7=AOX>W'?G_ #D4VZQ]FESP-ASCZ4[:58')
M;J,?4C^5,N_^/6;_ '&_E0!^&'_!1YO^+B7:Y7._(&1Z#L3^OM[U\65]J?\
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MV39C.H8\S9R<1#C.SGKTW-C).U<Y;\VZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_0[_@CZ/^+G:D2,KD9(7./NXY[?GW[U^>-?H=_P1[_Y
M*AJ3;<@<$XR!D+['_(- '[-4444 %%%% !2#/.?PI:0-G/M[4 ?SZ?\ !0X_
M\9%:L,]O7_Z_]/\ ZWE'P&4_\+!L" N=Z_,>O7I7J_\ P4./_&16K#/;U_\
MK_T_^MY1\!E/_"P; @+G>OS'KUZ4 ?IQ\4+Q;G6M/C4L?L^G6\)5LX7Y2<+\
MQ&,,.@4<G@G+-Q]=A\4+Q;G6M/C4L?L^G6\)5LX7Y2<+\Q&,,.@4<G@G+-Q]
M !1110 4444 %%%% !1110 4444 %%%% !7S#_P4;3R_C1:IM\O99HNS;MQ\
MJ\8VKC'3&U,?W5Z#Z>KY@_X*-H8_C1:(5V;;)5";-NW"J,8VKC'IM7'3:O0
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M **** "BBB@ HHHH **** "BBB@ KQ3]OEF/PW^'H8# BEP0V?\ EL_'L?\
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M6RV @G/^K7&>A/./R^M>2_LA_L#W?P/^,FJ:WJ">9IS.[6P(R!@G!R<],]*
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M^"@_[;TG@70+KPWX?@Q=3+Y<COCN1D>H_GWK]#)H%GBDB<9C<8////6OBO\
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M*MW_ ,?4W^^W\Z^IO^"<LT5O\<S+/O\ )2W+/Y<HB; 5B<.2-I_VLC&#\PH
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M]3Z[AD<]^AH _%^OT#_8+R?V??B)SP'MQC _Y^8J_/ROT#_8-Y_9]^(1ZX:
M9/;_ $J+@>U 'I5%%% !1110 4444 %%%% !1110 4444 %%%% '+?M(1X_9
M9UV39C.H8\S9R<1#C.SGKTW-C).U<Y;\VZ_23]I"/'[+.NR;,9U#'F;.3B(<
M9V<]>FYL9)VKG+?FW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7Z'?\ !'M=WQ0U(@;B.V">,+D].W'>OSQK]#O^"/O_ "5#4CQP>F,_W!Z>
M_MVH _9JBBB@ HHHH *0'KQC^M+2#/.?PH _GT_X*''_ (R*U89[>O\ ]?\
MI_\ 6\H^ RG_ (6#8$!<[U^8]>O2O5_^"AQ_XR*U89[>O_U_Z?\ UO*/@,I_
MX6#8$!<[U^8]>O2@#]./BA>+<ZUI\:EC]GTZWA*MG"_*3A?F(QAAT"CD\$Y9
MN/KL/BA>+<ZUI\:EC]GTZWA*MG"_*3A?F(QAAT"CD\$Y9N/H **** "BBB@
MHHHH **** "BBB@ HHHH *^8?^"C:>7\:+5"NPK9HH7;LV@*HQMVKCZ;4QTV
MKT'T]7S!_P %&X_*^-%HFW9MLE&S;MVX51C;M7;C'3:N/[J]  ?*-%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5]0_\$ZP3^T9H_<9'&,^O^>AK
MY>KZ@_X)UX/[1NCC^+(POKU[=_RH _H&89*\ X/?MQVH#'/W2.OI0V,KG/7C
M&?3O1L^8=P,GGDY_SF@!U%%% #(VW8.[=\H/ X^HI],C;=@[MWR@\#CZBGT
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M_9UV_P#"Y?#&]=R?:ERN,Y&>F.]?I%X\+-XTUPN"K?;)<@D$_>/I0!A4444
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M#G>P!SU%%% !1110 4444 %%%% !1110 4H4?W@.OK24H8CCCOV'>@!****
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M(^\,=/NY//Y4@S&H 4$!>B\?@!_]>C<200IVX],'G_"D+LI&<#IGC@?CW]*
M'*V[..@.,TZD4Y4'&/8TM !1110 4444 %%%% !7@O[;F!^SUXC)_P">3=>A
M^4\?Y]#7O5>#?MM\?L]^(F!VXB))7J/E//\ GV^H /YU;O\ X^IO]]OYU]7?
M\$U7:/\ :!@=(9+AEBW"*,C<Y 8[1D@9XZD@=>17RC=_\?4W^^W\Z^JO^";M
MO)>?'I((G\N22'8LGS?*2&Y^5E;CKD$'@X(H ^GJ*** "BBB@ HHHH ****
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M'<]NU 'Z9_"52/V:_A_D?\M+KMC^&'V_S[UK=%Z;<C^(=>>W'^<&LCX1@?\
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M%%% !7U!_P $Z\']HW1Q_%D87UZ]N_Y5\OU]0_\ !.OG]HS1QMSDC^O'^0:
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M5+P<<'SG_3I^OK0!\.T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 4444 %%%% !1110 4444 %%%% !1110!].?L)J&^)5OE0?WPZQEO[O\
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M HHHH **** "BBB@ HHHH **** "BBB@ KP;]MLD?L]^(L<'RCALX(.T]_\
M/8]J]YKP7]MS _9Z\1D_\\FZ]#\IX_SZ&@#^=:[_ ./J;_?;^=?57_!-VWDO
M/CTD$3^7))#L63YOE)#<_*RMQUR"#P<$5\JW?_'U-_OM_.OJ;_@G+-%;_',R
MS[_)2W+/Y<HB; 5B<.2-I_VLC&#\PH ^HJ*** "BBB@ HHHH **** "BBB@
MHHHH **** .F\(MM\/\ COD+_P 4]/U_Z[0U^3&M9&L7X*[3Y\GR^GS'BOUG
M\(MM\/\ COD+_P 4]/U_Z[0U^2^L8_M>^QR//?&?]XT ?17_  3Y7=^T=H?R
M@X/7J1^A_/\ 45_0C'_JUQQP.@Q^G:OY[O\ @GSS^T=H8QDYS]W/ZX./T^M?
MT(Q_ZM<<<#H,?IVH =1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC_A']. &W$"#!ZCCIT%>$^$OV%?ACX+UR'5=.TQ8[N+E&V \YSWS_DU]!6L
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MD9Z8[U^D7CPLWC37"X*M]LER"03]X^E &%1110 4444 %%%% !1110 4444
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M\H/(X/\ WSG@'OQV[T ?G/X<8KX@TP@X_P!)C'_CPK]7?%KAK;PTJGY5T:V
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MU_0C'_JUXQP.N?ZT .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)Z<9_I2TC9
MVG'![9H 8J[E (8#;C[QS_GWJMK.GKJVF7%HXRLJ[2#TY]:L;51B"<;@%"J,
M$ <=N>_X4X94GY0<GJO!_P XQ0!^%O\ P4N^%\'PY^(R>5&$-S)OZ\\@GOSW
MS^/M7Q97[,_\%,/V2]:^+UJWB[3-[#3HPY1,MD8.?EZ@^W]>OXVWUC/IMY+;
M7,;131L596'<'% '[F?\$JW)_9_C#*%.4/S+ACP1UP/Z^QK[1:09.&&T<E@1
MQUSGVXQ7Y+?\$R_VOM&\&QV7@'49%A%QCYY!@[N!Z<^Y_2OUBL]3M-2C$MI<
M)<KC<#$^0>W^?PH M;AN SSUQ0K;E!'?U&*3:2,$]\\<=Z%7:H'&!TP,#':@
M!U%%% !3?,&TG#=,_=-.INT<<9P<C/- #=Y+$?*.<<9/OSZ<?S_,:,MN'?!
M;N,]N/PI6RP8;01@C:W1O_K4X=^<_P!* $"GKG'.<9SGM3JCV[G)].^.1TX'
M'0_Y]I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"OJ)QI]T<X_=-WQV/N/YU_.M^VYD_M%>)\AL>:0">GWCP/S_6OZ*=0_
MX\;G+;1Y;?,>W!YK^=7]MK)_:)\3,5P3*<\8YW-QU/8B@#J?V#?^2F1#'_+0
M'(SV7'/'^U[?RK]\O"?_ "+]F>#F->5& >![#_/Y5^!O[!O_ "4V+CK)UY[#
MZ8[^W4^M?OEX3_Y%^S/!S&O*C / ]A_G\J ->OQ[_P""QK$^.M)'S'  /7'0
MX[_[W&._7I7["5^/7_!8[GQWI WD]&V]AP03C/NO/X>M 'YN5^F'P9&/V<_!
MG&,RS]NORQ^W^/\ 0?F?7Z8?!D8_9S\&<8S+/VZ_+'[?X_T !NT444 %%%%
M!1110 4444 %%%% !1110 4]SNY^]EC\QZGZ\TRGN=W/WLL?F/4_7F@#R#]O
M)?\ BR_P])P>;@CC/_+Q)^7^?6O@ZOO#]O'_ )(Q\/N>]QV/_/Q)_GFO@^@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .X^")Q\6/#')&;Q.G?
MZU_2AX 7;X)T0;0O^B1\#Z?0?RK^:_X(_P#)6/#' /\ IB=3_*OZ4/ "[?!.
MB#:%_P!$CX'T^@_E0!T%%%% !1110 5^>_\ P5Y;'PJM>6'RGJ?7<,CGOT-?
MH17Y[_\ !7EL?"JUY8?*>I]=PR.>_0T ?B_7Z!_L&Y/[/OQ"/#8: 9[K_I47
M']:_/ROT#_8-4_\ #/OQ")48W08;&#_Q]1?G_P#6H ]*HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Y;]I"/'[+.NR;,9U#'F;.3B(<9V<]>FYL9)VKG+
M?FW7Z2?M(1X_99UV39C.H8\S9R<1#C.SGKTW-C).U<Y;\VZ "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *_0[_ ((^_P#)4-2/'!Z8S_<'I[^W
M:OSQK]#_ /@CV"WQ0U+&0<Y##Z+D=.XSZ4 ?LS1110 4444 %-7&6P<G///3
MBG4@/7C']: /Y]/^"AQ_XR*U89[>O_U_Z?\ UO*/@,I_X6#8$!<[U^8]>O2O
M5_\ @H<?^,BM6&>WK_\ 7_I_];RCX#*?^%@V! 7.]?F/7KTH _3CXH7BW.M:
M?&I8_9].MX2K9PORDX7YB,88= HY/!.6;CZ[#XH7BW.M:?&I8_9].MX2K9PO
MRDX7YB,88= HY/!.6;CZ "BBB@ HHHH **** "BBB@ HHHH **** "OF#_@H
MW'Y7QHM$V[-MDHV;=NW"J,;=J[<8Z;5Q_=7H/I^OF#_@HTHC^-%M&%V;;- 4
MV[=I"J,8VKM^FU?]U>@ /E&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_K![_P"?>@#\W_VDO^2U>*>=W^E-_P#JKS.O2_VD,?\ "ZO%..GVMOYUYI0
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M_?;^=?5W_!-5VC_:!@=(9+AEBW"*,C<Y 8[1D@9XZD@=>10!]-4444 %%%%
M!1110 4444 %%%% !1110 4444 =-X3;;X>\>$?]"[/^/[V'BOR9UO\ Y#5_
MSN_TB3YCW^8\U^LWA%MOA_QWR%_XIZ?K_P!=H:_)C6LC6+\%=I\^3Y?3YCQ0
M!]%?\$^5+?M&:)PQ /\ =R/KT/\ G/(K^A"/_5KQC@=<_P!:_GN_X)\KN_:.
MT/Y0<'KU(_0_G^HK^A&/_5KQC@=<_P!: '4444 %%%% !1110 4444 %%%%
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M/@!=O@G1!M"_Z)'P/I]!_*OYK_@CG_A;'AC!P/MB9YZU_2AX 7;X)T0;0O\
MHD? ^GT'\J .@HHHH **** "OSW_ ."O+8^%5KRP^4]3Z[AD<]^AK]"*_/?_
M (*\MCX56O+#Y3U/KN&1SWZ&@#\7Z_0+]@M0/V?OB&2/F+08/M]JB_*OS]K]
M _V#<_\ #/OQ"X*_-!VX/^E1<T >E4444 %%%% !1110 4444 %%%% !1110
M 4444 <M^TA'C]EG79-F,ZACS-G)Q$.,[.>O3<V,D[5SEOS;K])/VD(\?LLZ
M[)LQG4,>9LY.(AQG9SUZ;FQDG:N<M^;= !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?H=_P $?5W?%#4N.<\$GC^ XZ=>/;I7YXU^AW_!'O'_
M  M#4@>GTY'"X.<'OQVZB@#]FJ*** "BBB@ I!GG/X4M(,\Y_"@#^?3_ (*'
M'_C(K5AGMZ__ %_Z?_6\H^ RG_A8-@0%SO7YCUZ]*]7_ ."AQ_XR*U89[>O_
M -?^G_UO*/@,I_X6#8$!<[U^8]>O2@#]./BA>+<ZUI\:EC]GTZWA*MG"_*3A
M?F(QAAT"CD\$Y9N/KL/BA>+<ZUI\:EC]GTZWA*MG"_*3A?F(QAAT"CD\$Y9N
M/H **** "BBB@ HHHH **** "BBB@ HHHH *^8?^"C:;/C1:J%V".S1"NW;L
M.U?EQM7'TVKC^ZO0?3U?,'_!1M?+^-%HFSR]EDJ[=NW&%7C&U<8Z8VKC'W5Z
M  ^4:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ@_X)UX/[1NC
MC^+(POKU[=_RKY?KZA_X)U\_M&:.-N<D?UX_R#0!_0*W5>2.>P]N].IK=5Y(
MY[#V[TZ@ HHHH 9&V[!W;OE!X''U%/ID;;L'=N^4'@<?44^@#Y@_;V;_ (LW
MJ@S_  =,^P]_Z?\ U_Y_=0(-]<D=/,;&/J?85_0%^WLW_%F]4&?X.F?8>_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG$0XSLYZ]-S8R3M7.6_-N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO?M(8_X75XIQT^UM_.O-*],_:2)/QJ\4Y_Y^F[YKS.@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /IW]A-=WQ,MAM5\2Y(/..!S[>Q[GBOWS\*
MY;PS8 JI_<* ">#QWK\#/V$UW_$NW&U7Q,&VGMQU[_TYQSZ?OEX47_BE]/&Q
M>8!\O8_7CO0!LT444 %%%% "-G:<<'MFOR _X*@L/MDH7;C&5'8+^)_H/TK]
M?V&Y2#W]#BOR!_X*A,6O[@$ODY8J?F!]\9X_[Y'<T ?G/X<&[Q!IG_7S'W_V
MA7ZN^+I/,M_#8#9VZ-;#:6^[D,<8W';USC"=<X.=[?E%X<Q_PD&F9X_TF/\
M]"%?J[XND+6_AL%LE=&M@5#[MO#''WCCKGHG7.#G>P!SU%%% !1110 4444
M%%%% !1110 4]6PH&YAUX'T_K3** "BBB@#,_;\)_P"%5^&PW+?V3;C[V<DP
MK^F,\8Y)_"OS%K].OV^@1\*?#2@G;_9%O@$ <>2F3CWX&<=\8[5^8M !110.
M>^* "BE9MW8 9S@4E !1110 4JJ6!(QQZD"DH'?G']: "BBB@ HHHH ****
M"BBAFW,3Z^@Q0!-9W4]G<+);2-',.%9.M?T,?L&75S>_L\:%+=S&>4J!O)SP
M !7\\<./-3/3<,]/Z\?G7]#7[!*[?V=]$&T*<<\YR<#)_/\ I0!]%1G*CG<.
MS9Z\=:=35)903WYZ8IU !1110 5X+^VY_P F^>(> ?W9'S' /RGC/'\_\1[U
M7@O[;C8_9Z\1@DA3$P/_ 'R3^?'^>H /YUKO_CZF_P!]OYU]7?\ !-5VC_:!
M@=(9+AEBW"*,C<Y 8[1D@9XZD@=>17RC=_\ 'U-_OM_.OJK_ ()NV\EY\>D@
MB?RY)(=BR?-\I(;GY65N.N00>#@B@#Z>HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH Z;PBVWP_P".^0O_ !3T_7_KM#7Y+ZQC^U[[ P//?&?]XU^M'A-M
MOA[QX1_T+L_X_O8>*_)G6_\ D-7_ #N_TB3YCW^8\T ?1'_!/E0W[1VA\ G.
M>A)_D?Z?6OZ$8SF-3G=P.0<YK^>__@GRI;]HS1.&(!_NY'UZ'_.>17]""9VK
MNY;'- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (4 =3^P;_R4R(8_Y: Y&>RXYX_VO;^5?OEX3_Y%^S/!S&O*C / ]A_G\J_
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M@YR&'T7(Z=QGTK\\*_0[_@CZN[XH:EQSG@D\?P''3KQ[=* /V:HHHH ****
M"D&><_A2TU<9;!R<\\].* /Y]?\ @H<?^,BM6&>WK_\ 7_I_];RCX#*?^%@V
M! 7.]?F/7KTKU?\ X*''_C(K5AGMZ_\ U_Z?_6\H^ RG_A8-@0%SO7YCUZ]*
M /TX^*%XMSK6GQJ6/V?3K>$JV<+\I.%^8C&&'0*.3P3EFX^NP^*%XMSK6GQJ
M6/V?3K>$JV<+\I.%^8C&&'0*.3P3EFX^@ HHHH **** "BBB@ HHHH ****
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M])G[+WC";QQ\'-$U2YD$EQ-&&;UY4'G\<UZOM+,"0O&??Z'\OYU^:W_!+_\
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M7!S@]^.W45^>-?H=_P $?1_Q<[4B1E<C)"YQ]W'/;\^_>@#]FJ*** "BBB@
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MA+_R;7\/SMV_O+KM_LP^W^?>M;HO3;D?Q#KSVX_S@T ,HHHH **** "BBB@
MHHHH **** "BBB@ KQ/]OC9_PKGX?;1M;RI<C&/^6TG./KGGOCVKVRO%/V^6
M8_#?X>A@,"*7!#9_Y;/Q['_$4 ?#M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?LQ_P1Y7;\+=1XVYR>G7E>>@Y_P%?H:W#$XQT&Y1DGGI
MTZ?XFOSR_P""/*[?A;J/&W.3TZ\KST'/^ K]#6X8G&.@W*,D\].G3_$T /HH
MHH **** .>^(3;?!&MG./]%?G..WU'\Z_FL^,_'Q3\2C&/\ 3&[8[#V%?TI_
M$)MO@C6SG'^BOSG';ZC^=?S6?&?CXI^)1C'^F-VQV'L* -7]G,%OC/X7 )4F
M[7YAU'-?H_XXV?\ "8ZWY?W/MDN,$G^(^M?F_P#LZ[?^%R^&-Z[D^U+E<9R,
M],=Z_2+QX6;QIKA<%6^V2Y!()^\?2@#"HHHH **** "BBB@ HHHH **** "B
MBB@!5. W)&1V[\UO>!?E\=:#T7_3X>AX_P!8/?\ S[U@J<!N2,CMWYK>\"_+
MXZT'HO\ I\/0\?ZP>_\ GWH _-[]I#'_  NKQ3CI]K;^=>:5Z9^TD2?C5XIS
M_P _3=\UYG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'T[^PF
MN_XEVXVJ^)@VT]N.O?\ ISCGT_?3PH2/#6GG&<0+@ \GBOP+_837?\2[<;5?
M$P;:>W'7O_3G'/I^^7A1<>%]/&W'[@<(<9_ES0!LT444 %%%% ",-RD'OZ'%
M?D#_ ,%1)-UY*Q(;()SG)YSVSW]<#^@_7YAN4@]_0XK\@?\ @J$^Z]F8$LS;
MCPQSC'7Z'Z#H: /SG\.8_P"$@TS/'^DQ_P#H0K]7?%TA:W\-@MDKHUL"H?=M
MX8X^\<=<]$ZYP<[V_*'P[_R,&F?]?47_ *&*_5[Q<V;?PVN_?LT:V7ELXX8]
M-QQUSC"=<X.=[ '/4444 %%%% !1110 4444 %%%% !112C;W)SSV_*@!***
M* ,S]OPG_A5?AL-RW]DVX^]G),*_IC/&.2?PK\Q:_3K]OH$?"GPTH)V_V1;X
M! ''DIDX]^!G'?&.U?F+0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #H3B5#G'S#V_J*_H9_8'_P"3=="&,8&.F/Z"OYYH3B5#G'S#V_J*_H:_
M8'X_9UT$8QQZ8_H/Y4 ?1E%%% !1110 5X+^VXV/V>O$8)(4Q,#_ -\D_GQ_
MGJ/>J\&_;;)'[/?B+'!\HX;."#M/?_/8]J /YU;O_CZF_P!]OYU]7?\ !-5V
MC_:!@=(9+AEBW"*,C<Y 8[1D@9XZD@=>17RC=_\ 'U-_OM_.OJK_ ()NV\EY
M\>D@B?RY)(=BR?-\I(;GY65N.N00>#@B@#Z>HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH Z;PFVWP]X\(_P"A=G_'][#Q7Y,ZW_R&K_G=_I$GS'O\QYK]
M9O"+;?#_ ([Y"_\ %/3]?^NT-?DQK61K%^"NT^?)\OI\QXH ^BO^"?*EOVC-
M$X8@'^[D?7H?\YY%?T(1_P"K7'' Z#'Z=J_GN_X)\KN_:.T/Y0<'KU(_0_G^
MHK^A&/\ U:XXX'08_3M0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CDY(]!C
MMD'G_/YU)2,VU23V]!F@",ME@1PW3:6&,XS@_GGCTI?EV@D_(O\ >]N_/THC
M!4XW!L#!Y/' [<^I_2E^9L-C:>P)SQQG/O0 O*Y"JN.O7'?FC<6Y7:RG!!SU
MH\L#IP>!GJ<#M_GUH5=I)ZD]^_TH ,O_ '5[]_R[4?-GH,9]>V/\:=10 W+_
M -U>W?\ /M1E_P"ZO?O^7:G44 -^;/08SZ]L?XT9?^ZO;O\ GVIU% $9<\\J
MO;.<X/;^=.SM/)')X_+_ /73J:R_*5!QGW/XT (K%NA!/!P>" ?7]:87W="W
M/*G(Z=,C'7UY]1^#XU*YSC_@/3W/YTHW*I)&3UVCZ=!0 *H.&*X/7#<X.,4Z
MF!CNQN!Y(.!^(^G%/H **** "BBB@ HHHH **** "BBB@ HHHH ***0L%Y)Q
MVH 6BF[AM+$X ZD\4,P49)_Q- #J8Y.< X)'08SVYY]*7=UP"<'%-=BL;'=A
MD'/& >/?M^/XT 87C3Q?IO@CP]=ZCJ=S'90I'(P9C@9 )]O\FOP)_;4^/$_Q
M8^)&J6L5RUQI=O*/(^8[1CVSC^M?1/\ P4G_ &P-3\2:E/X%TNZ:"*WDVRM"
MQ&5YXZ\]._MZDG\YY9GGD+R,7<]6;J: $56D8*JEF] ,FO6_A_\  /4?%7A^
MZU6YC>&*,94'(_SD9[]O:LGX$_"W6OBAX^TNQTNS>YC6X7SF"D@+U/0'M7ZC
M?M%?!NP^$?P#M_LL(CNFMP)0N-S$@8STSR2<>_MP ?CYJ=J+'4+BW4Y$;E?R
M[5!(H5B V[_]=6]8?S]7NR#D&5@#D8ZXZU2H _<S_@E(NWX!1G:RYVG+=^.O
MU]?<&OMAV^]P-P/R9[G';./>OB;_ ()2JO\ PH5&&W)V],\<#U]<9[]>IK[;
MW%LXX'J0?7GB@ 7C("[1G\^^:^'_ /@JMXFN/#OP:1H)&3S.&VDY(R?>OM]6
M5?E&T ': #[9Q7P+_P %=Y4'P;MT8X/7!/7D]L^O?ZT ?BO/,]Q,\LAW.YR2
M:81M_P#UT44 ?J;_ ,$<]%M[P:K<R(#)&Y(W+GH6]O3/YU^K&-HVJ0#CY5QP
M/P]*_+C_ ((SY_L_6NZAFYP>,[N_X?S]Z_4@KNR#RI&-IZ4 ,#%LE5P"020,
M$].Q'^<5\[_M\2&/]G;7,'&Y2O7'53[C_#UXS7T2Q56Z;B/F/<C@\X_#M7SQ
M^WJOF?L\ZXN?E(P>,T ?SR3,&E<CH6)')/\ .FLI5B",$<$&I+A2MQ*"<D,1
MG\:C..,#ZT ?>?\ P2.CW?&V<@<_)VZX(_SSQ7[9.0I5L>O\))QC_P"M7X2?
M\$R?%4/AGXR;[AMJ2%1S^O8_TZFOW3TN^&I6<=PN"K@$%>G0?U_SWH LE=Z@
M-_P)>H/'2F[@RDOMVCDG.0".OY8H7)W;2N[')"\;NGK[=/:C(C8EBHXSN)&<
M _R&?UH <,;B0.>A./\ /K3JCX3EV7=C.3@8'&<>U/9MJDGMZ#- "T4@;.?;
MVI-ZYQN&<XQGOC./RH AU!MEC<L.,1L>?H:_G5_;:(_X:)\3 '<!*0/FSQN;
MC\\U_15J#;+&Y8<8C8\_0U_.M^VUQ^T3XF4'A92,9)/WCSS_ )XH ZC]@W_D
MID0Q_P M <C/9<<\?[7M_*OWR\)_\B_9G@YC7E1@'@>P_P _E7X&_L&_\E-B
MXZR=>>P^F._MU/K7[Y>$_P#D7[,\',:\J, \#V'^?RH UZ_'O_@L:Q/CK21\
MQP #UQT.._\ O<8[]>E?L)7X]?\ !8[GQWI WD]&V]AP03C/NO/X>M 'YN5^
MF'P9&/V<_!G&,RS]NORQ^W^/]!^9]?IA\&1C]G/P9QC,L_;K\L?M_C_0 &[1
M110 4444 %%%% !1110 4444 %%%% !3W.[G[V6/S'J?KS3*>YW<_>RQ^8]3
M]>: /'_V\?\ DC'P^^MQWQ_R\2?G7P?7WC^WDW_%E_AZ.G-P.._^D2'G/]/3
MZU\'4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!V_P1Q_PMCPO
MG_G]3%?TH^ %V^"=$&T+_HD? ^GT'\J_FO\ @CG_ (6QX8P<#[8F>>M?TH>
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MU_;.TXX/;-?D#_P5"_X_9D!P "1'S@ >O.<_@/?I0!^<_APX\0:9QG_28_\
MT(5^KOBYLV_AM=^_9HULO+9QPQZ;CCKG&$ZYP<[V_*+PXQ7Q!IA!Q_I,8_\
M'A7ZN^+7#6WAI5/RKHUL N?N\,<8W';USC"=<X.=[ '/4444 %%%% !1110
M4444 %%%% !2AF' ) Y[^O6DHH **** ,K]OK;_PJGPX  O_ !*;;<H!Q_J4
MP,=SSZ=!^%?F/7Z=?M^$_P#"J_#8;EO[)MQ][.285_3&>,<D_A7YBT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 Z$XE0YQ\P]OZBOZ&?V!U"_
MLZZ%@8XYXQ_0?RK^>:$XE0YQ\P]OZBOZ&?V!UV_LZZ%].F,8]N@H ^C:***
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M8]?\:^1_VW_VRM+^"/@>[M-+NE?7I 8Q""-X/';.>F[GU'M7O?QN^)=K\)/
M5[K]S(L8A4G<S!=Q"GK[]/TK^?/]IKXJR_%GXF7^K"Y::U=LQJ2<=!SC_/'Z
M@'$?$/QQ>?$7Q9>Z]?DFZNCN?)[]_P!2:Q=*LSJ.IVEJHR9I5CX!/4@57CB>
M9D5!N9VVJHZD_P"37Z!?\$]_V&KGXB^($\1^*K40Z; P>!F4G/&>A&/4?GVY
MH ^U?^">_P"RSIGPE\(1>(9;2-[V_BWJ\B?,,^Q'89X/0G\D_P""BTCKX&FC
M4OL$'RJK8QZ8Y_#CUZ5]>^&]"M_#.BV>EVD82WMTVJ%  'M_GTKY _X*+L/^
M$&N0^%'D<D$],_Y_/OTH _#;6L#5KK;]WS#C'3';'-4CCMS5K5<_VI=YY;S6
M)X[Y-56&UB/3T.: /W*_X)1X7X"(,Y+%2< XZ#O^H]0?K7VVQ&TL!\P! )4D
M_E^%?$W_  2FW#X!QACDD@YVGL IYQSR./\ '-?; ^\"OS9.&;CISQ^!H =M
M(;(/!ZU^?G_!728?\*GB4M@=,>IP??\ +CN>G6OT!C8[57J<#ZXQU(//K7YX
M_P#!78/_ ,*WC8$A, 'G@\?7^G:@#\::*** /UA_X(T _P!FZR1S][/&>-S<
M^W;\Z_4>ORX_X(T_\@O63C^(]O=_:OU%/RG))QP,8H ),;>6V^ASW/%>&_ME
MV:WWP/UF%Q\C1MNQZ;3[_P"<U[F<]N*\6_:Z&[X+ZP/6-NIQVH _G6\4V::?
MX@OH$^ZLK<#MS_G^G%95=!X^C6/Q=J2KT$K#]2 /RQ]>O>N?H ]>_9EU:32O
MB)8O&6'[U<[/O?>'3KC\NU?T+_""XDN?A]I+RY\PQ+NR".<"OYUOV?4+?$*Q
M(P1YBY&,GK]#Z_YZ5_1%\%M__"M])ROEMY?"E<8.!GCCODT =P/FPP) QTQB
MF*WF D'#?>'S9'(Z]>G^%*WR;0!M5<#L >V/\^U.52N/FSCC_"@ 8D#CU';/
M>D4[QDGHQZ?4CUJAKFMVOAK2KC4;^=(;:%=TC.<#..V3QTZ5X!-^WY\)8+AX
MFUN,%&VGYQV(!_K^7O0!]&*RQ_+CD#)P.. .@_PI_P V>HQGT[8_QKYM_P"'
M@7PD_P"@W'^#C_/K^GOA#_P4"^$O;6XCU_Y:#T_Q_F/? !]&7V6T^Y'5_+8<
M CG;VY_K7\Z_[;!#?M"^)""2OFD G)_B/?/([_C7[-S?M_?"1H9 -:C?Y6X#
M \<_TP?S_'\3OVL?&5CX\^-VN:SII5K.X(9"I)XR<<DGMCH<"@#OOV#1_P 7
M-A..?,X.WV'?'T_,_C^^7A;GP_:%<#,:X...@]A_G\A^!_[!9V_$V(J</Y@/
M7I@<$>G4\\>W<5^]_A%<>'; XQF)3V]!_GF@#75MR@COZC%?CU_P6.8?\)WI
M()8\C _A'RG]3C].O:OV&K\>_P#@L:Q/CK21\QP #UQT.._^]QCOUZ4 ?FW7
MZ8?!D8_9S\&<8S+/VZ_+'[?X_P!!^9]?IA\&1C]G/P9QC,L_;K\L?M_C_0 &
M[1110 4444 %%%% !1110 4444 %%%% !3W.[G[V6/S'J?KS3*>YW<_>RQ^8
M]3]>: /(/V\,_P#"E_A_C/6XSC'_ #\2=:^#J^\?V\E_XLO\/2<'FX(XS_R\
M2?E_GUKX.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#M_@B?^
M+L>%^,_Z:GX5_2CX 7;X)T0;0O\ HD? ^GT'\J_FO^")Q\6/#')&;Q.G?ZU_
M2AX 7;X)T0;0O^B1\#Z?0?RH Z"BBB@ HHHH *_/?_@KRV/A5:\L/E/4^NX9
M'/?H:_0BOSW_ ."O+8^%5KRP^4]3Z[AD<]^AH _%^OT#_8-4_P##/OQ")48W
M08;&#_Q]1?G_ /6K\_*_0+]@M0/V?OB&2/F+08/M]JB_*@#TNBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#EOVD(\?LLZ[)LQG4,>9LY.(AQG9SUZ;FQD
MG:N<M^;=?I)^TA'C]EG79-F,ZACS-G)Q$.,[.>O3<V,D[5SEOS;H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]#O^"/O_)4-2/'!Z8S_ '!Z
M>_MVK\\:_0__ ((]@M\4-2QD'.0P^BY'3N,^E '[,T444 %%%% !2#/.?PI:
M:N,M@Y.>>>G% '\^O_!0X_\ &16K#/;U_P#K_P!/_K>4? 93_P +!L" N=Z_
M,>O7I7J__!0X_P#&16K#/;U_^O\ T_\ K>4? 93_ ,+!L" N=Z_,>O7I0!^G
M'Q0O%N=:T^-2Q^SZ=;PE6SA?E)POS$8PPZ!1R>"<LW'UV'Q0O%N=:T^-2Q^S
MZ=;PE6SA?E)POS$8PPZ!1R>"<LW'T %%%% !1110 4444 %%%% !1110 444
M4 %?,'_!1N/ROC1:)MV;;)1LV[=N%48V[5VXQTVKC^ZO0?3]?,'_  4:41_&
MBVC"[-MF@*;=NTA5&,;5V_3:O^ZO0 'RC1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %?4'_  3KP?VC=''\61A?7KV[_E7R_7U#_P $Z^?VC-'&
MW.2/Z\?Y!H _H%89*\ X/?MQVIU-89*\ X/?MQVI.=W)8?-QP,=/Y4 /HHHH
M 9&V[!W;OE!X''U%/ID;;L'=N^4'@<?44^@#Y@_;V;_BS>J#/\'3/L/?^G_U
M_P"?W4%VWUR,8Q(PP,^I]>:_H"_;V;_BS>J#/\'3/L/?^G_U_P"?W4/^/ZYR
M,?O&ZC'<]NU 'Z9_"7_DVOX?G;M_>77;_9A]O\^]:W1>FW(_B'7GMQ_G!K)^
M$JD?LU_#_(_Y:77;'\,/M_GWK6Z+TVY'\0Z\]N/\X- #**** "BBB@ HHHH
M**** "BBB@ HHHH *\4_;Y9C\-_AZ& P(I<$-G_EL_'L?\17M=>*?M\@CX;_
M  ]^<L/*EX..#YS_ *=/U]: /AVBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /V8_X(\KM^%NH\;<Y/3KRO/0<_X"OT-;AB<8Z#<HR3STZ=
M/\37YY?\$>5V_"W4>-N<GIUY7GH.?\!7Z&MPQ.,=!N49)YZ=.G^)H ?1110
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M:S%>BEN,\8_*E!Z\8_K0 M%-W'.-IZXSQZ=:=0 4444 %%%% !1110 4444
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M*=\RXP=W8[NI]_YT ?E__P %5OVC/%?P\UB#PII$KV]CJ$6)9 Q&>IP"/P_
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M@SC&99^W7Y8_;_'^@_,^OTP^#(Q^SGX,XQF6?MU^6/V_Q_H #=HHHH ****
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MGX?;1M;RI<C&/^6TG./KGGOCVKVRO%/V^68_#?X>A@,"*7!#9_Y;/Q['_$4
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MOV:-;+RV<<,>FXXZYQA.N<'.]@#GJ*** "BBB@ HHHH **** "BBB@ HHHH
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M_A9L7IYF>GH/I[^OKZ\_OEX3_P"1?LSP<QKRHP#P/8?Y_*OP._8,7=\3H3@
M"4#=C.,KU)[#C]37[X^$\_\ "/V1( )C7H!Z8]/:@#7K\>_^"QK$^.M)'S'
M /7'0X[_ .]QCOUZ5^PE?CU_P6.Y\=Z0-Y/1MO8<$$XS[KS^'K0!^;E?IA\&
M1C]G/P9QC,L_;K\L?M_C_0?F?7Z8?!D8_9S\&<8S+/VZ_+'[?X_T !NT444
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MCQ^RSKLFS&=0QYFSDXB'&=G/7IN;&2=JYRWYMT %%%% !1110 4444 %%%%
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M_0C&<QJ<[N!R#G- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^#J^\/V\?^2,?#[GO<=C_P _$G^>:^#Z "BBB@ HHHH **** "BBB@ HHHH
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M^$?LB0 3&O0#TQZ>U?@;^P</^+G0'@G?^(X'M_7_ .O^^7A/ \/V0 &/+7!
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M^DQ_^A"OU=\7-FW\-KOW[-&MEY;..&/3<<=<XPG7.#G>WY1>'&*^(-,(./\
M28Q_X\*_5WQ:X:V\-*I^5=&M@%S]WACC&X[>N<83KG!SO8 YZBBB@ HHHH *
M*** "BBB@ HHHH *4*QY"DCGMZ=:2E&WN#GGO^5 "4444 9G[?A/_"J_#8;E
MO[)MQ][.285_3&>,<D_A7YBU^G7[?0(^%/AI03M_LBWP" ./)3)Q[\#..^,=
MJ_,6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** '0G$J'./F'M_
M45_0S^P.H7]G70L#''/&/Z#^5?SS0G$J'./F'M_45_0S^P.NW]G70OITQC'M
MT% 'T;1110 4444 %>"_MN8'[/7B,G_GDW7H?E/'^?0U[U7@W[;?'[/?B)@=
MN(B25ZCY3S_GV^H /YU;O_CZF_WV_G7U=_P35=H_V@8'2&2X98MPBC(W.0&.
MT9(&>.I('7D5\HW?_'U-_OM_.OJK_@F[;R7GQZ2")_+DDAV+)\WRDAN?E96X
MZY!!X."* /IZBBB@ HHHH **** "BBB@ HHHH **** "BBB@#IO"+;?#_COD
M+_Q3T_7_ *[0U^2^L8_M>^QR//?&?]XU^M'A/_D7O'@+;0?#LXS_ -M8:_)G
M6R6UJ_)Z_:),X.?XCWH ^B/^"?//[1VAC&3G/W<_K@X_3ZU_0C&NV-1C& !@
MX_I7\]__  3Y&[]HS1.,\Y_^OC!_/C'KS7]"$:[8U&,8 &#C^E #J*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***0GIQG^E ">6"V3R.N#R,\<_I4<V8;>9NIVDYZ$X'?'TH(
M,C9&.@!!/(SU&1T/3\OQHNL_9)L\_(W\C0!^,'_!3;XO:WKWB:;13.T-G$^#
MMS@\XQG/MZ#OSWKX!>\GDW;II&W==S$YK[0_X*.*?^%A7N"/O@X^@'K]>OKC
MUX^*J "B@,1D XSP:D5#<3A5/+MP7/\ ,T ,9MQS@ ]\5+:VDNH7,<$$9>1R
M%"J"?;-?I;_P3O\ V*_"GQ5\)7&J>*T6=^2L8 )SP>..1^-?:VC_ /!/#X3:
M+?Q7<&F8DCZ?(OIC/- 'XX^$_P!B?XG>,M*34-/T=WMV&0S(P[X]/;M_CC[O
M_9A_X)=Z1J'A%;CQS#MOF )PN"<C'3'U]1T]\_I+X8\)Z;X1TR&QT^!8XHQ@
M':,],5KJ^<95ESZ_3/:@#Y.\)_\ !.GX;>!YKF\M+96E:,CE.G!_Q/Y#ZU^-
M_P"USHMMX=^.6OZ?:(J002%%"GIACQ^'2OZ.M0;_ (E]T?N_NW[^QYZ_UK^=
M/]M3+?M#>)6/>3'4$]3SU- 'AA4C!(QGD5^B?_!)5MOBZ[/&-YSDXXXS^-?G
M97Z)_P#!)AR/%EUCLY'8>G^- '[*$;O_ -=(ORXS]YNI4=3C_P"M2D].,_TI
M,;E)^9"P]>G]* &[6V\ (W^RW'/4].O7_)IJX9ER,$\@DG/)SC].1[5*._.?
MZ4T[=VW^(D$[>OU/Y4 "J(\#DD\?S.?2GTQ64G.,,>#W(XS@X_SS3Z "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"VW_\ 52TC
M#<I![^AQ0!&F67<.7'!.1\V!TSCUS2!@N58D*.06;& ,?CU^OZU+CYB?ZTFW
MG()'.3^5 ""/YLD+U)^[SGH#^7%*OW0<DYYY&#2D;O\ ]= &W_\ 70 M%%%
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M?S9RT' ''_'U%UX_SFOS]K] _P!@O_DWWXB8Y&^WS]?M,5 'I5%%% !1110
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M%JFWR]EFB[-NW'RKQC:N,=,;4Q_=7H #Y0HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH _9C_@CRNWX6ZCQMSD].O*\]!S_ ("OT-;AB<8Z#<HR3STZ=/\
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M<X.=[ '/4444 %%%% !1110 4444 %%%% !1110 4444 97[?6W_ (53X<
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MIBN!+$QPF!Z^GU%?(M% '[D:'_P52^'.H&UAD/[YP [!NO'7'^1^5?5OP_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3_F;_4#D#)Z4 ;%%%% !1110 C'"DXS["OR!_P""H6?MLRC/R@\C@_\ ?.>
M>_';O7Z_,<*3C/L*_(#_ (*AX%],I/*@@;A@'WP#Q^0_2@#\Y_#O_(P:9_U]
M1?\ H8K]7O%S9M_#:[]^S1K9>6SCACTW''7.,)US@YWM^47APX\0:9QG_28_
M_0A7ZN^+FS;^&UW[]FC6R\MG'#'IN..N<83KG!SO8 YZBBB@ HHHH **** "
MBBB@ HHHH *4*/[P'7UI*4,1QQW[#O0 E%%% &9^WT"/A3X:4$[?[(M\ @#C
MR4R<>_ SCOC':OS%K]./V^MO_"J?#@ "_P#$IMMR@''^I3 QW//IT'X5^8]
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M/T[5_/=_P3YY_:.T,8R<Y^[G]<''Z?6OZ$8_]6N..!T&/T[4 .HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ IK*6'!P1T]/_KTZB@"/;Y>2%7'3Y1R% Z>_P#]>A5??N) ]0.>
MW3..F<_YXIY&[_\ 70%"\ 8[T ,$C%L!._N.Y]O;]?QIMQ'#>0RV\RJ\;YC9
M6/WLC./RJ01H,$*HQP..G^<FG4 >7ZS^S7\/M<^TO<>'[8SSKAIMH+9P<'U[
M^O85\+_'+_@E)_PF?B*2]\.S?88V)(C0X49]R3_*OTWQ\P/]:6@#^>;]IK]B
MKQ9^SWK4%L;>XU.WF^ZT:;CR>.!VZ#\17@UYX3UG3X3+<Z7=01_WI(B/?^5?
MTZ^(_ ^@^+BAUC2[>_*?=,R9/TKRCXQ?LF^"_B3X/N]*MM&M+*:1&4,B8ZY]
MQ_D4 ?SET5^I&M?\$;YXDNKBVU?Y%W.D:L,XYXZ]O\/>OAWXN_LM^,_AIXMG
MTI-&NKR).DD:Y[XY_P ^M 'C-"XW#/ [XK6UOPEK/AM5.J:;<6.[@><FVLF@
M KZ@_8L_:HL_V:];FO+FW\\2/D@CKWQTSCCU'X\5\OT4 ?LOX1_X*W^&?$GB
M&QTR2R6V%RX3S&R IQZX]<_@/?C[GTCXF>&=6T^VNXM9M-MQ&LH!E&>0.V?I
M^=?S"03R6TR2Q.T<B'<K*<$&NVTOXW^-]*D@,/B*]\N'&R,O\HQ0!_33:7D-
M]");>198ST9>AIRR;MHRI;D'GTX)'X_SK\G/V,_^"C=__:FE^#=8C>YDN<()
MY,G'3V.3R>_I7ZNV-P+K3XKC>RB2,/EAM*Y'IB@"U135PK%<*O4@#OZG\S3J
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 %%%% '<?!'/_"V/#&#@?;$SSUK^E#P NWP3H@VA?\
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M1QC/K_GH:^7J^H/^"=>#^T;HX_BR,+Z]>W?\J /Z!F&2O .#W[<=J=36&2O
M.#W[<=J=0 4444 ,C;=@[MWR@\#CZBGTR-MV#NW?*#P./J*?0!\P?M[-_P 6
M;U09_@Z9]A[_ -/_ *_\_P!J.1J%UG)/FM][KU-?T _M[-_Q9O5!G^#IGV'O
M_3_Z_P#/[J"[;ZY&,8D88&?4^O- 'Z9?",#_ (9K^'^.1YEUS_P&'V_S[UK]
M%Z;<C^(=>>W'^<&LGX2_\FU_#\[=O[RZ[?[,/M_GWK6Z+TVY'\0Z\]N/\X-
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M_A<OAC>NY/M2Y7&<C/3'>OTB\>%F\::X7!5OMDN02"?O'TH PJ*** "BBB@
MHHHH **** "BBB@ HHHH 53@-R1D=N_-;W@7Y?'6@]%_T^'H>/\ 6#W_ ,^]
M8*G ;DC([=^:WO OR^.M!Z+_ *?#T/'^L'O_ )]Z /S>_:0Q_P +J\4XZ?:V
M_G7FE>F?M)$GXU>*<_\ /TW?->9T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!]._L)KO^)=N-JOB8-M/;CKW_ *<XY]/WR\*_+X8L#C:3 "2H
MR>G7IUQ7X&_L)KO^)=N-JOB8-M/;CKW_ *<XY]/WS\)\>&=/"+R(5XZ#.,T
M;%%%% !1110 C'"DXS["OR!_X*A,4O)UW, O&T$+G.><9X_(=QFOU^9@JDDX
M Y)-?D#_ ,%0FVWLR_*K*""N[E2>V ?Z8Z=J /SG\.,5\0:80<?Z3&/_ !X5
M^KOBUPUMX:53\JZ-; +G[O#'&-QV]<XPG7.#G>WY1>'!N\0:9_U\Q]_]H5^K
MOBZ3S+?PV V=NC6PVEONY#'&-QV]<XPG7.#G>P!SU%%% !1110 4444 %%%%
M !1110 4444 %%%% &9^WX3_ ,*K\-AN6_LFW'WLY)A7],9XQR3^%?F+7Z=?
MM] CX4^&E!.W^R+? ( X\E,G'OP,X[XQVK\Q: "BBB@ HHHH **** "BBB@
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M^1_I]:_H1C_U:\8X'7/]: '4444 %%%% !1110 4444 %%%% !1110 4444
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MDUK+I=KB92"?+&[IC(/7T_2OB/QE_P $E_!/BCQ)?:L+OR_M4OF&-688]?\
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MOT"_8+(_X9^^(>-P^:#/H?\ 2HO;_/-?G[7Z!_L%Y/[/OQ$YX#VXQ@?\_,5
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M7R_C1:)L\O99*NW;MQA5XQM7&.F-JXQ]U>@ /E&BBB@ HHHH **** "BBB@
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MO/;C_.#61\(P/^&:_A_CD>9=<_\  8?;_/O6OT7IMR/XAUY[<?YP: &4444
M%%%% !1110 4444 %%%% !1110 5XI^WR"/AO\/?G+#RI>#C@^<_Z=/U]:]K
MKQ/]OC9_PKGX?;1M;RI<C&/^6TG./KGGOCVH ^'J*** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-;.TXSGIQC(]^: #S
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MS/!S&O*C / ]A_G\J ->OQY_X+',/^$[TD$L>1@?PCY3^IQ^G7M7[#5^/?\
MP6-8GQUI(^8X !ZXZ''?_>XQWZ]* /S;K],/@R,?LY^#.,9EG[=?EC]O\?Z#
M\SZ_3#X,C'[.?@SC&99^W7Y8_;_'^@ -VBBB@ HHHH **** "BBB@ HHHH *
M*** "GN=W/WLL?F/4_7FF4]SNY^]EC\QZGZ\T >/_MX_\D8^'WUN.^/^7B3\
MZ^#Z^\?V\F_XLO\ #T=.;@<=_P#2)#SG^GI]:^#J "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH [?X(X_X6QX7S_P _J8K^E'P NWP3H@VA?]$C
MX'T^@_E7\U_P1S_PMCPQ@X'VQ,\]:_I0\ +M\$Z(-H7_ $2/@?3Z#^5 '044
M44 %%%% !7Y[_P#!7EL?"JUY8?*>I]=PR.>_0U^A%?GO_P %>6Q\*K7EA\IZ
MGUW#(Y[]#0!^+]?H'^P;S^S[\0CUPT R>W^E1<#VK\_*_0/]@W_DWWXA'"G#
M0#..1_I47'3_ #Q0!Z51110 4444 %%%% !1110 4444 %%%% !1110!RW[2
M$>/V6==DV8SJ&/,V<G$0XSLYZ]-S8R3M7.6_-NOTD_:0CQ^RSKLFS&=0QYFS
MDXB'&=G/7IN;&2=JYRWYMT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 5XI^WRS'X;_#T,!@12X(;/\ RV?CV/\
MB*]KKQ3]OD$?#?X>_.6'E2\''!\Y_P!.GZ^M 'P[1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% '[,?\$>5V_"W4>-N<GIUY7GH.?\!7Z&MP
MQ.,=!N49)YZ=.G^)K\\O^"/*[?A;J/&W.3TZ\KST'/\ @*_0UN&)QCH-RC)/
M/3IT_P 30 ^BBB@ HHHH Y[XA-M\$:V<X_T5^<X[?4?SK^:SXS\?%/Q*,8_T
MQNV.P]A7]*?Q";;X(ULYQ_HK\YQV^H_G7\UGQGX^*?B48Q_IC=L=A["@#4_9
MUV_\+E\,;UW)]J7*XSD9Z8[U^D7CPLWC37"X*M]LER"03]X^E?F]^SGG_A<_
MA?: 6^UK@$X'6OTA\=*5\9ZV"<XO)>=NW^(]NU &%1110 4444 %%%% !111
M0 4444 %%%% "J<!N2,CMWYK>\"_+XZT'HO^GP]#Q_K![_Y]ZP5. W)&1V[\
MUO>!?E\=:#T7_3X>AX_U@]_\^] 'YO\ [21)^-7BG/\ S]-WS7F=>F?M)?\
M):O%/.[_ $IO_P!5>9T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!]._L)KO\ B7;C:KXF#;3VXZ]_Z<XY]/WS\)_-X9T_EL&%1Z8XQQ7X&?L)
MKO\ B7;C:KXF#;3VXZ]_Z<XY]/WS\*L5\,V!)5<0+ACTZ=30!L4444 %%%%
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MYK^BG43C3[HYQ^Z;OCL?<?SK^=;]MK_DXKQ1R/\ 7'C'/4T =3^P8N[XG0G
M $H&[&<97J3V''ZFOWQ\)Y_X1^R) !,:] /3'I[5^!O[!P_XN= >"=_XC@>W
M]?\ Z_[Y>$\#P_9  8\M<$ \C'';T_E^% &O7X]?\%CN?'>D#>3T;;V'!!.,
M^Z\_AZU^PM?CS_P6.8?\)WI()8\C _A'RG]3C].O:@#\W:_3#X,C'[.?@SC&
M99^W7Y8_;_'^@_,^OTP^#(Q^SGX,XQF6?MU^6/V_Q_H #=HHHH **** "BBB
M@ HHHH **** "BBB@ I[G=S][+'YCU/UYIE/<[N?O98_,>I^O- 'D'[>&?\
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M7C']: /Y]/\ @H<?^,BM6&>WK_\ 7_I_];RCX#*?^%@V! 7.]?F/7KTKU?\
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M ?SZ?\%#C_QD5JPSV]?_ *_]/_K>4? 93_PL&P("YWK\QZ]>E>K_ /!0X_\
M&16K#/;U_P#K_P!/_K>4? 93_P +!L" N=Z_,>O7I0!^G'Q0O%N=:T^-2Q^S
MZ=;PE6SA?E)POS$8PPZ!1R>"<LW'UV'Q0O%N=:T^-2Q^SZ=;PE6SA?E)POS$
M8PPZ!1R>"<LW'T %%%% !1110 4444 %%%% !1110 4444 %?,'_  4:41_&
MBVC"[-MF@*;=NTA5&,;5V_3:O^ZO0?3]?,/_  4;39\:+50NP1V:(5V[=AVK
M\N-JX^FU<?W5Z  ^4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP<<'SG_3I^OK7M=>)_M\;/\ A7/P^VC:WE2Y&,?\MI.<?7//?'M0!\/4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^S'_!'E=OPMU'C;G)
MZ=>5YZ#G_ 5^AK<,3C'0;E&2>>G3I_B:_/+_ ((\KM^%NH\;<Y/3KRO/0<_X
M"OT-;AB<8Z#<HR3STZ=/\30 ^BBB@ HHHH Y[XA-M\$:V<X_T5^<X[?4?SK^
M:SXS\?%/Q*,8_P!,;MCL/85_2G\0FV^"-;.<?Z*_.<=OJ/YU_-9\9^/BGXE&
M,?Z8W;'8>PH U?V<\_\ "Y_"^T M]K7 )P.M?I#XZ4KXSUL$YQ>2\[=O\1[=
MJ_-[]G,%OC/X7 )4F[7YAU'-?H_XXV?\)CK?E_<^V2XP2?XCZT 8E%%% !11
M10 4444 %%%% !1110 4444 *IP&Y(R.W?FM[P+\OCK0>B_Z?#T/'^L'O_GW
MK!4X#<D9';OS6]X%^7QUH/1?]/AZ'C_6#W_S[T ?F_\ M)?\EJ\4\[O]*;_]
M5>9UZ7^TAC_A=7BG'3[6W\Z\TH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#Z=_837?\2[<;5?$P;:>W'7O_3G'/I^^GA3=_PC6GXP#Y"X/7M7
MX%_L)KO^)=N-JOB8-M/;CKW_ *<XY]/WR\*K_P 4Q8?+R8!D*>3QZ^N* -FB
MBB@ HHHH 1AN4@]_0XK\@O\ @J)DWD^]@>2=K=>?QSU']T"OU]8X4G&?85^0
M/_!4+/VV91GY0>1P?^^<\ ]^.W>@#\YO#O\ R,&F?]?47_H8K]7O%S9M_#:[
M]^S1K9>6SCACTW''7.,)US@YWM^47APX\0:9QG_28_\ T(5^KOBYLV_AM=^_
M9HULO+9QPQZ;CCKG&$ZYP<[V .>HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ROV^MO\ PJGPX  O_$IMMR@''^I3 QW//IT'X5^8]?IU^WX3_P *K\-A
MN6_LFW'WLY)A7],9XQR3^%?F+0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% #H3B5#G'S#V_J*_H:_8'X_9UT$8QQZ8_H/Y5_/+"<2H<X^8>W]1
M7]#/[ ZA?V=="P,<<\8_H/Y4 ?1M%%% !1110 5X-^VV2/V>_$6.#Y1PV<$'
M:>_^>Q[5[S7@O[;F!^SUXC)_YY-UZ'Y3Q_GT- '\ZUW_ ,?4W^^W\Z^IO^"<
MLT5O\<S+/O\ )2W+/Y<HB; 5B<.2-I_VLC&#\PKY9N_^/J;_ 'V_G7U=_P $
MU7:/]H&!TADN&6+<(HR-SD!CM&2!GCJ2!UY% 'TU1110 4444 %%%% !1110
M 4444 %%%% !1110!TWA'(\/^/"O)_X1V?CU_>P\5^3.M_\ (:O^=W^D2?,>
M_P QYK]9O">3X>\>8Z_\([/C_O[#[U^3.MX&M7X'3[1)C'^\?>@#IOA/HNN:
M[XM@M_#[LFH\%-F<YSQ@=Z]=\2?%_P".GPYUA=*N+S5(_L^-BJCN"H[9^A[<
M<]^I?_P3_MTNOVAM'CEC$L9(!#+D=_\ 9./S%?K]^TIK_P '_@_X7O/$&OV>
MG2ZA$A\N!2K2-CGI[<?BHS0!^5GQ<_;"E^)WPJT[P_XAMBNM6VUI2X.[<,X/
MZ^GY=FW/[:GBF'X3Z?X3\'>?'=0@%VME+,@)]!SG.WM]:P?#_P 'Y?VO/C-K
M$_A:Q;3]+*><#&I"CD^Q]#T[_7-:/P=U+0?V2_CW>Z5XVL%U*&%UC^<9^4G[
MW3T!]/Y4 .^"7Q"^-7Q,\?:=;276I36J,#(\D;JH7..G<?AT%?M[I.FW_P#P
MJ&&SEDVZ@;$J6)W'<<_3)_*N3^#NE?"OQ=H]AKOA2UL'>Z19OW1&_=P22/7_
M #U''L2(L*A5&$& % H _"W]IKQ5\;/A+\2-2CAO;];&1SL:%6<#)SCKT.3C
MVK*T']M7Q?;_  SU?PMXR:Z>6Y5E62X#(S \C@C/KZ]..P'[+_&'3_AOH^DW
M>L>,+>PQ;Q-(/M& 3P1@?7)_[Z]*_&7]H#Q!X7_:F^.VF:'X(L?L$;3FVWPQ
M8R <;OS]L\Y- $/P7_:X_P"%6_#[5M-T>'&MW!8Q%5P02" 00 <Y(]AGBN%_
MX7S\:_%EX+%;K4Y3.Y*0M"Z@;O<]N:Z3QO\  >\_9'^*?AZ^\26AU'2B!,WF
M#*L 5Z\?7/'%?JW^S-X@^#'QS\&Z?JFEZ?8Q:GL57@<!),X Z?@/PQ0!U7[#
M]EKUC\%-/7Q&9#JC*ID\S.1P>#_/\:^4_P#@HUK?Q*\ _P#$Q\.2W*P.Q&+;
M)QS@X Z_0?F>E?I-8Z?;:1;I!:P"*$' 5!P/_K?Y]36!XU\.>&=<TYF\2V]N
M]K@[_M!.W@<_A@'\Z /PN^&'[:7Q,\$W5V_B*ZOI[*X0KYD\;(!G((R>QR>1
MWQ7,_#?]H#3_  S\1-5\27,"RW-RQ:/Y,X)SQ_3@]\]>:^A?^"@OQ@^%VNW_
M /PA?A*P@%S'(8VN8(\\L_7/3OG/?'US\^>/_P!D7Q#\.?!>B^,!!+?Z=,T4
MKJ%S\A(/3'N/_P!9X '^,_VK/BYXBU&=[*ZU*UTYB52*.-V4@>XX].!7Z%?\
M$IM>\8:]I>JW'BC[1\Q8QFX#!CGG)SSS[^GX54_89^)OP9^*GAN/P[JVFV%M
MJ]HHB*W"!0YPIY. ,Y'XX'IQ]]>$O!6@>$;11H5A#:P,.!"!C!_PY_,T ;\B
MEFSZ=,8R">,\^G]32MN)[@=!MQZ=>::WS<IPV,G& V,''4>OK1NSN)9D7!(.
M,<8'//\ 7\J ):*** "BBB@ HHHH **** "BBB@ HHHH **** "FR8V\MM]#
MGN>*=2%@O)..U #<%E/!!;J"V,?Y]J9=-NLY2.\9ZC':@_?8]P<^I"X'0<]2
M/:BY7_1Y@  64^W:@#\2/^"DWB>>^\;75F6RJDJ!N)XSGD>P)'3M7PI7VG_P
M4>7_ (N)>M@XWKG\!QC\^G^!KXLH [_X$VQN/BCH?R[@LX/)('MG@_KQQ7](
M7PX??\/]#+M@?9$!.<8 &/Y5_.C^S7$)/BSHV5R?-7G /?.,8/IZ&OZ,/ARO
M_%!Z*H^7%LJCCD=O3^E '1MA<-MSCN!D@?Y%(F<MGGID\]<=AZ48"D[<%R,C
M)Y/_ -;G]:5,],8 X&3DT ?C[_P57\!2W7C!M75=^ 2#@#H"?4\8(Z8'7ZU^
M;=?L;_P4\M8I?#\[-%N?D L<D< 8ZCG\>XZU^.5 !12\R, !DG@ "OJ[]C7]
MBC6OCYXMMY-4M)K/1$97\X\*P')Y[\#Z=<^E 'C'PW^ OB[XB:K90V6C7)M)
MW ^T;#M*Y'((Z]1^=?K?^QY_P3MT;X2PQ:SXCBAU&>9/,*S -MZX'(R.Q_3F
MOJOX:_!#PK\-/">G:3;Z9:[K:,*9F09)"X//T%>B A5PHSMP-JXXH S-#\.:
M3X:@>'2K"&R3O'"NTGKZ_C6GRV0WUR.._3K0J[<@=/=B33) %Z#9VW8'<]OQ
MP: $4^6<!1CGA5QDX& .?3^7:G,4;!(5@?DSQ^7Y\4#][&0>F2#TZ9Z=_P#/
MI3%#Q\8)YYQ_%\O_ -8=3_\ 7 'QX< LH+8!)VD=^.O\NU24U51E4J%(^\"/
M?O\ K3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"OJ#;+&Y8<8C8\_0U_.K^VT /VBO$X':7'4D_>;DY_SQ7]%6H9-C<@=
M?+;&/H?<5_.K^VTP;]HGQ,1R#*3V_O,.H^GZT =3^P</^+G0'@G?^(X'M_7_
M .O^^7A/ \/V0 &/+7! /(QQV]/Y?A7X&_L&_P#)3(AC_EH#D9[+CGC_ &O;
M^5?OEX3_ .1?LSP<QKRHP#P/8?Y_*@#7K\>?^"QS#_A.])!+'D8'\(^4_J<?
MIU[5^PU?CW_P6-8GQUI(^8X !ZXZ''?_ 'N,=^O2@#\VZ_3#X,C'[.?@SC&9
M9^W7Y8_;_'^@_,^OTP^#(Q^SGX,XQF6?MU^6/V_Q_H #=HHHH **** "BBB@
M HHHH **** "BBB@ I[G=S][+'YCU/UYIE/<[N?O98_,>I^O- 'D'[>3?\67
M^'HZ<W X[_Z1(><_T]/K7P=7WC^WAG_A2_P_QGK<9QC_ )^).M?!U !1110
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M4,>9LY.(AQG9SUZ;FQDG:N<M^;= !1110 4444 %%%% !1110 4444 %%%%
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M'\,/M_GWK6Z+TVY'\0Z\]N/\X- #**** "BBB@ HHHH **** "BBB@ HHHH
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M?T%W%G#J-JL5U$LT9P2KC@GW''\J /DC_@GO^S_:_#7X8Q7MS8BVU*X3#?*
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MX/7D8)Y&?3T _P :D9-WN#PP/((YH9=V0QROICJ,=#0 ZBBB@ HHHH ****
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M@9[_ .>C5Q(=O4 MZGGV/;K_ )Q5#Q%XDL/"NGR7^HW*P6\>-Q9@,=>?\^E
M&H&#<@Y[4M?*/Q6_;^^'OA;0+TZ9JJSZC$#M 8  \'/49^E?GYXG_P""KWQ!
M_MR[73ROV0.57(SQG..O/?ZX]Z /VO52O5BW&.<?G3J_#Z/_ (*R?$OS 9%W
M*>HW^Y_/@^W4U]%?L\?\%08?$.L0IXMG\J L S.0".N?YDY]/QH _3,E]QVY
M//T'3ITZ=.F:<=V>",<=OSKS7X=_M#>#/BA.L6A:G'<LWO[?Y_7TKT<JRX/R
MX')V@]>_ ZYY_P#KT /#'@,N"?3D9IU0QQ\9Q@_WNIZ\CD=.!SWJ:@ HHHH
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M%% !1110 4444 %%%% !1110 4444 %%%% '<?!$X^+'ACDC-XG3O]:_I0\
M+M\$Z(-H7_1(^!]/H/Y5_-?\$?\ DK'AC@'_ $Q.I_E7]*'@!=O@G1!M"_Z)
M'P/I]!_*@#H**** "BBB@ K\]_\ @KRV/A5:\L/E/4^NX9'/?H:_0BOSW_X*
M\MCX56O+#Y3U/KN&1SWZ&@#\7Z_0/]@U3_PS[\0B5&-T&&Q@_P#'U%^?_P!:
MOS\K] OV"U _9^^(9(^8M!@^WVJ+\J /2Z*** "BBB@ HHHH **** "BBB@
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MT7_3X>AX_P!8/?\ S[U@J<!N2,CMWYK>\"_+XZT'HO\ I\/0\?ZP>_\ GWH
M_-[]I#'_  NKQ3CI]K;^=>:5Z9^TD2?C5XIS_P _3=\UYG0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'T[^PFN_XEVXVJ^)@VT]N.O?\ ISCG
MT_?+PJ /#%@6P@, )(..W7/TK\#?V$UW_$NW&U7Q,&VGMQU[_P!.<<^G[Y>%
M,+X7L,%5 A^]@X[\\X^M &S1110 4444 (V=IQP>V:_(+_@J%A;R4#Y  0!N
M.1UXQG/Z#Z^GZ^MG:<<'MFOR _X*A?+>3#Y0HSA>I7VP3^N!VH _.CPYC_A(
M-,SQ_I,?_H0K]7?%TA:W\-@MDKHUL"H?=MX8X^\<=<]$ZYP<[V_*'P[_ ,C!
MIG_7U%_Z&*_5[Q<V;?PVN_?LT:V7ELXX8]-QQUSC"=<X.=[ '/4444 %%%%
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M5BK @X(Y!%=-X#^(FL_#OQ!;ZOI-TT=S"X< G@D'.?SK-\2^&K_PGJ\^G:C
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M;1D].Y[#WIU% $,BEU')ZGYB.0>GITYZ\476?LDV1CY&_D:?YAW8V_49&>N
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M0 _:*\3@=I<=23]YN3G_ #Q0!U/[!P_XN= >"=_XC@>W]?\ Z_[Y>$\#P_9
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MZ9]A[_T_^O\ S^Z@NV^N1C&)&&!GU/KS7] 7[>S?\6;U09_@Z9]A[_T_^O\
MS^ZA_P ?USD8_>-U&.Y[=J /TS^$O_)M?P_.W;^\NNW^S#[?Y]ZUNB]-N1_$
M.O/;C_.#63\)5(_9K^'^1_RTNNV/X8?;_/O6MT7IMR/XAUY[<?YP: &4444
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M]A7]*?Q";;X(ULYQ_HK\YQV^H_G7\UGQGX^*?B48Q_IC=L=A["@#4_9UV_\
M"Y?#&]=R?:ERN,Y&>F.]?I%X\+-XTUPN"K?;)<@D$_>/I7YO?LYY_P"%S^%]
MH!;[6N 3@=:_2'QTI7QGK8)SB\EYV[?XCV[4 85%%% !1110 4444 %%%% !
M1110 4444 *IP&Y(R.W?FM[P+\OCK0>B_P"GP]#Q_K![_P"?>L%3@-R1D=N_
M-;W@7Y?'6@]%_P!/AZ'C_6#W_P ^] 'YO_M)$GXU>*<_\_3=\UYG7IG[27_)
M:O%/.[_2F_\ U5YG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 4444 %%%% '3>$?^1?\ '?!/_%/3]#C_ );0U^3&M?\ (8O^0?W\G*C
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M-?J/)CJ1TZ;C@$YX_4"OR\_X(TM_Q+=8&5ZMQCGJW?\ #_/-?J,QPI.,^PH
M212RX!^O..*^=OV]EW_L[ZV,X/&#D_TKZ(9BJDG"]?F[#W/2O!_VV(/M'P'U
MM!_SS<\_[ISW';TH _G6N!MN)1@+ACPO0<TQE*@'J#W[?2KFN0&UUF^B.!MG
M<?*,#[QJE0!]S?\ !*/6(M)^-$CS$;?E[=.G)].@_IDU^WX(D =#]#S@C/\
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M^W^/]!^9]?IA\&1C]G/P9QC,L_;K\L?M_C_0 &[1110 4444 %%%% !1110
M4444 %%%% !3W.[G[V6/S'J?KS3*>YW<_>RQ^8]3]>: /'_V\?\ DC'P^Y[W
M'8_\_$G^>:^#Z^\/V\?^2,?#[ZW'?'_+Q)^=?!] !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 =Q\$?^2L>&. ?],3J?Y5_2AX 7;X)T0;0O^B1
M\#Z?0?RK^:[X(X_X6QX7S_S^IBOZ4? "[?!.B#:%_P!$CX'T^@_E0!T%%%%
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M* "BBB@ HHHH **** "BBB@ HHHH **** /IW]A-=_Q+MQM5\3!MI[<=>_\
M3G'/I^^7A4#_ (1BP)&,P#.W.3Q[=\5^!O[":[_B7;C:KXF#;3VXZ]_Z<XY]
M/WR\*8'A?3]N5'D#[J\_7% &S1110 4444 (V=IQP>V:_('_ (*A96]F PH
M.%#X*CTY/]!Z5^OS9VG'![9K\@/^"H+#[9*%VXQE1V"_B?Z#]* /SG\._P#(
MP:9_U]1?^ABOU>\7-FW\-KOW[-&MEY;..&/3<<=<XPG7.#G>WY1>'#CQ!IG&
M?])C_P#0A7ZN^+FS;^&UW[]FC6R\MG'#'IN..N<83KG!SO8 YZBBB@ HHHH
M**** "BBB@ HHHH *4,1QQW[#O244 %%%% &9^WX3_PJOPV&Y;^R;<?>SDF%
M?TQGC')/X5^8M?IU^WT"/A3X:4$[?[(M\ @#CR4R<>_ SCOC':OS%H ****
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M@B@#Z>HHHH **** "BBB@ HHHH **** "BBB@ HHHH Z;PCG_A'_ !WMZ_\
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MP!GCG_(_*F%BW).>U?1?[)G[+_B/XQ>.M,E.FM_8H<-++("!C/T/O0!]5?\
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MASZ\#GI_D8H [0*H.0H!Y[>O6FB3@?O$/"]O4_7OV_K3FW9&,8[@_P"?K3J
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MW[\=J=2'/&/QIJL<CY@PR1\HH ?1110 R-MV#NW?*#P./J*?3(VW8.[=\H/
MX^HI] 'S!^WLW_%F]4&?X.F?8>_]/_K_ ,_VHY&H76<D^:WWNO4U_0#^WLW_
M !9O5!G^#IGV'O\ T_\ K_S^Z@NV^N1C&)&&!GU/KS0!^F?PE4C]FOX?Y'_+
M2Z[8_AA]O\^]:W1>FW(_B'7GMQ_G!K(^$8'_  S7\/\ '(\RZY_X##[?Y]ZU
M^B]-N1_$.O/;C_.#0 RBBB@ HHHH **** "BBB@ HHHH **** "O%/V^01\-
M_A[\Y8>5+P<<'SG_ $Z?KZU[77B?[?&S_A7/P^VC:WE2Y&,?\MI.<?7//?'M
M0!\/4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^S'_  1Y
M7;\+=1XVYR>G7E>>@Y_P%?H:W#$XQT&Y1DGGITZ?XFOSR_X(\KM^%NH\;<Y/
M3KRO/0<_X"OT-;AB<8Z#<HR3STZ=/\30 ^BBB@ HHHH Y[XA-M\$:V<X_P!%
M?G..WU'\Z_FL^,_'Q3\2C&/],;MCL/85_2G\0FV^"-;.<?Z*_.<=OJ/YU_-9
M\9^/BGXE&,?Z8W;'8>PH U?V<\_\+G\+[0"WVM< G ZU^D/CI2OC/6P3G%Y+
MSMV_Q'MVK\WOV<P6^,_A< E2;M?F'4<U^C_CC9_PF.M^7]S[9+C!)_B/K0!B
M4444 %%%% !1110 4444 %%%% !1110 JG ;DC([=^:WO OR^.M!Z+_I\/0\
M?ZP>_P#GWK!4X#<D9';OS6]X%^7QUH/1?]/AZ'C_ %@]_P#/O0!^;_[27_):
MO%/.[_2F_P#U5YG7I?[2&/\ A=7BG'3[6W\Z\TH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#Z=_837?\ $NW&U7Q,&VGMQU[_ -.<<^G[Z>$\
MKX9T['S'R%QGC\*_ O\ 837?\2[<;5?$P;:>W'7O_3G'/I^^7A5<^&+#Y%):
M 9'8\8YX]* -FBBB@ HHHH 1L[3C@]LU^07_  5$D_TRXSN7&1MW<\YYY.?T
M&?RQ^OK,%4DG '))K\@/^"H'RWTZ]&&=R^8,J<=,9Q^0&?QH _.CPXQ7Q!IA
M!Q_I,8_\>%?J[XM<-;>&E4_*NC6P"Y^[PQQC<=O7.,)US@YWM^47AP;O$&F?
M]?,??_:%?J[XND\RW\-@-G;HUL-I;[N0QQC<=O7.,)US@YWL <]1110 4444
M %%%% !1110 4444 %%%/5<J#M8]>1]/Z4 ,HHHH ROV^MO_  JGPX  O_$I
MMMR@''^I3 QW//IT'X5^8]?IU^WX3_PJOPV&Y;^R;<?>SDF%?TQGC')/X5^8
MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .A.)4.<?,/;^HK^
MAG]@==O[.NA?3IC&/;H*_GFA.)4.<?,/;^HK^AG]@?(_9UT($8P./\X% 'T;
M1110 4444 %>#?MM\?L]^(F!VXB))7J/E//^?;ZCWFO!?VW/^3?/$/ /[LCY
MC@'Y3QGC^?\ B #^=:[_ ./J;_?;^=?4W_!.6:*W^.9EGW^2EN6?RY1$V K$
MX<D;3_M9&,'YA7RS=_\ 'U-_OM_.OJ[_ ()JNT?[0,#I#)<,L6X11D;G(#':
M,D#/'4D#KR* /IJBBB@ HHHH **** "BBB@ HHHH **** "BBB@#IO"/_(O^
M.^"?^*>GZ''_ "VAK\F-:R=8OR6W'SY/F]?F/-?K/X1_Y%_QWP3_ ,4]/T./
M^6T-?DOK!SJ]\0,?OWX'^\: *E%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5^N'_!)7_D6=VW_@>W+#I[?A]/KS^1]?KC_P254_\(P0 >1@<8SR
M#@G'')]?0]\D _3>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /S\_X*]$?\*CM 3M.#U/H2>!GO].WXU^+5?M+_P %>&"_"*V4MPPW8W'D
MY(Z9Q^G;\OQ:H ?#"9G5%^\QP!S^=2W6GW-CM\^!X@W0L.#^-;/P]LTU#QMH
MULZ[UEN%0KUSFOV8UC_@GUX,\?? ^TN+*W']KR6@DC94 ).,?3L>U 'XC*Q5
M@0<$<@BN_P#A;\:O$?PIUR'4=,O9F,9!$;R948]CG\JO_'3X ^)/@/XD?3=<
MMV1&8F*7:0"N>/Z_E7F- 'Z<_LV_\%2M:U+Q=!:>-)-MCQEL]>@Y(_#)]_89
M_1OX;?M*>!_BM="WT#5$N96Z+D<CU_S[U_-77?\ PI^-WB;X0ZT-1T2\=)!_
M"SG_ #_]<4 ?TS[><@D<Y/Y4N[YB/Z5^*7P3_P""G7C)?&D(\5S"33Y&&3N+
M'&22.G/^>:^^=,_X*4?"JXM;?S[_ &SL%##< ,Y /&,]Q^O3% 'UK17F?PE_
M:!\*?&2'S-!NUDXR%+C/^?IZC\/2O,3CYE].OOC^=  S!>N>F> 33J8!N7(D
M)!!P1COT/2GT %%-W$_=7/7KP,BD60,"00PR -ISUQ_C0 ^BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **:S;%)/0=?;WH5CD@C!_2@!U-; &XG
M 7G.<"G5\_\ [6O[0MI\$_ -S?17,?VQD;8H//0\XS@\XQ^AH \X_;?_ &T-
M/^"OA::ST6Y67665E:-2-Z\8.!GW _'KBOQ1^)WQ6USXJ:]-J>L7,DKR'.UF
MS5[XU?%K4_BUXROM5O;EY8Y)"RJ2<=?<FO/EY8 G'N: "G0PO<2+'&I=V. H
MZFI+.SFU"ZBMK>-I9I6"HJC))-?I1^PO_P $\[CQ"T'B'QC;;;=CYL*R1D#&
M.#R/Q_'M0!\^_LN_L3>*?BKXDT^[O[&2/1RP+'81N!(!'(]#_GBOVU^"_P $
M=!^#7A6'2=+M(4(0!V"#KCH#Z=*Z3P7X$T?P!H\6GZ5;+%$F &"#/H.@["NA
M9=P]#V/<>] #&(;);[F.=P( 4COGKTI5^5@,KN]3U8#_ .N?\YI5CV A0JC(
MZ+VXIP&W_P#70 M? /\ P5X4?\*;@8X/'3D=SUYYZ^E??:R;FV\ \Y&>>W;\
M?U%?!O\ P5NLY;SX+Q>4K-MY('U/O[4 ?B91110!^KW_  1G_P"0?K9QG#,,
M@Y ^]P?2OU*K\L/^"--U''9ZU&S8+.P 8=\]!^GYFOU.)Z<9_I0 '/;BOGC]
MNZZ-I^S_ *TZYW;6X49;[I''([D?G7T.K;E!'?U&*^</V_/^3=-=Y7!1AM8D
M9)4XYR.G7GTH _GMO)/.O)Y"=Q:1FW#ODU#3Y_\ 72=_F/7/K[TR@#ZS_P""
M=?@E?&7Q<CC9-PA8..">1CMCZ'\#7[R:+IJ:+I,%I'B,1KM&XYYZ#^G2OQ:_
MX)'QQS?&Z960,0%)Z>W_ -?\_K7[:'<6ZX7]>M !M#_>3U'S =*$;=[CJ&'0
MT,#N![?4CU_.A5/4G+8P?3\J /EC]L[]CC1OV@O#]YJCQJ^LVL):W;R]S X/
M_P!:OR.O/V"?BM;W<T<6BR2QH[*K[3R < G'3CG\_0U_0QM+*5<*PQ@^_KQ2
M>2F[.Q<^N/?/\^: /YX?^&#_ (M?] "4?5&']/\ .#Z'!_PP?\6O^@!*?HC'
M^G^<CU&?Z'?(CZ^6O8_=';I0+>(# B0#G^$=^M '\\,G["/Q:C1F_L"4A03P
MA_P_SD>HKQ#Q5X7O_!NN7&DZE'Y5Y <.GIR1_2OZB+J.&.SF)CCV+&V01@8P
M?\3^9K^=G]MZ16_:*\3!%55\UCM3H/G88QGC&/:@#I_V#<?\+,CX.3(.QQP/
MI[__ *N_[X>%\'P[9[AN7RES@'!X'08_05^!W[!N/^%FQ@#GS 3^7']?TYYP
M?WR\*'/A^R[_ +I>1G!X'08X_"@#7K\>?^"QS#_A.])!+'D8'\(^4_J<?IU[
M5^PU?CW_ ,%C6)\=:2/F.  >N.AQW_WN,=^O2@#\VZ_3#X,C'[.?@SC&99^W
M7Y8_;_'^@_,^OTP^#(Q^SGX,XQF6?MU^6/V_Q_H #=HHHH **** "BBB@ HH
MHH **** "BBB@ I[G=S][+'YCU/UYIE/<[N?O98_,>I^O- 'D'[>2_\ %E_A
MZ3@\W!'&?^7B3\O\^M?!U?>'[>/_ "1CX?<][CL?^?B3_/-?!] !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 =Q\$3CXL>&.2,WB=._UK^E#P N
MWP3H@VA?]$CX'T^@_E7\U_P1_P"2L>&. ?\ 3$ZG^5?TH> %V^"=$&T+_HD?
M ^GT'\J .@HHHH **** "OSW_P""O+8^%5KRP^4]3Z[AD<]^AK]"*_/?_@KR
MV/A5:\L/E/4^NX9'/?H: /Q?K] OV"_^3?OB'\V<M!P!Q_Q]1=>/\YK\_:_0
M/]@O_DWWXB8Y&^WS]?M,5 'I5%%% !1110 4444 %%%% !1110 4444 %%%%
M '+?M(1X_99UV39C.H8\S9R<1#C.SGKTW-C).U<Y;\VZ_23]I"/'[+.NR;,9
MU#'F;.3B(<9V<]>FYL9)VKG+?FW0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7Z'_ /!'L%OBAJ6,@YR&'T7(Z=QGTK\\*_0[_@CZN[XH:EQS
MG@D\?P''3KQ[=* /V:HHHH **** "D&><_A2T@&,^_O0!_/I_P %#C_QD5JP
MSV]?_K_T_P#K>4? 93_PL&P("YWK\QZ]>E>K_P#!0X_\9%:L,]O7_P"O_3_Z
MWE'P&4_\+!L" N=Z_,>O7I0!^G'Q0O%N=:T^-2Q^SZ=;PE6SA?E)POS$8PPZ
M!1R>"<LW'UV'Q0O%N=:T^-2Q^SZ=;PE6SA?E)POS$8PPZ!1R>"<LW'T %%%%
M !1110 4444 %%%% !1110 4444 %?,'_!1I1'\:+:,+LVV: IMV[2%48QM7
M;]-J_P"ZO0?3]?,/_!1M-GQHM5"[!'9HA7;MV':ORXVKCZ;5Q_=7H #Y0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "OJ#_ ()UX/[1NCC^+(PO
MKU[=_P J^7Z^H?\ @G7S^T9HXVYR1_7C_(- '] K=5^7//7TXZ_Y]:7'S _U
MI&ZKP3SV/MWIU !1110 R-MV#NW?*#P./J*?3(VW8.[=\H/ X^HI] 'S!^WL
MW_%F]4&?X.F?8>_]/_K_ ,_NH?\ ']<Y&/WC=1CN>W:OZ OV]F_XLWJ@S_!T
MS[#W_I_]?^?W4/\ C^N>,?O&Z8]3Z<4 ?IG\)?\ DVOX?G;M_>77;_9A]O\
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M?4W_  3EFBM_CF99]_DI;EG\N41-@*Q.')&T_P"UD8P?F% 'U%1110 4444
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M?\B_IWR[?W"#;Z<=/\_K0!?&2=PY&X\*V?;_ "*DIFTY'S'IRV>>/;ISS3Z
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MS(O)/4GU.>./RKY'7&"#^?>@#ZU_8"^/"_"KX@65C(P1+RXV;F;C!QV[#/\
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MMV#NW?*#P./J*?3(VW8.[=\H/ X^HI] 'S!^WLW_ !9O5!G^#IGV'O\ T_\
MK_S^Z@0;ZY(Z>8V,?4^PK^@+]O9O^+-ZH,_P=,^P]_Z?_7_G^U'(U"ZSDGS6
M^]UZF@#],?A&!_PS7\/\<CS+KG_@,/M_GWK7Z+TVY'\0Z\]N/\X-9/PE_P"3
M:_A^=NW]Y==O]F'V_P ^]:W1>FW(_B'7GMQ_G!H 91110 4444 %%%% !111
M0 4444 %%%% !7B?[?&S_A7/P^VC:WE2Y&,?\MI.<?7//?'M7ME>*?M\LQ^&
M_P /0P&!%+@AL_\ +9^/8_XB@#X=HHHH **** "BBB@ HHHH **** "BBB@
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MNY5^=<;LJIR!@#C /N<G X-?K]7X_?\ !4+'VZ<8Y&?E8\?7J,=/[HSCOTH
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M6J_:;_@KR?\ BS]N"<<<<XSSP.O./F^F:_%F@#IOAG_R/VA?]?2U_23\%?\
MDE^A;5V'[,O'8<#MQ7\VWPS_ .1^T+_KZ6OZ2O@HNWX8Z#@$+]G7&1CC [4
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M^I]*_2O2;/\ L[3+6USGRHU3\A0!.K/T(YX[8[\GO^524W:O/RCDY/'?UIU
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M?A4G_A&;#/'[A<%>3T],5^!G[":[_B7;C:KXF#;3VXZ]_P"G..?3]\_":_\
M%,:</N9A'W?YT ;%%%% !1110 C9VG'![9K\@?\ @J$=MW,,E4R0$ R![')Z
M\CL#S7Z^N=JL<A<#JW05^0?_  5$4K?3*,IMW#Y6X [#D^QYP,^^* /SF\.#
M=X@TS_KYC[_[0K]7?%TGF6_AL!L[=&MAM+?=R&.,;CMZYQA.N<'.]ORB\.8_
MX2#3,\?Z3'_Z$*_5WQ=(6M_#8+9*Z-; J'W;>&./O''7/1.N<'.]@#GJ***
M"BBB@ HHHH **** "BBB@ HHHH **** ,K]OK;_PJGPX  O_ !*;;<H!Q_J4
MP,=SSZ=!^%?F/7Z=?M^$_P#"J_#8;EO[)MQ][.285_3&>,<D_A7YBT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 Z$XE0YQ\P]OZBOZ&?V!\C]
MG70@1C X_P X%?SS0G$J'./F'M_45_0S^P/_ ,FZZ$,8P,=,?T% 'T;1110
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M<1#C.SGKTW-C).U<Y;\VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3TZ\KST'/^ K]#6X8G&.@W*,D\].G3_$U^>7_!'E=OPMU'C;G)Z=>5YZ#G_
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MZ;OFO,Z],_:2_P"2U>*>=W^E-_\ JKS.@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /IW]A-=_Q+MQM5\3!MI[<=>_].<<^G[Y>%?F\,6'&[,
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MB$<*<- ,XY'^E1<=/\\4 >E4444 %%%% !1110 4444 %%%% !1110 4444
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M^SKM_P"%R^&-Z[D^U+E<9R,],=Z_2+QX6;QIKA<%6^V2Y!()^\?2@#"HHHH
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MG]/7+?D?7ZX_\$E?F\,;NN%^\!N(.3G'7I\O'OTYH _3>BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 5]0(6QN2>GEMG!QV/>OYU?VVL_P##1/B8$Y(E([_WF/?ZU_15
MJ!"V-R3T\MLX..Q[U_.M^VT"/VB/$H.6_>GYCG&=S' YZ<_K0!U'[!O_ "4R
M(8_Y: Y&>RXYX_VO;^5?OEX3_P"1?LSP<QKRHP#P/8?Y_*OP-_8-_P"2FQ<=
M9.O/8?3'?VZGUK]\O"?_ "+]F>#F->5& >![#_/Y4 :]?CW_ ,%C6)\=:2/F
M.  >N.AQW_WN,=^O2OV$K\>O^"QW/CO2!O)Z-M[#@@G&?=>?P]: /S<K],/@
MR,?LY^#.,9EG[=?EC]O\?Z#\SZ_3#X,C'[.?@SC&99^W7Y8_;_'^@ -VBBB@
M HHHH **** "BBB@ HHHH **** "GN=W/WLL?F/4_7FF4]SNY^]EC\QZGZ\T
M >0?MY+_ ,67^'I.#S<$<9_Y>)/R_P ^M?!U?>'[>/\ R1CX?<][CL?^?B3_
M #S7P?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '<?!$X^+'A
MCDC-XG3O]:_I0\ +M\$Z(-H7_1(^!]/H/Y5_-?\ !'_DK'AC@'_3$ZG^5?TH
M> %V^"=$&T+_ *)'P/I]!_*@#H**** "BBB@ K\]_P#@KRV/A5:\L/E/4^NX
M9'/?H:_0BOSW_P""O+8^%5KRP^4]3Z[AD<]^AH _%^OT"_8+ _X9^^(9"]&@
M!8GG_CZBZ?Y[5^?M?H'^P;_R;[\0NWS0=.<_Z5%R?0T >E4444 %%%% !111
M0 4444 %%%% !1110 4444 <M^TA'C]EG79-F,ZACS-G)Q$.,[.>O3<V,D[5
MSEOS;K])/VD(\?LLZ[)LQG4,>9LY.(AQG9SUZ;FQDG:N<M^;= !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %?H=_P1]'_%SM2)&5R,D+G'W<<]
MOS[]Z_/&OT._X(]_\E0U)MN0."<9 R%]C_D&@#]FJ*** "BBB@ I >O&/ZTM
M(,\Y_"@#^?3_ (*''_C(K5AGMZ__ %_Z?_6\H^ RG_A8-@0%SO7YCUZ]*]7_
M ."AQ_XR*U89[>O_ -?^G_UO*/@,I_X6#8$!<[U^8]>O2@#]./BA>+<ZUI\:
MEC]GTZWA*MG"_*3A?F(QAAT"CD\$Y9N/KL/BA>+<ZUI\:EC]GTZWA*MG"_*3
MA?F(QAAT"CD\$Y9N/H **** "BBB@ HHHH **** "BBB@ HHHH *^8?^"C:>
M7\:+5-OE[+-%V;=N/E7C&U<8Z8VIC^ZO0?3U?,'_  4;0Q_&BT0KLVV2J$V;
M=N%48QM7&/3:N.FU>@ /E&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *^H?^"=?/[1FCC;G)']>/\@U\O5]0_\ !.L$_M&:/W&1QC/K_GH: /Z!
M6ZKR1SV'MWHW#..>N.A],T-U7YL<]/7CI_GTH"GKG'.<9SGM0 ZBBB@!D;;L
M'=N^4'@<?44^F1MNP=V[Y0>!Q]13Z /F#]O9O^+-ZH,_P=,^P]_Z?_7_ )_=
M0_X_KG(Q^\;J,=SV[5_0%^WLW_%F]4&?X.F?8>_]/_K_ ,_NH?\ ']<\8_>-
MTQZGTXH _3/X2J1^S7\/\C_EI==L?PP^W^?>M;HO3;D?Q#KSVX_S@UD?",#_
M (9K^'^.1YEUS_P&'V_S[UK]%Z;<C^(=>>W'^<&@!E%%% !1110 4444 %%%
M% !1110 4444 %>*?M\@CX;_  ]^<L/*EX..#YS_ *=/U]:]KKQ/]OC9_P *
MY^'VT;6\J7(QC_EM)SCZYY[X]J /AZBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /V8_P""/*[?A;J/&W.3TZ\KST'/^ K]#6X8G&.@W*,D
M\].G3_$U^>7_  1Y7;\+=1XVYR>G7E>>@Y_P%?H:W#$XQT&Y1DGGITZ?XF@!
M]%%% !1110!SWQ";;X(ULYQ_HK\YQV^H_G7\UGQGX^*?B48Q_IC=L=A["OZ4
M_B$VWP1K9SC_ $5^<X[?4?SK^:SXS\?%/Q*,8_TQNV.P]A0!J_LYY_X7/X7V
M@%OM:X!.!UK](?'2E?&>M@G.+R7G;M_B/;M7YO?LY@M\9_"X!*DW:_,.HYK]
M'_'&S_A,=;\O[GVR7&"3_$?6@#$HHHH **** "BBB@ HHHH **** "BBB@!5
M. W)&1V[\UO>!?E\=:#T7_3X>AX_U@]_\^]8*G ;DC([=^:WO OR^.M!Z+_I
M\/0\?ZP>_P#GWH _-_\ :2_Y+5XIYW?Z4W_ZJ\SKTO\ :0Q_PNKQ3CI]K;^=
M>:4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]._L)KO\ B7;C
M:KXF#;3VXZ]_Z<XY]/WR\*_+X8L&^5#Y );MTZG\*_ W]A-=_P 2[<;5?$P;
M:>W'7O\ TYQSZ?OEX4POA>PP54"'[V#COSSCZT ;-%%% !1110 C9VG'![9K
M\@/^"H3?Z9,@&T#.(RW'UZYX]P,^_2OU_;.TXX/;-?D#_P %0CMNYADJF2 @
M&0/8Y/7D=@>: /SG\.8_X2#3,\?Z3'_Z$*_5WQ=(6M_#8+9*Z-; J'W;>&./
MO''7/1.N<'.]ORA\._\ (P:9_P!?47_H8K]7O%S9M_#:[]^S1K9>6SCACTW'
M'7.,)US@YWL <]1110 4444 %%%% !1110 4444 %*%)YX[]QVI*4,/[H/7U
MH 2BBB@#*_;ZV_\ "J?#@ "_\2FVW* <?ZE,#'<\^G0?A7YCU^G7[?A/_"J_
M#8;EO[)MQ][.285_3&>,<D_A7YBT %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 Z$XE0YQ\P]OZBOZ&?V!_^3=="&,8&.F/Z"OYYH3B5#G'S#V_
MJ*_H:_8'X_9UT$8QQZ8_H/Y4 ?1E%%% !1110 5X+^VXV/V>O$8)(4Q,#_WR
M3^?'^>H]ZKP;]MLD?L]^(L<'RCALX(.T]_\ /8]J /YU;O\ X^IO]]OYU]3?
M\$Y9HK?XYF6??Y*6Y9_+E$38"L3AR1M/^UD8P?F%?+-W_P ?4W^^W\Z^KO\
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M6B;=FVR4;-NW;A5&-NU=N,=-JX_NKT !\HT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7U!_P $Z\']HW1Q_%D87UZ]N_Y5\OU]0_\ !.OG]HS1
MQMSDC^O'^0: /Z!CGC ^M+36&2O .#W[<=J=0 4444 ,C;=@[MWR@\#CZBGT
MR-MV#NW?*#P./J*?0!\P?M[-_P 6;U09_@Z9]A[_ -/_ *_\_NH$&^N2.GF-
MC'U/L*_H"_;V;_BS>J#/\'3/L/?^G_U_Y_M1R-0NLY)\UOO=>IH _3+X2_\
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M>B_Z?#T/'^L'O_GWK!4X#<D9';OS6]X%^7QUH/1?]/AZ'C_6#W_S[T ?F_\
MM)$GXU>*<_\ /TW?->9UZ9^TE_R6KQ3SN_TIO_U5YG0 4444 %%%% !1110
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M)C'_ (\*_5WQ:X:V\-*I^5=&M@%S]WACC&X[>N<83KG!SO8 YZBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#,_;Z!'PI\-*"=O]D6^ 0!QY*9./?@9QWQ
MCM7YBU^G'[?6W_A5/AP !?\ B4VVY0#C_4I@8[GGTZ#\*_,>@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** '0G$J'./F'M_45_0S^P.H7]G70L#
M''/&/Z#^5?SS0G$J'./F'M_45_0S^P.NW]G70OITQC'MT% 'T;1110 4444
M%>"_MN8'[/7B,G_GDW7H?E/'^?0U[U7@W[;?'[/?B)@=N(B25ZCY3S_GV^H
M/YU;O_CZF_WV_G7U5_P3=MY+SX])!$_ER20[%D^;Y20W/RLK<=<@@\'!%?*M
MW_Q]3?[[?SKZF_X)RS16_P <S+/O\E+<L_ERB)L!6)PY(VG_ &LC&#\PH ^H
MJ*** "BBB@ HHHH **** "BBB@ HHHH **** .F\(_\ (O\ CO@G_BGI^AQ_
MRVAK\F-:R=8OR6W'SY/F]?F/-?K/X1_Y%_QWP3_Q3T_0X_Y;0U^2^L'.KWQ
MQ^_?@?[QH J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7ZX?\
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MWUN!5&(U$C+GEL?Y_,5_-S7W]_P3?_:ZN?ASKFG^!&BS;WS[0>N#D#/3OZ4
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MH *^H?\ @G6"?VC-'[C(XQGU_P ]#7R]7U!_P3KP?VC=''\61A?7KV[_ )4
M?T#,,E> <'OVX[4!B6(&TX.#S[4-U7Y<\]?3CK_GUHV],_,0<@GM0 ZBBB@!
MD;;L'=N^4'@<?44^F1MNP=V[Y0>!Q]13Z /F#]O9O^+-ZH,_P=,^P]_Z?_7_
M )_=07;?7(QC$C# SZGUYK^@+]O9O^+-ZH,_P=,^P]_Z?_7_ )_=0_X_KG(Q
M^\;J,=SV[4 ?IE\(P/\ AFOX?XY'F77/_ 8?;_/O6OT7IMR/XAUY[<?YP:R?
MA+_R;7\/SMV_O+KM_LP^W^?>M;HO3;D?Q#KSVX_S@T ,HHHH **** "BBB@
MHHHH **** "BBB@ KQ/]OC9_PKGX?;1M;RI<C&/^6TG./KGGOCVKVRO%/V^6
M8_#?X>A@,"*7!#9_Y;/Q['_$4 ?#M%%% !1110 4444 %%%% !1110 4444
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M3X:4$[?[(M\ @#CR4R<>_ SCOC':OS%H **** "BBB@ HHHH **** "BBB@
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MT3XF!.2)2._]YCW^M '5?L&+N^)T)P !*!NQG&5ZD]AQ^IK]\?">?^$?LB0
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MT7_3X>AX_P!8/?\ S[U@J<!N2,CMWYK>\"_+XZT'HO\ I\/0\?ZP>_\ GWH
M_-_]I+_DM7BGG=_I3?\ ZJ\SKTO]I#'_  NKQ3CI]K;^=>:4 %%%% !1110
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M !GU30]%NC!9V[L!EB >>@]P/3'7ZUXB/^"D/Q<50!J?U_>,![=.G?IQ[<4
M?OXR[A@].X['VIGRJ^2<X/)X^\<8_'!Q7X,>'?\ @HY\5[KQ!I\,^H-)#+<Q
MHRAR2P+8QC'OVP/;IC]M_@[KEUXF^'.B:G>,?M%Q &<>^!Z@'^76@#LE;')5
MAG!YYZ\8I]1K'\HP%3Y<':.GICZ<]JDH **** "BBB@ HHHH **** "BBB@
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M0[_@CW_R5#4FVY X)QD#(7V/^0:_/&OT._X(]KN^*&I$#<1VP3QA<GIVX[T
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MVY'\0Z\]N/\ .#63\)5(_9K^'^1_RTNNV/X8?;_/O6MT7IMR/XAUY[<?YP:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"OJ&38W('7RVQCZ'W%?SJ_MM,&_:)\3$<@RD]O[S#J/I^M?T5:
MADV-R!U\ML8^A]Q7\ZO[;+!OVB/$S#H93Z?WCZ=L8H ZK]@Q=WQ.A.  )0-V
M,XRO4GL./U-?OCX3S_PC]D2 "8UZ >F/3VK\#?V#A_Q<Z \$[_Q' ]OZ_P#U
M_P!\O">!X?L@ ,>6N" >1CCMZ?R_"@#7K\>O^"QW/CO2!O)Z-M[#@@G&?=>?
MP]:_86OQY_X+',/^$[TD$L>1@?PCY3^IQ^G7M0!^;M?IA\&1C]G/P9QC,L_;
MK\L?M_C_ $'YGU^F'P9&/V<_!G&,RS]NORQ^W^/]  ;M%%% !1110 4444 %
M%%% !1110 4444 %/<[N?O98_,>I^O-,I[G=S][+'YCU/UYH \@_;R7_ (LO
M\/2<'FX(XS_R\2?E_GUKX.K[P_;Q_P"2,?#[GO<=C_S\2?YYKX/H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#N/@B<?%CPQR1F\3IW^M?TH>
M%V^"=$&T+_HD? ^GT'\J_FO^"/\ R5CPQP#_ *8G4_RK^E#P NWP3H@VA?\
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M.W^R+? ( X\E,G'OP,X[XQVK\Q: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ="<2H<X^8>W]17]#/[ __ ";KH0QC QTQ_05_/-"<2H<X^8>W
M]17]#7[ _'[.N@C&./3']!_*@#Z,HHHH **** "O!?VW&Q^SUXC!)"F)@?\
MODG\^/\ /4>]5X-^VV2/V>_$6.#Y1PV<$':>_P#GL>U '\ZMW_Q]3?[[?SKZ
MN_X)JNT?[0,#I#)<,L6X11D;G(#':,D#/'4D#KR*^4;O_CZF_P!]OYU]5?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1\#Z?0?RH Z"BBB@ HHHH *_/?\ X*\MCX56O+#Y3U/KN&1SWZ&OT(K\]_\
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M/7C']: /Y]/^"AQ_XR*U89[>O_U_Z?\ UO*/@,I_X6#8$!<[U^8]>O2O5_\
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M]<D=/,;&/J?85_0%^WLW_%F]4&?X.F?8>_\ 3_Z_\_VHY&H76<D^:WWNO4T
M?IE\)5(_9K^'^1_RTNNV/X8?;_/O6MT7IMR/XAUY[<?YP:R/A&!_PS7\/\<C
MS+KG_@,/M_GWK7Z+TVY'\0Z\]N/\X- #**** "BBB@ HHHH **** "BBB@ H
MHHH *\4_;Y!'PW^'OSEAY4O!QP?.?].GZ^M>UUXG^WQL_P"%<_#[:-K>5+D8
MQ_RVDYQ]<\]\>U 'P]1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '[,?\$>5V_"W4>-N<GIUY7GH.?\!7Z&MPQ.,=!N49)YZ=.G^)K\\O\
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M0!^;_P"TE_R6KQ3SN_TIO_U5YG7I?[2&/^%U>*<=/M;?SKS2@ HHHH ****
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M!QV]?J/TKH8I#(N2,=\;2,?G^- "[OFQO7[V,=^F<=>O>GTW)STXSW/MVIU
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M#/;U_P#K_P!/_K>4? 93_P +!L" N=Z_,>O7I7J__!0X_P#&16K#/;U_^O\
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MX*A';=S#)5,D! ,@>QR>O([ \T ?G/X<&[Q!IG_7S'W_ -H5^KOBZ3S+?PV
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M/V_Q_H/S/K],/@R,?LY^#.,9EG[=?EC]O\?Z  W:*** "BBB@ HHHH ****
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M3B(<9V<]>FYL9)VKG+?FW0 4444 %%%% !1110 4444 %%%% !1110 4444
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M&-NU<?3:F.FU>@^GJ^8/^"C<?E?&BT3;LVV2C9MV[<*HQMVKMQCIM7']U>@
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MD%"\ 8[TM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9_Q_6OU_.=PZXZ]L?3_/I7XE_P#!)&14^-<V]T &WY6X/4?_ *_P-?MH^3@
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M6)\=:2/F.  >N.AQW_WN,=^O2OV$K\>O^"QW/CO2!O)Z-M[#@@G&?=>?P]:
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MC]GTZWA*MG"_*3A?F(QAAT"CD\$Y9N/H **** "BBB@ HHHH **** "BBB@
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MK\\O^"/*[?A;J/&W.3TZ\KST'/\ @*_0UN&)QCH-RC)//3IT_P 30 ^BBB@
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M#GJ*** "BBB@ HHHH **** "BBB@ HHI0H_O =?6@!**** ,K]OK;_PJGPX
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MCY2I12N,*HQCI\J_[J]  ?*=%%% !1110 4444 %%%% !1110 4444 %%%%
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MP+\OCK0>B_Z?#T/'^L'O_GWK!4X#<D9';OS6[X#.?'.@8&"VH0 *N>\B\=:
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MHK^AG]@?_DW70AC&!CIC^@K^>:'/FIC).X?=ZU_0[^P9!)!^SKH ="F5XR,
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MSZ9X]CW]/45^>W_!7>/_ (MC$V[ XXS]1Z\=_P!*_0U5VDGJ3W[_ $K\_O\
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M+7Q&U/Q,R[/M;9"\_*,DXY[<US*^$=9;IIT_7'*XIO\ PBFK_P#0/F'U&/\
M/]: .\^ GQB;X.>)DU9$WLKAA\N<<8_EUQCM7WUIO_!8]K.RA@?1V8Q*%#>5
MG.!WZ?I[5^9?_"(ZQN*_V?-D9R,?Y_\ KT?\(CK'/_$OFR!G&.?R_P ]_0T
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M_F0,9X_X^KH8_P#(AQ^OT]?A?_A$]8_Z!MQ_WP:/^$3UC_H&W'_?!H ^Z/\
MAO#X7G_F0,9X_P"/JZ&/_(AQ^OT]3_AO#X7G_F0,9X_X^KH8_P#(AQ^OT]?A
M?_A$]8_Z!MQ_WP:/^$3UC_H&W'_?!H ^Z/\ AO#X7G_F0,9X_P"/JZ&/_(AQ
M^OT]3_AO#X7G_F0,9X_X^KH8_P#(AQ^OT]?A?_A$]8_Z!MQ_WP:/^$3UC_H&
MW'_?!H ^Z/\ AO#X7G_F0,9X_P"/JZ&/_(AQ^OT]3_AO#X7G_F0,9X_X^KH8
M_P#(AQ^OT]?A?_A$]8_Z!MQ_WP:/^$3UC_H&W'_?!H ^Z/\ AO#X7G_F0,9X
M_P"/JZ&/_(AQ^OT]3_AO#X7G_F0,9X_X^KH8_P#(AQ^OT]?A?_A$]8_Z!MQ_
MWP:/^$3UC_H&W'_?!H ^Z/\ AO#X7G_F0,9X_P"/JZ&/_(AQ^OT]3_AO#X7G
M_F0,9X_X^KH8_P#(AQ^OT]?A?_A$]8_Z!MQ_WP:/^$3UC_H&W'_?!H ^H/C[
M^U_X=^(_P]N_#/AKP\=$AO'5[A?-E?>R@A3\[-T#-^=?)57;[1+_ $U0UU:R
M0+QRP]:I4 %%6K'2[O4Y-EK TS>BU</A/65_YAUQZ_<H R:*U?\ A$]8_P"@
M;<?]\&C_ (1/6/\ H&W'_?!H RJ*U?\ A$]8_P"@;<?]\&C_ (1/6/\ H&W'
M_?!H RJ*U?\ A$]8_P"@;<?]\&C_ (1/6/\ H&W'_?!H RJ*U?\ A$]8_P"@
M;<?]\&C_ (1/6/\ H&W'_?!H RJ*U?\ A$]8_P"@;<?]\&C_ (1/6/\ H&W'
M_?!H RJ*U?\ A$]8_P"@;<?]\&C_ (1/6/\ H&W'_?!H RJ*U?\ A$]8_P"@
M;<?]\&C_ (1/6/\ H&W'_?!H RJ^BOV.?VJ'_9?\4W>JK;M<"88*@9SP!Z>F
M:\*_X1/6/^@;<?\ ?!H_X1/6/^@;<?\ ?!H _3__ (?,?]0;&/\ IC_G^G]"
M?\/E_P#J#^_^J_\ K?X?4]_S _X1/6/^@;<?]\&C_A$]8_Z!MQ_WP: /T_\
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MJ.Q_PWA\+_\ H0/?_CZNO_CG^/U';X7_ .$4U?\ Z!\WY?I]?;V-'_"*:O\
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M^GR]:;_PB>L?] VX_P"^#0!E45J_\(GK'_0-N/\ O@T?\(GK'_0-N/\ O@T
M95%:O_")ZQ_T#;C_ +X-'_")ZQ_T#;C_ +X- &516K_PB>L?] VX_P"^#1_P
MB>L?] VX_P"^#0!E45J_\(GK'_0-N/\ O@T?\(GK'_0-N/\ O@T 95%:O_")
MZQ_T#;C_ +X-'_")ZQ_T#;C_ +X- &516K_PB>L?] VX_P"^#2MX3UE6(.G7
M'''"9H [GX#_ !A;X/>)H]46,NRN'^Z#TQ^/K_2OOS3?^"QS6=C!;OI.XQKL
MWF+\N?\ ZWX5^97_  B>L[2?[.N/3[E!\)ZP,'^SYB#R, '/T]?\F@#]/O\
MA\P/^@,1WYA_E_G\1V/^'R__ %!_?_5?_6_Q^H[?F$WA'65ZZ=/UQPN:;_PB
M>L?] VX_[X- 'Z?_ /#Y?_J#^_\ JO\ ZW^/U'8_X?+_ /4']_\ 5?\ UO\
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MF_+]/K[>XH ^Z/\ AO#X7\_\4!T;_GZNCZ\?ZP9'OQTZ4C?MX?"_YL?#_/7
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M[H_X;R^%Y_YI_C'_ $]77_QW_#^A/^&\/A?_ -"![_\ 'U=?_'/\/J>_PO\
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M@T?\(GK'_0-N/^^#0!]T?\-X?"__ *$#W_X^KK_XY_A]3W/^&\/A?_T('O\
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M_P"^#1_PB>L?] VX_P"^#0!E45J_\(GK'_0-N/\ O@T?\(GK'_0-N/\ O@T
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MW_+(QD$TG_#!?@EB0;6WV\\;6(&<\XSZ'GZG\?I]B5&>PY/&30Q(P>V>>,T
M?,,G[!O@I\'[-;]"""&/7''7D=?3H*<W["/@O&1:P9QTY/IW(X[CCM]>/IMF
M96]N.V>_^?I2JI7JQ;C'./SH ^8E_8.\%J/^/> OMP6PWK]>WZ^U(/V"_!"M
M@6MN%!!&T,#Z?RX_#WX^GUSM&>3WQ2;3G.X]<XX].E 'S$O[!O@G:N;:WSU.
M%;@XZCGUS^?YB_L&^"/E_P!&M\YSPK<=<XYYZ_S/M7T_3=IX^8]<]OR_SZ4
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M?O#KZ\^_ZT?\,'^"E!(M;<L>O#<GUYSV_$8Z]Q]/TASQC\: /F+_ (8.\$@
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M,&^"-V?LEOU)Z-Z8'.?U_"@?L%^!Q@?9;?'RC[K=!SZ^O0=NOM7T_10!\O\
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MM+^S_P#L4^$M>^&FF7][;QB::,!P4YR!DCU')^O!_'\8_A;G_A.-+P"2)5/
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M5/Y^OX$X&3^/T[R&QU[DGTY]J=0!\P?\,'>"VQ^XA7CDJIX_J<>YQR3CU/\
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M&[/V:WZ@YVMZ<GK^'^<5]/T4 ?, _8-\$JHVVUNK8 QM; '/'7MG^?3/"?\
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M=*_(C_@C6)O^$JUPF!Q%VDP2&X/MCCGKZ#UR/UTD/7EA\I^Z,_TZT .50J@
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M$WEK\K C^$>W_P!?UQB@#UI!M51@+@=%Z"G444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 444U_NMP3QT4X- "*?FV[BQ P?\^O(K\B?^"R'S>+-(;.><=?]
ME1TS[5^NZCYB3N]LGCM_GFOR%_X+)-,/&&BJ(F,/7>.0./K]/Q;MCD _-.OV
M[_X))@_\*+)'W2%W?D,=OKW-?B)7[<?\$D6=O@:V^&1-N%W,..,>W]: /O"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBFMU7@GGL?;O0 C'[Q&0WW>0
M2/R_&LWQ&/\ BF]2 ' MY  %QC /;'^?:M#<&^4C)! ^8CD]>W? S6=XJRWA
MK4\*<^0^/R//T[T ?S=_M*J5^-GBC/\ S]-@YR#VZY->^_\ !.F,2>/(1C=^
M]"L.O?&3]-P].O7ICY^_:.=I/C1XH9D:/-TV WY>I^GX5[Y_P3K:1OB!"(XR
MY\T*IZ@'DD>W'?CH/:@#]T]%WMH]J2?G,0.2/45<7=GG( /?&3U_3I5/1&QH
M]JQ4K^[!(Q^/  JX,L"K888P1MP#Z_A0 *O0J3CH=V>V?7^=*@&T%>%P,+C&
M*:^5RP&<9;J>N.F*<I!9MH^K#')Z?TH =1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'
M(PVD9P1R3G[ON>>G%24UCU W9]0.F>_- #=A*LIVX.>#EO7K_A3E^^P^AZ\_
MEVZ?SIA&UMS<!CCK[\<\?ESUI\;;EYZ]QZ>QH _+?_@J1M;3Y,#@[MH*G@8.
M.N??U_$U^56FY.I6H'7S4QCZCW%?JC_P5(F;[+.#$=QW D^I!X]<\]P?Z5^5
MFGY%];$+O/F+A2,YY'% ']&W['/'[/\ X94  +"H  Q_ M>S?=CSG:1G+?='
M7DX_6O%?V-9#_P ,]^&6D!7]PI)8$#&U1GD#TKVOG: -PPN=O4_3)X[&@!>)
M593ZX(X/X?B/YT^HV7Y@3\V3P#T'3_#O3UX4#.?<T +1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'D?[5C;?@7XFY"_N&Z_P"Z:_F^UC']KWV!@>>^,_[Q
MK^C_ /:P=H_@/XG9%WM]G;"^O!K^<#6"QU>^+A@_GOD-USN/6@#Z+_X)\Y/[
M1FB#&1G/K^F#^?ZBOZ#P2JH#@'IRV>W;UK^>O_@G^TB_M':"1 SIDDR!2P7!
M''3T/UXK^A6/_5K\NS@?*.WM0 @4L=WW20.PS]"?\]Z?42H57&.!MZ9 XQTY
MZ>WM[U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !39%W*!C/(/;U]Z=39/ND[M@[MZ<4 1_=3+9?
MGH>!G/;/OT_"ED;8KL-V!U]>@Y&>*D'?G/\ 2H+C'V*8#;@(P&T<#@\4 ?,/
MQB_;[\%_!O6)--U4J;A#M89QCISC/^00:\V_X>U_#0_W1GU?./;KSU'/L?:O
MA#_@HU9(WQ,NY5.2LA/!) /4\9^O;'7I7QK0!^W/_#VOX:'^Z,^KYQ[=>>HY
M]C[4?\/:_AH?[HSZOG'MUYZCGV/M7XC44 ?MS_P]K^&A_NC/J^<>W7GJ.?8^
MU'_#VOX:'^Z,^KYQ[=>>HY]C[5^(U% '[<_\/:_AH?[HSZOG'MUYZCGV/M1_
MP]K^&A_NC/J^<>W7GJ.?8^U?B-10!^W/_#VOX:'^Z,^KYQ[=>>HY]C[4?\/:
M_AH?[HSZOG'MUYZCGV/M7XC44 ?MS_P]K^&A_NC/J^<>W7GJ.?8^U'_#VOX:
M'^Z,^KYQ[=>>HY]C[5^(U% '[<_\/:_AH?[HSZOG'MUYZCGV/M1_P]K^&A_N
MC/J^<>W7GJ.?8^U?B-10!^[OP]_X*:> /B)XJM-#L=HN;H[47))!) '3.>M?
M8=K<)=V<4^5*,H?.,#]:_G!_9)MQ=?'?PXIR=LRMP<?QK['^5?T9>%\_\([I
MN0P_T=/O?04 :2],9)(X)(ZTZBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ IAVNQ4_-P01V[<&GTUP65@.N/7'
MZT &TX;YB,].G%1[?WFYOE&[(X'7I^9S_+\9&7=CO_LGIU'/X4TQGL><8W$<
MDCITQ[\>] %+6]#M?$.FRV5]&LL4@(Z=*_,O]M#_ ()O3:]<7OB+P?;>4(LR
M.B+QCJ3U[^_>OU#VYSDD\Y],4VXMTNK>6"0;HY%*,/4$8- '\N6L>$]5T/5;
MK3[FQG$]O(8WVQDC(/6LJ6&2%BLB-&W]UA@U_25J7[*OPTU:\N+JZ\.023SL
M7=\#.3G)Z>_^<FOC3]J3_@ET/B%XCCO?!FS3XN250 *,]!@].?TH _'ZK$>G
M7<GW+69_]V,G^GN*_1WPG_P2$\4V>OVL^HW_ )EFC[F4@=/0\<Y&?;D"ONKX
M;_L*_#_PSHT$&I:1!=S(H4[D5N1ZY7U^HY]Z /QZ^ ?[%/C3XY+'/:6D]O;,
M0?FB()%?L]^RS^S#HWP)\$V4#VB#4U!:5V R3@<G]?SKUSP=\/=!\!VOV?1+
M".SBQC"@5TE #(\G.Y@6'!"]/\]*?110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5'M\OGZ#H2<?7Z]ZDIBQ[>N
M&.<YQSTQGZT -:7: 1UZ;,CKC//_ -;UI5'S*0,@?*"1R/7D_04OECCL!]T+
MD8''^%*J[>!PN,!>PH ^0_VZOV2KW]I+2T6Q5C=P@"-QV( Z=>WJ,9SZU\M?
MLY_\$P_%7@'XB6>N:ZS21VSADPI4#G.>GH/T]Z_6+G<..*0;^,A1Z]_P_E0!
M3M(?L&FP6PQF.(*<<8^4^G3IZCZU;4!F9N#S@'.?3/TY'Z4N"P4G@CG@\?\
MUZ1E+,.VWD9 (_\ UX_G0 ;@&)V^Q.#GV_#FGTW"I\Q. ,DDGCUI2P& 3C/
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M0.GI2-)A<@KW /7D=L=^_P"5 $E%(#GMBEH **:K%NJE>,\X_*AB>PR<>O%
M#J*:74'!8 \=_7I3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *:S;<=,DX&3C_/%.I&4,I!&0>"#
M0 W:&!P6!Y&>?7WJ*\MTNK2>W*_+(I##'!!SD=1UY[]ZDV$9/RD]1C(R??\
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MSSZ8/49_.GKG:,\GOBFK^[4 E0H  P,#/^<4^@ HHHH **** "BBB@ HHHH
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M8?G4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT= O)Z?6HU&WY O8+][! YYP.GX?IBI0,9]_>@!:*** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR/SZU?K*\+X_L&S & L:C;Z<#CU_/FM6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD.>PS3/FV\
M%CT'3!Z\F@"2BHU<L,!AD@D;B"<YY&!Z<4HD]<8R1D'CKC'UH ?7.^-O'>B>
M =)>_P!<O([.U"GF1@ ?;\>E2>,/&6F^"M)GOM2G2WBCC9PTC  D \<FOQ"_
M;C_;8UWXQ^([[P[I][-!I%E+LCDB)4N.>.OH>W_Z@#ZW_:$_X*EQ?#_7)+'P
MTD=^NX[9 VX=L_T_.OE3XF?\%+O%GCS2;NR4RVXF5E#1D@\^O/OGVY^E?%,T
M\MQ)OED:5^FYV)-,H Z:Z^)?BB\NYKB36[OS)6+,%D(')R>*WO WQX\7>"=9
MAOHM7NKCRR&VR2%N1G')^M>=T4 ?H7X,_P""M/BCPQHL5C-:M=&-=H9@.,#
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M&<TJ#;@)M*=.O/?/UY_K3U8,H(.0>010 M%%% !1110 4444 %%%% !1110
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M=>,4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !13</\ WE[]OR[T-N[$#CN,\T .IK+E@>G^UWZCC\:')'.Y5[?,._:C
M=NP%/XXR.#S0 @8L1R!GD ]2,>G;DTF26)!^7.,J<]#Z8^N?\X59">J\\?+D
M9 /K^OY5G:[K]CX6TM]1U.=;>WC&'E8@=B>IQGO0 WQ)XDTWPKI,U_J]S';6
MD8)9WX&/Q]J_ 7]M3XO:EK_QTUB71]<N&TW_ )9>7+P0<CM['UKZ/_X*'?MU
M'QDMSX.\+WK"Q+L#-$0<CZ@_3_\ 5G/YMS3R7$ADED:5SR6=B2?Q- &]_P +
M#\3;=O\ ;M]MYR/./.1@U^B/_!(C7M;USQUJK7^HSW, <D+(V?X<GMZ]LC]*
M_,VOTD_X(Y<>.M5Z#(?J.O"=./\ /Z4 ?L%D[@.V#V^G>G4F/F!_K2T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M /4Z*0<=\TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-CCE?8?[/<YK\VZ_2/\ X(Y@?\)YJAV_,0V&Y]!Q_P#J]Z /V%HHHH ****
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MX?\ @KX!OM,N)HYKW4(C"J!L[2>_![<?E7X(^*M236/$FIWT?"7%P\H_%B:
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M,\C@]..OI3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P %4O&WB3P_X\2+3=4FM+8-D^3)COU')/.5_/\ /X"'Q9\8C/\ Q4FH<_\
M38U]S?\ !6J4-X_'<;L'D\\G;SGG@9Y'J<\U^=M '6M\6O&3=?$>H=<\2D4@
M^+/C$9_XJ34.?^FQKDZ* .L_X6QXPP0?$>H$$8(,Q(YK?\!_%7QE/XVT9!X@
MO7,EW&"I?@_,.3_CVQ7FE='\.&"^/-")Z?:T[D=_;^7>@#^E'X.32W7PS\.S
M3[FE:U4EG^]SU_7Z=*[%E)8$<?B?Y?B?TKCO@W_R3'P]\N&^RKNQZ\_G7:4
M,.$V@?*H], >@'^?2DB4*N/XAP3MQ^ ]N:DHH *_GX_X**G/[16KG.?F;W]/
M<U_0/7\_'_!14Y_:*U<YS\S>_I[F@#Y>K4\*Y_X272\9S]ICP1C@[ASST^M9
M=:?AC_D8],XSBYC/3/1@?2@#^DC]FSCX*>%N,?Z*O;_ZU>EI]U>"..C')KS3
M]FW_ )(KX7XQ_HJ\8]OI^/XUZ6GW5X(XZ,<F@!U%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,-RD'OZ'%+2
M-G:<<'MF@!C8Y554_P 6TGOG(_7/-9/C"S^W^';R''WD;MG'!YZ?SK6R5(5=
MNT'' ^[P./RS^E#QF:)E;@,.GI['!H _GD_;ETO^R_C1>QXVY+';@CJ0?IWZ
M]\BOG:OKO_@IGIJZ=^T!=1J" H;/<9)'O[?_ *J^1* +V@R>7KFGMG&+B/GT
M^8>QK^C?]DAO,^!'AQMNW,0XQ_LK["OYQ-)S_:EG@X/G)C(_VA7]&G['>/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/0DX.1@YSGO]/\* )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[W/3OUKS;]FSCX*>%N,?Z*O;_P"M7I:'<JG(;(ZKT- #J*** "BBB@ HHHH
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M(.0>012;2!@'OGGGO2KG:,C![XH 6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &,WS<N !CCZY
M'^?I1M^;.Q?O9SWZ8STZ]J&;#$;U'3@^Y^O>C W],G.><\<8X_SWH ^1O^"F
MS#_AGB^!8=&XX]!GJ<'@&OP3K][?^"FS%?V=[WG;][G(']WO[8S]/6OP2H *
M_23_ ((Y _\ "=:KA>,/DX]DYZ?Y_2OS;K](_P#@CFO_ !7>J'I]\].O">W^
M<?A0!^PM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?Y[]^#W3\G:3SWVYX!/H#^OL: ')M7;A-A*],= .WZT^FJ!P5X'7;C'7G/\
MGUIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,HVG'! )Q]?SQ7Z.4 ,C/3EC\H^\,?TZT^FJQ;JI7C/./RIU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 -9BO12W&>,?E3J:RANN>F."13J "F]&)(Z\#&3_\ J[T;F/\
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M3:VS!MT,2C XS@>N!Z?XU<5=I/7W/'S<#FD;+,,=B.Q_'OS_ (TY%*]6SV%
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX'^<5)&NQ0,_@!@#CM40_=MACMR-QP1@<DG\/?'?\IZ "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH 0C./;WI%55Z*!QC@=O2G44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !12*P900<@\@BEH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD+!>2<=J6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI P.0#G'!H 6BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BDW#<1GGKBEH ***0,#D Y
MQP: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ***3<-Q&>>N* %HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***1F"J23@#DDT +1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIUX]:<JA1@#_ !- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "D9@JDDX Y)-+2'GOB@!#NSP!CCO\ G1N/(^7>.=N?RINQ54EA
MNQWQDX'(^M#*2V/?.#R.,?D?_P!= #OFST&,^O;'^--D<KC!QGCD=\@#O[].
M]*RA?N@!N0#MSC/-)N#8^;8WW<9&0<9^F:  JK-R!DYRK<DCH<>W2DRKML;Y
MAZ'\>HQT^M+LW,=OR@'I@COD]^?_ -=(JE552,*,?=]<\ 8[#Z?UH 5E+9(&
M/]DDC.#QTH(+*R]1R"6'Z8[CFG+E8QQD@= <_J:8S%6(Q\QYQDG/;\.V>.]
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MA[XX_*G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !32N6!XP/;G/\
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M+344JHR>P&,Y_6G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI]ZS-5\0Z7X=MO/U*[ALHP,%GXVCL#C/K6%_PMSP5][_ (2&QS][[W/IZ=:
M.M79Y?S!1\@W;O3WS^/6E56R-PW$'J>,<=1_GUKD_P#A;G@MFP?$5B2K8'S]
M_P OUK2TGQSH'B$E-/U6"[)'/E,<CM^% &TS @L.A PV[ //'^?>I*:H/4\9
MZC)//'2G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 444ASV&: $9BN,#\<9[BFJN[J<J. "/3')S[CK0\ACY8JH[
MY/'4=_Z5S-]\4O"FF7!@N]<M;>=?O1R,<CZ\4 =,K"1E.5..1CGKT/Y9IR#:
MJC 7 Z+T%<C_ ,+?\&<?\5'8\C/WS_A3?^%O^"U.[_A(K')'7<<_RH ZYU&<
MG:/NCYA[_P"<41L> =W3^)><]^>G<=/>N1_X7!X+C;:/$-EWR5;C.?I6QHOB
MS1=>C!TN^@O%..83QZ4 :Y8[B!C.#A3WZ<_2D9MS;&P5)QR.O'3W_P#K&A6/
MS$AL9XX]\?\ U_QI)'.'';GDY4 8]?\ /Z4 +&IX.&'&3G')]\=^*/+*X.!G
M_94 \GGKV-.9-V03GD'H.,5'_"0N2IRWR_Q \\$=.O\ GK0 [B1<-SWQ@@8.
M>#2JS-VQSR#P1Q^M4-6US3M$C>34;F.VBV]9"<$?3\ZY]_B_X+^96\16)'0_
M,2/Y4 =B6 P"<9X%-9]K =NAX]>G/^>HKDC\7_!BY_XJ.QX./OG_  I!\8/!
M9S_Q4=EQ_MG_  H Z[=NC8$9;&"JGG..F:7(7<3\O/<]>G2N/'Q>\&28'_"0
M69^; &XG)X[8KH=+U[3]>A633KR*[B/S;XFR,?E0!=^7[P/.<9'/< C]*#AL
M;L*WW3USR,D \?Y%)S'&<[AP/FR#M_$^G7FN;U3XF>%M"O&M=0UFULKKJ8Y&
MY/ ].M '2JV&P2"V[!Y[XSP/Z4NWD':I.[).,=L9^N.*Y+_A;W@S_H8['M_R
MT]?PKIM/U"VU*U2:RECGA.-K(>,?Y_E0!/Y8:-5*@ #&T=.F,>XI-Q9,].#D
MJ<D'VXY[TX95CQU/KGM_GI4?*D$CD+Z%OJ.F?3_"@ 8;6Z 'G&T $Y.<#)]N
M:FJ-G9<$C]>OH.W)XI8V+ =P,@DD9R#CM0 ^BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"P7DG':DW#:6)P!U)XH =
M12!@<@'..#5'6M<LO#]BUY?SK;VZ_>=B ![T 2WU_;Z3;/<W4WE0+U9SP.>O
M^?2OE?\ :L_;H\,_ _PNEWH]Y#J6I.?]5&0<Y^49KX[_ &W/^"B6IS>(-1\(
M>'786,;,#-"XZY ZY]CZC\.*_.+7O%.J^);B2;4;V:Y9V+;78[1GT% 'VG\=
M_P#@IWXE^+7ATZ?:0MIC[>&A)4YSG.1]>A';BOD";XH^*YI&D;7KPLQS_K*Y
M:CC:..: .G;XG^*V^]K]Z><\R=SWI?\ A:'BSG_BH+[T_P!:?3'\JY>B@#J/
M^%H>+./^*@OO3_6GTQ_*M3PU\;O%_AW6K?4%UN\G,3[BCR'!Y!/X\#\JX.B@
M#]'/AO\ \%:M:\+:9:Z=>V?VE4"AI74D=>?S_#I7Z4_L^_M&>'/CAX7MKBSO
M4?4'4>9;$<C(Z$?GUK^;JO6?V??VB/$/P#\8V^LZ;<RR1)C,#-E>,=CVQ_2@
M#^DS:Q/)'!R#S^6/I2%E$8"$!=N1MZXQU []J^:?V2/VO=-_:$T>-3(BZE@%
MHRV>O0YQ^&/8>M?3#9/ X&/O=Q0 B_*><+N/"CIW/YTJJ1CG&.,9S]#FAT\Q
M2">""","A67<=O?.2!Z<4 >2?M57EU8?!/Q!/:2&&986VR XP=IQR.?\GV%?
MSS:U\3/%7]L7_P#Q/+L?OY.%DR/O&OZ%OVL"/^%'>(\GGR&(Y'ICUSW_ %_"
MOYQ_$7_(P:G_ -?4O_H9H UV^)WBMF).O7I)Y),E?<W_  3-\9^)-9^(42WV
MHS7,.0-S/DXR!@]?7T[=.#7YY5]]_P#!,#YO'MO\JR<CG&<<@>GTY]@,'!H
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MZ@ HI"P& 3C/ I-ZYQN&<XQGOC./RH =13?,7:#G.1N&.<CVH9@O4\XSCO\
ME0 ZBBB@ HIID49'7'7 S_GK2LP522< <DF@!:*;N''.,G SQ1N&T,3@'UXZ
MT .HI P;D'/:D\Q=H(Y&,@J,\4 .HI"P& 3C/ I/,3:#N7&-V<]O6@!U%-+
M'&>>.!R>:7<-P&>>N* %HII=0<%@#QW]>E.H **;N&<<]<=#Z9HWKG&X9SC&
M>^,X_*@!U%-#J3@,">>_IUI2P& 3C/ H 6BFJZMT8'C/![>M"NK=&!XSP>WK
M0 ZBFJZMT8'C/![>M.H ***0L%Y)QVH 6BF[AM+ Y ].>E&X<\YP<''- #J*
M0-N__52T %%%-9U7JP'&>3V]: '44C-M4D]O09I-P 8DX"]2>!0 ZBD+;?\
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MH *:QP5Y R>_?CM3J* &H=RJ<ALCJO0TGR2?W7^7Z\'^AQ2N2.=RKV^8=^U
M)W$'ZCB@ 9@O4\XSCO\ E4-_?0:99S75S(L5O"N]W8X %%]?1:;:RW5PX2"-
M=S,>,>]?F1^W]_P4%313>>#O!US]H2<-%/-$Y^4@$9![<X/MGOV />?VEO\
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M]:YBB@#IS\3O%9P#KUZ0.!^\KZ\_X)^_M1ZYX;^(%KH&IZC/>07<FT"1B>I
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M@,=!C].WXTJ*1STW<D$#.?P].E #Z*** "BBB@ HHHH **** "BBB@ HHHH
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M3G^,U_1S^U4?^+&^(3\Q_P!';KQGY#U&1SWZ=C7\XNO?\AS4<'=_I,GS#O\
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MMZ+S0!:9RI  )/ICKP>_3M_G-+G:/F(Z_3OQ4:P@A21AAUX'.".><^@I_*<
M#EN !CZY_6@!-WRX7.,[=V<GTSW[^OO3MQ.1T;MP2/:FJR[2V=Q Y./FZ9Y'
MX]/>AD^9=HQC)Z#&<_SZ_F: #S"&)P2#PHX&<?7OU_*ALJV<,0.?T/  Z_\
MUZH>(->LO#&EW&H7TRPP1*78LV.@[9KYZOO^"@GPHL+R6W?5,O&VT_,/Z9%
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MW!<@@D ]#C^5 'P5<?\ !(SX;M;R".3$FT;>.^/\0/\ ZU?#/[1G_!/?Q9X
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M_P %"_A.PS_:J@^A?'?'I0!]-,A,>,EB!ZXSQ[4F"&; ZD'*@?Y[?E7S(O\
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MS^M(6&U2Q (&[<RD >OTX-?,S_\ !0KX41LP;554KUW2 8YQZ4U?^"A_PE+
M'5E7_>;_ .MS0!]., NU1@ MZX]_Q_\ UTW:JJVY6(;.5QGU/05Y=\)/VD?!
MOQLEDA\/7J7+ID.A;G&/3%>J-&&Z^WZ'- #<'=A2WJ<_4GCB@87D JQQG()/
M)Z?S^E5[C5+6Q!$TJ1-D_+G!/)_S^-1?V]ISD?Z5&Q'(]N.OY4 7>2 N>6!R
MK'!ZCN/3/\N:$8MMR>W8$ ].3Z?2JG]NV#, MU$Q_P![GGT]3TXJS;W4=RNZ
M-@Z'HRY(/ /]: )J*** "BBB@ HHHH *CEY7;\O/3)_BZCM_G%24W:58D!<'
MKV/U]^U #8V 8KQU[ CN>H_#KWH;=SRWIE<=S[^E*%*@<<CC[QZ9_GBDY*[0
M=Y7J=V#G@C.* '*V6(QTSG!SCT_2F[1[,<C<% Z\<_A2M'N/.&!X.X9XQTI&
MRS#'KD97&,'!Y^E #64Q\@_(,$EF/'8]3TQ_+/-+D,X!Y//(!!'/'X<?CBE5
MPJ@ <!<X48P.PQU__50\(DSGOGK@]L9Y_P \T #,C*-QP,9PW'&.<C\:&8@Y
M)V@<\\# ZDG]?PI3EUR"&5@,8./J<_2@]2H)W'K@_=XZ\_2@ 8_,>6'3H/?Z
M4K9X(SUZ#%-CD+>C9P?E8$ 8Z_3(-!W;B5SC(S^F>OMZ>] $-\2--N"20?);
M.X@'[I]"/YU_.9^V,Q;X_P#B0DY_>D?^/M7]&6I;3I=WM"E3"YZX!R#WK^<_
M]LHY_:"\2'.29"2??<V>] 'B5%*N,$' [Y.?RIT<+22J@&2V/N\T -P-N<Y/
MIBM#P[KL_AO6+;4;;_70MN'./U[4V^T>YTQ5DD5TZ$':1VZC_/<50+$X!.<<
M"@#]Y_\ @FS\6=3^*WPC%UJ19G@ C4L?3&0!Z?CVKZ^S\W5OO>G'3Z=*_-+_
M ()._%/2M+\$OH$SJERX  /!8XSZ>N/S![U^EQ8E-RCWQCGZ4  ;YR,Y]@.G
MU/XBJVH!AIMWE\'RF^8<8^7M_P#KJ27/W22!GJ0/48/X9X^G0UX-^V9\8KKX
M,_"V[U>T(21D*[N<C_ =.1WQ0!^)'[9T\\G[0/B5)IS,!+D?-N Y(QGOTKPZ
MNG^)'CBY^(GC"_UV[R9KERQ)))/).>?K6)H]F=0U6UME7<TL@4#UR: *='\(
M.?PKUSXK? _4_AKX=LM2NHFBCG48W C&<# /<<]??U->1T .A.)4.<?,/;^H
MK]UO^"8N?^%/+GC*CJO)^[WVC^OU/;\*83B5#G'S#V_J*_=?_@F*W_%GP.GR
M+[$^^,#Z9YZ=1W /LW<><#D''/%-;_5LGWVV]#@Y^HH\P98*>3T/49Z=/;C-
M*J\#DX4\=<^G/K0!^('_  4B^ &M:#\0]1\8M"PL9R26['O_ "R?PKX9K]W_
M /@IWX3NO%'P+FAL;42RIN8LJY(&0>?0=>2,=:_":]LIM/N7@G0QRH<$&@#[
M5_X)F_'"R^%GQ&G&L7I2WNV$2(S <G'KUY_+VK]P-)U2'6-+@OH#F&9=ZE><
MC^M?R[^&+YM-\0Z;<"1HQ'<QN60X/#>_MG\Z_H+_ &-?CEHOQ0^&>CV6GW"R
MW-K $;N3@9)[=ORZ>E 'T,,%< ,=I QNY_'G\:$8LPR<]1\O0],_3G/&:7Y8
MR.-JXQUX'H,?C3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"-V^8+CT[X[_KT/Y4V,,&(.W?@$GKGD^^?\/>I&"JK$
MG ^\3GTI(P54 @  8P!C^O2@#XS_ ."BWQFT;1/A/J7AQYU6^G! 57&<<88=
M/_K9K\)J^Y_^"K.O7LGQL:Q,C"V(8A58D'!((Z^N?K^@^&* "OIG]A/X)V/Q
MK^*$.G7J+(D+K)LQG(!'!X]<?7!KYFK]'_\ @DS\/M3TWXBMK<L,BPR$*,Y'
M&!GL0<9]>XH _6OP?X=MO!?A?3M'M8XXDMH@@5<*"?4_C@?B*VE7<H./O')/
M*GV_I_GBG,H88(_Q%- *YXZ9.%  .3_/_&@ SYBG&#QG'56!SCG%#_Q?-C:,
MX7J.O/O^7:D9/F!^88[]>I'X]OI3\%L9X]0">OUH 1EP %49R2#C@'GG_/K3
M%;YMH^\O !.>,C.>>?7/N*D4'&3P3R><BAPOWFZ+SR>/7/Z4 >$?MH?#'4/B
MS\%]0T+3(?,NGRRL%)*_EV_P'6OY^?B%\/=2^&/BBXT36$V7<#$,F/0XYY_K
M7]/:DCS/XB#T4^W3GI_D]Z_GX_X*'9/[1&K-C:"3\OIT]^G2@#YC*\9!!'%:
MOA$X\4Z006!^U1X*G!^\*R=QV@9XZXJSI=U]AU&VN-Q7RI%?(]CF@#^E/]G&
M_BOO@YX:,<C2,MJ@<LVX]..<>F*]*W_,%QS]1T]:^-/^"=OQ8/C3P+:Z49-X
MM4PJ@Y  '!&1T]Z^R]HYZ\G/4T >0_M7N%^"'B('(W0/WX^Z??UQ_+O7\XWB
M!@VO:D0<@W,I!'^^:_HX_:Q91\$/$62 ?(;&3CG';D=L_P">#_./KYW:]J1R
M&S<R<KT/S&@"A7WW_P $OQN\=P C?@K_ +7&3@=#T/M[?7X$K[[_ ."7_P#R
M/ML1RP*D%03@[OH?]D?ACMB@#]K:J:E(T.EW;@%F2%R <9. ?YU;JGK W:1?
M ]X'Z''\)H _$+]IK]L[XA>%_B]K.EZ?J,L-O;RX&'P",GIU'4#/7OZUY2O[
M=GQ/5 %U60<8_P!:V.F  .W^>^",7]L;GXXZZ<YW3,<C'<Y[$_SKQ"@#ZR^%
M?[:_Q&U;XD:';75^\\5Q<A'7><L,YQTQU'IT..U?NWX*NY+_ ,)Z7<RG,LL"
MNWU/7_/\J_FJ^"./^%L>& <?\?B\G/O_ )_&OZ4/ .5\$Z)PW_'K'@' (&!]
M.U &XP"@CGG)8@')_+OT_*D0%1E]V<CN3V _SP/I3F4#G(!W Y;GVX_SWJAX
M@URW\.Z9->W3".&-22['@8&>?U_*@#"^)WQ,T7X4^%[K7M:N(X+:$?,68 \#
M_P"N/SK\D_VE/^"FWB'4O%LP\#W7V>QR2I1L8^N/KGOUYZ5QO_!0O]J;7O'?
MQ OO#^GZ@R:$K-\JG&[D<C!Q^O'/3G/Q(JEF  R3P * .Y^)7QE\3?%2^-SK
ME[),Q.2-Y.>3U_,UPU%6;?2[RZV^3:S2AC@%8R0?QH CM+J6QNHKB!S'-$P=
M&!P00<BOJ7X4?\%!/B%X%OM(LY[]FT:W=5DC#?P _0]N*\UMOV7?&EUX9&M"
MQD6#;N.4/M_C7EEYHM_8S213V<\;QD@[HV'0X]/I^= '[^:?^U1H'Q5^ >HZ
MYH-W&FH06>3'O'WPI!'_ -;WK\D/$?[<OQ,M?$6J1QZI(%6=T&9&'0X'0]/O
M'C^]UR :\:\%_&#Q+X"TNYT[2KYX;.XSYD88@'.?\3^9]:Y&^NC>W3W#G,DA
M+-DD\D_Y_P \4 ?0C?MW_$\D_P#$UDQ_UU;\?YGZ9]ACZ _8>_:R\>>/OC=8
MZ/JMX]S8S%25+9"\\<8]SV]!V%?GI7U1_P $X?\ DXO3,#GY<'&2.>W'7MSZ
MT ?O\V,<YZCIGUIK?-P-W.1CD=\$YQ^5.8$J<=>HYQ36VJI& $5<%2,+C\O0
M&@!&1BRX^]CEAQ_GJ>.:\C_:$_:2\,?L_>'1=ZO<1B:6,B&)7 Y[?Y[<>M0_
MM+?M):%^SUX1EU+5)E\UXV$:J06!P0#^!%?A!^T;^T9XA^/'BV]NM0O9)M-\
M]F@C8GIVX)X[<4 >^?%S_@I=X[U#Q9<GPU>&+3UD)1MQ7."0..HXXZU\M?%3
MXR>(_C!JRZAK]VUQ*H( +$]3FN&IT<;R-A%9SUPHS0 VBO0_ /P-\3_$"!Y[
M'3[CRESSY9R<=?Z]?\,W_&'[.GB[P;I[7EW8RF-201Y9SP?T_P#U>N  <5X+
M\::IX"UR'5=)G:"YB.1@D ^E?5?P[_X*3?$32M>LQJ]\9-/5@'^8XP!CGCT]
M!Z5\=RV\L.?,B>/G'S*1SZ5'0!_0M^S'^V3X5^.]O#IUO<Q1:LB?O(]P49]O
M7/\ GT'T<%96X.5XP&/_ -;_ #FOYC/A?\5-=^$OB*+5]"NY+:=65CL;&<'-
M?N1^Q5^V-I'QZ\,6.ERR@ZY GES<_>; /^- 'U9(K,"/E9<?=8=>O_UJ11\P
MP,$9^\,\$]C^%"J&ST='&<X'/^/&/RI489. ,DG.WD<<=?6@#P?]KSQQJ7@?
MX;ZAJ&G,R3Q1,5*]1A>H_J?;G/?\8[[]NCXEQZE.5U&1-LC +YA&.@]/]D?K
MZFOV"_;AVK\*=3/ /EL>W]T9.=PQP/\ ZQ[_ ,^^K_\ (6O?^N[_ /H1H ^@
M#^W=\4&4 ZM(.,$B4^F./SZG)_$ C]9_V0_CQ_QC5%XR\97JHZ@-)O?& ,]S
MVQ_+O7X&UZ;%^T)XMM_ A\)PWC0Z7L\O8CD #&.!^OXT ?9W[3G_  4UUNZ\
M42P^!KEHK16."K84\\G(YZBOC;XL?M'>,?C(@37[YYE]-Y/M7F<=K<7'S)#)
M+GG<JDYYQ_.O4_"_[,_C/Q5H?]IP:?-'#C.TPDG^?7VH \FJ2WN)+2>.:%S'
M+&P96'4$5T'BGX>ZYX1O&@OK"9=O\:H2*YN@#Z9^&_[>WQ&\!KIUE'J#/IL#
M!71G).S//;DX^M?K%^RK^VAH7QFT6WMIIX4U1E&Y/,'+9QG(]<@=/\:_ 2O6
M/V:OB9J'PY^*.B75O=-%:_: 9%+8 YY/Z4 ?TF*RE!(I8KC(ZG@\]*;)O;C&
M['.,8'7CJ/;_ .MTKD?A7X\L/'_A&PN[&594\A0S(3_='L/Z5V7*L,<@]?\
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MY^\?6JU 'Z1?\$_?VI_&GQ(^-EOHVM7;7%FP7N6(&,8P!Z*/3_']A&7<5/\
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M<=^!_P#6K\+?'GC;4?'WB*YU34IWGED8E2[%B!]30![Y\2/V_/B3XV75-/\
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M)),QN.20./KD8H N^7A9 1A<%>$'3' 'TYZU(H 9\=SSQCL/SIL:GC*CJ3T
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MWW%=WR9)Z@GV&,9Y'UK]R-NUA@;1D],\YY_#G_/-.5@W3/3/((H _/GX6_\
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M_P!5.H **** "BBD)Z<9_I0 M%-W';G:<XSMXS]*19-S8^4XSG#9[X'\C^5
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MGX+^)6B_892BS7 1NYY],_RQS0!_2E'()D$RC<"ORC S[C/Y?E4BJ%4 # '
M KGOA_=-J7@G1KB7YGEMU<[ASZUT*J%4 # '  H 6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1#R ,9QU]>:_??X=^,H/B%X3T_7[5=D-TFX+CMUX^O'Y5_,1I*AM4LP1D&9
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M'8* !ZG%15]-_L#_  IM?BM\8+?3[M$DAC978-Z Y]^^.W'\@#ZZ_P""?_\
MP3YBDC@\7^,[5+JPNHP\4$B _+@''(_I[^U?H9X>_9[\"^%\?V;HD-N  /E5
M1G'3H/\ .377^$_#\7A7P[9:9 N([= @50!6HRJF#MW,!U().![^O)H \Y\4
M?L[^!O&"@:GH\=QCE=V" ?7&*_/']NW_ ()[VUA:S>)/"D*VME;YD95'8\MW
MZY([=CBOU4C/;..P4GT.,\\^E<I\5_#G_"8?#W6-+&X?:8-H"\$Y[=10!_,9
M>6K6-W-;N<O$Y0X]CBH:]<_:1^#=Y\(?'5]:79_UL[,%&,#/./6O(Z -'PXI
M?7+)1U,@%?T)?L.C;\$].XQ\J]L=V]A_GUZU_/AX78CQ!8\9!E4%>QYZ5_0=
M^PY_R1'32!C**>1C^]VP/\^O6@#Z&HHHH **** "BBB@ KY;_P""BG_)O>J
MMM^1^2<8^[SU_P ^HKZDKY<_X*)MM_9]U+Y@HVL3GIC*Y[_Y_F ?S]5]K_\
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M:IK:V3]Y)I2A%QCN"../RX_"OYYOBUX3OO"7CK5[:\MWA#7,C)N!R?F/7WH
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M^O45^$\.?-3'7<,=?Z<_E7[J_P#!,-0OP?Z8)52/DP#TR>GT]<]CU% 'V?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\_X*(W\EQ^T%JD#$;8R3M&./3N3TK]WOB1XXM/AYX5N]:O95A@@&2S8Q^O\
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MH)_;B/\ Q:C43QPA&2<8X[<_IG\#7\^VK_\ (6O?^N[_ /H1H J5]^?\$P_
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M[4  W9Y QSW_ "H&[/. .>/Y4;<*0N%/TXS494J2<X^; +,<<CTSSR?;]!0
MY5);)X; /'./4 GMQ1L#9*N?3J2,Y_Q_PI[<J1G'N*8OWL]"<$[AV],_7ZT
M>6_M0-L^"?B0YQ_H[<_\!;W'\Z_F_P#$W_(Q:H,8Q<R#C!Z,?2OZ0?VGFV_!
M/Q(?F.+=ONG'\)SSD8XS7\WWB;_D8M3^7;_I,G_H1H S:^X?^"8R[OB9 /\
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M_B?L/LK@_D?ZXK^;;Q1@^)-5Q@#[5)C'IN.*_I)_:0./@QXFY7_CV8[6S\V
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MC]#C\>U/8A/F(QZMQP!GK_GO35RJ L<;><+D]NGJ: '?-GH,9]>V/\:^ /\
M@KV2/@[:\X!]^O+=MW]#7W^?F8?+T/4_3J/Y5\ ?\%>GV_!VV&X?-QMSSU/.
M,_T- 'XL4444 ?K7_P $;6:30=9.=P#'L<#&1UQU^IK]/:_,/_@C9&PT'6"V
MYN6ZCI^.#_,=/PK].AG><_AZ?R]_TH =1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 R1002V2 .W4=>1CG-,+,[!0?7!!
MQW ]3TR>HZCM3I%+94Y*L". /;KG\:7_ %9ZD[C@+G\?\_2@#P/]MSPO<^*_
M@3K-I90-+=,C!2HR?NGBOYZ/$'AV^\,ZC)97\+03H2-K=?KBOZC+ZPAU2SEM
M[A%DB?(VLIQTQR._>OP]_P""C?[.OB#PK\3]1\1VFG%= =I"'7/RG@].>QSV
MH ^(V.6) Q["M?PIX@NO#.O6=_:3O;O'*I9D;&0&!K)Y8\+VZ#V'6D92K$$8
M(X(- ']"?[%/QXT;XE_#/2M-BO%EU.UB"RKD9W8R?3^77\A])XVJJC=]<Y_/
M/^>:_FS_ &?_ -H[Q)^S_P"(QJ6D7$C1G&8=QQ[\>F.U?K#^S?\ \%(_#'B[
M0U/B_4%M+LKDL[Y.=H.<?GP.?8<"@#[I7+YR& /([?AZ]N_K36RF1T^7.5!
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M6<'L1@'N>.WY4 ?2\F%^<\#N>AX/KGH.:/X09..V#C!.>#_A]:>% R0,9Y-
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MFRNC^'OB"7PWXNTN\C=D"W";MO7K_P#7H _II\$WRZEX8L+E%4"2,'*]_?\
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M2XY_:$M^2,;!D#)&=W^'_P"OM^[K-M8$G Z=L9R,4 <W\1K%=2\$ZO%(611
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M=(\1P6,DFEVK_--_#Z\G&.W3Z^E?+V@Z'>>)-7M=-L(6GNKAPB(HYYK]W_\
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M![]N.U.IK#)7@'![]N.U 'P[_P %8F ^ K@DJ,,?8^H^\.Q/UX%?AW7[C?\
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M<X_'_/:@!IX[YHHJ:SC\Z\@C W%I%7:>^30!^@__  2)T*XC^*%QJ$D1\AB
MK%>.V#G'K]/Z5^S//F ]L?Y[_P">:^0?^">_P1T[P?\ "_3->CC47-R@;>$P
MQXSU(XZ_KZ5]?##-D!3C@-WZ\C]* /RU_P""S'_'CHG'\2]O]WVK\HZ_5W_@
MLR!]AT/')RN>.G3_ #V_Q_**@!T.?-3&2=P^[UK]U_\ @F&I'P=SLV_*I^X
M#G'.?P]_?'0?A1#S*@QGYAVS_0U^ZO\ P3#3'P=R%S\J_,.@SCV&3Q[XQUH
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M%WX4Z/\ &#P7>Z%JMM'+%<(<,Z\@D8_S]*[AAN4@]_0XI: /Y^/VOOV.-=^
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M<]_J?YUX?7MO[8!GF^.GB F%PBR,0Q!.>>N<GC&._>O%/)D&<HP_#Z_X'\J
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M+%0J= I[8]OY4 ?$K=<9! X! ZUZ+\&?CMXE^!^M/J.@7+1NV,KN.![X]?\
MZU<)=:7>6,\EO-;2)(C$$&,]02/2H&M9E4DPR #DDJ: /L#_ (>@_%DYS=+G
M[PY[\'^8_2O"_C3^T/XJ^..H)<:]=NX3^$.3NXQS^9XKS/[/+G'E/G.,;3UQ
MG'Y5[O\ LZ_LB^+OCSJ5O)8VDD>G+(#(S(>5Y/7'&<'M0!YIX3^%6O\ C+2;
MG4M/M7DLX!EI I(ZX/\ GWKDIX6MYI(G^_&Q5L>H.*_=X?LP^'_@G^R]J]H+
M2-=1%F_F%E )8J1ST.>_7U]37X8>)FW>(M4(Z?:9/P^8\4 9M?5'_!."/?\
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M\MM.Y2>>,Y/Y#K_.O)?CQ_P4(\;?%#2[K0H[IH]-ERC[<KP>" >OK^=?(M%
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M_!/Q*0H9C;-E.3G@G'4<?TK^;SQ+'-)XCU,M#(':YDRK+SG<?\#0!E5]0_\
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M< 8QUJ&UMX].M8X(QB&,8&2/E%3JH50 , < "@!:*** "BBB@ HHHH ****
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M/_AA?X3?] %0?PQ^H]A^OJ:^"OV;_P#@J%+X5TBQTWQ-(UQ,[+&2Q+8ZCO\
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M3V!'_P!:G,@QT)/3.>>3SS_GI29,C#;T4]<_X?CU[BB-2O&>0><#&>!USUH
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MG_/]: /G_P#X87^$W;05&.G3]>.>@_7U-;G@G]DOX>> -9CU/2-)6"Z08#@
M'IZ_@#]17L3?N]VWC@D#;D?7CZT2_=]3_"IQR>H_E0 ;O,VE>!U#9X_0]Q3D
M7;VV]@ >,#I2+A 06. 0/F_#OWIG).-C<CG+$8SU_EV_2@ S_$!SNR54<_=Z
M'G&?K[4EU:QWEL]M,#)'(I5O<5(6X5@<#@8;CJ1^M(T>Y5&<]MQ_GC&,Y H
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M#/XTZ@#\0IO^"2_Q*69E23*]!NCP?\\C\Q3%_P""3/Q,91^]7)_V/\^PQ_M
MY[5^WL<A<<J5. >G%#2JJ[L@C;N'(Y% 'X^_!7_@E1XJTGXAZ7=^*"L^D1/F
M:/:5)'?^H_ _6OT.T+]BWX8>'[B">UT.(30X()1<9  !QCV_7MUKW,3+SGY0
M,G)(['!_S[TFT[E/S#..#DXZDYYQW_SQ0!6TO3K;1;.*QLXEB@C "(.P)/7B
MK4F%!"_*Y!P![GKCZ]\4?*R[4XZD$=,@]\>_]:;'G<VTJ1G[H(]>>WL?Q)H
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MI'@O1;D^/K'[=>-POF+@'Z#J._Y\8ZU^A!;;_P#JI@D#<-A>G\1!SG^61^-
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M /GW_AA?X3]] C)/7@8_SR?S&,8&#_AACX3]_#\7Y8_SU/Y^PQ]!44 ?/O\
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MCP/7.,_U]:\F7_@DQ\33G]X,]/\ 5_7W]1CMUK]OE8-TSTSR"*4L!@$XSP*
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M_LE?\$R;7P7<SW'CRV6^;# ;D_Q]QT]!^7Z1!CG[I'7TH8C:V[Y57G.<>^:
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M^S?4;ZWM8O\ 632+&OU)P*_;;_@FG^S??_"'PL-:N-VS4$+98\D$9]/<=/\
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MDJ!T/S8.#T_6FW%G%>0F*=?-C.<JW0^WZT ?R^>-O!][X'\176EZA$T,L3,
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MX 1PP[<94G\^0#^M244 1,1'V484E>@  QQ3U!48[#@<Y-.HH :P.01R>G7
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M #&PO\.XK\W.3UST_7BF[/+)/"!0.<87 SQU]/7BI2H."1G'(I: (]GIN&W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4(_X(X:!\I.K'ALD!C@\\C_/3GVQ^EH;.?;VI&8\X7GH,]#Q^E 'YH_\.;M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^;^?7I0 W[KXSSPNYEY..?QXST]Z<P$BY Y*\9RIY_44K*64@'![4BL!\P7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *CDC#*V!RW!_''/OQ4E% #$);G(*MR"#GZ8XI&W[
MB!['/3C/3ISW_3ZU)10 G\0.?PIC,P4$_+W8YX'3/]?_ *U244 0M&?+ ;!(
M&T'&[.1CGVS[]NM2@Y[8I:* $;.TXX/;-1A?,8DG!'3D94D>G3^?4U+10!&R
M_+M"X4<  #VP1]/Z4OECDJ &ZC(X!YYQ^)I]% #=QW'C(Z=.GO\ RH90W7/3
M'!(IU% $;95&P?<=<CU]<]_Y4HC()^8\GU_'O^-/HH 1<[1D8/?%+110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'(
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M.'W3MX//WL]:=10!'@R'G*G&1P.,CU]>OYTJY)+=%//.<]!^7TI]% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
